---
document_datetime: 2025-02-19 09:44:25
document_pages: 306
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/nemluvio-epar-public-assessment-report_en.pdf
document_name: nemluvio-epar-public-assessment-report_en.pdf
version: success
processing_time: 289.0553799
conversion_datetime: 2025-12-23 22:04:16.570117
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

12 December 2024 EMA/CHMP/487280/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Nemluvio

International non-proprietary name: nemolizumab

Procedure No. EMEA/H/C/006149/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure.............................................12                                  |                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier                                                                                             | ...................................................................................12                   |
| 1.2. Legal basis, dossier content                                                                                          | ................................................................................12                      |
| 1.3. Information on Paediatric requirements                                                                                | ................................................................12                                      |
| 1.4. Information relating to orphan market exclusivity                                                                     | ..................................................12                                                    |
| 1.4.1. Similarity.......................................................................................................12 |                                                                                                         |
| 1.4.2. New active Substance status                                                                                         | ............................................................................13                          |
| 1.5. Scientific advice.................................................................................................13  |                                                                                                         |
| 1.6. Steps taken for the assessment of the product                                                                         | ......................................................13                                                |
| 2. Scientific discussion                                                                                                   | ..............................................................................15                        |
| 2.1. Problem statement                                                                                                     | ............................................................................................15          |
| 2.1.1. Disease or condition                                                                                                | ........................................................................................15              |
| 2.1.2. Epidemiology..................................................................................................15    |                                                                                                         |
| 2.1.3. Biologic features, aetiology and pathogenesis                                                                       | .....................................................16                                                 |
| 2.1.4. Clinical presentation, diagnosis .........................................................................16        |                                                                                                         |
| 2.1.5. Management                                                                                                          | ..................................................................................................17    |
| 2.2. About the product..............................................................................................18     |                                                                                                         |
| 2.3. Type of Application and aspects on development....................................................19                  |                                                                                                         |
| 2.4. Quality aspects..................................................................................................20   |                                                                                                         |
| 2.4.1. Introduction                                                                                                        | ...................................................................................................20   |
| 2.4.2. Active Substance                                                                                                    | ............................................................................................20          |
| 2.4.3. Finished Medicinal Product................................................................................26        |                                                                                                         |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects..............................32                       |                                                                                                         |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects.......................33                         |                                                                                                         |
| 2.5. Non-clinical aspects                                                                                                  | ...........................................................................................33           |
| 2.5.1. Introduction                                                                                                        | ...................................................................................................33   |
| 2.5.2. Pharmacology.................................................................................................34     |                                                                                                         |
| 2.5.3. Pharmacokinetics............................................................................................36      |                                                                                                         |
| 2.5.4. Toxicology                                                                                                          | .....................................................................................................38 |
| 2.5.5. Ecotoxicity/environmental risk assessment.........................................................42                |                                                                                                         |
| 2.5.6. Discussion on non-clinical aspects                                                                                  | .....................................................................42                                 |
| 2.5.7. Conclusion on the non-clinical aspects                                                                              | ...............................................................46                                       |
| 2.6. Clinical aspects..................................................................................................47  |                                                                                                         |
| 2.6.1. Introduction                                                                                                        | ...................................................................................................47   |
| 2.6.2. Clinical pharmacology......................................................................................49       |                                                                                                         |
| 2.6.3. Discussion on clinical pharmacology                                                                                 | ..................................................................62                                    |
| 2.6.4. Conclusions on clinical pharmacology.................................................................67             |                                                                                                         |
| 2.6.5. Clinical efficacy - Atopic dermatitis....................................................................67         |                                                                                                         |
| 2.6.6. Discussion on clinical efficacy..........................................................................129        |                                                                                                         |
| 2.6.7. Conclusions on the clinical efficacy...................................................................139          |                                                                                                         |
| 2.6.8. Clinical efficacy - Prurigo nodularis                                                                               | ..................................................................139                                   |
| 2.6.9. Discussion on clinical efficacy - Prurigo Nodularis                                                                 | ..............................................183                                                       |
| 2.6.10. Conclusions on clinical efficacy - Prurigo Nodularis                                                               | ...........................................189                                                          |

<div style=\"page-break-after: always\"></div>

2.6.11. Clinical safety .............................................................................................189

2.6.12. Discussion on clinical safety ..........................................................................267

2.6.13. Conclusions on the clinical safety...................................................................285

2.7. Risk Management Plan......................................................................................286

2.7.1. Safety concerns ............................................................................................286

2.7.2. Pharmacovigilance plan..................................................................................286

2.7.3. Risk minimisation measures............................................................................288

2.7.4. Conclusion ...................................................................................................288

2.8. Pharmacovigilance ...........................................................................................289

2.8.1. Pharmacovigilance system..............................................................................289

2.8.2. Periodic Safety Update Reports submission requirements....................................289

2.9. Product information..........................................................................................289

2.9.1. User consultation ..........................................................................................289

2.9.2. Additional monitoring.....................................................................................289

3. Benefit-Risk Balance............................................................................290

3.1. Therapeutic Context .........................................................................................290

3.1.1. Disease or condition ......................................................................................290

3.1.2. Available therapies and unmet medical need.....................................................290

3.1.3. Main clinical studies.......................................................................................290

3.2. Favourable effects............................................................................................291

3.3. Uncertainties and limitations about favourable effects ...........................................293

3.4. Unfavourable effects.........................................................................................294

3.5. Uncertainties and limitations about unfavourable effects........................................294

3.6. Effects Table ...................................................................................................295

3.7. Benefit-risk assessment and discussion...............................................................298

3.7.1. Importance of favourable and unfavourable effects............................................298

3.7.2. Balance of benefits and risks...........................................................................299

3.7.3. Additional considerations on the benefit-risk balance..........................................300

3.8. Conclusions.....................................................................................................300

4. Recommendations ...............................................................................300

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                                                      |
|----------------|-------------------------------------------------------------------------------------------------|
| λ asc          | Ascending transition rate constant                                                              |
| λ desc         | Descending transition rate constant                                                             |
| ACT            | Asthma Control Test                                                                             |
| AD             | Atopic Dermatitis                                                                               |
| ADA            | AntiDrug Antibody                                                                               |
| ADCC           | Antibody-Dependent Cell-mediated Cytotoxicity                                                   |
| ADR            | Adverse Drug Reaction                                                                           |
| AE             | Adverse Event                                                                                   |
| AESI           | Adverse Event of Special Interest                                                               |
| ALB            | Albumin                                                                                         |
| ALT            | ALanine aminoTransferase                                                                        |
| ANCOVA         | Analysis of Covariance                                                                          |
| AR             | Adverse Reaction                                                                                |
| AST            | ASpartate aminoTransferase                                                                      |
| AUC            | Area Under the concentration-time Curve                                                         |
| AUC 0-28d      | Area Under the concentration-time Curve from time 0 to 28 days post dose                        |
| AUC 0-inf      | Area Under the concentration-time Curve from time 0 extrapolated to infinity                    |
| AUC 0-last     | Area Under the concentration-time Curve from time 0 to the time of the last quantifiable sample |
| AUC τ , ss     | Area Under the concentration-time Curve during a dosing interval at steady state                |
| BIMO           | Bioresearch Monitoring                                                                          |
| BMI            | Body Mass Index                                                                                 |
| BSA            | Body Surface Area                                                                               |
| BW             | Body Weight                                                                                     |
| CAD            | Carcinogenicity Risk Assessment Document                                                        |
| CCI            | Commercially Confidential Information                                                           |
| CDC            | Complement Dependent Cytotoxicity                                                               |
| CHO            | Chinese Hamster Ovary (cell)                                                                    |
| CI             | Confidence interval                                                                             |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                            |
|----------------|-------------------------------------------------------|
| CKD-aP         | Chronic Kidney Disease-associated Pruritus            |
| CL/F           | Apparent Clearance                                    |
| C max          | Maximum Concentration                                 |
| C max,ss       | Maximum Concentration at steady state                 |
| CDR            | Complementarity-Determining Region                    |
| CMC            | Chemistry, Manufacturing, and Controls                |
| CoA            | Certificate of Analysis                               |
| COP            | Critical Operational Process                          |
| COPD           | Chronic Obstructive Pulmonary Disease                 |
| COVID          | Coronavirus Disease                                   |
| CPK            | Creatine Phosphokinase                                |
| CPP            | Critical Process Parameter                            |
| CQA            | Critical Quality Attribute                            |
| CRO            | Contract research organization                        |
| CRS            | Cytokine Release Syndrome                             |
| C-QT           | Concentration-QT                                      |
| C1q            | Complement component 1q                               |
| CSR            | Clinical Study Report                                 |
| C trough       | Trough Concentration                                  |
| C trough,ss    | Trough Concentration at steady state                  |
| CVD            | Cardiovascular Disease                                |
| CXCL           | Cysteine-X-Cysteine motif Ligand                      |
| DCC            | Dual-Chamber Cartridge                                |
| DCC-AI         | Dual-Chamber Cartridge assembled with an AutoInjector |
| DCS            | Dual-Chamber Syringe                                  |
| DDI            | Drug Drug Interaction                                 |
| DS             | Drug Substance                                        |
| DSC            | Differential Scanning Calorimetry                     |
| DSCI           | Development Core Safety Information                   |
| DIBD           | Development International Birth Date                  |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                                                                |
|----------------|-------------------------------------------------------------------------------------------|
| DLP            | Data Lock Point                                                                           |
| DLQI           | Dermatology Life Quality Index                                                            |
| DNA            | Deoxyribonucleic Acid                                                                     |
| DP             | Drug Product                                                                              |
| DSUR           | Development Safety Update Report                                                          |
| E desc         | Nemolizumab effect on descending transition rate constants for all descending transitions |
| EASI           | Eczema Area and Severity Index                                                            |
| ECG            | Electrocardiogram                                                                         |
| ECLIA          | Electrochemiluminescence Immunoassay                                                      |
| EF 1           | Inhibiting concentration effect of nemolizumab                                            |
| EFD            | Embryo-Fetal Developmental toxicity                                                       |
| eCRF           | electronic Case Report Form                                                               |
| eGFR           | estimated Glomerular Filtration Rate                                                      |
| ELISA          | Enzyme-Linked Immunosorbent Assay                                                         |
| EMA            | European Medicines Agency                                                                 |
| EPAR           | European Public Assessment Report                                                         |
| ePPND          | enhanced Pre- and Postnatal Development Study                                             |
| ESKD           | End-stage Kidney Disease                                                                  |
| EU             | European Union                                                                            |
| F              | Bioavailability                                                                           |
| Fc γ R         | Fc gamma receptors                                                                        |
| FDA            | Food and Drug Administration                                                              |
| FUQ            | Follow-up Form                                                                            |
| GLP            | Good Laboratory Practice                                                                  |
| GMP            | Good Manufacturing Practice                                                               |
| GVP            | Good pharmacoVigilance Practice                                                           |
| HbcAb          | Hepatitis B Core Antibody                                                                 |
| HbsAg          | Hepatitis B Surface Antigen                                                               |
| HC             | Heavy Chain                                                                               |
| HADS           | Hospital Anxiety and Depression Scale                                                     |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                      |
|----------------|-------------------------------------------------|
| HCP            | HealthCare Professional                         |
| HFE            | Human Factors Engineering                       |
| HIV            | Human Immunodeficiency Virus                    |
| HR             | Hazard Ratio                                    |
| HMW            | High molecular weight species                   |
| IAC            | Independent Adjudication Committee              |
| IB             | Investigator's Brochure                         |
| IC 50          | Concentration achieving half-maximal inhibition |
| ICF            | Informed Consent Form                           |
| ICH            | International Council for Harmonization         |
| ICSR           | Individual Case Safety Reports                  |
| IFN            | Interferon                                      |
| Ig             | Immunoglobulin                                  |
| IGA            | Investigator Global Assessment                  |
| IgG            | Immunoglobulin G                                |
| IIV            | InterIndividual Variability                     |
| IL             | Interleukin                                     |
| IL- (6, 8, 31) | Interleukin- (6, 8, 31)                         |
| IL-31RA        | Interleukin-31 Receptor A                       |
| I max          | maximum inhibition                              |
| IMP            | Investigational Medicinal Product               |
| IND            | Investigational New Drug                        |
| IP             | Interferon gamma-induced Protein                |
| IPC            | In-Process Control                              |
| IPT            | In-Process Test                                 |
| IRR            | Injection-Related Reaction                      |
| ISE            | Integrated Summary of Efficacy                  |
| ISI            | Integrated Summary of Immunogenicity            |
| ISS            | Integrated Summary of Safety                    |
| iSMP           | integrated Safety Management Plan               |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                   |
|----------------|----------------------------------------------|
| ITT            | Intent-To-Treat                              |
| IV             | IntraVenous                                  |
| JAK            | Janus Kinase                                 |
| K a            | First-order absorption rate constant         |
| K D            | Dissociation constant                        |
| K out          | Rate constant for loss of response           |
| LD             | Loading Dose                                 |
| LIVCA          | Limit of in vitro cell age                   |
| LMWS           | Low molecular weight species                 |
| LOCF           | Last observation carried forward             |
| LTE            | Long-Term Extension                          |
| MAA            | Marketing Authorization Application          |
| mAb            | monoclonal Antibody                          |
| MALT           | Mucosa-Associated Lymphoid Tissue            |
| MAR            | Missing At Random                            |
| MCB            | Master Cell Bank                             |
| MedDRA         | Medical Dictionary for Regulatory Activities |
| MI             | Myocardial Infarction                        |
| MMRM           | Mixed model repeated measurements            |
| MMV            | Murine Minute Virus                          |
| MOA            | Mechanism of action                          |
| MP             | Medicinal Product                            |
| MRHD           | Maximal Recommended Human Dose               |
| mRNA           | Messenger Ribonucleic Acid                   |
| MSD            | Meso Scale Discovery                         |
| MSP            | Modelling and Simulation Plan                |
| MSU            | Month Safety Update                          |
| NAb            | Neutralizing Antidrug antibody               |
| NOAEL          | No-observed-adverse-effect level             |
| NRS            | Numerical rating scale                       |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                                  |
|----------------|-------------------------------------------------------------|
| OMICS          | Transcriptomic and Proteomic Assessments                    |
| OR             | Odd Ratio                                                   |
| OSMR           | Oncostatin M Receptor                                       |
| pCCI           | Physical Container Closure Integrity                        |
| PCR            | Polymerase Chain Reaction                                   |
| PD             | Pharmacodynamic                                             |
| PGAD           | Patient Global Assessment of Disease                        |
| PGA            | Physician's Global Assessment                               |
| PEF            | Peak Expiratory Flow                                        |
| CCPIL          | Patient Information Leaflet                                 |
| PIP            | Paediatric Investigational Plan                             |
| PK             | PharmacoKinetic                                             |
| PMDA           | Pharmaceuticals and Medical Devices Agency                  |
| PN             | Prurigo Nodularis                                           |
| PK/PD          | PharmacoKinetic/PharmacoDynamic                             |
| PopPK          | PoPulation PharmacoKinetic(s)                               |
| PPC            | Post-Process Cells                                          |
| PPD            | Protected Personal Data                                     |
| PP NRS         | Peak Pruritus Numerical Rating Scale                        |
| PPQ            | Process Performance Qualification                           |
| PSP            | Pediatric Study Plan                                        |
| PT             | Preferred Term                                              |
| PY             | Person years                                                |
| QA             | Quality Assurance                                           |
| Q4W            | Once every 4 weeks                                          |
| Q8W            | Once every 8 weeks                                          |
| QoL            | Quality of Life                                             |
| QTc            | Heart rate-corrected QT                                     |
| QTcB           | Heart rate-corrected QT interval using Bazett's formula     |
| QTcF           | Heart rate-corrected QT interval using Fridericia's formula |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                       |
|----------------|--------------------------------------------------|
| RMP            | Risk Management Plan                             |
| RNA            | Ribonucleic Acid                                 |
| RR             | Relative Risk                                    |
| RSE            | Relative Standard Error                          |
| SAE            | Serious Adverse Event                            |
| SAF            | Safety                                           |
| SAP            | Statistical Analysis Plan                        |
| SC             | Subcutaneous                                     |
| SDM            | Scale Down Models                                |
| SHPT           | Secondary Hyperparathyroidism                    |
| sIGA           | static Investigator global assessment            |
| SmPC           | Summary of Product Characteristics               |
| SOC            | System Organ Class                               |
| SSC            | Systemic Sclerosis                               |
| STAT           | Signal Transducer and Activator of Transcription |
| SUSAR          | Serious Unexpected Suspected Adverse Reaction    |
| sWFI           | Sterile water for injection                      |
| t 1/2          | Terminal half-life                               |
| TARC           | Thymus and activation-regulated chemokine        |
| TB             | Tuberculosis                                     |
| TCI            | Topical Calcineurin Inhibitor                    |
| TCS            | Topical CorticoSteroid                           |
| TEAE           | Treatment-Emergent Adverse Event                 |
| tEASI          | Logit-transformed Eczema Area and Severity Index |
| T max          | Time to Maximum Concentration                    |
| TNF            | Tumor Necrosis Factor                            |
| TSE            | Transmissible Spongiform Encephalopathy          |
| UFDF           | UltraFiltration and DiaFiltration                |
| UK             | United Kingdom                                   |
| ULN            | Upper Limit of Normal                            |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                      |
|----------------|---------------------------------|
| UP             | Uremic Pruritus                 |
| US/USA         | United States (of America)      |
| UV             | Ultraviolet                     |
| USP            | United States Pharmacopeia      |
| VAS            | Visual Analog Scale             |
| Vd/F           | Apparent volume of distribution |
| VP             | Visible Particle                |
| WCB            | Working Cell bank               |
| YO             | Years Old                       |

<div style=\"page-break-after: always\"></div>

## 1.  Background information on the procedure

## 1.1.  Submission of the dossier

The applicant Galderma International submitted on 12 January 2024 an application for marketing authorisation to the European Medicines Agency (EMA) for Nemluvio, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The applicant applied for the following indications:

## Atopic dermatitis (AD)

Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

## Prurigo nodularis (PN)

Nemluvio is indicated for the treatment of prurigo nodularis.

## 1.2.  Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application.

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3.  Information on paediatric requirements

## Information on paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0277/2023 on the agreement of a paediatric investigation plan (PIP) for the treatment of atopic dermatitis and EMA Decision(s) P/0119/2020 the granting of a (product-specific) waiver for the treatment of prurigo nodularis.  At the time of submission of the application, the PIP P/0277/2023 was not yet completed as some measures were deferred.

## 1.4.  Information relating to orphan market exclusivity

## 1.4.1.  Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.4.2.  New active substance status

The applicant requested the active substance nemolizumab contained in the above medicinal product

<div style=\"page-break-after: always\"></div>

to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.5.  Scientific advice

The applicant received the following scientific advice on the development relevant for the indication subject to the present application:

| Date             | Reference                 | SAWP co-ordinators                                       |
|------------------|---------------------------|----------------------------------------------------------|
| 27 June 2019     | EMA/CHMP/SAWP/344150/2019 | Dr Elena Wolff-Holz and Dr Paolo Foggi                   |
| 30 January 2020  | EMA/CHMP/SAWP/25069/2020  | Dr Walter Janssens and Dr Finbarr Patrick Leacy          |
| 28 May 2020      | EMA/CHMP/SAWP/265227/2020 | Prof. Dieter Deforce and Dr Carin Bergquist              |
| 12 November 2020 | EMA/CHMP/SAWP/580831/2020 | Dr Ewa Balkowiec-Iskra and Prof. Flora Musuamba Tshinanu |

The scientific advice pertained to the following quality, and clinical aspects:

-  A comparability assessment plan between drug substances manufactured in different buildings, a process performance qualification (PPQ) for the dual-chamber syringe (DCS) 30 mg using a bracketing approach at the lyophilisation step and the possibility to manufacture multiple strengths of the drug product in vials from a single bulk solution for paediatric patients.
-  The overall clinical development program, in particular, the extrapolation of efficacy data to support therapeutic use in children, the pharmacokinetic (PK) modelling strategy, dosing regimen, study duration, study population, sample size, choice of endpoints, proposed safety database, enrolment strategy for adolescents, the clinical pharmacology program.

## 1.6.  Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Kristina Dunder

Co-Rapporteur:Margareta Bego

| The application was received by the EMA on                                                   | 12 January 2024   |
|----------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                     | 1 February 2024   |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on | 25 April 2024     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on | 6 May 2024        |
| The Co-Rapporteur's Critique was circulated to all CHMP and PRAC members on                  | 6 May 2024        |

<div style=\"page-break-after: always\"></div>

| The PRAC Rapporteur's updated Assessment Report was circulated to all PRAC and CHMP members on                                                                                           | 16 May 2024       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                  | 30 May 2024       |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                      | 13 August 2024    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                          | 23 September 2024 |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 03 October 2024   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 10 October 2024   |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                  | 17 October 2024   |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                          | 11 November 2024  |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint updated Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on         | 27 November 2024  |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint updated Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on         | 06 December 2024  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Nemluvio on | 12 December 2024  |

## 2.  Scientific discussion

## 2.1.  Problem statement

## 2.1.1.  Disease or condition

The proposed indications are:

Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

Nemluvio is indicated for the treatment of prurigo nodularis.

Atopic dermatitis

<div style=\"page-break-after: always\"></div>

Atopic dermatitis (AD) is a chronic disease of skin barrier dysfunction and immune responses to bacterial and environmental antigens and allergens, characterized by pruritus (itching), xerosis (skin dryness), and eczematous lesions whose features include erythema, infiltration/papulation, oozing with crusting, excoriations, and lichenification. The three hallmarks of AD are: skin barrier disruption (pillar 1), pruritus (pillar 2), and inflammation (pillar 3). Although not a life-threatening disease, AD has a marked negative impact on patients' quality of life (QoL), and depression and anxiety have been reported as comorbidities in AD patients [Linnet 1999].

## Prurigo nodularis

Prurigo nodularis (PN) is an under-recognized inflammatory skin condition that is characterized by the presence of multiple, intensely pruritic (itchy), excoriated nodules that typically develop on the extensor surfaces and on the trunk of the body (Ständer 2019; Whang 2021, Whang 2022).

Patients with PN report itch as the most burdensome and disturbing symptom but may also experience pain, burning, stinging, and other disturbing sensory skin sensations (Kowalski 2019; Huang 2020c; Kwatra 2020; Pereira 2020; Ständer 2020a; Aggarwal 2021; Elmariah 2021). Furthermore, PN is associated with significant psychological distress; patients with PN are 2.8 times more likely to suffer from depression and anxiety vs. healthy individuals (Dhawan 2018; Brenaut 2019; Huang 2020c; Ständer 2020a).

## 2.1.2.  Epidemiology

## Atopic dermatitis

Atopic dermatitis is estimated to occur in 10% to 20% of the population (Weidinger 2016) and up to 25% of children (Eichenfield 2014; Langan 2020).

## Prurigo nodularis

Epidemiological data suggest that PN is a rare disease (Ständer 2020a; Ständer 2020b; Whang 2021, Whang 2022), with an estimated prevalence of 36.7 to 43.9 per 100,000, in a United States (of America) (USA/US) population (Ständer 2020b). In Europe, prevalence estimates span from approximately 7 per 100,000 in Poland to 111 per 100,000 in Germany, with 33 per 100,000 in the United Kingdom (UK), and 8.4 to 46.7 per 100,000 in France (Huang 2020a ; Ryczek 2020; Ständer 2020b; Misery 2021; Morgan 2022). Prurigo nodularis appears to affect females and the elderly more frequently (Iking 2013), with the modal age group of disease between 51 to 65 years of age (Boozalis 2018). Prurigo nodularis is associated with many dermatologic, systemic, neurologic, and psychiatric comorbidities, which may exacerbate itch severity and complicate management of the disease (Boozalis 2018; Ständer 2020c; Huang 2020b). However, PN may persist despite the resolution of underlying conditions (Kowalski 2019).

## 2.1.3.  Biologic features, aetiology and pathogenesis

The cause of AD, although still not completely understood, is multifactorial and involves a complex interrelation between susceptibility genes, immunological factors, infections, and environmental factors to produce a skin barrier disturbance as well as immunologic dysregulation and inflammation (Rutkowski 2014). Upon stimulation with allergens, dendritic cells in the skin stimulate type 2 helper T cells (Th2) and cause the subsequent release of pro-inflammatory cytokines, including IL-4, IL-5, IL13, and IL-31.

The pathophysiological pillars of PN are pruritus, inflammation, altered neuronal and epidermal architecture and differentiation, as well as dermal fibrosis. Interleukin (IL)-31 has emerged as a novel

<div style=\"page-break-after: always\"></div>

neuroimmune cytokine playing a key role in the pathophysiology of PN (Dillon 2004; Gibbs 2019) and is produced by immune cells, including type 2 helper T cell lymphocytes, basophils, mast cells, eosinophils, and myeloid cells, as well as nonimmune cells, including keratinocytes and fibroblasts (Takamori 2018; Gibbs 2019; Alkon 2021). Interleukin-31 signals through the heterodimeric IL31RA/oncostatin M receptor β that is expressed on a diverse network of immune and non-immune cells in the skin, including epidermal keratinocytes, microvascular endothelial cells, dermal fibroblasts, and dorsal root ganglion neurons (Garbers 2012; Bağci 2018; Takamori 2018; Gibbs 2019). Upon binding to IL-31RA, IL-31 induces itch and contributes to inflammation and skin barrier disruption (Zhang 2008; Wang 2020). Lesions from patients with PN have a 50-fold increase in the expression of IL-31 and IL-31R compared to healthy skin (Hashimoto 2021). To date, nemolizumab is the only treatment designed to specifically target IL-31RA to block IL-31 from binding to its receptor (Kabashima 2021; Tsoi 2022).

## 2.1.4.  Clinical presentation, diagnosis

Both AD and PN are characterised by itching as one of the main symptoms. Atopic dermatitis often affects young children or infants, while prurigo nodularis affects middle aged to older individuals.

For a child that gets AD, the disease can often improve or heal out during adolescence, but also adult individuals are affected by AD. Prurigo nodularis is a chronic disease. One feature of AD and PN is that disease activity often varies over time.

## 2.1.5.  Management

No treatment capable of curing AD has been established. The treatment goal for AD is to reduce skin inflammation and pruritus, restore skin barrier function, and improve QoL. Atopic dermatitis treatment guidelines established for the US (Sidbury 2023), Europe (Wollenberg 2022), and Japan (Saeki 2021) recommend topical corticosteroids (TCSs) of appropriate potency according to the severity of eruptions as first-line treatment.

Topical calcineurin inhibitors (TCIs) remain recommended as second-line therapy in patients who do not respond adequately to TCSs or in whom they are contraindicated. For pruritus alleviation, there are limited targeted antipruritic treatment options. Currently, drugs such as antihistamines are prescribed for pruritus when there has been an inadequate response to topical or systemic treatments.

Systemic therapies such as oral corticosteroids, cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil are commonly used in moderate-to-severe AD. However, most of these treatments have not been approved in this indication and their use is limited by their side effects.

With the introduction of novel systemic targeted therapies for AD, including biologics (e.g., anti-IL-4 and/or IL-13 monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab) along with small molecule immunosuppressives (e.g., Janus Kinase (JAK) inhibitors: abrocitinib, baricitinib, and upadacitinib), current treatment guidelines have been recently updated in the US (Davis 2023) and Europe (Wollenberg 2022; European Dermatology Forum 2022) and indicate a need to incorporate a step-wise approach in systemic treatment for moderate to severe AD (Boguniewicz 2017; Ghazal 2022).

There are other monoclonal Antibody (mAb) medicinal products authorised for similar indications, e.g.:

- -Ebglyss (2023) - Lebrikizumab, is a monoclonal antibody designed to neutralise IL-13. By doing so, lebrikizumab prevents IL-13 from causing skin inflammation and relieves disease symptoms. It is

<div style=\"page-break-after: always\"></div>

indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

- -Adtralza  (2021)  -  Tralokinumab,  is  a  monoclonal  antibody  designed  to  neutralise  IL-13.  By neutralising IL-13, tralokinumab prevents IL-13 from working and thereby reduces the inflammation and patient's symptoms. It is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
- -Dupixent (2017) - Dupilumab, is a monoclonal antibody designed to block receptors (targets) for IL-4 and IL-13. By blocking the receptors, dupilumab prevents IL-4 and IL-13 from working and relieves disease symptoms. It is indicated for the treatment of Atopic dermatitis, Asthma, Chronic rhinosinusitis with nasal polyposis (CRSwNP), Prurigo Nodularis (PN) and Eosinophilic esophagitis (EoE).

## Prurigo nodularis

Key goals of PN treatment are to reduce or eliminate pruritus, heal skin lesions, and improve sleep and overall health-related QoL (Ständer 2020a; Pereira 2021).

There are limited disease management options for PN. The current consensus treatment guideline (Ständer 2020a) advises following a multi-modal approach including general strategies to control pruritus, treatment of concomitant, potentially pruritogenic diseases and treatments directed at the pruriginous skin lesions. The stepwise approach includes moisturizers, antipruritic topicals, topical corticosteroids, and topical calcineurin inhibitors as first steps (Weisshaar 2012). Other topical therapies such as Vitamin D3 analogues, topical anesthetics, and topical capsaicin are also used, but data regarding efficacy are lacking. Antihistamines are often used in PN treatment, but evidence of an antipruritic effect is low. Additional lesion-directed therapies include intralesional injections of corticosteroids and cryotherapy; however, these are impractical to use in more widespread disease. Second steps are mainly widespread skin-directed therapies like ultraviolet phototherapy, or systemic therapies targeting the immunologic (methotrexate or cyclosporine) and/or the neural (gabapentin, antidepressants) components of the disease; however, these have limited evidence to support their efficacy and safety in PN. Third steps include opioid receptor antagonists, thalidomide, and dupilumab, a biological treatment that targets IL4/13, which received approval in the PN indication in the US in September 2022 (DUPIXENT USPI) and in the European Union (EU) in December 2022 (DUPIXENT SmPC).

## Unmet clinical need

There is an unmet clinical need, especially for PN, and concerning both AD and PN for products with efficacy on itch, one of the main bothersome symptoms of both diseases.

## 2.2.  About the product

Nemluvio is presented as powder and solvent for solution for injection containing 30 mg of nemolizumab as active substance and is available in a pre-filled pen or pre-filled syringe. Nemolizumab is produced by recombinant deoxyribonucleic acid (DNA) technology in Chinese Hamster ovary cells.

Nemolizumab is a humanised IgG2 monoclonal antibody that inhibits interleukin-31 (IL-31) signalling by binding selectively to interleukin-31 receptor alpha (IL-31 RA). IL-31 is a naturally occurring cytokine that is involved in pruritus, inflammation, epidermal dysregulation, and fibrosis. Nemolizumab inhibited IL-31-induced responses including the release of proinflammatory cytokines and chemokines.

<div style=\"page-break-after: always\"></div>

Additionally, nemolizumab restores barrier integrity in AD and normalizes epidermal differentiation by blocking profibrotic processes in PN.

The pharmacological classification is: Other dermatological preparations, agents for dermatitis, excluding corticosteroids, ATC code: D11AH12

The initially claimed indications are:

- Atopic dermatitis (AD): Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

- Prurigo nodularis (PN): Nemluvio is indicated for the treatment of prurigo nodularis.

The final approved indications are:

- Atopic dermatitis (AD): Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

- Prurigo nodularis (PN): Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy

The proposed posology is described in the SmPC section 4.2. and summarised below:

## -Atopic dermatitis (AD)

The recommended dosage of Nemluvio is:

An initial dose of 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks (Q4W)

After 16 weeks of treatment, for patients who achieve clinical response, the recommended maintenance dose of is 30 mg every 8 weeks (Q8W).

Nemluvio can be used with or without topical corticosteroids (TCS). Topical calcineurin inhibitors (TCI) may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas. Any use of topical therapies should be tapered and subsequently discontinued when the disease has sufficiently improved.

## - Prurigo nodularis (PN)

The recommended dose of Nemluvio for patients weighing &lt; 90 kg is an initial dose of 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks (Q4W).

The recommended dose for patients weighing ≥ 90 kg is an initial dose of 60 mg dose (two 30 mg injections), followed by 60 mg given every 4 weeks (Q4W).

In Japan, Nemolizumab 60 mg was approved for the treatment of pruritus associated with AD (only when existing treatments are inadequate) in patients aged 13 years and older, in March 2022 (Tradename Mitchga, marketed in Japan by Maruho Co., Ltd.). Mitchga was launched in Japan on 08 Aug 2022.On 26 Mar 2024, Maruho Co., Ltd. also obtained the marketing authorisation in Japan for the indication: treatment of prurigo nodularis in adults and children aged ≥ 13 years (only when existing treatment is insufficiently effective).

<div style=\"page-break-after: always\"></div>

## 2.3.  Type of application and aspects on development

This submission refers to a type of application which is complete and independent referring to Article 8.3 of Directive 2001/83/EC.

The clinical programs of nemolizumab for the treatment of moderate-to-severe AD in patients 12 years and older who are candidates for systemic therapy and for the treatment of PN in adults were conducted globally in North America (Canada and the US), in Europe (Austria, Belgium, Bulgaria, Czech Republic, Estonia, France, Georgia, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Spain), United Kingdom, and in Asia-Pacific (Australia, Korea, New Zealand, Singapore).

Two commercial drug product presentations are available: a fully disposable, single-dose dual chamber cartridge assembled with auto-injector (DCC-AI) and dual-chamber syringe (DCS). Upon reconstitution with water for injection, the drug formulation was the same for the DCC-AI and the DCS. Comparative analytical (structural and functional) characterization and 1 pharmacokinetic (PK) bridging study were done to support the similarity of the 2 presentations of the drug product. The data presented in this Marketing Authorisation Application (MAA) fulfills the relevant agreements with the health authorities (HAs) regarding comparability.

The route of administration and formulation used for the Phase 3 studies are the same as those intended for future commercial use.

A drug-drug interaction study evaluating the effect of nemolizumab on the PK of a drug 'cocktail' representative of cytochrome P450 (CYP450) substrates in adult subjects with moderate-to-severe AD (SPR.201593) was ongoing at the time of MAA and was submitted during the procedure, while a vaccine immunization response to tetanus and meningococcal vaccination study in adults and adolescents with moderate-to-severe AD (SPR.118380) is still ongoing and the study reports will be submitted as post-approval variation per agreements with the HAs.

The AD and PN programs were developed and conducted separately, and as such, the data are presented separately.

The therapeutic indication in AD includes children and adolescents from the age of 12, while the indication in PN concerns adult individuals. The AD population is in general younger than the PN population.

## 2.4.  Quality aspects

## 2.4.1.  Introduction

The finished product (FP) Nemluvio is presented as powder and solvent for solution for injection containing 30 mg of nemolizumab as active substance (AS).

Other ingredients are: sucrose, trometamol, trometamol hydrochloride (for pH-adjustment), arginine hydrochloride and poloxamer 188. The solvent is water for injections.

The product is available in:

- a) Pre-filled pen: single-use dual-chamber borosilicate glass type 1 cartridge in an auto-injector, with a stainless steel staked needle.

Pack size: pack of 1 pre-filled pen and multipacks containing 2 or 3 pre-filled pens (2 packs of 1 or 3 packs of 1).

<div style=\"page-break-after: always\"></div>

- b) Pre-filled syringe: single-use dual-chamber pre-filled syringe (PFS) in a borosilicate glass type 1, co-packaged with a 27G needle (stainless steel) with safety shield.

Pack size: pack of 1 pre-filled syringe.

## 2.4.2.  Active substance

## 2.4.2.1.  General information

Nemolizumab is a recombinant humanized monoclonal antibody based on a human immunoglobulin G2 (IgG2) framework containing heavy chain VH and light chain VL kappa subgroup sequences. The recombinant antibody is produced in Chinese hamster ovary (CHO) cells and consists of two heavy chains (445 amino acid residues each) and two light chains (214 amino acid residues each).

Nemolizumab is a humanized anti-human interleukin-31 receptor alpha (IL-31RA) monoclonal antibody. After IL-31RA binds to its ligand, interleukin-31 (IL-31), IL-31RA forms a heterodimer with the oncostatin M receptor, which activates the Janus kinase (JAK)/signal transducer and activator of transcription signalling pathway and transmits signals for cellular activity. By binding to IL-31RA, nemolizumab competitively blocks the binding of IL-31 to its receptor, thereby blocking subsequent transduction of the IL-31 signal into the cell.

Like other complex glycoproteins, nemolizumab displays a certain amount of microheterogeneity in terms of different degrees of glycosylation and modifications of amino acids. General properties of the antibody have been acceptably provided, including amino acid sequences. The information provided in this section is found acceptable.

During the assessment, the applicant was requested to further substantiate the New Active Substance (NAS) claim with comparative results from the amino acid sequence searches showing that nemolizumab differs from any active substances previously authorised as part of a medicinal product in the European Union (MO). The applicant adequately addressed this request, and the AS is considered as NAS.

## 2.4.2.2.  Manufacture, characterisation and process controls

## Manufacturer(s)

The active substance is manufactured at Chugai Pharma Manufacturing Co. Ltd., 5-5-1 Ukima, Kita, 115-0051 Tokyo, Japan. All active substance manufacturers with addresses and respective activities performed have been provided. The operations performed include manufacturing, release and stability testing, as well as cell bank storage. All sites involved in manufacture and quality control (QC) testing of the AS operate in accordance with EU GMP.

## Description of the manufacturing process

Nemolizumab active substance is produced in a fed-batch process using a Chinese hamster ovary (CHO) cell line. The source is the working cell bank (WCB), which is derived from the master cell bank (MCB). After a WCB cell thaw, the cell culture process for production of active substance involves mainly three stages: seed train, inoculum train, and production culture. The culture is harvested by separating the secreted molecule in the cell culture fluid from cells and cell debris, by centrifugation and filtration.

The purification process consists of chromatography steps and additional steps for removal and inactivation of potential viral contaminants (inactivation by low pH and virus retentive filtration). The

<div style=\"page-break-after: always\"></div>

final purification step is concentration and buffer exchange using ultrafiltration and diafiltration (UFDF). Protein concentration and buffer composition are adjusted to the AS specification by diluting the UFDF pool with dilution buffer.

One batch of AS is defined as the material generated from the harvest of a single production culture. The descriptions of the batch numbering system and the process scale are found acceptable.

Descriptions of the process operations are provided, including the assignment of critical process parameters and associated in-process controls (IPCs) to each unit operation. Representative chromatograms are provided, for all chromatography steps. The manufacturing process is well described, both in flow charts and in detailed narrative descriptions.

The nemolizumab active substance manufacturing process has been adequately described and is considered acceptable.

## Hold Times

In-process pools may be held for specified times at specified temperatures prior to further processing. The description of the hold times is assessed to be acceptable.

## Reprocessing

Reprocessing is only allowed for certain manufacturing steps and may be performed in a limited number of circumstances the reprocessing approaches are found acceptable.

## Filling, Storage &amp; Shipping of Active Substance

The filling of the conditioned UFDF pool is described.

The storage container is shipped to a FP production site. Storage containers with frozen AS solution are shipped according to qualified procedures. The temperature is monitored during transport.

The description of filling, storage and transport of AS is in general considered acceptable.

## Raw materials

A list of the raw materials used in the manufacture of nemolizumab is provided, which includes the name of the raw material; the corresponding compendial standards, if the raw materials is of animal or recombinant origin; and the stage of the manufacturing process in which it is used. No raw materials of human origin are used. All media used in cell culture processes are chemically defined proprietary media, free from substances of animal origin and free of proteins, except for the raw material produced by yeast. The raw materials have been described in sufficient detail.

In-house specifications for non-compendial raw materials are presented and found acceptable for the intended use.

Although it is stated that the composition of the medium and feed is proprietary to the supplier, the qualitative composition is provided, and it has been confirmed that there is an agreement between the applicant and the supplier to ensure that the applicant is informed about any changes in proprietary cell culture media and feed.

Detailed information has been provided regarding history of cell substrate, origin, and construction of the expression plasmid. The amino acid substitutions and deletions introduced to improve the properties of the antibody have been described in sufficient detail.

The preparation of master cell bank (MCB), working cell bank (WCB) and post-process cell (PPC) has been described in sufficient detail. Description of preparation and testing of future WCBs has also been provided. The information is acceptable.

<div style=\"page-break-after: always\"></div>

The characterisation and purity testing of the cell banks is in compliance with ICHQ5A and ICHQ5D. The results are as expected for CHO cells with no detection of viral contamination and only virus like particles identified.

## Control of critical steps and intermediates

Critical Quality Attributes (CQAs) were determined using a risk ranking and filtering tool that assesses the possible impact of each quality attribute on bioactivity, pharmacokinetics, immunogenicity risk, and safety. The outcome of the CQA assessment is provided. The approach and presentation of the CQAs are found acceptable.

Process parameter criticality is based on an assessment of process validation data for the impact of each process parameter on the CQAs. The criticality assessments are performed and the methodology for the assessment is described. The approach is found acceptable.

All steps containing critical process parameters (CPPs) are defined as critical steps. For each critical step, all CPPs are properly summarized. These process parameters are found correctly included in the process description section.

IPCs have been established as part of the control system. The proposed limits for the IPCs are summarized in tables, with action limits or acceptance criteria. The IPCs and their limits are found acceptable.

All IPC tests and limits applied to the cell culture, harvest and purification process are described and summarized and a comparison has been performed with the process description sections.

Depending on criticality, IPCs are tested against action limits or acceptance criteria. Action limits and acceptance criteria are defined as described, with respect to evaluations of root cause, corrective actions and impact to product quality. It is described that excursions of acceptance criteria always must lead to batch rejection if the investigation indicates that the excursion was not due to sampling or laboratory error. The description of the deviation procedures is found acceptable.

## Process validation

The active substance commercial manufacturing process was validated

All deviations are acceptably described and assessed not to impact the product quality or the PPQ evaluation.

For the process performance qualification (PPQ) batches, all CQAs and QAs are in general similar among batches. The levels of product and process related impurities in the in-process pools and active substance are acceptably presented and discussed. Data on potency and composition and strength of AS for the PPQ batches are acceptably summarized. It is acknowledged that the data are similar among the PPQ batches, and in accordance with the AS acceptance criteria.

Hence, it is acknowledged that the PPQ data confirm that the process has been validated adequately at the commercial manufacturing site and scale.

Process validation studies of cell culture steps included the evaluation of process parameter acceptable ranges and identification of CPPs. The process validation studies were performed using qualified scaledown models (SDMs) or at manufacturing scale.

Process validation of purification steps included the evaluation of process parameter acceptable ranges and  identification  of  CPPs.  The  studies  are  performed  using  qualified  scale-down  models  (SDMs)  to support the purification process. The SDM conclusions are found to be acceptable. For virus retentive filtration the scale down model is acceptably justified.

<div style=\"page-break-after: always\"></div>

The conclusions drawn on purification acceptable ranges and CPP identifications are found acceptable. The CPPs and ranges described are found to be properly included in the process description.

It is demonstrated that the process is robust in its clearance of raw materials to levels below the acceptance criteria.

Process linkage studies were designed to challenge individual steps or the overall process with higher levels of process- and product-related impurities than are typically present. The studies, performed as spiking studies or skip step studies, successfully demonstrated the clearance of process-related impurities.

The reuse of chromatography resins and the ultrafiltration and diafiltration (UFDF) membrane were evaluated in a study performed with a qualified scale-down model. The studies and the resulting resin lifetime limits are acceptably presented.

The shipping qualification was performed using AS filled in bags under commercial shipping conditions. It is acknowledged that shipping qualification studies demonstrate that the shipping process is capable of maintaining frozen AS inside the storage container at the recommended storage temperature, during air and ground shipment. The shipping validation approaches and results are found acceptable.

Overall, the active substance manufacturing process has been validated adequately.

## Manufacturing process development

An overview of the use of the AS derived from different process versions is presented (toxicological studies, clinical studies and commercial batches).

Several important changes have been introduced during the development of the manufacturing process. For each change, a comparability study has been carried out demonstrating that, apart from some expected differences, the change did not have a significant influence on the quality of the product.

Descriptions of the AS process changes are provided, together with flow charts comparing the different processes. The differences between the process variants are acceptably presented and justified.

## Comparability Studies

Comparability exercises were performed throughout the development for assessing AS comparability before and after changes made in the manufacturing process and the results were provided. It is in general agreed that the presented data showed that the manufacturing process changes did not have an adverse impact on quality, safety, or efficacy of the product.

## Characterisation

A comprehensive physicochemical and biological characterization of the molecule is presented. In general, the results show that nemolizumab has the covalent structure, post-translational modifications, and other characteristics of a typical monospecific human IgG2 antibody derived from CHO cells. State-of-the are techniques were used to address identity, higher order structure, heterogeneity pattern, biological functions and purities/impurities.

## Impurities

Presence, identity and risk assessments of product- and process related impurities arising from e.g., raw materials, manufacturing process and product-related degradation, were discussed.

The applicant refers to product-related substances and product-related impurities as 'product-related variants' due to the difficulty to isolate and differentiate some molecular variants. The characterization of the product-related variants is found acceptable.

<div style=\"page-break-after: always\"></div>

Batch results confirm efficient removal of all the process-related impurities. Robust clearance of raw materials is shown. Contaminants are thoroughly controlled during the manufacturing process and the capability of the AS process for virus removal has been demonstrated. This is found acceptable.

## 2.4.2.3.  Specifications

Specifications  are  set  in  accordance  with  ICH  Q6B.  All  relevant  characteristics  of  AS  are  adequately covered.

The  commercial  release  and  stability  specifications  for  AS  are  acceptably  presented.  The  proposed specification limits (for both AS and FP) are in general acceptably justified.

Some of the analytical procedures have been properly validated in accordance with the corresponding ICH guideline Q2 (R1) and are acceptably described. The remaining analytical procedures have been adequately described and are either performed according to pharmacopeia or presented in the finished product section.

It is described that a combination of the following information was utilized to develop the specification acceptance criteria: Clinical experience, product specific knowledge, prior knowledge, formulation development studies, current compendia or regulatory guidelines, and storage/process effects.

A number of CQAs are proposed to not be tested at AS and indirect control can be argued. The argumentation is found acceptable.

## Batch analysis

Batch analysis data of the active substance were provided. The results are within the specifications and confirm consistency of the manufacturing process.

An overview of the batches manufactured to date is acceptably provided. It is acknowledged that all batch analysis results met the specifications that were in force at the time of testing and release for each batch. It is also acknowledged that all available release data from batches produced during the PPQ campaign met the acceptance criteria of the proposed commercial specification.

## Reference standards

The system for reference standards is acceptably constructed and described

A two-tiered reference standard system, consisting of a primary and a secondary reference material, was established for commercial use.

Future reference materials will be prepared and qualified according to defined protocols.

## Container closure

The container closure system for the AS is acceptably described

-  Nemolizumab AS is stored in single-use bags. The ready-to-use bags are delivered pre-assembled, clean, and sterilized. Specifications for the bags are presented.
-  The single-use bags passed testing according to USP, Ph. Eur. 3.1.7., and comply with U.S. FDA 21 CFR 177.1350.
-  Regarding the TSE/BSE risk, the bags conform to the European Guidance EMA/410/01 and Ph. Eur. 5.2.8.
-  To assess leachables and extractables for the single-use bags, the chosen approach was considered acceptable.

<div style=\"page-break-after: always\"></div>

It is acknowledged that the extractables and leachables studies demonstrated the suitability of the singleuse bags, and that the bags are suitable for the storage of the AS.

## 2.4.2.4.  Stability

The AS shelf life is based on long-term (real-time/recommended storage conditions), primary stability data generated from primary stability batches, controlled for 60 months. All batches are assessed to be representative of the commercial manufacturing process and to be stored in a AS container representative of the commercial product.

The results of the long-term stability studies are provided. Results to date meet study and commercial shelf-life acceptance criteria, and no change was observed for all attributes tested.

Data from stress (40°C) and accelerated (5°C) studies from primary stability batches, and supportive stability studies (at recommended storage conditions and 5°C) provide additional stability data for the AS.

The post-approval annual stability program is described and found acceptable.

The information provided is found acceptable and the proposed AS shelf life of 60 months when stored at under recommended storage condition is supported.

## 2.4.3.  Finished Medicinal Product

## 2.4.3.1.  Description of the product and pharmaceutical development

The finished product (FP) Nemluvio is provided as a sterile lyophilized powder and solvent for solution for injection, for subcutaneous (SC) use. It contains 30 mg of nemolizumab as active substance (in chamber 1) and sucrose, trometamol, trometamol hydrochloride (for pH-adjustment), arginine hydrochloride and poloxamer 188. It has no preservatives. The solvent is water for injections (in chamber 2). Two different presentations are described:

- Pre-filled pen: single-use dual-chamber cartridge in an auto-injector (DCC-AI)
- Pre-filled syringe: single-use dual-chamber pre-filled syringe (DCS)

There are no formula overages in the Nemolizumab FP. The target fill volume was selected to allow a nominal injection volume to deliver a 30 mg dose.

The excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards (except for trometamol hydrochloride) and are commonly used excipients in parenteral formulations for biological products. For non-compendial excipient Trometamol Hydrochloride, the provided specification is adequately justified. Analytical methods are sufficiently described. Validation results are provided for non-compendial analytical methods. All acceptance criteria for the validation were met and the methods are considered suitable for its purpose and validated in line with ICH Q2(R2).

There are no novel excipients used in the finished product formulation or excipients of human or animal origin. Information provided on excipients is acceptable.

The primary packaging components are compliant with appropriate Ph. Eur. monographs for primary containers and closures.

The pre-filled pen is composed of single-use dual-chamber borosilicate glass type 1 cartridge in an auto-injector, with a stainless steel staked needle.

<div style=\"page-break-after: always\"></div>

The pre-filled syringe is a single-use dual-chamber pre-filled syringe in a borosilicate glass type 1, copackaged with a 27G needle (stainless steel) with safety shield.

The composition of the FP (DCS and DCC-AI) and an overview of the devices is provided.

## Formulation development

The formulation was changed during the development. The main changes made during the FP development and an overview of the use of the manufactured batches are presented.

Bridging studies between DCS and DCC-AI have been performed and are described. The formulation between the DCS and DCC-AI remains the same except for filling volume.

The formulation development studies were followed by a multivariate formulation robustness study. Data Analysis Procedure for the multivariate study is sufficiently described. The selected formulation has been shown to maintain the stability at the recommended storage conditions, since it was simulated that the worst-case formulation met the specification at end of the shelf life.

The pharmaceutical development has been systematically described and all the formulations and process changes over time has been summarized and described. In addition, comparability studies have been conducted between the FP versions over time. The pre-clinical and clinical studies have also been summarized and presented and they include all the FP versions mentioned above.

Visible particles (VPs) were observed in both dual chamber syringe (DCS) 30 mg and dual chamber cartridge (DCC) assembled with auto-injector subassemblies (AI) 30 mg from reconstituted product.

The applicant sufficiently investigated the formation of VPs, appropriately characterised VPs and included adequate quality control strategy, with VPs levels being monitored during FP release and stability testing.

The formulation development section describes and justifies the chosen formulation and is sufficiently comprehensive. The conclusion that the formulation is sufficiently robust to ensure that the FP is stable during manufacture, storage, transportation, and administration is supported.

## Manufacturing process development

The FP manufacturing process development has mainly focused on comparing the different FP processes from a quality perspective. The actual development of the manufacturing process with identification of critical process parameters and the entire development of the freeze-drying process have been presented. Information regarding the sterile filters used has been adequately presented. The suggested hold-times and maximum batch size have been defined.

Comparability studies were performed between the different versions of developed FP.

The comparability between the different FP versions have been adequately described and it is agreed to that the products are comparable.

## Container closure

Essential performance requirements (EPRs) are performance attributes responsible for the performance of the device constituent part at the point of use, and necessary for the delivery of the FP.

The front closure of the DCS comprises of a snap-on cap with luer lock adapter to be combined with a compatible needle. A compatible needle is included (co-packaged) with the finished product. The copackaged needle is equipped with a safety shield to prevent needle stick injuries.

<div style=\"page-break-after: always\"></div>

The primary packaging DCC is fully assembled in the DCC-AI. The DCC-AI is equipped with the Needle Isolation Technology NIT to prevent sharp injuries. The information in this section of the dossier is found acceptable. Notified Body Opinion Reports (NBOp) for both DCS and DCC-AI have been provided.

Extractable and leachables, compatibility of silicone oil and elemental impurity studies have been performed. The materials used are compliant to the standards applicable for their use.

The information provided is considered acceptable.

## 2.4.3.2.  Manufacture of the product and process controls

## Manufacturer(s)

An overview of all sites involved in the manufacture of the FP has been provided.

All  sites  involved  in  manufacture  and  quality  control  (QC)  testing  of  the  finished  product  operate  in accordance with EU GMP.

## Description of manufacturing process and process control

The Nemolizumab AS consists of a recombinant humanized monoclonal antibody based on a human immunoglobulin G2 (IgG2). Excipients are added to the AS to produce the formulated AS. The formulated AS bulk is sterile filtered and frozen. The FP formulation (before lyophilization) is prepared by dilution of the thawed pre-formulated AS with water for injection at a nominal concentration of 30 mg, followed by bioburden reduction and sterile filtration before filling.

The FP manufacturing process for DCS and DCC-AI are summarized in flow charts and detailed in a written narrative.

The process includes thawing of formulated bulk AS, dilution with water for injection and filtration of the bulk FP solution, in-line sterile filtration, aseptic filling of front chamber, lyophilization, semistoppering, bioburden reduction filtration of water for injection, in-line sterile filtration of water for injection, filling of rear chamber with water for injection, and stoppering. The filled DCS/DCC are stored at 2 - 8°C before further processing.

For both DCS and DCC solutions and for water for injection, the filters used consist of two 0.2 μm PVDF sterile filters where the first filter is used as a bioburden filter and the latter is used as an in-line sterile filter. The sterile filters are subjected to both pre-use and post-use filter integrity testing.

For DCS the following step involves, labelling, assembly of finger rest and plunger rod. Functional tests are presented and are included as IPC and in the release specification. The secondary packaging includes assembled syringe with co-packaged needles placed in a sealed blister and in a folding box.

For DCC the second step involves shipping and assembly of naked DCC and AI followed by labelling.  In the secondary packaging DCC-AI is placed in a folding box.

The suggested hold times for the manufacturing processes for both DCS and DCC are sufficiently supported with both physicochemical and microbiological data.

The manufacturing process and the in-process controls are acceptably described and deemed suitable for controlling and monitoring the manufacturing process.

## Control of critical steps

Process steps and related in-process controls (IPCs) /critical in-process controls (CIPCs)/ in-process tests (IPTs) have been adequately identified and presented. The development of the control strategy for the FP has been sufficiently described and process parameter ranges have been adequately defined and justified. Critical and non-critical steps were adequately identified and presented.

<div style=\"page-break-after: always\"></div>

## Process validation

The process validation covered production scale batches (PPQ) of DCS and DCC-AI. Overall, the results of IPCs/IPTs/CIPCs and process characterization samples met their predefined acceptance criteria, and all critical operational parameters were controlled within their predefined ranges. All release results met FP release specification, and all process validation batches demonstrated consistent quality profiles, demonstrating that the FP can be consistently manufactured within predefined processing parameters.

Batch data are provided for all commercial scale, Clinical and PPQ batches used for process validation and clinical studies for both DCS and DCC-AI. Stability studies have been performed on these batches and are currently ongoing at long-term (2-8 °C), accelerated and stressed conditions.

The assembly processes were validated using three PPQ batches for each presentation (DCS and DCCAI). For DCS the assembly process includes labelling, assembly of finger rest and plunger rod. Also, FP quality testing after assembly was performed and all the results met the acceptance criteria. This is found acceptable.

For DCC-AI the validation includes assembly operations of different batches of AI front subassembly, rear subassembly and DCC. Process performance was consistent between PPQ batches. FP quality testing after assembly was performed and all the results met the acceptance criteria. This is found acceptable.

Shipping qualification and simulation of transportation studies were performed and support the transportation during commercial distribution.

The information provided in this section of the dossier is sufficiently detailed and acceptable.

## 2.4.3.3.  Product specification

Specifications are set in accordance with ICH Q6B. All relevant characteristics of the FP are adequately covered.

The proposed acceptance criteria are at large found acceptable. The acceptance criteria for visible particles have also been acceptably justified. The functional tests for DCS and DCC-AI differ due to different mechanical systems. However, the functional tests have been adequately presented and the acceptance criteria have been adequately justified.

The principles of the analytical procedures for the non-compendial methods are sufficiently described. Some of the analytical procedures used for testing the FP are also used for testing the AS, and the differences in sample preparations are outlined in the dossier. Some of the methods cover both AS and FP. Typical chromatograms are enclosed where applicable and the System suitability criteria are specified and found adequate. Descriptions of the analytical procedures and the product-specific method validation are not provided for the pharmacopeial methods, and the reference to respective Ph. Eur. monograph is given, which is considered acceptable.

The analytical procedures were validated in accordance with ICH Q2 and the compendial methods have been verified according to the appropriate compendial chapters. This is acceptable.

The qualified testing sites for DCS and DCC-AI are listed in the dossier. And analytical methods transfer reports are attached. The provided data are sufficient.

Impurities

<div style=\"page-break-after: always\"></div>

Potential process- and product-related impurities are addressed in AS section. No new impurities have been identified in the FP compared to the ones already identified for the AS.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided it is accepted that no risk was identified on the possible presence of nitrosamine impurities in the active substance or the related finished product. Therefore, no additional control measures are deemed necessary.

The potential presence of elemental impurities in the finished product has been assessed on a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. No risk associated with elemental impurities was found.

## Batch analyses

Batch analyses data has been provided for DCS batches and for DCC-AI batches The batch analysis data complies  overall  with  the  limits  in  the  proposed  FP  release  specification  in  place  at  the  time  of manufacture and confirm process and product consistency.

In conclusion, the batch data provided confirms the consistency of the manufacturing process.

## Reference Standards or Materials

The reference standard used for finished product testing is the same as for the active substance.

## Container closure

The FP will be supplied in two presentations, as dual chamber syringe (DCS) and a dual chamber cartridge (DCC) assembled with autoinjector (AI)).

Sufficient information on quality control of the packaging components is presented (description of materials, specifications, CoAs, representative drawing). Sufficient description of non-compendial methods for testing primary packaging components of DCS and DCC-AI is given. Reference to relevant Ph. Eur. monographs is stated for compendial analytical methods.

The primary packaging components for both DCS and DCC-AI are compliant with appropriate Ph. Eur. monographs for primary containers and closures.

Sterilisation of the syringes and cartridges, stoppers and closures are described and integrity testing is verified during routine production and stability studies.

The combination of the dual chamber cartridge and the pen injector forms a single integral product and is not considered as a separate medical device. Results from a human factor usability study of the pen injector and the Instructions for use (IFU) is provided in the dossier.

The device parts of the DCS and DCC-AI have been reviewed for conformity with the relevant general requirements outlined in Chapter I of Annex I of Regulation (EU) 2017/745 by BSI Group. The reviewed Notified Body Opinion Reports have been attached in the dossier.

Suitability of the container closure systems to protect from microbial contamination during storage, transportation and use was demonstrated during long-term stability and shipping validation studies. Suitability was also confirmed by the results of extractables and leachables testing. Furthermore, it has

<div style=\"page-break-after: always\"></div>

also been demonstrated that the intended user population can safely and effectively operate the DCS and DCC-AI to deliver a complete dose, using the instructions for use.

## 2.4.3.4.  Stability of the product

## Stability summary and conclusion

The proposed shelf life for the finished product is 3 years for the DCS presentation and 30 months for the DCC-AI presentation when stored at the recommended storage condition at 2°C to 8°C.

## Stability data

An overview of produced lots is provided with lot number, site, container, date of manufacture and when stability was started, storage conditions and available data expressed in months. Stability protocols and results are presented.

The stability studies are performed in accordance with ICH Q5C, Stability Testing of Biotechnological / Biological Products and the same container closure system is used for the primary stability batches as well as for the supportive batch. Compatibility between the container closure system and the FP has been presented.

All batches are representative of the manufacturing process, are of the same formulation, and are packaged in the same container closure system as for marketing, with minor differences in terms of the FP presentation which are adequately justified.

All available stability results (for both DCS and DCC-AI batches) met the acceptance criteria for all tested CQAs in all tested conditions through the proposed shelf life. No trends or meaningful changes have been observed in long-term conditions, whereas in accelerated conditions a trend was observed but without any significant change. The results demonstrate consistent behaviour across the batches and manufacturing sites.

## DCS

Stability data has been provided at long-term, accelerated and stressed conditions. All stability results available for the PPQ batches and clinical batches stored at 2 °C to 8 °C complies with the proposed end-of-shelf-life/stability specification for the FP. For the DCS naked presentation, real-time (36 months) data are available. For DCS assembled in secondary packaging up to 24 months real time data are available for physico-chemical testing and bioassay and up to 36 months for functional testing.

At accelerated and stressed conditions the changes observed were not considered significant.

## Functionality studies-DCS

Stress stability studies were performed for secondary packaging process to investigate the degradation trend for functional test items. All results available for the functional testing complies with the proposed end-of-shelf-life/stability specification for FP.

## DCC-AI

Stability data has been provided at long-term and accelerated conditions. All stability results available for the PPQ batches and clinical batches stored at 2 °C to 8 °C complies with the proposed end-ofshelf-life/stability specification for FP. For the DCC cartridge alone real time data for up to 30 months are available. For DCC assembled in AI, real-time data of 18 months are available and up to 24 months for real time data for functional testing.

<div style=\"page-break-after: always\"></div>

At accelerated conditions no meaningful changes were observed.

## Functionality studies-DCC-AI

For functional test items, an accelerated aging approach is performed. This approach has been adequately described and is endorsed.

## Photostability studies

Light exposure stability evaluation study was performed during the manufacturing process development and the results indicated that the light exposure had impact on the protein stability during manufacturing. Stability of the FP when exposed to light was investigated for each presentation. ICH Q1B conditions were used. The results demonstrated that the AS is sensitive to light and that the secondary package provides adequate protection from light. The suggested recommendation 'store in original carton in order to protect from light' are in line with what is stated in the in section 6.4 in the SmPC.

Compatibility of the FP with the container closure systems (DCS or DCC) and in-use stability studies have been adequately demonstrated during development.

## Freeze thaw studies

To support the temperature allowance required for manufacturing, shipping, handling, temperature excursion (TE) study was performed for one DCS and two AI batches. The results met the acceptance criteria up to the 12-month time-point testing for both presentations.

## In-use stability

In-use stability has been studied to simulate in-use conditions and to verify the chemical and physical stability of the FP. From the compatibility and in-use stability results provided it is agreed that chemical and physical in-use stability of the reconstituted solution of FP has been demonstrated for 4 hours at room temperature. These in-use stability recommendations are in line with what is stated in the in section 6.3 in the SmPC.

## Post-approval stability protocol and stability commitment

Ongoing stability studies and post-approval stability studies will be performed according to the protocols described and the applicant commits to continue these studies through the proposed shelflife. Post-approval annual stability protocol is considered acceptable.

Overall, the proposed shelf life for the finished product of 3 years for the DCS presentation and 30 months for the DCC-AI presentation when stored at the recommended storage condition at 2°C to 8°C is considered acceptable.

## 2.4.3.5.  Adventitious agents

Raw materials of biological origin used in cell bank development and/or in establishing MCB and WCB have been described in sufficient detail. Certificates of Suitability to the Ph Eur TSE safety monograph have been provided.

Acceptable information on the origin of the animal-derived ingredients has been provided.

The description of the cell banking system including results from testing for bacteria, fungi, mycoplasma, and virus contamination has been provided.

The results show no bacteria, fungi, mycoplasma, or viral contamination in the MCB, WCB or PPC.

<div style=\"page-break-after: always\"></div>

The viral clearance studies have been performed in line with requirements in ICHQ5A. The studies have been performed using worst case settings for viral reduction.

Overall, the information provided for this section is acceptable.

## 2.4.4.  Discussion on chemical, pharmaceutical and biological aspects

Nemolizumab is a recombinant humanized monoclonal antibody based on a IgG2. The target protein nemolizumab is produced in CHO cells in a bioreactor operated in fed-batch mode. The purification process consists of a series of packed bed chromatographic and membrane filtration techniques, virus inactivation and virus filtration. The information on manufacture of the AS is found acceptable.

Differences between the different versions of the AS manufacturing process used during development were in general clearly described. Comparability between process versions was demonstrated, showing the AS manufactured with the commercial process version is representative of the AS used in the clinical trials.

During the assessment, a request was raised (MO) to further substantiate the NAS claim. The applicant adequately addressed this request, and the AS is considered as NAS.

The finished product Nemluvio is provided as a sterile lyophilized powder and solvent for solution for injection, for subcutaneous (SC) use. The chosen formulation of the FP was justified. Comparability between different versions of the FP manufacturing process was demonstrated and it was concluded that the two FP presentations (DCS and DCC-AI) are comparable.

Manufacturing, preparation and testing of cell banks are acceptably presented. Characterisation of nemolizumab was acceptably performed using an extensive panel of appropriate state-of-the art methods.

The FP manufacturing process is adequately described and validated. FP stability studies have been provided and support the proposed FP shelf-life. Adventitious agents control strategy is considered appropriate.

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5.  Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

In conclusion, the dossier presented by the applicant contains adequate information to support the approval of this application.

<div style=\"page-break-after: always\"></div>

## 2.5.  Non-clinical aspects

## 2.5.1.  Introduction

Nemolizumab is a humanized anti-human IL-31RA monoclonal antibody of IgG2 subclass with 2 heavy chains (445 amino acid residues each, glycosylated at 297-Asn) and 2 light chains (214 amino acid residues each) connected by 16 disulfide bonds. Several amino acid substitutions and deletions were introduced into the human IgG2 constant region to improve the properties of nemolizumab by reducing its structural heterogeneity. The proposed mechanism of action for nemolizumab in the treatment of atopic dermatitis (AD) and Prurigo nodularis (PN) includes binding to the IL-31 receptor A (IL-31RA, dimerized with the beta chain of the oncostatin M receptor [OSMR]) and inhibition of subsequent IL-31 binding and IL-31-induced signalling in the cell. Cell types that are proposed to be involved in the pathophysiology of AD and PN and express IL-31RA include immune cells (e.g., mononuclear phagocytes, granulocytes) and structural cells (e.g., neurons, fibroblasts, keratinocytes). The IL-31 pathway is indicated to be involved in processes proposed to represent hallmarks in the pathogenesis of AD and PN, i.e., skin abnormalities (altered epidermal differentiation and skin barrier disruption), pruritus (itching) and skin inflammation, and for PN, also skin fibrosis.

<!-- image -->

Akt=protein kinase B; ERK=extracellular signal-reguhted kinase; IL-31=interleukin-31; IL-31RA=interleukin-31 receptor A; JAK=Janus kinase; JNK=e-Jun N-terminal kinase, MAPK=mitogen-activated protein kinase; OSMR=oncostatin Mreceptor (specifically, OSMRβ subunit); STAT=sianal traneducer and activator of transuription

Figure 1: Mechanism of action

## 2.5.2.  Pharmacology

Studies conducted to characterize the nonclinical pharmacology of nemolizumab include in vitro studies of affinity to IL-31RA, inhibition of binding of IL-31, functional and selective inhibition of IL-31 activity via IL-31A receptors as well as cellular distribution of IL-31RA in human AD skin tissue. In addition, binding to various human and cynomolgus Fc receptors, binding to human C1q, induction of antibodydependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) has been evaluated. In vivo pharmacology studies investigating the itch-inhibiting effect of nemolizumab in a cynomolgus monkey model and effects of an anti-mouse IL-31RA surrogate antibody in a mite antigeninduced AD mouse model were also provided. Safety pharmacology parameters were monitored in the GLP toxicity studies performed in cynomolgus monkeys.

<div style=\"page-break-after: always\"></div>

## 2.5.2.1.  Primary pharmacodynamic studies

## In-vitro

Binding affinity of nemolizumab to human and cynomolgus monkey soluble IL-31RA determined by using a surface plasmon resonance (SPR) assay was high with dissociation constants (KD) 0.374 nmol/L (0.054 µg/mL) and 0.191 nmol/L, respectively. The binding affinity to human soluble IL-31RA in terms of KD indicates that enough amounts of nemolizumab will be available for binding to IL-31RA in AD or PN patients following SC administration of 30 mg every fourth week with a predicted mean steady state trough concentration (Ctrough) of 2.63 and 3.04 µg/mL, respectively. No binding of nemolizumab to the soluble form of mouse, rat or rabbit IL-31A was detected by SPR at conditions of maximum sensitivity.

Nemolizumab was shown to inhibit binding of human or cynomolgus monkey IL-31 to DG44 cells (dihydrofolate reductase deficient Chinese hamster ovary cells) engineered to express human or monkey IL-31RA (HNT15 and CNT13, respectively) on the cell surface in a concentration dependent manner. Furthermore, both human and cynomolgus monkey IL-31-dependent proliferation of Ba/F3 cells expressing the corresponding human and cynomolgus monkey IL-31RA and OSMR, was inhibited in a concentration dependent manner, demonstrating functional effect. Moreover, nemolizumab inhibited human IL-31 dependent signal transducer and activator of transcription 3 (STAT3) phosphorylation in human lung carcinoma cells (A549 cells) as well as IL-31-induced production of IL6, matrix metalloproteinases 1 (MMP-1) and 3 (MMP-3), and apoptosis in human epidermal keratinocytes (HaCaT cells) in a concentration-dependent manner. The IL-6- or OSM-dependent proliferation of TF-1 cells via activation of the related hgp130 receptor was however unaffected which indicates a selective inhibition of nemolizumab on IL-31 induced cell signalling via IL-31RA. Immunohistochemistry of skin tissue from AD patients indicated that IL-31RA is expressed in nerve endings but not in macrophages. Available study data do therefore support the hypothesis for involvement of IL-31RA and IL-31 signalling in neurons and keratinocytes in the pathophysiology of AD and PN.

Binding affinity or binding of nemolizumab, a modified IgG2 antibody, to human and cynomolgus neonatal Fc receptors (FcRn) and Fc-gamma receptors (FcγR) was determined by SPR. The binding affinity of nemolizumab to the soluble forms of human and cynomolgus monkey FcRn (KD-values of 2.1 to 2.5 and 2.1 to 2.2 µmol/L, respectively) was comparable to that of the IgG2 control antibody panitumumab (KD-values of 2.2 to 2.7 and 2.2 to 2.3 µmol/L, respectively), suggesting that the halflife of nemolizumab is unaffected by the modifications in the Fc region. The binding of nemolizumab to eight human types of FcγRs (Ia, IIa, IIb, IIIa and IIIb, including single nucleotide polymorphisms) and to human C1q (measured by ELISA), was either comparable to or weaker than that of the IgG2 control antibody panitumumab and weaker than that of the IgG1 control antibody rituximab, indicating a low potential for ADCC, CDC and cytokine release. This was confirmed in ADCC and CDC assays using human A549 cells overexpressing IL-31RA together with human peripheral blood mononuclear cells (PBMCs) and serum, respectively, as effector system.

## In-vivo

Based on presented data nemolizumab appears to cross react only to IL-31RA in cynomolgus monkeys. No monkey AD model exists, however, in vivo studies were conducted to assess the effect of nemolizumab in the cynomolgus monkey in an IL-31-induced itch model. Itching or pruritus is one of the symptoms in both AD and PD. Itching behaviors and scratching induced by intravenous administration of 1 µg/kg cynomolgus IL-31 the day after intravenous administration of 3 to 100 µg/kg nemolizumab, subcutaneous administration of 1 mg/kg nemolizumab or vehicle, was observed by

<div style=\"page-break-after: always\"></div>

watching a 2-hour video recording. In these studies, nemolizumab revealed a clear reduction of itching behavior after both intravenous and subcutaneous administration. When intravenously administrated the concentration achieving half-maximal inhibition (IC50) of nemolizumab for the inhibition of scratching was 462 ng/mL. This indicates that enough amounts of nemolizumab will be available for binding to IL-31RA in AD or PN patients following SC administration of 30 mg every fourth week with a predicted mean steady state Ctrough of 2.63 and 3.04 µg/mL, respectively. After 1 mg/kg subcutaneous administration (the clinical route) a clear itch-inhibiting effect occurred on day 28 as well as on day 56.

In addition, by using a mouse surrogate anti-IL31RA monoclonal antibody (BM095) the effect of blocking IL-31RA in a mite antigen-induced AD mouse model was evaluated. The results revealed a reduction of scratching movements and of the exacerbation of dermatitis symptoms (ear thickness, pinna dermatitis score) during intravenous administration of 20 mg/kg BM095 twice a week for a total of seven times.

## 2.5.2.2.  Secondary pharmacodynamic studies

No specific secondary pharmacodynamic studies were provided. Studies showing selectivity for IL-31RA and IL-31-induced signalling compared to the related human pg130 receptor and signalling via other cytokines in the same family, and low potential for ADCC or CDC activity in a human cell line engineered to overexpress human IL-31RA are provided. Furthermore, in vitro studies of nemolizumab in human blood did not indicate a high risk for cytokine release. In addition, in vitro tissue crossreactivity studies showed that the distribution pattern of IL-31RA was overall similar between human and cynomolgus monkey tissues matching those reported as sites of IL-31RA expression, and no toxicological target organs or tissues were identified in the repeated dose toxicity studies in cynomolgus monkey.

## 2.5.2.3.  Safety pharmacology programme

Safety pharmacology parameters were studied in GLP toxicity studies in cynomolgus monkeys, which is in line with ICH S6(R1). No significant effects on the cardiovascular system (ECG and/or blood pressure) were observed in the 3- and/or 6-month toxicity studies and no significant effects on the respiratory (respiratory rate) and central nervous systems (general behaviour and neurobehavioral function) were observed in the 6-month toxicity study during subcutaneous repeated administration of 1 to 25 mg/kg nemolizumab every second week with exposure levels providing acceptable margins to the clinical exposure. In the 6-month toxicity study the estimated margins to the clinical exposure were 43- to 49-fold. Similarly, there were no significant effects on cardiac function (ECG) in offspring following subcutaneous administration of 1 or 25 mg/kg nemolizumab every second week from PND 35 and for 26 weeks until PND 217 in the enhanced pre- and postnatal development (ePPND) study. Furthermore, the histopathological examination of organs and tissues related to the central nervous, respiratory, cardiovascular, and urinary systems revealed no abnormal findings, and the urinalysis readings conducted in the toxicity studies were within the normal range, indicating no abnormal effects on renal function either.

## 2.5.2.4.  Pharmacodynamic drug interactions

Not applicable

<div style=\"page-break-after: always\"></div>

## 2.5.3.  Pharmacokinetics

Nemolizumab showed cross-reactivity in cynomolgus monkey but not in mice, rats or rabbits. The nonclinical pharmacokinetics (PK) of nemolizumab was evaluated in the toxicological species cynomolgus monkeys after single subcutaneous (SC) and intravenous (IV) administration (PK) and after multiple SC dosing in the toxicological studies in cynomolgus monkeys (toxicokinetics, TK). In addition, distribution of nemolizumab in cynomolgus monkeys after single SC administrations was evaluated by quantitative whole body autoradioluminography (QWBA) and placental transport as well as excretion into milk was investigated in the ePPND study conducted in cynomolgus monkeys. TK and PK parameters of nemolizumab were calculated based on plasma concentration versus time data excluding time points with detected ADAs and summarized without animals with ADAs.

## Analytical methods

The method used for analyses of nemolizumab plasma concentrations in non-clinical GLP studies was a validated enzyme-linked immunosorbent assay (ELISA) using human IL-31 receptor A as the capture reagent, rabbit anti-nemolizumab idiotyp antibody that recognizes the complementarity-determining region (CDR) in nemolizumab as detection antibody, and alkaline phosphatase-conjugated goat antirabbit IgG antibody for spectrophotometrically quantification of immobilised nemolizumab by measurement of fluorescence intensity from 4-Methylumbelliferyl phosphate. It was validated based on GLP principles and confirmed to meet relevant acceptance criteria. The analytical procedure with electrochemiluminescence immunoassay (ECLIA) and ELISA for evaluation of anti-drug antibody (ADA) production (including neutralizing capacity) in cynomolgus monkey plasma is considered adequate. It uses purified anti-nemolizumab idiotyp antibody that recognizes the CDR in nemolizumab as positive control and includes a screening test, a titration test, an inhibition test and a confirmation test.

## Plasma PK

## Single dose

The plasma PK of nemolizumab following IV single dose administration of 0.04 to 1 mg/kg to male cynomolgus monkeys (n=3) was non-linear with a higher than dose proportional increase in plasma exposure in terms of AUC0-inf between the 2 lowest doses, 0.04 and 0.2 mg/kg, and a dose linear increase between 0.2 and 1.0 mg/kg. The non-linear increase in AUC0-inf between 0.04 and 0.2 mg/kg reflects the decrease in mean total body clearance (CLtotal) from 0.411 to 0.147 mL/h/kg and resulting increase in mean elimination half-life (t½) from 3.33 to 13.6 days, which is possibly due to target mediated drug elimination and saturation of binding to the target (IL-31RA). Mean CLtotal and mean t½ at 1.0 mg/kg was 0.147 mL/h/kg and 14.9 days, respectively. The volume of distribution at steady state (Vss) ranged from 54.4 mL/kg at 0.04 mg/kg to 67.6-71.2 mL/kg at 0.2-1 mg/kg, which is close to the cynomolgus monkey plasma volume (45 mL/kg).

Following SC administration of 0.04 to 1 mg/kg to male cynomolgus monkeys (n=3), absorption of nemolizumab was slow, mean Tmax ranged from 3.33 to 4.33 days. Elimination was also slow with a mean t1/2 of 3.14 days at 0.04 mg/kg, which increased to 11.5 and 12.8 days at 0.2 and 1 mg/kg, respectively. Whereas the increase in Cmax was approximately dose proportional over the studied dose range the AUC0-inf showed greater than dose-proportional increase between 0.04 and 0.2 mg/kg and a dose linear increase between 0.2 and 1.0 mg/kg as for IV administration. Similarly, the non-linear increase in AUC0-inf between 0.04 and 0.2 mg/kg resulted from a decreased elimination as reflected by the increase in mean t½ from 3.14 to 11.5 days. Absolute bioavailability (F) calculated by comparison with AUCinf following IV administration was 72.1, 71.9 and 74.6 % following doses of 0.04, 0.2 and 1 mg/kg, respectively, indicating good absorption from SC tissues.

## Repeated dose

<div style=\"page-break-after: always\"></div>

Toxicokinetics of nemolizumab were determined in male and female cynomolgus monkeys (n=4) following repeated SC administration of 1 to 25 mg/kg once every second week for 3 and 6 months.

There were no obvious changes in the Tmax with repeated dosing and the Cmax and AUC0-14d after the 1 st , 4 th  and 6 th  dose in the 3-month study and after the 1 st , 6 th , 11 th  and 13 th  dose in the 6-month study increased with increasing dose in an approximately dose linear manner.

Based on mean Cmax and AUC0-14d, steady state appears to have been reached after the 6 th  dose (i.e., at 10-12 weeks) in both the 3- and 6-month studies, which is in line with the elimination t1/2 of approximately 13 days.

Due to the elimination t1/2 of approximately 13 days dosing once every second week is not expected to result in any important accumulation during treatment. The estimated mean accumulation factors (AUC0-14d ratio relative to 1st dosing) were 1.3 to 2.7-fold at steady state in the 3- and 6-month studies.

The mean AUC0-inf in males following single dose treatment was comparable to the AUC0-14d at steady state in the 3- and 6-month studies indicating time-independent PK.

No obvious sex differences in PK, i.e., 2-fold and above, were found. Plasma exposure in terms of mean Cmax and AUC0-14d was slightly lower in females than in males (0.7-to 0.9-fold and 0.6- to 0.9fold, respectively, in the 3-month study and 0.7-to 1.0-fold and 0.7- to 1.0-fold, respectively, in the 6month study).

## Distribution

## Quantitative whole-body autoradioluminography

Concentrations of nemolizumab-derived radioactivity in plasma and in blood were evaluated together with 22 tissues in 5 male cynomolgus monkeys at 1, 2, 7, 14 and 28 days following a single SC dose of 1.0 mg/kg  125 I-nemolizumab (about 5 MBq/kg) using a γ-counter and QWBA.

The highest radioactivity level observed in the thyroid (at all time points) and the relatively high radioactivity observed in the gastrointestinal tract (especially the stomach) were considered to represent free iodine, released and temporarily accumulated in the thyroid. Otherwise, high radioactivity levels were generally found in tissues with high blood flow, such as the lung, liver, kidney, spleen and heart, whereas the distribution to the brain, spinal cord and eyeballs was low. Tissues expressing the antigen of nemolizumab, i.e., the IL-31 receptor, or IL-31 (thymus, dorsal root ganglion, testis and bladder) had moderate distribution of radioactivity. The radioactivity concentrations in all tissues except the thyroid reached maximum levels on 1 or 2 days after administration and were lower than that in plasma at all time points. Tissue to plasma ratios generally remains rather constant over the 28-day period.

## Placental transport and excretion into milk

Placental transport and excretion of nemolizumab into milk were investigated in the ePPND study in cynomolgus monkeys. Following SC administration of 1 or 25 mg/kg nemolizumab to pregnant animals (n=16) every second week from GD 20 to GD 174 or earlier, and to the offspring every second week from PND 35 and for 26 weeks until PND 217, concentrations in plasma of dams and offspring and in milk were measured on PNDs/LDs 7, 21 35, 63 and 91. Mean plasma concentration in offspring on PND 7 (7.68 µg/mL) was almost comparable to that in dams measured on the same day (8.24 µg/mL). Mean concentrations in milk on the same day were very low (0.4% of the corresponding maternal plasma levels).

<div style=\"page-break-after: always\"></div>

## 2.5.4.  Toxicology

The toxicity profile of nemolizumab has been evaluated in an S6-compliant programme with Cynomolgus monkey as animal species used for the studies. No nemolizumab cross-reactivity was observed with mouse, rat or rabbit IL-31RA in Biacore studies, but nemolizumab was shown to bind to monkey soluble IL-31RA with a similar affinity as to human IL-31RA. This similarity was also seen in various bioactivity assays, why the Cynomolgus monkey was selected as a relevant species for the toxicology studies. Monkey is a suitable species for the nemolizumab evaluation based on pharmacology and since it demonstrates a similar tissue cross-reactivity profile as for human tissues.

The pivotal toxicology studies were performed with SC injection as this is the route of administration that will be used clinically. Evaluation of general toxicity was performed by biweekly administration of nemolizumab to cynomolgus monkeys for up to 26 weeks by the SC route (up to 25mg/kg). These studies also included evaluation of reproductive organs as well as safety pharmacology evaluations and cytokine analyses.

No genotoxicity studies have been performed in the programme since nemolizumab is an IgG2 subclass antibody and is therefore unlikely to directly interact with DNA or other chromosomal components. Further, no standard carcinogenicity studies have been performed, as standard carcinogenicity assays are considered inappropriate for mAb products. However, the applicant has submitted a product-specific Carcinogenicity Assessment Document (CAD) performed in accordance with the ICH S6 (R1) guideline, addressing the potential carcinogenic risk associated with nemolizumab treatment.

Evaluation of the effects on pre- and postnatal development was performed in an ePPND study in cynomolgus monkey which also included direct exposure of juvenile animals to nemolizumab.

## 2.5.4.1.  Single dose toxicity

No single dose studies have been performed with nemolizumab, and none are considered needed. However, in line with the ICH M3 (R2) guidance, evaluations related to the acute toxicity were performed as part of the 13-week RDT study. No relevant (acute) toxicities were identified in Cynomolgus monkey after a single dose up to 25mg/kg.

## 2.5.4.2.  Repeat dose toxicity

Two RDT studies have been performed, but no adverse findings were identified, why no organ-specific list of toxicities have been included

## 2.5.4.3.  Genotoxicity

The genotoxicity studies routinely conducted for pharmaceuticals are not applicable to antibody pharmaceuticals and therefore are not needed. It is not expected that nemolizumab would interact directly with DNA or other chromosomal material.

## 2.5.4.4.  Carcinogenicity

The applicant has performed and submitted a weight of evidence (WoE) evaluation of carcinogenic risks associated with nemolizumab treatment. Literature studies do not support that blockade of IL31RA is associated with hormonal perturbation which could trigger a carcinogenic response, and there are no findings in the performed toxicity program with nemolizumab which would suggest a

<div style=\"page-break-after: always\"></div>

carcinogenic potential of the substance. There are studies (both in vitro and in vivo) in the publication domain suggesting both antitumor and tumor promoting effects in breast cancer models of IL-31 blockade, but the clinical relevance of these studies is unclear.

## 2.5.4.5.  Reproductive and developmental toxicity

No Fertility and Early Embryonic Development (FEED) study has been performed. However, potential effects on male and female reproductive organs have been evaluated in the RDT studies in Cynomolgus monkey (3-7 years old at study start). Additionally, the applicant requested an expert review from another animal testing facility (Covance, Germany) on the adequacy of 26-week repeat-dose toxicity study to address male fertility concerns due to the reports on the presence of nemolizumab target mRNA (IL-31RA) in the testis of cynomolgous monkey and human, raising the potential concerns for effects on spermatogenesis. Since the duration of spermatogenesis in cynomolgous monkeys is approximately six weeks, the study was assessed to be appropriate since it covered at least the fourfold time period. No nemolizumab-related effects were identified in male or female reproduction organs or in other endpoints related to male or female fertility.

No Embryo-Fetal Developmental toxicity (EFD) study has been performed. While the ePPND study, where Non-Human Primates (NHPs) are generally selected by ultrasound scanning at GD 18-20 to start on study, gives no information regarding effects of exposure during implantation and earliest stages of embryogenesis, an ePPND study can be conducted instead of an EFD study in accordance with ICH S5.

The applicant has submitted an ePPND study in Cynomolgus monkey where nemolizumab was administered SC at dose levels of 0 (vehicle control), 1, and 25 mg/kg Q2W to from the start of organogenesis (GD20) to delivery, with a total of 9 to 12 treatments. In addition, nemolizumab was also administered directly to the postnatal offspring (using the same dose as the respective dam) from PND35 and for 26 weeks until PND217 (14 doses in total). All dams were allowed to deliver naturally and nurse the offspring until Day 220, and the offspring was necropsied on PND220.

No dams died during the study and no nemolizumab-related effects were identified regarding body weight, food consumption, hematology or blood chemistry during gestation or lactation.  Cmax and AUC0-14d of nemolizumab increased almost dose-proportionally in dams during their treatment period. After parturition, plasma concentrations decreased but was still detected until between LD 147 in the 25-mg/kg group. 4 of 16 dams (1-mg/kg group) and 3/16 dams (25-mg/kg group) were positive for ADA, with neutralizing effect in 1 mg/kg dams.

Concentration in milk corresponded to 0.4% of plasma levels in both groups but was below the LLOQ &lt;8.00 ng/mL) in all 1mg/kg dams from LD 35, but at 25mg/kg quantifiable levels were present on LD91.  On PND7, nemolizumab concentrations in plasma in offspring was comparable to the dams. After the start of dosing (PND35), the plasma nemolizumab concentrations in offspring increased with dosing, was generally higher than in dams and almost reached SS on PND91.

However, 2/14 offspring died on PNDs 1 and 3 and an additional offspring died on PND 14 giving a total of 3 early deaths in the 25mg/kg dose group. These figures are outside the historical control data. According to the applicant, histopathology revealed changes related to malnutrition and subsequent stress, and these changes might have been associated with the cause of death or deterioration of condition. Overall, the applicant considered that the increased incidence of offspring death during the early postnatal period in the 25 mg/kg/2-week group was unrelated to nemolizumab treatment (see further elaboration in the discussion).

<div style=\"page-break-after: always\"></div>

Full supernumerary rib and short supernumerary rib were observed in 1-2 nemolizumab-exposed offspring in control and 25mg/kg, but this was considered incidental. Absolute ovary and testes weights were reduced on PND220 but without microscopic correlation. Thus, the treatment was overall well tolerated. Therefore, the NOAEL was set at 25mg/kg/day (corresponding to an AUC0-14d of 55800 µg·h/mL, Cmax 219 µg/mL).

## Juvenile toxicity

An ePPND study has been performed in Cynomolgus monkey which included direct exposure of juvenile monkeys from PND35. There were no adverse toxicities identified in the study supporting a developmental NOAEL of 25mg/kg/day. The age of the monkeys at study start was ~1 month, which corresponds to a paediatric patient from birth.

## 2.5.4.6.  Toxicokinetic data

TK data have been generated in three pivotal in vivo studies in Cynomolgus monkey. The studies have used SC exposure, which is also the intended clinical administration route. ADA developed in several animals in the studies due to the humanized nature of the nemolizumab which is recognized as a foreign protein in cynomolgus monkeys. In some animals, the ADA had a neutralizing effect, why the TK data have been presented both including and excluding these animals. While exposure was clearly affected in some animals, the overall impression is that the presence of ADA did not impact the reliability of the study and the conclusions regarding nemolizumab toxicity.

Overall, the data show that Cmax and AUC0-14d increased dose-proportionally with repeated dosing in both sexes, and the plasma concentrations for the ADA-positive animals were lower than those for the ADA-negative animals. Further TK/PK data are available in the PK section

The indications intended for Nemluvio are Atopic dermatitis (AD) and Prurigo nodularis (PN). The applicant has provided with exposure margin calculations to clinical exposure based on the popPK model in the Phase 3 pivotal study conducted in patients with PN (Study SPR.203065) and the Phase 2b study (SPR.114322) in AD patients exposed to a 60 mg loading dose of nemolizumab (dose used in Phase 3). ( Table 1 ).

Table 1: TK data and margins to clinical exposure for the pivotal studies

| Species and type of study [Study number]   | Sex   | NOAEL (mg/kg)   | Animal exposure measured during the first 14 days (reported) 1)   | Animal exposure measured during the first 14 days (reported) 1)   | Corresponding animal exposure during the first 28 days 2) 3)   | Corresponding animal exposure during the first 28 days 2) 3)   | Exposure in ADpatients exposed to 60 mg loading dose in study SPR.114322 4)   | Exposure in ADpatients exposed to 60 mg loading dose in study SPR.114322 4)   | Safety margin (ratio animal /human exposure)   | Safety margin (ratio animal /human exposure)   | Exposure in PNpatients exposed to 60 mg loading dose in study SPR.203065 5)   | Exposure in PNpatients exposed to 60 mg loading dose in study SPR.203065 5)   | Safety margin (ratio animal /human exposure)   | Safety margin (ratio animal /human exposure)   |
|--------------------------------------------|-------|-----------------|-------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                                            |       |                 | AUC 0-14d (µg·h/mL)                                               | C max (µg/mL)                                                     | AUC 0-28d (µg·day/mL)                                          | C max (µg/mL)                                                  | AUC 0-28d (µg·day/mL)                                                         | C max (µg/mL)                                                                 | AUC                                            | C max                                          | AUC 0-28d (µg·day/mL)                                                         | C max (µg/mL)                                                                 | AUC                                            | C max                                          |
| Monkey 6- monthSC toxicity study           | M     | 25              | 51400                                                             | 187                                                               | 4283                                                           | 187                                                            | 100.27                                                                        | 5.46                                                                          | 43                                             | 34                                             | 136.66                                                                        | 6.74                                                                          | 31                                             | 28                                             |
| [TOX12- 0076]                              | F     | 25              | 58600                                                             | 230                                                               | 4883                                                           | 230                                                            | 100.27                                                                        | 5.46                                                                          | 49                                             | 42                                             | 136.66                                                                        | 6.74                                                                          | 36                                             | 34                                             |
| Monkey ePPND study [TOX14- 0140]           | F     | 25              | 55800                                                             | 219                                                               | 4650                                                           | 219                                                            | 100.27                                                                        | 5.46                                                                          | 46                                             | 40                                             | 136.66                                                                        | 6.74                                                                          | 34                                             | 32                                             |

1) Mean AUC0-14d and Cmax measured in male and female cynomolgus monkeys exposed to 25 mg/kg of nemolizumab

- 2) Mean AUC extrapolated to 28 days AUC0-28d
- 3) Mean AUC0-28d at steady state (after 13th dose) was 7233 μg·day/mL in females and 8416 μg·day/mL in males
- 4) Mean AUC0-28d and Cmax obtained with NCA in Phase 2b study (SPR.114322) in AD patients exposed to a 60 mg

<div style=\"page-break-after: always\"></div>

loading dose of nemolizumab (dose used in Phase 3)

5) Mean AUC0-28d and Cmax calculated from the popPK model in the Phase 3 pivotal study conducted in patients with PN

(Study SPR.203065).

## 2.5.4.7.  Local Tolerance

The applicant produced a local tolerance study in Kbl:NZW rabbits to support the formulation used during the Phase I trial. The study did not identify any irritant effects of nemolizumab following subcutaneous injection at a dose volume of 0.9 mL/site. Subsequent improvements of the formulation included addition of 250 mmol/L sucrose, and this new formulation was evaluated in the chronic RDT study in Cynomolgus monkey to support Phase 2a studies.

## 2.5.4.8.  Other toxicity studies

## TCR

A tissue cross-reactivity study was performed to evaluate the potential cross-reactivity of nemolizumab with cryosections of normal human and cynomolgus monkey tissues. Overall, the staining pattern produced with nemolizumab was consistent with what is known regarding human IL-31 receptor expression in literature, and the staining pattern was similar in human and Cynomolgus monkey tissue.

## In vitro Risk Estimation of Cytokine Release Syndrome

An in vitro non-GLP study was conducted to estimate the risk of cytokine release syndrome at first-inhuman administration of nemolizumab by measuring IL-10, IL-8 and TNF levels in whole blood incubated with nemolizumab for 24 hours. An increase in TNF or IL-6 concentration was observed in 2 samples after nemolizumab exposure (1 sample for each of the cytokines), but the levels were considerably lower than the levels reached with the positive controls (alemtuzumab and TGN1412a (an identical-sequence antibody made in-house)).

## 2.5.5.  Ecotoxicity/environmental risk assessment

The applicant has provided a justification for not performing ERA studies. The drug product is composed of naturally occurring amino acids, why nemolizumab is not expected to pose a risk to the environment.

## 2.5.6.  Discussion on non-clinical aspects

The non-clinical pharmacological profile of nemolizumab has been evaluated in accordance with ICH S6 (R1) and is overall considered adequately characterized. The in vitro studies provided show high affinity of nemolizumab to human and cynomolgus IL-31RA, inhibition of IL-31 binding to IL-31RA and inhibition of IL-31 dependent function and signaling via IL-31RA, which support the molecular aspects of the proposed mechanism of action at a cellular level. Furthermore, in vivo data from a cynomolgus monkey itch model provide support for effect of nemolizumab on IL-31-induced itching. Reduction of scratching and exacerbation of dermatitis symptoms by a mouse surrogate anti-IL31RA antibody in a mite antigen-induced mouse AD model provides further support for that blocking of IL-31RA could ameliorate itching and inflammation. The mechanism of action of nemolizumab is adequately described in SmPC section 5.1.

<div style=\"page-break-after: always\"></div>

No affinity of nemolizumab to mouse, rat or rabbit IL-31RA was detected. Of the species investigated for binding to IL-31RA, cynomolgus monkey was thus the only pharmacologically relevant species for use in toxicity studies. The affinity to the human version was not higher than to the version in cynomolgus monkey, i.e., estimated margins between animal and clinical exposure do not need to be adjusted for differences in potency.

No specific secondary pharmacodynamic studies were conducted, which is in line with ICH S6(R1) and acceptable. The data provided, which indicated selectivity for IL-31RA and IL-31-induced signalling, low potential for ADCC, CDC and cytokine release, and did not identify any toxicological target organs or tissues in the cynomolgus monkey toxicity studies, are overall considered sufficient for nonclinical evaluation of safety associated with potential secondary pharmacodynamic effects.

The provided PK data is in line with ICH S6(R1) and the evaluation of the PK profile of nemolizumab in cynomolgus monkey (the only pharmacologically relevant species) is overall considered adequate. The validation of the ELISA method used for TK analyses of nemolizumab in the pivotal toxicology studies in cynomolgus monkeys was performed based on GLP principles and relevant acceptance criteria were met.

Investigations of plasma PK following IV and SC administration of nemolizumab and distribution following SC administration of radiolabelled nemolizumab showed slow absorption from SC tissue, a limited distribution to tissues with high blood flow (e.g., the lung, liver, kidney, spleen and heart, as reflected by the volume of distribution), no specific tissues with accumulation and a slow parallel elimination from tissues and plasma. Due to confounding factors such as in vivo degradation, release of label from the protein following degradation, and potential reincorporation of radiolabelled amino acids into the endogenous protein pool, distribution studies with radiolabelled biologics should generally be interpreted with caution. Milk concentrations and plasma concentrations in dams and offspring following SC administration to dams during pregnancy and to offspring from PND35 showed low excretion of nemolizumab into milk and transplacental transport during pregnancy.

The toxicity profile of nemolizumab has been evaluated in an S6-compliant programme with Cynomolgus monkey as animal species used for the studies. No nemolizumab cross-reactivity was observed with mouse, rat or rabbit IL-31RA in Biacore studies, but nemolizumab was shown to bind to monkey soluble IL-31RA with a similar affinity as to human IL-31RA. This similarity was also seen in various bioactivity assays, and for this reason the Cynomolgus monkey was selected as a relevant species for the toxicology studies. It is agreed that monkey is a suitable species for the nemolizumab evaluation based on pharmacology since it demonstrates a similar tissue cross-reactivity profile as for human tissues.

The pivotal toxicology studies were performed with SC injection as this is the route of administration that will be used clinically. Evaluation of general toxicity was performed by biweekly administration of nemolizumab to cynomolgus monkeys for up to 26 weeks by the SC route (up to 2mg/kg). These studies also included evaluation of reproductive organs as well as safety pharmacology evaluations and cytokine analyses. The applicant performed a 3-month RTD study in Cynomolgus monkey with SC nemolizumab exposure Q2W at doses of 1, 5 and 25mg/kg. There were no unscheduled deaths, and the treatment was overall well tolerated. 26 weeks of nemolizumab treatment (with a 17-week recovery period) using SC dosing was well tolerated in Cynomolgus monkey, and no mortalities or adverse toxicities were noted. As in the shorter 3-month study, selected significant hematology and serum chemistry effects were identified on different time-points. These findings were without correlating macro- or microscopic findings and are not considered adverse.

ADA were detected in both RTD studies, and in some animals neutralizing effects were evident. As expected, there was a good correlation between the development of ADA and loss of exposure to nemolizumab.

<div style=\"page-break-after: always\"></div>

No genotoxicity studies have been performed in the programme since nemolizumab is an IgG2 subclass antibody and is therefore unlikely to directly interact with DNA or other chromosomal components. Further, no standard carcinogenicity studies have been performed, as standard carcinogenicity assays are considered inappropriate for mAb products. However, the applicant has submitted a product-specific Carcinogenicity Assessment Document (CAD) performed in accordance with the ICH S6 (R1) guideline, addressing the potential carcinogenic risk associated with nemolizumab treatment. The overarching conclusion is that based on current knowledge and as presented in the CAD document, there is limited support of a carcinogenic effect associated with blockade of IL-31R

Evaluation of the effects on pre- and postnatal development was performed in an ePPND study in cynomolgus monkey which also included direct exposure (PND35-217) of juvenile animals to nemolizumab. No clear differences in gestation lengths were noted between groups. First trimester abortions were within historical control data in all groups, and no abortions occurred in 2 nd  or 3 rd trimester. Stillbirth occurred in 3/14 (21.4%) dams only in the 1mg/kg group (within historical control data). In total, live offspring was similar (13 (5 males and 8 females), 11 (6 males and 5 females), and 14 (4 males and 10 females) at 0, 1 and 25mg/kg respectively.

Concentration in milk corresponded to 0.4% of plasma levels in both treatment groups and decreased steadily from day 7 to day 91 LD, being below the LLOQ &lt;8.00 ng/mL) in milk of all 1mg/kg dams from LD 35. At 25mg/kg, low (but quantifiable levels were still present in the milk of a few dams at LD91.  In the pups, nemolizumab concentrations in plasma in offspring was comparable to the dams at PND7. The plasma concentration then gradually decreased in the pups until the start of direct dosing on PND 35, indicating that exposure in pups up to this time-points were mainly a consequence of placental transfer. After the start of dosing of the pups (PND35), the plasma nemolizumab concentrations in offspring increased with dosing, was generally higher than in dams and almost reached steady state on PND91.

2/14 offspring died on PNDs 1 and 3 and an additional offspring died on PND 14 giving a total of 3 early deaths in the 25mg/kg dose group. These figures are outside the historical control data. Given that fetal mAb exposure increases during the third trimester and is further increased via the first milk (colostrum), the deaths occurred at a time of high nemolizumab exposure. No abnormalities were observed in any examination including nursing behaviour in their dam, and no abnormalities in clinical signs were observed in the offspring that died before confirmation of their death, suggesting that the deaths may be due to acute effects. Therefore, the applicant was asked further to discuss the increased incidence of offspring death during the early postnatal period in the 25mg/kg group including potential mechanisms of the deaths, the relation to IL-31 signalling and the clinical relevance.

Regarding the increased deaths from PND 0-7, the applicant correctly notes that there is generally a significant infant loss at term and shortly thereafter in NHPs (DOI: 10.1002/bdrb.20234, https://doi.org/10.1002/ajp.1350020202) but also that the incidence seen in the 25 mg/kg group (14.3%) is higher compared to controls (7.1%) and historical control data from the laboratory (2.6%, range 0-7.7%).

The study was performed in 2016 and the historical control data dates from 2015. Based on the most recent historical control data from the test facility (SNBL, Kagoshima, Japan) the incidence is now 6.0% with a range of 0.0 to 30.0% and that is why the applicant suggests that the incidence in the study is within the current control range, and that other laboratories have similar historical control incidences (tabulated data). However, given that historical control data are constantly evolving due to e.g. genetic drift of the animals and environmental factors, it is generally held that the most appropriate historical control data are collected within 5 years of the study. This is to ensure that the conditions under which the historical control data were collected are consistent with those of the

<div style=\"page-break-after: always\"></div>

current study to avoid introducing bias. Therefore, while the new control data is informative, the 2015 data are considered more relevant as background data for the present study.

One additional death occurred in the 25mg/kg group, at PND14 with an incidence of 8.3% which is higher than historical control data (PND8-30: mean 1.6%, range 0.0 to 4.6%). The new historical control data presented is lower for this laboratory, and the data from the other laboratories are even lower. However, given the low number of subjects in each group (n= 14 in the 25mg/kg dose-group), a single dead animal is a large fraction of the total number of animals.

There are no clear reasons (i.e. 'mechanisms') identified for the death of animal 10212N (died on PND 1) whereas malnutrition is proposed for animal 10202N (PND3) (and substantiated by lack of milk in stomach and histopathological signs). Malnutrition and stress are also proposed as causes of death for animal 0203N (PND 14) based on histopathology. While probable explanations based on the presented data, it is difficult to conclude on causes.

In any case, there are no clear IL-31 associated effects, and based on presented background data there are no developmental effects anticipated from the IL-31RA treatment. No obvious phenotype is seen in IL-31RA - / -  mice (https://doi.org/10.1016/j.ejcb.2011.07.006). While it is challenging to use knock-out animals to predict the functional consequences of reducing protein expression due to i.e. compensatory mechanisms and developmental adaptions which can complicate the interpretations, all other live offspring in the present study developed normally supporting that the findings may be incidental. This conclusion is also supported in an Expert Review which was included in the initial application.

Based on the human clinical data, 10 subjects with AD (9 nemolizumab, 1 placebo) became pregnant during participation in the clinical studies (see clinical AR). All subjects were prematurely discontinued study drug treatment as per the study protocol. The spontaneous abortions (18%) were consistent with the range of expected spontaneous abortions in the general population. While the data are very limited and the outcome of 4 pregnancies remain unknown, there are no findings presented supporting nemolizumab-induced developmental effects.

The collective impression is that while the incidence of deaths in the 25mg/kg/day group (identified at 43x and 34x clinical exposures for AUC in AD and PN patients respectively) are higher than both the current control and the historical control data, the absolute number of dead animals is low and there is no obvious mechanism identified for the increased deaths except possibly malnutrition and stress. All surviving animals in the study developed normally, and malnutrition and stress (induced by e.g. maternal neglect) would not be considered a translationally relevant clinical risk. Further, there is no plausible relation to IL-31 exposure identified. Therefore, the overall conclusion is that the increased deaths identified in the study are not likely related to IL-31 exposure, but the risk cannot be excluded. This is properly reflected in the current SmPC section 4.6. and 5.3. As a precautionary measure, it is preferable to avoid the use of nemolizumab during pregnancy. No nemolizumab-related findings were identified in the offspring.  Full supernumerary rib and short supernumerary rib were observed in 1-2 nemolizumab-exposed offspring in control and 25mg/kg, but this was considered incidental. Absolute ovary and testes weights were reduced on PND220 but without microscopic correlation.

Regarding breast-feeding, it is not known whether or to what extent nemolizumab is excreted in human milk. In the ePPND study, the concentration of nemolizumab in breast milk was considered low (0.4% of plasma levels). It can therefore be assumed that the concentration of nemolizumab in human breast milk is low. Antibodies are degraded by the acidity in the stomach and further proteolytic breakdown during the passage of the GI tract. Therefore, with the exclusion of the first milk which may contain higher concentrations, it should be safe to breast-feed during treatment with neolizumab. This is properly reflected in section 4.6. breastfeeding of the SmPC.

<div style=\"page-break-after: always\"></div>

A juvenile part of the ePPND study included direct exposure of juvenile monkeys from PND35. There were no adverse toxicities identified in the study supporting a developmental NOAEL of 25mg/kg/day. The age of the monkeys at study start was ~1 month, which corresponds to a pediatric patient from birth.

The toxicokinetics of nemolizumab was evaluated in both general toxicity studies and in the ePPND study. Nemolizumab exposure was generally similar in males and females and overall increased proportionally with dose. Several animals in the studies developed Anti-drug antibodies (ADA) and some animals showed neutralization activity. These animals often showed reduced exposure to nemolizumab, why TK information consistently included calculations both including and excluding ADApositive animals. Despite the ADA positive animals, the validity of the studies was retained.

The applicant has provided a justification for not performing ERA studies which is accepted.   The active substance is a natural substance, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, nemolizumab is not expected to pose a risk to the environment.

The overall impression is that nemolizumab was well tolerated in Cynomolgus monkey at doses up to 25 mg/kg/2W. The toxicities identified were few and overall non-adverse. However, increased offspring deaths were identified in the ePPND study which should receive further attention, as reflected in section 4.6. pregnancy

## 2.5.7.  Conclusion on the non-clinical aspects

Pharmacology studies provided adequate evidence that nemolizumab binds to human and monkey IL31RA, inhibits the binding of IL-31 to IL-31RA and inhibits IL-31 signalling via IL-31RA. Nemolizumab inhibited monkey itching behaviour induced by systemic administration of IL-31. Mouse IL-31RA neutralizing antibody inhibited the total number of scratching movements and exacerbation of dermatitis symptoms in a mite antigen-induced AD mouse model but had no effect on inflammatory components of the disease (i.e. the extent of lesion, eosinophil infiltration, and oedema).

Pharmacokinetic properties of nemolizumab are sufficiently described and do not differentiate from other monoclonal antibodies.

In vitro and in vivo toxicity studies conducted with nemolizumab identified no unexpected toxicities or off-target findings, with the exception of higher postnatal loss in ePPND study in dams treated with high dose of 25 kg/mg/q2w. Although there is low probability that this finding is treatment-related and the clinical relevance is unknown, due to the magnitude of effect, lack of possibility to determine dosedependency and the absence of literature data on the possible IL-31/IL-31RA role in pregnancy/early postnatal period, the risk cannot be excluded. As a precautionary measure, it is preferable to avoid the use of nemolizumab during pregnancy.

Overall, the applicant provided a comprehensive evaluation of pharmacological, pharmacokinetic and toxicological properties of nemolizumab which supports the intended clinical use.

## 2.6.  Clinical aspects

## 2.6.1.  Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

<div style=\"page-break-after: always\"></div>

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

##  Tabular overview of clinical studies

Table 2 summarises the clinical studies with nemolizumab where PK data is available. Four AD studies were conducted in Japanese subjects without PK sampling: 1 Phase 1 (M525101-05) and 3 Phase 3 (M525101-01, M525101-02, and M525101-04), and 1 ongoing study (Phase 2/3 PN study M52510111).

Four additional studies ongoing at the time of the MAA submission, an interim study report for RD.06.SRE.202699 and no reports were available for RD.06.SRE.118126 (AD paediatrics), RD.06.SRE.118380 (AD, vaccination), and RD.06.SRE.201591 (AD Efficacy/Safety (E/S)).

<div style=\"page-break-after: always\"></div>

Table 2: Clinical studies with PK data for s.c. nemolizumab

| Study identifier   | Study design                                                  | Population                                                                   | Nemolizumab dosing regimen                                                                     |
|--------------------|---------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Phase I            |                                                               |                                                                              |                                                                                                |
| RD.06.SRE. 201590  | Relative bioavailability, parallel group, open label          | HV, n=192                                                                    | 60 mg as AI or DCS single dose                                                                 |
| CIM001JP           | SAD, placebo controlled                                       | Part A HV Japanese, n=56:8 Part B HV White n=24:8 Part C AD Japanese n=36:12 | 0.003, 0.01, 0.03, 0.1, 0.3, 1 and 3 mg/kg single dose                                         |
| RD.06.SRE.201593   | Cocktail DDI                                                  | AD, n=16                                                                     | LD 60 mg then 30 mg Q4W                                                                        |
| Phase II           |                                                               |                                                                              |                                                                                                |
| RD.06.SRE. 114322  | Dose ranging, placebo-controlled, double-blind, 24 weeks      | AD, n =226                                                                   | 10 mg Q4W (LD 20 mg) 30 mg Q4W (LD 60 mg) 90 mg Q4W                                            |
| RD.06.SRE. 116912  | PK in adolescents, 16 weeks                                   | AD adolescents 13-17y, n=18                                                  | 30 mg Q4W (LD 60 mg)                                                                           |
| CIM003JG           | Dose finding, placebo-controlled, double-blind, 12 + 52 weeks | AD, n=164                                                                    | Part A 0.1, 0.5 or 2 mg/kg Q4W, 2 mg/kg Q8W Part B: placebo re- randomised to nemolizumab      |
| RD.06.SRE. 115828  | Placebo-controlled, double-blind, 12 weeks                    | PN, n=70                                                                     | 0.5 mg/kg Q4W                                                                                  |
| CIM106JP           | Dose ranging, placebo-controlled                              | Haemodialysis patients with pruritus, n=69                                   | 0.125, 0.5 or 2 mg/kg single dose                                                              |
| Phase III & LTE    |                                                               |                                                                              |                                                                                                |
| RD.06.SRE. 118161  | E/S double-blind, placebo-controlled, 16 + 32 weeks           | AD adults & adolescents, n=941                                               | Initial: LD 60 mg then 30 mg Q4W Maintenance (responders): 1:1:1 30 mg Q4W, Q8W or placebo Q4W |
| RD.06.SRE. 118163  | LTE, 200 weeks                                                | AD incl adolescents from earlier studies, n=1847                             | 30 mg Q4W                                                                                      |

<div style=\"page-break-after: always\"></div>

| RD.06.SRE. 118169         | E/S double-blind, placebo-controlled, 16 + 32 weeks   | AD adult & adolescents, n=787   | Initial: LD 60 mg then 30 mg Q4W Maintenance (responders): 1:1:1 30 mg Q4W, Q8W or placebo Q4W   |
|---------------------------|-------------------------------------------------------|---------------------------------|--------------------------------------------------------------------------------------------------|
| RD.06.SRE. 202685         | E/S double-blind, placebo-controlled, 24 weeks        | PN, n=286                       | <90 kg: 30 mg Q4W (60 mg LD) ≥90kg: 60 mg Q4W                                                    |
| RD.06.SRE. 202699 ongoing | LTE, 184 weeks                                        | PN, n=508                       | <90 kg: 30 mg Q4W (60 mg LD) ≥90kg: 60 mg Q4W                                                    |
| RD.06.SRE. 203065         | E/S double-blind, placebo-controlled, 16 weeks        | PN, n=274                       | <90 kg: 30 mg Q4W (60 mg LD) ≥90kg: 60 mg Q4W                                                    |

HV: healthy volunteer, AD: atopic dermatitis, PN: prurigo nodularis, AI: autoinjector, DCS: dual chamber syringe, LD: loading dose, E/S: efficacy and safety, LTE: long term extension

## 2.6.2.  Clinical pharmacology

The general outline of the clinical pharmacology package was agreed in EMA/CHMP/SAWP/493960/2019 and EMA/CHMP/SAWP/265227/2020, see section 1.5. Scientific Advice for further details

## 2.6.2.1.  Pharmacokinetics

## Bioanalytical methods

PK

An enzyme-linked immunosorbent assay (ELISA) method for the quantification of serum nemolizumab was developed and fully validated (Shin Nippon Biomedical Laboratories - SNBL). The ELISA method was transferred to a second bioanalytical laboratory (Syneos Health Clinique), validated and crossvalidated with the initial ELISA. The ELISA was used in all studies.

The ELISA method employed a microplate coated with recombinant human IL-31RA to bind to nemolizumab. The captured nemolizumab was detected using a rabbit anti-nemolizumab antibody followed by a horseradish peroxidase (HRP)-conjugated goat anti rabbit IgG. Colorimetric detection yielded a signal intensity that was proportional to the concentration of nemolizumab.

All validations and the cross validation performed within preset criteria based on current bioanalysis guidelines. The within study validation demonstrated accuracy and precision within acceptance criteria. ISR was performed and passed for all studies and all samples were measured within the established long-term stability.

## Immunogenicity

A 3-tiered testing strategy (antidrug antibody (ADA) screening, confirmation and characterization ie titer, neutralization antibody (NAb), IgE) was applied for analysis of samples from Phase 2 and Phase 3

<div style=\"page-break-after: always\"></div>

clinical studies. The NAb assay was not applied for Phase 1. Anti-nemolizumab IgE was measured in Phase 1/2 studies only. The same PC antibody (affinity purified rabbit anti-nemolizumab polyclonal IgG lot S003G29) was used to validate and control the ADA and NAb assays validated by the respective CRO laboratories, thereby enabling comparison of the performance between the assays.

A validated ADA assay method using a homogeneous electrochemiluminescence (ECL) format was applied for testing of ADA testing in all clinical studies. Essentially, the same assay format was successively validated by three contract research organization (CRO) laboratories (Chugai Pharmaceutical, LSI Medience and Syneos Health). The main methodological difference between the three assays was the sample pretreatment step involving mild acid dissociation for the ADA assay method validated by Syneos Health to increase drug tolerance.

Briefly, serum samples were coincubated with a neutralizing master mix of Biotinylated-nemolizumab and Ruthenylated-nemolizumab. In the presence of ADAs, an immune-complex was formed and then captured onto a streptavidin-coated MSD plate via a Biotin-Avidin bond, prior to detection of the ECL signal, which was directly proportional to the amount of ADA.

Standard methodology for the determination of cutpoints (healthy, AD or PN patients) was applied and when required cutpoint adjustments were conducted upon change of critical reagent batches or instruments. In clinical studies, the population specific cutpoint determined in the validation was generally used for ADA, which was considered adequate or conservative based on the false positive rate of pre-dose samples being between 2 and 11%. Most studies were in that range or slightly higher.

The Chugai assay (used in studies CIM001JP, CIM003JG and CIM106JP) was fully validated with a sensitivity of 13.2 ng/mL in serum. Nemolizumab at 10 μg/mL reduced the ECL signal for the 50 ng/mL PC to below that of the negative control, whereas the signal remained positive for the 1000 ng/mL PC.

The LSI Medience assay (used in studies phase 2 studies 114322, 115828 and 116912) was fully validated with a sensitivity of 14.7 ng/mL in serum. Drug tolerance up to 4000 ng/mL nemolizumab was demonstrated for 100 ng/mL of PC. The presence of IL-31, but foremost IL-31RA was found to increase the ECL signal and could generate false-positive signals. However, target interference was not evident from the matrix selectivity experiments, nor was it apparent during testing of clinical samples.

The Syneos assay (used in all phase 3 studies including LTE and in study 201590) was fully validated with a sensitivity of 10.3 ng/mL in serum. Positive control concentration of 16, 50, 100 and 2500 ng/mL tolerated up to 5, 10, 15 and 100 µg/mL nemolizumab, respectively. Due to limited availability of serum samples from treatment-naïve subjects with PN, and since comparable assay sensitivity and cut point values for the AD and PN populations were observed, the cut points determined for the AD population were applied in the pivotal clinical studies in subjects with PN.

The NAb assay was developed by Chugai and validated successively at LSI Medience and Syneos Health with minor changes such as reagent batches. Study samples from phase 3 studies and study 201590 were analysed at Syneos, while all other studies were analysed at LSI Medience. NAbs were not analysed in study CIM001JP.

Human IL-31-dependent Ba/F3 cells were used as the assay system to detect NAb in human serum. When IL-31 binds to the receptor complex, JAK kinases are activated, leading to cell proliferation. Nemolizumab binds to the cell receptor to block binding of the IL-31 agonist, thereby reducing IL-31induced cell proliferation. NAb can reverse the antagonistic effect of nemolizumab by competitive inhibition of the binding of nemolizumab to IL-31RA. The end point is the measurement of absorbance of a formazan dye whose level is proportional to the number of viable cells.

Sensitivity was 14661 ng/mL PC for the Syneos assay. At 16010 ng/mL PC, the assay tolerated 10 µg/mL nemolizumab. The validation cutpoint was determined using 30 normal human serum samples.

<div style=\"page-break-after: always\"></div>

Later cutpoints were determined in AD and PN serum (n=38 each from studies 118161 and 203065). These were used in all subsequent studies. For the assay at LSI 50 individual AD patients samples were used for the cutoff determination.

## Evaluation and qualification of models

A population PK analysis (popPK) was performed on a combined dataset from 6 studies in subjects with AD and 3 studies in subjects with PN. A total of 13236 PK data from 1952 subjects from 12 to 85 years of age (1555 [79.7%] subjects with AD and 397 [20.3%] of subjects with PN) were pooled and analysed using a non-linear mixed effects model. The covariates considered for the analysis were demographic factors (age, albumin, BSA, sex, body weight [WGT], lean body weight, antidrug antibody [ADA], estimated glomerular filtration rate [eGFR], hepatic impairment, renal impairment, IgE total bilirubin, total protein, creatinine clearance [CrCL], serum creatinine, race, region and ethnicity), extrinsic factor (device, formulation), disease status (AD or PN).

Nemolizumab PK was adequately described by a 1-compartment model with first-order absorption with a lag time and linear elimination. Parameters were estimated with good precision (relative standard error [RSE] of &lt;30%). The final model included the following covariates: WGT, serum albumin (ALB), CrCL, sex, race, and ethnicity effects on apparent Clearance (CL/F) and WGT and ALB effects on V/F. The final model parameter estimates are presented in the table below.

| Table 3: Parameter estimates for the final population pharmacokinetic model   | Table 3: Parameter estimates for the final population pharmacokinetic model   | Table 3: Parameter estimates for the final population pharmacokinetic model   | Table 3: Parameter estimates for the final population pharmacokinetic model   | Table 3: Parameter estimates for the final population pharmacokinetic model   |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Parameter                                                                     | Point estimate                                                                | IIV (%CV)                                                                     | %RSE                                                                          | Shrinkage (%)                                                                 |
| CL/F (L/day)                                                                  | 0.263                                                                         | -                                                                             | 1.3                                                                           | -                                                                             |
| V/F (L)                                                                       | 7.670                                                                         | -                                                                             | 1.3                                                                           | -                                                                             |
| K a (1/day)                                                                   | 0.476                                                                         | -                                                                             | 7.7                                                                           | -                                                                             |
| ALAG (day)                                                                    | 0.043                                                                         | -                                                                             | 23.0                                                                          | -                                                                             |
| RUV a                                                                         | 0.200                                                                         | -                                                                             | 1.8                                                                           | 11.9                                                                          |
| Dose effect on F b                                                            | -0.144                                                                        | -                                                                             | 10.0                                                                          | -                                                                             |
| ALB effect on CL/F b                                                          | -1.350                                                                        | -                                                                             | 9.2                                                                           | -                                                                             |
| CRCL effect on CL/F b                                                         | 0.168                                                                         | -                                                                             | 15.0                                                                          | -                                                                             |
| Ethnicity (Hispanic or Latino) effect on CL/F                                 | 0.226                                                                         | -                                                                             | 20.0                                                                          | -                                                                             |
| Race (other race) effect on CL/F                                              | 0.186                                                                         | -                                                                             | 9.5                                                                           | -                                                                             |
| Sex (male) effect on CL/F                                                     | 0.100                                                                         | -                                                                             | 16.0                                                                          | -                                                                             |
| WGT effect on CL/F b                                                          | 0.662                                                                         | -                                                                             | 6.0                                                                           | -                                                                             |
| ALB effect on V/F b                                                           | -0.535                                                                        | -                                                                             | 29.0                                                                          | -                                                                             |
| WGT effect on V/F b                                                           | 0.802                                                                         | -                                                                             | 5.3                                                                           | -                                                                             |
| IIV on CL/F c,d                                                               | 0.109                                                                         | 33.9                                                                          | 2.2                                                                           | 6.2                                                                           |
| IIV on V/F c,d                                                                | 0.110                                                                         | 34.1                                                                          | 6.2                                                                           | 26.3                                                                          |
| IIV on K a c                                                                  | 0.344                                                                         | 64.1                                                                          | 10.0                                                                          | 68.9                                                                          |

%CV=percentage of the coefficient of variation; %RSE=percentage of the RSE; ALAG=absorption lag time; ALB=albumin; CL/F=apparent clearance; CRCL=creatinine clearance; F= bioavailability; IIV=interindividual variability; Ka=first-order absorption rate constant; RSE=relative standard error; RUV=residual unexplained variability; V/F=apparent volume of distribution; WGT=body weight a Standard deviation for the additive component of the residual unexplained variability on log-scale.

b Coefficient of the power relationship.

c Estimated variance.

d A correlation of 61.7% was estimated between CL/F and V/F.

<div style=\"page-break-after: always\"></div>

The popPK model could sufficiently well describe the data as displayed in the visual predictive check graph below.

<!-- image -->

percentiles.

Abbreviations:Cl=confidenceinterval;Pl=predictioninterval;PK=pharmacokinetic(s);VPC=visualpredictive check

Figure 2: Prediction-Corrected VPC Versus Time Since First Dose for the Base Population PK Model Log-scale

## Absorption

Three drug substance processes and two dosage forms have been used during the development. The DCS was used in the Phase 3 studies whereas vial and syringe were used in the Phase 2 studies. Therefore, the drug product dosage form (liquid or lyophilized) and the drug product presentation (vial and DCS) were added as covariates in the final popPK model developed using pooled clinical data obtained in subjects with AD or PN.

No data on absolute bioavailability are available.

Phase 1 relative bioavailability study 201590 compared the absorption of a single dose of nemolizumab administered with DCC AI (test) versus DCS (reference) in healthy adult volunteers, which was similar. The point estimates for Cmax and for AUC0-inf were close to 100% and the 90% CIs were within 80125% for the sum of all injection sites. The PK results were consistent among the 3 injection sites (arm, abdomen, and thigh). Injection site was not associated with any statistically significant effect. Descriptive statistics for nemolizumab PK parameters in serum are provided in Table 4 . Mean nemolizumab concentration-time profile following a single 60-mg SC dose via the DCC-AI and the DCS are presented in Figure 3 .

<div style=\"page-break-after: always\"></div>

Table 4: Serum nemolizumab pharmacokinetic parameters following administration of 60 mg SC nemolizumab (PK population; Study 201590)

| PK parameter (unit)    | DCC-AI             | DCC-AI             | DCC-AI             | DCC-AI             | DCS                | DCS                | DCS                | DCS                |
|------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| PK parameter (unit)    | Abdomen (N=32)     | Arm (N=32)         | Thigh (N=32)       | Overall (N=96)     | Abdomen (N=32)     | Arm (N=32)         | Thigh (N=32)       | Overall (N=96)     |
| AUC 0-last (μg•day/mL) | 262±92.9           | 231±59.9           | 259±61.5           | 250±73.6           | 258±72.0           | 245±75.8           | 277±77.3           | 260±75.4           |
| AUC 0-inf (μg•day/mL)  | 290±93.9 a         | 246±78.7           | 275±81.1           | 270±85.8           | 273±81.7           | 263±91.4           | 299±94.6           | 279±89.7           |
| C max (μg/mL)          | 8.47±3.00          | 7.29±1.83          | 8.23±1.89          | 8.00±2.34          | 7.73±1.99          | 7.05±2.36          | 7.74±2.54          | 7.51±2.31          |
| T max (day)            | 4.00 (1.00, 21.99) | 5.97 (2.99, 21.98) | 4.99 (2.96, 11.00) | 4.99 (1.00, 21.99) | 4.49 (2.96, 21.99) | 7.48 (1.00, 22.00) | 5.00 (2.98, 11.00) | 5.99 (1.00, 22.00) |
| t 1/2 (day)            | 18.5±6.22 a        | 18.1±5.76          | 17.3±5.90          | 18.0±5.91b         | 17.7±3.62          | 18.2±5.40          | 19.6±4.29          | 18.5±4.52          |
| CL/F (L/day)           | 0.235±0.096 a      | 0.263±0.067        | 0.235±0.063        | 0.244±0.077 b      | 0.247±0.112        | 0.262±0.122        | 0.220±0.070        | 0.243±0.104        |
| V/F (L)                | 5.83±2.08 a        | 6.59±1.88          | 5.52±1.04          | 5.98±1.76b         | 5.96±1.69          | 6.34±1.79          | 5.94±1.22          | 6.08±1.58          |

a n=31

b n=95

Note: All subjects received a single dose of nemolizumab 60 mg (2×30 mg injections). Tmax values are presented as median (minimum, maximum). Other parameters are presented as arithmetic mean (±SD).

<!-- image -->

Program: /CA37094/sas\\_prg/pksas/adam\\_meangraph.sas 29JUN2023 14:05

Figure 3: Arithmetic mean (SD) serum nemolizumab concentration time profiles following administration of 60 mg SC nemolizumab via DCC-AI or DCS (PK population; Study 201590)

<div style=\"page-break-after: always\"></div>

## Distribution

In the single dose study 201590 ( Table 4 ), V/F was 5.98 L for the DCC-AI and 6.08L for the DCS.

In the popPK analysis, based on AD and PN patient data, the apparent volume of distribution (V/F) was estimated to 7.67 L.

## Elimination

No specific studies have been performed to characterize the elimination of nemolizumab. Nemolizumab is expected to be degraded into peptides and its constituent amino acids through proteolysis.

In the single dose study 201590 ( Table 4 ), CL/F was 0.24 L/day for both presentations and t1/2 was 18 and 18.5 days for the DCC-AI and the DCS, respectively.

In the popPK analysis, based on AD and PN patient data, the apparent clearance (CL/F) was estimated to 0.263 L/day the mean (±SD) t1/2 was calculated to 18.9±4.96 days in subjects with AD or PN (based on individual parameter estimates).

## Dose proportionality and time dependencies

In study CIM001JP, single doses of 0.003, 0.01, 0.03, 0.1, 0.3, 1, or 3 mg/kg nemolizumab s.c. were administered to healthy subjects. AUCinf, AUClast, and Cmax increased in a dose-dependent manner between 0.03 to 3 mg/kg. This was similar in study CIM106JP in haemodialysis patients with pruritus where PK parameter for 0.125, 0.5, 2.0 mg/kg nemolizumab s.c showed dose proportionality.

In the popPK analysis, a moderate impact of the nemolizumab dose in SC bioavailability (F) was detected with a slight decrease in F by 9.49% and 14.6% in subjects treated at the 60 mg and 90 mg doses, respectively.

Accumulation ratios were examined in study 114322 (10, 30, or 90 mg Q4W), where minimal accumulation was observed and in study CIM003JG in AD patients, where the ratio of accumulation at Q4W (0.1, 0.5 and 2 mg/kg) ranged from 1.64-1.99 while it was 2.11 for 2 mg/kg Q8W.

## Immunogenicity

The overall incidence of treatment-emergent ADA and NAb was 11.2% and 0.5%, respectively, in the Phase 3 AD studies ( Table 5 ) and 12.8% and 3.4%, respectively, in the Phase 3 PN studies ( Table 6 ). In AD, 73 subjects (6.6%) had persistent ADAs, 47 subjects (4.3%) had transient ADAs and 3 subjects (0.3%) had treatment boosted ADAs. In PN, 32 subjects (8.9%) had persistent ADAs ,  12 subjects (3.4%) had transient ADAs and 2 subjects (0.6%) had treatment boosted ADAs. The median ADA titers ranged from 10 to 100 across the 2 indications. In PN patients, maximum ADA titers up to 320 were observed in Study 202685, 80 in Study 203065 and 2560 in the LTE Study 202699 (at week 16 and early termination). In AD patients, maximum ADA titers up to 1280 were observed in Study 118161, 320 in Study 118169 and 1280 in the LTE 118163.

<div style=\"page-break-after: always\"></div>

Table 5: Summary of immunogenicity in Phase 3 AD studies including LTE

| ADA/NAb status                | Study11816l+LTE (Study 118163) (N=596)   | Study118169+LTE (Study 118163) (N=504)   | Study11816l+LTE and Study118169+LTE (N=1100)   |
|-------------------------------|------------------------------------------|------------------------------------------|------------------------------------------------|
| Preexisting ADA, n (%)        | 24 (4.0)                                 | 23 (4.6)                                 | 47 (4.3)                                       |
| Treatment-emergent ADA, n (%) | 67 (11.2)                                | 56 (11.1)                                | 123 (11.2)                                     |
| Treatment-induced             | 64 (10.7)                                | 56 (11.1)                                | 120 (10.9)                                     |
| Transient                     | 28 (4.7)                                 | 19 (3.8)                                 | 47 (4.3)                                       |
| Persistent                    | 36 (6.0)                                 | 37 (7.3)                                 | 73 (6.6)                                       |
| Treatment-boosted             | 3 (0.5)                                  | 0                                        | 3 (0.3)                                        |
| NAb positive, n (%)           | 3 (0.5)                                  | 2 (0.4)                                  | 5 (0.5)                                        |
| Time to ADA onset (weeks)     |                                          |                                          |                                                |
| 11                            | 64                                       | 56                                       | 120                                            |
| Mean (SD)                     | 27.7 (18.81)                             | 31.5 (24.99)                             | 29.5 (21.90)                                   |
| Median                        | 24.1                                     | 24.1                                     | 24.1                                           |
| Min, max                      | 4.0, 75.1                                | 2.14, 108.0                              | 2.14, 108.0                                    |
| Duration of ADA (weeks)       |                                          |                                          |                                                |
|                               | 32                                       | 28                                       | 60                                             |
| Mean (SD)                     | 29.7 (19.91)                             | 39.0 (24.38)                             | 34.0 (22.40)                                   |
| Median                        | 25.6                                     | 36.3                                     | 32.2                                           |
| Min, max                      | 3.71, 80.3                               | 4.29,105.0                               | 3.71, 105.0                                    |

AD=atopic dermatitis; ADA=antidrug antibody; L TE=long-term extension; Max=maximum; Min=minimum; N=number of subjects in the studies; n=number of subjects with available data; NAb=neutralizing antibody; SD=standard deviation

Note: Percentages for screening and confirmation tests are based on the number of subjects with available data at the analysis visit within each study and ADA category. Preexisting ADA refers to baseline from pivotal studies.

Source: Appendix 3 Table 14.2.1.1

Table 6: Summary of immunogenicity in Phase 3 PN studies including LTE

| ADA/NAb status                | Study202685+LTE (Study 202699) (N=182)   | Study203065+LTE (Study 202699) (N=176)   | Study202685+LTEand Study203065+LTE (N=358)   |
|-------------------------------|------------------------------------------|------------------------------------------|----------------------------------------------|
| Preexisting ADA, n (%)        | 5 (2.7)                                  | 3 (1.7)                                  | 8 (2.2)                                      |
| Treatment-emergent ADA, n (%) | 21 (11.5)                                | 25 (14.2)                                | 46 (12.8)                                    |
| Treatment-induced             | 21 (11.5)                                | 23 (13.1)                                | 44 (12.3)                                    |
| Transient                     | 7 (3.8)                                  | 5 (2.8)                                  | 12 (3.4)                                     |
| Persistent                    | 14 (7.7)                                 | 18 (10.2)                                | 32 (8.9)                                     |
| Treatment-boosted             | 0                                        | 2(1.1)                                   | 2 (0.6)                                      |
| NAb positive, n (%)           | 0                                        | 12 (6.8)                                 | 12 (3.4)                                     |
| Time to ADA onset (weeks)     | Time to ADA onset (weeks)                | Time to ADA onset (weeks)                | Time to ADA onset (weeks)                    |
| n                             | 21                                       | 23                                       | 44                                           |
| Mean (SD)                     | 28 (14.75)                               | 30 (18.03)                               | 29.1 (16.39)                                 |
| Median                        | 24.1                                     | 32.1                                     | 24.1                                         |
| Min, max                      | 8.14, 75.7                               | 7.86, 68.7                               | 7.86, 75.7                                   |
| Duration of ADA (weeks)       | Duration of ADA (weeks)                  | Duration of ADA (weeks)                  | Duration of ADA (weeks)                      |
|                               | 13                                       | 17                                       | 30                                           |
| Mean (SD)                     | 30.6 (16.85)                             | 34.9 (23.16)                             | 33.0 (20.45)                                 |
| Median                        | 28.1                                     | 29.0                                     | 28.6                                         |
| Min, max                      | 8.14, 59.1                               | 8.57,99.3                                | 8.14,99.3                                    |

ADA=antidrug antibody; LTE=long-term extension; Max=maximum; Min=minimum; N=number of subjects in the studies; =number of subjects with available data; NAb=neutralizing antibody; PN=prurigo nodularis; SD=standard deviation

Note: Percentages for screening and confirmation tests are based on the number of subjects with available data at the analysis visit within each study and ADA category. Preexisting ADA refers to baseline from pivotal studies.

Source: Appendix 4 Table 14.2.1.1

<div style=\"page-break-after: always\"></div>

ADA status were used to assess the impact of immunogenicity on PK, clinical efficacy, and clinical safety.

Figure 4: Individual serum drug concentration (Ctrough) vs. time for the Phase 3 AD studies (118161, 118169 and LTE) by ADA category

<!-- image -->

Figure 5: Mean ±SD serum drug concentration (Ctrough) vs. time for the Phase 3 PN studies (202685, 203065 and LTE) by ADA category

<!-- image -->

Figure 4 and Figure 5 depict nemolizumab c/t profiles stratified by ADA serology in AD and PN phase 3 studies, respectively. ADA positive status had no discernible impact on observed nemolizumab serum concentration vs. time profiles.

<div style=\"page-break-after: always\"></div>

## Target population

Sparse PK data was acquired from studies in the respective populations and is included in the popPK analysis. No difference was identified in the nemolizumab PK profiles between subjects with AD and subjects with PN. All PK data from studies in the respective patient population is included in the popPK analysis, and a summary of steady-state exposure per patient population is presented below.

Table 7: Summary of post hoc nemolizumab steady-state exposures in subjects with AD or PN receiving 30 mg Q4W (60 mg LD) by disease state

| PK parameter         | AD (N=1555)        | PN (N=397)         |
|----------------------|--------------------|--------------------|
| C max,ss (µg/mL)     |                    |                    |
| Geo. mean (geo. CV%) | 5.15 (36.2)        | 5.17 (35.6)        |
| Median [min, max]    | 5.15 [1.38, 19.3]  | 5.28 [1.46, 12.3]  |
| C trough,ss (µg/mL)  |                    |                    |
| Geo. mean (geo. CV%) | 2.21 (57.1)        | 2.45 (51.9)        |
| Median [min, max]    | 2.32 [0.101, 11.4] | 2.54 [0.368, 7.86] |
| AUC τ,ss (µg•day/mL) |                    |                    |
| Geo. mean (geo. CV%) | 105 (41.5)         | 109 (40.6)         |
| Median [min, max]    | 106 [20.3, 418]    | 113 [29.9, 289]    |

AD=atopic dermatitis; AUC τ,ss =area under the concentration-time curve during a dosing interval at steady state; Cmax,ss=maximum concentration at steady state (Week 12); Ctrough,ss=trough concentration at steady state (Week 16); CV%=percentage of the coefficient of variation; Geo.=geometric; LD=loading dose; Max=maximum; Min=minimum; N=total number of subjects; PK=pharmacokinetic; PN=prurigo nodularis; Q4W=once every 4 weeks

## Prurigo Nodularis

All PN studies were conducted in adults only. In phase 2 study 115828, nemolizumab was administered as 0.5 mg/kg s.c. injections. In the phase 3 and LTE studies, the intended commercial posology was administered: 30 mg nemolizumab Q4W (with a 60-mg loading dose at Baseline) for patients with BW &lt;90kg or 60 mg nemolizumab Q4W (no loading dose at Baseline) for patients with BW ≥ 90 kg.

In studies in PN patients, subjects &lt;90 kg (on nemolizumab 30 mg Q4W with a 60-mg loading dose) reached steady state by Week 4, while subjects ≥90 kg (on nemolizumab 60 mg Q4W) reached steady state approximately at Week 12-16.

## Atopic Dermatitis

Adolescents from 12 years of age were included in the phase 2 study 116912 and in phase 3 studies as well as in the LTE.

In the dose finding study 114322, nemolizumab doses of 10, 30, or 90 mg Q4W were administered with a loading dose at the Baseline Visit for the 10 mg and 30 mg nemolizumab groups (20 mg and 60 mg, respectively). For the 90 mg group, the same dose was administered at each injection visit. Nemolizumab trough concentrations appeared relatively constant across the 24-week exposure period and accumulation ratios were below 1 except in the 90 mg dose group where minimal accumulation was observed, and steady state was reached after Week 16. Over the dose range of 10 mg to 90 mg, Cmax and AUC appeared to increase in a less than dose-proportional manner.

In the phase 3 and LTE studies, patients received 30 mg nemolizumab Q4W with a 60 mg loading dose, and depending on clinical response, were re-randomized at week 16 to 30 mg nemolizumab Q4W

<div style=\"page-break-after: always\"></div>

or Q8W (or placebo). The posology was the same for adolescents as for adults and was not BW based. The Q4W posology with loading dose and switch to Q8W after 16 weeks in case of response is identical to the proposed commercial posology.

## Special populations

The difference in PK between Japanese and White males was assessed in study CIM001JP, where the point estimates for AUC and Cmax ranged from 0.82 to 1.07 for 0.3, 1 and 3 mg/kg nemolizumab.

Study 116912 assessed the PK and safety of nemolizumab in adolescent AD patients who received abdominal subcutaneous injections of 30 mg nemolizumab Q4W over a 16-week treatment period, with a loading dose of 60 mg on Day 1.

After Q4W subcutaneous administrations of nemolizumab in adolescents (N=18), Cmax of 6532.9 ± 2329.9 ng/mL (range 2500 to 11100 ng/mL) were observed 1 to 2 weeks after administration subcutaneous injection of the loading dose (60 mg). Steady-state condition was achieved by Week 4 with mean Ctrough ranging from 2935 ± 1029 ng/mL to 3292 ± 2018 ng/mL over the treatment period up to Week 16 ( Figure 6 ).

Figure 6: Mean ±SD nemolizumab concentrations in adolescents (PK population, study 116912)

<!-- image -->

An NCA was performed on the PK population. Mean (±SD) AUC values calculated from the observed predose samples at 0 to 4, 8, 12, and 16 weeks were, 122.3 ± 44.1 μg*day/mL, 233.3 ± 80.1 μg*day/mL, 332.9 ± 121.7 μg*day/mL, and 372.9 ± 149.9 μg*day/mL, respectively.

Nemolizumab exposure was lower in subjects with higher body weight as reported in the table below.

<div style=\"page-break-after: always\"></div>

Table 8: PK parameters by weight quartile.

| Body weight (kg)      |   1 st Quartile [30.8 to 62.0] |   2 nd Quartile [62.0 to 74.0] |   3 rd Quartile [74.0 to 87.1] |   4 th Quartile [87.1 to 181] |
|-----------------------|--------------------------------|--------------------------------|--------------------------------|-------------------------------|
| C max,ss (µg/mL)      |                           6.64 |                           5.48 |                           4.86 |                          3.99 |
| C trough,ss (µg/mL)   |                           2.92 |                           2.39 |                           2.18 |                          1.72 |
| AUC 𝜏 ,ss (µg•day/mL) |                         137    |                         113    |                         101    |                         81.6  |

AUCt,ss  Area under the concentration-time curve during a dosing interval ( 𝜏 ) at steady state; Cmax,ss  Maximum concentration at steady state; Ctrough,ss Predose concentration at steady state. PK parameters calculated with population PK model (N=1952)

The number of elderly subjects in the PK population is presented in Table 9 .

## Table 9: Subjects above 65 years of age included in the PK population - by studies and overall.

| PK Trials   | Age ≥ 65-74 n/N (%)   | Age 75-84 n/N (%)   | Age 85+ n/N (%)   |
|-------------|-----------------------|---------------------|-------------------|
| CIM001JP    | 0 / 27 (0.0%)         | 0 / 27 (0.0%)       | 0 / 27 (0.0%)     |
| CIM003JG    | 0 / 248 (0.0%)        | 0 / 248 (0.0%)      | 0 / 248 (0.0%)    |
| SPR.114322  | 11 / 169 (6.5%)       | 4/169 (2.4%)        | 0 / 169 (0.0%)    |
| SPR.116912  | 0 / 18 (0.0%)         | 0 / 18 (0.0%)       | 0 / 18 (0.0%)     |
| SPR.118161  | 27 / 594 (4.5%)       | 3 / 594 (0.5%)      | 0 / 594 (0.0%)    |
| SPR.118169  | 26 / 499 (5.2%)       | 11 / 499 (2.2%)     | 0 / 499 (0.0%)    |
| SPR.115828  | 8 / 34 (23.5%)        | 4 / 34 (11.8%)      | 1 / 34 (2.9%)     |
| SPR.202685  | 51 / 183 (27.9%)      | 12 / 183 (6.6%)     | 0 / 183 (0.0%)    |
| SPR.203065  | 39 / 180 (21.7%)      | 9 / 180 (5.0%)      | 0 / 180 (0.0%)    |
| Overall     | 162 / 1952 (8.3%)     | 43 / 1952 (2.2%)    | 1 / 1952 (0.1%)   |

## Pharmacokinetic interaction studies

A clinical drug-drug interaction study (201593) was conducted in subjects with moderate-to-severe AD with CYP substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 (caffeine 100 mg, warfarin sodium 10 mg, omeprazole 20 mg, metoprolol tartrate 100 mg and midazolam 2 mg, respectively) at baseline or on week 9 of nemolizumab given as 60 mg loading dose, followed by two doses of 30 mg Q4W. Cmax and AUC ratios ranged from 88.24% to 107.81%. The 90% CI was generally within 80125%, with a few cases where it lay below 80%.

## Exposure relevant for safety evaluation

The steady-state exposure, based on the final population PK analysis are reported in Table 10 .

<div style=\"page-break-after: always\"></div>

Table 10: Steady-state exposure parameters (mean [±SD]) estimated by the nemolizumab population pharmacokinetic model

| Dose regimen                    | PK parameter         | PK parameter      | PK parameter        |
|---------------------------------|----------------------|-------------------|---------------------|
| Dose regimen                    | AUC τ,ss (μg•day/mL) | C max,ss (μg/mL)  | C trough,ss (μg/mL) |
| Atopic dermatitis               | Atopic dermatitis    | Atopic dermatitis | Atopic dermatitis   |
| 60 mg LD + 30 mg Q4W            | 117 (±46)            | 5.59 (±1.95)      | 2.63 (±1.27)        |
| 60 mg LD + 30 mg Q8W            | 34.2 (±17.4)         | 1.92 (±0.841)     | 0.738 (±0.440)      |
| Prurigo nodularis               | Prurigo nodularis    | Prurigo nodularis | Prurigo nodularis   |
| BW <90 kg: 60 mg LD + 30 mg Q4W | 130 (±42.0)          | 6.05 (±1.70)      | 3.04 (±1.23)        |
| BW ≥90 kg: 60 mg Q4W            | 160 (±57.7)          | 7.55 (±2.37)      | 3.66 (±1.63)        |

AUC τ,ss =area under the concentration-time curve during a dosing interval at steady state; Cmax,ss=maximum concentration at steady state; Ctrough,ss=trough concentration at steady state; LD=loading dose; Q4W=once every 4 weeks; Q8W=once every 8 weeks; SD=standard deviation

## Pharmacokinetics using human biomaterials

Not applicable

## 2.6.2.2.  Pharmacodynamics

## Mechanism of action

Nemolizumab is a humanized monoclonal antibody of the IgG2 subclass which inhibits IL-31 signalling by binding to the IL-31 receptor alpha (IL-31RA). It competitively blocks the binding of IL-31 to its receptor, thereby preventing subsequent transduction of the IL-31 signal into the cell. A role for IL-31 and IL-31RA signalling has been demonstrated both in the pathophysiology of AD and PN.

## Primary and Secondary pharmacology

Nemolizumab inhibits IL-31RA mediated IL-31 signalling by binding to human and monkey IL-31RA. Nemolizumab in vivo inhibited monkey itching behaviour induced by the administration of IL-31. Moreover, mouse IL-31RA neutralizing antibody inhibited the total number of scratching movements and the exacerbation of dermatitis symptoms in a mite antigen-induced AD mouse model. These data suggest that the blocking of IL-31 signalling by nemolizumab could be useful as an AD treatment method.

No secondary pharmacodynamic studies have been conducted with nemolizumab.

Relationship between concentration and effect and on safety

Atopic Dermatitis

Effect

<div style=\"page-break-after: always\"></div>

Population PK/PD models for eczema area and severity index (EASI), investigator global assessment (IGA), and weekly average peak pruritus numerical rating scale (PP NRS) were developed based only on available data from subjects with AD enrolled in Phase 1, Phase 2, and pivotal Phase 3 studies.

An indirect response model with a maximum inhibitory effect (Imax) of nemolizumab and a constant placebo effect on the production of the EASI response was found adequate to describe the data. The model accounted for the bounded nature of the EASI score (between 0 and 72). The concentration leading to half of the Imax (IC50) was 4.27 μg/mL.

A 4-compartment continuous time Markov model was used to describe IGA observations with a common stimulating drug effect (linear relationship with concentration) on all descending transitions. The slope parameter of the drug effect was found at 0.09640 L/μg. An effect of baseline IGA score on all descending transitions was characterized   resulting in a lower response rate for patients with higher baseline values. Female subjects were found to have approximately 41% higher descending transition rate constants (i.e., are more likely to improve) compared to male subjects.

An indirect response model with an Imax model and a constant placebo effect on the production of the PP NRS response was found adequate to describe the data. The model accounted for the bounded nature of the PP NRS score (between 0 and 10). The concentration leading to half of the Imax (IC50) was 0.654 μg/mL.

PK/PD simulations to evaluate the impact of body weight (i.e. exposure) showed the following: No relevant difference was detected in the clinical response at week 16 when subjects with &lt;90 kg and subjects ≥90 kg were treated with the same dosing regimen, 60 mg LD + 30 mg, Q4W until week 12 despite the differences in exposure.

## Safety

Based on data collected in the pivotal Phase 3 studies, no relationship was identified between steadystate systemic exposure and the incidence of AD, newly diagnosed asthma or worsening of asthma, and facial and peripheral oedema.

Similarly, the C-QT analysis performed in CIM003JG study indicate absence of relationship between systemic exposure and corrected QT interval values.

## Prurigo Nodularis

## Effect

Population PK/PD models for eczema investigator global assessment (IGA), and weekly average peak pruritus numerical rating scale (PP NRS) were developed based only on available data from subjects with PN enrolled in Phase 2, and pivotal Phase 3 studies.

A 4-compartment continuous time Markov model was used to describe IGA observations with a common stimulating drug effect (linear relationship with concentrations) on all descending transitions and an inhibiting drug effect (linear relationship with concentrations) on all ascending transitions. The slope parameter for the descending transitions was found at 0.525 L/μg, while the slope parameter for the ascending transitions was found at -0.0832 L/μg. An effect of baseline IGA score on all ascending transitions was characterised, suggesting a lower response rate for subjects with higher baseline values.

An indirect response model with a maximum inhibitory effect (Imax) model and a constant placebo effect on the production of the PP NRS response was found adequate to describe the data. The model accounted for the bounded nature of the PP NRS score (between 0 and 10). The concentration leading to half of the Imax was 0.357 μg/mL.

<div style=\"page-break-after: always\"></div>

PK/PD simulations to evaluate the impact of body weight (i.e. exposure) showed the following: 1) PP NRS responder rate at week 16 was not impacted by body weight and response rate in subjects with PN, and body weight ≥90 kg was similar with both dosing regimens. 2) The IGA responder rate was lower in subjects with PN and BW ≥90 kg if treated with the 60 mg (LD) + 30 mg Q4W dosing regimen compared to 60 mg Q4W. 3) The IGA response rate was similar in the 2 BW groups when subjects with PN and BW ≥90 kg were treated at the dose of 60 mg Q4W.

## Safety

Based on data collected in the pivotal Phase 3 studies, no relationship was identified between steadystate systemic exposure and the incidence of headache, newly diagnosed asthma or worsening of asthma, facial oedema, and peripheral oedema.

No secondary pharmacodynamic studies have been conducted with nemolizumab.

## 2.6.3.  Discussion on clinical pharmacology

## · Bioanalytical methods

Analytical methods were generally in line with the current relevant guidelines.

The ELISA for nemolizumab was fully validated and cross-validated, with adequate performance of the pre-study and within study validation, including ISR and long-term stability.

All three ADA methods are adequately validated using state of the art methodology and show adequate sensitivity. Drug tolerance is likely sufficient in all three methods, considering Ctrough levels around 4 µg/mL nemolizumab. Thus, considering critical reagents are the same and the positive control is similar, the ADA serology can be compared between studies. The effect of nemolizumab on the ECL signal is however decreased by the acid pre-treatment introduced in the Syneos method, thus titers should not be compared between methods.

Cutpoints were determined for both AD and PN population (Syneos assay). It is agreed that they are comparable, with the AD cutpoint being slightly more conservative if used in the PN population, thus it is agreed that the use of the same cutpoint is acceptable. It also has the advantage of enabling comparisons between populations.

The NAb assays were fully validated, however their sensitivity is poor, with 14661 ng/mL PC for the Syneos assay. Drug tolerance was only investigated at nAb levels that were relevant for the sensitivity of the assay. Overall, the methods seem validated, however due to poor sensitivity, samples with low ADA titers are unlikely to be positive in the nAb method, even if they have neutralizing potential. Since the immunogenicity is relatively low, and the ADA methods showed good performance, the issue is not pursued. The immunogenicity text has been updated as requested

## Population PK analysis

A population PK analysis was performed using combined data from 6 studies in subjects with AD (Studies CIM001JP, CIM003JG, 114322, 116912, 118161, and 118169) and 3 studies in subjects with PN (Studies 115828, 202685, and 203065). Adequate data, data handling, and model development methodology have been used. The final model describes the AD and PN patient data well and the results are considered reliable to predict individual exposure and support claims on pharmacokinetics in special populations.

<div style=\"page-break-after: always\"></div>

## · Absorption

Three different DS processes were used across the development of nemolizumab (G1, G2.1 and G2.2). No comparison of the PK of the different DS has been presented. As G2.2 has been used in the phase 3 studies and the device study, both immunogenicity and a PK profile with rich PK sampling are available for the intended commercial substance and no additional comparison of PK is required.

Overall, BE between DCC AI and DCS is demonstrated. BE is also demonstrated for each injection site for the most important parameters Cmax and AUCinf, however for some of the other parameters, the 90% confidence interval was not always within 80-125, which is expected given the smaller group size.

A statistical comparison of the injection sites between each other was not planned. The exposure with the AI is slightly higher when administered in the abdomen, however generally within the variability of the study. Thus, it is agreed that Nemluvio can be administered in the thigh, abdomen or arm as proposed in the SmPC section 4.2, and that no further description of the PK for each injection site is needed in the SmPC.

Cmax and tmax described in the SmPC are from study 201590 for the DCS. In comparison, the DCC-AI has a Cmax of 8 µg/mL and tmax of 6 days. The SmPC text in section 5.2. was updated to reflect both arms of the study.

The time to steady state description is based on studies in the respective target population and is acceptable.

Moderate impact of the dose on the bioavailability was identified in the PopPK analysis, consistent with the finding of less than proportional increase in systemic exposure with doses exceeding 30 mg (see Dose proportionality).

The applicant did not provide information regarding the relative bioavailability of the 30 mg dose calculated in the PopPK analysis. Only the relative decreases in bioavailability of the higher nemolizumab doses of 60 mg and 90 mg were stated in the SmPC. As requested, the information for 90 mg was deleted.

## · Distribution

The absence of in vitro distribution studies is acceptable for an antibody. The estimated apparent volume of distribution (V/F) obtained from PopPK analysis in AD population aligns well with the volume of distribution estimated in the Phase I studies (CIM001JP and RD.06.SRE.201590) and generally consistent with the typical volume of distribution expected for monoclonal antibodies, indicating limited extravascular distribution. This is adequately described in the SmPC section 5.2. with popPK; and it was clarified that it is V/F that is described.

## · Elimination

Proteolytic degradation is expected and the lack of studies characterizing the elimination is acceptable. This is adequately described in the SmPC section 5.2.; and it was clarified that it is CL/F that is described.

## · Dose proportionality, time dependencies and immunogenicity

PK was dose-proportional in the range 0.03 to 3 mg/kg after single doses of nemolizumab. However, a less than proportional increase was noted at steady state in the multiple-dose study within the dosage

<div style=\"page-break-after: always\"></div>

range of 10 to 90 mg. No target mediated drug disposition was apparent at those doses in the healthy, AD or haemodialysis with pruritus populations. This is adequately reflected in the SmPC section 5.2..

The PK of nemolizumab is not time dependent as evidenced by the measurement of median accumulation below 2 and the absence of significant differences in exposure during steady state compared to single-dose administration.

Immunogenicity of nemolizumab was relatively low and similar between populations of AD and PN. While mean Ctrough concentrations were lower in ADA positive patients, the standard deviation was wide and overlapping. It is thus agreed that there is no clinically relevant impact of immunogenicity on PK as reflected in SmPC section 5.1.

## · Target population

Generally, sparse sampling was used in patient's studies, which is adequate. All PK from studies in the target populations, AD and PN, is included in the popPK model. The population (AD or PN) did not have a relevant impact on the PK of nemolizumab.

Based on the results from the Phase I study CIM001JP patients with AD exerted 23 to 26% lower exposure compared to healthy subjects. The SmPC was however insufficiently updated to present PK parameters measured in patients (both AD and PN) since differences rate of exposure are anticipated. The SmPC has been revised to report exposure in AD and PN patients.

## · Special populations

Based on the popPK analysis, age, sex, race, ethnicity, baseline disease severity, estimated glomerular filtration rate (eGFR), creatinine clearance, serum albumin, total protein, bilirubin, and ADA status did not have a clinically relevant impact on the nemolizumab PK profile, which is agreed. It should be noted that creatinine clearance was included as a covariate on CL/F in the final popPK analysis. However, the exposure range across creatinine clearance categories did not exceed the exposure range across for example body weight quartiles.

Given that nemolizumab is a monoclonal antibody no dedicated studies have been conducted in patients with renal or hepatic impairment. However, the data did not encompass a category for severe hepatic or renal impairment, which is adequately reflected in the SmPC section 5.2.

The popPK results show that there is a decrease in exposure with increasing body weight. Nonetheless, there was an overlap in exposure between the weight quartiles. Thus, based on exposure range, there is no clear indication that a dosing adjustment is warranted for increased body weight. Since the difference in exposure was not clinically relevant, the SmPC text in section 5.2 was shortened.

It is agreed that there were no differences in PK between Japanese and White males, which is as expected for a monoclonal antibody.

The same dose as in adults is proposed for adolescents from 12 years of age for the AD indication, based on their inclusion in phase 2 study 116912, the phase 3 studies and LTE. It is agreed that the systemic exposure was similar between adults and adolescents.

The lack of data in paediatric patients below age 12 for AD, and total lack of data in paediatric patients with PN is adequately reflected in the SmPC section 5.2.

<div style=\"page-break-after: always\"></div>

## · Pharmacokinetic interaction studies

It is agreed that there was no clinically relevant impact of nemolizumab on the PK of selected CYP substrates and that the interaction risk can be excluded. This is reflected in the SmPC section 4.5.

## · PK/PD for efficacy, AD population

Standard methodology has been used in the analyses. Phase II and phase III study data, including a wide dose range of 0.1- 2 mg/kg and 10 - 90 mg, were used in the PK/PD analyses. Very limited data was available beyond 16 weeks of treatment (only study SPR114322).

## EASI

The relationship between PK and EASI was best described by a turnover model with an inhibitory effect on the EASI response. The model describes the data reasonably well. It is noted that the estimated IC50 value (i.e. the concentration that gives 50% of the inhibitory effect) is 4.27 µg/mL which is higher than Ctrough,ss for both 60 mg LD + 30 mg Q4W and 60 mg LD + 30 mg Q8W dosing regimens.

## IGA

The IGA score was described by a Markov model where the transition rate between states (i.e. scores) is estimated. The inclusion criterion was IGA ≥ 3 and it is not clear whether the lack of transitions from low scores early in the studies could affect the parameter estimates. Nonetheless, the model indicates that transitions to lower states can be associated with increasing exposure. Notably, upon closer examination of Table 30 . it was observed that the CIs for the overall IGA responder rate of patients with &lt;90 kg and those with ≥ 90 kg, both receiving 30 mg (60 mg LD) QW4, do not overlap, hence suggesting response difference between the groups. An IGA response rate among AD patients weighing ≥ 90 kg was approximately 17% lower compared to those weighing &lt;90 kg. The applicant argues that there is a large overlap in exposure distribution between responders/non-responders and therefore an increased exposure would not be clinically meaningful. However, the responders have consistently slightly higher exposure, both in patients &lt;/ ≥ 90 kg.

The applicant was asked to consider conducting PK/PD efficacy simulation of the clinical endpoints (EASI-75, PP NRS and IGA response rate) at Week 16 in subjects with AD for the patient group of ≥90 kg receiving 60 mg of nemolizumab QW4, mirroring the approach taken for the PN patients. In response to questions, the applicant developed a PK/PD model using pooled data from the AD clinical development program to predict the proportion of responders at week 16 for EASI-75, PP-NRS, and IGA in subjects weighing ≥ 90 kg who received 60 mg of nemolizumab Q4W. While the 60 mg nemolizumab Q4W dosage resulted in a 1.8-fold increase in systemic exposure in patients weighing ≥ 90 kg compared to the 30 mg (60 mg LD) dose, the model did not suggest a clinically meaningful improvement in efficacy. However, the model predicted similar efficacy for the 30 mg (60 mg LD) Q4W dose in both patients weighing &lt; 90 kg and those ≥ 90 kg for EASI-75, PP-NRS, and IGA endpoints. These predictions, however, are not consistent with the clinical results from the post hoc analysis, which indicated lower efficacy for patients weighing ≥ 90 kg on both IGA and EASI-75 endpoints, with results comparable to placebo. A significant effect was only observed for the PP-NRS endpoint. This information is reflected in the SmPC Section 5.1.

## PP NRS

The relationship between PK and PP NRS was best described by a turnover model with an inhibitory effect on the PP NRS response. The results display a decreasing weekly average PP NRS with increasing nemolizumab concentrations, with an IC50 estimated to be 0.654 μg/mL. The IC50 value is lower than the Ctrough,ss for both proposed AD dosing regimens (Q4W and Q8W).

<div style=\"page-break-after: always\"></div>

## · PK/PD for efficacy, PN population

Standard methodology has been used in the analyses. Three studies in the PN population were included in the analyses; Studies 115828, 202685, and 203065. Across the 3 studies, nemolizumab was administered according to the following dosing regimens: 0.5 mg/kg, 30 mg Q4W with a 60 mg loading dose for subjects with body weight &lt;90 kg, or 60 mg Q4W for subjects with body weight ≥ 90 kg. Given the limited dose range included in the PK/PD analyses, the results should be interpreted with caution since confounding effects cannot be excluded.

## IGA

The IGA score was described by a Markov model where the transition rate between states (i.e. scores) is estimated. The inclusion criterion was IGA ≥ 3 and it is not clear whether the lack of transitions from low scores early in the studies could affect the parameter estimates. An increase of the transition to low scores and a decrease of the transition to high scores was observed with increasing nemolizumab concentrations. It is somewhat surprising that an effect of nemolizumab concentration could be identified both on descending and ascending transitions, and this finding further emphasises that the parameter estimates (values) should be interpreted with caution.

## PP NRS

The relationship between PK and PP NRS was best described by a turnover model with an inhibitory effect on the PP NRS response. The results display a decreasing weekly average PP NRS with increasing nemolizumab concentrations, with an IC50 estimated to be 0.357 μg/mL. The IC50 value is lower than the Ctrough,ss in the PN dosing regimen.

## · Exposure-safety, AD population

Logistic regression analyses were performed based on the phase 3 studies (Studies 118161 and 118169) which is an acceptable analysis approach. Ctrough,ss was used as the exposure metric which might does not reflect the highest concentrations possibly important for safety assessment. However, given that only one dose regimen has been evaluated in the phase 3 studies, subjects with high exposure in the analysis would be expected to also have the highest Ctrough. Thus, Ctrough,ss is an acceptable exposure metric in this case. Investigated safety events were: eczematous reactions, headache, newly diagnosed asthma or worsening of asthma, facial oedema, and peripheral oedema. No exposure-safety relationships were identified.

## · Exposure-safety, PN population

Logistic regression analyses were performed based on the phase 3 studies (Studies 202685 and 203065) which is an acceptable analysis approach. Ctrough,ss was used as the exposure metric which is acceptable with the same reasoning as for the AD population. Investigated safety events were: eczematous reactions, headache, newly diagnosed asthma or worsening of asthma, facial oedema, and peripheral oedema. No exposure-safety relationships were identified.

## · Concentration-QT analysis

A concentration-QTc analysis was performed in study Study CIM003JG (AD patients). Maximum dose in the study was 2 mg/kg which more than double the proposed loading dose of 60 mg, hence the exposure range is considered adequate. The confidence interval for the estimated slope includes zero (regardless of QTcB or QTcF formula). According to reporting standards for Conc-QTc analyses, the

<div style=\"page-break-after: always\"></div>

confidence interval (CI) around the slope should be visualized as the upper limit for the CI should not exceed 10 msec. However, the reported slope is negative and the risk for increased QTc interval with increasing dose is very low, thus the results are considered acceptable.

## · Dose justification

It is apparent that nemolizumab PK is affected by body weight, with decreasing concentration with increasing body weight. The exposure range within each body weight quartile (range 31-181 kg) show that there is a considerable overlap across all body weight quartiles. Furthermore, the exposureresponse models indicate a limited effect of exposure in the sought dosing interval. Nonetheless, a trend towards a relevant effect with increasing exposure was detected for the PP NRS response in the PN population, and for IGA response in the AD population. Further clarification was requested from the applicant, based on submitted results of the PK/PD simulations, regarding the rationale behind opting for weight-based dosing for PN patients but not for those with AD based on the IGA response rate simulations. In response to questions, the applicant provided information that show that the responders have consistently slightly higher exposure, both in patients &lt;/≥90 kg. Simulation data does not indicate a clinically meaningful benefit from the higher dose, however the post-hoc analysis of the clinical data shows reduced efficacy of nemolizumab in patients ≥90 kg, with no difference from placebo for both the IGA and EASI-75 endpoints, though there is effect in reducing pruritus (PP NRS endpoint). The 60 mg dose in patients ≥90 kg results in exposure levels 30% higher than those seen in patients &lt;90 kg receiving the 30 mg dose, and the safety profile of the 60 mg dose has been demonstrated to be acceptable for patients ≥90 kg in the PN indication.

## · Pharmacodynamic interactions

The applicant will submit the clinical study reports for vaccine study (SPR.118380) post-approval as a recommendation (REC).

## 2.6.4.  Conclusions on clinical pharmacology

The pharmacokinetics of nemolizumab is well described. The results of the ongoing vaccine study are recommended to be submitted when available.

Overall, the clinical pharmacology package is considered acceptable and in support of this marketing authorisation application (MAA).

## 2.6.5.  Clinical efficacy - atopic dermatitis

A total of 17 studies were used to support the evaluation of efficacy and safety of nemolizumab in AD.

Focus will be on the two completed, pivotal, double-blind, placebo-controlled, Phase 3 studies RD.06.SPR.118161 and RD.06.SPR.118169.

## 2.6.5.1.  Dose response studies

Three Phase 2 studies have been performed.

<div style=\"page-break-after: always\"></div>

## Study CIM003JG A Phase II, Randomized, Double-blind, Placebo-controlled, Multiple dose study to evaluate the Safety, Tolerability and Efficacy of CIM331 in Atopic Dermatitis Patients who are Inadequately Controlled by or Intolerant to Topical Therapy.

The study was performed in two parts. Part A was a randomized, double blind, placebo-controlled, parallel assignment design (Week 0 to 12). Part B was a double-blind extension phase in which subjects continued to receive treatment with nemolizumab for a further 52 weeks. The doses investigated of nemolizumab were 0.1, 0.5, or 2.0 mg/kg SC Q4W, or 2.0 mg/kg SC Q8W, or placebo in Part A. Subjects randomized to a nemolizumab regimen in Part A continued to receive the same nemolizumab dose in Part B, while subjects randomized to placebo in Part A were re-randomized to nemolizumab 0.1, 0.5, or 2.0 mg/kg SC Q4W in Part B.

The primary endpoint was percentage improvement from baseline in pruritus VAS at Week 12. Further, several secondary efficacy endpoints were improvement from baseline in pruritus VAS, EASI, SCORAD, sIGA, BSA of AD involvement, pruritus VRS and sleep disturbance VAS at Week 12 of clinical relevance for AD.

## Study RD.03.SPR.114322 - A randomized, double-blind, multicentre, parallel-group, placebocontrolled, dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects with severe pruritus receiving topical corticosteroids.

The study objectives were to investigate the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe AD subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments. The secondary objectives were to evaluate the safety of nemolizumab and to characterize its PK profile.

Each subject was randomized to receive subcutaneous injections of nemolizumab (10, 30, or 90 mg, depending upon randomized treatment group) or placebo Q4W (Weeks 4, 8, 12, 16 and 20). A loading dose was administered at the Baseline Visit (Day 1) for the 10mg and 30 mg groups (20 mg and 60 mg, respectively) and for the 90 mg group, the same dose was administered at each injection visit. The dose that subsequently was chosen for MAA, 30 mg with a 60-mg loading dose, was included in the study.

The primary efficacy endpoint was the percent change from Baseline in EASI to Week 24. Further, several secondary efficacy endpoints at Week 24 of clinical relevance for AD were also included.

## RD.06.SPR.116912 - A Multicentre, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics and Safety of Nemolizumab (CD14152) in Adolescent Subjects (12-17 years) with Moderate-to-Severe Atopic Dermatitis and Associated Pruritus

Pharmacokinetics and safety of 30 mg of nemolizumab SC Q4W, with a loading dose of 60 mg on Day 1, was investigated in adolescent subjects (12 to 17 years of age). The study enrolled 20 adolescent subjects who were assessed for safety and efficacy, and 14 subjects were evaluated for PK.

## 2.6.5.2.  Main studies

Two Phase 3 studies with identical design are the main support for the proposed indication in moderate to severe atopic dermatitis.

<div style=\"page-break-after: always\"></div>

Study RD.06.SRE.118161 (ARCADIA 1)- A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Study RD.06.SRE.118169 (ARCADIA 2) - A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

In addition, a long-term study ( SIR.118163 ), designed to evaluate the long-term safety, and efficacy as secondary objective of nemolizumab has been performed. A 200-week long-term follow up study is ongoing.

## Methods

##  Study Participants

Figure 7: Study schema of the pivotal Phase 3 studies SPR.118161 and SPR.118169 (figure from the study reports)

<!-- image -->

## Efficacy measurements

The most important efficacy measurement for assessment of primary and key secondary efficacy are shown below.

<div style=\"page-break-after: always\"></div>

Table 11: Investigator's global assessment (IGA)

|   Score | Category     | Description                                                                                                   |
|---------|--------------|---------------------------------------------------------------------------------------------------------------|
|       0 | Clear        | Minor, residual hypopigmentation/hyperpigmentation, no erythema or induration/papulation, no oozing/crusting. |
|       1 | Almost Clear | Trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting.              |
|       2 | Mild         | Faint pink erythema with mild induration/papulation and no oozing/crusting.                                   |
|       3 | Moderate     | Pink-red erythema with moderate induration/papulation with or without oozing/crusting.                        |
|       4 | Severe       | Deep or bright red erythema with severe induration/papulation with oozing/crusting.                           |

Table 12: Eczema area and severity index (EASI)

| Body region      | Eczema area and severity index score   |
|------------------|----------------------------------------|
| Head/Neck (H)    | (E + I + Ex + L) x Area x 0.1          |
| Upper limbs (UL) | (E + I + Ex + L) x Area x 0.2          |
| Trunk (T)        | (E + I + Ex + L) x Area x 0.3          |
| Lower limbs (LL) | (E + I + Ex + L) x Area x 0.4          |
| EASI=            | Sum of the above 4 body region scores  |

E=erythema; Ex=excoriation; I=induration/papulation; L=lichenification

The degree of severity of each sign (E, I, Ex, L) in each of the 4 body regions was evaluated based on a scale ranging from 0 to 3 (0: none; 1: mild; 2: moderate; 3: severe), with half points allowed.

Area (the affected body area) was defined as follows: 0=0%; 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. Among the four zones, trunk includes the genital area, and lower limbs include the buttocks.

## Pruritus numerical rating scale (NRS)

The Pruritus NRS is a scale used by subjects to report the intensity of their pruritus (itch) during the last 24 hours. Two measures were assessed: the PP NRS is an assessment of the peak/maximum itch intensity in that period while the Average Pruritus Numerical Rating Scale (AP NRS) provides a measure of overall/average pruritus intensity. The PP NRS has been validated in other AD clinical trials in adults, and the minimum clinically important difference was shown to be a 4-point reduction.

Main inclusion criteria were: 1. Subject was male or female, aged ≥12 years at the screening visit. 2. Subject had chronic AD for at least 2 years before the screening visit and confirmed according to American Academy of Dermatology Consensus Criteria at the time of the screening visit. 3. Subject had EASI score ≥16 at both the screening and baseline visits. 4. Subject had IGA score ≥3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits. 5. Subject had AD involvement ≥10% of BSA at both the screening and baseline visits. 6. Subject had PP NRS score of at least 4.0 at the screening and baseline visits. 7. Subject had documented recent history (within 6 months before the screening visit) of inadequate response to topical medications (TCS with or without TCI). All subjects must have demonstrated inadequate response to TCS.

Key exclusion criteria were: 1. Subject had a body weight &lt;30 kg, 2. Subjects meeting 1 or more of the following criteria at screening or baseline: Had an exacerbation of asthma requiring hospitalization in the preceding 12 months, reported asthma that had not been well-controlled during the preceding 3

<div style=\"page-break-after: always\"></div>

months, asthma control test (ACT) ≤19 (only for subjects with a history of asthma) and peak expiratory flow (PEF) &lt;80% of the predicted value. 3. Subjects with a current medical history of chronic obstructive pulmonary disease and/or chronic bronchitis.

## Treatments

The test product in the study was nemolizumab 30 mg, which is a lyophilized powder in a dual chamber syringe (DCS) for solution for SC injection. The 30 mg dose of nemolizumab administered every fourth week was selected based on the safety, tolerability, and efficacy data from the Phase 2b dose-ranging study SRE.114322. The study drug was administered Q4W at Weeks 4, 8, and 12 by a single SC injection of either nemolizumab 30 mg or vehicle injection. During maintenance treatment the study drug was administered Q4W or Q8W from week 16 to 48.

All study drug injections occurred at the study site. For subjects willing and able to self-inject or to have their caregiver inject study drug, study site staff provided training on study drug injections. The eCRF recorded who performed the study drug injection at each visit.

Subjects continued to use background topical therapy (moisturisers and for instance topical corticosteroids of different potency), which was adjusted according to disease activity and tolerability based on the Investigator's clinical judgment and recorded.

Rescue treatment were treatments directed to treat AD and included topical and systemic treatments. Subjects receiving any rescue therapies were to be considered treatment failures during the studies.

## Objectives

The primary objective was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

The secondary objective was to evaluate the efficacy and safety of maintenance treatment with nemolizumab for up to an additional 32 weeks.

The statistical hypothesis was superiority of treatment with nemolizumab versus treatment with vehicle injection.

## Outcomes/endpoints

The co-primary efficacy endpoints were the proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear]) and a ≥2-point reduction from baseline and the proportion of subjects with EASI-75 (≥75% improvement in EASI from baseline) at Week 16.

Key secondary efficacy endpoints were:

- Proportion of subjects with an improvement of PP NRS ≥4 at Week 16
- Proportion of subjects with PP NRS &lt;2 at Week 16
- Proportion of subjects with an improvement of sleep disturbance NRS (SD NRS) ≥4 at Week 16
- Proportion of subjects with an improvement of PP NRS ≥4 at Week 4
- Proportion of subjects with PP NRS &lt;2 at Week 4
- Proportion of subjects with an improvement of PP NRS ≥4 at Week 2
- Proportion of subjects with an improvement of PP NRS ≥4 at Week 1
- Proportion of subjects with EASI-75 and improvement of PP NRS ≥4 at Week 16
- Proportion of subjects with IGA success and improvement of PP NRS ≥4 at Week 16

<div style=\"page-break-after: always\"></div>

Furthermore, several secondary efficacy endpoints were investigated.

## Sample size

In Arcadia 1 and Arcadia 2, n=270 subjects (n= 90 placebo, n=180 nemolizumab) were stated to have 90% power to detect 1) a difference of 18% in the proportion of subjects with IGA success at week 16 (30% IGA success in the nemolizumab group and 12% in the placebo group) as well as 2) a difference in proportion of EASI-75 response of 30% at week 16 (49% EASI-75 in nemolizumab group and 19% in placebo group) with a two-sided significance level of 2.5% and assuming a drop-out rate of 15%.

To ensure sufficient exposure with nemolizumab and sufficient size of safety database the applicant increased the sample size to n=750 (n = 250 placebo, n = 500 nemolizumab) in both studies.

## Randomisation and blinding (masking)

## Randomisation

Initial treatment period: In each of the two identically designed studies Arcadia 1 and Arcadia 2, approximately n=750 subjects, including a minimum of n=130 subjects aged 12 to 17 years, who met eligibility criteria were to be randomised 2:1 to receive either nemolizumab or placebo. Randomisation was stratified by baseline disease severity: PP NRS &lt; 7 and PP NRS ≥ 7 as well as IGA = 3 and IGA = 4 and a minimum of n=250 subjects were to be randomised into each PP NRS strata.

Maintenance treatment period: All nemolizumab-treated subjects who were clinical responders, defined as IGA success or EASI-75 at week 16 (i.e., the end of initial treatment period) were to be rerandomized (1:1:1) to the following treatment regimens: 1) nemolizumab injections Q4W, 2) nemolizumab Q8W (with placebo injections in-between active treatments) or 3) placebo Q4W, during the maintenance period. All placebo-treated subjects who responded to placebo during the initial treatment period continued to receive placebo Q4W during the maintenance period.

## Blinding

Both studies were double-blinded clinical studies where the treatment assignments were blinded to patients, to the Sponsor's study team members, and to the members of the study centre staff, including those responsible for dual-chamber, single-use syringe (DCS) preparation. To ensure doubleblind administration of study drug, the study centre pharmacist(s) or other qualified personnel were to prepare all nemolizumab or placebo treatments and were not to be involved with any study assessments and were not to discuss any aspects of study drug reconstitution with the subject/caregiver or study staff involved in subject interviews or study assessments. In addition, to maintain the integrity of the study blinding, the bioanalytical laboratory staff who processed/analysed the PK/pharmacodynamics (PD)/PharmacoGenetics (PGx) samples were not to provide any information to sponsor, Contract Research Organization (CRO), or investigational study centre personnel directly involved with the ongoing conduct of the study that may have led to unblinding.

## Statistical methods

Arcadia 1 and Arcadia 2 were identically designed. The SAPs of the studies were similar. There were no amendments to the SAPs and the SAPs were finalised before database lock.

## Analysis sets

Primary, key secondary, and other secondary efficacy endpoints were to be evaluated in two populations: 1) the full intention to treat (ITT) population and 2) in a subpopulation of subjects in the

<div style=\"page-break-after: always\"></div>

ITT population with a baseline PP NRS ≥ 7. Primary and key secondary efficacy endpoint analyses during the initial treatment period in these two populations were to be type I error controlled.

The ITT populations during the initial treatment period were to consist of all randomised subjects under the treatment group 'as randomised'. If a subject was incorrectly stratified into a stratum, the stratum assigned during randomisation was to be used in the efficacy analyses. In a similar manner, during the maintenance period, the ITT populations were to include re-randomised subjects who were treatment responders during the initial treatment period. Treatment responders in the placebo group during the initial treatment period were also to be included as a separate treatment arm during the maintenance period.

Efficacy analyses on primary and key secondary endpoints were also to be performed based on the per protocol (PP) populations, and these analyses were to be treated as supportive analyses.

## Error probabilities and adjustment for multiplicity

In both studies, to control the type I error at 5% significance level, a serial gatekeeping approach were to be implemented. The co-primary endpoints were to be tested at 2.5% significance level for each population (the full ITT population and the subpopulation with baseline PP NRS ≥ 7). If both coprimary endpoints were statistically significant at 2.5% level, key secondary endpoints were to be tested sequentially with a hierarchical testing procedure following the pre-specified order of the key secondary endpoints (as specified in section: Primary Objective), and subsequent testing were to stop if a test was not statistically significant. If p &lt; 2.5% for all co-primary and key secondary endpoints in at least one population, then 2.5% were to be recycled to test the other population at 5% significance level.

No interim analyses were planned nor performed.

## Main analysis methods for primary and key secondary efficacy endpoints

Treatment discontinuation and rescue therapy were defined as intercurrent events and the strategies to handle these were to be by the treatment policy strategy and composite strategy, respectively. For subjects who discontinued treatment, the observed response at week 16 (or week 1, 2, and 4, respectively, for some of the key secondary efficacy endpoints) were to be used in the analyses. Subjects using rescue therapies prior to week 16 for primary endpoints (or week 1, 2, and 4, respectively, for some of the key secondary endpoints) were to be considered as treatment failures/non-responders. Subjects with missing values at week 16 assessment (or week 1, 2, and 4 assessments for some of the key secondary endpoints) were also considered as treatment failures.

The primary efficacy analyses were to concern the two co-primary endpoints: 1) proportion of subjects with an IGA success at week 16 and 2) proportion of subjects with EASI-75 at week 16 in the two populations (i.e., the full ITT population and the subpopulation of subjects in ITT population with baseline PP NRS ≥ 7). Both co-primary endpoints were to be analysed by means of Cochran-MantelHaenszel (CMH) tests adjusted for the randomized stratification variables, i.e., IGA severity (moderate/severe) and PP NRS (≥ 7/&lt; 7) at baseline for full ITT population, and IGA severity only for PP NRS ≥ 7 population. The CMH tests were to be evaluated under a two-sided alpha level of 2.5%; unadjusted CMH tests were also to be performed. In addition, the applicant planned to present estimates of the treatment unadjusted differences with corresponding two-sided 95% confidence intervals (CIs) and strata-adjusted differences with corresponding two-sided 97.5% CIs and p-values. Analyses of key secondary efficacy endpoints were planned to be the same as for the primary endpoints, for both full ITT population and the population with baseline PP NRS ≥ 7. Primary and key secondary efficacy endpoint analyses during the initial treatment period in the two populations were to be type I error controlled.

<div style=\"page-break-after: always\"></div>

## Main analysis methods for other secondary efficacy endpoints

Other secondary endpoints were not to be type I error controlled.

The analyses of other secondary efficacy endpoints during the initial treatment period were to involve both the full ITT population and the subpopulation with baseline PP NRS ≥ 7. Binary secondary endpoints were to be analysed in a similar way as the primary and key secondary endpoints. Continuous endpoints were to be analysed by means of analysis of covariance (ANCOVA) with missing values imputed using MI under MAR assumption, and by Mixed model repeated measurements (MMRM). Analyses on the sleep diaries, pain frequency/intensity, number of days free of topical rescue therapy, incidence of therapy, itch-free days, and WPAI:AD were to be summarized descriptively using the observed data.

All secondary endpoints during the maintenance period were to be descriptively summarised by treatment group and visit, for the full ITT population.

## Handling of missing data

The primary methods to impute missing values were declared to be as follows:

-  Binary endpoints: missing values were to be treated as a non-responder during the initial treatment period.
-  Continuous endpoints: missing values during the initial treatment period were to be imputed with MI under MAR assumption, and the MMRM approach was also to be used for selected secondary endpoints (see above).
-  Quality of life (QoL) endpoints: the applicant declares that missing values on QoL endpoints may be imputed using LOCF when applicable.

## Sensitivity analyses

According to the SAPs, the below sensitivity analyses on primary and key secondary endpoints were planned. In all analyses except for those performed on OC population, assessments on or after rescue therapy were to be considered as non-responders.

-  Tipping point analyses: non-responders due to missing data were to be converted to responders in successive increments (Δ) for both treatment groups, to assess the robustness of analyses; the value of Δ that overturned the primary results represented the tipping point.
-  Analyses in which missing values were to be imputed by means of MI.
-  Analyses in which missing values were imputed by means of LOCF. Missing post-baseline values were to be carried forward from the last non-missing post-baseline value.
-  Analyses on OC populations: the OC populations were to comprise all available data and for subjects that received any rescue medication, the data post-rescue therapy was to be analysed as observed and not considered as a treatment failure.
-  Analyses on PP populations: the PP populations were to comprise all subjects in the ITT populations who had no major protocol deviations that would have led to a significant effect on the efficacy of the study treatment.
-  Analyses on the ITT populations but using the 'actual stratum', not 'randomised stratum'.

## Planned subgroup analyses

The following subgroup analyses were planned:

<div style=\"page-break-after: always\"></div>

-  Region (Europe, North America, Asia-Pacific)
-  Age groups (12-17, 18-65, and &gt;65 years)
-  Sex
-  Race (white, black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, other)
-  Baseline IGA (3 or 4)
-  Baseline PP NRS (≥ 7 or &lt; 7)
-  Previous use of systemic therapy for AD (yes/no)
-  Previous use of any biologic therapy for AD (yes/no)
-  Previous use of any immunosuppressive or immunomodulatory drugs for AD (yes/no)
-  Previous use of Dupilumab for AD (yes/no)
-  Previous use of Cyclosporine for AD (yes/no)
-  Country

## Results

##  Participant flow

The two pivotal Phase 3 studies, ARCADIA 1 (SPR.118161) and ARCADIA 2 (SPR.118169), were designed to compare efficacy and safety of nemolizumab to placebo in adolescent and adult subjects with moderate to severe AD not adequately controlled with topical treatments. The two studies were identical in terms of study design and investigated a dose of 30 mg (with 60 mg loading dose) administered subcutaneously every month (i.e., Q4W) during an initial treatment period, from baseline to Week 16 (last dose at Week 12). This 16-week initial treatment was followed by a maintenance period from Week 16 to Week 48 (last dose at Week 44), during which responder subjects at Week 16 (i.e., IGA 0/1 or EASI-75) were re-randomized to investigate two dosing intervals (i.e., Q4W and Q8W) as compared to placebo. All placebo-treated subjects who responded to placebo during the Initial Period continued to receive placebo Q4W in the Maintenance Period.

The information for the flowchart for the two pivotal studies, is provided for each treatment period per study in Figure 8 , Figure 9 , Figure 10 and Figure 11 .

<div style=\"page-break-after: always\"></div>

## Study SPR.118161 (ARCADIA 1)

## Figure 8: Subject disposition - Initial treatment period - ARCADIA 1

<!-- image -->

Note: The percentage for screening failures was based on the number of screened subjects. The percentage for the reason of screening failures was based on the number of screening failures. The other percentages were based on the number of randomized subjects.

*Four subjects in the nemolizumab group were randomized but not treated: study drug assigned although subject was a screen failure , failure to complete the required 4 days for PP NRS per inclusion criterion #6 , and erroneous Asthma Control Test value entry (22 rather than 17; Asthma Control Test ≤19 was exclusionary per exclusion criterion #2c).

<div style=\"page-break-after: always\"></div>

Figure 9: Subject disposition - Maintenance treatment period - ARCADIA 1

<!-- image -->

Clinical responders are defined as IGA 0/1 or EASI-75 at Week 16. All subjects were treated.

The percentages were based on the number of re-randomized subjects or subjects re-assigned to Placebo.

<div style=\"page-break-after: always\"></div>

## Study SPR.118169 (ARCADIA 2)

Figure 10: Subject disposition - Initial treatment period - ARCADIA 2

<!-- image -->

Note: The percentage for screening failures was based on the number of screened subjects. The percentage for the reason of screening failures was based on the number of screening failures. The other percentages were based on the number of randomized subjects.

* Three subjects in the nemolizumab group were randomized but not treated: insufficient kits available at site randomized in error without TB test result available and subject withdrew consent prior to TB test result, ineligible per baseline PP NRS scores of 3.5, 3.333, and 2.5 (PP NRS of at least 4.0 was required per inclusion criterion #6;),
- ** Two subjects in the placebo group were randomized but not treated: ineligible Asthma Control Test value of 19; Asthma Control Test ≤19 was exclusionary per exclusion criterion #2c . In addition, although no exclusion criteria were met, placebo Subject should have been a screening failure based upon the Investigator's request for hematologist consult of the subject's low white blood cell count at screening and baseline.

<div style=\"page-break-after: always\"></div>

Figure 11: Subject disposition - Maintenance treatment period - ARCADIA 2

<!-- image -->

Clinical responders are defined as IGA 0/1 or EASI-75 at Week 16. The following 3 subjects were not treated.

* One subject in the nemolizumab 30mg Q4W to Q4W was randomized but not treated. This subject was clinical responder at Week 16 but enrolled by mistake in the LTE.
- ** One subject in nemolizumab 30mg Q4W to placebo was randomized but not treated due to abnormal ECG at Week 16 requiring further evaluation; then, subject withdrawal consent for the trial.
- *** One subject in placebo reassigned to placebo was not treated due to dosing hold beginning Week 12 in the initial treatment period until Week 20, then the subject was early terminated due to site closure.

The percentages were based on the number of re-randomized subjects or subjects re-assigned to Placebo.

## Initial treatment period

The subject disposition in studies SRE.118161 and SRE.118169 can be seen in the table below.

<div style=\"page-break-after: always\"></div>

Table 13: Subject disposition in studies SPR.118161 and SPR.118169 - initial treatment period (ITT population) (table from SCE)

| Number of subjects                                          | SPR.118161     | SPR.118161   | SPR.118161   | SPR.118169     | SPR.118169   | SPR.118169   | Overall total   |
|-------------------------------------------------------------|----------------|--------------|--------------|----------------|--------------|--------------|-----------------|
| Number of subjects                                          | Nemo 30 mg Q4W | Placebo      | Total        | Nemo 30 mg Q4W | Placebo      | Total        | Overall total   |
| Number of subjects                                          | N=620          | N=321        | N=941        | N=522          | N=265        | N=787        | N=1728          |
| Number of subjects                                          | n (%)          | n (%)        | n (%)        | n (%)          | n (%)        | n (%)        | n (%)           |
| Randomized                                                  | 620 (100)      | 321 (100)    | 941 (100)    | 522 (100)      | 265 (100)    | 787 (100)    | 1728 (100)      |
| Randomized but not treated                                  | 4 (0.6)        | 0            | 4 (0.4)      | 3 (0.6)        | 2 (0.8)      | 5 (0.6)      | 9 (0.5)         |
| Treated                                                     | 616 (99.4)     | 321 (100)    | 937 (99.6)   | 519 (99.4)     | 263 (99.2)   | 782 (99.4)   | 1719 (99.5)     |
| Completed treatment                                         | 560 (90.3)     | 296 (92.2)   | 856 (91.0)   | 470 (90.0)     | 241 (90.9)   | 711 (90.3)   | 1567 (90.7)     |
| Discontinued treatment                                      | 56 (9.0)       | 25 (7.8)     | 81 (8.6)     | 49 (9.4)       | 22 (8.3)     | 71 (9.0)     | 152 (8.8)       |
| Primary reason for discontinuation of treatment             |                |              |              |                |              |              |                 |
| Pregnancy                                                   | 2 (0.3)        | 0            | 2 (0.2)      | 0              | 0            | 0            | 2 (0.1)         |
| Lack of efficacy                                            | 5 (0.8)        | 2 (0.6)      | 7 (0.7)      | 3 (0.6)        | 0            | 3 (0.4)      | 10 (0.6)        |
| Adverse event                                               | 9 (1.5)        | 9 (2.8)      | 18 (1.9)     | 17 (3.3)       | 4 (1.5)      | 21 (2.7)     | 39 (2.3)        |
| Subject's request                                           | 25 (4.0)       | 11 (3.4)     | 36 (3.8)     | 24 (4.6)       | 15 (5.7)     | 39 (5.0)     | 75 (4.3)        |
| COVID-19                                                    | 0              | 0            | 0            | 0              | 0            | 0            | 0               |
| Lost to follow-up                                           | 10 (1.6)       | 0            | 10 (1.1)     | 1 (0.2)        | 1 (0.4)      | 2 (0.3)      | 12 (0.7)        |
| Protocol deviation                                          | 4 (0.6)        | 3 (0.9)      | 7 (0.7)      | 3 (0.6)        | 2 (0.8)      | 5 (0.6)      | 12 (0.7)        |
| Physician/principal investigator decision                   | 1 (0.2)        | 0            | 1 (0.1)      | 1 (0.2)        | 0            | 1 (0.1)      | 2 (0.1)         |
| Other                                                       | 0              | 0            | 0            | 0              | 0            | 0            | 0               |
| Completed/exited the study after initial treatment period   | 289 (46.6)     | 199 (62.0)   | 488 (51.9)   | 234 (44.8)     | 156 (58.9)   | 390 (49.6)   | 878 (50.8)      |
| Discontinued from the study during initial treatment period | 59 (9.5)       | 22 (6.9)     | 81 (8.6)     | 53 (10.2)      | 24 (9.1)     | 77 (9.8)     | 158 (9.1)       |
| Primary reason for discontinuation from the study           |                |              |              |                |              |              |                 |
| Pregnancy                                                   | 2 (0.3)        | 0            | 2 (0.2)      | 0              | 0            | 0            | 2 (0.1)         |
| Lack of efficacy                                            | 4 (0.6)        | 2 (0.6)      | 6 (0.6)      | 3 (0.6)        | 0            | 3 (0.4)      | 9 (0.5)         |
| Adverse event                                               | 8 (1.3)        | 5 (1.6)      | 13 (1.4)     | 18 (3.4)       | 4 (1.5)      | 22 (2.8)     | 35 (2.0)        |
| Subject's request                                           | 25 (4.0)       | 12 (3.7)     | 37 (3.9)     | 25 (4.8)       | 15 (5.7)     | 40 (5.1)     | 77 (4.5)        |
| COVID-19                                                    | 0              | 1 (0.3)      | 1 (0.1)      | 0              | 2 (0.8)      | 2 (0.3)      | 3 (0.2)         |
| Lost to follow-up                                           | 10 (1.6)       | 0            | 10 (1.1)     | 1 (0.2)        | 1 (0.4)      | 2 (0.3)      | 12 (0.7)        |
| Protocol deviation                                          | 8 (1.3)        | 3 (0.9)      | 11 (1.2)     | 4 (0.8)        | 3 (1.1)      | 7 (0.9)      | 18 (1.0)        |
| Other                                                       | 2 (0.3)        | 0            | 2 (0.2)      | 2 (0.4)        | 1 (0.4)      | 3 (0.4)      | 5 (0.3)         |
| COVID-19                                                    | 0              | 0            | 0            | 0              | 0            | 0            | 0               |

<div style=\"page-break-after: always\"></div>

| Rolled over to long-term extension after initial treatment period   | 282 (45.5)   | 192 (59.8)   | 474 (50.4)   | 230 (44.1)   | 152 (57.4)   | 382 (48.5)   | 856 (49.5)   |
|---------------------------------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Completed follow-up after initial treatment period                  | 21 (3.4)     | 16 (5.0)     | 37 (3.9)     | 16 (3.1)     | 7 (2.6)      | 23 (2.9)     | 60 (3.5)     |

ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q4W=every 4 weeks

Note: Percentages were based on the number of subjects in the ITT population of each treatment group. Subject (Study SRE.118161) was randomized to nemolizumab after early termination and received mixed dose of nemolizumab and placebo at baseline. For analysis, the actual treatment group was the same as the planned treatment group (nemolizumab).

## Maintenance period

At Week 16, 507 nemolizumab-treated subjects who met the clinical responder criteria (defined as an IGA of 0 [clear] or 1 [almost clear] or an EASI-75) were re-randomized to receive nemolizumab Q4W (N=169), nemolizumab Q8W (N=169), or placebo (N=169) during the maintenance period.

Table 14: Subject disposition in studies SPR.118161 and SPR.118169 - maintenance period (ITT population) (table from SCE)

|                                                           | Nemo 30 mg Q4W to Q4W   | Nemo 30 mg Q4W to Q8W   | Nemo 30 mg Q4W to Placebo   | Total a    |
|-----------------------------------------------------------|-------------------------|-------------------------|-----------------------------|------------|
|                                                           | N=169                   | N=169                   | N=169                       | N=507      |
|                                                           | n (%)                   | n (%)                   | n (%)                       | n (%)      |
| Re-randomized                                             | 169 (100)               | 169 (100)               | 169 (100)                   | 507 (100)  |
| Re-randomized but not treated                             | 1 (0.6) b               | 0                       | 1 (0.6) b                   | 2 (0.4)    |
| Treated                                                   | 168 (99.4)              | 169 (100)               | 168 (99.4)                  | 505 (99.6) |
| Completed maintenance period treatment                    | 141 (83.4)              | 147 (87.0)              | 134 (79.3)                  | 422 (83.2) |
| Discontinued maintenance period treatment                 | 27 (16.0)               | 22 (13.0)               | 34 (20.1)                   | 83 (16.4)  |
| Primary reason for treatment discontinuation              |                         |                         |                             |            |
| Pregnancy                                                 | 0                       | 0                       | 0                           | 0          |
| Lack of efficacy                                          | 6 (3.6)                 | 5 (3.0)                 | 15 (8.9)                    | 26 (5.1)   |
| Adverse event                                             | 4 (2.4)                 | 5 (3.0)                 | 4 (2.4)                     | 13 (2.6)   |
| Subject's request                                         | 8 (4.7)                 | 7 (4.1)                 | 6 (3.6)                     | 21 (4.1)   |
| COVID-19                                                  | 0                       | 0                       | 0                           | 0          |
| Lost to follow-up                                         | 1 (0.6)                 | 1 (0.6)                 | 4 (2.4)                     | 6 (1.2)    |
| Protocol deviation                                        | 1 (0.6)                 | 0                       | 1 (0.6)                     | 2 (0.4)    |
| Physician/PI Decision                                     | 3 (1.8)                 | 2 (1.2)                 | 1 (0.6)                     | 6 (1.2)    |
| Other                                                     | 4 (2.4)                 | 2 (1.2)                 | 3 (1.8)                     | 9 (1.8)    |
| COVID-19                                                  | 0                       | 0                       | 0                           | 0          |
| Completed the study after maintenance period              | 142 (84.0)              | 147 (87.0)              | 133 (78.7)                  | 422 (83.2) |
| Discontinued from the study during the maintenance period | 27 (16.0)               | 22 (13.0)               | 36 (21.3)                   | 85 (16.8)  |
| Primary reason for study discontinuation                  |                         |                         |                             |            |
| Pregnancy                                                 | 0                       | 0                       | 1 (0.6)                     | 1 (0.2)    |

<div style=\"page-break-after: always\"></div>

| Lack of efficacy                   | 6 (3.6)    | 5 (3.0)    | 14 (8.3)   | 25 (4.9)   |
|------------------------------------|------------|------------|------------|------------|
| Adverse Event                      | 5 (3.0)    | 5 (3.0)    | 4 (2.4)    | 14 (2.8)   |
| Subject's request                  | 8 (4.7)    | 7 (4.1)    | 6 (3.6)    | 21(4.1)    |
| COVID-19                           | 1 (0.6)    | 0          | 0          | 1 (0.2)    |
| Lost to follow-up                  | 2 (1.2)    | 1 (0.6)    | 6 (3.6)    | 9 (1.8)    |
| Protocol Deviation                 | 1 (0.6)    | 0          | 1 (0.6)    | 2 (0.4)    |
| Other                              | 5 (3.0)    | 4 (2.4)    | 4 (2.4)    | 13 (2.6)   |
| COVID-19                           | 0          | 0          | 0          | 0          |
| Rolled over to long-term extension | 145 (85.8) | 152 (89.9) | 136 (80.5) | 433 (85.4) |
| Completed follow-up                | 9 (5.3)    | 9 (5.3)    | 14 (8.3)   | 32 (6.3)   |

ITT=intent-to-treat; N=number of subjects in the treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q4W=every 4 weeks; Q8W=every 8 weeks

Note: Percentages were based on the number of subjects in each treatment group.

a) Total was for all subjects who were re-randomized to the Maintenance Period from nemolizumab 30 mg group in the Initial Treatment Period.

b) One subject (re-randomized to Q4W) was erroneously enrolled in the long-term extension study instead of being treated in the Maintenance Period. One subject (re-randomized to placebo) was not dosed with study drug because the subject had an abnormal electrocardiogram at the time per the Principal Investigator and discussions with medical monitor; therefore, no dosing was to occur at this visit.

## Recruitment

In study SPR.118161 date of the first subject randomized was 09 August 2019. Date of last subject last visit was 11 August 2022. Database lock was 15 November 2022. A total of 161 sites randomized and treated at least 1 subject in Australia, Asia, EU, New Zealand, and United States.

In study SPR.118169 date of the first subject randomized was 13 August 2019. Date of last subject last visit was 26 September 2022. Database lock was 06 December 2022. A total of 120 sites randomized and treated at least 1 subject in Asia, EU, and United States.

## Conduct of the study

No major amendments were made to the protocol.

The protocol deviations seem to be well balanced between the study groups and are considered not to seriously affect the assessment of the results.

## Baseline data

The subject demographic and baseline characteristics for the ITT population in studies SPR.118161 and SPR.118169 can be seen in the tables below.

<div style=\"page-break-after: always\"></div>

Table 15: Demographic and baseline characteristics in studies SPR.118161 and SPR.118169 - initial treatment period (ITT population) (table 11 from the SCS)

| Characteristic                            | SPR.118161     | SPR.118161   | SPR.118161   | SPR.118169     | SPR.118169   | SPR.118169   | Overall total   |
|-------------------------------------------|----------------|--------------|--------------|----------------|--------------|--------------|-----------------|
|                                           | Nemo 30 mg Q4W | Placebo      | Total        | Nemo 30 mg Q4W | Placebo      | Total        |                 |
|                                           | N=620          | N=321        | N=941        | N=522          | N=265        | N=787        | N=1728          |
| Age (years)                               |                |              |              |                |              |              |                 |
| Mean (SD)                                 | 33.5 (15.92)   | 33.3 (15.61) | 33.4 (15.81) | 34.9 (17.66)   | 35.2 (16.98) | 35.0 (17.42) | 34.1 (16.58)    |
| Median                                    | 29.0           | 29.0         | 29.0         | 30.0           | 32.0         | 31.0         | 30.0            |
| Q1, Q3                                    | 21.0, 43.0     | 21.0, 45.0   | 21.0, 44.0   | 20.0, 48.0     | 21.0, 46.0   | 20.0, 48.0   | 21.0, 45.0      |
| Minimum, maximum                          | 12, 82         | 12, 81       | 12, 82       | 12, 84         | 12, 85       | 12, 85       | 12, 85          |
| Age group, n (%)                          |                |              |              |                |              |              |                 |
| 12-17 years                               | 85 (13.7)      | 49 (15.3)    | 134 (14.2)   | 91 (17.4)      | 41 (15.5)    | 132 (16.8)   | 266 (15.4)      |
| 18-65 years                               | 505 (81.5)     | 263 (81.9)   | 768 (81.6)   | 394 (75.5)     | 209 (78.9)   | 603 (76.6)   | 1371 (79.3)     |
| >65 years                                 | 30 (4.8)       | 9 (2.8)      | 39 (4.1)     | 37 (7.1)       | 15 (5.7)     | 52 (6.6)     | 91 (5.3)        |
| Not reported                              | 0              | 0            | 0            | 0              | 0            | 0            | 0               |
| Sex, n (%)                                |                |              |              |                |              |              |                 |
| Male                                      | 323 (52.1)     | 177 (55.1)   | 500 (53.1)   | 252 (48.3)     | 129 (48.7)   | 381 (48.4)   | 881 (51.0)      |
| Female                                    | 297 (47.9)     | 144 (44.9)   | 441 (46.9)   | 270 (51.7)     | 136 (51.3)   | 406 (51.6)   | 847 (49.0)      |
| Region, n (%)                             |                |              |              |                |              |              |                 |
| Asia Pacific                              | 98 (15.8)      | 52 (16.2)    | 150 (15.9)   | 10 (1.9)       | 4 (1.5)      | 14 (1.8)     | 164 (9.5)       |
| Europe                                    | 316 (51.0)     | 164 (51.1)   | 480 (51.0)   | 381 (73.0)     | 197 (74.3)   | 578 (73.4)   | 1058 (61.2)     |
| North America                             | 206 (33.2)     | 105 (32.7)   | 311 (33.0)   | 131 (25.1)     | 64 (24.2)    | 195 (24.8)   | 506 (29.3)      |
| Ethnicity, n (%)                          |                |              |              |                |              |              |                 |
| Hispanic or Latino                        | 64 (10.3)      | 32 (10.0)    | 96 (10.2)    | 44 (8.4)       | 19 (7.2)     | 63 (8.0)     | 159 (9.2)       |
| Not Hispanic or Latino                    | 552 (89.0)     | 288 (89.7)   | 840 (89.3)   | 464 (88.9)     | 244 (92.1)   | 708 (90.0)   | 1548 (89.6)     |
| Not reported                              | 2 (0.3)        | 1 (0.3)      | 3 (0.3)      | 12 (2.3)       | 2 (0.8)      | 14 (1.8)     | 17 (1.0)        |
| Unknown                                   | 2 (0.3)        | 0            | 2 (0.2)      | 2 (0.4)        | 0            | 2 (0.3)      | 4 (0.2)         |
| Race, n (%)                               |                |              |              |                |              |              |                 |
| White                                     | 451 (72.7)     | 244 (76.0)   | 695 (73.9)   | 458 (87.7)     | 227 (85.7)   | 685 (87.0)   | 1380 (79.9)     |
| Black or African American                 | 36 (5.8)       | 18 (5.6)     | 54 (5.7)     | 25 (4.8)       | 20 (7.5)     | 45 (5.7)     | 99 (5.7)        |
| Asian                                     | 117 (18.9)     | 51 (15.9)    | 168 (17.9)   | 35 (6.7)       | 18 (6.8)     | 53 (6.7)     | 221 (12.8)      |
| American Indian or Alaska Native          | 2 (0.3)        | 3 (0.9)      | 5 (0.5)      | 1 (0.2)        | 0            | 1 (0.1)      | 6 (0.3)         |
| Native Hawaiian or Other Pacific Islander | 1 (0.2)        | 0            | 1 (0.1)      | 1 (0.2)        | 0            | 1 (0.1)      | 2 (0.1)         |
| Other                                     | 3 (0.5)        | 1 (0.3)      | 4 (0.4)      | 2 (0.4)        | 0            | 2 (0.3)      | 6 (0.3)         |
| Multiple: White, Asian                    | 4 (0.6)        | 4 (1.2)      | 8 (0.9)      | 0              | 0            | 0            | 8 (0.5)         |

<div style=\"page-break-after: always\"></div>

| Multiple: White, Black or African American                                    | 3 (0.5)           | 0                 | 3 (0.3)           | 0                | 0                | 0                | 3 (0.2)           |
|-------------------------------------------------------------------------------|-------------------|-------------------|-------------------|------------------|------------------|------------------|-------------------|
| Multiple: Black or African America, Native Hawaiian or Other Pacific Islander | 1 (0.2)           | 0                 | 1 (0.1)           | 0                | 0                | 0                | 1 (0.1)           |
| Multiple: White, American Indian or Alaska Native                             | 1 (0.2)           | 0                 | 1 (0.1)           | 0                | 0                | 0                | 1 (0.1)           |
| Multiple: White, Other                                                        | 1 (0.2)           | 0                 | 1 (0.1)           | 0                | 0                | 0                | 1 (0.1)           |
| Height (cm) at baseline                                                       |                   |                   |                   |                  |                  |                  |                   |
| Mean (SD)                                                                     | 169.524 (10.0702) | 169.973 (10.4706) | 169.677 (10.2052) | 169.439 (9.9977) | 169.101 (9.2930) | 169.325 (9.7614) | 169.517 (10.0042) |
| Median                                                                        | 170.000           | 170.000           | 170.000           | 169.000          | 169.700          | 169.000          | 170.000           |
| Q1, Q3                                                                        | 162.560, 177.000  | 163.000, 178.000  | 162.992, 177.000  | 162.000, 176.000 | 163.000, 176.000 | 162.500, 176.000 | 162.560, 176.650  |
| Minimum, maximum                                                              | 129.54, 194.00    | 124.46, 197.00    | 124.46, 197.00    | 141.00, 201.00   | 140.00, 195.00   | 140.00, 201.00   | 124.46, 201.00    |
| Weight (kg) at baseline                                                       |                   |                   |                   |                  |                  |                  |                   |
| Mean (SD)                                                                     | 75.082 (18.6175)  | 76.927 (18.8919)  | 75.711 (18.7220)  | 74.640 (17.4557) | 73.440 (19.6148) | 74.236 (18.2077) | 75.040 (18.4988)  |
| Median                                                                        | 73.564            | 75.000            | 74.000            | 72.537           | 70.760           | 71.900           | 73.000            |
| Q1, Q3                                                                        | 61.644, 85.864    | 63.500, 88.450    | 62.600, 86.800    | 61.700, 85.600   | 60.000, 83.500   | 60.900, 85.000   | 61.500, 86.000    |
| Minimum, maximum                                                              | 31.50, 143.10     | 32.60, 134.26     | 31.50, 143.10     | 30.80, 141.50    | 32.00, 170.55    | 30.80, 170.55    | 30.80, 170.55     |
| Weight (kg) at baseline (subjects 12-17 years)                                | n=85              | n=49              | n=134             | n=91             | n=41             | n=132            | n=266             |
| Mean (SD)                                                                     | 59.559 (15.1146)  | 61.367 (18.1151)  | 60.220 (16.2321)  | 66.315 (16.9891) | 57.812 (12.4763) | 63.674 (16.1687) | 61.934 (16.2624)  |
| Median                                                                        | 57.000            | 60.781            | 58.350            | 65.000           | 59.000           | 60.850           | 60.000            |
| Q1, Q3                                                                        | 47.700, 68.000    | 49.895, 68.500    | 48.900, 68.500    | 55.300, 74.800   | 51.000, 66.000   | 54.000, 72.200   | 51.100, 71.000    |

| Characteristic                                 | SPR.118161       | SPR.118161       | SPR.118161       | SPR.118169       | SPR.118169       | SPR.118169       | Overall total    |
|------------------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Characteristic                                 | Nemo 30 mg Q4W   | Placebo          | Total            | Nemo 30 mg Q4W   | Placebo          | Total            | Overall total    |
| Characteristic                                 | N=620            | N=321            | N=941            | N=522            | N=265            | N=787            | N=1728           |
| Minimum, maximum                               | 31.50, 106.00    | 32.60, 133.70    | 31.50, 133.70    | 30.80, 141.50    | 32.00, 82.40     | 30.80, 141.50    | 30.80, 141.50    |
| Weight (kg) at baseline (subjects 18-65 years) | n=505            | n=263            | n=768            | n=394            | n=209            | n=603            | n=1371           |
| Mean (SD)                                      | 77.194 (17.9459) | 79.744 (17.6275) | 78.067 (17.8671) | 76.069 (17.2891) | 76.707 (19.6760) | 76.290 (18.1382) | 77.286 (18.0019) |
| Median                                         | 75.700           | 77.800           | 76.000           | 73.441           | 73.000           | 73.000           | 75.000           |
| Q1, Q3                                         | 63.800, 87.271   | 67.000, 90.100   | 65.000, 88.425   | 62.300, 86.200   | 61.700, 86.500   | 62.000, 86.500   | 64.000, 87.700   |
| Minimum, maximum                               | 37.10, 143.10    | 46.00, 134.26    | 37.10, 143.10    | 44.00, 138.80    | 43.70, 170.55    | 43.70, 170.55    | 37.10, 170.55    |
| Weight (kg) at baseline (subjects >65 years)   | n=30             | n=9              | n=39             | n=37             | n=15             | n=52             | n=91             |

<div style=\"page-break-after: always\"></div>

| Mean (SD)                                        | 83.522 (16.7902)                    | 79.305 (19.5080)                    | 82.549 (17.2771)                    | 79.905 (14.1063)                    | 70.640 (13.2470)                    | 77.232 (14.3735)                    | 79.511 (15.8147)                    |
|--------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Median                                           | 81.329                              | 83.600                              | 83.400                              | 79.300                              | 68.000                              | 75.700                              | 78.925                              |
| Q1, Q3                                           | 72.000, 91.000                      | 55.100, 95.254                      | 70.760, 93.400                      | 73.000, 88.000                      | 64.200, 77.300                      | 68.100, 86.368                      | 69.000, 90.000                      |
| Minimum, maximum                                 | 55.00, 123.80                       | 53.98, 99.34                        | 53.98, 123.80                       | 51.26, 120.30                       | 55.00, 105.69                       | 51.26, 120.30                       | 51.26, 123.80                       |
| Body mass index (kg/m 2 )                        |                                     |                                     |                                     |                                     |                                     |                                     |                                     |
| Mean (SD)                                        | 26.007 (5.7276)                     | 26.526 (5.7649)                     | 26.184 (5.7426)                     | 25.896 (5.2333)                     | 25.596 (6.3432)                     | 25.795 (5.6292)                     | 26.007 (5.6929)                     |
| Median                                           | 25.069                              | 25.488                              | 25.236                              | 24.859                              | 24.536                              | 24.731                              | 24.939                              |
| Q1, Q3                                           | 21.843, 29.008                      | 22.424, 29.623                      | 22.052, 29.142                      | 22.069, 28.858                      | 21.259, 28.283                      | 21.846, 28.666                      | 21.958, 28.950                      |
| Minimum, maximum                                 | 14.78, 51.48                        | 14.96, 46.60                        | 14.78, 51.48                        | 15.01, 48.87                        | 14.94, 65.11                        | 14.94, 65.11                        | 14.78, 65.11                        |
| Body mass index (kg/m 2 ) (subjects 12-17 years) | n=85                                | n=49                                | n=134                               | n=91                                | n=41                                | n=132                               | n=266                               |
| Mean (SD)                                        | 22.194 (4.6539)                     | 22.348 (4.8792)                     | 22.251 (4.7198)                     | 23.754 (5.2252)                     | 21.045 (3.5345)                     | 22.913 (4.9148)                     | 22.579 (4.8199)                     |
| Median                                           | 21.050                              | 21.967                              | 21.615                              | 23.035                              | 20.447                              | 22.020                              | 21.795                              |
| Q1, Q3                                           | 19.054, 24.671                      | 18.741, 24.453                      | 18.973, 24.490                      | 20.349, 26.158                      | 18.286, 23.844                      | 19.378, 25.046                      | 19.255, 24.798                      |
| Minimum, maximum                                 | 14.78, 39.38                        | 14.96, 39.07                        | 14.78, 39.38                        | 15.01, 40.04                        | 14.94, 27.72                        | 14.94, 40.04                        | 14.78, 40.04                        |
| Body mass index (kg/m 2 ) (subjects 18-65 years) | n=505                               | n=263                               | n=768                               | n=394                               | n=209                               | n=603                               | n=1371                              |
| Mean (SD)                                        | 26.412 (5.5637)                     | 27.177 (5.6033)                     | 26.674 (5.5855)                     | 26.220 (5.1876)                     | 26.359 (6.5034)                     | 26.268 (5.6732)                     | 26.495 (5.6258)                     |
| Median                                           | 25.649                              | 26.004                              | 25.783                              | 25.007                              | 24.918                              | 25.000                              | 25.469                              |
| Q1, Q3                                           | 22.531, 29.218                      | 23.396, 30.245                      | 22.844, 29.498                      | 22.477, 29.229                      | 21.972, 29.297                      | 22.109, 29.297                      | 22.505, 29.366                      |
| Minimum, maximum                                 | 16.10, 51.48                        | 16.44, 46.60                        | 16.10, 51.48                        | 16.65, 48.87                        | 17.51, 65.11                        | 16.65, 65.11                        | 16.10, 65.11                        |
| Body mass index (kg/m 2 ) (subjects >65 years)   | n=30                                | n=9                                 | n=39                                | n=37                                | n=15                                | n=52                                | n=91                                |
| Mean (SD)                                        | 29.989 (6.1371)                     | 30.260 (4.6649)                     | 30.052 (5.7740)                     | 27.711 (4.2644)                     | 27.406 (4.6727)                     | 27.623 (4.3416)                     | 28.664 (5.1204)                     |
| Median                                           | 29.223                              | 32.252                              | 29.837                              | 27.236                              | 27.634                              | 27.375                              | 28.280                              |
| Characteristic                                   | SPR.118161 SPR.118169 Overall total | SPR.118161 SPR.118169 Overall total | SPR.118161 SPR.118169 Overall total | SPR.118161 SPR.118169 Overall total | SPR.118161 SPR.118169 Overall total | SPR.118161 SPR.118169 Overall total | SPR.118161 SPR.118169 Overall total |
| Characteristic                                   | Nemo 30 mg Q4W                      | Placebo                             | Total                               | Nemo 30 mg Q4W                      | Placebo                             | Total                               |                                     |
| Characteristic                                   | N=620                               | N=321                               | N=941                               | N=522                               | N=265                               | N=787                               | N=1728                              |
| Q1, Q3                                           | 25.061, 34.330                      | 25.178, 33.026                      | 25.061, 34.330                      | 25.606, 29.753                      | 23.529, 29.998                      | 24.450, 29.809                      | 24.475, 32.252                      |
| Minimum, maximum                                 | 20.70, 48.28                        | 23.24, 34.99                        | 20.70, 48.28                        | 20.91, 39.47                        | 20.20, 36.09                        | 20.20, 39.47                        | 20.20, 48.28                        |
| Smoking status, n (%)                            |                                     |                                     |                                     |                                     |                                     |                                     |                                     |
| Never                                            | 453 (73.1)                          | 247 (76.9)                          | 700 (74.4)                          | 390 (74.7)                          | 207 (78.1)                          | 597 (75.9)                          | 1297 (75.1)                         |
| Former                                           | 83 (13.4)                           | 30 (9.3)                            | 113 (12.0)                          | 55 (10.5)                           | 23 (8.7)                            | 78 (9.9)                            | 191 (11.1)                          |
| Current                                          | 84 (13.5)                           | 44 (13.7)                           | 128 (13.6)                          | 77 (14.8)                           | 35 (13.2)                           | 112 (14.2)                          | 240 (13.9)                          |
| Not reported                                     | 0                                   | 0                                   | 0                                   | 0                                   | 0                                   | 0                                   | 0                                   |

<div style=\"page-break-after: always\"></div>

ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q1=first quartile; Q3=third quartile; Q4W=every 4 weeks

Note: Percentages were based on the number of subjects in the ITT population of each treatment group. Baseline was defined as the latest valid value prior to first injection of study drug. For subjects randomized but not treated, the baseline value was the latest value prior to treatment assignment.

## Baseline disease characteristics

Baseline disease characteristics for the Initial Treatment Period in studies SPR.118161 and SPR.118169 can be seen in the table below.

Table 16: Baseline disease characteristics in studies SPR.118161 and SPR.118169 - initial treatment period (ITT population) (table 12 from SCS)

| Characteristic        | SPR.118161     | SPR.118161     | SPR.118161     | SPR.118169     | SPR.118169     | SPR.118169     | Overall total   |
|-----------------------|----------------|----------------|----------------|----------------|----------------|----------------|-----------------|
| Characteristic        | Nemo 30 mg Q4W | Placebo        | Total          | Nemo 30 mg Q4W | Placebo        | Total          | Overall total   |
| Characteristic        | N=620          | N=321          | N=941          | N=522          | N=265          | N=787          | N=1728          |
| IGA category, n (%)   |                |                |                |                |                |                |                 |
| Clear (0)             | 0              | 0              | 0              | 0              | 0              | 0              | 0               |
| Almost clear (1)      | 0              | 0              | 0              | 0              | 0              | 0              | 0               |
| Mild (2)              | 0              | 0              | 0              | 0              | 0              | 0              | 0               |
| Moderate (3)          | 438 (70.6)     | 236 (73.5)     | 674 (71.6)     | 352 (67.4)     | 185 (69.8)     | 537 (68.2)     | 1211 (70.1)     |
| Severe (4)            | 182 (29.4)     | 85 (26.5)      | 267 (28.4)     | 170 (32.6)     | 80 (30.2)      | 250 (31.8)     | 517 (29.9)      |
| Not reported          | 0              | 0              | 0              | 0              | 0              | 0              | 0               |
| EASI score, n (%)     |                |                |                |                |                |                |                 |
| Mean (SD)             | 27.77 (10.643) | 27.06 (9.374)  | 27.53 (10.228) | 27.43 (10.807) | 27.58 (10.879) | 27.48 (10.824) | 27.51 (10.501)  |
| Median                | 24.40          | 24.80          | 24.60          | 24.25          | 24.40          | 24.30          | 24.40           |
| Q1, Q3                | 19.65, 32.40   | 19.70, 32.20   | 19.70, 32.40   | 19.00, 32.60   | 18.60, 33.30   | 18.80, 33.00   | 19.20, 32.60    |
| Minimum, maximum      | 16.0, 70.8     | 16.0, 61.7     | 16.0, 70.8     | 13.4, 72.0     | 16.0, 66.0     | 13.4, 72.0     | 13.4, 72.0      |
| Weekly average PP NRS | n=618          | n=320          | n=938          | n=521          | n=264          | n=785          | n=1723          |
| Mean (SD)             | 7.170 (1.3991) | 7.150 (1.4409) | 7.163 (1.4127) | 7.038 (1.5271) | 7.164 (1.5100) | 7.081 (1.5216) | 7.126 (1.4635)  |
| Median                | 7.286          | 7.286          | 7.286          | 7.000          | 7.183          | 7.143          | 7.167           |
| Q1, Q3                | 6.286, 8.000   | 6.155, 8.143   | 6.286, 8.143   | 6.000, 8.167   | 6.000, 8.310   | 6.000, 8.250   | 6.143, 8.143    |
| Minimum, maximum      | 1.71, 10.00    | 4.00, 10.00    | 1.71, 10.00    | 3.43, 10.00    | 3.71, 10.00    | 3.43, 10.00    | 1.71, 10.00     |
| <7 a                  | 246 (39.7)     | 127 (39.6)     | 373 (39.6)     | 241 (46.2)     | 113 (42.6)     | 354 (45.0)     | 727 (42.1)      |
| ≥7 a                  | 372 (60.0)     | 193 (60.1)     | 565 (60.0)     | 280 (53.6)     | 151 (57.0)     | 431 (54.8)     | 996 (57.6)      |
| Not reported          | 2 (0.3)        | 1 (0.3)        | 3 (0.3)        | 1 (0.2)        | 1 (0.4)        | 2 (0.3)        | 5 (0.3)         |

| Characteristic        | SPR.118161     | SPR.118161   | SPR.118161   | SPR.118169     | SPR.118169   | SPR.118169   | Overall total   |
|-----------------------|----------------|--------------|--------------|----------------|--------------|--------------|-----------------|
|                       | Nemo 30 mg Q4W | Placebo      | Total        | Nemo 30 mg Q4W | Placebo      | Total        |                 |
|                       | N=620          | N=321        | N=941        | N=522          | N=265        | N=787        | N=1728          |
| Weekly average AP NRS | n=618          | n=320        | n=938        | n=521          | n=264        | n=785        | n=1723          |

<div style=\"page-break-after: always\"></div>

| Mean (SD)                 | 6.457 (1.5726)   | 6.473 (1.6031)   | 6.463 (1.5823)   | 6.468 (1.6751)       | 6.501 (1.6747)       | 6.479 (1.6740)   | 6.470 (1.6242)   |
|---------------------------|------------------|------------------|------------------|----------------------|----------------------|------------------|------------------|
| Median                    | 6.429            | 6.429            | 6.429            | 6.500                | 6.500                | 6.500            | 6.500            |
| Q1, Q3                    | 5.400, 7.600     | 5.286, 7.571     | 5.286, 7.600     | 5.167, 7.714         | 5.286, 7.714         | 5.200, 7.714     | 5.286, 7.600     |
| Minimum, maximum          | 1.14, 10.00      | 2.40, 10.00      | 1.14, 10.00      | 2.14, 10.00          | 2.00, 10.00          | 2.00, 10.00      | 1.14, 10.00      |
| Weekly average SD NRS     | n=610            | n=320            | n=930            | n=517                | n=263                | n=780            | n=1710           |
| Mean (SD)                 | 5.938 (2.1399)   | 5.742 (2.2615)   | 5.870 (2.1833)   | 5.754 (2.3033)       | 5.723 (2.3573)       | 5.743 (2.3202)   | 5.812 (2.2470)   |
| Median                    | 6.250            | 6.000            | 6.143            | 6.143                | 6.000                | 6.000            | 6.143            |
| Q1, Q3                    | 4.857, 7.429     | 4.429, 7.500     | 4.714, 7.429     | 4.286, 7.500         | 4.286, 7.500         | 4.286, 7.500     | 4.571, 7.500     |
| Minimum, maximum          | 0.00, 10.00      | 0.00, 9.86       | 0.00, 10.00      | 0.00, 10.00          | 0.00, 10.00          | 0.00, 10.00      | 0.00, 10.00      |
| BSA (%) of AD Involvement |                  |                  |                  |                      |                      |                  |                  |
| Mean (SD)                 | 44.85 (19.892)   | 43.81 (18.652)   | 44.49 (19.474)   | 44.61 (19.420)       | 44.95 (19.278)       | 44.73 (19.360)   | 44.60 (19.417)   |
| Median                    | 41.75            | 41.00            | 41.00            | 41.25                | 43.00                | 42.00            | 41.50            |
| Q1, Q3                    | 30.00, 57.00     | 29.00, 56.00     | 30.00, 56.00     | 30.00, 57.00         | 30.00, 57.50         | 30.00, 57.00     | 30.00, 57.00     |
| Minimum, maximum          | 11.0, 99.0       | 11.5, 99.0       | 11.0, 99.0       | 10.0, 98.0           | 11.0, 97.0           | 10.0, 98.0       | 10.0, 99.0       |
| SCORAD                    | n=619            | n=321            | n=940            |                      |                      |                  | n=1727           |
| Mean (SD)                 | 64.09 (11.646)   | 63.32 (11.279)   | 63.83 (11.522)   | 64.87 (11.977) 64.35 | 64.93 (13.317) 63.00 | 64.89 (12.436)   | 64.31 (11.955)   |
| Median                    | 62.60            | 62.80            | 62.80            |                      |                      | 63.60            | 63.20            |
| Q1, Q3                    | 55.80, 71.30     | 54.70, 70.40     | 55.60, 71.00     | 56.10, 73.10         | 54.60, 74.40         | 55.60, 73.60     | 55.60, 72.20     |
| Minimum, maximum          | 32.2, 96.0       | 32.2, 98.6       | 32.2, 98.6       | 37.9, 99.2           | 28.6, 96.1           | 28.6, 99.2       | 28.6, 99.2       |
| Pain frequency, n (%)     |                  |                  |                  |                      |                      |                  |                  |
| Never                     | 28 (4.5)         | 14 (4.4)         | 42 (4.5)         | 23 (4.4)             | 14 (5.3)             | 37 (4.7)         | 79 (4.6)         |
| Less than once a week     | 50 (8.1)         | 22 (6.9)         | 72 (7.7)         | 46 (8.8)             | 28 (10.6)            | 74 (9.4)         | 146 (8.4)        |
| 1-2 days a week           | 84 (13.5)        | 51 (15.9)        | 135 (14.3)       | 79 (15.1)            | 42 (15.8)            | 121 (15.4)       | 256 (14.8)       |
| 3-4 days a week           | 140 (22.6)       | 75 (23.4)        | 215 (22.8)       | 133 (25.5)           | 54 (20.4)            | 187 (23.8)       | 402 (23.3)       |
| 5-6 days a week           | 116 (18.7)       | 46 (14.3)        | 162 (17.2)       | 69 (13.2)            | 47 (17.7)            | 116 (14.7)       | 278 (16.1)       |
| Everyday                  | 193 (31.1)       | 108 (33.6)       | 301 (32.0)       | 165 (31.6)           | 74 (27.9)            | 239 (30.4)       | 540 (31.3)       |
| Not reported              | 9 (1.5)          | 5 (1.6)          | 14 (1.5)         | 7 (1.3)              | 6 (2.3)              | 13 (1.7)         | 27 (1.6)         |
| Pain intensity, n (%)     |                  |                  |                  |                      |                      |                  |                  |
| 0                         | 23 (3.7)         | 12 (3.7)         | 35 (3.7)         | 26 (5.0)             | 12 (4.5)             | 38 (4.8)         | 73 (4.2)         |
| 1                         | 16 (2.6)         | 6 (1.9)          | 22 (2.3)         | 14 (2.7)             | 8 (3.0)              | 22 (2.8)         | 44 (2.5)         |
| 2                         | 24 (3.9)         | 11 (3.4)         | 35 (3.7)         | 31 (5.9)             | 10 (3.8)             | 41 (5.2)         | 76 (4.4)         |
| 3                         | 31 (5.0)         | 18 (5.6)         | 49 (5.2)         | 29 (5.6)             | 16 (6.0)             | 45 (5.7)         | 94 (5.4)         |
| 4                         | 40 (6.5)         | 20 (6.2)         | 60 (6.4)         | 43 (8.2)             | 27 (10.2)            | 70 (8.9)         | 130 (7.5)        |
| 5                         | 65 (10.5)        | 36 (11.2)        | 101 (10.7)       | 49 (9.4)             | 23 (8.7)             | 72 (9.1)         | 173 (10.0)       |
| 6                         | 79 (12.7)        | 50 (15.6)        | 129 (13.7)       | 62 (11.9)            | 32 (12.1)            | 94 (11.9)        | 223 (12.9)       |
| 7                         | 129 (20.8)       | 53 (16.5)        | 182 (19.3)       | 91 (17.4)            | 36 (13.6)            | 127 (16.1)       | 309 (17.9)       |
| 8                         | 94 (15.2)        | 66 (20.6)        | 160 (17.0)       | 94 (18.0)            | 53 (20.0)            | 147 (18.7)       | 307 (17.8)       |
| 9                         | 77 (12.4)        | 32 (10.0)        | 109 (11.6)       | 43 (8.2)             | 31 (11.7)            | 74 (9.4)         | 183 (10.6)       |
| 10                        | 33 (5.3)         | 12 (3.7)         | 45 (4.8)         | 33 (6.3)             | 11 (4.2)             | 44 (5.6)         | 89 (5.2)         |
| Characteristic            |                  | SPR.118161       |                  |                      | SPR.118169           |                  | Overall total    |
|                           | Nemo 30          | Placebo          | Total            | Nemo 30              | Placebo              | Total            |                  |

<div style=\"page-break-after: always\"></div>

|                                                       | N=620       | N=321       | N=941          | N=522       | N=265       | N=787          | N=1728         |
|-------------------------------------------------------|-------------|-------------|----------------|-------------|-------------|----------------|----------------|
| Not reported                                          | 9 (1.5)     | 5 (1.6)     | 14 (1.5)       | 7 (1.3)     | 6 (2.3)     | 13 (1.7)       | 27 (1.6)       |
| Pain intensity                                        | n=611       | n=316       | not calculated | n=515       | n=259       | not calculated | not calculated |
| Mean (SD)                                             | 6.2 (2.50)  | 6.2 (2.41)  | not calculated | 5.9 (2.66)  | 6.0 (2.62)  | not calculated | not calculated |
| Median                                                | 7.0         | 7.0         | not calculated | 7.0         | 7.0         | not calculated | not calculated |
| Q1, Q3                                                | 5.0, 8.0    | 5.0, 8.0    | not calculated | 4.0, 8.0    | 4.0, 8.0    | not calculated | not calculated |
| Minimum, maximum                                      | 0, 10       | 0, 10       | not calculated | 0, 10       | 0, 10       | not calculated | not calculated |
| Dermatology Life Quality Index total score            | n=540       | n=279       | n=819          | n=440       | n=228       | n=668          | n=1487         |
| Mean (SD)                                             | 15.4 (6.60) | 15.5 (6.75) | 15.5 (6.65)    | 14.5 (6.85) | 14.2 (6.98) | 14.4 (6.90)    | 15.0 (6.78)    |
| Median                                                | 15.0        | 15.0        | 15.0           | 14.0        | 14.0        | 14.0           | 15.0           |
| Q1, Q3                                                | 10.0, 20.0  | 10.0, 21.0  | 10.0, 20.0     | 10.0, 19.5  | 8.5, 20.0   | 9.0, 20.0      | 10.0, 20.0     |
| Minimum, maximum                                      | 1, 30       | 1, 30       | 1, 30          | 1, 30       | 1, 30       | 1, 30          | 1, 30          |
| Children's Dermatology Life Quality Index total score | n=71        | n=37        | n=108          | n=75        | n=30        | n=105          | n=213          |
| Mean (SD)                                             | 12.7 (6.70) | 12.5 (5.83) | 12.6 (6.39)    | 12.2 (5.98) | 12.4 (5.40) | 12.3 (5.80)    | 12.5 (6.09)    |
| Median                                                | 12.0        | 13.0        | 13.0           | 11.0        | 14.0        | 11.0           | 12.0           |
| Q1, Q3                                                | 8.0, 18.0   | 8.0, 17.0   | 8.0, 17.0      | 7.0, 17.0   | 8.0, 17.0   | 7.0, 17.0      | 8.0, 17.0      |
| Minimum, maximum                                      | 1, 30       | 2, 23       | 1, 30          | 1, 26       | 2, 21       | 1, 26          | 1, 30          |
| Previous systemic treatment for AD, n (%)             |             |             |                |             |             |                |                |
| Any systemic therapy                                  | 413 (66.6)  | 213 (66.4)  | 626 (66.5)     | 313 (60.0)  | 154 (58.1)  | 467 (59.3)     | 1093 (63.3)    |
| Any biologic therapy                                  | 38 (6.1)    | 24 (7.5)    | 62 (6.6)       | 28 (5.4)    | 19 (7.2)    | 47 (6.0)       | 109 (6.3)      |
| Any immunosuppressive or immunomodulatory drugs       | 236 (38.1)  | 117 (36.4)  | 353 (37.5)     | 152 (29.1)  | 84 (31.7)   | 236 (30.0)     | 589 (34.1)     |
| Use of dupilumab                                      | 36 (5.8)    | 19 (5.9)    | 55 (5.8)       | 27 (5.2)    | 17 (6.4)    | 44 (5.6)       | 99 (5.7)       |
| Use of cyclosporine                                   | 92 (14.8)   | 41 (12.8)   | 133 (14.1)     | 70 (13.4)   | 39 (14.7)   | 109 (13.9)     | 242 (14.0)     |

AD=atopic dermatitis; AP NRS=Average Pruritus Numerical Rating Scale; BSA=body surface area; EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with available data; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q1=first quartile; Q3=third quartile; Q4W=every 4 weeks; SCORAD=SCORing Atopic Dermatitis; SD NRS=Sleep Disturbance Numerical Rating Scale

Note: Percentages were based on the number of subjects in each treatment group. Baseline was defined as the latest valid value prior to first injection of study drug. For subjects randomized but not treated, the baseline value was the latest value prior to treatment assignment. A minimum of 4 daily scores out of 7 days immediately preceding baseline was required for the PP NRS, AP NRS, and SD NRS score calculation. Pain intensity was evaluated on a scale of 0-10 (0: no pain, 10: worst unbearable pain).

a) A minimum of 250 subjects were to be randomized in each PP NRS strata. Number and percentage based on actual value, not randomization factor.

## Maintenance period

Demographic and baseline characteristics were generally similar among re-randomized groups in the maintenance period. In each group, most subjects were female (57.4% to 63.3%), white (84.6% to 87.0%), and not Hispanic or Latino (82.8% to 92.3%). Mean age ranged from 31.5 years to 35.2 years across the groups. The percentage of adolescent subjects (aged 12 to 17 years) was similar across the groups (18.3% to 20.1%).

## Numbers analysed

A summary of analysis populations for the initial treatment period and the maintenance period in study SRE.118161 is presented below.

<div style=\"page-break-after: always\"></div>

Table 17: Analysis populations - initial treatment period (all randomized subjects) study RD.06.SRE.118161 (table from the study report)

| Analysis population               | Nemolizumab 30 mg Q4W   | Placebo    |
|-----------------------------------|-------------------------|------------|
|                                   | N=620                   | N=321      |
|                                   | n (%)                   | n (%)      |
| Intent-to-treat population        | 620 (100)               | 321 (100)  |
| Subjects with baseline PP NRS ≥7- | 406 (65.5)              | 210 (65.4) |

| Analysis population                  | Nemolizumab 30 mg Q4W   | Placebo    |
|--------------------------------------|-------------------------|------------|
| Analysis population                  | N=620                   | N=321      |
| Analysis population                  | n (%)                   | n (%)      |
| Per-protocol population              | 501 (80.8)              | 256 (79.8) |
| Safely populallon                    | 616 (100)               | 321 (100)  |
| Pharmacokinetic analysis populationo | 593 (96.3)              | 0          |

PP NRS=Peak Prunitus Numeric Raling Scale a)A minimum of 250 subjects were to be randomized in each PP NRS strala.

b)Percentages Were based on the number of subjecis in each trealment group. Safely and pharmacokinetic populations Were summarized by aclual treatment group and percentages were based on number of subjects in safely population

Table 18: Analysis populations - maintenance period (all enrolled subjects) study RD.06.SRE.118161 (table from the study report)

| Analysis population                                         | Nemo 30 mg Q4W to Q4W N=90 n (%)   | Nemo 30 mg Q4W to Q8W N=91 n (%)   | Nemo 30 mg Q4W to Placebo N=91 n (%)   | Re-assigned to Placebo a N'=100 n (%)   |
|-------------------------------------------------------------|------------------------------------|------------------------------------|----------------------------------------|-----------------------------------------|
| Intent-to-treat population b                                | 90 (100)                           | 91 (100)                           | 91 (100)                               | --                                      |
| Enrolled subjects in maintenance period population          | 90 (100)                           | 91 (100)                           | 91 (100)                               | 100 (100)                               |
| Safety population c                                         | 91 (100)                           | 90 (100)                           | 91 (100)                               | --                                      |
| Enrolled safety subjects in maintenance period population c | 91 (100)                           | 90 (100)                           | 91 (100)                               | 100 (100)                               |
| Pharmacokinetic population c                                | 89 (97.8)                          | 86 (95.6)                          | 0                                      | --                                      |

N=number of subjects in the treatment group; N'=number of subjects who responded to placebo and continued to receive placebo in Maintenance Period; n=number of subjects with available data; Nemo=nemolizumab; Q4W=every 4 weeks; Q8W=every 8 weeks

Note: Percentages were based on the number of subjects in each treatment group. Safety and pharmacokinetic populations were summarized by actual treatment group and percentages were based on number of subjects in safety population. One subject was re-randomized to nemolizumab Q8W for the Maintenance Period, but erroneously received nemolizumab three times consecutively. For  analysis,  the  actual  treatment  group  was  nemolizumab/nemolizumab  Q4W,  while  the  planned  treatment  group  was nemolizumab/nemolizumab Q8W.

- a) Subjects in the placebo group were not part of the intent-to-treat population and were not re-randomized. Placebo group in the Maintenance  Period  was  for  all  placebo-treated  subjects  who  were  randomized  and  responded  to  placebo  during  the  Initial Treatment Period and continued to receive placebo during the Maintenance Period.
- b) The intent-to-treat  population  in  the  Maintenance  Period  included  subjects  who  completed  the  Initial  Treatment  Period,  were responders at Week 16, and were re-randomized to the Maintenance Period.
- c) Percentages  were  based  on  the  number  of  subjects  in  each  treatment  group.  Safety  and  pharmacokinetic  populations  were summarized by actual treatment group and percentages were based on number of subjects in safety population. One subject was re-randomized to nemolizumab Q8W for the Maintenance Period, but erroneously received nemolizumab three times consecutively. For  analysis,  the  actual  treatment  group  was  nemolizumab/nemolizumab  Q4W,  while  the  planned  treatment  group  was nemolizumab/nemolizumab Q8W

<div style=\"page-break-after: always\"></div>

A summary of analysis populations for the initial treatment period and the maintenance period in study SRE.118169 is presented below.

Table 19: Analysis populations - initial treatment period (all randomized subjects) study RD.06.SRE.118169 (table from the study report)

| Analysispopulation                 | Nemolizumab 30 mg Q4W   | Placebo    |
|------------------------------------|-------------------------|------------|
|                                    | N=522                   | N=265      |
|                                    | n (%)                   | n (%)      |
| Inlenl-to-treat population         | 522 (100)               | 265 (100)  |
| Subjecls with baseline PP NRS 27-  | 316 (60.5)              | 164 (61.9) |
| Per-prolocol populalion            | 454 (87.0)              | 227 (85.7) |
| Salety populatlon*                 | 519 (100)               | 263 (100)  |
| Pharmacokinelicanalysispopulationb | 499 (96.1)              | 0          |

N=number of subjects in the treatment group: n=number of subjecls with available datar PP NRS=Peak Pruritus NumericRaling Scale:Q4vW=every 4weeks

Note: Percenlages were based on the number of subjects in each treatment group. Safety and pharmacokinelic population.

a)A minimum of 250 subjects were to be randomized in each PP NRS strata

- b)Percentages Were based on the number of subjects in each trealment group. Safely and pharmacokinetic safety population

Table 20: Analysis populations - maintenance period (all enrolled subjects) study RD.06.SRE.118169 (table from the study report)

| Analysis population                                       | Nemo 30 mg Q4W toQ4W   | Nemo 30 mg Q4W toQ8W   | Nemo 30 mg Q4W toPlacebo   | Re-assigned to Placebo\"   |
|-----------------------------------------------------------|------------------------|------------------------|----------------------------|---------------------------|
| Intent-to-treat populationb                               | N=79 n (%) 79 (100)    | N=78 n (%) 78 (100)    | 8L=N n (%) 78 (100)        | N'=85 n(%6)               |
| Enrolled subjecls inmaintenanceperiod population          | 79 (100)               | 78 (100)               | 78 (100)                   | 85 (100)                  |
| Safety population                                         | 79 (100)               | 77 (100)               | 77 (100)                   |                           |
| Enrolled safety subjects in maintenance period population | 79 (100)               | 77 (100)               | 77 (100)                   | 84 (100)                  |
| Pharmacokinetic population-                               | 77 (97.5)              |                        | 0                          |                           |
|                                                           |                        | 75 (97.4)              |                            |                           |

N=number of subjecis In the trealment group: N=number of subjecls who responded to placebo and continued to receiveplaceboinMaintenancePeriod:n=numberofsubjectswithavailabledala:Nemo=nemolizumab Q4vluevery 4 weeks; O8wlevery 8 weeks

Note: Percenlages Were based on the number of subjecis in each trealment group. Inlent-to-treat populalion in percentages were based on number of subjecis In safety populallon.

- group in the Mainlenance Period was for all placebo-treated subjecls Who Were randomized and responded to placebo during the Inlial Trealment Period and continued to recelve placebo duning the Malnlenance Period
- b The inlent-to-treat populalion in the Mainlenance Period included subjecls who completed the: Inilial Trealment Perlod, were responders at Week 16, and were re-randomlzed to the Malntenance Perlod.
- Percenlages were based on the number of subjects in each treatment group. Safety and phamacokinelic populalions were summanized by actual trealmenl group and percenlages were based on number of subjecls in Safety population. For analysis, the actual treatment group was nemolizumabinemollzumab Q4w, while the planned trealment group was nemolizumab/nemolizumab Qsw

## Outcomes and estimation

In this overview AR, the results with the co-primary efficacy endpoints and the key secondary efficacy endpoints will be shown in tables (see below).

## Co-Primary efficacy endpoints

-  IGA success and EASI-75 at week 16

<div style=\"page-break-after: always\"></div>

The table below presents the results of the co-primary endpoints, the proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥2-point reduction from baseline) at Week 16, and the proportion of subjects with EASI-75 (≥75% improvement in EASI from baseline) at Week 16.

<div style=\"page-break-after: always\"></div>

Table 21: Summary of co-primary efficacy endpoints from studies SPR.118161 and SPR.118169 - initial treatment period (ITT population) (table 13 from the SCE)

| Endpoint                                        | SPR.118161     | SPR.118161   | SPR.118161           | SPR.118161           | SPR.118169     | SPR.118169   | SPR.118169           | SPR.118169           |
|-------------------------------------------------|----------------|--------------|----------------------|----------------------|----------------|--------------|----------------------|----------------------|
| Endpoint                                        | Treatment      | Treatment    | Treatment difference | Treatment difference | Treatment      | Treatment    | Treatment difference | Treatment difference |
| Endpoint                                        | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              |
| IGA success at Week 16                          |                |              |                      |                      |                |              |                      |                      |
| Full population                                 | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                           | 221 (35.6)     | 79 (24.6)    |                      |                      | 197 (37.7)     | 69 (26.0)    |                      |                      |
| Unadjusted proportion difference 95% CI         | 11.0           |              | 5.0, 17.1            | 0.0006               | 11.7           |              | 5.0, 18.4            | 0.0010               |
| Strata-adjusted proportion difference 97.5% CI  | 11.5           |              | 4.7, 18.3            | 0.0003               | 12.2           |              | 4.6, 19.8            | 0.0006               |
| Severe pruritus population (baseline PP NRS ≥7) | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                           | 144 (35.5)     | 45 (21.4)    |                      |                      | 116 (36.7)     | 36 (22.0)    |                      |                      |
| Unadjusted proportion difference 95% CI         | 14.0           |              | 6.8, 21.3            | 0.0003               | 14.8           |              | 6.5, 23.0            | 0.0010               |
| Strata-adjusted proportion difference 97.5% CI  | 14.3           |              | 6.1, 22.5            | 0.0002               | 14.9           |              | 5.6, 24.3            | 0.0008               |
| EASI-75 at Week 16                              |                |              |                      |                      |                |              |                      |                      |
| Full population                                 | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                           | 270 (43.5)     | 93 (29.0)    |                      |                      | 220 (42.1)     | 80 (30.2)    |                      |                      |
| Unadjusted proportion difference 95% CI         | 14.6           |              | 8.3, 20.9            | <0.0001              | 12.0           |              | 5.0, 18.9            | 0.0011               |
| Strata-adjusted proportion difference 97.5% CI  | 14.9           |              | 7.8, 22.0            | <0.0001              | 12.5           |              | 4.6, 20.3            | 0.0006               |
| Severe pruritus population (baseline PP NRS ≥7) | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                           | 169 (41.6)     | 50 (23.8)    |                      |                      | 130 (41.1)     | 41 (25.0)    |                      |                      |
| Unadjusted proportion difference 95% CI         | 17.8           |              | 10.3, 25.3           | <0.0001              | 16.1           |              | 7.6, 24.7            | 0.0005               |
| Strata-adjusted proportion difference 97.5% CI  | 18.1           |              | 9.6, 26.6            | <0.0001              | 16.3           |              | 6.6, 26.0            | 0.0004               |

EASI=Eczema Area and Severity Index; EASI-75=≥75% improvement in EASI from baseline; IGA=Investigator's Global Assessment; ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with IGA success or EASI-75; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks

Note: IGA success was defined as subjects with 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline. Percentages were based on number of subjects in the population of each treatment group. Baseline value was the last valid value prior to first injection of study drug of the Initial Treatment Period. If a subject received any rescue therapy, the data on or after receipt of rescue therapy were considered not evaluable for analysis, and the subject was considered treatment failure. Subjects with missing result at a visit were considered non-responders for that visit. Unadjusted p-values were from the Mantel-Haenszel Chi-square test. Strata-adjusted p-values were from CochranMantel-Haenszel test adjusting for the randomization stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS [≥7, &lt;7] for full population; IGA severity only for Baseline PP NRS ≥7 population).

## Key secondary efficacy endpoints

The key secondary endpoints were tested sequentially following hierarchical testing procedure using the pre-specified order of endpoints.

The table below presents the results of the key secondary efficacy endpoint, an improvement in PPNRS (peak pruritus numerical rating scale) of ≥4-at week 1, week 2, week 4, and at Week 16.

-  PP NRS improvement of ≥4 from baseline at week 1, week 2, week 4, and week 16

<div style=\"page-break-after: always\"></div>

Table 22: Proportion of subjects with weekly average PP NRS improvement of ≥4 from baseline at week 1, week 2, week 4, and week 16 from studies SPR.118161 and SPR.118169 (missing as non-responder) - initial treatment period (ITT population) (table 14 from the SCE)

| Endpoint                                            | SPR.118161     | SPR.118161   | SPR.118161           | SPR.118161           | SPR.118169     | SPR.118169   | SPR.118169           | SPR.118169           |
|-----------------------------------------------------|----------------|--------------|----------------------|----------------------|----------------|--------------|----------------------|----------------------|
|                                                     | Treatment      | Treatment    | Treatment difference | Treatment difference | Treatment      | Treatment    | Treatment difference | Treatment difference |
|                                                     | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              |
| Improvement of ≥4 from baseline in PP NRS at Week 1 |                |              |                      |                      |                |              |                      |                      |
| Full population                                     | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                               | 29 (4.7)       | 4 (1.2)      |                      |                      | 35 (6.7)       | 1 (0.4)      |                      |                      |
| Unadjusted proportion difference 95% CI             | 3.4            |              | 1.4, 5.5             | 0.0067               | 6.3            |              | 4.1, 8.6             | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI      | 3.4            |              | 1.1, 5.8             | 0.0064               | 6.4            |              | 3.8, 9.1             | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7)     | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                               | 25 (6.2)       | 4 (1.9)      |                      |                      | 27 (8.5)       | 1 (0.6)      |                      |                      |
| Unadjusted proportion difference 95% CI             | 4.3            |              | 1.3, 7.2             | 0.0183               | 7.9            |              | 4.6, 11.2            | 0.0004               |
| Strata-adjusted proportion difference 97.5% CI      | 4.3            |              | 0.9, 7.7             | 0.0177               | 8.0            |              | 4.2, 11.8            | 0.0004               |
| Improvement of ≥4 from baseline in PP NRS at Week 2 |                |              |                      |                      |                |              |                      |                      |
| Full population                                     | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                               | 110 (17.7)     | 10 (3.1)     |                      |                      | 88 (16.9)      | 5 (1.9)      |                      |                      |
| Unadjusted proportion difference 95% CI             | 14.6           |              | 11.1, 18.2           | <0.0001              | 15.0           |              | 11.4, 18.6           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI      | 14.6           |              | 10.6, 18.7           | <0.0001              | 15.1           |              | 11.0, 19.2           | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7)     | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                               | 84 (20.7)      | 8 (3.8)      |                      |                      | 61 (19.3)      | 5 (3.0)      |                      |                      |
| Unadjusted proportion difference 95% CI             | 16.9           |              | 12.2, 21.6           | <0.0001              | 16.3           |              | 11.2, 21.3           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI      | 16.9           |              | 11.5, 22.3           | <0.0001              | 16.3           |              | 10.5, 22.1           | <0.0001              |

<div style=\"page-break-after: always\"></div>

| Endpoint                                             | SPR.118161     | SPR.118161   | SPR.118161           | SPR.118161           | SPR.118169     | SPR.118169   | SPR.118169           | SPR.118169           |
|------------------------------------------------------|----------------|--------------|----------------------|----------------------|----------------|--------------|----------------------|----------------------|
|                                                      | Treatment      | Treatment    | Treatment difference | Treatment difference | Treatment      | Treatment    | Treatment difference | Treatment difference |
|                                                      | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              |
| Improvement of ≥4 from baseline in PP NRS at Week 4  |                |              |                      |                      |                |              |                      |                      |
| Full population                                      | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                                | 170 (27.4)     | 21 (6.5)     |                      |                      | 136 (26.1)     | 14 (5.3)     |                      |                      |
| Unadjusted proportion difference 95% CI              | 20.9           |              | 16.4, 25.3           | <0.0001              | 20.8           |              | 16.1, 25.4           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI       | 20.9           |              | 15.8, 26.0           | <0.0001              | 20.9           |              | 15.6, 26.1           | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7)      | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                                | 115 (28.3)     | 15 (7.1)     |                      |                      | 96 (30.4)      | 13 ( 7.9)    |                      |                      |
| Unadjusted proportion difference 95% CI              | 21.2           |              | 15.6, 26.8           | <0.0001              | 22.5           |              | 15.9, 29.0           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI       | 21.2           |              | 14.8, 27.6           | <0.0001              | 22.5           |              | 15.0, 29.9           | <0.0001              |
| Improvement of ≥4 from baseline in PP NRS at Week 16 |                |              |                      |                      |                |              |                      |                      |
| Full population                                      | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                                | 265 (42.7)     | 57 (17.8)    |                      |                      | 214 (41.0)     | 48 (18.1)    |                      |                      |
| Unadjusted proportion difference 95% CI              | 25.0           |              | 19.3, 30.7           | <0.0001              | 22.9           |              | 16.6, 29.2           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI       | 24.9           |              | 18.4, 31.5           | <0.0001              | 23.2           |              | 15.7, 30.1           | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7)      | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                                | 187 (46.1)     | 39 (18.6)    |                      |                      | 153 (48.4)     | 35 (21.3)    |                      |                      |
| Unadjusted proportion difference 95% CI              | 27.5           |              | 20.3, 34.6           | <0.0001              | 27.1           |              | 18.7, 35.4           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI       | 27.5           |              | 19.4, 35.7           | <0.0001              | 27.1           |              | 17.5, 36.6           | <0.0001              |

IGA=Investigator's Global Assessment; ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects  in  the  ITT  population  of  each  treatment  group;  n=number  of  subjects  with  PP NRS  improvement  of ≥4; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks

Note: Percentages were based on number of subjects in the population of each treatment group. Weekly PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. Baseline value was the weekly score derived using 7 consecutive days diary data prior to first injection of study drug of the Initial Treatment  Period.  If  a  subject  received  any  rescue  therapy,  the  data  on  or  after  receipt  of  rescue  therapy  were considered treatment failures. Subjects with missing results at a visit were considered non-responders for that visit. Unadjusted p-values were from Mantel-Haenszel Chi-square test. Strata-adjusted p-values were from Cochran-MantelHaenszel test adjusting for the randomized stratification variables (IGA severity and PP NRS for full population; IGA severity only for baseline PP NRS ≥7 population).

The table below presents the results of the key secondary efficacy endpoint, the proportion of subjects with weekly average PP NRS &lt;2 at week 4 and week 16.

## PP NRS &lt;2 at week 4 and week 16

<div style=\"page-break-after: always\"></div>

Table 23: Proportion of subjects with weekly average PP NRS &lt;2 at week 4 and week 16 from studies SPR.118161 and SPR.118169 (missing as non-responder) - initial treatment period (ITT population) (table 15 from the SCE)

| Endpoint                                        | SPR.118161     | SPR.118161   | SPR.118161           | SPR.118161           | SPR.118169     | SPR.118169   | SPR.118169           | SPR.118169           |
|-------------------------------------------------|----------------|--------------|----------------------|----------------------|----------------|--------------|----------------------|----------------------|
|                                                 | Treatment      | Treatment    | Treatment difference | Treatment difference | Treatment      | Treatment    | Treatment difference | Treatment difference |
|                                                 | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              |
| PP NRS <2 at Week 4                             |                |              |                      |                      |                |              |                      |                      |
| Full population                                 | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                           | 99 (16.0)      | 12 (3.7)     |                      |                      | 83 (15.9)      | 7 (2.6)      |                      |                      |
| Unadjusted proportion difference 95% CI         | 12.2           |              | 8.7, 15.8            | <0.0001              | 13.3           |              | 9.6, 16.9            | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI  | 12.2           |              | 8.2, 16.3            | <0.0001              | 13.2           |              | 9.0, 17.4            | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7) | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                           | 51 (12.6)      | 6 (2.9)      |                      |                      | 35 (11.1)      | 2 (1.2)      |                      |                      |
| Unadjusted proportion difference 95% CI         | 9.7            |              | 5.8, 13.6            | <0.0001              | 9.9            |              | 6.0, 13.7            | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI  | 9.7            |              | 5.2, 14.2            | <0.0001              | 9.9            |              | 5.5, 14.3            | <0.0001              |
| PP NRS <2 at Week 16                            |                |              |                      |                      |                |              |                      |                      |
| Full population                                 | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                           | 190 (30.6)     | 36 (11.2)    |                      |                      | 148 (28.4)     | 30 (11.3)    |                      |                      |
| Unadjusted proportion difference 95% CI         | 19.4           |              | 14.4, 24.4           | <0.0001              | 17.0           |              | 11.6, 22.5           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI  | 19.5           |              | 13.7, 25.2           | <0.0001              | 17.1           |              | 10.9, 23.3           | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7) | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                           | 113 (27.8)     | 16 (7.6)     |                      |                      | 85 (26.9)      | 14 (8.5)     |                      |                      |
| Unadjusted proportion difference 95% CI         | 20.2           |              | 14.6, 25.9           | <0.0001              | 18.4           |              | 11.9, 24.9           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI  | 20.3           |              | 13.8, 26.8           | <0.0001              | 18.4           |              | 11.0, 25.8           | <0.0001              |

IGA=Investigator's Global Assessment; ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with PP NRS &lt;2; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks

Note: Percentages were based on number of subjects in each treatment group. Weekly PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a subject received any rescue therapy, the data on or after receipt of rescue therapy were considered treatment failures. Subjects with missing results at  a  visit  were  considered  non-responders for that visit. Unadjusted p-values were from Mantel-Haenszel Chi-square test. Strata-adjusted p-values were from Cochran-MantelHaenszel test adjusting for the randomized stratification variables (IGA severity and PP NRS for full population; IGA severity only for baseline PP NRS ≥7 population).

<div style=\"page-break-after: always\"></div>

The table below presents the results of the key secondary efficacy endpoint, the proportion of subjects with weekly average SD NRS (sleep disturbance numerical rating scale) improvement of ≥4 from baseline at week 16.

## SD NRS improvement ≥4 from baseline at week 16

<div style=\"page-break-after: always\"></div>

Table 24: Proportion of subjects with weekly average SD NRS improvement of ≥4 from baseline at week 16 from studies SPR.118161 and SPR.118169 (missing as non-responder) - initial treatment period (ITT population) (table 16 from the SCE)

| Endpoint                                             | SPR.118161     | SPR.118161   | SPR.118161           | SPR.118161           | SPR.118169     | SPR.118169   | SPR.118169           | SPR.118169           |
|------------------------------------------------------|----------------|--------------|----------------------|----------------------|----------------|--------------|----------------------|----------------------|
|                                                      | Treatment      | Treatment    | Treatment difference | Treatment difference | Treatment      | Treatment    | Treatment difference | Treatment difference |
|                                                      | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              |
| Improvement of ≥4 from baseline in SD NRS at Week 16 |                |              |                      |                      |                |              |                      |                      |
| Full population                                      | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                                | 235 (37.9)     | 64 (19.9)    |                      |                      | 175 (33.5)     | 43 (16.2)    |                      |                      |
| Unadjusted proportion difference 95% CI              | 18.0           |              | 12.2, 23.8           | <0.0001              | 17.3           |              | 11.3, 23.3           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI       | 17.9           |              | 11.3, 24.5           | <0.0001              | 17.5           |              | 10.8, 24.3           | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7)      | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                                | 171 (42.1)     | 47 (22.4)    |                      |                      | 135 (42.7)     | 34 (20.7)    |                      |                      |
| Unadjusted proportion difference 95% CI              | 19.7           |              | 12.3, 27.1           | <0.0001              | 22.0           |              | 13.7, 30.3           | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI       | 19.7           |              | 11.2, 28.2           | <0.0001              | 21.9           |              | 12.5, 31.4           | <0.0001              |

IGA=Investigator's Global Assessment; ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with SD NRS improvement of ≥4; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks; SD NRS=Sleep Disturbance Numerical Rating Scale

Note: Percentages were based on number of subjects in each treatment group. Weekly SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. Baseline value was the weekly score derived using 7 consecutive days diary data prior to first injection of study drug of the Initial Treatment Period. If a subject received any rescue therapy, the data on or after receipt of rescue therapy were considered treatment failures. Subjects with missing results at a visit were considered nonresponders for that visit.  Unadjusted  p-values  were  from  Mantel-Haenszel  Chi-square  test.  Strata-adjusted  p-values  were  from  Cochran-Mantel-Haenszel  test  adjusting  for  the randomized stratification variables (IGA severity and PP NRS for full population; IGA severity only for baseline PP NRS ≥7 population).

<div style=\"page-break-after: always\"></div>

The table below presents the results of the key secondary efficacy endpoint, the proportion of subjects with EASI-75 and weekly average PP NRS improvement of ≥4 from baseline at week 16 from studies.

EASI-75 and PP NRS improvement ≥4 from baseline at week 16

<div style=\"page-break-after: always\"></div>

Table 25: Proportion of subjects with EASI-75 and weekly average PP NRS improvement of ≥4 from baseline at week 16 from studies SPR.118161 and SPR.118169 (missing as non-responder) - initial treatment period (ITT population) (table 17 from the SCE)

| Endpoint                                                                     | SPR.118161     | SPR.118161   | SPR.118161           | SPR.118161           | SPR.118169     | SPR.118169   | SPR.118169           | SPR.118169           |
|------------------------------------------------------------------------------|----------------|--------------|----------------------|----------------------|----------------|--------------|----------------------|----------------------|
|                                                                              | Treatment      | Treatment    | Treatment difference | Treatment difference | Treatment      | Treatment    | Treatment difference | Treatment difference |
|                                                                              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              |
| EASI-75 improvement and improvement of ≥4 from baseline in PP NRS at Week 16 |                |              |                      |                      |                |              |                      |                      |
| Full population                                                              | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                                                        | 147 (23.7)     | 36 (11.2)    |                      |                      | 120 (23.0)     | 26 (9.8)     |                      |                      |
| Unadjusted proportion difference 95% CI                                      | 12.5           |              | 7.7, 17.3            | <0.0001              | 13.2           |              | 8.1, 18.3            | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI                               | 12.6           |              | 7.1, 18.1            | <0.0001              | 13.4           |              | 7.6, 19.2            | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7)                              | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                                                        | 105 (25.9)     | 24 (11.4)    |                      |                      | 85 (26.9)      | 17 (10.4)    |                      |                      |
| Unadjusted proportion difference 95% CI                                      | 14.4           |              | 8.4, 20.5            | <0.0001              | 16.5           |              | 9.8, 23.3            | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI                               | 14.5           |              | 7.6, 21.5            | <0.0001              | 16.6           |              | 8.9, 24.3            | <0.0001              |

EASI=Eczema Area and Severity Index; EASI-75=≥75% improvement in EASI from baseline; IGA=Investigator's Global Assessment; ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with EASI-75 improvement and PP NRS improvement of ≥4 from baseline; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks

Note: Percentages were based on number of subjects in each treatment group. Weekly PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. Baseline EASI score was the last valid value prior to first injection of study drug of the Initial Treatment Period, and baseline PP NRS was derived using 7 consecutive days diary data prior to first injection of study drug. If a subject received any rescue therapy, the data on or after receipt of rescue therapy were considered treatment failures.  Subjects  with  missing  results  were  considered  non-responders.  Unadjusted  p-values  were  from  Mantel-Haenszel  Chi-square  test.  Strata-adjusted  p-values  were  from Cochran-Mantel-Haenszel test adjusting for the randomized stratification variables (IGA severity and PP NRS for full population; IGA severity only for baseline PP NRS ≥7 population).

<div style=\"page-break-after: always\"></div>

##  IGA success and PP NRS improvement ≥4 from baseline at week 16

The table below presents the results of the key secondary efficacy endpoint, the proportion of subjects with an IGA success and weekly average PP NRS improvement of ≥4 from baseline at week 16.

<div style=\"page-break-after: always\"></div>

Table 26: Proportion of subjects with an IGA success and weekly average PP NRS improvement of ≥4 from baseline at week 16 from studies SPR.118161 and SPR.118169 (missing as non-responder) - initial treatment period (ITT population) (table 18 from the SCE)

| Endpoint                                                             | SPR.118161     | SPR.118161   | SPR.118161           | SPR.118161           | SPR.118169     | SPR.118169   | SPR.118169           | SPR.118169           |
|----------------------------------------------------------------------|----------------|--------------|----------------------|----------------------|----------------|--------------|----------------------|----------------------|
|                                                                      | Treatment      | Treatment    | Treatment difference | Treatment difference | Treatment      | Treatment    | Treatment difference | Treatment difference |
|                                                                      | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              | Nemo 30 mg Q4W | Placebo      | CI                   | P-value              |
| IGA success and improvement of ≥4 from baseline in PP NRS at Week 16 |                |              |                      |                      |                |              |                      |                      |
| Full population                                                      | N=620          | N=321        |                      |                      | N=522          | N=265        |                      |                      |
| n (%)                                                                | 122 (19.7)     | 30 (9.3)     |                      |                      | 107 (20.5)     | 23 (8.7)     |                      |                      |
| Unadjusted proportion difference 95% CI                              | 10.3           |              | 5.9, 14.8            | <0.0001              | 11.8           |              | 7.0, 16.7            | <0.0001              |
| Strata-adjusted proportion difference 97.5% CI                       | 10.5           |              | 5.4, 15.6            | <0.0001              | 12.1           |              | 6.6, 17.6            | <0.0001              |
| Severe pruritus population (baseline PP NRS ≥7)                      | N=406          | N=210        |                      |                      | N=316          | N=164        |                      |                      |
| n (%)                                                                | 88 (21.7)      | 21 (10.0)    |                      |                      | 75 (23.7)      | 17 (10.4)    |                      |                      |
| Unadjusted proportion difference 95% CI                              | 11.7           |              | 6.0, 17.4            | 0.0003               | 13.4           |              | 6.8, 20.0            | 0.0004               |
| Strata-adjusted proportion difference 97.5% CI                       | 11.8           |              | 5.3, 18.3            | 0.0003               | 13.4           |              | 5.9, 21.0            | 0.0004               |

IGA=Investigator's Global Assessment; ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with IGA success and PP NRS improvement of ≥4 from baseline; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks Note: IGA success was defined as subjects with 0 (clear) or 1 (almost clear) and at least 2-grade improvement from baseline. Percentages were based on number of subjects in each treatment group. Weekly PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. Baseline IGA score was the last valid value prior to first injection of study drug of the Initial Treatment Period, and Baseline PP NRS was derived using 7 consecutive days diary data prior to first injection of study drug. If a subject received any rescue therapy, the data on or after receipt of rescue therapy were considered treatment failures. Subjects with missing results of IGA values or PP NRS improvement at Week 16 were considered non-responders. Unadjusted p-values were from Mantel-Haenszel Chi-square test. Strata-adjusted p-values were from Cochran-MantelHaenszel test adjusting for the randomized stratification variables (IGA severity and PP NRS for full population; IGA severity only for baseline PP NRS ≥7 population).

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

Subgroup analysis of proportion of subjects with an IGA Success and achievement of EASI-75 in study SPR.118161 in the full population is shown below.

Study SPR.118161

## IGA

## Figure 12: Subgroup Analysis of Proportion of Subjects with an IGA Success at Week 16 with Forest Plot - Missing as Non-Responder - Initial Period ITT Population (table from the study

report SPR.118161)

<!-- image -->

0

-100

-50

50

100

Nemolizumab

Unadjusted

<div style=\"page-break-after: always\"></div>

<!-- image -->

-100

-50

0

50

100

laueuesossy Teqoia 5,xo4ebrasoauI = Ho1lTenxsaul soueprzuoy = Io leaep otqetrene 4arm saosfqns go xequnu = u luoraeindod su4 ug s4osfqne go xaqunu = N :eoaoN PP NRS = Peak Pruritus Numeric Rating Scale; ITT = intent-to-treat; NE = not estimated. IGA success is defined as subjects with 0 (clear) or 1 (almost clear) and at least 2-gzade improvement from Baseline. Percentages (e) are based on number of subjects in each treatment group. If a subject received any rescue therapy, the data after receipt of rescue therapy is considered treatment failure. Unadjusted p-value is from Mantel-Haenszel Chi-square test. Strata adjusted p-values are from Cochran-Mantel-Haenszel (CMH) test adjusting the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NR8 [27, &lt;7] for full population; IGA severity only for Baseline PP NRs &gt;=7 population) . 'sdnox6 aueuarex4 uoaMa2q souexeg3TP p24snlpr-r4ex4s go 4Tns9x sua uo p9suq 57 4oTd 4r9xog Program: t-14-02-01-01-10.sas, Run date:21JUN2023 02:15, DBL Date: 15NOV2022 Listing source (s) : 16.2.6.1

## EASI-75

Figure 13: Subgroup Analysis of Proportion of Subjects with EASI-75 at Week 16 with Forest Plot - Missing as Non-Responder - Initial Period ITT Population (table from the study report SPR.118161)

<!-- image -->

0

50

-100

-50

100

<div style=\"page-break-after: always\"></div>

<!-- image -->

Study SPR.118169

Subgroup analysis of proportion of subjects with an IGA Success and achievement of EASI-75 in study SPR.118169 in the full population is shown below.

## IGA

Figure 14: Subgroup Analysis of Proportion of Subjects with an IGA Success at Week 16 with Forest Plot - Missing as Non-Responder - Initial Period ITT Population (table from the study report SPR.118169)

<!-- image -->

-100

-50

0

50

100

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## EASI-75

Figure 15: Subgroup Analysis of Proportion of Subjects with EASI-75 at Week 16 with Forest Plot - Missing as Non-Responder - Initial Period ITT Population (table from the study report SPR.118169)

<!-- image -->

-100

-50

0

50

100

<div style=\"page-break-after: always\"></div>

<!-- image -->

-100

-50

0

50

100

```
Notes: N = number of subjects in the population; n = number of subjects with available data; CI = Confidence Interval;EASI = Eczema Area and Severity Index; PP NRS = Peak Pruritus Numeric Rating Scale; ITT = intent-to-treat; NE = not estimated. EA3I-75 defined as ≥ 75e improvement in EASI from Baseline. ·dnoxb 4uewawaxa yoes ur saosfqne go xequmu uo poeeq exe (e) sobequeoxed If a subject received any rescue therapy, the data after receipt of rescue therapy is considered treatment failure. Unadjusted p-value is from Mantel-Haenszel Chi-square test. Strata adjusted p-values are from Cochran-Mantel-Haenszel (CMH) test adjusting the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRs [27, <7] for full population; IGh severity only for Baseline PP NRs >=7 population) . Program:t-14-02-01-02-10.sas, Run date: 14JUN2023 06:06, DBL Date: 06DEC2022 Listing source (=) : 16.2.6.2
```

## Maintenance period (week 16 to week 48)

The endpoints of the Maintenance Period were analysed and presented by the following subgroups: region, age group, sex, race, and country.

## Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 27: Summary of efficacy for trial RD.06.SPR.118161 (ARCADIA 1)

| Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis   | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis                                                                                                                                       | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis                                                                                                                                                                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                               | EUdraCT: 2019-001887-31 Protocol ID: RD.06.SPR.118161                                                                                                                                                                                                                                                              | EUdraCT: 2019-001887-31 Protocol ID: RD.06.SPR.118161                                                                                                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                         | This was a Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group study that evaluated the efficacy and safety of nemolizumab in adult and adolescent subjects with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medications. | This was a Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group study that evaluated the efficacy and safety of nemolizumab in adult and adolescent subjects with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medications.                                                                                                                   |
| Design                                                                                                                                                                         | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                     | The study consisted of 4 periods over approximately 60 weeks:  Screening Period (approximately 2 to 4 weeks before planned Day 1/baseline, including run-in of at least 14 days),  Initial Treatment Period (Day 1/baseline to Week 16 Pre-dose),  Maintenance Period (Week 16 to Week 48)  Follow-up Period (unless the subject was a non- responder at Week 16, at which their participation could have lasted up to 28 weeks) |

<div style=\"page-break-after: always\"></div>

| Hypothesis                | Subjects treated by nemolizumab will have significant improvement in atopic dermatitis signs and symptoms after 16 weeks of treatment compared to placebo treated subjects.   | Subjects treated by nemolizumab will have significant improvement in atopic dermatitis signs and symptoms after 16 weeks of treatment compared to placebo treated subjects.   | Subjects treated by nemolizumab will have significant improvement in atopic dermatitis signs and symptoms after 16 weeks of treatment compared to placebo treated subjects.                                                   |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups         | Initial nemo Q4W                                                                                                                                                              | Initial nemo Q4W                                                                                                                                                              | A total of 620 subjects were randomized to nemolizumab in the Initial Treatment Period.                                                                                                                                       |
| Treatments groups         | Initial plac Q4W                                                                                                                                                              | Initial plac Q4W                                                                                                                                                              | A total of 321 subjects were randomized to placebo in the Initial Treatment Period.                                                                                                                                           |
| Treatments groups         | Maint nemo Q4W                                                                                                                                                                | Maint nemo Q4W                                                                                                                                                                | At Week 16, 90 nemolizumab-treated subjects who were clinical responders were re-randomized to receive nemolizumab Q4W                                                                                                        |
| Treatments groups         | Maint nemo Q8W                                                                                                                                                                | Maint nemo Q8W                                                                                                                                                                | during the Maintenance Period At Week 16, 91 nemolizumab-treated subjects who were clinical responders were re-randomized to receive nemolizumab Q8W during the Maintenance Period                                            |
| Treatments groups         | Maint plac Q4W                                                                                                                                                                | Maint plac Q4W                                                                                                                                                                | At Week 16, 91 nemolizumab-treated subjects who were clinical responders were re-randomized to receive placebo during the Maintenance Period                                                                                  |
| Treatments groups         | Plac to plac                                                                                                                                                                  | Plac to plac                                                                                                                                                                  | Placebo group in the Maintenance Period was for all placebo treated subjects who were randomized and responded to placebo during the Initial Treatment Period and continued to receive placebo during the Maintenance Period. |
| Endpoints and definitions | Co-Primary endpoint                                                                                                                                                           | IGA success                                                                                                                                                                   | Proportion of subjects with IGA success (defined as an IGA of 0 [clear] or 1 [almost clear]) and a ≥2-point reduction from baseline at Week 16.                                                                               |
| Endpoints and definitions | Co-Primary endpoint                                                                                                                                                           | EASI-75                                                                                                                                                                       | Proportion of subjects with EASI-75 (≥75% improvement in EASI from baseline) at Week 16.                                                                                                                                      |
| Endpoints and definitions | Key Secondary                                                                                                                                                                 | PP NRS improveme nt ≥ 4 at Week 16                                                                                                                                            | Proportion of subjects with PP NRS improvement ≥ 4 at Week 16                                                                                                                                                                 |
| Endpoints and definitions | Key Secondary                                                                                                                                                                 | PP NRS < 2 at Week 16                                                                                                                                                         | Proportion of subjects with PP NRS < 2 at Week 16                                                                                                                                                                             |
| Endpoints and definitions | Key Secondary                                                                                                                                                                 | SD NRS improveme nt ≥ 4 at Week 16                                                                                                                                            | Proportion of subjects with sleep disturbance NRS (SD NRS) improvement ≥ 4 at Week 16                                                                                                                                         |
| Endpoints and definitions | Key Secondary                                                                                                                                                                 | PP NRS improveme nt ≥ 4 at Week 4                                                                                                                                             | Proportion of subjects with PP NRS improvement ≥ 4 at Week 4                                                                                                                                                                  |
| Endpoints and definitions | Key Secondary                                                                                                                                                                 | PP NRS < 2 at Week 4                                                                                                                                                          | Proportion of subjects with PP NRS < 2 at Week 4                                                                                                                                                                              |
| Endpoints and definitions | Key Secondary                                                                                                                                                                 | PP NRS improveme nt ≥ 4 at Week 2                                                                                                                                             | Proportion of subjects with PP NRS improvement ≥ 4 at Week 2                                                                                                                                                                  |
| Endpoints and definitions | Key Secondary                                                                                                                                                                 | PP NRS improveme nt ≥ 4 at Week 1                                                                                                                                             | Proportion of subjects with PP NRS improvement ≥ 4 at Week 1                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|               | Key Secondary                         | EASI-75 and PP NRS improveme nt ≥ 4          | Proportion of subjects with EASI-75 and PP NRS improvement ≥ 4 at Week 16     |
|---------------|---------------------------------------|----------------------------------------------|-------------------------------------------------------------------------------|
|               | Key Secondary                         | IGA success and PP NRS improveme nt ≥ 4      | Proportion of subjects with IGA success and PP NRS improvement ≥ 4 at Week 16 |
|               | Maintenance Pooled Secondary Efficacy | IGA success from Initial Baseline at Week 16 | Proportion of subjects with IGA 0 or 1 at Week 16 (Maintenance Baseline)      |
|               | Maintenance Pooled Secondary Efficacy | IGA success from Initial Baseline at Week 48 | Proportion of subjects with IGA 0 or 1 at Week 48                             |
|               | Maintenance Pooled Secondary Efficacy | EASI-75 from Initial Baseline at Week 16     | Proportion of subjects with EASI-75 at Week 16 (Maintenance baseline)         |
|               | Maintenance Pooled Secondary Efficacy | EASI-75 from Initial Baseline at Week 48     | Proportion of subjects with EASI-75 at Week 48                                |
| Database lock | 15 Nov 2022                           | 15 Nov 2022                                  | 15 Nov 2022                                                                   |

## Results and Analysis

## Co-Primary Endpoints Analysis

If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered nonresponders for analysis.

Both co-primary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test adjusted for the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[&gt;/=7, &lt;7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS&gt;=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT.

To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. The co-primary endpoints are tested first at 2.5% significance level for each population. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started sequentially using hierarchical testing procedure.

As a sensitivity analysis, the same analysis is carried out for PP population.

ITT population

- -Full population which includes all subjects in ITT
- -Baseline PPNRS &gt;=7 population which includes subjects in ITT with PPNRS &gt;=7 (randomized stratification)

## PP population

- -Full population which includes all subjects in PP
- -Baseline PPNRS &gt;=7 population which includes subjects in PP with PPNRS &gt;=7 (randomized stratification)

## Analysis description

## Analysis population and time point description

<div style=\"page-break-after: always\"></div>

|                                                 | Timepoint: Week 16                             | Timepoint: Week 16                             | Timepoint: Week 16                             |
|-------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Descriptive statistics and estimate variability | Treatment group                                | Initial nemo Q4W                               | Initial plac Q4W                               |
| Descriptive statistics and estimate variability | ITT population - Full population               | ITT population - Full population               | ITT population - Full population               |
| Descriptive statistics and estimate variability | Number of subjects                             | 620                                            | 321                                            |
| Descriptive statistics and estimate variability | IGA success (proportion)                       | 221 (35.6)                                     | 79 (24.6)                                      |
| Descriptive statistics and estimate variability | EASI-75 (proportion)                           | 270 (43.5)                                     | 93 (29.0)                                      |
| Descriptive statistics and estimate variability | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population |
| Descriptive statistics and estimate variability | Number of subjects                             | 406                                            | 210                                            |
| Descriptive statistics and estimate variability | IGA success (proportion)                       | 114 (35.5)                                     | 45 (21.4)                                      |
| Descriptive statistics and estimate variability | EASI-75 (proportion)                           | 169 (41.6)                                     | 50 (23.8)                                      |
| Effect estimate per comparison                  | ITT population - Full population               | ITT population - Full population               | ITT population - Full population               |
| Effect estimate per comparison                  | IGA success                                    | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| Effect estimate per comparison                  | IGA success                                    | Strata-adjusted proportion difference (%)      | 11.5                                           |
| Effect estimate per comparison                  | IGA success                                    | Strata-adjusted 97.5% CI (%)                   | 4.7, 18.3                                      |
| Effect estimate per comparison                  | IGA success                                    | P-value                                        | 0.0003                                         |
| Effect estimate per comparison                  | EASI-75                                        | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| Effect estimate per comparison                  | EASI-75                                        | Strata-adjusted proportion                     | 14.9                                           |
| Effect estimate per comparison                  | EASI-75                                        | difference (%) Strata-adjusted 97.5% CI (%)    | 7.8, 22.0                                      |
| Effect estimate per comparison                  | EASI-75                                        | P-value                                        | <0.0001                                        |
| Effect estimate per comparison                  | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population |
| Effect estimate per comparison                  | IGA success                                    | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| Effect estimate per comparison                  | IGA success                                    | Strata-adjusted proportion difference (%)      | 14.3                                           |
| Effect estimate per comparison                  | IGA success                                    | Strata-adjusted 97.5% CI (%)                   | 6.1, 22.5                                      |
| Effect estimate per comparison                  | IGA success                                    | P-value                                        | 0.0002                                         |
| Effect estimate per comparison                  | EASI-75                                        | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| Effect estimate per comparison                  | EASI-75                                        | Strata-adjusted proportion                     | 18.1                                           |
| Effect estimate per comparison                  | EASI-75                                        | difference (%) Strata-adjusted 97.5% CI (%)    | 9.6, 26.6                                      |
| Effect estimate per comparison                  | EASI-75                                        |                                                | <0.0001                                        |
| Analysis                                        | Secondary Endpoints Analysis                   |                                                |                                                |
| description                                     |                                                |                                                |                                                |
| Key                                             |                                                |                                                |                                                |
|                                                 |                                                | P-value                                        | P-value                                        |

<div style=\"page-break-after: always\"></div>

|                                                 | If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non- responders for analysis. All key secondary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started at 2.5% significance level using hierarchical testing procedure in an order listed below, and stopping the subsequent test when non-significant result is found. As a sensitivity analysis, the same analysis is carried out for PP population.   | If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non- responders for analysis. All key secondary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started at 2.5% significance level using hierarchical testing procedure in an order listed below, and stopping the subsequent test when non-significant result is found. As a sensitivity analysis, the same analysis is carried out for PP population.   | If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non- responders for analysis. All key secondary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started at 2.5% significance level using hierarchical testing procedure in an order listed below, and stopping the subsequent test when non-significant result is found. As a sensitivity analysis, the same analysis is carried out for PP population.   |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP - Baseline PPNRS >=7 population which includes subjects in PP with PPNRS >=7 (randomized stratification) Timepoint: Week 1, Week 2, Week 4, or Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP - Baseline PPNRS >=7 population which includes subjects in PP with PPNRS >=7 (randomized stratification) Timepoint: Week 1, Week 2, Week 4, or Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP - Baseline PPNRS >=7 population which includes subjects in PP with PPNRS >=7 (randomized stratification) Timepoint: Week 1, Week 2, Week 4, or Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Initial nemo Q4W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 620                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 321                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | PP NRS improvement ≥ 4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 265 (42.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 57 (17.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | PP NRS < 2 at                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 190 (30.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 36 (11.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Week 16 SD NRS improvement ≥ 4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 235 (37.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 64 (19.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | PP NRS improvement ≥ 4 at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 170 (27.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21 (6.5%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | PP NRS < 2 at                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 99 (16%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 12 (3.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Week 4 PP NRS improvement ≥ 4 at Week 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 110 (17.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10 (3.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | PP NRS improvement ≥ 4 at Week 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 29 (4.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 4 (1.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | EASI-75 and PP NRS improvement ≥ 4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 147 (23.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 36 (11.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | IGA success and PP NRS improvement ≥ 4 at Week 16       | IGA success and PP NRS improvement ≥ 4 at Week 16       | 122 (19.7%)                                    | 30 (9.3%)                                      |
|---------------------|---------------------------------------------------------|---------------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                     | ITT population - Baseline PPNRS >=7 population          | ITT population - Baseline PPNRS >=7 population          | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population |
|                     | Number of subjects                                      | Number of subjects                                      | 406                                            | 210                                            |
|                     | PP NRS improvement ≥ 4 at Week 16                       | PP NRS improvement ≥ 4 at Week 16                       | 187 (46.1%)                                    | 39 (18.6%)                                     |
|                     | PP NRS < 2 at Week 16                                   | PP NRS < 2 at Week 16                                   | 113 (27.8%)                                    | 16 (7.6%)                                      |
|                     | SD NRS improvement ≥ 4 at Week 16                       | SD NRS improvement ≥ 4 at Week 16                       | 171 (42.1%)                                    | 47 (22.4%)                                     |
|                     | PP NRS improvement ≥ 4 at Week 4                        | PP NRS improvement ≥ 4 at Week 4                        | 115 (28.3%)                                    | 15 (7.1%)                                      |
|                     | PP NRS < 2 at Week 4                                    | PP NRS < 2 at Week 4                                    | 51 (12.6%)                                     | 6 (2.9%)                                       |
|                     | PP NRS improvement ≥ 4 at Week 2                        | PP NRS improvement ≥ 4 at Week 2                        | 84 (20.7%)                                     | 8 (3.8%)                                       |
|                     | PP NRS improvement ≥ 4                                  | PP NRS improvement ≥ 4                                  | 25 (6.2%)                                      | 4 (1.9%)                                       |
|                     | at Week 1 EASI-75 and PP NRS improvement ≥ 4 at Week 16 | at Week 1 EASI-75 and PP NRS improvement ≥ 4 at Week 16 | 105 (25.9%)                                    | 24 (11.4%)                                     |
|                     | IGA success and PP NRS improvement ≥ 4 at Week 16       | IGA success and PP NRS improvement ≥ 4 at Week 16       | 88 (21.7%)                                     | 21 (10%)                                       |
| Effect estimate per | ITT population - Full population                        | ITT population - Full population                        | ITT population - Full population               | ITT population - Full population               |
| comparison          | PP NRS improvement ≥ 4                                  | Comparison groups                                       | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
|                     | at Week 16                                              | Strata-adjusted proportion difference (%)               | Strata-adjusted proportion difference (%)      | 24.9                                           |
|                     |                                                         | Strata-adjusted 97.5% CI (%)                            | Strata-adjusted 97.5% CI (%)                   | 18.4, 31.5                                     |
|                     |                                                         | P-value                                                 | P-value                                        | <0.0001                                        |
|                     | PP NRS < 2 at                                           | Comparison groups                                       | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
|                     | Week 16                                                 | Strata-adjusted proportion difference (%)               | Strata-adjusted proportion difference (%)      | 19.5                                           |
|                     |                                                         | Strata-adjusted 97.5% CI (%)                            | Strata-adjusted 97.5% CI (%)                   | 13.7, 25.2                                     |
|                     |                                                         | P-value                                                 | P-value                                        | <0.0001                                        |
|                     | SD NRS                                                  | Comparison groups                                       | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
|                     | improvement ≥ 4 at Week 16                              | Strata-adjusted proportion                              | difference (%)                                 | 17.9                                           |
|                     |                                                         | Strata-adjusted 97.5% CI (%)                            | Strata-adjusted 97.5% CI (%)                   | 11.3, 24.5                                     |
|                     |                                                         | P-value                                                 | P-value                                        | <0.0001                                        |

<div style=\"page-break-after: always\"></div>

| PP NRS improvement ≥ 4 at Week 4                  | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
|---------------------------------------------------|------------------------------------------------|------------------------------------------------|
| PP NRS improvement ≥ 4 at Week 4                  | Strata-adjusted proportion difference (%)      | 20.9                                           |
| PP NRS improvement ≥ 4 at Week 4                  | Strata-adjusted 97.5% CI (%)                   | 15.8, 26.0                                     |
| PP NRS improvement ≥ 4 at Week 4                  | P-value                                        | <0.0001                                        |
| PP NRS < 2 at Week 4                              | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS < 2 at Week 4                              | Strata-adjusted proportion difference (%)      | 12.2                                           |
| PP NRS < 2 at Week 4                              | Strata-adjusted 97.5% CI (%)                   | 8.2, 16.3                                      |
| PP NRS < 2 at Week 4                              | P-value                                        | <0.0001                                        |
| PP NRS improvement ≥ 4 at Week 2                  | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS improvement ≥ 4 at Week 2                  | Strata-adjusted proportion difference (%)      | 14.6                                           |
| PP NRS improvement ≥ 4 at Week 2                  | Strata-adjusted 97.5% CI (%)                   | 10.6, 18.7                                     |
| PP NRS improvement ≥ 4 at Week 2                  | P-value                                        | <0.0001                                        |
| PP NRS improvement ≥ 4 at Week 1                  | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS improvement ≥ 4 at Week 1                  | Strata-adjusted proportion difference (%)      | 3.4                                            |
| PP NRS improvement ≥ 4 at Week 1                  | Strata-adjusted 97.5% CI (%)                   | 1.1, 5.8                                       |
| PP NRS improvement ≥ 4 at Week 1                  | P-value                                        | 0.0064                                         |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16     | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16     | Strata-adjusted proportion difference (%)      | 12.6                                           |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16     | Strata-adjusted 97.5% CI (%)                   | 7.1, 18.1                                      |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16     | P-value                                        | <0.0001                                        |
| IGA success and PP NRS improvement ≥ 4 at Week 16 | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| IGA success and PP NRS improvement ≥ 4 at Week 16 | Strata-adjusted proportion difference (%)      | 10.5                                           |
| IGA success and PP NRS improvement ≥ 4 at Week 16 | Strata-adjusted 97.5% CI (%)                   | 5.4, 15.6                                      |
| IGA success and PP NRS improvement ≥ 4 at Week 16 | P-value                                        | <0.0001                                        |
| ITT population - Baseline PPNRS >=7 population    | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population |
| PP NRS improvement ≥ 4 at Week 16                 | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS improvement ≥ 4 at Week 16                 | Strata-adjusted proportion difference (%)      | 27.5                                           |
| PP NRS improvement ≥ 4 at Week 16                 | Strata-adjusted 97.5% CI (%)                   | 19.4, 35.7                                     |
| PP NRS improvement ≥ 4 at Week 16                 | P-value                                        | <0.0001                                        |
| PP NRS < 2 at Week 16                             | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS < 2 at Week 16                             | Strata-adjusted proportion difference (%)      | 20.3                                           |
| PP NRS < 2 at Week 16                             | Strata-adjusted 97.5% CI (%)                   | 13.8, 26.8                                     |
| PP NRS < 2 at Week 16                             | P-value                                        | <0.0001                                        |
| SD NRS                                            | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |

<div style=\"page-break-after: always\"></div>

| improvement ≥ 4 at Week 16                                                                                                                                                                                                                                                                                                                                                            | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                             | 19.7                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| improvement ≥ 4 at Week 16                                                                                                                                                                                                                                                                                                                                                            | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                          | 11.2, 28.2                                                                                                                                                                                                                                                                                                                                                                            |
| improvement ≥ 4 at Week 16                                                                                                                                                                                                                                                                                                                                                            | P-value                                                                                                                                                                                                                                                                                                                                                                               | <0.0001                                                                                                                                                                                                                                                                                                                                                                               |
| PP NRS improvement ≥ 4 at Week 4                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                     | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                 |
| PP NRS improvement ≥ 4 at Week 4                                                                                                                                                                                                                                                                                                                                                      | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                             | 21.2                                                                                                                                                                                                                                                                                                                                                                                  |
| PP NRS improvement ≥ 4 at Week 4                                                                                                                                                                                                                                                                                                                                                      | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                          | 14.8, 27.6                                                                                                                                                                                                                                                                                                                                                                            |
| PP NRS improvement ≥ 4 at Week 4                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                               | <0.0001                                                                                                                                                                                                                                                                                                                                                                               |
| PP NRS < 2 at Week 4 P-value                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                                     | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                 |
| PP NRS < 2 at Week 4 P-value                                                                                                                                                                                                                                                                                                                                                          | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                             | 9.7                                                                                                                                                                                                                                                                                                                                                                                   |
| PP NRS < 2 at Week 4 P-value                                                                                                                                                                                                                                                                                                                                                          | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                          | 5.2, 14.2                                                                                                                                                                                                                                                                                                                                                                             |
| PP NRS < 2 at Week 4 P-value                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                       | <0.0001                                                                                                                                                                                                                                                                                                                                                                               |
| PP NRS improvement ≥ 4 at Week 2                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                     | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                 |
| PP NRS improvement ≥ 4 at Week 2                                                                                                                                                                                                                                                                                                                                                      | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                             | 16.9                                                                                                                                                                                                                                                                                                                                                                                  |
| PP NRS improvement ≥ 4 at Week 2                                                                                                                                                                                                                                                                                                                                                      | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                          | 11.5, 22.3                                                                                                                                                                                                                                                                                                                                                                            |
| PP NRS improvement ≥ 4 at Week 2                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                               | <0.0001                                                                                                                                                                                                                                                                                                                                                                               |
| PP NRS improvement ≥ 4 at Week 1                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                     | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                 |
| PP NRS improvement ≥ 4 at Week 1                                                                                                                                                                                                                                                                                                                                                      | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                             | 4.3                                                                                                                                                                                                                                                                                                                                                                                   |
| PP NRS improvement ≥ 4 at Week 1                                                                                                                                                                                                                                                                                                                                                      | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                          | 0.9, 7.7                                                                                                                                                                                                                                                                                                                                                                              |
| PP NRS improvement ≥ 4 at Week 1                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                               | 0.0177                                                                                                                                                                                                                                                                                                                                                                                |
| EASI-75 and PP                                                                                                                                                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                                                                                                                                                     | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                 |
| EASI-75 and PP                                                                                                                                                                                                                                                                                                                                                                        | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                             | 14.5                                                                                                                                                                                                                                                                                                                                                                                  |
| EASI-75 and PP                                                                                                                                                                                                                                                                                                                                                                        | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                          | 7.6, 21.5                                                                                                                                                                                                                                                                                                                                                                             |
| EASI-75 and PP                                                                                                                                                                                                                                                                                                                                                                        | P-value                                                                                                                                                                                                                                                                                                                                                                               | <0.0001                                                                                                                                                                                                                                                                                                                                                                               |
| IGA success and PP                                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                                     | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                 |
| IGA success and PP                                                                                                                                                                                                                                                                                                                                                                    | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                             | 11.8                                                                                                                                                                                                                                                                                                                                                                                  |
| IGA success and PP                                                                                                                                                                                                                                                                                                                                                                    | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                          | 5.3, 18.3                                                                                                                                                                                                                                                                                                                                                                             |
| IGA success and PP                                                                                                                                                                                                                                                                                                                                                                    | P-value                                                                                                                                                                                                                                                                                                                                                                               | 0.0003                                                                                                                                                                                                                                                                                                                                                                                |
| Analysis description Maintenance Pooled Secondary Endpoints Analysis Maintenance period data of two pivotal studies were combined in order to assess the effect during the maintenance period. If a subject received any rescue therapy, the data after the receipt of rescue therapy was considered treatment failure. Subjects with missing result at the visit was considered non- | Analysis description Maintenance Pooled Secondary Endpoints Analysis Maintenance period data of two pivotal studies were combined in order to assess the effect during the maintenance period. If a subject received any rescue therapy, the data after the receipt of rescue therapy was considered treatment failure. Subjects with missing result at the visit was considered non- | Analysis description Maintenance Pooled Secondary Endpoints Analysis Maintenance period data of two pivotal studies were combined in order to assess the effect during the maintenance period. If a subject received any rescue therapy, the data after the receipt of rescue therapy was considered treatment failure. Subjects with missing result at the visit was considered non- |
| ITT population: this is a pooled population of two pivotal studies, and only includes subjects who treated by Initial nemo Q4W during Initial treatment period and re-randomized to the maintenance period in each pivotal study.                                                                                                                                                     | ITT population: this is a pooled population of two pivotal studies, and only includes subjects who treated by Initial nemo Q4W during Initial treatment period and re-randomized to the maintenance period in each pivotal study.                                                                                                                                                     | ITT population: this is a pooled population of two pivotal studies, and only includes subjects who treated by Initial nemo Q4W during Initial treatment period and re-randomized to the maintenance period in each pivotal study.                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| point description                               |                                                           |                                           |                                   |                                   |
|-------------------------------------------------|-----------------------------------------------------------|-------------------------------------------|-----------------------------------|-----------------------------------|
| Descriptive statistics and estimate variability | Treatment group                                           | Maint nemo Q4W                            | Maint nemo Q8W                    | Maint plac Q4W                    |
| Descriptive statistics and estimate variability | Number of subjects                                        | 169                                       | 169                               | 169                               |
| Descriptive statistics and estimate variability | IGA success from Initial Baseline at Week 16 (proportion) | 142 (84.0)                                | 142 (84.0)                        | 131 (77.5)                        |
| Descriptive statistics and estimate variability | IGA success from Initial Baseline at Week 48 (proportion) | 104 (61.5)                                | 102 (60.4)                        | 84 (49.7)                         |
| Descriptive statistics and estimate variability | EASI-75 from Initial Baseline at Week 16 (proportion)     | 163 (96.4)                                | 163 (96.4)                        | 157 (92.9)                        |
| Descriptive statistics and estimate variability | EASI-75 from Initial Baseline at Week 48 (proportion)     | 129 (76.3)                                | 128 (75.7)                        | 108 (63.9)                        |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | Comparison groups                         | Maint nemo Q4W vs. Maint plac Q4W | Maint nemo Q4W vs. Maint plac Q4W |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | Strata-adjusted proportion difference (%) |                                   |                                   |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | Strata-adjusted 95% CI (%)                | 1.3, 22.3                         | 1.3, 22.3                         |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | P-value                                   | 0.0290                            | 0.0290                            |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | Comparison groups                         | Maint nemo Q8W vs. Maint plac Q4W | Maint nemo Q8W vs. Maint plac Q4W |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | Strata-adjusted proportion difference (%) | 10.7                              | 10.7                              |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | Strata-adjusted 95% CI (%)                | 0.3, 21.0                         | 0.3, 21.0                         |
| Effect estimate per comparison                  | IGA success from Initial Baseline at Week 48              | P-value                                   | 0.0465                            | 0.0465                            |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | Comparison groups                         | Maint nemo Q4W vs. Maint plac Q4W | Maint nemo Q4W vs. Maint plac Q4W |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | Strata-adjusted proportion difference (%) | 12.4                              | 12.4                              |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | Strata-adjusted 95% CI (%)                | 2.7, 22.0                         | 2.7, 22.0                         |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | P-value                                   | 0.0129                            | 0.0129                            |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | Comparison groups                         | Maint nemo Q8W vs. Maint plac Q4W | Maint nemo Q8W vs. Maint plac Q4W |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | Strata-adjusted proportion difference (%) | 11.8                              | 11.8                              |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | Strata-adjusted 95% CI (%)                | 2.1, 21.5                         | 2.1, 21.5                         |
| Effect estimate per comparison                  | EASI-75 from Initial Baseline at Week 48                  | P-value                                   | 0.0179                            | 0.0179                            |

<div style=\"page-break-after: always\"></div>

Table 28: Summary of efficacy for trial RD.06.SPR.118169 (ARCADIA 2)

| Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis   | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis                                                                                                                                                 | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis                                                                                                                                                 | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                     | Protocol ID: RD.06.SPR.118169 EudraCT: 2019-001888-75                                                                                                                                                                                                                                                              | Protocol ID: RD.06.SPR.118169 EudraCT: 2019-001888-75                                                                                                                                                                                                                                                              | Protocol ID: RD.06.SPR.118169 EudraCT: 2019-001888-75                                                                                                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                               | This was a Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group study that evaluated the efficacy and safety of nemolizumab in adult and adolescent subjects with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medications. | This was a Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group study that evaluated the efficacy and safety of nemolizumab in adult and adolescent subjects with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medications. | This was a Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group study that evaluated the efficacy and safety of nemolizumab in adult and adolescent subjects with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medications.                                                                                                      |
|                                                                                                                                                                      | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                     | The study consisted of 4 periods over approximately 60 weeks:  Screening (approximately 2 to 4 weeks before planned Day 1/baseline, including run-in of at least 14 days),  Initial Treatment Period (Day 1/baseline to Week 16 predose),  Maintenance Period (Week 16 to Week 48),  Follow-up (unless the subject was a non- responder at Week 16, at which their participation could have lasted up to 28 weeks). |
| Hypothesis                                                                                                                                                           | Subjects treated by nemolizumab will have significant improvement in atopic dermatitis signs and symptoms after 16 weeks of treatment compared to placebo treated subjects.                                                                                                                                        | Subjects treated by nemolizumab will have significant improvement in atopic dermatitis signs and symptoms after 16 weeks of treatment compared to placebo treated subjects.                                                                                                                                        | Subjects treated by nemolizumab will have significant improvement in atopic dermatitis signs and symptoms after 16 weeks of treatment compared to placebo treated subjects.                                                                                                                                                                                                                                             |
| Treatments groups                                                                                                                                                    | Initial nemo Q4W                                                                                                                                                                                                                                                                                                   | Initial nemo Q4W                                                                                                                                                                                                                                                                                                   | A total of 522 subjects were randomized to nemolizumab in the Initial Treatment Period.                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                    | Initial plac Q4W                                                                                                                                                                                                                                                                                                   | Initial plac Q4W                                                                                                                                                                                                                                                                                                   | A total of 265 subjects were randomized to placebo in the Initial Treatment Period.                                                                                                                                                                                                                                                                                                                                     |
| Treatments groups                                                                                                                                                    | Maint nemo Q4W                                                                                                                                                                                                                                                                                                     | Maint nemo Q4W                                                                                                                                                                                                                                                                                                     | At Week 16, 79 nemolizumab-treated subjects who were clinical responders were re- randomized to receive nemolizumab Q4W during the Maintenance Period                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                    | Maint nemo Q8W                                                                                                                                                                                                                                                                                                     | Maint nemo Q8W                                                                                                                                                                                                                                                                                                     | At Week 16, 78 nemolizumab-treated subjects who were clinical responders were re- randomized to receive nemolizumab Q8W during the Maintenance Period                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                    | Maint plac Q4W                                                                                                                                                                                                                                                                                                     | Maint plac Q4W                                                                                                                                                                                                                                                                                                     | At Week 16, 78 nemolizumab-treated subjects who were clinical responders were re- randomized to receive placebo during the Maintenance Period                                                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                    | Plac to plac                                                                                                                                                                                                                                                                                                       | Plac to plac                                                                                                                                                                                                                                                                                                       | Placebo group in the Maintenance Period was for all placebo treated subjects who were randomized and responded to placebo during the Initial Treatment Period and continued to receive placebo during the Maintenance Period.                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                            | Co-Primary endpoint                                                                                                                                                                                                                                                                                                | IGA success                                                                                                                                                                                                                                                                                                        | Proportion of subjects with IGA success (defined as an IGA of 0 [clear] or 1 [almost clear]) and a ≥2-point reduction from baseline at Week 16.                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|               | Co-Primary endpoint                   | EASI-75                                      | Proportion of subjects with EASI-75 (≥75% improvement in EASI from baseline) at Week 16.   |
|---------------|---------------------------------------|----------------------------------------------|--------------------------------------------------------------------------------------------|
|               | Key Secondary                         | PP NRS improvement ≥ 4 at Week 16            | Proportion of subjects with PP NRS improvement ≥ 4 at Week 16                              |
|               | Key Secondary                         | PP NRS < 2 at Week 16                        | Proportion of subjects with PP NRS < 2 at Week 16                                          |
|               | Key Secondary                         | SD NRS improvement ≥ 4 at Week 16            | Proportion of subjects with sleep disturbance NRS (SD NRS) improvement ≥ 4 at Week 16      |
|               | Key Secondary                         | PP NRS improvement ≥ 4 at Week 4             | Proportion of subjects with PP NRS improvement ≥ 4 at Week 4                               |
|               | Key Secondary                         | PP NRS < 2 at Week 4                         | Proportion of subjects with PP NRS < 2 at Week 4                                           |
|               | Key Secondary                         | PP NRS improvement ≥ 4 at Week 2             | Proportion of subjects with PP NRS improvement ≥ 4 at Week 2                               |
|               | Key Secondary                         | PP NRS improvement ≥ 4 at Week 1             | Proportion of subjects with PP NRS improvement ≥ 4 at Week 1                               |
|               | Key Secondary                         | EASI-75 and PP NRS improvement ≥ 4           | Proportion of subjects with EASI-75 and PP NRS improvement ≥ 4 at Week 16                  |
|               | Key Secondary                         | IGA success and PP NRS improvement ≥ 4       | Proportion of subjects with IGA success and PP NRS improvement ≥ 4 at Week 16              |
|               | Maintenance Pooled Secondary Efficacy | IGA success from Initial Baseline at Week 16 | Proportion of subjects with IGA 0 or 1 at Week 16 (Maintenance Baseline)                   |
|               | Maintenance Pooled Secondary Efficacy | IGA success from Initial Baseline at Week 48 | Proportion of subjects with IGA 0 or 1 at Week 48                                          |
|               | Maintenance Pooled Secondary Efficacy | EASI-75 from Initial Baseline at Week 16     | Proportion of subjects with EASI-75 at Week 16 (Maintenance baseline)                      |
|               | Maintenance Pooled Secondary Efficacy | EASI-75 from Initial Baseline at Week 48     | Proportion of subjects with EASI-75 at Week 48                                             |
| Database lock | 06 Dec 2022                           |                                              |                                                                                            |

<div style=\"page-break-after: always\"></div>

| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                            | Co-Primary Endpoints Analysis If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non-responders for analysis. Both co-primary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test adjusted for the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. The co-primary endpoints are tested first at 2.5% significance level for each population. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started sequentially using hierarchical testing procedure. | Co-Primary Endpoints Analysis If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non-responders for analysis. Both co-primary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test adjusted for the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. The co-primary endpoints are tested first at 2.5% significance level for each population. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started sequentially using hierarchical testing procedure. | Co-Primary Endpoints Analysis If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non-responders for analysis. Both co-primary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test adjusted for the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. The co-primary endpoints are tested first at 2.5% significance level for each population. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started sequentially using hierarchical testing procedure. |
| Analysis description                            | As a sensitivity analysis, the same analysis is carried out for PP population.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | As a sensitivity analysis, the same analysis is carried out for PP population.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | As a sensitivity analysis, the same analysis is carried out for PP population.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Analysis population and time point description  | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP - Baseline PPNRS >=7 population which includes subjects in PP with PPNRS >=7 (randomized stratification) Timepoint: Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP - Baseline PPNRS >=7 population which includes subjects in PP with PPNRS >=7 (randomized stratification) Timepoint: Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP - Baseline PPNRS >=7 population which includes subjects in PP with PPNRS >=7 (randomized stratification) Timepoint: Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Initial nemo Q4W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 522                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 265                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | IGA success (proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 197 (37.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 69 (26)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | EASI-75 (proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 220 (42.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 80 (30.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | ITT population - Baseline PPNRS >=7 population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | ITT population - Baseline PPNRS >=7 population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | ITT population - Baseline PPNRS >=7 population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 316                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 164                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | IGA success (proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 116 (36.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 36 (22.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | EASI-75 (proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 130 (41.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 41 (25.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison                  | IGA success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Initial nemo Q4W vs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | IGA success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Initial plac Q4W 12.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | IGA success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 4.6, 19.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | IGA success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                  | EASI-75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Initial nemo Q4W vs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | EASI-75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Strata-adjusted proportion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Initial plac Q4W 12.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | EASI-75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | difference (%) Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4.6, 20.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.0006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | ITT population - Baseline PPNRS >=7 population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population - Baseline PPNRS >=7 population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ITT population - Baseline PPNRS >=7 population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                 | IGA success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Initial nemo Q4W vs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Initial plac Q4W 14.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 5.6, 24.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.0008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                 | EASI-75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Strata-adjusted proportion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | difference (%) Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 6.6, 26.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.0004                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis description                            | Key Secondary Endpoints Analysis If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non-responders for analysis. All key secondary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. | Key Secondary Endpoints Analysis If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non-responders for analysis. All key secondary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. | Key Secondary Endpoints Analysis If a subject received any rescue therapy, the data after the receipt of rescue therapy is considered treatment failure. Subjects with missing result at the visit are considered non-responders for analysis. All key secondary endpoints are analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA severity [3=moderate, 4=severe] and PP NRS[>/=7, <7] for ITT Full population; IGA severity [3=moderate, 4=severe] for ITT Baseline PPNRS>=7 population) to compare the two treatment groups (Initial nemo Q4W vs. Initial plac Q4W) for the populations on ITT. |
|                                                 | To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started at 2.5% significance level using hierarchical testing procedure in an order listed below, and stopping the subsequent test when non-significant result is found.                                                                                                                                                                                                                                                                         | To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started at 2.5% significance level using hierarchical testing procedure in an order listed below, and stopping the subsequent test when non-significant result is found.                                                                                                                                                                                                                                                                         | To control the type 1 error at 5% significance level, a serial gatekeeping approach is implemented. If both co-primary endpoints are statistically significant, then the testing of key secondary endpoints are started at 2.5% significance level using hierarchical testing procedure in an order listed below, and stopping the subsequent test when non-significant result is found.                                                                                                                                                                                                                                                                         |
| Analysis population and time point description  | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP                                                                                                                                                                                                                                                                                                                                                                                                                  | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP                                                                                                                                                                                                                                                                                                                                                                                                                  | ITT population - Full population which includes all subjects in ITT - Baseline PPNRS >=7 population which includes subjects in ITT with PPNRS >=7 (randomized stratification) PP population - Full population which includes all subjects in PP                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Initial nemo Q4W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Initial plac Q4W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                 | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ITT population - Full population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                 | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 522                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 265                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                 | PP NRS improvement ≥ 4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 214 (41)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 48 (18.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                | PP NRS < 2 at Week                                | 148 (28.4)                                     | 30 (11.3)                                      |
|--------------------------------|---------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                                | 16 SD NRS improvement ≥ 4 at Week 16              | 175 (33.5)                                     | 43 (16.2)                                      |
|                                | PP NRS improvement ≥ 4 at Week 4                  | 136 (26.1)                                     | 14 (5.3)                                       |
|                                | PP NRS < 2 at Week                                | 83 (15.9)                                      | 7 (2.6)                                        |
|                                | 4 PP NRS improvement ≥ 4 at Week 2                | 88 (16.9)                                      | 5 (1.9)                                        |
|                                | PP NRS improvement ≥ 4 at Week 1                  | 35 (6.7)                                       | 1 (0.4)                                        |
|                                | EASI-75 and PP NRS improvement ≥ 4 at Week 16     | 120 (23)                                       | 26 (9.8)                                       |
|                                | IGA success and PP NRS improvement ≥ 4 at Week 16 | 107 (20.5)                                     | 23 (8.7)                                       |
|                                | ITT population - Baseline PPNRS >=7 population    | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population |
|                                | Number of subjects                                | 316                                            | 164                                            |
|                                | PP NRS improvement ≥ 4 at Week 16                 | 153 (48.4)                                     | 35 (21.3)                                      |
|                                | PP NRS < 2 at Week                                | 85 (26.9)                                      | 14 (8.5)                                       |
|                                | 16 SD NRS improvement ≥ 4 at Week 16              | 135 (42.7)                                     | 34 (20.7)                                      |
|                                | PP NRS improvement ≥ 4 at Week 4                  | 96 (30.4)                                      | 13 (7.9)                                       |
|                                | PP NRS < 2 at Week                                | 35 (11.1)                                      | 2 (1.2)                                        |
|                                | 4 PP NRS improvement ≥ 4 at Week 2                | 61 (19.3)                                      | 5 (3.0)                                        |
|                                | PP NRS improvement ≥ 4 at Week 1                  | 27 (8.5)                                       | 1 (0.6)                                        |
|                                | EASI-75 and PP NRS improvement ≥ 4 at Week 16     | 85 (26.9)                                      | 17 (10.4)                                      |
|                                | IGA success and PP NRS improvement ≥ 4 at Week 16 | 75 (23.7)                                      | 17 (10.4)                                      |
| Effect estimate per comparison | ITT population - Full population                  | ITT population - Full population               | ITT population - Full population               |
| Effect estimate per comparison | PP NRS improvement ≥ 4 at Week 16                 | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| Effect estimate per comparison | PP NRS improvement ≥ 4 at Week 16                 | Strata-adjusted proportion difference (%)      | 23.2                                           |

<div style=\"page-break-after: always\"></div>

|                                               | Strata-adjusted 97.5% CI (%)              | 16.1, 30.3                            |
|-----------------------------------------------|-------------------------------------------|---------------------------------------|
|                                               | P-value                                   | <0.0001                               |
| PP NRS < 2 at Week 16                         | Comparison groups                         | Initial nemo Q4W vs. Initial plac Q4W |
| PP NRS < 2 at Week 16                         | Strata-adjusted proportion difference (%) | 17.1                                  |
| PP NRS < 2 at Week 16                         | Strata-adjusted 97.5% CI (%)              | 10.9, 23.3                            |
| PP NRS < 2 at Week 16                         | P-value                                   | <0.0001                               |
| SD NRS improvement ≥ 4 at Week 16             | Comparison groups                         | Initial nemo Q4W vs. Initial plac Q4W |
| SD NRS improvement ≥ 4 at Week 16             | Strata-adjusted proportion difference (%) | 17.5                                  |
| SD NRS improvement ≥ 4 at Week 16             | Strata-adjusted 97.5% CI (%)              | 10.8, 24.6                            |
| SD NRS improvement ≥ 4 at Week 16             | P-value                                   | <0.0001                               |
| PP NRS improvement ≥ 4 at Week 4              | Comparison groups                         | Initial nemo Q4W vs. Initial plac Q4W |
| PP NRS improvement ≥ 4 at Week 4              | Strata-adjusted proportion difference (%) | 20.9                                  |
| PP NRS improvement ≥ 4 at Week 4              | Strata-adjusted 97.5% CI (%)              | 15.6, 26.1                            |
| PP NRS improvement ≥ 4 at Week 4              | P-value                                   | <0.0001                               |
| PP NRS < 2 at Week 4                          | Comparison groups                         | Initial nemo Q4W vs. Initial plac Q4W |
| PP NRS < 2 at Week 4                          | Strata-adjusted proportion difference (%) | 13.2                                  |
| PP NRS < 2 at Week 4                          | Strata-adjusted 97.5% CI (%)              | 9.0, 17.4                             |
| PP NRS < 2 at Week 4                          | P-value                                   | <0.0001                               |
| PP NRS improvement ≥ 4 at Week 2              | Comparison groups                         | Initial nemo Q4W vs. Initial plac Q4W |
| PP NRS improvement ≥ 4 at Week 2              | Strata-adjusted proportion difference (%) | 15.1                                  |
| PP NRS improvement ≥ 4 at Week 2              | Strata-adjusted 97.5% CI (%)              | 11.0, 19.2                            |
| PP NRS improvement ≥ 4 at Week 2              | P-value                                   | <0.0001                               |
| PP NRS improvement ≥ 4 at Week 1              | Comparison groups                         | Initial nemo Q4W vs. Initial plac Q4W |
| PP NRS improvement ≥ 4 at Week 1              | Strata-adjusted proportion difference (%) | 6.4                                   |
| PP NRS improvement ≥ 4 at Week 1              | Strata-adjusted 97.5% CI (%)              | 3.8, 9.1                              |
| PP NRS improvement ≥ 4 at Week 1              | P-value                                   | <0.0001                               |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16 | Comparison groups                         | Initial nemo Q4W vs. Initial plac Q4W |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16 | Strata-adjusted proportion difference (%) | 13.4                                  |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16 | Strata-adjusted 97.5% CI (%)              | 7.6, 19.2                             |
| EASI-75 and PP NRS improvement ≥ 4 at Week 16 | P-value                                   | <0.0001                               |

<div style=\"page-break-after: always\"></div>

| IGA success and PP NRS improvement ≥ 4 at Week 16   | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
|-----------------------------------------------------|------------------------------------------------|------------------------------------------------|
| IGA success and PP NRS improvement ≥ 4 at Week 16   | Strata-adjusted proportion difference (%)      | 12.1                                           |
| IGA success and PP NRS improvement ≥ 4 at Week 16   | Strata-adjusted 97.5% CI (%)                   | 6.6, 17.6                                      |
| IGA success and PP NRS improvement ≥ 4 at Week 16   | P-value                                        | <0.0001                                        |
| ITT population - Baseline PPNRS >=7 population      | ITT population - Baseline PPNRS >=7 population | ITT population - Baseline PPNRS >=7 population |
| PP NRS improvement ≥ 4 at Week 16                   | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS improvement ≥ 4 at Week 16                   | Strata-adjusted proportion difference (%)      | 27.1                                           |
| PP NRS improvement ≥ 4 at Week 16                   | Strata-adjusted 97.5% CI (%)                   | 17.5, 36.6                                     |
| PP NRS improvement ≥ 4 at Week 16                   | P-value                                        | <0.0001                                        |
| PP NRS < 2 at Week 16                               | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS < 2 at Week 16                               | Strata-adjusted proportion difference (%)      | 18.4                                           |
| PP NRS < 2 at Week 16                               | Strata-adjusted 97.5% CI (%)                   | 11.0, 25.8                                     |
| PP NRS < 2 at Week 16                               | P-value                                        | <0.0001                                        |
| SD NRS improvement ≥ 4 at Week 16                   | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| SD NRS improvement ≥ 4 at Week 16                   | Strata-adjusted proportion difference (%)      | 21.9                                           |
| SD NRS improvement ≥ 4 at Week 16                   | Strata-adjusted 97.5% CI (%)                   | 12.5, 31.4                                     |
| SD NRS improvement ≥ 4 at Week 16                   | P-value                                        | <0.0001                                        |
| PP NRS improvement ≥ 4 at Week 4                    | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS improvement ≥ 4 at Week 4                    | Strata-adjusted proportion difference (%)      | 22.5                                           |
| PP NRS improvement ≥ 4 at Week 4                    | Strata-adjusted 97.5% CI (%)                   | 15.0, 29.9                                     |
| PP NRS improvement ≥ 4 at Week 4                    | P-value                                        | <0.0001                                        |
| PP NRS < 2 at Week 4                                | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS < 2 at Week 4                                | Strata-adjusted proportion difference (%)      | 9.9                                            |
| PP NRS < 2 at Week 4                                | Strata-adjusted 97.5% CI (%)                   | 5.5, 14.3                                      |
| PP NRS < 2 at Week 4                                | P-value                                        | 0.0001                                         |
| PP NRS improvement ≥ 4 at Week 2                    | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |
| PP NRS improvement ≥ 4 at Week 2                    | Strata-adjusted proportion difference (%)      | 16.3                                           |
| PP NRS improvement ≥ 4 at Week 2                    | Strata-adjusted 97.5% CI (%)                   | 10.5, 22.1                                     |
| PP NRS improvement ≥ 4 at Week 2                    | P-value                                        | <0.0001                                        |
| PP NRS improvement ≥ 4 at                           | Comparison groups                              | Initial nemo Q4W vs. Initial plac Q4W          |

<div style=\"page-break-after: always\"></div>

|                                                 | Week 1                                                                                                                                                                                                                            | Strata-adjusted proportion difference (%)                                                                                                                                                                                         | Strata-adjusted proportion difference (%)                                                                                                                                                                                         | 8.0                                                                                                                                                                                                                               |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                                                                                                                                                                                                                                   | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                      | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                      | 4.2, 11.8                                                                                                                                                                                                                         |
|                                                 |                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                           | 0.0004                                                                                                                                                                                                                            |
|                                                 | EASI-75 and PP NRS improvement ≥ 4 at Week 16                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                 | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                             |
|                                                 |                                                                                                                                                                                                                                   | Strata-adjusted proportion difference (%)                                                                                                                                                                                         | Strata-adjusted proportion difference (%)                                                                                                                                                                                         | 16.6                                                                                                                                                                                                                              |
|                                                 |                                                                                                                                                                                                                                   | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                      | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                      | 8.9, 24.3                                                                                                                                                                                                                         |
|                                                 |                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                           | <0.0001                                                                                                                                                                                                                           |
|                                                 | IGA success and PP NRS improvement ≥ 4 at Week 16                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                 | Initial nemo Q4W vs. Initial plac Q4W                                                                                                                                                                                             |
|                                                 |                                                                                                                                                                                                                                   | Strata-adjusted proportion difference (%)                                                                                                                                                                                         | Strata-adjusted proportion difference (%)                                                                                                                                                                                         | 13.4                                                                                                                                                                                                                              |
|                                                 |                                                                                                                                                                                                                                   | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                      | Strata-adjusted 97.5% CI (%)                                                                                                                                                                                                      | 5.9, 21.0                                                                                                                                                                                                                         |
|                                                 |                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                           | 0.0004                                                                                                                                                                                                                            |
| Analysis description                            | Maintenance Pooled Secondary Endpoints Analysis Maintenance period data of two pivotal studies were combined in order to assess the effect during the maintenance period.                                                         | Maintenance Pooled Secondary Endpoints Analysis Maintenance period data of two pivotal studies were combined in order to assess the effect during the maintenance period.                                                         | Maintenance Pooled Secondary Endpoints Analysis Maintenance period data of two pivotal studies were combined in order to assess the effect during the maintenance period.                                                         | Maintenance Pooled Secondary Endpoints Analysis Maintenance period data of two pivotal studies were combined in order to assess the effect during the maintenance period.                                                         |
|                                                 | If a subject received any rescue therapy, the data after the receipt of rescue therapy was considered treatment failure. Subjects with missing result at the visit was considered non-responders for analysis.                    | If a subject received any rescue therapy, the data after the receipt of rescue therapy was considered treatment failure. Subjects with missing result at the visit was considered non-responders for analysis.                    | If a subject received any rescue therapy, the data after the receipt of rescue therapy was considered treatment failure. Subjects with missing result at the visit was considered non-responders for analysis.                    | If a subject received any rescue therapy, the data after the receipt of rescue therapy was considered treatment failure. Subjects with missing result at the visit was considered non-responders for analysis.                    |
|                                                 | The endpoint was analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA, PP NRS) to compare the treatment groups.                                                      | The endpoint was analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA, PP NRS) to compare the treatment groups.                                                      | The endpoint was analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA, PP NRS) to compare the treatment groups.                                                      | The endpoint was analysed using Cochran-Mantel-Haenszel (CMH) test which was adjusted the randomized stratification variables (IGA, PP NRS) to compare the treatment groups.                                                      |
| Analysis population and time point description  | ITT population: this is a pooled population of two pivotal studies, and only includes subjects who treated by Initial nemo Q4W during Initial treatment period and re-randomized to the maintenance period in each pivotal study. | ITT population: this is a pooled population of two pivotal studies, and only includes subjects who treated by Initial nemo Q4W during Initial treatment period and re-randomized to the maintenance period in each pivotal study. | ITT population: this is a pooled population of two pivotal studies, and only includes subjects who treated by Initial nemo Q4W during Initial treatment period and re-randomized to the maintenance period in each pivotal study. | ITT population: this is a pooled population of two pivotal studies, and only includes subjects who treated by Initial nemo Q4W during Initial treatment period and re-randomized to the maintenance period in each pivotal study. |
|                                                 | Timepoint: Week 16, Week 48                                                                                                                                                                                                       | Timepoint: Week 16, Week 48                                                                                                                                                                                                       | Timepoint: Week 16, Week 48                                                                                                                                                                                                       | Timepoint: Week 16, Week 48                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                   | Maint nemo Q4W                                                                                                                                                                                                                    | Maint nemo Q8W                                                                                                                                                                                                                    | Maint plac Q4W                                                                                                                                                                                                                    |
|                                                 | Number of subjects                                                                                                                                                                                                                | 169                                                                                                                                                                                                                               | 169                                                                                                                                                                                                                               | 169                                                                                                                                                                                                                               |
|                                                 | IGA success from Initial Baseline at Week 16 (proportion)                                                                                                                                                                         | 142 (84.0)                                                                                                                                                                                                                        | 142 (84.0)                                                                                                                                                                                                                        | 131 (77.5)                                                                                                                                                                                                                        |
|                                                 | IGA success from Initial Baseline at Week 48 (proportion)                                                                                                                                                                         | 104 (61.5)                                                                                                                                                                                                                        | 102 (60.4)                                                                                                                                                                                                                        | 84 (49.7)                                                                                                                                                                                                                         |
|                                                 | EASI-75 from Initial Baseline at Week 16 (proportion)                                                                                                                                                                             | 163 (96.4)                                                                                                                                                                                                                        | 163 (96.4)                                                                                                                                                                                                                        | 157 (92.9)                                                                                                                                                                                                                        |
|                                                 | EASI-75 from Initial Baseline at Week 48 (proportion)                                                                                                                                                                             | 129 (76.3)                                                                                                                                                                                                                        | 128 (75.7)                                                                                                                                                                                                                        | 108 (63.9)                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | IGA success from Initial Baseline at                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                 | Maint nemo Q4W vs. Maint plac Q4W                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Week 48                                      | Strata-adjusted proportion difference (%)   | 11.8                              |
|----------------------------------------------|---------------------------------------------|-----------------------------------|
| Week 48                                      | Strata-adjusted 95% CI (%)                  | 1.3, 22.3                         |
| Week 48                                      | P-value                                     | 0.0290                            |
| IGA success from Initial Baseline at Week 48 | Comparison groups                           | Maint nemo Q8W vs. Maint plac Q4W |
| IGA success from Initial Baseline at Week 48 | Strata-adjusted proportion difference (%)   | 10.7                              |
| IGA success from Initial Baseline at Week 48 | Strata-adjusted 95% CI (%)                  | 0.3, 21.0                         |
| IGA success from Initial Baseline at Week 48 | P-value                                     | 0.0465                            |
| EASI-75 from Initial Baseline at Week 48     | Comparison groups                           | Maint nemo Q4W vs. Maint plac Q4W |
| EASI-75 from Initial Baseline at Week 48     | Strata-adjusted proportion difference (%)   | 12.4                              |
| EASI-75 from Initial Baseline at Week 48     | Strata-adjusted 95% CI (%)                  | 2.7, 22.0                         |
| EASI-75 from Initial Baseline at Week 48     | P-value                                     | 0.0129                            |
| EASI-75 from Initial Baseline at Week 48     | Comparison groups                           | Maint nemo Q8W vs. Maint plac Q4W |
| EASI-75 from Initial Baseline at Week 48     | Strata-adjusted proportion difference (%)   | 11.8                              |
| EASI-75 from Initial Baseline at Week 48     | Strata-adjusted 95% CI (%)                  | 2.1, 21.5                         |
| EASI-75 from Initial Baseline at Week 48     | P-value                                     | 0.0179                            |

## 2.6.5.3.  Clinical studies in special populations

The applicant populated the table with information corresponding to the 2311 subjects included in the ITT population (N=36 for study CIM001JP part C, N=264 for study CIM003JG, N= 20 for study SPR.116912, N=226 for study SPR.114322, N=941 for study SPR.118161 and N=787 for study SPR.118169 and 37 subjects directly enrolled in the LTE study SPR.118163). Subjects who rolled over into study SPR.118163 from feeder-controlled studies were not populated in the non-controlled trials column to avoid double-counting.

Table 29: Number of subjects with renal- and hepatic impairment in AD

|                                                               | Controlled Trials   | Non-controlled trials   |
|---------------------------------------------------------------|---------------------|-------------------------|
| Renal impairment* patients (Subjects number /total number)    | 12/2254             | 0                       |
| Hepatic impairment** patients (Subjects number /total number) | 16/2254             | 0                       |
| Paediatric patients <18 years (Subjects number /total number) | 266/2254            | 57/57                   |
| Age 65-74 (Subjects number /total number)                     | 99/2254             | 0                       |
| Age 75-84 (Subjects number /total number)                     | 24/2254             | 0                       |
| Age 85+ (Subjects number /total number)                       | 1/2254              | 0                       |
| Other (Subjects number /total number)                         | 1864/2254           | 0                       |

* Renal impairment is defined as having CKD Stage 3b, 4 or 5 (KDIGO definition)

** Hepatic impairment was defined based on the NCI-ODWG definition

<div style=\"page-break-after: always\"></div>

## 2.6.5.4.  In vitro biomarker test for patient selection for efficacy

Not applicable.

## 2.6.5.5.  Analysis performed across trials (pooled analyses and meta-analysis)

## Maintenance period (week 16 to week 48)

At Week 16, all subjects were evaluated for clinical response, defined as IGA 0/1 or EASI-75. Clinical responders from the nemolizumab group were re-randomized to different treatment groups, nemolizumab Q4W or Q8W or placebo up to Week 48.

## Results

## IGA

-  Proportion of subjects with IGA success at week 48

The proportion of subjects with IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥2-grade improvement from baseline) at Week 48 is shown in the table below.

<div style=\"page-break-after: always\"></div>

Table 30: Proportion of subjects with an IGA success at week 48 - maintenance period (ITT population) (table 37 from SCE)

| Analysis                                                            | SPR.118161                 | SPR.118161                 | SPR.118161                     | SPR.118169                 | SPR.118169                 | SPR.118169                     | AD POOL                     | AD POOL                     | AD POOL                         |
|---------------------------------------------------------------------|----------------------------|----------------------------|--------------------------------|----------------------------|----------------------------|--------------------------------|-----------------------------|-----------------------------|---------------------------------|
|                                                                     | Nemo 30 mg Q4W to Q4W N=90 | Nemo 30 mg Q4W to Q8W N=91 | Nemo 30 mg Q4W to Placebo N=91 | Nemo 30 mg Q4W to Q4W N=79 | Nemo 30 mg Q4W to Q8W N=78 | Nemo 30 mg Q4W to Placebo N=78 | Nemo 30 mg Q4W to Q4W N=169 | Nemo 30 mg Q4W to Q8W N=169 | Nemo 30 mg Q4W to Placebo N=169 |
| IGA success                                                         |                            |                            |                                |                            |                            |                                |                             |                             |                                 |
| (NRI), m/n (%)                                                      | 54/90 (60.0)               | 48/91 (52.7)               | 38/91 (41.8)                   | 50/79 (63.3)               | 54/78 (69.2)               | 46/78 (59.0)                   | 104/169 (61.5)              | 102/16 9 (60.4)             | 84/169 (49.7)                   |
| (OC), m/n (%)                                                       | 54/78 (69.2)               | 49/81 (60.5)               | 38/68 (55.9)                   | 50/68 (73.5)               | 54/69 (78.3)               | 46/65 (70.8)                   | 104/146 (71.2)              | 103/150 (68.7)              | 84/133 (63.2)                   |
| Continuous maintenance of IGA success                               | n=77                       | n=73                       | n=68                           | n=65                       | n=69                       | n=63                           | n=142                       | n=142                       | n=131                           |
| (NRI) a , m 1 /n (%)                                                | --                         | --                         | --                             | --                         | --                         | --                             | 45/142 (31.7)               | 53/142 (37.3)               | 41/131 (31.3)                   |
| (OC) a , m 1 /n (%)                                                 | 25/66 (37.9)               | 22/64 (34.4)               | 17/51 (33.3)                   | 24/55 (43.6)               | 32/61 (52.5)               | 24/55 (43.6)                   | 49/121 (40.5)               | 54/125 (43.2)               | 41/106 (38.7)                   |
| Maintenance of IGA success at visit summarized (NRI) b , m 2 /n (%) | --                         | --                         | --                             | --                         | --                         | --                             | 90/142 (63.4)               | 91/142 (64.1)               | 72/131 (55.0)                   |

IGA=Investigator's Global Assessment; ITT=intent-to-treat; m=number of subjects with IGA success; m 1 =number of subjects maintaining IGA success at all visits; m 2 =number of subjects maintaining IGA success at the visit summarized; n=number of subjects with available data or number of subjects with data after imputation; N=number of subjects in the population; NRI=non-responder imputation; OC=observed cases; Q4W=every 4 weeks; Q8W=every 8 weeks

Note: IGA success was defined as subjects with 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from initial baseline. Percentage was calculated using the number of subjects with available data (n) at the analysis visit as the denominator. In NRI, data on or after receipt of rescue therapy were considered treatment failure and subjects with missing data at a visit were considered nonresponders. For the AD POOL analysis, initial baseline value was the last valid value prior to first injection of study drug of the Initial Treatment Period. Week 16 measurement served as baseline measurement. If Week 16 measurement was missing, the last valid non-missing measurement prior to Week 16 was taken as the Maintenance baseline measurement for the Maintenance Period.

a) For continuous maintenance, maintaining IGA success was defined as a subject who achieved IGA success at all visits from Week 16 up to and including the visit summarized. In SRE.118161 and SRE.118169, all observed data even after use of rescue therapy were included; no imputations for missing data.

b) In the post hoc analysis, maintaining IGA success was defined as subjects who achieved IGA success at the visit summarized. Initial baseline value was the last valid value prior to first injection of study drug of the Initial Treatment Period. Percentage was calculated using the number of subjects with available data at the analysis visit as the denominator. For NRI, subjects with data collected on or after use of rescue therapy or with missing data at a visit were considered non-responders.

<div style=\"page-break-after: always\"></div>

## EASI

-  Proportion of subjects with EASI-50, EASI-75, and EASI-90 at each visit from week 16 to week 48

The proportion of subjects with EASI-75 (defined as ≥75% improvement in EASI from initial baseline) at Week 48 is shown in the table below.

<div style=\"page-break-after: always\"></div>

Table 31: Proportion of subjects with EASI-75 at week 48 - maintenance period (ITT population) (table 38 from SCE AD)

| Analysis                                                        | SPR.118161                 | SPR.118161                 | SPR.118161                     | SPR.118169                 | SPR.118169                 | SPR.118169                     | AD POOL                     | AD POOL                     | AD POOL                         |
|-----------------------------------------------------------------|----------------------------|----------------------------|--------------------------------|----------------------------|----------------------------|--------------------------------|-----------------------------|-----------------------------|---------------------------------|
|                                                                 | Nemo 30 mg Q4W to Q4W N=90 | Nemo 30 mg Q4W to Q8W N=91 | Nemo 30 mg Q4W to Placebo N=91 | Nemo 30 mg Q4W to Q4W N=79 | Nemo 30 mg Q4W to Q8W N=78 | Nemo 30 mg Q4W to Placebo N=78 | Nemo 30 mg Q4W to Q4W N=169 | Nemo 30 mg Q4W to Q8W N=169 | Nemo 30 mg Q4W to Placebo N=169 |
| EASI-75                                                         |                            |                            |                                |                            |                            |                                |                             |                             |                                 |
| (NRI), m/n (%)                                                  | 67/90 (74.4)               | 67/91 (73.6)               | 55/91 (60.4)                   | 62/79 (78.5)               | 61/78 (78.2)               | 53/78 (67.9)                   | 129/169 (76.3)              | 128/16 9 (75.7)             | 108/16 9 (63.9)                 |
| (OC), m/n (%)                                                   | 67/78 (85.9)               | 69/81 (85.2)               | 55/68 (80.9)                   | 62/68 (91.2)               | 61/69 (88.4)               | 53/65 (81.5)                   | 129/146 (88.4)              | 130/150 (86.7)              | 108/133 (81.2)                  |
| Continuous maintenance of EASI-75                               | n=89                       | n=88                       | n=88                           | n=74                       | n=75                       | n=69                           | n=163                       | n=163                       | n=157                           |
| (NRI) a , m 1 /n (%)                                            | --                         | --                         | --                             | --                         | --                         | --                             | 91/163 (55.8)               | 96/163 (58.9)               | 70/157 (44.6)                   |
| (OC) a , m 1 /n (%)                                             | 54/77 (70.1)               | 52/79 (65.8)               | 37/67 (55.2)                   | 45/63 (71.4)               | 49/66 (74.2)               | 37/57 (64.9)                   | 99/140 (70.7)               | 101/145 (69.7)              | 74/124 (59.7)                   |
| Maintenance of EASI-75 at visit summarized (NRI) b , m 2 /n (%) | --                         | --                         | --                             | --                         | --                         | --                             | 123/163 (75.5)              | 125/163 (76.7)              | 102/157 (65.0)                  |

EASI=Eczema Area and Severity Index; EASI-75=≥75% improvement in EASI from baseline; IGA=Investigator's Global Assessment; ITT=intent-to-treat; m=number of subjects with EASI-75; m 1 =number of subjects maintaining EASI-75 at all visits; m 2 =number of subjects maintaining EASI-75 at the visit summarized; n=number of subjects with available data or number of subjects with data after imputation; N=number of subjects in the population; NRI=non-responder imputation; OC=observed cases; Q4W=every 4 weeks; Q8W=every 8 weeks

Note: Percentage was calculated using the number of subjects with available data (n) at the analysis visit as the denominator. In NRI, data on or after receipt of rescue therapy were considered treatment failure and subjects with missing data at a visit were considered non-responders. For the AD POOL analysis, initial baseline value was the last valid value prior to first injection of study drug of the Initial Treatment Period. Week 16 measurement served as baseline measurement. If Week 16 measurement was missing, the last valid non-missing measurement prior to Week 16 was taken as the Maintenance baseline measurement for the Maintenance Period.

- c) For continuous maintenance, maintaining EASI-75 was defined as a subject who achieved EASI-75 at all visits from Week 16 up to and including the visit summarized. In SRE.118161 and SRE.118169, all observed data even after use of rescue therapy were included; no imputations for missing data.

d) In the post hoc analysis, maintaining EASI-75 was defined as subjects who achieved EASI-75 at the visit summarized. Initial baseline value was the last valid value prior to first injection of study drug of the Initial Treatment Period. Percentage was calculated using the number of subjects with available data at the analysis visit as the denominator. For NRI, subjects with data collected on or after use of rescue therapy or with missing data at a visit were considered non-responders.

<div style=\"page-break-after: always\"></div>

## 2.6.5.6.  Supportive study(ies)

Please see section 2.6.6. below for information on supportive studies.

For information on Human factor studies, please see indication prurigo nodularis.

## 2.6.6.  Discussion on clinical efficacy

## Design and conduct of clinical studies

The main clinical efficacy data supporting the indication in atopic dermatitis (AD) for nemolizumab are the phase 3 studies SPR.118161 (ARCADIA 1) and SPR.118169 (ARCADIA 2), and the extension study SIR.118163. In addition, three phase 2 studies (study CIM003JG, study SPR.114322 and study SRE.116912) have been performed of which the Phase 2b dose finding study, study SPR.114322, is the most important. Phase 3 studies performed in support of approval of nemolizumab in Japan are considered supportive.

The proposed indication is treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

## Phase 2 studies

## Study SRE.114322

One Phase 2b study has been performed (study SRE.114322). The study was randomised, doubleblind, placebo-controlled designed to assess the efficacy, safety, and PK of nemolizumab in subjects with moderate-to-severe AD and severe pruritus (PP NRS ≥7) receiving TCS who were not adequately controlled with topical treatments.

The study objectives were to investigate the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe AD subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments. The secondary objectives were to evaluate the safety of nemolizumab and to characterize its PK profile.

Eligibility criteria were adequately reflecting the target patient group for treatment of AD. Patients were required to have had AD for &gt;2 years before screening, defined as an average EASI score of ≥12, an IGA score ≥3 and AD involvement ≥10% of BSA. Moreover, eligible patients should have severe pruritus (PP NRS ≥7).

Each subject was randomized to receive subcutaneous injections of nemolizumab (10, 30, or 90 mg) or placebo Q4W (Weeks 4, 8, 12, 16 and 20). A loading dose was administered at the Baseline Visit (Day 1) for the 10mg and 30 mg groups (20 mg and 60 mg, respectively) and for the 90 mg group, the same dose was administered at each injection visit. The dose that subsequently was chosen for MAA, 30 mg with a 60-mg loading dose, was included in the study.

The primary efficacy endpoint was the percent change from baseline in EASI at Week 24. Further, several secondary efficacy endpoints at Week 24 of clinical relevance for AD were also included.

The study aims were dose-ranging, safety, and efficacy of nemolizumab prior to planning of the Phase 3 clinical AD program. Overall, the design of the study was acceptable.

## Study CIM003JG

Study CIM001JP is a Phase 2a dose-ranging study conducted in adults with inadequately controlled moderate-to-severe AD. The study was performed in 2 parts. Part A was a randomized, double blind,

<div style=\"page-break-after: always\"></div>

placebo-controlled, parallel assignment design (Week 0 to 12). Part B was a double-blind extension phase in which subjects continued to receive treatment with nemolizumab for a further 52 weeks (Weeks 12 to 64).

The primary study objective was to evaluate the dose response profile of nemolizumab in the treatment of pruritus, defined by the percentage improvement in pruritus from baseline to Week 12, assessed by patients using the pruritus VAS. The doses investigated of nemolizumab were 0.1, 0.5, or 2.0 mg/kg SC Q4W, or 2.0 mg/kg SC Q8W, or placebo in Part A. Subjects randomized to a nemolizumab regimen in Part A continued to receive the same nemolizumab dose in Part B, while subjects randomized to placebo in Part A were re-randomized to nemolizumab 0.1, 0.5, or 2.0 mg/kg SC Q4W in Part B.

Overall, the design of the study was acceptable, both Part A and Part B being dose ranging studies over several doses. Part A included a placebo arm, while in Part B all subjects were on active treatment. The dose that subsequently was chosen for MAA 30 mg, is approximately like the dose 0.5 mg/kg SC Q4W, which was included in the study.

## Study SPR.116912

Study SPR.116912 is a Phase 2, open-label, single-group study to evaluate the PK and safety of 30 mg of nemolizumab in adolescent subjects (12 to 17 years of age), with moderate-to-severe AD and associated pruritus. Subjects received SC injections of nemolizumab (30 mg) Q4W over a 16-week treatment period, with a loading dose of 60 mg on Day 1. The study enrolled 20 adolescent subjects who were assessed for safety and efficacy, and 14 subjects were evaluated for PK. There was an interim evaluation after 8 weeks of treatment that evaluated PK in adolescents versus adults. The design of this supportive study is considered acceptable.

## Phase 3 studies in support of the AD indication for nemolizumab

## SRE.118161 (ARCADIA 1) and SRE.118169 (ARCADIA 2)

The application contains two identical pivotal phase 3 studies, SRE.118161 (ARCADIA 1) and SRE.118169 (ARCADIA 2). Furthermore, a long-term study (SIR.118163), designed to evaluate the long-term safety, and efficacy as secondary objective, of nemolizumab has been performed. The two identical clinical studies are randomised, double-blind, placebo-controlled, multicentre studíes. The studies consisted of 4 periods over approximately 60 weeks: screening, initial treatment period (Day 1/baseline to Week 16), maintenance period (Week 16 to Week 48), and follow-up (unless the subject was a non-responder at Week 16).

During the initial treatment period, the subjects were randomised 2:1 to SC injection with 30 mg nemolizumab at week 4, week 8, week 12 and week 16 following a loading dose of 60 mg at baseline or the matching placebo SC injection. In the maintenance period, patients that were responders were re-randomized 1:1:1: to nemolizumab 30 mg Q4W, 30 mg Q8W, or matching placebo SC injection.

Results of the initial treatment period was evaluated at week 16, while results in the maintenance period was evaluated at week 48. Long-term follow up (up to 200 weeks) is ongoing.

To be eligible for the study, subjects should be above 12 years old and have chronic AD according to American Academy of Dermatology Consensus Criteria for ≥2 years, Eczema Area and Severity Index (EASI) score ≥16, Investigator's Global Assessment (IGA) score ≥3, AD involvement ≥10% of body surface area (BSA), Peak Pruritus Numeric Rating Scale (PP NRS) score ≥4.0 at both screening and baseline visits. The subjects should also have a documented history of inadequate response to topical medications (topical corticosteroids [TCS] with or without topical calcineurin inhibitors [TCI]). Key exclusion criteria included body weight &lt;30 kg and asthma exacerbation requiring hospitalization in the preceding 12 months or asthma that had not been well controlled during the preceding 3 months.

<div style=\"page-break-after: always\"></div>

Overall, both inclusion and exclusion criteria are considered adequate, they are seen in development programs for other AD medicinal products.

The randomisation procedure appears to have been appropriate. Eligible subjects were during the initial treatment period randomised at baseline in a 2:1 ratio to receive to receive either nemolizumab or placebo. Randomisation was stratified by baseline disease severity: PP NRS &lt; 7 and PP NRS &gt;= 7 as well as IGA = 3 and IGA = 4 and a minimum of n=250 subjects were to be randomised into each PP NRS strata.

Both studies are double-blinded and the reasons for unblinding are endorsed. Appropriate steps seem to have been taken with regards to minimising the possible detectable differences between nemolizumab and placebo during the reconstitution process.

The 30 mg dose of nemolizumab was selected based on the Phase 2b dose-ranging study SRE.114322 and other supportive data. The drug treatment started with a loading dose of 60 mg at baseline. During maintenance treatment the study drug was administered Q4W or Q8W from week 16 to 48. All study drug injections occurred at the study site by either the study site clinic staff, the subject or the caregiver following training on study drug injections. To conclude, there are no outstanding issues on the proposed dosing of nemolizumab. The 30 mg dose was chosen for the clinical Phase 3 program, and its efficacy and safety in subjects with AD is the topic of this assessment.

Subjects continued to use background topical therapy (a medium-potency topical corticosteroid [TCS] for the body, and a low-potency TCS or a topical calcineurin inhibitor [TCI] for sensitive areas such as the face, neck, and intertriginous areas), which was adjusted according to disease activity and tolerability based on the Investigator's clinical judgment. To concluded on background therapy, the AD lesions were treated as recommended in treatment guidelines including tapering and discontinuation when the lesions improved. However, it should be noted that the efficacy of nemolizumab as monotherapy has not been investigated.

Prohibited medications during the studies were, among others, non-authorized low- and mid-potency TCS, and other systemic treatment for AD. Moreover, the use of systemic corticosteroids during the study was prohibited, except when used as rescue therapy for AD.

Rescue treatment were treatments directed to treat AD and included topical and systemic treatments. Subjects receiving any rescue therapies were to be considered treatment failures during the studies.

The primary objective of the initial treatment period was to evaluate the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-tosevere atopic dermatitis (AD) not adequately controlled with topical treatments. The secondary objective was to evaluate the efficacy and safety of maintenance treatment with nemolizumab for up to an additional 32 weeks.

In the initial treatment period, the co-primary efficacy endpoints were 1) the proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear]) and a ≥2-point reduction from baseline and 2) the proportion of subjects with EASI-75 (≥75% improvement in EASI from baseline) at Week 16. The choice of these endpoints has been discussed and agreed in scientific advice. Furthermore, they are often seen in development programs for AD and therefore accepted in this application.

Key secondary efficacy endpoints were 1) proportion of subjects with an improvement of PP NRS ≥4 at Week 16, 2) Proportion of subjects with PP NRS &lt;2 at Week 16, 3) Proportion of subjects with an improvement of sleep disturbance NRS (SD NRS) ≥4 at Week 16, 4) Proportion of subjects with an improvement of PP NRS ≥4 at Week 4. Moreover, 5) Proportion of subjects with PP NRS &lt;2 at Week 4, 6) Proportion of subjects with an improvement of PP NRS ≥4 at Week 2, 7) Proportion of subjects with

<div style=\"page-break-after: always\"></div>

an improvement of PP NRS ≥4 at Week 1, 8) Proportion of subjects with EASI-75 and improvement of PP NRS ≥4 at Week 16 and 9) Proportion of subjects with IGA success and improvement of PP NRS ≥4 at Week 16. Additional assessments were performed at weeks 2, 4 and 8.

Several additional secondary efficacy and exploratory measurements were also investigated.

## Maintenance period of SRE.118161 and SRE.118169 studies

A randomized withdrawal design was used to evaluate the maintenance of response for nemolizumab treatment during the 48-week maintenance period. At Week 16, all nemolizumab-treated subjects who were clinical responders, defined as IGA success or EASI-75 at week 16 (i.e., the end of initial treatment period) were to be re-randomized (1:1:1) to the following treatment regimens: 1) Nemolizumab injections Q4W, 2) Nemolizumab Q8W (with placebo injections in-between active treatments) or 3) placebo Q4W. All placebo-treated subjects who responded to placebo during the initial treatment period continued to receive placebo Q4W during the maintenance period. In transitioning to the maintenance period, subjects generally continued the same background topical therapy used in the initial treatment period, with adjustments, as determined by the Investigator.

## Statistical considerations

The planned sample size in both Arcadia 1 and Arcadia 2, respectively, during the initial treatment period was 750 subjects, randomised with a ratio of 2:1 to receive either nemolizumab or placebo. The sample size calculations in both studies were performed for both co-primary endpoints and were expected to have 90% power to reject both co-primary hypotheses with a two-sided significance level of 2.5%. The calculations appear to have been appropriate. There were no planned interim analyses for efficacy, and none were performed.

The SAPs of Arcadia 1 and Arcadia 2 were similar. There were no amendments to the SAPs and the SAPs were finalised before database lock.

Primary, key secondary, and other secondary efficacy endpoints were evaluated in two populations: the full ITT population and in a subpopulation of subjects in the ITT population with a baseline PP NRS ≥ 7, which is agreed. It is noted that the subpopulations of subjects with baseline PP NRS ≥ 7 comprise approximately 60-65% of the full ITT populations.

Primary and key secondary efficacy endpoint analyses during the initial treatment period in the two populations were type I error controlled using a serial gatekeeping approach with 2.5% alpha. There were no type I error control for endpoints evaluated after re-randomisation. This approach is accepted.

In primary and key secondary analyses missing values were treated as non-responders. Treatment discontinuation was handled by the treatment policy strategy, using the observed response. The composite strategy was used for the intercurrent event rescue therapy, where data on or after the initiation of rescue therapy were defined as treatment failure. The proportions with rescue medications were slightly higher in the placebo arms, compared to nemolizumab arms. Tipping point analyses were performed as a planned sensitivity analysis challenging this imputation, which is appreciated.

The statistical analysis method used for the binary primary and key secondary efficacy endpoints was the Cochran-Mantel-Haenszel (CMH) test, adjusted by randomisation strata; the choice of method is supported. Primary and key secondary efficacy analyses were prespecified. The statistical analysis methods used for other secondary endpoints involved the CMH test as well as MMRM and ANCOVA with MI under MAR assumption (MI-MAR). The continuous endpoints were not based on imputation assuming MNAR and were not coherent with the worst-case imputation performed on the binary endpoints. Of note is that this does not concern the type I error controlled co-primary and key secondary endpoint analyses. The performed subgroup analyses were adequate.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

## Phase 2 studies

## Study CIM003JG

The difference versus placebo in least squares (LS) mean percentage reduction from baseline in pruritus VAS in the PP population was greater at the 0.5 mg/kg and 2.0 mg/kg dose levels (41.16% and 40.39%, both p&lt;0.0001 versus placebo) than at the 0.1 mg/kg dose level (21.39%, p=0.0027 versus placebo) at week 12, showing evidence of a dose response. The primary efficacy objective was therefore met.

At Week 12, the highest LS mean improvement (61.24%) in reduction in pruritus VAS was achieved at a dose of 0.5 mg/kg Q4W. The secondary efficacy endpoints supported the primary efficacy endpoint. Over the course of the study, improvements in the dermatitis scores were most marked in the 0.5 mg/kg Q4W group with no evidence of additional improvement in efficacy at 2.0 mg Q4W or 2.0 mg/kg Q8W.

In Part B, the mean percent change in pruritus VAS at Week 64 were - 44.70% (32.00%), -41.29% (64.16%) and -47.48% (72.70%), in the nemolizumab 0.1 mg/kg, 0.5 mg/kg and 2.0 mg/kg groups, respectively, showing evidence of a maintained response during long-term treatment.

To conclude, a dose response for nemolizumab was demonstrated for several clinical endpoints, most importantly reduction in pruritus VAS, supporting the clinical proof-of-concept for the treatment of AD. There was no evidence to suggest that nemolizumab administered at 2.0 mg/kg was more effective than the 0.5 mg/kg dose (the dose proposed for marketing) administered Q4W. The safety profile of nemolizumab is considered manageable.

## Study SRE.114322

For the primary efficacy endpoint (percent change from Baseline in EASI at week 24), statistical significance was only demonstrated for the nemolizumab 30 mg group. The percent change from baseline was -68.8% LS-mean, compared with -52.1% in the placebo group (LS-mean difference 16.7%) (95% CI -30.2, -3.2; p=0.016). Borderline statistical significance was demonstrated for the nemolizumab 10 mg group, while no statistical significance was shown for the nemolizumab 90 mg group.

One of the secondary efficacy endpoints measured effect of nemolizumab on pruritus. An absolute and percent reduction in weekly average peak pruritus NRS at Week 24 was seen for all nemolizumab doses compared with placebo which were statistically significant (p≤0.002). The peak pruritus NRS responder rate (improvement of weekly average peak pruritus NRS ≥4) was statistically significant for all nemolizumab doses compared with placebo at all timepoints from Week 2 onwards (p≤0.05). Nemolizumab demonstrated an onset of action on pruritus during Week 1 (p=0.042 for the 30 mg nemolizumab dose). In an ad hoc analysis for the EASI≥16 subpopulation, statistically significant differences were seen for all nemolizumab doses compared with placebo at all timepoints from Week 2 onwards (p&lt;0.05).

To conclude, a dose response for nemolizumab was demonstrated for several clinical endpoints assessed of relevance for the treatment of moderate to severe AD. The study results demonstrate that of the 3 doses evaluated, nemolizumab 30 mg (with a 60-mg loading dose) seemed the best choice for efficacy based on results with IGA, EASI, and pruritus scores.

## Supportive study SRE.116912

Due to the small number of included subjects, efficacy will not be commented upon.

<div style=\"page-break-after: always\"></div>

## Phase 3 studies

## SRE.118161 (ARCADIA 1) and SRE.118169 (ARCADIA 2)

Initial treatment period (efficacy evaluation at week 16)

In total, 1142 subjects were randomised to the nemolizumab groups, and 586 to the placebo groups of the clinical studies SRE.118161 and SRE.118169. In the nemolizumab groups (30 mg q4W), 1135/1142 received at least 1 dose of study drug of which 1030 subjects completed the study. 105 nemolizumab treated subjects discontinued the study. 584/586 received at least 1 vehicle dose of which 537 subjects completed the study. 47 vehicle treated subjects discontinued the study.

Randomised subjects were enrolled across 161 sites in study SRE.118161 and 120 sites in SRE.118169 in several countries and geographic regions, including Asia, US, Canada, and Europe. Overall, there was a high (90.0-92.2%) completion rate, and  similar proportions of subjects completed study SRE.118161 and SRE.118169 across the treatment groups. The most common reason for discontinuation was subject request in both SRE.118161 (4.0% nemolizumab, 3.7% placebo) and SRE.118169 (4.8% nemolizumab, 5.7% placebo).

Major protocol deviations were reported for 28% (259/941) of subjects in ARCADIA 1 and 26% (202/787) in ARCADIA 2 during the Initial period. During the Maintenance period, major protocol deviations were reported for 8% (21/272) of subjects in ARCADIA 1 and 14% (33/235) in ARCADIA 2 in the ITT population. Most of the events reported were in regard to enrollment criteria, informed consent and other (an incorrect randomization stratification by PP NRS, IGA, or both PP NRS and IGA), visit/procedure required and concomitant medications. Only subjects with a major protocol deviation that may have had a significant effect on the efficacy of the study drug were excluded from the perprotocol (PP) population which resulted in exclusion of 184 subjects in ARCADIA 1 and 106 subjects in ARCADIA 2 study.

The demographics characteristics were well balanced between the nemolizumab and placebo groups in the initial treatment period. 51% of subjects were male, the mean age was 34 years, with 266/1728 being adolescent subjects. The majority (80%) of subjects were white. The population represented moderate-to-severe AD as measured by the baseline IGA scores (70.1% had an IGA score of 3 and 29.9% an IGA score of 4) and EASI (mean baseline 27.51). Subjects reported moderate-to-severe itching, with mean weekly average PP NRS at baseline of 7. Overall, 63.3% of subjects received any previous systemic treatment for AD.

In the maintenance period (weeks 16 to 48) most subjects were female (57.4% to 63.3%) and white (84.6% to 87.0%). Mean age ranged from 31.5 years to 35.2 years across the groups. The percentage of adolescent subjects (aged 12 to 17 years) was similar across the treatment groups (18.3% to 20.1%).

To conclude, the demographic characteristics in studies SRE.118161 SRE.118169  and the LTE Study 118163 is considered well representative of the target population moderate to severe AD.

The datasets analysed for nemolizumab in study SRE.118161 during the initial treatment period 30 mg Q4W was the ITT population where 620 completed out of 620 patients that started treatment. The other datasets analysed were subjects with baseline NRS ≥7 (406/620), PPP (501/620), safety (616/620), and the pharmacokinetic analysis population (593/620).

The datasets for the placebo group were ITT (321/321), subjects with baseline NRS ≥7 (210/321), PPP (256/321), and safety (321/321). No pharmacokinetic analysis was performed.

In the maintenance period (ITT population) 272 completed out of 272 patients that started treatment. Enrolled subjects in maintenance period population were 90/90 in the nemolizumab 30 mg Q4W to

<div style=\"page-break-after: always\"></div>

Q4W group, 91/91 in nemolizumab 30 mg Q4W to Q8W and 91/91 in 30 mg Q4W to placebo group. Other analysis populations were safety population and Enrolled safety subjects in maintenance period population with similar numbers of attendees as above.

The datasets analysed for nemolizumab in study SRE.118169 during the initial treatment period 30 mg Q4W was the ITT population where 522 completed out of 522 patients that started treatment. The other datasets analysed were subjects with baseline NRS ≥7 (316/522), PPP (454/522), safety (519/522), and the pharmacokinetic analysis population (499/522).

The datasets for the placebo group were ITT (265/265), subjects with baseline NRS ≥7 (164/265), PPP (227/265), and safety (263/265). No pharmacokinetic analysis was performed.

In the maintenance period (ITT population) 235 completed out of 235 patients that started treatment. Enrolled subjects in maintenance period population were 79/79 in the nemolizumab 30 mg Q4W to Q4W group, 78/78 in nemolizumab 30 mg Q4W to Q8W and 78/78 in 30 mg Q4W to placebo group. Other analysis populations were safety population and Enrolled safety subjects in maintenance period population with similar numbers of attendees as above.

The use of rescue medications was 31/620 (5%) in the nemolizumab group and 24/321 (7.5%) in the vehicle group in study SRE.118161 during the initial treatment period. The corresponding results in study SRE.118169 were 16/522 (3.1%) in the nemolizumab group and 12/265 (4.5%) in the vehicle group. As could be expected the use of rescue medication was higher among vehicle treated subjects. The same pattern was also noted during the maintenance period, where subjects randomised to nemolizumab 30 mg Q4W to placebo needed rescue medication to a higher extend than subjects on active treatment.

## Efficacy results - initial treatment period (week 0 - 16)

In study SPR.118161, nemolizumab was statistically significantly superior to placebo with respect to the co-primary efficacy endpoint IGA success (35.6% vs 24.6%, the unadjusted proportion of difference for active - placebo was 11.0 (95% CI 5.0 to 17.1) in the full population, and 14.0 (95% CI 6.8 to 21.3) in the severe pruritus population. The corresponding results obtained in study SPR.118169 were 37.7% vs 26.0%, the difference for active - placebo was 11.7 (95% CI 5.0 to 18.4) in the full population, and 14.8 (95% CI 6.5 to 23.0) in the severe pruritus population.

In study SPR.118161, results obtained with EASI-75 score were 43.5% for nemolizumab vs 29.0% for vehicle injection which resulted in a difference for active - placebo of 14.6 (95% CI 8.3 to 20.9) in the full population, and 17.8 (95% CI 10.3 to 25.3) in the severe pruritus population. The corresponding results obtained in study SPR.118169 were 42.1% vs 30.2%, the difference for active placebo was 12.0 (95% CI 5.0 to 18.9) in the full population, and 16.1 (95% CI 7.6 to 24.7) in the severe pruritus population.

Although statistically significant, the treatment effect is modest due to a rather high percentage of placebo-responders. The applicant discussed possible reasons behind this finding. The observed placebo response in the two pivotal studies was consistent with the expected effect of TCS/TCI on inflammation and their less pronounced effect on pruritus, which is evident in the improvement of IGA and EASI scores and less so in scores involving any pruritus scale. Considering the data presented, it can be concluded that patients in the placebo arm had a significant response owing to antiinflammatory effects of TCS and their slightly more frequent use compared to patients in nemolizumab group. Patients experienced visible improvements (reduced inflammation, pruritus relief), reinforcing their belief in treatment efficacy, and leading to a stronger placebo response. The combination of objective improvement (reduced inflammation) and subjective relief (itch reduction) enhanced overall treatment perception.

<div style=\"page-break-after: always\"></div>

Results for both co-primary endpoints were consistent in the severe pruritus population (baseline PP NRS ≥7) as well as across sensitivity (i.e., excluding COVID-19 affected visits) analyses. The efficacy level of the vehicle was, as could be expected, less in the severe pruritus population which results in a slightly larger effect size (active - placebo), however the difference to the overall population is not marked. Due to small differences between the overall population and the severe pruritus population only the results for the ITT population (i.e., the overall population) is presented in the SmPC section 5.1.

Both co-primary efficacy endpoints were met at week 16 as IGA success improved (defined as an IGA of 0 (clear) or 1 (almost clear) and a ≥ 2-point improvement from baseline) and the proportion of subjects with EASI-75 (≥75% improvement in EASI from baseline). The differences between nemolizumab and vehicle are statistically significant (p &lt; 0.001) for both co-primary efficacy endpoints. From a numerical perspective, the differences between active and placebo are assessed as modest.

The key secondary efficacy endpoints all measured the efficacy of nemolizumab on itch using the endpoint PP-NRS (peak pruritus numerical rating scale) either as single endpoint or in combination with IGA or EASI. Moreover, the efficacy of nemolizumab in the sleep disturbance numerical rating scale (SD NRS) was investigated. All the results referred to below are obtained with multiplicity controlled clinical endpoints.

In study SPR.118161, the analysis of the key secondary efficacy endpoints, 1) Proportion of subjects with an improvement of PP NRS ≥ 4 at Week 1 showed that nemolizumab was statistically significantly superior to placebo (p&lt;0.0067) with 4.7 for nemolizumab treatment and 1.2 in the vehicle group. The unadjusted proportion of difference for active - placebo was 3.4 (95% CI 1.4 to 5.5) in the full population. At week 2, the values were 17.7 in the nemolizumab group and 3.1 in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 14.6 (95% CI 11.1 to 18.2) in the full population. At week 4, the values were 27.4 in the nemolizumab group and 6.5 in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 20.9 (95% CI 16.4 to 25.3) in the full population. At week 16, the values were 42.7 in the nemolizumab group and 17.8 in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 25.0 (95% CI 19.3 to 30.7) in the full population.

The corresponding results obtained in study SPR.118169 at week 1 were 6.7 in the nemolizumab group and 0.4 in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 6.3 (95% CI 4.1 to 8.6) in the full population. At week 2, the values were 16.9 in the nemolizumab group and 1.9 in the vehicle group (p&lt;0.0001) The unadjusted proportion of difference for active - placebo was 15.0 (95% CI 11.4 to 18.6) in the full population. At week 4, the values were 26.1 in the nemolizumab group and 5.3 in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 20.8 (95% CI 16.1 to 25.4) in the full population. At week 16, the values were 41.0 in the nemolizumab group and 18.1 in the vehicle group (p&lt;0.0001) The unadjusted proportion of difference for active - placebo was 22.9 (95% CI 16.6 to 29.2) in the full population.

In study SPR.118161, the analysis of the key secondary efficacy endpoints, 2) Proportion of subjects with PP NRS &lt; 2 at week 4 and week 16 showed that nemolizumab was statistically significantly superior to placebo (p&lt;0.0001) at week 4 with 16.0 for nemolizumab treatment and 3.7 in the vehicle group. The unadjusted proportion of difference for active - placebo was 12.2 (95% CI 8.7 to 15.8) in the full population. At week 16, the values were 30.6 in the nemolizumab group and 11.2 in the vehicle group (p&lt;0.0001) The unadjusted proportion of difference for active - placebo was 19.4 (95% CI 14.4 to 24.4) in the full population.

The corresponding results obtained in study SPR.118169 at week 4 were 15.9 in the nemolizumab group and 2.6 in the vehicle group (p&lt;0.0001) The unadjusted proportion of difference for active -

<div style=\"page-break-after: always\"></div>

placebo was 13.3 (95% CI 9.6 to 16.9) in the full population. At week 16, the values were 28.4 in the nemolizumab group and 11.3 in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 17.0 (95% CI 11.6 to 22.5) in the full population.

In study SPR.118161, the analysis of the key secondary efficacy endpoints, 3) Proportion of subjects with an improvement of sleep disturbance NRS (SD NRS) ≥ 4 at Week 16 showed that nemolizumab was statistically significantly superior to placebo (p&lt;0.0001) at week 16 with 37.9 for nemolizumab treatment and 19.9 in the vehicle group. The unadjusted proportion of difference for active - placebo was 18.0 (95% CI 12.2 to 23.8) in the full population.

The corresponding results obtained in study SPR.118169 were 33.5 in the nemolizumab group and 16.2 in the vehicle group (p&lt;0.0001) The unadjusted proportion of difference for active - placebo was 17.3 (95% CI 11.3 to 23.3) in the full population.

In study SPR.118161, the analysis of the key secondary efficacy endpoints, 4) Proportion of subjects with EASI-75 and improvement of PP NRS ≥ 4 at Week 16 showed that nemolizumab was statistically significantly superior to placebo (p&lt;0.0001) at week 16 with 23.7 for nemolizumab treatment and 11.2 in the vehicle group. The unadjusted proportion of difference for active - placebo was 12.5 (95% CI 7.7 to 17.3) in the full population.

The corresponding results obtained in study SPR.118169 were 23.0 in the nemolizumab group and 9.8 in the vehicle group (p&lt;0.0001) The unadjusted proportion of difference for active - placebo was 13.2 (95% CI 8.1 to 18.3) in the full population.

In study SPR.118161, the analysis of the key secondary efficacy endpoints, 5) Proportion of subjects with IGA success and improvement of PP NRS ≥ 4 at Week 16 showed that nemolizumab was statistically significantly superior to placebo (p&lt;0.0001) at week 16 with 19.7 for nemolizumab treatment and 9.3 in the vehicle group. The unadjusted proportion of difference for active - placebo was 10.3 (95% CI 5.9 to 14.8) in the full population.

The corresponding results obtained in study SPR.118169 were 20.5 in the nemolizumab group and 8.7 in the vehicle group (p&lt;0.0001) The unadjusted proportion of difference for active - placebo was 11.8 (95% CI 7.0 to 16.7) in the full population.

In analogy with the reasoning on the results of the co-primary endpoints, the ITT population is suggested to present the results with nemolizumab for the key secondary endpoints in the SmPC section 5.1.

Concerning patient reported outcomes, moderate to severe AD often has negative consequences on the subject's quality of life, for instance impacted sleep due to itch. The results on patient reported outcomes for nemolizumab are not multiplicity controlled and not accepted for presentation in the SmPC section 5.1.

To conclude, it is considered that the totality of data provided, the results obtained with the co-primary efficacy endpoints and the key secondary efficacy endpoints demonstrate an effect of nemolizumab at the proposed dose in the target population combined with topical AD therapy, patients with moderate to severe AD. Statistically significant efficacy has been demonstrated using several well-known clinical efficacy endpoints often seen in development programs for AD. The results are considered clinically relevant, although the efficacy level (active treatment minus vehicle treatment) is considered modest.

## Efficacy results -maintenance period (week 16 to 48)

Among subjects with IGA success at Week 16, the nemolizumab Q4W to Q4W and nemolizumab Q4W to Q8W groups had similar maintenance of response at each timepoint investigated up to week 48, and higher when compared with nemolizumab Q4W to placebo group at Week 48.  Similarly, among

<div style=\"page-break-after: always\"></div>

subjects with EASI-75 response at Week 16, the proportion who maintained EASI-75 was similar between nemolizumab Q4W to Q4W and Q4W to Q8W dosing regimens and higher as compared with nemolizumab Q4W to placebo group at Week 48.

Concerning efficacy on itch, the proportion who maintained an improvement of ≥4 from initial baseline in weekly average PP NRS was higher in the nemolizumab Q4W to Q4W and nemolizumab Q4W to Q8W groups compared with nemolizumab Q4W to placebo at Week 48, in the missing as non-responder analysis.

## Sub-group results, studies SPR.118161 and SPR.118169

The treatment effects in subgroups (i.e., age, sex, race, ethnicity, region, baseline IGA, baseline PP NRS, and previous use of systemic therapy for AD) are generally consistent with the results in the overall population, the point estimate for each tested endpoint was consistently in favour of nemolizumab compared with placebo across all subgroups during the initial treatment period. This pattern was observed in pivotal Phase 3 studies.

Body weight was determined as a significant predictor of nemolizumab exposure. A post-hoc subgroup analysis by body weight (BW) categories (&lt;90 kg and ≥ 90 kg) in the ITT population was requested which showed reduced efficacy of nemolizumab in patients ≥ 90 kg, with no difference from placebo for both the IGA and EASI-75 endpoints. However, the observed response (and consequently the treatment effect) was more pronounced and similar to &lt;90 kg group in scores involving pruritus scale (PP NRS endpoint). An update of the SmPC section 4.2 was requested, that if an inadequate clinical response is achieved in patients weighing ≥ 90 kg, both a higher initial dose and higher maintenance dose could be considered. Although the results demonstrated lower efficacy for anti-inflammatory response in patients with BW ≥90 kg, it was agreed that the anti-pruritic effect of nemolizumab should be sufficient for a positive B/R in this subgroup. No specific dose adjustment is recommended based on body weight for the indication AD. Additionally, a wording for part 5.1 of the SmPC was implemented to describe the results in this subgroup of patients. Moreover, the treatment effects for adolescents (SRE.118161 and SRE.118169) were generally consistent with the results in the overall population.

## EFFICACY DATA - LTE study (interim report, cut-off date 30 Sep 2022)

Of the 1751 enrolled subjects, 422 (24.1%) subjects discontinued treatment. Overall, the most common reasons for discontinuation of treatment were subject request. Efficacy discussions are focused on data up to Week 56. The proportion of all subjects with an IGA score of 0-1 at LTE baseline was 23.9% and increased to 48.9% at Week 56. The proportion of all subjects with EASI-75 at LTE baseline was 33.7% and increased to 75.6% at Week 56. Mean percent BSA affected by AD in all subjects 25.773 at LTE baseline and 11.196 at Week 56. Consistent improvements were observed with the antipruritic activity of nemolizumab and sleep up to Week 56. Improvements over time were also observed for low disease activity (clear, almost clear, or mild based on PGAD) and satisfaction with study treatment (good, very good, or excellent based on PGAT) in all subjects up to Week 56. The interim results analysis also demonstrated a trend of convergence of treatment effect over time in nemolizumab-naïve, nemolizumab continuous, and nemolizumab re-treated subjects.

The study is currently ongoing and is planned to be finalized in early 2027.

## Supportive studies

Nemolizumab is approved in Japan for the treatment of pruritus associated with AD (only when existing treatments are inadequate) in patients aged 13 years and older. The performed studies differ in several aspects compared with the present application for approval in EU; demographic characteristics, level of itch of the included subjects, dosage of nemolizumab and the primary endpoint used. The relevance of the supportive studies is assessed as limited.

<div style=\"page-break-after: always\"></div>

## Assessment of paediatric data on clinical efficacy

The efficacy of nemolizumab 30 mg is similar in the adult and adolescent populations. Please refer to section 5.1. of the SmPC.

## 2.6.7.  Conclusions on the clinical efficacy

The overall design of the pivotal Phase 3 studies SRE.118161 and SRE.118169 and its extension study SRE.118163 is endorsed. The efficacy of nemolizumab 30 mg Q4W SC after a 60 mg loading dose compared with vehicle injection was evaluated at week 16 in the pivotal studies. Efficacy evaluation at week 48 in the LTE SRE.118163 of the  the maintenance phase of the pivotal studies is descriptive. A long-term efficacy and safety follow up study is ongoing.

In studies SRE.118161 and SRE.118169, both co-primary efficacy endpoints were met with convincing statistically significant results compared with placebo at week 16. Furthermore, several key secondary endpoints that investigated efficacy on itch were similarly statistically significant, and thus supportive of the co-primary endpoints. A clinically relevant efficacy of nemolizumab 30 mg has thus been demonstrated in subjects with atopic dermatitis above 12 years of age, although the efficacy is considered modest in numerical values.

Overall, the improvements seen at Week 16 are considered clinically meaningful from an efficacy pointof-view.

## 2.6.8.  Clinical efficacy - prurigo nodularis

A total of 19 studies were acquired or conducted by the Sponsor and used to support the evaluation of efficacy and safety of nemolizumab in PN as of the 10 Mar 2023 Marketing Authorisation Application (MAA) cutoff date.

## 2.6.8.1.  Dose-response studies

## Supportive Phase 2a study

## Study SPR.115828 - A study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)

This was a Phase 2a, randomised, placebo-controlled, double-blind, parallel-group, multicentre study to evaluate the safety and efficacy of nemolizumab in subjects suffering from PN, which can be viewed as a proof-of-concept study to evaluate the potential for nemolizumab to have effect on pruritus in adult patients with PN. Only one dose level was used, thus it was not a dose ranging study.

Key inclusion criteria were chronic PN for ≥ 6 months and severe pruritus defined by the mean of the worst daily intensity of numerical rating scale (NRS) score ≥ 7 over the previous week at baseline.

Key exclusion criteria were chronic pruritus resulting from another active condition other than PN; unilateral lesions of prurigo; and medical history of asthma meeting any of the protocol-specified criteria.

A total of 70 subjects were randomized 1:1 to receive nemolizumab or placebo, with each subject receiving 3 SC injections of 0.5 mg/kg of nemolizumab or matching placebo Q4W (baseline, Week 4, and Week 8) and 60 subjects (85.7%) completed the study. Randomization was stratified by background of atopy (presence or absence).

<div style=\"page-break-after: always\"></div>

The percent change from Baseline in pruritus NRS to week 4 (weekly average of the peak) was the primary efficacy endpoint. For the primary endpoint, a greater percent change from Baseline to week 4 was observed in the nemolizumab group, -53.4% LS-mean compared with -15.3% in the placebo group (difference between treatment groups -38.0%) and the difference was statistically significant (95% CI -51.0, -25.0; p&lt;0.001).

Nemolizumab was statistically significantly more efficacious than placebo in reducing weekly average of the peak pruritus NRS scores at all timepoints (Weeks 1, 2, 4, 8, 12, 16, and 18, p&lt;0.001). Statistical significance was observed for both absolute and percent changes of weekly average of the peak pruritus NRS, and absolute and percent changes for weekly average of the average pruritus NRS.

The results of this Phase 2a study (SPR.115828) along with modelling and simulation tools determined a flat dose for utilization in the Phase 3 studies.

## 2.6.8.2.  Main studies

The focus in the assessment aeport will be on the two completed, pivotal, double-blind, placebocontrolled, Phase 3 studies RD.06.SPR.202685 (Olympia 1) and RD.06.SPR.203065 (Olympia 2).

## Study RD.06.SPR.202685 and Study RD.06.SPR.203065:

## A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Prurigo Nodularis

## Methods

Both pivotal studies were global, phase 3, randomized, double-blind, placebo-controlled, multicentre, parallel-group trials designed to evaluate the efficacy and safety of nemolizumab in adult subjects with PN.

Figures describing the study design of the pivotal Phase 3 clinical studies SPR.202685 and SPR.203065 can be seen below ( Figure 16 and Figure 17 ).

<div style=\"page-break-after: always\"></div>

Figure 16: Study design SPR.202685

<!-- image -->

## BL=baseline; W=week

- *: Applicable for subjects who did not participate in the long-term extension study only.
- **: Loading dose (2 injections) administered at baseline visit for subjects weighing &lt;90 kg.
- ***: 2 injections administered at all applicable visits for subjects weighing ≥90 kg at the baseline visit.

## Figure 17: Study design SPR.203065

<!-- image -->

-  :Nemolizumab30mgadministration Placeboadministration

## BL=baseline; W=week

- *: Applicable only for subjects who did not participate in the long-term extension study.
- **: Loading dose (2 injections) administered at baseline visit for subjects weighing &lt;90 kg.
- ***: 2 injections administered at all applicable visits for subjects weighing ≥90 kg at the baseline visit.

<div style=\"page-break-after: always\"></div>

Each study consisted of 3 periods over approximately 28 (SPR.203065) or 36 (SPR.202685) weeks: screening (up to 4 weeks), a 16-week (SPR.203065) or 24-week (SPR.202685) treatment period, and an 8-week follow-up period (12 weeks after the last study drug injection).

Eligible subjects were randomized 2:1 to receive either 60 mg of nemolizumab or placebo via 2 subcutaneous (SC) injections at baseline. Subjects were stratified by study centre and baseline body weight (&lt;90 kg and ≥90 kg). Thereafter, study drug was to be administered every 4 weeks (Q4W) at Weeks 4, 8, and 12 (SPR.203065) or at Weeks 4, 8, 12, 16, and 20 (SPR.202685) by a single SC injection of either nemolizumab 30 mg or placebo for subjects weighing &lt;90 kg at baseline or by 2 SC injections of either nemolizumab 30 mg or placebo for subjects weighing ≥90 kg at baseline.

At the end of the treatment period, consenting subjects may have been eligible to enrol in the LTE study (SPR.202699).

## Study participants

Key inclusion criteria were the same for each pivotal study and included male or female subjects ≥18 years of age at the time of screening with a clinical diagnosis of PN for at least 6 months (with PN lesions on upper limbs, trunk, and/or lower limbs, at least 20 nodules on the entire body with a bilateral distribution, an Investigator's Global Assessment (IGA) score ≥3 at both the screening and baseline visits), severe pruritus based on the Peak Pruritus Numerical Rating Scale (PP NRS), defined as a PP NRS score ≥7.0 for the 24-hour period immediately preceding the screening visit or a mean of the daily intensity of the PP NRS score ≥7.0 over the previous week at the baseline visit.

Key exclusion criteria were the same for each pivotal study and included body weight &lt;30 kg; chronic pruritus resulting from another active condition other than PN; unilateral lesions of prurigo; history of or current confounding skin condition; active AD in the last 3 months; meeting 1 or more of the protocol-specified respiratory (i.e., asthma, ACT, and/or PEF) criteria; and current medical history of chronic obstructive pulmonary disease and/or chronic bronchitis.

## Treatments

Study drug was supplied as a lyophilized powder in a pre-filled, single-use, dual chamber syringe (DCS) for solution for SC injection only after reconstitution. The lyophilized nemolizumab powder was in chamber 1 and water for injection as a reconstitution liquid was in chamber 2 of the DCS. After reconstitution, each DCS contained 61.5 mg/mL of nemolizumab to deliver a dose of 30 mg with nominal injection volume of 0.49 mL.

The duration of treatment was 24 weeks with last injection at Week 20 in study SPR.202685 and 16 weeks with last injection at Week 12 in study SPR.203065.

The pivotal Phase 3 studies utilized a flat dose, which was considered more efficient as it provided several benefits, including ease of preparation for auto-injection and reduced chance of errors that could have been made in calculating, preparing, and administering a weight-based dose. The switch from a body weight-based dose to a flat dose was supported by the results of the Phase 2 study conducted in subjects with PN and by modelling and simulations (popPK and PK/PD models).

Overall, the popPK and PK/PD analyses showed that a dose increase to 60 mg Q4W in subjects with a body weight ≥90 kg maintained comparable exposure and comparable IGA responder rate as those observed in the overall population treated with 0.5 mg/kg weight-based dose.

Subjects with a body weight &lt;90 kg received a 30-mg dose administered Q4W (with a loading dose of 60 mg at baseline).

<div style=\"page-break-after: always\"></div>

Subjects with a body weight ≥90 kg received a 60-mg dose administered Q4W without a loading dose at baseline.

## Rescue therapy

If deemed to be medically necessary by the Investigator (e.g., to control intolerable PN signs/symptoms), rescue therapies could have been prescribed to the subjects. Rescue therapy must not have been prescribed during the screening period.

As a general guideline and per individual Investigator judgment, rescue therapy was not to be prescribed within the first 4 weeks after baseline to allow a minimum time for study drug exposure.

The use of any rescue therapies was to be documented in the eCRF. Rescue therapies included:

-  Topical corticosteroids
-  Topical calcineurin inhibitors
-  Oral antihistamines
-  Systemic or intralesional corticosteroids
-  Biologics (including their biosimilars)
-  Systemic nonsteroidal immunosuppressants/immunomodulators
-  Phototherapy
-  Gabapentinoids

## Objectives

The primary objective of both pivotal studies was to assess the efficacy of nemolizumab compared to placebo in subjects ≥ 18 years of age with PN after a 16-week treatment period.

For SPR.202685, the 24-week treatment period included assessment of the primary efficacy endpoints after 16 weeks of treatment, with an assessment of sustained efficacy following an additional 8 weeks (i.e., Week 24).

The secondary objectives were to assess the safety, pharmacokinetics (PK), and immunogenicity of nemolizumab compared to placebo.

## Outcomes/endpoints

In this report, the results with the two primary efficacy endpoints and the key secondary efficacy endpoints will be shown in tables (see below).

## Primary efficacy endpoints

There were 2 primary efficacy endpoints in the pivotal studies:

-  The proportion of subjects with an improvement of ≥ 4 from baseline in PP NRS at Week 16
-  The proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥ 2-grade improvement from baseline) at Week 16.

## Key secondary efficacy endpoints

There were 5 key secondary endpoints in the pivotal studies:

-  Proportion of subjects with an improvement of ≥ 4 from baseline in PP NRS at Week 4
-  Proportion of subjects with PP NRS &lt;2 at Week 16

<div style=\"page-break-after: always\"></div>

-  Proportion of subjects with an improvement of ≥ 4 from baseline in Sleep Disturbance Numeric Rating Scale (SD NRS) at Week 16
-  Proportion of subjects with an improvement of ≥ 4 from baseline in SD NRS at Week 4
-  Proportion of subjects with PP NRS &lt;2 at Week 4

Furthermore, a number of secondary efficacy endpoints were investigated.

The primary efficacy outcome measures were:

## Investigator's global assessment

The IGA is a 5-point scale used by the Investigator or trained designee to evaluate the global severity of PN ( Figure 18 ). The Investigator reviewed the subject's skin and assigned a score of 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), or 4 (severe). Treatment response/success was defined as 0 (clear) or 1 (almost clear) and a ≥ 2-point improvement from baseline.

Figure 18: Investigator's global assessment

|   Score | Category     | Description                           |
|---------|--------------|---------------------------------------|
|       0 | Clear        | No nodules                            |
|       1 | Almost Clear | Rare palpable pruriginous nodules     |
|       2 | Mild         | Few palpable pruriginous nodules      |
|       3 | Moderate     | Many palpable pruriginous nodules     |
|       4 | Severe       | Abundant palpable pruriginous nodules |

Peak pruritus numeric rating scale (PP NRS)/average pruritus numeric rating scale (AP NRS)

The PP NRS was a scale used by subjects to report the intensity of their pruritus (itch) during the last 24 hours. The PP NRS is an assessment of the maximum itch intensity in that period while the AP NRS provides a measure of average pruritus intensity. The AP NRS and PP NRS were to be completed by the subject once daily in the evening.

Each numeric rating scale (NRS) asked for a unit score on an 11-point scale (0 to 10) where 0 was 'no itch' and 10 was the 'worst itch imaginable'. The 2 questions asked were:

## Sleep disturbance numeric rating scale (SD NRS)

An NRS relating to sleep disturbance was to be completed by the subject once daily in the morning and, if possible, within 1 hour of getting out of bed, to report the degree of his/her sleep loss related to PN. The SD NRS asked for a unit score on an 11-point scale (0-10).

## Sample size

In Olympia 1 and Olympia 2, a sample size of n = 270 (n = 180 nemolizumab, n = 90 placebo) was stated to have 90% power to detect 1) an absolute difference of 30% in the proportion of subjects with PP NRS improvement from baseline to week 16 (50% in the nemolizumab group and 20% in the placebo group) as well as 2) an absolute difference of 20% in the proportion of subjects with IGA success from baseline to week 16 (30% in the nemolizumab group and 10% in the placebo group) with a two-sided significance level of 5% and assuming a drop-out rate of 15%.

## Randomisation and blinding (masking)

## Randomisation

<div style=\"page-break-after: always\"></div>

In each of the two similarly designed studies Olympia 1 and Olympia 2, approximately 270 subjects aged ≥ 18 years who met eligibility criteria were to be randomised with a ratio of 2:1 to receive either nemolizumab or placebo. Randomisation was to be stratified by study site (77 in Olympia 1 and 55 in Olympia 2) and baseline body weight (&lt; 90 kg vs. ≥ 90 kg). At the end of the treatment period (24 weeks in Olympia 1 and 16 weeks in Olympia 2) consenting subjects may have been eligible to enter an active treatment long-term extension (LTE) study.

## Blinding

Both studies were double-blinded clinical studies where the treatment assignments were blinded to patients, the Sponsor's study team members, and to the members of study centre staff, including those responsible for dual-chamber, single-use syringe (DCS) preparation. To ensure double-blind administration of study drug, the study centre pharmacist(s) or other qualified personnel were to prepare all nemolizumab or placebo treatments and were not to be involved with any study assessments and were not to discuss any aspects of study drug reconstitution with the subject/caregiver or study staff involved in subject interviews or study assessments. In addition, to maintain the integrity of the study blinding, the bioanalytical laboratory staff who processed/analysed the PK/pharmacodynamics (PD)/PGx samples were not to provide any information to sponsor, CRO, or investigational study centre personnel directly involved with the ongoing conduct of the study that may have led to unblinding.

## Statistical methods

Olympia 1 and Olympia 2 were similarly designed studies, although with different lengths of treatment periods (24 weeks in Olympia 1 and 16 weeks in Olympia 2). The SAPs were similar. There were no amendments to the SAP of Olympia 1 and the SAP was finalised prior to database lock. There was an addendum to the SAP of Olympia 2 that occurred after database lock and unblinding.

## Analysis sets

The intent-to-treat (ITT) populations were the primary populations in all efficacy analyses. The ITT populations were to consist of all randomised subjects under the treatment group 'as randomised' and under the stratum 'as randomised'.

Efficacy analyses on primary, key secondary, and some of the other secondary endpoints were also to be performed based on the per protocol (PP) populations, and these analyses were to be treated as supportive analyses.

## Error probabilities and adjustment for multiplicity

In both studies, to control the type I error at 5% significance level, a fixed sequential testing approach were to be implemented. The primary endpoints were to be tested at 5% significance level in a predefined order: 1) PP NRS improvement and 2) IGA success. If both primary endpoints were statistically significant at 5% level, key secondary endpoints were to be tested in the order specified in section Primary Objective, and subsequent testing were to stop if a test was not statistically significant. Secondary endpoints were not to be controlled for multiplicity.

No interim analyses were planned nor performed.

## Main analysis methods for primary and key secondary efficacy endpoints

The primary efficacy analyses were to concern the primary endpoints: 1) proportion of subjects with an improvement of ≥ 4 in PP NRS from baseline to week 16, and 2) proportion of subjects with an IGA

<div style=\"page-break-after: always\"></div>

success at week 16 (defined as an IGA response of 0 or 1 and a ≥ 2-point reduction from baseline). Primary and key secondary efficacy endpoint analyses were to be type I error controlled (see below).

Treatment discontinuation and rescue therapy were to be defined as intercurrent events and the strategies to handle these were to be by the treatment policy strategy and composite strategy, respectively. For subjects who discontinued treatment, the observed response at week 16 (or week 4 for some of the key secondary efficacy endpoints) were to be used in the analyses. Subjects using rescue therapies prior to week 16 for primary endpoints (or week 4 for some of the key secondary endpoints) were to be considered as treatment failures/non-responders. Subjects with missing values at week 16 assessment (or week 4 assessment for some of the key secondary endpoints) were also considered as non-responders.

Both primary and key secondary endpoints were to be analysed by means of Cochran-Mantel-Haenszel (CMH) tests adjusted for the randomised stratification variables, i.e., analysis centre and weight at randomisation (≥ 90 kg/&lt; 90 kg). The CMH tests were to be evaluated under a two-sided alpha level of 5% and the 95% confidence intervals (CIs) were to be based on the Wald statistic, controlling for the stratification variables; strata-adjusted proportion differences were also to be obtained using weighted averages of the stratum-specific proportions. In addition, unadjusted CMH tests were also to be performed.

## Main analysis methods for other secondary efficacy endpoints

The analyses of other secondary efficacy endpoints were similar in both studies after Olympia 2 SAP addendum. The analyses of the secondary endpoints included the full treatment period (24 weeks in Olympia 1 and 16 weeks in Olympia 2), including all or selected intermediate assessments. The other secondary efficacy endpoint analyses were not to be type I error controlled.

Binary secondary endpoints were to be analysed in a similar way as the primary and key secondary endpoints. Continuous secondary endpoints were to be analysed by means of mixed model repeated measurements (MMRM) and/or by analysis of covariance (ANCOVA), in which missing data were to be imputed by means of multiple imputation (MI) under the missing at random (MAR) assumption. Analyses on the sleep diaries were to be summarized descriptively.

## Handling of missing data

The primary methods to impute missing values were declared to be as follows:

-  Binary endpoints: missing values were to be treated as non-responders/treatment failures during the treatment period.
-  Continuous endpoints (except for EQ-5D and HADS, for which only observed data were analysed): missing values during the treatment period were to be imputed with MI under MAR assumption, and the MMRM approach was also to be used for selected secondary endpoints (see above).

## Sensitivity analyses

The below sensitivity analyses on primary and key secondary efficacy endpoints were planned. In all analyses except for those performed on OC population, assessments on or after rescue therapy were to be considered as non-responders.

-  Tipping point analyses: non-responders due to missing data were to be converted to responders in successive increments (Δ) for both treatment groups, to assess the robustness of analyses; the value of Δ that overturned the primary results represented the tipping point.
-  Analyses in which missing values were to be imputed by means of MI, assuming MAR.

<div style=\"page-break-after: always\"></div>

-  Analyses in which missing values were to be imputed by means of pattern-mixture model under assumption missing not at random (MNAR) controlled-based pattern imputation, where observations in the placebo treatment groups were to be used for imputation.
-  Analyses in which missing values were imputed by means of LOCF. Missing post-baseline values were to be carried forward from the last non-missing post-baseline value.
-  Analyses on OC populations: the OC populations were to comprise all available data and for subjects that received any rescue medication, the data post-rescue therapy was to be analysed as observed and not considered as a treatment failure.
-  Analyses on PP populations: the PP populations were to comprise all subjects in the ITT populations who had no major protocol deviations that would have led to a significant effect on the efficacy of the study treatment.
-  Analyses on the ITT populations but using the 'actual stratum', not 'randomised stratum'.
-  Analyses in which COVID-19 affected visits were excluded.
-  Analyses in which at least 2 and 3 assessments, respectively, instead of at least 4, were used to calculate the PP NRS weekly averages.

## Planned subgroup analyses

The following subgroup analyses were planned for the primary and key secondary efficacy endpoints:

-  Region (Europe, North America [and Asia-Pacific for Olympia 2])
-  Age groups (18-65 and &gt; 65 years)
-  Sex
-  Race (white, black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, other)
-  Weight at randomisation (≥ 90 kg and &lt; 90 kg)
-  Baseline IGA (3 or 4)

## Results

## Participant flow

The two pivotal Phase 3 studies, OLYMPIA 1 (SPR.202685) and OLYMPIA 2 (SPR.203065), were designed to compare the efficacy and safety of nemolizumab to placebo in adult subjects with moderate to severe PN. The study designs allowed for the independent substantiation of efficacy for nemolizumab based on evaluation of the primary endpoints after a 16-week treatment period. Both studies had the same objectives and primary endpoints at Week 16. To provide additional placebocontrolled data beyond Week 16 to satisfy requirements of specific health authorities, after a 16-week treatment period, the treatment duration of SPR.202685 was extended by 8 weeks (i.e., 24-week Treatment Period).

<div style=\"page-break-after: always\"></div>

## Study SPR.202685 (OLYMPIA 1)

## Figure 19: Subject disposition - OLYMPIA 1

<!-- image -->

Three subjects in the nemolizumab group were randomized but not treated: Study drug assigned but not dosed due to prohibited therapy intake, randomized despite eligibility criteria not met .

## Study SPR.203065 (OLYMPIA 2)

<div style=\"page-break-after: always\"></div>

Figure 20: Subject disposition - Olympia 2

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 32: Subject disposition in studies SPR.202685 and SPR.203065 (intent-to-treat population)

| Number of subjects                                | SPR.202685   | SPR.202685   | SPR.202685   | SPR.203065   | SPR.203065   | SPR.203065   | Overall Total   |
|---------------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|-----------------|
| Number of subjects                                | Nemo Q4W     | Placebo      | Total        | Nemo Q4W     | Placebo      | Total        | Overall Total   |
| Number of subjects                                | N=190        | N=96         | N=286        | N=183        | N=91         | N=274        | N=560           |
| Number of subjects                                | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)           |
| Randomized                                        | 190 (100)    | 96 (100)     | 286 (100)    | 183 (100)    | 91 (100)     | 274 (100)    | 560 (100)       |
| Randomized but not treated                        | 3 (1.6)      | 1 (1.0)      | 4 (1.4)      | 0            | 0            | 0            | 4 (0.7)         |
| Treated                                           | 187 (98.4)   | 95 (99.0)    | 282 (98.6)   | 183 (100)    | 91 (100)     | 274 (100)    | 556 (99.3)      |
| Completed treatment                               | 168 (88.4)   | 85 (88.5)    | 253 (88.5)   | 175 (95.6)   | 87 (95.6)    | 262 (95.6)   | 515 (92.0)      |
| Discontinued treatment                            | 19 (10.0)    | 10 (10.4)    | 29 (10.1)    | 8 (4.4)      | 4 (4.4)      | 12 (4.4)     | 41 (7.3)        |
| Primary reason for discontinuation of treatment   |              |              |              |              |              |              |                 |
| Pregnancy                                         | 0            | 0            | 0            | 0            | 1 (1.1)      | 1 (0.4)      | 1 (0.2)         |
| Lack of efficacy                                  | 0            | 0            | 0            | 1 (0.5)      | 1 (1.1)      | 2 (0.7)      | 2 (0.4)         |
| Adverse event                                     | 11 (5.8)     | 4 (4.2)      | 15 (5.2)     | 4 (2.2)      | 2 (2.2)      | 6 (2.2)      | 21 (3.8)        |
| Subject's request                                 | 8 (4.2)      | 4 (4.2)      | 12 (4.2)     | 1 (0.5)      | 0            | 1 (0.4)      | 13 (2.3)        |
| Lost to follow-up                                 | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Protocol deviation                                | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Physician/primary investigator decision           | 0            | 1 (1.0)      | 1 (0.3)      | 1 (0.5)      | 0            | 1 (0.4)      | 2 (0.4)         |
| Sponsor decision                                  | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Other: COVID-19                                   | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Other: inability to attend appointments           | 0            | 0            | 0            | 1 (0.5)      | 0            | 1 (0.4)      | 1 (0.2)         |
| Other: site permanently closed                    | 0            | 1 (1.0)      | 1 (0.3)      | 0            | 0            | 0            | 1 (0.2)         |
| Completed the study                               | 166 (87.4)   | 83 (86.5)    | 249 (87.1)   | 174 (95.1)   | 88 (96.7)    | 262 (95.6)   | 511 (91.3)      |
| Discontinued from the study                       | 24 (12.6)    | 13 (13.5)    | 37 (12.9)    | 9 (4.9)      | 3 (3.3)      | 12 (4.4)     | 49 (8.8)        |
| Primary reason for discontinuation from the study |              |              |              |              |              |              |                 |
| Pregnancy                                         | 0            | 0            | 0            | 0            | 1 (1.1)      | 1 (0.4)      | 1 (0.2)         |
| Lack of efficacy                                  | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Adverse event                                     | 12 (6.3)     | 4 (4.2)      | 16 (5.6)     | 4 (2.2)      | 2 (2.2)      | 6 (2.2)      | 22 (3.9)        |
| Subject's request                                 | 10 (5.3)     | 6 (6.3)      | 16 (5.6)     | 2 (1.1)      | 0            | 2 (0.7)      | 18 (3.2)        |
| Lost to follow-up                                 | 0            | 0            | 0            | 2 (1.1)      | 0            | 2 (0.7)      | 2 (0.4)         |
| Protocol deviation                                | 2 (1.1)      | 1 (1.0)      | 3 (1.0)      | 0            | 0            | 0            | 3 (0.5)         |
| Physician decision                                | 0            | 1 (1.0)      | 1 (0.3)      | 1 (0.5)      | 0            | 1 (0.4)      | 2 (0.4)         |
| Sponsor decision                                  | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Other: COVID-19                                   | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Other: Permanent site closure                     | 0            | 1 (1.0)      | 1 (0.3)      | 0            | 0            | 0            | 1 (0.2)         |
| Rolled over to long-term extension                | 155 (81.6)   | 78 (81.3)    | 233 (81.5)   | 171 (93.4)   | 86 (94.5)    | 257 (93.8)   | 490 (87.5)      |
| Completed follow-up                               | 19 (10.0)    | 10 (10.4)    | 29 (10.1)    | 6 (3.3)      | 3 (3.3)      | 9 (3.3)      | 38 (6.8)        |

ISE=Integrated Summary of Effectiveness; N=number of subjects in the treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q4W=every 4 weeks Note. Percentages were based on the number of subjects in each treatment group.

<div style=\"page-break-after: always\"></div>

## Recruitment

In study SPR.202685 , the first subject was randomized on 21 Oct 2020 and the last subject last visit was on 21 Feb 2023. In study SPR.203065, The first subject was randomized on 29 Oct 2020 and the last subject last visit was on 30 Mar 2022.

In study SPR.202685, subjects were randomized at 77 investigational sites in 10 countries: Austria, Canada, Denmark, Germany, Hungary, Italy, Poland, Sweden, the United Kingdom, and the US.

In study SPR.203065, subjects were randomized at 55 study sites in 9 countries: Belgium, Canada, France, Netherlands, Poland, South Korea, Spain, Switzerland, and the US.

## Conduct of the study

There were 4 amendments to the original protocols, identical for both studies, whereof 2 were prior to subject enrolment. These amendments were not considered to have affected the interpretation of study results as they were minor and occurred prior to study unblinding.

## Study SPR.202685

The percentage of subjects with at least 1 major protocol deviation was similar in the nemolizumab and placebo treatment groups (19.5% and 21.9%, respectively). The most common major protocol deviation pertained to inclusion or exclusion criteria (7.4% nemolizumab, 9.4% placebo).

The percentage of subjects who had a COVID-19-related major protocol deviation was similar in the nemolizumab and placebo groups (0.5% and 2.1%, respectively).

## Study SPR.203065

The percentage of subjects with at least 1 major protocol deviation was similar in the nemolizumab and placebo treatment groups (16.9% and 17.6%, respectively). The most common major protocol deviations pertained to inclusion or exclusion criteria (4.9% nemolizumab, 6.6% placebo) and study procedure/subject compliance (4.9% nemolizumab, 5.5% placebo). No subject had a COVID-19related major protocol deviation.

## Baseline data

## Demographic characteristics

Across the 2 studies, mean age ranged from 52.7 to 57.5 years, and the proportion of female subjects ranged from 58.0% to 61.3%. Overall, the majority of subjects were White (81.4%) and 8.8% (4.2% SPR.202685 and 13.5% SPR.203065) were Asian; 93.6% of subjects were not Hispanic or Latino. The majority of subjects were enrolled in Europe (70.5%) and North America (25.5%).

Mean weight was higher in the nemolizumab group (87.07 kg) compared with the placebo group (80.81 kg) in SPR.202685 and overall (84.96 kg) compared with SPR.203065 overall (80.04 kg). Similarly, the proportion of subjects weighing ≥ 90 kg at baseline was higher for nemolizumab (38.4%) compared with placebo (30.2%) in SPR.202685 and overall (35.7%) compared with SPR.203065 overall (27.4%).

<div style=\"page-break-after: always\"></div>

Table 33: Demographic and baseline characteristics in studies SPR.202685 and SPR.203065 (intent-to-treat population)

| Characteristic                                                                    | SPR.202685           | SPR.202685            | SPR.202685             | SPR.203065       | SPR.203065            | SPR.203065             | Overall Total          |
|-----------------------------------------------------------------------------------|----------------------|-----------------------|------------------------|------------------|-----------------------|------------------------|------------------------|
|                                                                                   | Nemo Q4W N=190       | Placebo N=96          | Total N=286            | Nemo Q4W N=183   | Placebo N=91          | Total N=274            | N=560                  |
| Age (years)                                                                       |                      |                       |                        |                  |                       |                        |                        |
| Mean (SD)                                                                         | 57.5 (12.77)         | 57.6 (13.36)          | 57.5 (12.95)           | 53.7 (14.41)     | 50.8 (15.00)          | 52.7 (14.64)           | 55.2 (14.00)           |
| Median                                                                            | 58.0                 | 59.0                  | 58.5                   | 55.0             | 53.0                  | 54.0                   | 57.0                   |
| Q1, Q3                                                                            | 49.0, 67.0           | 47.0, 67.5            | 49.0, 67.0             | 43.0, 66.0       | 40.0, 63.0            | 42.0, 64.0             | 46.0, 66.0             |
| Minimum, maximum                                                                  | 24, 82               | 23, 84                | 23, 84                 | 20, 81           | 18, 78                | 18, 81                 | 18, 84                 |
| Age group, n (%)                                                                  |                      |                       |                        |                  |                       |                        |                        |
| 18-65 years                                                                       | 136 (71.6)           | 68 (70.8)             | 204 (71.3)             | 137 (74.9)       | 77 (84.6)             | 214 (78.1)             | 418 (74.6)             |
| >65 years                                                                         | 54 (28.4)            | 28 (29.2)             | 82 (28.7)              | 46 (25.1)        | 14 (15.4)             | 60 (21.9)              | 142 (25.4)             |
| Sex, n (%)                                                                        |                      |                       |                        |                  |                       |                        |                        |
| Male                                                                              | 80 (42.1)            | 40 (41.7)             | 120 (42.0)             | 70 (38.3)        | 36 (39.6)             | 106 (38.7)             | 226 (40.4)             |
| Female                                                                            | 110 (57.9)           | 56 (58.3)             | 166 (58.0)             | 113 (61.7)       | 55 (60.4)             | 168 (61.3)             | 334 (59.6)             |
| Region, n (%)                                                                     |                      |                       |                        |                  |                       |                        |                        |
| Europe                                                                            | 141 (74.2)           | 71 (74.0)             | 212 (74.1)             | 122 (66.7)       | 61 (67.0)             | 183 (66.8)             | 395 (70.5)             |
| North America                                                                     | 49 (25.8)            | 25 (26.0)             | 74 (25.9)              | 47 (25.7)        | 22 (24.2)             | 69 (25.2)              | 143 (25.5)             |
| Asia Pacific                                                                      | 0                    | 0                     | 0                      | 14 (7.7)         | 8 (8.8)               | 22 (8.0)               | 22 (3.9)               |
| Ethnicity, n (%)                                                                  |                      |                       |                        |                  |                       |                        |                        |
| Hispanic or Latino                                                                | 4 (2.1)              | 5 (5.2)               | 9 (3.1)                | 5 (2.7)          | 7 (7.7)               | 12 (4.4)               | 21 (3.8)               |
| Not Hispanic or Latino                                                            | 184 (96.8)           | 88 (91.7)             | 272 (95.1)             | 173 (94.5)       | 79 (86.8)             | 252 (92.0)             | 524 (93.6)             |
| Unknown                                                                           | 1 (0.5)              | 0                     | 1 (0.3)                | 0                | 0                     | 0                      | 1 (0.2)                |
| Not reported                                                                      | 1 (0.5)              | 3 (3.1)               | 4 (1.4)                | 5 (2.7)          | 5 (5.5)               | 10 (3.6)               | 14 (2.5)               |
| Race, n (%)                                                                       |                      |                       |                        |                  |                       |                        |                        |
| American Indian or Alaska Native                                                  | 1 (0.5)              | 0                     | 1 (0.3)                | 0                | 0                     | 0                      | 1 (0.2)                |
| Asian                                                                             | 10 (5.3)             | 2 (2.1)               | 12 (4.2)               | 23 (12.6)        | 14 (15.4)             | 37 (13.5)              | 49 (8.8)               |
| Black or African American                                                         | 18 (9.5)             | 10 (10.4)             | 28 (9.8)               | 5 (2.7)          | 7 (7.7)               | 12 (4.4)               | 40 (7.1)               |
| Native Hawaiian or Other Pacific                                                  | 0                    | 0                     | 0                      | 2 (1.1)          | 0                     | 2 (0.7)                | 2 (0.4)                |
| White                                                                             | 160 (84.2)           | 81 (84.4)             | 241 (84.3)             | 147 (80.3)       | 68 (74.7)             | 215 (78.5)             | 456 (81.4)             |
| Other                                                                             | 1 (0.5)              | 2 (2.1)               | 3 (1.0)                | 5 (2.7)          | 2 (2.2)               | 7 (2.6)                | 10 (1.8)               |
| Multiple                                                                          | 0                    | 0                     | 0                      | 0                | 0                     | 0                      | 0                      |
| Not reported                                                                      | 0                    | 1 (1.0)               | 1 (0.3)                | 1 (0.5)          | 0                     | 1 (0.4)                | 2 (0.4)                |
| Height (cm) at baseline                                                           |                      |                       |                        | n=182            | n=91                  | n=273                  | n=559                  |
| Mean (SD)                                                                         | 169.97 (9.481)       | 168.89 (9.945)        | 169.61 (9.635)         | 167.89 (8.468)   | 167.67 (10.808)       | 167.81 (9.294)         | 168.73 (9.504)         |
| Median                                                                            | 169.75               | 168.00                | 169.00                 | 167.00           | 167.00 160.00,        | 167.00 161.50,         | 168.00 162.00,         |
| Q1, Q3                                                                            | 164.00, 176.00       | 160.00, 177.25        | 162.60, 176.00         | 162.00, 174.00   | 175.00                | 174.00                 | 175.00                 |
| Minimum, maximum                                                                  | 149.5, 196.9         | 147.5, 188.0          | 147.5, 196.9           | 145.0, 190.0     | 139.0, 192.0          | 139.0, 192.0           | 139.0, 196.9           |
| Weight (kg) at baseline                                                           |                      |                       |                        |                  |                       |                        |                        |
| Mean (SD)                                                                         | 87.07 (21.784)       | 80.81 (17.764)        | 84.96 (20.703)         | 79.65 (17.762)   | 80.83 (22.313)        | 80.04 (19.359)         | 82.56 (20.190)         |
| Median                                                                            | 84.05                | 80.50                 | 83.60                  | 79.00            | 74.00                 | 77.05                  | 80.00                  |
| Q1, Q3                                                                            |                      | 66.75,                | 70.00,                 | 65.20,           | 66.50, 93.20          | 66.00, 92.00           | 67.60,                 |
|                                                                                   | 72.60, 99.00         | 92.80                 | 97.10                  | 92.00 38.7,      |                       |                        | 94.65                  |
| Minimum, maximum                                                                  | 39.1, 180.5          | 43.5, 129.0 67 (69.8) | 39.1, 180.5 184 (64.3) | 137.0 132 (72.1) | 42.5, 160.0 67 (73.6) | 38.7, 160.0 199 (72.6) | 38.7, 180.5 383 (68.4) |
| Weight a t b a s e l i n e <90 kg, n (%) Weight a t b a s e l i n e ≥90 kg, n (%) | 117 (61.6) 73 (38.4) | 29 (30.2)             | 102 (35.7) (64.3)      | 51 (27.9) (71.6) | 24 (26.4) 67 (73.6)   | 75 (27.4) 198 (72.3)   | 177 (31.6) 382 (68.2)  |
| Weight at randomization <90                                                       | 117 (61.6)           | 67 (69.8)             |                        |                  |                       |                        |                        |
| kg, (%)                                                                           |                      |                       | 184                    | 131              |                       |                        |                        |

<div style=\"page-break-after: always\"></div>

| Weight at randomization ≥90 kg, n (%)   | 73 (38.4)     | 29 (30.2)     | 102 (35.7)    | 52 (28.4)     | 24 (26.4)     | 76 (27.7)     | 178 (31.8)    |
|-----------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Body mass index (kg/m 2 )               |               |               |               | n=182         | n=91          | n=273         | n=559         |
| Mean (SD)                               | 30.00 (6.543) | 28.20 (5.207) | 29.39 (6.177) | 28.16 (5.348) | 28.49 (5.899) | 28.27 (5.529) | 28.85 (5.891) |
| Median                                  | 28.99         | 27.33         | 28.76         | 27.56         | 27.85         | 27.81         | 28.20         |
| Q1, Q3                                  | 25.65, 32.75  | 24.22, 31.45  | 25.27, 32.11  | 24.22, 30.97  | 23.80, 31.65  | 24.09, 31.29  | 24.55, 31.96  |
| Minimum, maximum                        | 16.8, 51.9    | 17.0, 49.9    | 16.8, 51.9    | 15.5, 44.2    | 18.2, 43.4    | 15.5, 44.2    | 15.5, 51.9    |
| Smoking status, n (%)                   |               |               |               |               |               |               |               |
| Never                                   | 109 (57.4)    | 44 (45.8)     | 153 (53.5)    | 109 (59.6)    | 61 (67.0)     | 170 (62.0)    | 323 (57.7)    |
| Former                                  | 49 (25.8)     | 28 (29.2)     | 77 (26.9)     | 45 (24.6)     | 20 (22.0)     | 65 (23.7)     | 142 (25.4)    |
| Current                                 | 32 (16.8)     | 24 (25.0)     | 56 (19.6)     | 29 (15.8)     | 10 (11.0)     | 39 (14.2)     | 95 (17.0)     |

ISE=Integrated Summary of Effectiveness; N=number of subjects in the treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q1=first quartile; Q3=third quartile; Q4W=every 4 weeks

Note: Percentages were based on the number of subjects in each treatment group. Baseline was defined as the last non-missing value before the first dose of study drug.

## Baseline disease characteristics

Subjects had moderate to- severe skin disease based on baseline IGA scores (58.0% moderate) and baseline weekly average PP NRS (mean 8.4580 [severe]). The percentage of subjects with severe IGA at baseline was higher in the nemolizumab group compared with the placebo group (43.7% and 35.4%, respectively) in SPR.202685 and similar between the nemolizumab and placebo groups (41.0% and 47.3%) in SPR.203065. Subjects had longstanding PN (overall mean duration 98.42 months), with a longer duration in SPR.203065 compared to SPR.202685 (105.64 and 91.51 months, respectively). Disease-related quality-of-life impact, as measured by DLQI, was substantial at baseline (mean baseline range: 16.5 to 17.1).

Table 34: Baseline disease characteristics in studies SPR.202685 and SPR.203065 (intentto-treat population)

| Characteristic        | SPR.202685       | SPR.202685       | SPR.202685       | SPR.203065       | SPR.203065       | SPR.203065       | Overall Total    |
|-----------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                       | Nemo Q4W         | Placebo          | Total            | Nemo Q4W Placebo | Nemo Q4W Placebo | Total            |                  |
|                       | N=190            | N=96             | N=286            | N=183            | N=91             | N=274            | N=560            |
| IGA category, n (%)   |                  |                  |                  |                  |                  |                  |                  |
| Clear (0)             | 0                | 0                | 0                | 0                | 0                | 0                | 0                |
| Almost clear (1)      | 0                | 0                | 0                | 0                | 0                | 0                | 0                |
| Mild (2)              | 0                | 0                | 0                | 0                | 0                | 0                | 0                |
| Moderate (3)          | 107 (56.3)       | 62 (64.6)        | 169 (59.1)       | 108 (59.0)       | 48 (52.7)        | 156 (56.9)       | 325 (58.0)       |
| Severe (4)            | 83 (43.7)        | 34 (35.4)        | 117 (40.9)       | 75 (41.0)        | 43 (47.3)        | 118 (43.1)       | 235 (42.0)       |
| Weekly average PP NRS | n=184            | n=96             | n=280            |                  |                  |                  | n=554            |
| Mean (SD)             | 8.4952 (0.94134) | 8.4371 (0.98758) | 8.4753 (0.95608) | 8.4745 (0.90096) | 8.3715 (0.98869) | 8.4403 (0.93047) | 8.4580 (0.94281) |
| Median                | 8.4143           | 8.4286           | 8.4286           | 8.4286           | 8.4286           | 8.4286           | 8.4286           |
| Q1, Q3                | 7.7143, 9.1667   | 7.6667, 9.1429   | 7.7143, 9.1429   | 7.8571, 9.0000   | 7.7143, 9.0000   | 7.8333, 9.0000   | 7.7143, 9.0000   |
| Minimum, maximum      | 5.857, 10.000    | 6.500, 10.000    | 5.857, 10.000    | 5.143, 10.000    | 4.571, 10.000    | 4.571, 10.000    | 4.571, 10.000    |
| Weekly average AP NRS | n=184            | n=94             | n=278            | n=178            | n=90             | n=268            | n=546            |
| Mean (SD)             | 8.2097 (1.10060) | 8.2265 (1.11419) | 8.2154 (1.10323) | 8.2945 (0.95191) | 8.2050 (1.08947) | 8.2644 (0.99907) | 8.2395 (1.05272) |
| Median                | 8.1667           | 8.0000           | 8.1548           | 8.2679           | 8.2250           | 8.2500           | 8.2000           |
| Q1, Q3                | 7.5714, 9.0000   | 7.2857, 9.1429   | 7.4286, 9.0000   | 7.7143, 9.0000   | 7.5714, 9.0000   | 7.6333, 9.0000   | 7.5714, 9.0000   |
| Minimum, maximum      | 4.857, 10.000    | 5.714, 10.000    | 4.857, 10.000    | 5.286, 10.000    | 4.571, 10.000    | 4.571, 10.000    | 4.571, 10.000    |
| Weekly average SD NRS |                  |                  |                  | n=182            | n=91             | n=273            | n=559            |

<div style=\"page-break-after: always\"></div>

| Mean (SD)                                              | 7.0100 (2.36737)   | 6.8886 (2.33491)   | 6.9692 (2.35312)   | 7.1871 (2.20899)   | 7.3066 (2.23320)   | 7.2269 (2.21370)   | 7.0951 (2.28769)   |
|--------------------------------------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Median                                                 | 7.8571             | 7.4286             | 7.6333             | 7.8571             | 8.0000             | 7.8571             | 7.8333             |
| Q1, Q3                                                 | 6.0000,            | 6.4286,            | 6.2857,            | 6.5714,            | 7.0000,            | 6.7143,            | 6.4286, 8.5714     |
|                                                        | 8.5714             | 8.2857             | 8.5714             | 8.5714             | 8.8571             | 8.7143 0.000,      | 0.000,             |
| Minimum, maximum                                       | 0.000, 10.000      | 0.000, 10.000      | 0.000, 10.000      | 0.000, 10.000      | 0.000, 10.000      | 10.000             | 10.000             |
| Pain frequency, n (%)                                  |                    |                    |                    |                    |                    |                    |                    |
| Never                                                  | 15 (7.9)           | 3 (3.1)            | 18 (6.3)           | 7 (3.8)            | 2 (2.2)            | 9 (3.3)            | 27 (4.8)           |
| Less than once a week                                  | 11 (5.8)           | 3 (3.1)            | 14 (4.9)           | 9 (4.9)            | 9 (9.9)            | 18 (6.6)           | 32 (5.7)           |
| 1-2 days a week                                        | 6 (3.2)            | 11 (11.5)          | 17 (5.9)           | 11 (6.0)           | 3 (3.3)            | 14 (5.1)           | 31 (5.5)           |
| 3-4 days a week                                        | 25 (13.2)          | 7 (7.3)            | 32 (11.2)          | 24 (13.1)          | 8 (8.8)            | 32 (11.7)          | 64 (11.4)          |
| 5-6 days a week                                        | 19 (10.0)          | 4 (4.2)            | 23 (8.0)           | 16 (8.7)           | 5 (5.5)            | 21 (7.7)           | 44 (7.9)           |
| Everyday                                               | 114 (60.0)         | 68 (70.8)          | 182 (63.6)         | 116 (63.4)         | 64 (70.3)          | 180 (65.7)         | 362 (64.6)         |
| Pain intensity                                         |                    |                    |                    |                    |                    |                    |                    |
| Mean (SD)                                              | 7.1 (2.90)         | 7.6 (2.45)         | 7.3 (2.77)         | 7.7 (2.37)         | 7.8 (2.32)         | 7.7 (2.35)         | 7.5 (2.58)         |
| Median                                                 | 8.0                | 8.0                | 8.0                | 8.0                | 8.0                | 8.0                | 8.0                |
| Q1, Q3                                                 | 6.0, 9.0           | 7.0, 9.0           | 7.0, 9.0           | 7.0, 9.0           | 7.0, 9.0           | 7.0, 9.0           | 7.0, 9.0           |
| Minimum, maximum                                       | 0, 10              | 0, 10              | 0, 10              | 0, 10              | 0, 10              | 0, 10              | 0, 10              |
| PAS item 2 (number of pruriginous lesions), n (%)      |                    |                    |                    |                    |                    |                    |                    |
| 0                                                      | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  |
| 1-19                                                   | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  |
| 20-100                                                 | 125 (65.8)         | 61 (63.5)          | 186 (65.0)         | 119 (65.0)         | 53 (58.2)          | 172 (62.8)         | 358 (63.9)         |
| >100                                                   | 65 (34.2)          | 35 (36.5)          | 100 (35.0)         | 64 (35.0)          | 38 (41.8)          | 102 (37.2)         | 202 (36.1)         |
| PAS item 4 (number of lesions in representative area)  |                    |                    |                    |                    |                    |                    |                    |
| Mean (SD)                                              | 23.0 (18.36)       | 17.7 (13.30)       | 21.2 (16.99)       | 21.7 (18.52)       | 25.5 (22.00)       | 22.9 (19.79)       | 22.1 (18.42)       |
| Median                                                 | 17.0               | 13.0               | 16.0               | 18.0               | 20.0               | 19.0               | 17.0               |
| Q1, Q3                                                 | 10.0, 30.0         | 8.0, 22.0          | 10.0, 26.0         | 10.0, 26.0         | 10.0, 30.0         | 10.0, 28.0         | 10.0, 28.0         |
| Minimum, maximum                                       | 1, 102             | 3, 70              | 1, 102             | 1, 140             | 5, 110             | 1, 140             | 1, 140             |
| PAS item 5a (excoriation/crusts), n (%)                |                    |                    |                    |                    |                    |                    |                    |
| 0%                                                     | 0                  | 0                  | 0                  | 1 (0.5)            | 0                  | 1 (0.4)            | 1 (0.2)            |
| 1-25%                                                  | 9 (4.7)            | 7 (7.3)            | 16 (5.6)           | 11 (6.0)           | 11 (12.1)          | 22 (8.0)           | 38 (6.8)           |
| 26-50%                                                 | 39 (20.5)          | 17 (17.7)          | 56 (19.6)          | 34 (18.6)          | 20 (22.0)          | 54 (19.7)          | 110 (19.6)         |
| 51-75%                                                 | 54 (28.4)          | 23 (24.0)          | 77 (26.9)          | 64 (35.0)          | 29 (31.9)          | 93 (33.9)          | 170 (30.4)         |
| 76-100%                                                | 88 (46.3)          | 49 (51.0)          | 137 (47.9)         | 73 (39.9)          | 31 (34.1)          | 104 (38.0)         | 241 (43.0)         |
| PAS item 5b (healed lesion stages), n (%)              |                    |                    |                    |                    |                    |                    |                    |
| 100%                                                   | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  |
| 76-99%                                                 | 1 (0.5)            | 2 (2.1)            | 3 (1.0)            | 3 (1.6)            | 0                  | 3 (1.1)            | 6 (1.1)            |
| 51-75%                                                 | 22 (11.6)          | 12 (12.5)          | 34 (11.9)          | 23 (12.6)          | 13 (14.3)          | 36 (13.1)          | 70 (12.5)          |
| 26-50%                                                 | 41 (21.6)          | 23 (24.0)          | 64 (22.4)          | 47 (25.7)          | 26 (28.6)          | 73 (26.6)          | 137 (24.5)         |
| 0-25%                                                  | 126 (66.3)         | 59 (61.5)          | 185 (64.7)         | 110 (60.1)         | 52 (57.1)          | 162 (59.1)         | 347 (62.0)         |
| Dermatology Life Quality Index total score at baseline |                    |                    |                    |                    |                    |                    |                    |
| Mean (SD)                                              | 17.1 (6.97)        | 16.9 (6.74)        | 17.0 (6.88)        | 16.5 (6.79)        | 17.1 (6.60)        | 16.7 (6.72)        | 16.9 (6.80)        |
| Median                                                 | 17.0               | 16.0               | 16.0               | 17.0               | 17.0               | 17.0               | 17.0               |
| Q1, Q3                                                 | 12.0, 23.0         | 12.0, 22.0         | 12.0, 23.0         | 12.0, 22.0         | 12.0, 22.0         | 12.0, 22.0         | 12.0, 22.0         |
| Minimum, maximum                                       | 2, 30              | 1, 30              | 1, 30              | 1, 30              | 4, 30              | 1, 30              | 1, 30              |
| Atopy background, n (%)                                |                    |                    |                    |                    |                    |                    |                    |
| Yes                                                    | 60 (31.6)          | 33 (34.4)          | 93 (32.5)          | 57 (31.1)          | 31 (34.1)          | 88 (32.1)          | 181 (32.3)         |
| No                                                     | 130 (68.4)         | 63 (65.6)          | 193 (67.5)         | 126 (68.9)         | 60 (65.9)          | 186 (67.9)         | 379 (67.7)         |
| Time since PN diagnosis (months)                       |                    |                    |                    |                    |                    |                    |                    |
| Mean (SD)                                              | 86.92 (85.281)     | 100.61 (98.567)    | 91.51 (90.019)     | 104.16 (100.715)   | 108.60 (114.927)   | 105.64 (105.456)   | 98.42 (98.044)     |

<div style=\"page-break-after: always\"></div>

| Median           | 61.77         | 62.29         | 61.90         | 69.59         | 68.70         | 69.19         | 64.25         |
|------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Q1, Q3           | 30.13, 116.40 | 25.54, 141.34 | 29.73, 124.75 | 33.81, 157.83 | 37.16, 134.51 | 34.37, 138.81 | 30.87, 132.19 |
| Minimum, maximum | 6.2, 580.1    | 6.1, 503.7    | 6.1, 580.1    | 6.2, 450.6    | 6.9, 621.1    | 6.2, 621.1    | 6.1, 621.1    |

AP NRS=Average  Pruritus Numerical Rating Scale; IGA=Investigator's Global Assessment; ISE=Integrated  Summary of Effectiveness; N=number of subjects in the treatment group; n=number of subjects with available data; Nemo=nemolizumab; PAS=Prurigo  Activity  Score;  PN=prurigo  nodularis;  PP  NRS=Peak  Pruritus  Numerical  Rating  Scale; Q1=first  quartile;  Q3=third quartile; Q4W=every 4 weeks; SD NRS=Sleep Disturbance Numerical Rating Scale

Note: Percentages were based on the number of subjects in each treatment group. Weekly average PP NRS and weekly average AP NRS were calculated as the average of 7 consecutive days of data up to the target study day (excluding) and set to missing, if less than 4 days of data were available. Weekly average SD NRS was calculated as the average of 7 consecutive days of data up to the target study day (inclusive) and set to missing, if less than 4 days of data were available. Baseline was defined as the last non-missing value or weekly value before the first dose of study drug. Time since PN diagnosis (months) was calculated as [(date of screening - date of PN diagnosis) + 1] / 30.4375.

## Prior PN treatment

Most enrolled subjects received at least 1 prior medication to treat their PN. The percentage of subjects with at least 1 select prior medication to treat their PN was consistent between treatment groups within each study and higher overall in SPR.203065 (84.7%) compared with SPR.202685 (63.3%),

Table 34 . A similar pattern was noted for the most frequently reported select prior PN category (topical corticosteroids [78.5% in SPR.2030665 and 52.8% in SPR.202685]); the most frequently reported select prior PN medication was clobetasol propionate ([38.7% in SPR.2030665 and 18.9% in SPR.202685). Prior systemic non-steroidal immunosuppressants were used by 19.0% of subjects in SPR.203065 and 12.2% of subjects in SPR.202685.

The percentage of subjects reporting prior systemic oral antihistamine use was higher in the nemolizumab group compared with the placebo group (24.2% and 13.5%, respectively) in SPR.202685 and similar between treatment groups in SPR.203065.

Table 35: Selected prior prurigo nodularis medications in studies SPR.202685 and SPR.203065 (intent-to-treat population)

| Group Subgroup                                                       | SPR.202685   | SPR.202685   | SPR.202685   | SPR.203065   | SPR.203065   | SPR.203065   |               |
|----------------------------------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|
| Group Subgroup                                                       | Nemo Q4W     | Placebo      | Total        | Nemo Q4W     | Placebo      | Total        | Overall Total |
| Group Subgroup                                                       | N=190        | N=96         | N=286        | N=183        | N=91         | N=274        | N=560         |
| Group Subgroup                                                       | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)         |
| Subjects with at least 1 selected prior prurigo nodularis medication | 121 (63.7)   | 60 (62.5)    | 181 (63.3)   | 153 (83.6)   | 79 (86.8)    | 232 (84.7)   | 413 (73.8)    |
| Topical                                                              | 106 (55.8)   | 54 (56.3)    | 160 (55.9)   | 144 (78.7)   | 72 (79.1)    | 216 (78.8)   | 376 (67.1)    |
| Topical corticosteroids                                              | 98 (51.6)    | 53 (55.2)    | 151 (52.8)   | 143 (78.1)   | 72 (79.1)    | 215 (78.5)   | 366 (65.4)    |
| Topical calcineurin inhibitors                                       | 19 (10.0)    | 8 (8.3)      | 27 (9.4)     | 28 (15.3)    | 11 (12.1)    | 39 (14.2)    | 66 (11.8)     |
| Topical other                                                        | 18 (9.5)     | 7 (7.3)      | 25 (8.7)     | 18 (9.8)     | 11 (12.1)    | 29 (10.6)    | 54 (9.6)      |
| Systemic                                                             | 81 (42.6)    | 33 (34.4)    | 114 (39.9)   | 104 (56.8)   | 57 (62.6)    | 161 (58.8)   | 275 (49.1)    |
| Systemic corticosteroids                                             | 28 (14.7)    | 11 (11.5)    | 39 (13.6)    | 36 (19.7)    | 21 (23.1)    | 57 (20.8)    | 96 (17.1)     |
| Systemic biologics                                                   | 8 (4.2)      | 2 (2.1)      | 10 (3.5)     | 4 (2.2)      | 3 (3.3)      | 7 (2.6)      | 17 (3.0)      |
| Systemic non-steroidal immunosuppressants/immunomodulators           | 23 (12.1)    | 12 (12.5)    | 35 (12.2)    | 35 (19.1)    | 17 (18.7)    | 52 (19.0)    | 87 (15.5)     |
| Systemic gabapentinoids                                              | 14 (7.4)     | 3 (3.1)      | 17 (5.9)     | 6 (3.3)      | 8 (8.8)      | 14 (5.1)     | 31 (5.5)      |
| Systemic oral antihistamines                                         | 46 (24.2)    | 13 (13.5)    | 59 (20.6)    | 71 (38.8)    | 33 (36.3)    | 104 (38.0)   | 163 (29.1)    |
| Systemic other                                                       | 22 (11.6)    | 5 (5.2)      | 27 (9.4)     | 9 (4.9)      | 7 (7.7)      | 16 (5.8)     | 43 (7.7)      |
| Intralesional corticosteroids                                        | 5 (2.6)      | 2 (2.1)      | 7 (2.4)      | 8 (4.4)      | 5 (5.5)      | 13 (4.7)     | 20 (3.6)      |

ISE=Integrated Summary of Effectiveness; N=number of subjects in the treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q4W=every 4 weeks

Note: Percentages were based on the number of subjects in each treatment group. In group or subgroup level, subjects were counted once where more than one prior medication was reported.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

From study SPR.202685, all 286 randomized subjects were included in the ITT population. Four subjects (3 randomized to nemolizumab, 1 randomized placebo) did not receive study drug, they were included in the ITT population, but excluded from the PP, safety, and PK populations. A total of 250 subjects were included in the PP population. Reasons for exclusion from the PP population are presented in Listing 16.2.2.1.

Table 36: Analysis populations (intent-to-treat population) SPR.202685

| Analysis population                 | Nemolizumab Q4W   | Placebo    |
|-------------------------------------|-------------------|------------|
|                                     | N=190             | N=96 n (%) |
|                                     | n (%)             |            |
| Intent-to-treat population          | 190 (100)         | 96 (100)   |
| Safety population                   | 187 (98.4)        | 95 (99.0)  |
| Per-protocol population             | 166 (87.4)        | 84 (87.5)  |
| Pharmacokinetic analysis population | 183 (96.3)        | 0          |

N=number of subjects in the treatment group; n=number of subjects with available data; Q4W=every 4 weeks Note: Percentages were based on the number of subjects in each treatment group.

From study SPR.203065, all 274 randomized subjects were included in the ITT and safety populations. A total of 242 subjects (159 nemolizumab, 83 placebo) were included in the PP population. Reasons for exclusion from the PP population are provided in Listing 16.2.2.1.

Table 37: Analysis populations (intent-to-treat population) SPR.203065

| Analysis population                 | Nemolizumab Q4W   | Placebo    |
|-------------------------------------|-------------------|------------|
|                                     | N=183             | N=91 n (%) |
|                                     | n (%)             |            |
| Intent-to-treat population          | 183 (100)         | 91 (100)   |
| Safety population                   | 183 (100)         | 91 (100)   |
| Per-protocol population             | 159 (86.9)        | 83 (91.2)  |
| Pharmacokinetic analysis population | 180 (98.4)        | 0          |

N=number of subjects in the treatment group; n=number of subjects with available data; Q4W=every 4 weeks Note: Percentages were based on the number of subjects in each treatment group.

## Outcomes and estimation

Nemolizumab was clinically and statistically significantly superior to placebo with respect to improvement of ≥ 4 from baseline in weekly average PP NRS (58.4% vs. 16.7% [SPR.202685] and 56.3% vs. 20.9% [SPR.203065]; p&lt;0.0001) and IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥ 2-grade improvement from baseline) (26.3% vs. 7.3% [SPR.202685] and 37.7% vs. 11.0% [SPR.203065]; p&lt;0.01) at Week 16 ( Table 38 ).

The proportion of nemolizumab-treated subjects with IGA success at Week 16 was numerically higher in SPR.203065 (37.7%) compared with SPR.202685 (26.3%) although the 95% CIs for the strataadjusted proportion differences overlap, supporting an overall consistency in effect between the studies.

Results for both primary efficacy endpoints were consistent across sensitivity analyses. Moreover, tipping point and MI analyses indicated that the results were robust to missing data.

<div style=\"page-break-after: always\"></div>

Table 38: Summary of primary efficacy endpoints from studies SPR.202685 and SPR.203065 (intent-to-treat population)

| Endpoint                                                    | SPR.202685   | SPR.202685   | SPR.202685           | SPR.202685           | SPR.203065   | SPR.203065   | SPR.203065           | SPR.203065           |
|-------------------------------------------------------------|--------------|--------------|----------------------|----------------------|--------------|--------------|----------------------|----------------------|
|                                                             | Treatment    | Treatment    | Treatment difference | Treatment difference | Treatment    | Treatment    | Treatment difference | Treatment difference |
|                                                             | Nemo 30mgQ4W | Placebo      | 95% CI               | P-value              | Nemo 30mgQ4W | Placebo      | 95% CI               | P-value              |
|                                                             | N=190        | N=96         |                      |                      | N=183        | N=91         |                      |                      |
|                                                             | n (%)        | n (%)        |                      |                      | n (%)        | n (%)        |                      |                      |
| Improvement of ≥4 from baseline in PP NRS at Week 16, n (%) | 111 (58.4)   | 16 (16.7)    |                      |                      | 103 (56.3)   | 19 (20.9)    |                      |                      |
| Unadjusted proportion difference (%)                        | 41.8         |              | 31.5, 52.0           | <0.0001              | 35.4         |              | 24.4, 46.4           | <0.0001              |
| Strata-adjusted proportion difference (%)                   | 40.1         |              | 29.4, 50.8           | <0.0001              | 37.4         |              | 26.3, 48.5           | <0.0001              |
| IGA success at Week 16, n (%)                               | 50 (26.3)    | 7 (7.3)      |                      |                      | 69 (37.7)    | 10 (11.0)    |                      |                      |
| Unadjusted proportion difference (%)                        | 19.0         |              | 10.9, 27.2           | 0.0001               | 26.7         |              | 17.2, 36.2           | <0.0001              |
| Strata-adjusted proportion difference (%)                   | 14.6         |              | 6.7, 22.6            | 0.0025               | 28.5         |              | 18.8, 38.2           | <0.0001              |

IGA=Investigator's  Global  Assessment;  ISE=Integrated  Summary  of  Effectiveness;  N=number  of  subjects  in  the  treatment  group;  n=number  of  subjects  with  available  and  imputed  data; Nemo=nemolizumab; PP NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks

Note: IGA success was defined as subjects with 0 (clear) or 1 (almost clear) and at least 2-grade improvement from baseline. Percentages were based on n. Weekly values were calculated as average of 7 consecutive days data up to the target study day (excluding) and set to missing, if less than 4 days data were available. Baseline was defined as the last non-missing weekly value before the first dose of study drug. If a subject received any rescue therapy, composite variable strategy was applied, the underlying data on or after receipt of rescue therapy was set as worst possible value, and  the  response  was  derived  from  underlying  data  value. Subjects  with  missing  results  were  considered  as  non-responders.  Unadjusted  and  strata-adjusted  p-values  for  between-group comparisons were from Mantel- Haenszel Chi-Square test and Cochran-Mantel-Haenszel test, respectively. Strata adjusted p-values were from Cochran-Mantel-Haenszel test using the randomized stratification variables (analysis centre and baseline body weight [&lt;90 kg, ≥90 kg]).

<div style=\"page-break-after: always\"></div>

All sensitivity and supportive analyses, including of the PP population as well as those in the ITT population (MI with MAR and MI with MNAR in which subjects were considered treatment failures on or after receiving rescue therapy, LOCF and OC analyses, using actual stratification, COVID-19 affected visits removed, ≥2 assessments required, and ≥3 assessments required), indicated that nemolizumab was superior to placebo for improvement of ≥4 from baseline in weekly average PP NRS at Week 16 (p&lt;0.0001).

## Key secondary endpoints

Peak pruritus numerical rating scale improvement of ≥ 4 from baseline at week 4 In each study, a clinically and statistically significantly greater proportion of subjects with an improvement of ≥ 4 from baseline in weekly average PP NRS was observed with nemolizumab compared with placebo at Week 4 (41.1% vs. 6.3% [SPR.202685] and 41.0% vs. 7.7% [SPR.203065]; p&lt;0.0001).

## Peak pruritus numerical rating scale &lt;2 at week 4 and week 16

In each study, a clinically and statistically significantly greater proportion of subjects with a weekly average PP NRS &lt;2 was observed with nemolizumab compared with placebo at Week 4 (21.6% vs. 1.0% [SPR.202685] and 19.7% vs. 2.2% [SPR.203065]; p&lt;0.0001) and at Week 16 (34.2% vs. 4.2% [SPR.202685] and 35.0% vs. 7.7% [SPR.203065]; p&lt;0.0001).

Sleep disturbance numerical rating scale improvement of ≥ 4 from baseline at week 4 and week 16 In each study, a clinically and statistically significantly greater proportion of subjects with an improvement of ≥ 4 from baseline in weekly average SD NRS was observed with nemolizumab compared with placebo at Week 4 (31.1% vs. 5.2% [SPR.202685] and 37.2% vs. 9.9% [SPR.203065]; p&lt;0.0001) and at Week 16 (50.0% vs. 11.5% [SPR.202685] and 51.9% vs. 20.9% [SPR.203065]; p&lt;0.0001).

## Rescue therapy

The percentage of subjects using concomitant medication as rescue therapy was lower with nemolizumab (6.3% and 4.9%) compared with placebo (19.8% and 15.4%) during the treatment period. A summary of concomitant medication as rescue therapy by treatment type (e.g., topical, phototherapy, systemic, intralesional corticosteroids), and corresponding subgroup is presented in Table 35 (SPR.202685) and Table 36 (SPR.203065). Across both treatment groups, topical corticosteroids were the most frequently used rescue therapy (5.3% and 4.4% nemolizumab, 15.6% and 12.1% placebo), followed by systemic oral antihistamines (1.1% and 1.6% nemolizumab, 5.2% and 6.6% placebo).

<div style=\"page-break-after: always\"></div>

Table 39: Concomitant medication of rescue therapy used by ≥2.0% of subjects in either treatment group during the treatment period (intent-to-treat population) SPR.202685

| Group                   | Nemolizumab Q4W   | Placebo   |
|-------------------------|-------------------|-----------|
| Subgroup                | N=190             | N=96      |
| Preferred term          | n (%)             | n (%)     |
| Any therapy             | 12 (6.3)          | 19 (19.8) |
| Topical                 | 11 (5.8)          | 16 (16.7) |
| Corticosteroids         | 10 (5.3)          | 15 (15.6) |
| Mometasone furoate      | 4 (2.1)           | 4 (4.2)   |
| Clobetasol propionate   | 2 (1.1)           | 7 (7.3)   |
| Mometasone              | 2 (1.1)           | 2 (2.1)   |
| Diflucortolone valerate | 0                 | 2 (2.1)   |
| Calcineurin inhibitors  | 1 (0.5)           | 2 (2.1)   |
| Systemic                | 2 (1.1)           | 7 (7.3)   |
| Oral antihistamines     | 2 (1.1)           | 5 (5.2)   |
| Ebastine                | 0                 | 2 (2.1)   |

N=number of subjects in the treatment group; n=number of subjects with available data; Q4W=every 4 weeks Note: Percentages (%) were based on number of subjects in each treatment group (N). In group, subgroup, or preferred term level, subjects were counted once where more than 1 rescue therapy was reported.

Table 40: Concomitant medication of rescue therapy used by ≥2.0% of subjects in either treatment group (intent-to-treat population) SPR.203065

| Group                      | Nemolizumab Q4W   | Placebo   |
|----------------------------|-------------------|-----------|
| Subgroup                   | N=183             | N=91      |
| Preferred term             | n (%)             | n (%)     |
| Any therapy                | 9 (4.9)           | 14 (15.4) |
| Topical                    | 9 (4.9)           | 11 (12.1) |
| Corticosteroids            | 8 (4.4)           | 11 (12.1) |
| Betamethasone dipropionate | 2 (1.1)           | 2 (2.2)   |
| Clobetasol propionate      | 1 (0.5)           | 6 (6.6)   |
| Clobetasol                 | 0                 | 2 (2.2)   |
| Systemic                   | 3 (1.6)           | 7 (7.7)   |
| Oral antihistamines        | 3 (1.6)           | 6 (6.6)   |
| Bilastine                  | 1 (0.5)           | 2 (2.2)   |
| Fexofenadine hydrochloride | 1 (0.5)           | 2 (2.2)   |
| Bepotastine besilate       | 0                 | 2 (2.2)   |
| Emedastine fumarate        | 0                 | 2 (2.2)   |
| Epinastine hydrochloride   | 0                 | 2 (2.2)   |

N=number of subjects in the treatment group; n=number of subjects with available data; Q4W=every 4 weeks

Note: Percentages (%) were based on number of subjects in each treatment group (N). In group, subgroup, or preferred term level, subjects were counted once where more than 1 rescue therapy was reported.

No subject in the nemolizumab treatment group had a rescue medical or surgical procedure during the treatment period. Two (2.1%) subjects in the placebo group of study SPR.202685 used ultraviolet light therapy as a rescue medical or surgical procedure during the treatment period.

## Ancillary analyses

For each primary and key secondary endpoint, the estimate of the treatment difference, corresponding 2-sided 95% CI, and unadjusted and strata-adjusted p-values for between-group

<div style=\"page-break-after: always\"></div>

comparisons were summarized by subgroups defined by region, age group, sex, race, body weight at randomization and baseline IGA score. Data were pooled from the two pivotal studies.

## Primary endpoint 1

The proportion of subjects with an improvement of ≥ 4 from baseline in weekly average PP NRS at Week 16 is shown by subgroup in Figure 21 . Results were directionally consistent with those of the primary analysis.

Figure 21: Forest Plot of Proportion of Subjects with an Improvement of &gt;= 4 from Baseline in Weekly Average PP NRS at Week 16 - Missing as Non-Responder. Pooled data.

Unadjusted

<!-- image -->

Unadjusted

Unadjusted

-100

-50

0

50

100

<!-- image -->

| Subgroup               | Strata-sdjusted diference (95% CI)   | Nemolizuab n / N(%)   | Placebo n/ N (%)   | difrence (95% CI)   | Unadjusted p-value   | Strate-adjusted diference (95% C1)   | Strata-sdjusted p-value   |
|------------------------|--------------------------------------|-----------------------|--------------------|---------------------|----------------------|--------------------------------------|---------------------------|
| Ethniity               |                                      |                       |                    |                     |                      |                                      |                           |
| Hispanic or Latino     |                                      | 4/9 (44.4)            | 1/ 12 (8.3)        | 36.1 ( 0.1, 72.1)   | 0.0606               | 62.5 ( 21.4, 100)                    | 0.0499                    |
| Not Hispanic or Latino |                                      | 206 / 357 (57.7)      | 32/ 167 (19.2)     | 38.5 ( 30.7, 46.4)  | [000'0>              | 39.1 ( 31.1, 47.1)                   | ≤0.0001                   |
| Region                 |                                      |                       |                    |                     |                      |                                      |                           |
| Europe                 |                                      | 158 / 263 (60.1)      | 25/ 132 (18.9)     | 41.1 ( 32.2, 50.1)  | ≤0.0001              | 40.9 ( 32.0, 49.9)                   | ≤0.0001                   |
| North America          |                                      | 52/ 96 (54.2)         | 9/ 47 (19.1)       | 35.0 ( 20.0, 50.0)  | [000'0>              | 35.4 ( 19.2, 51.6)                   | 0.0002                    |
| Asia Pacific           |                                      | 4/ 14 (28.0)          | 1/ 8 (12.5)        | 16.1 (-16.9, 49.0)  | 0.3979               | 20.8 (-14.3, 56.0)                   | 0.3042                    |

-100

OS-

0

50

100

<!-- image -->

| Subgroup                       | Strata-adjusted diference (95% CI)   | Nemolizmab n/ N(%)   | Plecebo n/ N(%)   | diference (95% CI   | Unadjusted p-value   | Strate-adjusted diference (95% CI)   | Strata-sdjusted p-value   |
|--------------------------------|--------------------------------------|----------------------|-------------------|---------------------|----------------------|--------------------------------------|---------------------------|
| Weight at Randomiztion         |                                      |                      |                   |                     |                      |                                      |                           |
| <9kg                           |                                      | 138 / 248 (55.0)     | 24 / 134 (17.9)   | 37.7 ( 28.8, 46.7)  | [000'0>              | 38.8 ( 29.8, 47.8)                   | ≤0.0001                   |
| >=90 kg                        |                                      | 76/ 125 (60.8)       | 11/ 53 (20.8)     | 40.0 ( 26.2, 53.9)  | [000'0>              | 38.5 ( 23.7, 53.4)                   | <0.0001                   |
| BaselineIGA Score              |                                      |                      |                   |                     |                      |                                      |                           |
| Moderate (3)                   |                                      | 118 / 215 (54.9)     | 26 / 110 (23.0)   | 31.2 ( 20.9, 41.6)  | [000'0>              | 30.6 ( 19.3, 42.0)                   | [000'0>                   |
| Sarere (4)                     |                                      | 96 / 158 (60.8)      | 9/ 77 (11.7)      | 49.1 ( 38.6, 59.5)  | [000'0>              | 49.1 ( 36.8, 61.3)                   | [000'0>                   |
| History of Atopy               |                                      |                      |                   |                     |                      |                                      |                           |
| Yes                            |                                      | 63 / 117 (53.8)      | 13 / 64 (20.3)    | 33.5 ( 20.2, 46.9)  | [000'0>              | 32.9 ( 16.7, 49.1)                   | 000°0                     |
| No                             |                                      | 151/ 256 (59.0)      | 22/ 123 (17.9)    | 41.1 ( 32.0, 50.2)  | ≤0.0001              | 42.0 ( 32.8, 51.2)                   | [000'0>                   |
| Prior Systemic Treatmentfor PN |                                      |                      |                   |                     |                      |                                      |                           |
|                                |                                      | 106 / 183 (57.9)     | 13 / 90 (14.4)    | 43.5 ( 33.3, 53.7)  | [000'0>              | 45.4( 34.9, 55.8)                    | ≤0.0001                   |
| No                             |                                      | 108 / 190 (56.8)     | 22/ 97 (22.7)     | 34.2 ( 23.3, 45.1)  | [0000>               | 32.7 ( 20.6, 44.9)                   | [000'0>                   |

100

50

0

-50

-100

<div style=\"page-break-after: always\"></div>

Notes: N = number of subjects in the treatment group; n = number of subjects with available and imputed data; CI = Confidence Interval; PP NRS = Peak Pruritus Numeric Rating Scale. Percentages (%) are based on n. Weekly values are calculated as average of 7 consecutive days data up to the target study day (excluding) and set to missing, if less than 4 days data are available. Baseline is defined as the last non-missing weekly value before the first dose of study drug. If a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as nonresponders. Unadjusted and strata-adjusted p-values for between-group comparisons are from Mantel-Haenszel Chi-Square test and Cochran-Mantel-Haenszel (CMH) test, respectively. Strata adjusted p-values are from CMH test using the randomized stratification variables (analysis centre and body weight at randomization (&lt; 90 kg, &gt;= 90 kg)).Forest plot is based on the result of strata-adjusted difference between treatment groups.

## -Primary endpoint 2

The proportion of subjects with IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥ 2-grade improvement from baseline) at Week 16 is shown by subgroup in Figure 22 . Results were directionally consistent with those of the primary analysis.

Figure 22: Forest Plot of Proportion of Subjects with an IGA Success at Week 16 Missing as Non-Responder. Pooled data.

<!-- image -->

yunuyusieu

-100

-50

0

50

100

<!-- image -->

| Subgroup               | Strata-sdjusted diference (95% CI)   | Nemolizmab n/ N (%)   | Placebo n/ N (%)   | diference (95% CI)   | Unadjusted p-value   | Strate-adjusted diference (95% C1)   | Strata-adjusted p-value   |
|------------------------|--------------------------------------|-----------------------|--------------------|----------------------|----------------------|--------------------------------------|---------------------------|
| Ethnidty               |                                      |                       |                    |                      |                      |                                      |                           |
| Hispanic or Latino     |                                      | 6/9(66.7)             | 2/ 12 (16.7)       | 50.0 ( 12.7, 87.3)   | 0.0227               | 43.8 ( 1.6, 85.9)                    | 0.0896                    |
| Not Hispanic or Latino |                                      | 110/ 357 (30.8)       | 15 / 167 (9.0)     | 21.8 ( 15.4, 28.3)   | ≤0.0001              | 19.9 ( 13.5, 26.3)                   | <0.0001                   |
| Region                 |                                      |                       |                    |                      |                      |                                      |                           |
| Europe                 |                                      | 85 / 263 (32.3)       | 7/ 132 (5.3)       | 27.0 ( 20.2, 33.8)   | [000'0>              | 26.2( 19.1, 33.2)                    | <0.0001                   |
| North America          |                                      | 30 / 96 (31.3)        | 9/47 (19.1)        | 12.1 ( -2.5, 26.7)   | 0.1283               | 9.4 ( 4.4, 23.2)                     | 0.2123                    |
| Asia Pacifc            |                                      | 4/ 14 (28.6)          | 1/ 8 (12.5)        | 16.1 (-16.9, 49.0)   | 0.3979               | 12.5 (-21.0, 46.0)                   | 0.5046                    |

100

50

0

-50

-100

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgroup                       | Strata-adjusted diference (95% C1)   | Strata-adjusted diference (95% C1)   | Nemolizumab n / N (%)   | Placebo n/ N (%)   | Unadjusted diference (95% CI)   | Unadjusted p-value   | Strate-adjusted diference (95% C1)   | Strata-adjusted p-value   |
|--------------------------------|--------------------------------------|--------------------------------------|-------------------------|--------------------|---------------------------------|----------------------|--------------------------------------|---------------------------|
| Weightat Randomiztion          |                                      |                                      |                         |                    |                                 |                      |                                      |                           |
| <90kg                          |                                      |                                      | 85 / 248 (34.3)         | 12 / 134 (9.0)     | 25.3 ( 17.7, 33.0)              | [000'0>              | 24.6 (16.9, 32.3)                    | [000'0>                   |
| >=90 kg                        |                                      |                                      | 34 / 125 (27.2)         | 5/53 (9.4)         | 17.8 (6.7,28.8)                 | 0.0090               | 13.8 (3.2, 24.4)                     | 0.0373                    |
| BaselineIGA Score              |                                      |                                      |                         |                    |                                 |                      |                                      |                           |
| Moderate (3)                   |                                      |                                      | 73 / 215 (34.0)         | 14 / 110 (12.7)    | 21.2 (12.3, 30.1)               | [000'0>              | 20.3 ( 11.2, 29.5)                   | 1000'0                    |
| Serere (4)                     |                                      |                                      | 46 / 158 (29.1)         | 3/77 (3.9)         | 25.2 ( 16.9, 33.5)              | [0000>               | 19.5(10.2,28.8)                      | 0.0005                    |
| History of Atopy               |                                      |                                      |                         |                    |                                 |                      |                                      |                           |
| Yes                            |                                      |                                      | 35 / 117 (29.9)         | 3/64 (4.7)         | 25.2 ( 15.4, 35.0)              | [0000>               | 20.3 (9.0, 31.6)                     | 0.0021                    |
| No                             |                                      |                                      | 84/ 256 (32.8)          | 14 / 123 (11.4)    | 21.4 ( 13.4, 29.5)              | [000'0>              | 18.7 (10.0, 27.3)                    | 0.0002                    |
| Prior Systemic Treatmentfor PN |                                      |                                      |                         |                    |                                 |                      |                                      |                           |
| Yes                            |                                      |                                      | 68 / 183 (37.2)         | 8/ 90 (8.9)        | 28.3 ( 19.1, 37.4)              | [000'0>              | 28.0 ( 18.7, 37.3)                   | [000'0>                   |
| No                             |                                      | -+                                   | 51/ 190 (26.8)          | 9197 (9.3)         | 17.6 (9.0, 26.1)                | 0.0005               | 15.8 (6.9, 24.7)                     | 0.0031                    |

-100

-50

0

50

100

Notes: N = number of subjects in the treatment group; n = number of subjects with available and imputed data; CI = Confidence Interval; IGA = Investigator's Global Assessment. Percentages (%) are based on n. IGA success is defined as subjects with 0 (clear) or 1 (almost clear) and at least 2-grade improvement from Baseline. Baseline is defined as the last non-missing value before the first dose of study drug. If a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as non-responders. Unadjusted and strata-adjusted p-values for between-group comparisons are from Mantel-Haenszel Chi-Square test and Cochran-Mantel-Haenszel (CMH) test, respectively. Strata adjusted p-values are from CMH test using the randomized stratification variables (analysis centre and body weight at randomization (&lt; 90 kg, &gt;= 90 kg). Forest plot is based on the result of strata-adjusted difference between treatment groups.

## 2.6.8.3.  Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 41: Summary of efficacy for trial Olympia RD.06.SPR.202685

| Study identifier          | (CD14152) in Subjects with Prurigo Nodularis Protocol Number: RD.06.SPR.202685 EudraCT Number: 2019-004293-25                                                                                                    | (CD14152) in Subjects with Prurigo Nodularis Protocol Number: RD.06.SPR.202685 EudraCT Number: 2019-004293-25                                                                                                    | (CD14152) in Subjects with Prurigo Nodularis Protocol Number: RD.06.SPR.202685 EudraCT Number: 2019-004293-25                                                                                                    |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | CT Number: NCT04501666 This was a phase 3, multicentre, double-blind, placebo-controlled, randomized (2:1), parallel-group study designed to evaluate the efficacy and safety of nemolizumab in subjects with PN | CT Number: NCT04501666 This was a phase 3, multicentre, double-blind, placebo-controlled, randomized (2:1), parallel-group study designed to evaluate the efficacy and safety of nemolizumab in subjects with PN | CT Number: NCT04501666 This was a phase 3, multicentre, double-blind, placebo-controlled, randomized (2:1), parallel-group study designed to evaluate the efficacy and safety of nemolizumab in subjects with PN |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                   | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                   | 24-week treatment period Screening period up to 4 weeks 8-week follow-up period                                                                                                                                  |
| Hypothesis                | Subjects treated with nemolizumab will have significant improvement in skin lesions and itch after 16 weeks of treatment compared to subjects treated with placebo.                                              | Subjects treated with nemolizumab will have significant improvement in skin lesions and itch after 16 weeks of treatment compared to subjects treated with placebo.                                              | Subjects treated with nemolizumab will have significant improvement in skin lesions and itch after 16 weeks of treatment compared to subjects treated with placebo.                                              |
| Treatments groups         | Nemolizumab Group (Q4W)                                                                                                                                                                                          | Nemolizumab Group (Q4W)                                                                                                                                                                                          | 190 subjects randomized 3 subjects randomized but not treated 187 subjects treated 168 completed treatment 19 discontinued treatment                                                                             |
| Treatments groups         | Placebo Group (Q4W)                                                                                                                                                                                              | Placebo Group (Q4W)                                                                                                                                                                                              | 96 subjects randomized 1 subject randomized but not treated 95 subjects treated 85 completed treatment 10 discontinued treatment                                                                                 |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                 | PP NRS Improvemen t≥4 at Week 16                                                                                                                                                                                 | Proportion of subjects with an improvement of ≥4 from baseline in PP NRS at Week 16.                                                                                                                             |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                 | IGA success at week 16                                                                                                                                                                                           | Proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥2-point improvement from baseline) at Week 16.                                                             |
| Endpoints and definitions | Key Secondary Endpoint                                                                                                                                                                                           | PP NRS improvemen t≥4 at Week                                                                                                                                                                                    | Proportion of subjects with an improvement of ≥4 from baseline in PP NRS at Week 4                                                                                                                               |

4

<div style=\"page-break-after: always\"></div>

|                         | Key Secondary Endpoint   | PP NRS <2 at Week 16                                 | Proportion of subjects with PP NRS < 2 at Week 16                                                                                                   |
|-------------------------|--------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|                         | Key Secondary Endpoint   | SD NRS improvement ≥4 at Week 16                     | Proportion of subjects with an improvement of ≥4 from baseline in SD NRS at Week 16                                                                 |
|                         | Key Secondary Endpoint   | SD NRS improvement ≥4 at Week 4                      | Proportion of subjects with an improvement of ≥4 from baseline in SD NRS at Week 4                                                                  |
|                         | Key Secondary Endpoint   | PP NRS <2 at Week 4                                  | Proportion of subjects with PP NRS < 2 at Week 4                                                                                                    |
|                         | Secondary Endpoint       | IGA Success at Week 4                                | Proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥2-point improvement from baseline) at Week 4. |
|                         | Secondary Endpoint       | Percentage change from baseline in PP NRS at Week 16 | Percentage change from baseline in PP NRS at Week 16                                                                                                |
|                         | Secondary Endpoint       | Percentage change from baseline in SD NRS at Week 16 | Percentage change from baseline in SD NRS at Week 16                                                                                                |
|                         | Secondary Endpoint       | Change from baseline in DLQI at Week 4               | Change from baseline in DLQI at Week 4                                                                                                              |
|                         | Secondary Endpoint       | Change from baseline in DLQI at Week 16              | Change from baseline in DLQI at Week 16                                                                                                             |
|                         | Secondary Endpoint       | DLQI improvemen t ≥4 at Week 4                       | Proportion of subjects with an improvement of ≥4 in DLQI at Week 4                                                                                  |
|                         | Secondary Endpoint       | DLQI improvemen t ≥4 at Week 16                      | Proportion of subjects with an improvement of ≥4 in DLQI at Week 16                                                                                 |
| Database lock 11APR2023 | Database lock 11APR2023  | Database lock 11APR2023                              | Database lock 11APR2023                                                                                                                             |
| Results and Analysis    | Results and Analysis     | Results and Analysis                                 | Results and Analysis                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Primary Analysis: For all the binary outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as non-responders. All primary endpoints, key secondary endpoints and secondary endpoints are analysed using a Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p-values are presented. Strata-adjusted proportion differences are obtained using weighted average of stratum-specific proportion using CMH. To control the type I error at 5% for primary and key secondary endpoints, a fixed sequential testing approach is implemented. For testing purposes, both primary endpoints are tested first in a predefined order as listed below at 5% significance level, and testing of key secondary endpoints will start only if both primary endpoints are successful at 5% level of significance. Key secondary endpoints are tested in an order listed below as well, stopping when non-significant result (p > 0.05) is found. For all the secondary continuous outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value. Missing of underlying value is assumed missing at random, and 50 complete datasets by MI with MAR assumption were generated. To estimate treatment difference, an ANCOVA model is used based on the 50 complete datasets, including treatment group and randomized stratification variables (analysis centre and body weight at randomization (< 90 kg, >= 90 kg)) as factors and the Baseline value as a covariate. The Least Squares Means (LS Means), standard error of LS Means, as well as the difference in LS Means between the   | Primary Analysis: For all the binary outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as non-responders. All primary endpoints, key secondary endpoints and secondary endpoints are analysed using a Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p-values are presented. Strata-adjusted proportion differences are obtained using weighted average of stratum-specific proportion using CMH. To control the type I error at 5% for primary and key secondary endpoints, a fixed sequential testing approach is implemented. For testing purposes, both primary endpoints are tested first in a predefined order as listed below at 5% significance level, and testing of key secondary endpoints will start only if both primary endpoints are successful at 5% level of significance. Key secondary endpoints are tested in an order listed below as well, stopping when non-significant result (p > 0.05) is found. For all the secondary continuous outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value. Missing of underlying value is assumed missing at random, and 50 complete datasets by MI with MAR assumption were generated. To estimate treatment difference, an ANCOVA model is used based on the 50 complete datasets, including treatment group and randomized stratification variables (analysis centre and body weight at randomization (< 90 kg, >= 90 kg)) as factors and the Baseline value as a covariate. The Least Squares Means (LS Means), standard error of LS Means, as well as the difference in LS Means between the   | Primary Analysis: For all the binary outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as non-responders. All primary endpoints, key secondary endpoints and secondary endpoints are analysed using a Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p-values are presented. Strata-adjusted proportion differences are obtained using weighted average of stratum-specific proportion using CMH. To control the type I error at 5% for primary and key secondary endpoints, a fixed sequential testing approach is implemented. For testing purposes, both primary endpoints are tested first in a predefined order as listed below at 5% significance level, and testing of key secondary endpoints will start only if both primary endpoints are successful at 5% level of significance. Key secondary endpoints are tested in an order listed below as well, stopping when non-significant result (p > 0.05) is found. For all the secondary continuous outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value. Missing of underlying value is assumed missing at random, and 50 complete datasets by MI with MAR assumption were generated. To estimate treatment difference, an ANCOVA model is used based on the 50 complete datasets, including treatment group and randomized stratification variables (analysis centre and body weight at randomization (< 90 kg, >= 90 kg)) as factors and the Baseline value as a covariate. The Least Squares Means (LS Means), standard error of LS Means, as well as the difference in LS Means between the   |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | ITT Population, Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | ITT Population, Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | ITT Population, Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Nemolizumab Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 190                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Primary - PP NRS improvement≥4 at Week 16 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 111 (58.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16 (16.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Primary - IGA success at week 16 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 50 (26.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 7 (7.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS improvement≥4 at Week 4 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 78 (41.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 6 (6.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS <2 at Week 16 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 65 (34.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 4 (4.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | Key Secondary - SD NRS improvement≥4 at Week 16 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 95 (50.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11 (11.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                 | Key Secondary - SD NRS improvement≥4 at Week 4 ( Proportion )   | 59 (31.1)                                 | 5 (5.2)                                          |
|---------------------------------|-----------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|
|                                 | Key Secondary - PP NRS <2 at Week 4 ( Proportion )              | 41 (21.6)                                 | 1 (1.0)                                          |
|                                 | Secondary- IGA Success at Week 4 ( Proportion )                 | 12 (6.3)                                  | 4 (4.2)                                          |
|                                 | Secondary- Percentage change from baseline in PP NRS at Week 16 |                                           |                                                  |
|                                 | Number of subjects                                              | 184                                       | 96                                               |
|                                 | LS means (standard error)                                       | -54.71 (2.715)                            | -18.69 (3.831)                                   |
|                                 | Secondary- Percentage change from baseline in SD NRS at Week 16 |                                           |                                                  |
|                                 | Number of subjects                                              | 187                                       | 94                                               |
|                                 | LS means (standard error)                                       | -52.47 (3.790)                            | -18.84 (5.325)                                   |
|                                 | Secondary- change from baseline in DLQI at Week 4               |                                           |                                                  |
|                                 | Number of subjects                                              | 190                                       | 96                                               |
|                                 | LS means (standard error)                                       | -7.83 (0.457)                             | -3.04 (0.647)                                    |
|                                 | Secondary- change from baseline in DLQI at Week 16              |                                           |                                                  |
|                                 | Number of subjects                                              | 190                                       | 96                                               |
|                                 | LS means (standard error)                                       | -8.57 (0.623)                             | -2.18 (0.874)                                    |
|                                 | Secondary- DLQI improvement ≥4 at Week 4 ( Proportion )         | 133 (70.0)                                | 41 (42.7)                                        |
|                                 | Secondary- DLQI improvement ≥4 at Week 16                       | 134 (70.5)                                | 41 (42.7)                                        |
| Effect estimates per comparison | ( Proportion ) Primary - PP NRS improvement≥4 at Week 16        | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | ( Proportion ) Primary - PP NRS improvement≥4 at Week 16        | Strata-adjusted proportion difference (%) | 40.1                                             |
| Effect estimates per comparison | ( Proportion ) Primary - PP NRS improvement≥4 at Week 16        | 95% Confidence Interval (%)               | [29.4, 50.8]                                     |
| Effect estimates per comparison | ( Proportion ) Primary - PP NRS improvement≥4 at Week 16        | P-value                                   | <0.0001                                          |
| Effect estimates per comparison | Primary - IGA success at week 16                                | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Primary - IGA success at week 16                                | Strata-adjusted proportion difference     | 14.6                                             |
| Effect estimates per comparison | Primary - IGA success at week 16                                | (%) 95% Confidence Interval (%)           | [6.7, 22.6]                                      |
| Effect estimates per comparison | Primary - IGA success at week 16                                | P-value                                   | 0.0025                                           |

<div style=\"page-break-after: always\"></div>

| Key Secondary - PP NRS improvement≥4 at Week 4   | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)   |
|--------------------------------------------------|-------------------------------------------|----------------------------------------------------|
| Key Secondary - PP NRS improvement≥4 at Week 4   | Strata-adjusted proportion difference (%) | 31.7                                               |
| Key Secondary - PP NRS improvement≥4 at Week 4   | 95% Confidence Interval (%)               | [23.0, 40.4]                                       |
| Key Secondary - PP NRS improvement≥4 at Week 4   | P-value                                   | <0.0001                                            |
| Key Secondary - PP NRS <2 at Week 16             | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)   |
| Key Secondary - PP NRS <2 at Week 16             | Strata-adjusted proportion difference (%) | 30.5                                               |
| Key Secondary - PP NRS <2 at Week 16             | 95% Confidence Interval (%)               | [22.3, 38.7]                                       |
|                                                  | P-value                                   | <0.0001                                            |
| Key Secondary - SD NRS improvement≥4 at Week 16  | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)   |
| Key Secondary - SD NRS improvement≥4 at Week 16  | Strata-adjusted proportion difference (%) | 38.0                                               |
| Key Secondary - SD NRS improvement≥4 at Week 16  | 95% Confidence Interval (%)               | [27.8, 48.2]                                       |
| Key Secondary - SD NRS improvement≥4 at Week 4   | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)   |
| Key Secondary - SD NRS improvement≥4 at Week 4   | Strata-adjusted proportion difference (%) | 22.7                                               |
| Key Secondary - SD NRS improvement≥4 at Week 4   | 95% Confidence Interval (%)               | [14.7, 30.7]                                       |
| Key Secondary - SD NRS improvement≥4 at Week 4   | P-value                                   | <0.0001                                            |
| Key Secondary - PP NRS <2 at Week 4              | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)   |
| Key Secondary - PP NRS <2 at Week 4              | Strata-adjusted proportion difference (%) | 18.7                                               |
| Key Secondary - PP NRS <2 at Week 4              | 95% Confidence Interval (%)               | [12.3, 25.0]                                       |
| Key Secondary - PP NRS <2 at Week 4              | P-value                                   | <0.0001                                            |
| Secondary- IGA Success at Week 4                 | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)   |
| Secondary- IGA Success at Week 4                 | Strata-adjusted proportion difference (%) | 1.2                                                |
| Secondary- IGA Success at Week 4                 | 95% Confidence Interval (%)               | [-4.0, 6.5]                                        |
| Secondary- IGA Success at Week 4                 | P-value                                   | 0.6663                                             |
| Secondary- Percentage change from baseline in PP | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)   |

<div style=\"page-break-after: always\"></div>

| NRS at Week 16                                                  | LS Mean difference (%)                    | -36.02                                                   |
|-----------------------------------------------------------------|-------------------------------------------|----------------------------------------------------------|
| NRS at Week 16                                                  | 95% Confidence Interval (%)               | [-44.91, -27.14]                                         |
| NRS at Week 16                                                  | P-value                                   | <0.0001                                                  |
| Secondary- Percentage change from baseline in SD NRS at Week 16 | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)         |
|                                                                 | LS Mean difference (%)                    | -33.63                                                   |
|                                                                 | 95% Confidence Interval (%)               | [-46.06, -21.21]                                         |
|                                                                 | P-value                                   | <0.0001                                                  |
| Secondary- change from baseline in DLQI at Week 4               | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)         |
| Secondary- change from baseline in DLQI at Week 4               | LS Mean difference                        | -4.80                                                    |
| Secondary- change from baseline in DLQI at Week 4               | 95% Confidence Interval                   | [-6.31, -3.29]                                           |
| Secondary- change from baseline in DLQI at Week 4               | P-value                                   | <0.0001                                                  |
| Secondary- change from baseline in DLQI at Week 16              | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)         |
|                                                                 | LS Mean difference                        | -6.39                                                    |
|                                                                 | 95% Confidence Interval                   | [-8.43, -4.35]                                           |
|                                                                 | P-value                                   | <0.0001                                                  |
| Secondary- DLQI improvement ≥4 at Week 4                        | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)         |
| Secondary- DLQI improvement ≥4 at Week 4                        | Strata-adjusted proportion difference (%) | 26.5                                                     |
| Secondary- DLQI improvement ≥4 at Week 4                        | 95% Confidence Interval (%)               | [14.0, 39.0]                                             |
| Secondary- DLQI improvement ≥4 at Week 16                       | P-value Comparison groups                 | <0.0001 Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
|                                                                 | Strata-adjusted proportion difference (%) | 27.5                                                     |
|                                                                 | 95% Confidence Interval (%)               | [15.8, 39.2]                                             |
|                                                                 | P-value                                   | <0.0001                                                  |

<div style=\"page-break-after: always\"></div>

| Notes                                           | Subject Disposition The number of subjects who completed the study was 166 (87.4%) in the nemolizumab group and 83 (86.5%) in the placebo group. Of subjects in the nemolizumab group who did not complete the study, the primary reason for discontinuation was adverse event (12 subjects, 6.3%), subject's request (10 subjects, 5.3%), and protocol deviation (2 subjects, 1.1%). Of subjects in the placebo group who did not complete the study, the primary reason for discontinuation was adverse event (4 subjects, 4.2%), subject's request (6 subjects, 6.3%), protocol                                                                                                                                                                                        | Subject Disposition The number of subjects who completed the study was 166 (87.4%) in the nemolizumab group and 83 (86.5%) in the placebo group. Of subjects in the nemolizumab group who did not complete the study, the primary reason for discontinuation was adverse event (12 subjects, 6.3%), subject's request (10 subjects, 5.3%), and protocol deviation (2 subjects, 1.1%). Of subjects in the placebo group who did not complete the study, the primary reason for discontinuation was adverse event (4 subjects, 4.2%), subject's request (6 subjects, 6.3%), protocol                                                                                                                                                                                        | Subject Disposition The number of subjects who completed the study was 166 (87.4%) in the nemolizumab group and 83 (86.5%) in the placebo group. Of subjects in the nemolizumab group who did not complete the study, the primary reason for discontinuation was adverse event (12 subjects, 6.3%), subject's request (10 subjects, 5.3%), and protocol deviation (2 subjects, 1.1%). Of subjects in the placebo group who did not complete the study, the primary reason for discontinuation was adverse event (4 subjects, 4.2%), subject's request (6 subjects, 6.3%), protocol                                                                                                                                                                                        |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                            | Secondary Analysis: If a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as non-responders. All primary endpoints and key secondary endpoints are analysed using a Cochran- Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p-values are presented. Strata- adjusted proportion differences are obtained using weighted average of stratum- specific proportion using CMH. | Secondary Analysis: If a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as non-responders. All primary endpoints and key secondary endpoints are analysed using a Cochran- Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p-values are presented. Strata- adjusted proportion differences are obtained using weighted average of stratum- specific proportion using CMH. | Secondary Analysis: If a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Subjects with missing results are considered as non-responders. All primary endpoints and key secondary endpoints are analysed using a Cochran- Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p-values are presented. Strata- adjusted proportion differences are obtained using weighted average of stratum- specific proportion using CMH. |
| Analysis population and time point description  | PP Population, Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PP Population, Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PP Population, Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Nemolizumab Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 166                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 84                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Primary - PP NRS improvement≥4 at Week 16 (Proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 103 (62.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15 (17.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Primary - IGA success at week 16 (Proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 48 (28.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 7 (8.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 71 (42.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 6 (7.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS <2 at Week 16 (Proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 59 (35.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 4 (4.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Key Secondary - SD NRS improvement≥4 at Week 16 (Proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 86 (51.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 10 (11.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Key Secondary - SD NRS improvement≥4 at Week 4 (Proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 53 (31.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3 (3.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS <2 at Week 4 (Proportion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 35 (21.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1 (1.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Effect estimates per comparison                 | Primary - PP NRS improvement≥4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                                                 | Strata-adjusted proportion difference (%)   | 43.3                                             |
|-------------------------------------------------|---------------------------------------------|--------------------------------------------------|
|                                                 | 95% Confidence Interval (%)                 | [31.3, 55.3]                                     |
|                                                 | P-value                                     | <0.0001                                          |
| Primary - IGA success at week 16                | Comparison groups                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
|                                                 | Strata-adjusted proportion difference       | 16.6                                             |
|                                                 | (%) 95% Confidence Interval (%)             | [7.7, 25.5]                                      |
|                                                 | P-value                                     | 0.0023                                           |
| Key Secondary - PP NRS improvement≥4 at Week 4  | Comparison groups                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
|                                                 | Strata-adjusted proportion difference (%)   | 32.8                                             |
|                                                 | 95% Confidence Interval (%)                 | [23.0, 42.5]                                     |
|                                                 | P-value                                     | <0.0001                                          |
| Key Secondary - PP NRS <2 at Week 16            | Comparison groups                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
|                                                 | Strata-adjusted proportion difference (%)   | 31.3                                             |
|                                                 | 95% Confidence Interval (%)                 | [22.1, 40.5]                                     |
|                                                 | P-value                                     | <0.0001                                          |
| Key Secondary - SD NRS improvement≥4 at Week 16 | Comparison groups                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
|                                                 | Strata-adjusted proportion difference (%)   | 40.1                                             |
|                                                 | 95% Confidence Interval (%)                 | [29.1, 51.0]                                     |
|                                                 | P-value                                     | <0.0001                                          |
| Key Secondary - SD NRS improvement≥4 at Week 4  | Comparison groups                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
|                                                 | Strata-adjusted proportion difference (%)   | 25.5                                             |
|                                                 | 95% Confidence Interval (%)                 | [17.1, 33.9]                                     |
|                                                 | P-value                                     | <0.0001                                          |
| Key Secondary - PP NRS <2 at Week 4             | Comparison groups                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |

<div style=\"page-break-after: always\"></div>

| Strata-adjusted proportion difference (%)   | 18.6         |
|---------------------------------------------|--------------|
| 95% Confidence Interval (%)                 | [11.6, 25.5] |
| P-value                                     | <0.0001      |

Table 42: Summary of efficacy for trial RD.06.SPR.203065

| Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Prurigo Nodularis   | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Prurigo Nodularis                                  | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Prurigo Nodularis                                  | Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of nemolizumab (CD14152) in Subjects with Prurigo Nodularis                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                            | Protocol Number: RD.06.SPR.203065 EudraCT Number: 2019-004789-17 CT Number: NCT04501679                                                                                                    | Protocol Number: RD.06.SPR.203065 EudraCT Number: 2019-004789-17 CT Number: NCT04501679                                                                                                    | Protocol Number: RD.06.SPR.203065 EudraCT Number: 2019-004789-17 CT Number: NCT04501679                                                                                                    |
| Design                                                                                                                                                      | This was a Phase 3, multicentre, double-blind, placebo-controlled, randomized (2:1), parallel-group study designed to evaluate the efficacy and safety of nemolizumab in subjects with PN. | This was a Phase 3, multicentre, double-blind, placebo-controlled, randomized (2:1), parallel-group study designed to evaluate the efficacy and safety of nemolizumab in subjects with PN. | This was a Phase 3, multicentre, double-blind, placebo-controlled, randomized (2:1), parallel-group study designed to evaluate the efficacy and safety of nemolizumab in subjects with PN. |
| Design                                                                                                                                                      | Duration of main phase:                                                                                                                                                                    | Duration of main phase:                                                                                                                                                                    | 16-week treatment period                                                                                                                                                                   |
| Design                                                                                                                                                      | Duration of Run-in phase:                                                                                                                                                                  | Duration of Run-in phase:                                                                                                                                                                  | screening period up to 4 weeks                                                                                                                                                             |
| Design                                                                                                                                                      | Duration of Extension phase:                                                                                                                                                               | Duration of Extension phase:                                                                                                                                                               | 8-week follow-up period                                                                                                                                                                    |
| Hypothesis                                                                                                                                                  | Subjects treated with nemolizumab will have significant improvement in skin lesions and itch after 16 weeks of treatment compared to subjects treated with placebo.                        | Subjects treated with nemolizumab will have significant improvement in skin lesions and itch after 16 weeks of treatment compared to subjects treated with placebo.                        | Subjects treated with nemolizumab will have significant improvement in skin lesions and itch after 16 weeks of treatment compared to subjects treated with placebo.                        |
| Treatments groups                                                                                                                                           | Nemolizumab Group (Q4W)                                                                                                                                                                    | Nemolizumab Group (Q4W)                                                                                                                                                                    | 183 subjects randomized 0 subjects randomized but not treated 183 subjects treated 175 completed treatment 8 discontinued treatment                                                        |
| Treatments groups                                                                                                                                           | Placebo Group (Q4W)                                                                                                                                                                        | Placebo Group (Q4W)                                                                                                                                                                        | 91 subjects randomized 0 subjects randomized but not treated 91 subjects treated 87 completed treatment 4 discontinued treatment                                                           |
| Endpoints and definitions                                                                                                                                   | Primary endpoint                                                                                                                                                                           | PP NRS improvement ≥4 at Week 16                                                                                                                                                           | Proportion of subjects with an improvement of ≥4 from baseline in PP NRS at Week 16.                                                                                                       |
| Endpoints and definitions                                                                                                                                   | Primary endpoint                                                                                                                                                                           | IGA success at week 16                                                                                                                                                                     | Proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥2-point improvement from baseline) at Week 16.                                       |

<div style=\"page-break-after: always\"></div>

|               | Key Secondary Endpoint   | PP NRS improvement ≥4 at Week 4                      | Proportion of subjects with an improvement of ≥4 from baseline in PP NRS at Week 4                                                                  |
|---------------|--------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|               | Key Secondary Endpoint   | PP NRS <2 at Week 16                                 | Proportion of subjects with PP NRS <2 at Week 16                                                                                                    |
|               | Key Secondary Endpoint   | SD NRS improvement ≥4 at Week 16                     | Proportion of subjects with an improvement of ≥4 from baseline in SD NRS at Week 16                                                                 |
|               | Key Secondary Endpoint   | SD NRS improvement ≥4 at Week 4                      | Proportion of subjects with an improvement of ≥4 from baseline in SD NRS at Week 4                                                                  |
|               | Key Secondary Endpoint   | PP NRS <2 at Week 4                                  | Proportion of subjects with PP NRS <2 at Week 4                                                                                                     |
|               | Secondary Endpoint       | IGA Success at Week 4                                | Proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥2-point improvement from baseline) at Week 4. |
|               | Secondary Endpoint       | Percentage change from baseline in PP NRS at Week 16 | Percentage change from baseline in PP NRS at Week 16                                                                                                |
|               | Secondary Endpoint       | Percentage change from baseline in SD NRS at Week 16 | Percentage change from baseline in SD NRS at Week 16                                                                                                |
|               | Secondary Endpoint       | Change from baseline in DLQI at Week 4               | Change from baseline in DLQI at Week 4                                                                                                              |
|               | Secondary Endpoint       | Change from baseline in DLQI at Week 16              | Change from baseline in DLQI at Week 16                                                                                                             |
|               | Secondary Endpoint       | DLQI improvement ≥4 at Week 4                        | Proportion of subjects with an improvement of ≥4 in DLQI at Week 4                                                                                  |
|               | Secondary Endpoint       | DLQI improvement ≥4 at Week 16                       | Proportion of subjects with an improvement of ≥4 in DLQI at Week 16                                                                                 |
| Database lock | 26MAY2022                |                                                      |                                                                                                                                                     |

## Results and Analysis

## Primary Analysis:

For all the binary outcome analyses, if a subject received any rescue therapy, the data at/after receipt of rescue therapy are considered as non-responders. Subjects with missing results are considered as non-responders. All primary endpoints, key secondary endpoints and secondary endpoints are analysed using a Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (&lt; 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and pvalues are presented. Strata-adjusted proportion differences are obtained using weighted average of stratum-specific proportion using CMH.

## Analysis description

<div style=\"page-break-after: always\"></div>

|                                                 | To control the type I error at 5% for primary and key secondary endpoints, a fixed sequential testing approach is implemented. For testing purposes, both primary endpoints are tested first in a predefined order as listed below at 5% significance level, and testing of key secondary endpoints will start only if both primary endpoints are successful at 5% level of significance. Key secondary endpoints are tested in an order listed below as well, stopping when non-significant result (p > 0.05) is found. For all the secondary continuous outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value. Missing of underlying value is assumed missing at random, and 50 complete datasets by MI with MAR assumption were generated. To estimate treatment difference, an ANCOVA model is used based on the 50 complete datasets, including treatment group and randomized stratification variables (analysis centre and body weight at randomization (< 90 kg, >= 90 kg)) as factors and the Baseline value as a covariate. The Least Squares Means (LS Means), standard error of LS Means, as well as the difference in LS Means between the treatment groups, the two-sided   | To control the type I error at 5% for primary and key secondary endpoints, a fixed sequential testing approach is implemented. For testing purposes, both primary endpoints are tested first in a predefined order as listed below at 5% significance level, and testing of key secondary endpoints will start only if both primary endpoints are successful at 5% level of significance. Key secondary endpoints are tested in an order listed below as well, stopping when non-significant result (p > 0.05) is found. For all the secondary continuous outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value. Missing of underlying value is assumed missing at random, and 50 complete datasets by MI with MAR assumption were generated. To estimate treatment difference, an ANCOVA model is used based on the 50 complete datasets, including treatment group and randomized stratification variables (analysis centre and body weight at randomization (< 90 kg, >= 90 kg)) as factors and the Baseline value as a covariate. The Least Squares Means (LS Means), standard error of LS Means, as well as the difference in LS Means between the treatment groups, the two-sided   | To control the type I error at 5% for primary and key secondary endpoints, a fixed sequential testing approach is implemented. For testing purposes, both primary endpoints are tested first in a predefined order as listed below at 5% significance level, and testing of key secondary endpoints will start only if both primary endpoints are successful at 5% level of significance. Key secondary endpoints are tested in an order listed below as well, stopping when non-significant result (p > 0.05) is found. For all the secondary continuous outcome analyses, if a subject received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value. Missing of underlying value is assumed missing at random, and 50 complete datasets by MI with MAR assumption were generated. To estimate treatment difference, an ANCOVA model is used based on the 50 complete datasets, including treatment group and randomized stratification variables (analysis centre and body weight at randomization (< 90 kg, >= 90 kg)) as factors and the Baseline value as a covariate. The Least Squares Means (LS Means), standard error of LS Means, as well as the difference in LS Means between the treatment groups, the two-sided   |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | ITT Population; Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | ITT Population; Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | ITT Population; Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Nemolizumab Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 183                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 91                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Primary - PP NRS improvement≥4 at Week 16 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 103 (56.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19 (20.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | Primary - IGA success at week 16 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 69 (37.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10 (11.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS improvement≥4 at Week 4 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 75 (41.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 7 (7.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS <2 at Week 16 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 64 (35.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 7 (7.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Key Secondary - SD NRS improvement≥4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 95 (51.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19 (20.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | ( Proportion ) Key Secondary - SD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 68 (37.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9 (9.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Key Secondary - PP NRS <2 at Week 4 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 36 (19.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2 (2.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Secondary- IGA Success at Week 4 ( Proportion )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18 (9.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1 (1.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                 | Secondary- Percentage change from baseline in PP NRS at Week 16   |                                           |                                                  |
|---------------------------------|-------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|
|                                 | Number of subjects                                                | 183                                       | 91                                               |
|                                 | LS means (standard error)                                         | -56.23 (3.197)                            | -18.85 (4.282)                                   |
|                                 | Secondary- Percentage change from baseline in SD NRS at Week 16   |                                           |                                                  |
|                                 | Number of subjects                                                | 180                                       | 90                                               |
|                                 | LS means (standard error)                                         | -53.14 (6.361)                            | -9.59 (8.491)                                    |
|                                 | Secondary- change from baseline in DLQI at Week 4                 |                                           |                                                  |
|                                 | Number of subjects                                                | 183                                       | 91                                               |
|                                 | LS means (standard error)                                         | -7.95 (0.586)                             | -1.90 (0.782)                                    |
|                                 | Secondary- change from baseline in DLQI at Week 16                |                                           |                                                  |
|                                 | Number of subjects                                                | 183                                       | 91                                               |
|                                 | LS means (standard error)                                         | -8.91 (0.686)                             | -0.75 (0.911)                                    |
|                                 | Secondary- DLQI improvement ≥4 at Week 4 ( Proportion )           | 126 (68.9)                                | 36 (39.6)                                        |
|                                 | Secondary- DLQI improvement ≥4 at Week 16 ( Proportion )          | 137 (74.9)                                | 36 (39.6)                                        |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)            | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)            | Strata-adjusted proportion difference (%) | 37.4                                             |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)            | 95% Confidence Interval (%)               | [26.3, 48.5]                                     |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)            | P-value                                   | <0.0001                                          |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)                     | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)                     | Strata-adjusted proportion difference (%) | 28.5                                             |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)                     | 95% Confidence Interval (%)               | [18.8, 38.2]                                     |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)                     | P-value                                   | <0.0001                                          |
| Effect estimates per comparison | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion)       | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion)       | Strata-adjusted proportion difference (%) | 33.4                                             |
| Effect estimates per comparison | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion)       | 95% Confidence Interval (%)               | [24.3, 42.4]                                     |

<div style=\"page-break-after: always\"></div>

|                                                                 | P-value                                                     | <0.0001                                               |
|-----------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------|
| Key Secondary - PP NRS <2 at Week 16 (Proportion)               | Comparison groups                                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)      |
|                                                                 | Strata-adjusted proportion difference (%)                   | 30.0                                                  |
|                                                                 | 95% Confidence Interval (%)                                 | [21.3, 38.6]                                          |
|                                                                 | P-value                                                     | <0.0001                                               |
| Key Secondary - SD NRS improvement≥4 at Week 16 (Proportion)    | Comparison groups Strata-adjusted proportion difference (%) | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) 31.9 |
|                                                                 | 95% Confidence Interval (%)                                 | [20.7, 43.2]                                          |
|                                                                 | P-value                                                     | <0.0001                                               |
| Key Secondary - SD NRS improvement≥4 at Week 4 (Proportion)     | Comparison groups                                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)      |
|                                                                 | Strata-adjusted proportion difference (%)                   | 27.9                                                  |
|                                                                 | 95% Confidence Interval (%)                                 | [18.4, 37.5]                                          |
|                                                                 | P-value                                                     | <0.0001                                               |
| Key Secondary - PP NRS <2 at Week 4 (Proportion)                | Comparison groups                                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)      |
|                                                                 | Strata-adjusted proportion difference (%)                   | 18.8                                                  |
|                                                                 | 95% Confidence Interval (%)                                 | [12.0, 25.7]                                          |
|                                                                 | P-value                                                     | <0.0001                                               |
| Secondary- IGA Success at Week 4                                | Comparison groups                                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)      |
|                                                                 | Strata-adjusted proportion difference (%)                   | 10.1                                                  |
|                                                                 | 95% Confidence Interval (%)                                 | [4.8, 15.4]                                           |
|                                                                 | P-value                                                     | 0.0022                                                |
| Secondary- Percentage change from baseline in PP NRS at Week 16 | Comparison groups                                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)      |
|                                                                 | LS mean difference (%)                                      | -37.38                                                |
|                                                                 | 95% Confidence Interval (%)                                 | [-46.80, -27.96]                                      |
|                                                                 | P-value                                                     | <0.0001                                               |
| Secondary- Percentage change from baseline in SD NRS at Week 16 | Comparison groups                                           | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)      |
|                                                                 | LS mean difference (%)                                      | -43.55                                                |
|                                                                 | 95% Confidence Interval (%)                                 | [-62.24, -24.87]                                      |

<div style=\"page-break-after: always\"></div>

|                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                | Secondary- change from baseline in DLQI at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                | Secondary- change from baseline in DLQI at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | LS mean difference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | -6.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                | Secondary- change from baseline in DLQI at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% Confidence Interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | [-7.77, -4.32]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                | Secondary- change from baseline in DLQI at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                | Secondary- change from baseline in DLQI at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                | Secondary- change from baseline in DLQI at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | LS mean difference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | -8.15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                | Secondary- change from baseline in DLQI at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 95% Confidence Interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | [-10.16, -6.14]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                | Secondary- change from baseline in DLQI at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                | Secondary- DLQI improvement ≥4 at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                | Secondary- DLQI improvement ≥4 at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                | Secondary- DLQI improvement ≥4 at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 95% Confidence Interval (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | [17.3, 42.5]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                | Secondary- DLQI improvement ≥4 at Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                | Secondary- DLQI improvement ≥4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                | Secondary- DLQI improvement ≥4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Strata-adjusted proportion difference (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 37.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                | Secondary- DLQI improvement ≥4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 95% Confidence Interval (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | [25.7, 49.0]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                | Secondary- DLQI improvement ≥4 at Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Notes                                          | Subject Disposition The number of subjects who completed the study was 174 (95.1%) in the nemolizumab group and 88 (96.7%) in the placebo group. Of subjects in the nemolizumab group who did not complete the study, the primary reason for discontinuation was adverse event (4 subjects, 2.2%), subject's request (2 subjects, 1.1%), lost to follow-up (2 subjects, 1.1%) and physician decision (1                                                                                                                                                                                                                                                              | Subject Disposition The number of subjects who completed the study was 174 (95.1%) in the nemolizumab group and 88 (96.7%) in the placebo group. Of subjects in the nemolizumab group who did not complete the study, the primary reason for discontinuation was adverse event (4 subjects, 2.2%), subject's request (2 subjects, 1.1%), lost to follow-up (2 subjects, 1.1%) and physician decision (1                                                                                                                                                                                                                                                              | Subject Disposition The number of subjects who completed the study was 174 (95.1%) in the nemolizumab group and 88 (96.7%) in the placebo group. Of subjects in the nemolizumab group who did not complete the study, the primary reason for discontinuation was adverse event (4 subjects, 2.2%), subject's request (2 subjects, 1.1%), lost to follow-up (2 subjects, 1.1%) and physician decision (1                                                                                                                                                                                                                                                              |
| Analysis description                           | Secondary analysis: If a subject received any rescue therapy, the data at/after receipt of rescue therapy are considered as non-responders. Subjects with missing results are considered as non-responders. All primary endpoints and key secondary endpoints were analysed using a Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p- values were presented. Strata-adjusted proportion differences will be obtained using weighted average of stratum-specific proportion using CMH. | Secondary analysis: If a subject received any rescue therapy, the data at/after receipt of rescue therapy are considered as non-responders. Subjects with missing results are considered as non-responders. All primary endpoints and key secondary endpoints were analysed using a Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p- values were presented. Strata-adjusted proportion differences will be obtained using weighted average of stratum-specific proportion using CMH. | Secondary analysis: If a subject received any rescue therapy, the data at/after receipt of rescue therapy are considered as non-responders. Subjects with missing results are considered as non-responders. All primary endpoints and key secondary endpoints were analysed using a Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization strata analysis centre and body weight at randomization (< 90 kg, ≥ 90 kg). The estimate of the treatment difference and corresponding two-sided 95% CI and p- values were presented. Strata-adjusted proportion differences will be obtained using weighted average of stratum-specific proportion using CMH. |
| Analysis population and time point description | PP Population; Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | PP Population; Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | PP Population; Week 16 & Week 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate            | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Nemolizumab Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Placebo Group (Q4W)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| variability                     |                                                             |                                           |                                                  |
|---------------------------------|-------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|
| variability                     | Number of subjects                                          | 159                                       | 83                                               |
| variability                     | Primary - PP NRS improvement≥4 at Week 16 (Proportion)      | 94 (59.1)                                 | 18 (21.7)                                        |
| variability                     | Primary - IGA success at week 16 (Proportion)               | 57 (35.8)                                 | 10 (12.0)                                        |
| variability                     | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion) | 68 (42.8)                                 | 7 (8.4)                                          |
| variability                     | Key Secondary - PP NRS <2 at Week 16 (Proportion)           | 58 (36.5)                                 | 7 (8.4)                                          |
| variability                     | Key Secondary - SD NRS improvement≥4 at Week 16             | 84 (52.8)                                 | 18 (21.7)                                        |
| variability                     | (Proportion)                                                |                                           |                                                  |
| variability                     | Key Secondary - SD NRS improvement≥4 at Week 4 (Proportion) | 61 (38.4)                                 | 9 (10.8)                                         |
| variability                     | Key Secondary - PP NRS <2 at Week 4 (Proportion)            | 31 (19.5)                                 | 2 (2.4)                                          |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)      | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)      | Strata-adjusted proportion difference (%) | 39.0                                             |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)      | 95% Confidence Interval (%)               | [27.0, 51.0]                                     |
| Effect estimates per comparison | Primary - PP NRS improvement≥4 at Week 16 (Proportion)      | P-value                                   | <0.0001                                          |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)               | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)               | Strata-adjusted proportion difference (%) | 24.1                                             |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)               | 95% Confidence Interval (%)               | [13.5, 34.8]                                     |
| Effect estimates per comparison | Primary - IGA success at week 16 (Proportion)               | P-value                                   | <0.0001                                          |
| Effect estimates per comparison | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion) | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion) | Strata-adjusted proportion difference (%) | 34.3                                             |
| Effect estimates per comparison | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion) | 95% Confidence Interval (%)               | [24.3, 44.4]                                     |
| Effect estimates per comparison | Key Secondary - PP NRS improvement≥4 at Week 4 (Proportion) | P-value                                   | <0.0001                                          |
| Effect estimates per comparison | Key Secondary - PP NRS <2 at Week 16 (Proportion)           | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Effect estimates per comparison | Key Secondary - PP NRS <2 at Week 16 (Proportion)           | Strata-adjusted proportion difference (%) | 30.8                                             |

<div style=\"page-break-after: always\"></div>

|                                                             | 95% Confidence Interval (%)               | [21.3, 40.3]                                     |
|-------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|
|                                                             | P-value                                   | <0.0001                                          |
| Key Secondary - SD NRS improvement≥4 at Week 16             | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| (Proportion)                                                | Strata-adjusted proportion difference (%) | 31.0                                             |
| (Proportion)                                                | 95% Confidence Interval (%)               | [18.6, 43.4]                                     |
| (Proportion)                                                | P-value                                   | <0.0001                                          |
| Key Secondary - SD NRS improvement≥4 at Week 4 (Proportion) | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Key Secondary - SD NRS improvement≥4 at Week 4 (Proportion) | Strata-adjusted proportion difference (%) | 29.3                                             |
| Key Secondary - SD NRS improvement≥4 at Week 4 (Proportion) | 95% Confidence Interval (%)               | [18.6, 40.0]                                     |
| Key Secondary - SD NRS improvement≥4 at Week 4 (Proportion) | P-value                                   | <0.0001                                          |
| Key Secondary - PP NRS <2 at Week 4 (Proportion)            | Comparison groups                         | Nemolizumab Group (Q4W) V.S. Placebo Group (Q4W) |
| Key Secondary - PP NRS <2 at Week 4 (Proportion)            | Strata-adjusted proportion difference (%) | 19.4                                             |
| Key Secondary - PP NRS <2 at Week 4 (Proportion)            | 95% Confidence Interval (%)               | [11.7, 27.1]                                     |
| Key Secondary - PP NRS <2 at Week 4 (Proportion)            | P-value                                   | <0.0001                                          |

## 2.6.8.4.  Clinical studies in special populations

Enrolled subjects were aged 18-84 years. The proportion of subjects older than 65 years was 29.2% (184/630 randomised subjects).  The applicant populated the table with information corresponding to the 630 subjects included in the ITT population (N=70 for study SPR.115828, N=286 for study SPR.202685 and N=274 for study SPR.203065). All subjects enrolled in the LTE study SPR.202699 rolled over from either the 2 pivotal studies or the Ph2a study (SPR.115828), therefore the baseline characteristics were not populated in the column non-controlled trials to avoid double-counting.

<div style=\"page-break-after: always\"></div>

Table 43: Number of subjects with renal- and hepatic impairment in PN

|                                                               | Controlled Trials   |   Non-controlled trials |
|---------------------------------------------------------------|---------------------|-------------------------|
| Renal impairment* patients (Subjects number /total number)    | 10/630              |                       0 |
| Hepatic impairment** patients (Subjects number /total number) | 2/630               |                       0 |
| Paediatric patients <18 years (Subjects number /total number) | 0                   |                       0 |
| Age 65-74 (Subjects number /total number)                     | 140/630             |                       0 |
| Age 75-84 (Subjects number /total number)                     | 44/630              |                       0 |
| Age 85+ (Subjects number /total number)                       | 1/630               |                       0 |
| Other (Subjects number /total number)                         | 445/630             |                       0 |

## 2.6.8.5.  In vitro biomarker test for patient selection for efficacy

Not applicable

## 2.6.8.6.  Analysis performed across trials (pooled analyses and meta-analysis)

The two pivotal studies SPR.202685 and SPR.203065, including pooled analyses, are presented and discussed above.

## 2.6.8.7.  Supportive study

## SPR.202699 - A Prospective, Multicentre, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

Study SPR.202699 is an ongoing, Phase 3, open-label, multicentre, LTE study designed to evaluate the safety and efficacy of nemolizumab in subjects with PN. The study population comprises subjects who had been enrolled in a prior nemolizumab Phase 2a study (SPR.115828) or prior Phase 3 pivotal study (SPR.202685 or SPR.203065).

Key inclusion criteria include male or female subjects ≥ 18 years of age who completed the treatment period in a Phase 3 pivotal study (SPR.202685 or SPR.203065) or who were previously randomized in the Phase 2a study (SPR.115828) who, in the opinion of the Investigator, may have benefitted from participation in the study.

Key exclusion criteria include subjects who experienced an AE during a prior nemolizumab study that, in the opinion of the Investigator, could have indicated that continued treatment with nemolizumab may have presented an unreasonable risk for the subject and body weight &lt;30 kg.

This LTE study included up to a 4-week screening period, up to a 184-week treatment period, and an 8-week follow-up period (12 weeks after the last study drug injection).

At Week 52, clinical responders, defined as subjects with an IGA score=0 or 1 and an improvement in the PP NRS score of ≥ 4 from baseline of the lead-in study, may have been eligible to exit the LTE study and enter the durability study (SPR.203890) (select countries/select sites).

## Objectives

Primary objective: The primary objective is to assess the long-term safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN).

<div style=\"page-break-after: always\"></div>

Secondary objective: The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152) in subjects with PN.

## Primary endpoint

Incidence and severity of adverse events (AEs), including AEs of special interest, treatmentemergent AEs, and serious AEs.

## Study design

Subjects' participation in the study will be up to 196 weeks. The study consists of an up to 4-week screening period, a 184-week treatment period, and an 8-week follow up period (12 weeks after their last study drug injection). Approximately 450 subjects are planned to be enrolled in this study.

## Preliminary results

As of the 10 Mar 2023 cutoff date for the LTE study, the mean treatment duration was 368.5 days. Of the 508 subjects who received at least 1 dose of nemolizumab, the number and percentage with ≥ 365 days of nemolizumab treatment in the study were 262 (51.6%).

The proportion of subjects with an IGA score of 0 or 1 at LTE baseline was 29.3% and further increased to 68.1% at Week 52. Following nemolizumab treatment in the LTE, the proportion of nemolizumab-naïve subjects achieving an IGA score of 0 or 1 increased over time, catching up with previously treated (continuous treatment and re-treated) subjects at Week 28. The proportion of subjects with an IGA score of 0 or 1 increased over time in the previously treated groups. At Week 52, the proportion of subjects achieving an IGA score of 0 or 1 was 76.2% in the re-treated group and 69.2% in the continuous nemolizumab group.

Following nemolizumab treatment in the LTE, the proportion of subjects with an improvement of ≥ 4 from lead-in baseline in weekly average PP NRS generally increased over time based on the observed case analysis.

The final clinical study report is expected early 2027.

## Human factor studies

Two Human Factors Engineering Reports have been submitted: one for each presentation of nemolizumab.

## Human Factors Engineering Report for Nemolizumab DCC-AI (RD.03.HFE.00002.R00)

This report described the human factors engineering (HFE) work performed during the development of Chugai Pharmaceuticals' and Galderma SA's ('Chugai/Galderma') single-use, single-dose, auto-injector ('AI' or 'pen'). The Nemolizumab DCC-AI contains a lyophilized drug powder (Nemolizumab 30 mg) and water for injection (WFI).

The Nemolizumab DCC-AI is a single-use (disposable), single-dose, auto-injector containing humanized monoclonal antibody - nemolizumab, and water for injection. Nemolizumab and its diluent (WFI) are stored in separate chambers of the dual-chamber cartridge and remain separated by a rubber stopper prior to mixing. Nemolizumab is stored in the front chamber (chamber 1) and WFI in the rear chamber (chamber 2). The DCC-AI has automated functions (transfer of diluent and priming: needle-based injection system [NIS] AUTO AI) built with pre-installed needle isolation technology (NIT).

The report describes several HFE activities undertaken between 2018 and 2022 by Chugai, conducted while developing the AI and its associated documentation (i.e., instructions for use [IFU] and associated package labels). The HFE work culminated in what Chugai/Galderma concluded to be a successful HF-validation (i.e., summative usability) test that was conducted from May-July 2022; a conclusion drawn from an intensive residual risk analysis of the safety-related test results.

<div style=\"page-break-after: always\"></div>

The purpose of the HF validation test was to validate that the DCC-AI and IFU are safe and effective for the intended users and uses, in the intended use environments. The HF validation test also served to identify any residual use errors that would or could result in harm, and to assess the effectiveness of risk management measures. The HF validation test was designed to expose use errors (i.e., mistakes) that could occur when the product is placed into actual use. The HF validation test was also designed to collect participants' subjective feedback regarding their interactions with the product. The participants in the usability test study were 110 individuals representing 7 distinct user groups. These groups represented both injection-experienced and injection-naive adults diagnosed with AD or PN (ages 18+), injection-experienced and injection-naive lay caregivers, injection-experienced and injection-naive adolescents diagnosed with AD (ages 12-17), as well as Healthcare Professionals (HCPs). This study population represents an adequate population of subject likely to be conducting nemolizumab s.c. injections if the product is approved. The steps performed are deemed adequate and include both evaluation of user tasks (performing the injections), as well as knowledge tasks (understanding the various steps of the IFU). The results on the performance of the different tasks were presented in the form of extensive tables not suitable for inclusion in the AR. The conclusion of the HFE report is that the risk management effort including residual risk discussion, verification/validation of effectiveness for control measures and use-related risks assessment for Nemolizumab DCC AI demonstrates that all identified risks are in the acceptable range. As can be expected, errors were encountered in various steps, however, in most instances by one or few subjects. As an example, for critical task 'Twist the gray cap', Emergo observed a total of 3 types of use errors, 2 types of close calls, and 1 type of assist with the potential for harm. As another example, for the knowledge task 'Interpret IFU storage instructions', Emergo observed a total of 6 types of use errors and 1 type of difficulty with the potential for harm. Most participants also provided their subjective assessment of the system and the instructions, after having completed all use scenarios and knowledge tasks. The moderator asked each participant whether they considered the product safe to use 'as is,' or whether it required modifications to ensure safe use. The majority of participants considered the product safe to use as is, however, some participants stated that the product required a modification to be considered safe to use; e.g. improve the AI's ergonomics, or add a clicking sound indicating the injection has completed. Many, but not all, participants considered that the IFU were clear. IFUs for products on the market with similar user interfaces. No additional risk control measure on

In the end of the report, a summary of residual risks was provided and carefully listed and discussed various risks and errors encountered. For most of these, it was concluded that 'The IFU steps and user interface are considered appropriate for the application, and in line with existing the user interface could reduce this risk which is mitigated as far possible.' In addition, for many risks/errors, it is stated that 'The HCP will instruct the users to prepare and inject the Nemolizumab AI at the first use.'

## Human Factors Engineering Report for the Nemolizumab Dual-Chamber Syringe (DCS) (RD.03.HFER.00001.R01)

The DCS is a pre-filled, single-use, single-dose dual-chamber syringe with needle safety shield that is intended to deliver medication subcutaneously. The DCS is accompanied by the needle in a blister and IFU within its packaging (i.e., a carton which holds a blister with the DCS and needle in a blister). Immediately prior to administration, users need to assemble the DCS with its needle and then push the plunger rod up to the plunger rod's first set of nubs to push fluid through the flow

<div style=\"page-break-after: always\"></div>

channel to reconstitute the liquid with the lyophilized powder. Then, users need to turn the plunger rod 90 degrees and push the plunger rod for priming. Just before injection, users turn the plunger rod 90 degrees again.

The HFER for the Nemolizumab Dual-Chamber Syringe device followed a similar structure as the report described above for the AI. Also, for this device, several HFE activities were conducted while developing the Nemolizumab prefilled, single-use, single-dose DCS and its associated documentation (i.e., instructions for use [IFU] and associated package labels).

The Human Factors (HF) validation comprised two studies in this case: one summative HF validation study (sHFS) and one supplemental HF validation study (Supplemental HFS).

To encourage users to read the IFU, highlighting that the DCS requires specific use steps compared to a standard pre-filled syringe, improvements were made to the labelling after the HF validation and results of a dedicated supplemental study showed their efficacy. As these are not expected to negatively impact the performance of critical tasks nor introduce additional risks, it was deemed that no further validation was needed and that the DCS and its associated materials are considered safe and effective for the intended users, uses, and use environments.

The intended users of the Nemolizumab Dual-Chamber Syringe are the same as those listed above for the AI. In the summative HF validation study (sHFS), 88 individuals representing 4 distinct user groups participated. The groups represented were similar to those included in the AI HF study. Also similar to the AI study, various use scenarios and knowledge tasks based on the IFU were assessed, and the results on the performance of different tasks were presented in the form of extensive tables not suitable for inclusion to this Assessment Report (AR).

For the syringe device, the injection needle needs to be attached. This critical task resulted in some problems (5 types of use errors, 3 types of close calls, and 1 difficulty with the potential for harm). Also other use errors, difficulties, close calls or need for assist were encountered for various steps, however, for most instances by a few subjects each.

Participants' subjective assessment was also provided and 73 out of 85 participants considered the product safe to use as is. 12 participants stated that the product required modification to be considered safe to use. 65 out of 85 participants considered the instructional resources clear and effective as is, while 20 participants stated that the instructional resources required some modifications to be considered clear and effective.

Following the summative HF validation study, Galderma decided to make some revisions of the instruction materials, i.e. the addition of a warning on the carton box, blister and IFU to emphasize the importance of reading and therefore ensure safe and effective use of the DCS. This had the aim to be additional risk mitigation to minimize use errors related mainly to users with injection experience, who assume that the DCS is a simple prefilled syringe, and who may consider they don't need to read the IFU. It was therefore decided to perform a supplemental HF study to assess the effectiveness of this mitigation on the user groups that did not look at the IFU during the sHFS and consequently failed important tasks, such as reconstitution. This additional step is noted and appreciated.

A total of 39 individuals, representing 3 distinct user groups, participated in this supplemental usability test. Also in the supplemental HF study, various kinds of use errors, difficulties, close calls or need for assist were encountered for various steps. Again, for steps like 'Attach the injection needle' and 'Dissolve medication' there were some use errors reported although overall in low numbers.

As for the subjective assessments in this supplemental HF study, the majority considered the product safe to use and that the instructions were clear, though some still did not.

<div style=\"page-break-after: always\"></div>

In the applicant's Residual Risk Analysis, they conclude that the results of the Supplemental HFS confirmed the results of the initial, summative HF study and showed improvement. They also discuss that HCPs will always perform the initial injections and should also instruct patients and/or caregivers how to perform injections themselves at home. This is acknowledged.

## 2.6.9.  Discussion on clinical efficacy - prurigo nodularis

## Design and conduct of clinical studies

## Phase 2 study

One phase 2a, randomised, placebo-controlled, double-blind, parallel-group, multicentre study to evaluate the safety and efficacy of nemolizumab in subjects suffering from PN was evaluated within this application. The study can be viewed as a proof-of-concept study to evaluate the potential for nemolizumab to have effect on pruritus in adult patients with PN.

Nemolizumab was more efficacious than placebo in reducing weekly average of the peak pruritus NRS scores at all timepoints (Weeks 1, 2, 4, 8, 12, 16, and 18, p&lt;0.001), supporting that nemolizumab has beneficial effects in patients with PN.

## Main studies

The efficacy results in the clinical studies of nemolizumab in the indication PN is derived from the 2 pivotal, phase 3 studies SPR.202685 (Olympia 1) and SPR.203065 (Olympia 2).

Study design: Both studies were designed as multinational, multi-centre, randomised, doubleblind, placebo-controlled studies to assess efficacy and safety of nemolizumab in adult participants with PN. The studies were identical except for study duration, where Olympia 1 had a 24-week duration and Olympia 2 had a 16-week duration of treatment with evaluation of the primary endpoint at week 16 in both studies. A duration of 24 weeks in one of the studies is agreed, since PN is a chronic condition which might require longer treatment duration to achieve efficacy. In the SmPC, no upper limitation of treatment duration is mentioned. Since PN is a chronic inflammatory condition in need of long-term treatment, it does not seem feasible to limit the duration of treatment, especially since a long-term study is ongoing and is expected to report data on longterm efficacy.

The study drug was administered Q4W, starting with 60 mg of nemolizumab or placebo given via 2 s.c. injections at baseline, followed by injections at week 4, 8 and 12 for both studies and last injection at week 16 for Olympia 1. Subjects weighing &lt;90 kg at baseline received 30 mg or placebo while subjects weighing ≥90 kg at baseline received 2 s.c. injections of either nemolizumab 30 mg or placebo. Dose modifications of the study drug were not permitted during the studies. The dose for AD is proposed to be a loading dose of 60 mg nemolizumab, followed by 30 mg Q4W for 16 weeks, thereafter 30 mg Q8W for patients who achieved clinical response. The proposed dosing in patients with PN was selected based on the results of the Phase 2a study in subjects with PN (SPR.115828) along with modelling and simulation tools. The proposed dosing is agreed to be adequate for the PN population and the choice to select placebo as comparator is considered acceptable.

Overall, the study design is relevant to evaluate the effect of nemolizumab in PN patients.

Patient population: Olympia 1 and Olympia 2 included subjects ≥18 years with a clinical diagnosis of PN since at least 6 months. Participants with a PP NRS score of ≥ 7 with a minimum of 20 PN lesions and IGA score ≥ 3 were eligible. The inclusion of patients with moderate to severe PN is relevant for evaluation of nemolizumab as a systemic treatment. Main inclusion criteria are

<div style=\"page-break-after: always\"></div>

acceptable, however only subjects with moderate to severe PN (IGA 3 or 4) and severe pruritus were allowed to be included in the studies, which was supported but not adequately reflected in the proposed indication wording. Therefore, a major objection was raised and the wording of the indication was subsequently amended in a way that clearly reflect target population, i.e. adult subjects with moderate to severe PN.

Key exclusion criteria included subjects with secondary PN due to other reasons and subjects with active AD the last 3 months. The study population is relevant and reflects the PN population with moderate to severe disease with similarity to previous studies on PN.

Subjects included could be treatment naïve or have received prior topical and/or systemic treatment for PN. No stratification or subgroup analysis was planned or performed based upon prior treatment. Concomitant treatment was not allowed unless it was used as rescue treatment. Subjects were allowed to continue their regular moisturizing treatment. It is not stated in the inclusion criteria whether other treatment, such as topical corticosteroids, should have been tried/failed before treatment with nemolizumab. This seem to not be in line with current treatment guidelines, where topical treatment is used as first-line treatment. Topical corticosteroids are not mentioned as an exclusion criterion, but the listing of 'Any other topical treatment other than moisturizer' as an exclusion criterion could be interpreted as use of topical corticosteroids was prohibited. During the treatment period, topical corticosteroids are registered as rescue treatment and nemolizumab was used as monotherapy.

Subjects had to stop using topical PN therapies during 2 weeks and systemic therapies and phototherapy during at least 4-8 weeks before randomisation. Dupilumab had to be stopped 10 weeks before randomisation. However, failure of prior therapies was not defined in the protocol, as there were no minimum requirements regarding adequate duration and dose of prior therapies. Therefore, it seems that the study protocol did not ensure that only subjects in need for systemic therapy are eligible. Additionally, 36.7% of subjects in Olympia 1 and 15.3% of subjects in Olympia 2 were completely treatment naive at randomisation which is somewhat surprising considering severity of PN required for inclusion. The applicant was asked to discuss whether nemolizumab is intended for use only in patients who are inadequately controlled on prior therapies and require systemic treatment. The majority of study subjects had experience of prior topical therapies, and the applicant agreed to add '...who are candidates for systemic therapy' to the indication.

The potential for corticosteroid (CS) sparing effect was not evaluated in the studies as subjects had to stop using topical CS for 2 weeks and systemic CS for 4 weeks before randomization. Considering this is not usual approach in clinical practice, i.e. it could be expected that some overlap between topical treatments/systemic corticosteroids and nemolizumab will occur. Tapering of corticosteroids and other concomitant therapies will be managed according to individual patient's needs and prescriber's clinical judgement. This is acceptable.

Endpoints: The primary objective of both pivotal studies was to assess the efficacy of nemolizumab compared to placebo in adults with PN after a 16-week treatment period, by the two primary endpoints:

- 1) The proportion of subjects with an improvement of ≥ 4 from baseline in PP NRS at Week 16
- 2) The proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥ 2-grade improvement from baseline) at Week 16.

The primary endpoints are considered adequate, but the second part of the second primary endpoint seem to be redundant, since all subjects had an IGA score of 3 or 4 at baseline, and thus could not reach 0 or 1 if the change was less than 2 points.

<div style=\"page-break-after: always\"></div>

Additional assessments on pruritus were included in the key secondary endpoints which analysed the proportion of subjects with PP NRS improvement ≥4 from baseline at week 4, PP NRS &lt;2 at week 4 and at week 16. The assessment on effect on pruritus at week 4 could be important since rapid onset of efficacy is valuable for patients with bothering symptoms, which was also assessed in other secondary endpoints.

Further key secondary endpoints were assessing impact on sleep by SD NRS improvement ≥4 from baseline at week 4 and at week 16. Patients with PN might have impaired sleep quality and the inclusion of SD NRS as key secondary endpoints is accepted, this evaluation could be seen as supportive for the primary results.

Other secondary endpoints included to further evaluate efficacy on sleep, pain frequency and intensity, patient-reported outcome assessments and quality of life assessment (Dermatology life quality index (DLQI) and Hospital anxiety and depression scale (HADS)) evaluations as well as weekly average PP NRS improvement from baseline at each visit through week 16. Efficacy was thus measured by a mixture of investigator- and patient-reported instruments, all considered as standard measurements by the applicant. In addition, clinical photographs were taken for consenting subjects.

## Human Factor studies

Two different presentations of nemolizumab are proposed for commercialising: a pre-filled pen (autoinjector, AI) and a pre-filled syringe (Dual-Chamber Syringe, DCS). Both are so-called dual chamber devices, i.e. they contain the active substance in a lyophilized powder and liquid for reconstitution, and the powder needs to be mixed with the liquid shortly before administration by SC injection. Human Factor studies have been performed for these respective devices, to address whether they can be safely used by the intended target populations. The two studies presented (report No. RD.03.HFE.00002.R00 for the DCC-AI and report No. RD.03.HFER.00001.R01 for the DCS) were performed as state-of-the-art HF studies and included relevant user groups.

## Efficacy data and additional analyses

## Main studies

In Olympia 1, 286/482 screened subjects were randomised and in Olympia 2, 274/424 screened subjects were randomised. In Olympia 1, 4 subjects (1 placebo and 3 nemolizumab) did not receive the allocated treatment. All randomised subjects were included in the ITT analyses as planned.

Rates of discontinuations of treatment and study were overall low (about 10% in Olympia 1 and about 4% in Olympia 2 study), with AEs being the most common reason in both studies. Lack of efficacy as reason for discontinuing treatment was rare.

Overall, subject demographics were well-balanced between treatment groups and across the studies with a population representative for the general PN population, with predominantly women and a mean age of 55.2 years, including 142 subjects older than 65 years (25.4%). The majority of subjects were white and from Europe or North America, which might affect generalisability for patients of other regions. Olympia 2 included, on average, younger subjects, more subjects from Asia Pacific, and subjects with lower baseline body weight. However, there were subjects included from a variety of regions and ethnicities included in the studies.

All study subjects had moderate (58.0%) to severe (42.0%) PN (IGA score 3-4) with a mean weakly PP NRS of 8.4580 at baseline. Mean time since PN diagnosis was 98.42 months. About a fourth (26.8%) of subjects had no prior treatment (topical or systemic) for their PN, which seem to

<div style=\"page-break-after: always\"></div>

be a high proportion given the severity of symptoms and possible effect on quality of life. Inclusion criteria allowed only subjects with moderate to severe PN (IGA 3 or 4) and severe pruritus to be included in the studies, which is adequately reflected in the wording of the indication.

Statistical considerations: The planned sample size in both Olympia 1 and Olympia 2, respectively, was 270 subjects. The sample size calculations in both studies were performed for both primary endpoints and were expected to have 90% power to reject both primary hypotheses with a two-sided significance level of 5%. The calculations appear to have been appropriate. There were no planned interim analyses for efficacy, and none were performed.

The SAPs of Olympia 1 and Olympia 2 were similar. There were no amendments to the SAP of Olympia 1 and the SAP was finalised prior to database lock. There was an addendum to the SAP of Olympia 2 that occurred after database lock and unblinding. The changes made have been accounted for and raise no concerns.

The ITT populations were the primary populations in all efficacy analyses, which is agreed. Primary and key secondary efficacy endpoint analyses during the treatment period were type I error controlled using a fixed sequential testing approach with a 5% alpha.

Analyses were performed as planned except it seems that subgroup analyses by history of athopy and prior treatments were not-preplanned although they have been presented in the dossier.

In primary and key secondary analyses missing values were treated as non-responders. Treatment discontinuation was handled by the treatment policy strategy (observed response). The composite strategy was used for the intercurrent event rescue therapy (treatment failure). Rescue therapy was more common in the placebo arms, compared to nemolizumab arms, but as tipping point analyses were performed as part of the planned sensitivity analyses in order to challenge the nonresponder imputation, the method of imputation is accepted.

The statistical analysis method used for the binary primary and key secondary efficacy endpoints was the Cochran-Mantel-Haenszel (CMH) test, adjusted by randomisation strata; the choice of method is supported. Primary and key secondary efficacy analyses were prespecified.

The statistical analysis methods used for other secondary endpoints involved the CMH test as well as MMRM and ANCOVA with MI under MAR assumption (MI-MAR). The continuous endpoints were not based on imputation assuming MNAR and were not coherent with the worst-case imputation performed on the binary endpoints. There were some unclarities regarding the planned analyses of some of the other secondary efficacy endpoints, and the text on the handling of the intercurrent event rescue therapy for other secondary endpoints was inconsistent. Of note is that these unclarities does not concern the type I error controlled co-primary and key secondary endpoint analyses. The performed subgroup analyses were adequate.

Results: Nemolizumab was clinically and statistically significantly more effective than placebo in PP NRS improvement and IGA success after 16 weeks of treatment; both primary efficacy endpoints were met. In nemolizumab treated subjects, 58.4% and 56.3% had ≥4 PP NRS improvement compared to 16.7% and 20.9% in the placebo group in Olympia 1 and Olympia 2, respectively. For the second endpoint IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥ 2grade improvement from baseline) 26.3% and 37.7% of nemolizumab treated subjects and 7.3% and 11.0% of placebo treated subjects achieved IGA success at week 16. Treatment compliance was overall high and consistent between treatment groups. The improvements in PP NRS and reductions of IGA seen in the primary analyses are assessed as clinically relevant. Use of rescue therapy was generally low during the studies, and more often in placebo group which indirectly also supports nemolizumab efficacy in the treatment of PN.

<div style=\"page-break-after: always\"></div>

The magnitude of treatment response was consistent between pivotal studies for PP NRS endpoint (56-58% in nemolizumab groups and 16-20% in placebo groups, with almost complete overlap in CIs), but much less consistent for IGA endpoint. In Olympia 2, strata-adjusted difference for IGA 0/1 between nemolizumab and placebo was double than observed in Olympia 1 (28.5% vs 14.6%, with marginal overap in CIs: 6.7-22.6 in Olympia 1 and 18.8-38.2 in Olympia 2). Although reasons for observed better efficacy in Olympia 2 are not obvious, considering both studies clearly demonstrated nemolizumab superiority over placebo, this issue was not pursued further.

The results were consistent in the subgroups defined by region, age group, sex, race, body weight at randomization and baseline IGA score. Number of patients in subgroups according to race other than White was too small for meaningful interpretations. No major deviations from overall efficacy results is observed in subgroups according to prior exposure to PN therapies (yes/no). All sensitivity and supportive analyses were supporting of nemolizumab efficacy.

The clinically and statistically significant improvements observed in the nemolizumab group for the primary endpoints were also observed for all key secondary endpoints. Other secondary endpoints included percent change of PP NRS from baseline to week 16, change in SD NRS and change in quality of life.

Efficacy of nemolizumab was persisting until week 24 in study Olympia 1 for the primary endpoint, key secondary endpoints and secondary endpoints. Overall results after 24 weeks of treatment in Olympia 1 indicate maintenance of effect with 43 subjectes (22.6%) achieving both NRS ≤4 and IGA success at week 16 and week 24. No further improvement on pruritus was seen after 16 weeks of treatment compared to the placebo group. However, among subjects without IGA success at week 16, 15.% acieved IGA success at week 24. After 16 weeks of treatment, 50 subjects (26.3%) achieved IGA success, which increased to 58 subjects (30.5%) at week 24. Based on these results, the applicant proposed that discontinuation of treatment should be considered after 24 weeks in non-responders. It was  agreed that skin lesions may need longer time to heal, but the wording by the applicant was not fully agreed. After discussion, the current proposal is to consider discontinuation in patients with no pruritus response after 16 weeks of treatment.

Evaluation of persistence of efficacy is lacking beyond 24 weeks. There is one ongoing study (SPR.202699) with a planned exposure time up to 184 weeks.  Final study data is estimated to be available early 2027.

Lack of information in children is accepted since a PIP waiver was adopted. Prurigo nodularis is a rare condition in children and it would be demanding to reach power in clinical studies.

Nemolizumab has been shown to be an efficacious treatment for patients with moderate to severe PN in the two pivotal studies, where both the primary endpoints and all key secondary and other secondary endpoints showed superiority over placebo.

## Supportive study

The ongoing long-term study SPR.202699 is evaluating long-term efficacy and safety of nemolizumab in treatment of PN. The preliminary results, including 262 subjects who received ≥365 days of treatment, shows increasing numbers of subjects with IGA success from 29.3% at baseline to 68.1% at week 52, as well as increasing numbers of PP NRS improvement from base line, supporting clinical efficacy. Since the long-term study is ongoing, there is not yet an upper limitation on treatment duration proposed in the SmPC.

## Durability study 203890 - Persistence of efficacy

During scientific advice (EMA/CHMP/SAWP/265227/2020) the CHMP emphasized importance of demonstration of maintenance of effect in a randomised withdrawal study in which responders

<div style=\"page-break-after: always\"></div>

would be re-randomised to continue nemolizumab or to placebo and followed for a sufficient duration to allow assessing the time to relapse. The applicant did not fully comply with the advice but is conducting two studies to show maintenance of effects (abovementioned LTE Study 202699) and to assess relapse upon withdrawal (durability Study 203890), which is considered acceptable, although it is not the usual approach. Data from SPRR.202699 is expected in 2027 and final study report of SPR.203890 was submitted within this application. Human Factor studies Both the AI and the pre-filled syringe are dual-chamber injection devices, which require some additional steps before use compared with injection devices for other products in which the active substance is presented in the form of a solution. Hence, this may require some additional attention from HCPs, patients and/or caregivers. Indeed, there were some errors reported for instance in the step 'Shake to dissolve the medicine' and also 'Check the medicine in the inspection window' (to notice undissolved particles) for the AI. Some participants were familiar with the EpiPen AI, which does not require shaking, etc. However, as pointed out, an HCP will instruct users how to handle and use the AI at the first use. Also, a warning has been added on the carton box, carton partition, and the IFU which states to 'CAREFULLY read and follow Instructions for Use. This pen requires specific steps before injection'. This is acknowledged. For the dual-chamber syringe, an initial summative HF study was conducted, followed by a supplemental, smaller study, after some revisions to the IFU/carton box were made. Some improvements were seen, and it was concluded by the applicant that risks have been reduced to the furthest extent possible. There are other dual-chamber injection devices available on the market for other injectable products. Examples were provided in the AI HFER, e.g. Bydureon Autoinjector and dual chamber pen for use in type II diabetes mellitus, Emgality, a pre-filled pen for use in migraine, and Skytrofa (single dose dual chamber cartridges for use with SKYTROFA Auto-Injector only) used in growth hormone deficiency. Thus, there are other products available for use in various conditions, in which preparation and mixings steps are necessary before injection. In the clinical trials performed in AD and PN patients, only the dual chamber syringe (DCS) has been used, but not the DCC Autoinjector (AI). In all pivotal studies (both AD and PN), all study drug injections occurred at the study site. For subjects willing and able to self-inject or to have their caregiver inject study drug, the study site staff provided training on study drug injections. Subjects or caregivers were then to be allowed to inject medication on subsequent visits under supervision by study site clinic staff. However, DCS preparation, including reconstitution, was performed by the pharmacist or other qualified personnel, and delivered for injection after reconstitution was complete. Hence, patients and caregivers have been given the opportunity to inject study drug themselves, but not at home and not with a need to perform the steps of reconstituting the solution for injection. All in all, it is concluded that state-of-the-art Human factor studies have been conducted for both nemolizumab presentations, dual-chamber syringe and dual chamber AI. Some errors and difficulties have been encountered in these studies, in some cases in steps relating to mixing and reconstituting the solution. It should be kept in mind that these devices require additional steps compared with more easy to use pre-filled syringes and AI:s, containing solutions that are ready to inject. Other products in other indications do however have similar types of devices (with a need for a mixing step), hence, this would not be the first product of this kind to be approved. While patients and caregivers could inject study drug themselves in the pivotal nemolizumab studies, they were not allowed to perform all steps of preparation themselves. It was however not clear

<div style=\"page-break-after: always\"></div>

how many patients/caregivers actually did inject study drug themselves at the clinical site and how this was perceived.

The SmPC section 4.2 states:

'Nemluvio is intended for use under the guidance of a healthcare professional. A patient may selfinject Nemluvio or the patient's caregiver may administer Nemluvio if their healthcare professional determines that this is appropriate. Prior to first injection, patients and/or caregivers should be given proper instructions for preparation and administration of Nemluvio according to the instructions for use at the end of the package leaflet.'

Thus, under the conditions described in the SmPC, it is considered reasonable to allow patients or care-givers to self-inject nemolizumab, at the discretion of the healthcare professional. The lack of 'real-life experience' on performing self-injections at home is noted, since patients or caregivers were not allowed to perform injections at home during the pivotal AD or PN clinical studies. However, this is not considered to preclude the possibility to allow self-injections, provided the prescriber considers this appropriate for the individual patient.

## 2.6.10.  Conclusions on clinical efficacy - prurigo nodularis

The efficacy results from the two pivotal phase 3 studies (SPR.202685/Olympia 1 and SPR.203065/Olympia 2) demonstrated that nemolizumab Q4W provided statistically significant reductions in the severity of pruritus and the number of PN lesions (as measured by PP-NRS and IGA scores) after 16 weeks in adult patients with moderate to severe PN compared to placebo.

An obvious limitation in treatment of this chronic condition is the lack of long-term efficacy data; both pivotal studies only included a 16 to 24-week treatment period. At Week 16, the treatment effect was significant for the primary and secondary endpoints in both studies and the effect was maintained at week 24 in Olympia 1. Further data on the maintenance of long-term efficacy beyond Week 24 are currently missing but is expected to be reported from the ongoing long term study for which the final study report is expected on Q3 2027.

Overall, the improvements seen at Week 16 are considered clinically meaningful from an efficacy point-of-view.

## 2.6.11.  Clinical safety

## 2.6.11.1.  Atopic dermatitis

The analysis of clinical safety and tolerability of nemolizumab in patients with atopic dermatitis (AD) are based on data derived from 3 clinical studies. The primary safety population was defined as all randomized or enrolled subjects who received at least 1 dose of study drug in the 2 pivotal Phase 3 studies (SPR.118161 and SPR.118169) and in the Phase 2 Study SPR.114322. These 3 studies were pooled because they were similar in study design, dose, dose regimen and population. Assessment of safety is primarily focusing on the 30 mg Q4W dose of nemolizumab proposed for marketing.

<div style=\"page-break-after: always\"></div>

Table 44: Primary safety population

| Population Description    | Study                                                                                 |
|---------------------------|---------------------------------------------------------------------------------------|
| Primary safety population | SPR.118161 (Initial + Maintenance Periods) SPR.118169 (Initial + Maintenance Periods) |
| Primary safety population | SPR.114322                                                                            |

Table 45: Treatment grouping for the primary safety population

| Treatment Designation in SCS   | Treatment Designation in CSR   | Study Identifier   |
|--------------------------------|--------------------------------|--------------------|
| Nemolizumab 10 mg Q4W          | Nemolizumab 10 mg Q4W          | SPR.114322         |
| Nemolizumab 30 mg Q4W          | Nemolizumab 30 mg Q4W          | SPR.118161         |
| Nemolizumab 30 mg Q4W          | Nemolizumab 30 mg Q4W          | SPR.118169         |
| Nemolizumab 30 mg Q4W          | Nemolizumab 30 mg Q4W          | SPR.114322         |
| Nemolizumab 30 mg Q8W          | Nemolizumab 30 mg Q8W          | SPR.118161         |
| Nemolizumab 30 mg Q8W          | Nemolizumab 30 mg Q8W          | SPR.118169         |
| Nemolizumab 90 mg Q4W          | Nemolizumab 90 mg Q4W          | SPR.114322         |
| Placebo                        | Placebo                        | SPR.118161         |
| Placebo                        | Placebo                        | SPR.118169         |
| Placebo                        | Placebo                        | SPR.114322         |

Initial period is up to week 16 or week 24. In the pivotal Studies SPR.118161 and SPR.118169 patients received study drug at baseline and Weeks 4, 8, and 12. Data from Study SPR.114322 were summarised with the Initial Period data from Studies SPR.118161 and SPR.118169. Subjects in Study SPR.114322 received study drug at baseline and Weeks 4, 8, 12, 16, and 20. Maintenance period is week 16 to week 48. For the Maintenance Period, only subjects who received at least 1 dose of study drug in the Maintenance Period of Studies SPR.118161 or SPR.118169 were included in the population.

## Additional studies with safety data

1. 5 supportive studies: 3 AD studies (Phase 2 studies CIM003JG and SPR.116912 and 1 ongoing, Phase 3 Long-term extension (LTE) study SIR.118163) and 2 Phase 1 studies, 1 in healthy volunteers (SPR.201590) and 1 in healthy volunteers and AD subjects (CIM001JP).

The ongoing LTE study (SPR.118163) is a Phase 3, multicentre, open-label, single-arm, LTE study designed to evaluate the long-term safety and efficacy of nemolizumab in adolescent and adult subjects with moderate to severe AD. Safety assessments included TEAEs, clinical laboratory tests, vital signs, ECGs, physical examinations, and respiratory assessments.

2. 9 studies that are ongoing or that evaluated other indications: 4 ongoing AD studies (Phase 2 studies SPR.118380, SPR.201593, and SPR.118126 and Phase 3 study SPR.201591) and 5 studies in other indications, including Phase 2 studies CIM106JP (CKDaP) and SPR.115828 (PN), 2 Phase 3 PN studies (SPR.202685 and SPR.203065) and 1 ongoing, Phase 3 LTE PN study (SIR.202699)

SPR.118380 is a vaccine study in a total of 220 subjects. SPR.118126 is a pediatric study in 36 subjects.

## 2.6.11.1.1.  Patient exposure

## Total AD exposure pool

The total AD exposure pool population was used for the summary of subject disposition and exposure data only. The AD exposure pool population pooled exposure data from SPR.118163 (LTE

<div style=\"page-break-after: always\"></div>

study) and its feeder studies: SPR.118161, SPR.118169, SPR.114322, SPR.116912, and SPR.201593. Exposure data for subjects from SPR.118163 were combined with the exposure data from the respective feeder studies to give an overall exposure.

Pooled exposure data were presented for nemolizumab 10 mg (SPR.114322), nemolizumab 30 mg (SPR.118163, SPR.118161, SPR.118169, SPR.114322, SPR.116912, and SPR.201593), nemolizumab 90 mg (SPR.114322), and all nemolizumab (SPR.118163, SPR.118161, SPR.118169, SPR.114322, SPR.116912, and SPR.201593) . Extent of exposure for the AD exposure pool population is presented below.

Table 46: Extent of exposure (AD exposure pool population)

|                                                         | Nemolizumab 10 mg N=55   | Nemolizumab 30 mg N=2007   | Nemolizumab 90 mg N=57   | All nemolizumab N=2111   |
|---------------------------------------------------------|--------------------------|----------------------------|--------------------------|--------------------------|
| Treatment duration (days)                               |                          |                            |                          |                          |
| Mean (SD)                                               | 153.8 (37.98)            | 405.2 (240.44)             | 152.7 (37.93)            | 393.4 (241.57)           |
| Median                                                  | 171.0                    | 424.0                      | 171.0                    | 402.0                    |
| Q1, Q3                                                  | 168.0, 174.0             | 176.0, 591.0               | 165.0, 172.0             | 171.0, 588.0             |
| Minimum, maximum                                        | 59, 178                  | 31, 1074                   | 31, 181                  | 31, 1074                 |
| Treatment duration (years)                              |                          |                            |                          |                          |
| Mean (SD)                                               | 0.42 (0.104)             | 1.11 (0.658)               | 0.42 (0.104)             | 1.08 (0.661)             |
| Median                                                  | 0.47                     | 1.16                       | 0.47                     | 1.10                     |
| Q1, Q3                                                  | 0.46, 0.48               | 0.48, 1.62                 | 0.45, 0.47               | 0.47, 1.61               |
| Minimum, maximum                                        | 0.2, 0.5                 | 0.1, 2.9                   | 0.1, 0.5                 | 0.1, 2.9                 |
| Number of treatments per subject                        |                          |                            |                          |                          |
| Mean (SD)                                               | 5.3 (1.33)               | 13.8 (8.31)                | 5.3 (1.34)               | 13.4 (8.34)              |
| Median                                                  | 6.0                      | 15.0                       | 6.0                      | 14.0                     |
| Q1, Q3                                                  | 5.0, 6.0                 | 6.0, 20.0                  | 5.0, 6.0                 | 6.0, 20.0                |
| Minimum, maximum                                        | 2, 6                     | 1, 38                      | 1, 6                     | 1, 38                    |
| Number of treatments per subject, n (%)                 |                          |                            |                          |                          |
| 1-5                                                     | 14 (25.5)                | 444 (22.1)                 | 15 (26.3)                | 472 (22.4)               |
| 6-10                                                    | 41 (74.5)                | 304 (15.1)                 | 42 (73.7)                | 380 (18.0)               |
| 11-15                                                   | 0                        | 351 (17.5)                 | 0                        | 351 (16.6)               |
| 16-20                                                   | 0                        | 438 (21.8)                 | 0                        | 436 (20.7)               |
| 21-25                                                   | 0                        | 318 (15.8)                 | 0                        | 315 (14.9)               |
| 26-30                                                   | 0                        | 115 (5.7)                  | 0                        | 120 (5.7)                |
| 31-35                                                   | 0                        | 32 (1.6)                   | 0                        | 31 (1.5)                 |
| 36-40                                                   | 0                        | 5 (0.2)                    | 0                        | 6 (0.3)                  |
| Subjects with ≥6 months exposure to nemolizumab, n (%)  | 0                        | 1497 (74.6)                | 0                        | 1498 (71.0)              |
| Subjects with ≥1 year exposure to nemolizumab, n (%)    | 0                        | 1148 (57.2)                | 0                        | 1148 (54.4)              |
| Subjects with ≥1.5 years exposure to nemolizumab, n (%) | 0                        | 645 (32.1)                 | 0                        | 646 (30.6)               |
| Subjects with ≥2 years exposure to nemolizumab, n (%)   | 0                        | 171 (8.5)                  | 0                        | 176 (8.3)                |

AD=atopic dermatitis; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects with available data; Q1=first quartile; Q3=third quartile

Note: Exposure data from the long-term extension study (SPR.118163) were pooled with the exposure data from the relevant feeder studies, to give a total overall exposure for each subject. Total exposure to a given dose of nemolizumab was presented under the corresponding column. Feeder studies were SRE.118161, SRE.118169, SRE.114322, SRE.116912, and SPR.201593.

<div style=\"page-break-after: always\"></div>

Table 47: Duration of exposure with nemolizumab 30 mg by age group (AD exposure pool population)

|                                                         | Age group (years)   | Age group (years)   | Age group (years)   |
|---------------------------------------------------------|---------------------|---------------------|---------------------|
|                                                         | 12 to 17 (N=307)    | 18 to 65 (N=1605)   | >65 (N=95)          |
| Subjects with ≥6 months exposure to nemolizumab, n (%)  | 258 (84.0)          | 1171 (73.0)         | 68 (71.6)           |
| Subjects with ≥1 year exposure to nemolizumab, n (%)    | 180 (58.6)          | 923 (57.5)          | 45 (47.4)           |
| Subjects with ≥1.5 years exposure to nemolizumab, n (%) | 61 (19.9)           | 557 (34.7)          | 27 (28.4)           |
| Subjects with ≥2 years exposure to nemolizumab, n (%)   | 20 (6.5)            | 143 (8.9)           | 8 (8.4)             |

AD=atopic dermatitis; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects with available data

Note: Exposure data from the long-term extension study (SPR.118163) were pooled with the exposure data from the relevant feeder studies, to give a total overall exposure for each subject. Total exposure to a given dose of nemolizumab was presented under the corresponding column. Feeder studies were SRE.118161, SRE.118169, SRE.114322, SRE.116912, and SPR.201593.

In the studies submitted as part of the marketing authorisation application a total of 2111 patients/healthy volunteers were exposed to at least 1 dose of nemolizumab. The number of adolescents of the total AD exposure pool is substantially lower compared to adults. However, the extent of exposure is considered acceptable. The adolescents will be further discussed in relation to the primary safety analyses and the inclusion of this population in the pivotal studies.

## Primary Safety Population

Initial period (up to week 16 or week 24)

A total of 1192 subjects, 1304 subjects, and 640 subjects were treated in the nemolizumab 30 mg Q4W, all nemolizumab, and placebo groups, respectively, with 1081 (90.7%), 1168 (89.6%), and 579 (90.5%) subjects, respectively, completing the Initial Period treatment. The primary safety population included all 176 adolescents 12-17 years of age who received nemolizumab 30 mg Q4W in the Initial Period.

Exposure of primary safety pool with the initial period and maintenance period presented in separate Table 48 and Table 49 below.

Table 48: Extent of exposure - initial period (primary safety population)

|                                  | Nemolizumab 30 mg Q4W N=1192   | All nemolizumab N=1304   | Placebo N=640   |
|----------------------------------|--------------------------------|--------------------------|-----------------|
| Treatment duration (days)        |                                |                          |                 |
| Mean (SD)                        | 112.5 (22.35)                  | 116.0 (26.62)            | 114.1 (23.48)   |
| Median                           | 115.0                          | 115.0                    | 115.0           |
| Q1, Q3                           | 114.0, 116.0                   | 114.0, 117.0             | 114.0, 116.0    |
| Minimum, maximum                 | 31, 191                        | 31, 191                  | 31, 179         |
| Treatment duration (years)       |                                |                          |                 |
| Mean (SD)                        | 0.308 (0.0612)                 | 0.318 (0.0729)           | 0.312 (0.0643)  |
| Median                           | 0.315                          | 0.315                    | 0.315           |
| Q1, Q3                           | 0.312, 0.318                   | 0.312, 0.320             | 0.312, 0.318    |
| Minimum, maximum                 | 0.08, 0.52                     | 0.08, 0.52               | 0.08, 0.49      |
| Number of treatments per subject |                                |                          |                 |
| Mean (SD)                        | 3.9 (0.79)                     | 4.0 (0.94)               | 3.9 (0.84)      |
| Median                           | 4.0                            | 4.0                      | 4.0             |
| Q1, Q3                           | 4.0, 4.0                       | 4.0, 4.0                 | 4.0, 4.0        |
| Minimum, maximum                 | 1, 6                           | 1, 6                     | 1, 6            |

<div style=\"page-break-after: always\"></div>

|                                         | Nemolizumab 30 mg Q4W N=1192   | All nemolizumab N=1304   | Placebo N=640   |
|-----------------------------------------|--------------------------------|--------------------------|-----------------|
| Number of treatments per subject, n (%) |                                |                          |                 |
| 1                                       | 36 (3.0)                       | 37 (2.8)                 | 16 (2.5)        |
| 2                                       | 46 (3.9)                       | 54 (4.1)                 | 26 (4.1)        |
| 3                                       | 53 (4.4)                       | 60 (4.6)                 | 35 (5.5)        |
| 4                                       | 1005 (84.3)                    | 1012 (77.6)              | 519 (81.1)      |
| 5                                       | 3 (0.3)                        | 9 (0.7)                  | 2 (0.3)         |
| 6                                       | 49 (4.1)                       | 132 (10.1)               | 42 (6.6)        |

ISS=Integrated Summary of Safety; N=number of subjects in the population; Q1=first quartile; Q3=third quartile; Q4W=every 4 weeks

## Table 49: Extent of exposure - maintenance period (primary safety population)

|                                         | Nemolizumab 30 mg Q4W to Q4W N=170 n (%)   | Nemolizumab 30 mg Q4W to Q8W N=167 n (%)   | Nemolizumab 30 mg Q4W to placebo N=168 n (%)   | Re-assigned to placebo a N1=184 n (%)   |
|-----------------------------------------|--------------------------------------------|--------------------------------------------|------------------------------------------------|-----------------------------------------|
| Treatment duration (days)               |                                            |                                            |                                                |                                         |
| Mean (SD)                               | 211.0 (41.90)                              | 211.4 (40.60)                              | 204.0 (45.28)                                  | 208.2 (45.04)                           |
| Median                                  | 226.0                                      | 227.0                                      | 226.0                                          | 226.5                                   |
| Q1, Q3                                  | 220.0, 229.0                               | 220.0, 227.0                               | 212.5, 227.5                                   | 220.0, 228.0                            |
| Minimum, maximum                        | 31, 252                                    | 31, 244                                    | 31, 248                                        | 31, 250                                 |
| Treatment duration (years)              |                                            |                                            |                                                |                                         |
| Mean (SD)                               | 0.578 (0.1147)                             | 0.579 (0.1111)                             | 0.558 (0.1240)                                 | 0.570 (0.1233)                          |
| Median                                  | 0.619                                      | 0.621                                      | 0.619                                          | 0.620                                   |
| Q1, Q3                                  | 0.602, 0.627                               | 0.602, 0.621                               | 0.582, 0.623                                   | 0.602, 0.624                            |
| Minimum, maximum                        | 0.08, 0.69                                 | 0.08, 0.67                                 | 0.08, 0.68                                     | 0.08, 0.68                              |
| Number of treatments per subject        |                                            |                                            |                                                |                                         |
| Mean (SD)                               | 7.3 (1.51)                                 | 7.4 (1.46)                                 | 7.1 (1.62)                                     | 7.2 (1.64)                              |
| Median                                  | 8.0                                        | 8.0                                        | 8.0                                            | 8.0                                     |
| Q1, Q3                                  | 8.0, 8.0                                   | 8.0, 8.0                                   | 7.0, 8.0                                       | 7.5, 8.0                                |
| Minimum, maximum                        | 1, 8                                       | 1, 8                                       | 1, 8                                           | 1, 8                                    |
| Number of treatments per subject, n (%) |                                            |                                            |                                                |                                         |
| 1                                       | 2 (1.2)                                    | 2 (1.2)                                    | 1 (0.6)                                        | 3 (1.6)                                 |
| 2                                       | 4 (2.4)                                    | 1 (0.6)                                    | 1 (0.6)                                        | 4 (2.2)                                 |
| 3                                       | 1 (0.6)                                    | 2 (1.2)                                    | 5 (3.0)                                        | 1 (0.5)                                 |
| 4                                       | 8 (4.7)                                    | 11 (6.6)                                   | 14 (8.3)                                       | 13 (7.1)                                |
| 5                                       | 3 (1.8)                                    | 4 (2.4)                                    | 13 (7.7)                                       | 5 (2.7)                                 |
| 6                                       | 5 (2.9)                                    | 3 (1.8)                                    | 5 (3.0)                                        | 3 (1.6)                                 |
| 7                                       | 18 (10.6)                                  | 13 (7.8)                                   | 13 (7.7)                                       | 17 (9.2)                                |
| 8                                       | 129 (75.9)                                 | 131 (78.4)                                 | 116 (69.0)                                     | 138 (75.0)                              |

ISS=Integrated  Summary  of  Safety;  N=number  of  subjects  in  the  population;  N1=number  of  subjects  who responded to placebo and continued to receive placebo in the Maintenance Period; Q1=first quartile; Q3=third quartile; Q4W=every 4 weeks; Q8W=every 8 weeks e) Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period. Patient disposition of pivotal studies

<div style=\"page-break-after: always\"></div>

Table 50: Subject disposition in studies SPR.118161 and SPR.118169 - initial treatment period (ITT population) (modified)

| Number of subjects                                          | SPR.118161     | SPR.118161   | SPR.118161   | SPR.118169     | SPR.118169   | SPR.118169   | Overall total   |
|-------------------------------------------------------------|----------------|--------------|--------------|----------------|--------------|--------------|-----------------|
| Number of subjects                                          | Nemo 30 mg Q4W | Placebo      | Total        | Nemo 30 mg Q4W | Placebo      | Total        | Overall total   |
| Number of subjects                                          | N=620          | N=321        | N=941        | N=522          | N=265        | N=787        | N=1728          |
| Number of subjects                                          | n (%)          | n (%)        | n (%)        | n (%)          | n (%)        | n (%)        | n (%)           |
| Randomized                                                  | 620 (100)      | 321 (100)    | 941 (100)    | 522 (100)      | 265 (100)    | 787 (100)    | 1728 (100)      |
| Randomized but not treated                                  | 4 (0.6)        | 0            | 4 (0.4)      | 3 (0.6)        | 2 (0.8)      | 5 (0.6)      | 9 (0.5)         |
| Treated                                                     | 616 (99.4)     | 321 (100)    | 937 (99.6)   | 519 (99.4)     | 263 (99.2)   | 782 (99.4)   | 1719 (99.5)     |
| Completed treatment                                         | 560 (90.3)     | 296 (92.2)   | 856 (91.0)   | 470 (90.0)     | 241 (90.9)   | 711 (90.3)   | 1567 (90.7)     |
| Discontinued treatment                                      | 56 (9.0)       | 25 (7.8)     | 81 (8.6)     | 49 (9.4)       | 22 (8.3)     | 71 (9.0)     | 152 (8.8)       |
| Primary reason for discontinuation of treatment             |                |              |              |                |              |              |                 |
| Pregnancy                                                   | 2 (0.3)        | 0            | 2 (0.2)      | 0              | 0            | 0            | 2 (0.1)         |
| Lack of efficacy                                            | 5 (0.8)        | 2 (0.6)      | 7 (0.7)      | 3 (0.6)        | 0            | 3 (0.4)      | 10 (0.6)        |
| Adverse event                                               | 9 (1.5)        | 9 (2.8)      | 18 (1.9)     | 17 (3.3)       | 4 (1.5)      | 21 (2.7)     | 39 (2.3)        |
| Subject's request                                           | 25 (4.0)       | 11 (3.4)     | 36 (3.8)     | 24 (4.6)       | 15 (5.7)     | 39 (5.0)     | 75 (4.3)        |
| COVID-19                                                    | 0              | 0            | 0            | 0              | 0            | 0            | 0               |
| Lost to follow-up                                           | 10 (1.6)       | 0            | 10 (1.1)     | 1 (0.2)        | 1 (0.4)      | 2 (0.3)      | 12 (0.7)        |
| Protocol deviation                                          | 4 (0.6)        | 3 (0.9)      | 7 (0.7)      | 3 (0.6)        | 2 (0.8)      | 5 (0.6)      | 12 (0.7)        |
| Physician/principal investigator decision                   | 1 (0.2)        | 0            | 1 (0.1)      | 1 (0.2)        | 0            | 1 (0.1)      | 2 (0.1)         |
| Other                                                       | 0              | 0            | 0            | 0              | 0            | 0            | 0               |
| Completed/exited the study after initial treatment period   | 289 (46.6)     | 199 (62.0)   | 488 (51.9)   | 234 (44.8)     | 156 (58.9)   | 390 (49.6)   | 878 (50.8)      |
| Discontinued from the study during initial treatment period | 59 (9.5)       | 22 (6.9)     | 81 (8.6)     | 53 (10.2)      | 24 (9.1)     | 77 (9.8)     | 158 (9.1)       |
| Primary reason for discontinuation from the study           |                |              |              |                |              |              |                 |
| Pregnancy                                                   | 2 (0.3)        | 0            | 2 (0.2)      | 0              | 0            | 0            | 2 (0.1)         |
| Lack of efficacy                                            | 4 (0.6)        | 2 (0.6)      | 6 (0.6)      | 3 (0.6)        | 0            | 3 (0.4)      | 9 (0.5)         |
| Adverse event                                               | 8 (1.3)        | 5 (1.6)      | 13 (1.4)     | 18 (3.4)       | 4 (1.5)      | 22 (2.8)     | 35 (2.0)        |
| Subject's request                                           | 25 (4.0)       | 12 (3.7)     | 37 (3.9)     | 25 (4.8)       | 15 (5.7)     | 40 (5.1)     | 77 (4.5)        |
| COVID-19                                                    | 0              | 1 (0.3)      | 1 (0.1)      | 0              | 2 (0.8)      | 2 (0.3)      | 3 (0.2)         |
| Lost to follow-up                                           | 10 (1.6)       | 0            | 10 (1.1)     | 1 (0.2)        | 1 (0.4)      | 2 (0.3)      | 12 (0.7)        |
| Protocol deviation                                          | 8 (1.3)        | 3 (0.9)      | 11 (1.2)     | 4 (0.8)        | 3 (1.1)      | 7 (0.9)      | 18 (1.0)        |
| Other                                                       | 2 (0.3)        | 0            | 2 (0.2)      | 2 (0.4)        | 1 (0.4)      | 3 (0.4)      | 5 (0.3)         |
| COVID-19                                                    | 0              | 0            | 0            | 0              | 0            | 0            | 0               |
| Rolled over to long-term extension after initial            | 282 (45.5)     | 192 (59.8)   | 474 (50.4)   | 230 (44.1)     | 152 (57.4)   | 382 (48.5)   | 856 (49.5)      |
| Completed follow-up after                                   | 21 (3.4)       | 16 (5.0)     | 37 (3.9)     | 16 (3.1)       | 7 (2.6)      | 23 (2.9)     | 60 (3.5)        |
| initial treatment period                                    |                |              |              |                |              |              |                 |

ISE=Integrated Summary of Effectiveness; ITT=intent-to-treat; N=number of subjects in the ITT population of each treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q4W=every 4 weeks

Note: Percentages were based on the number of subjects in the ITT population of each treatment group. One subject (Study SRE.118161) was randomized to nemolizumab after early termination and received mixed dose of nemolizumab and placebo at baseline. For analysis, the actual treatment group was the same as the planned treatment group (nemolizumab).

<div style=\"page-break-after: always\"></div>

In adolescents 167 patients out of 176 included patients seem to have completed the initial study period and for patients aged 18-65, 846 out of included 944 patients completed the initial period. For patients &gt;65, it seems that 68 completed of 72 included patient, a somewhat limited amount. Please refer to the section on RMP and the discussion of the safety specification. A total of 578 patients appears to have completed the maintenance period for up to 48 weeks.

From the summary of subject dispositions (eg discontinuation from study and primary reasons etc) of the pivotal studies included in the primary safety analyses, discontinuation rates during the initial phase were similar in active treatment arms between studies and there was no marked difference compared to the placebo arms. The most common reasons for discontinuation during the initial phase were at subject's request and in the maintenance phase due to lack of efficacy and at subject's request. The reason for discontinuation of treatment due to AEs were almost similar between the initial and maintenance phase, 2.4 and 2.8 % respectively.

<div style=\"page-break-after: always\"></div>

Table 51: Subject disposition in studies SPR.118161 and SPR.118169 - maintenance period (ITT population) (modified)

|                                                           | Nemo 30 mg Q4W to Q4W   | Nemo 30 mg Q4W to Q8W   | Nemo 30 mg Q4W to Placebo   | Total a    |
|-----------------------------------------------------------|-------------------------|-------------------------|-----------------------------|------------|
|                                                           | N=169                   | N=169                   | N=169                       | N=507      |
|                                                           | n (%)                   | n (%)                   | n (%)                       | n (%)      |
| Re-randomized                                             | 169 (100)               | 169 (100)               | 169 (100)                   | 507 (100)  |
| Re-randomized but not treated                             | 1 (0.6) b               | 0                       | 1 (0.6) b                   | 2 (0.4)    |
| Treated                                                   | 168 (99.4)              | 169 (100)               | 168 (99.4)                  | 505 (99.6) |
| Completed maintenance period treatment                    | 141 (83.4)              | 147 (87.0)              | 134 (79.3)                  | 422 (83.2) |
| Discontinued maintenance period treatment                 | 27 (16.0)               | 22 (13.0)               | 34 (20.1)                   | 83 (16.4)  |
| Primary reason for treatment discontinuation              |                         |                         |                             |            |
| Pregnancy                                                 | 0                       | 0                       | 0                           | 0          |
| Lack of efficacy                                          | 6 (3.6)                 | 5 (3.0)                 | 15 (8.9)                    | 26 (5.1)   |
| Adverse event                                             | 4 (2.4)                 | 5 (3.0)                 | 4 (2.4)                     | 13 (2.6)   |
| Subject's request                                         | 8 (4.7)                 | 7 (4.1)                 | 6 (3.6)                     | 21 (4.1)   |
| COVID-19                                                  | 0                       | 0                       | 0                           | 0          |
| Lost to follow-up                                         | 1 (0.6)                 | 1 (0.6)                 | 4 (2.4)                     | 6 (1.2)    |
| Protocol deviation                                        | 1 (0.6)                 | 0                       | 1 (0.6)                     | 2 (0.4)    |
| Physician/PI Decision                                     | 3 (1.8)                 | 2 (1.2)                 | 1 (0.6)                     | 6 (1.2)    |
| Other                                                     | 4 (2.4)                 | 2 (1.2)                 | 3 (1.8)                     | 9 (1.8)    |
| COVID-19                                                  | 0                       | 0                       | 0                           | 0          |
| Completed the study after maintenance period              | 142 (84.0)              | 147 (87.0)              | 133 (78.7)                  | 422 (83.2) |
| Discontinued from the study during the maintenance period | 27 (16.0)               | 22 (13.0)               | 36 (21.3)                   | 85 (16.8)  |
| Primary reason for study discontinuation                  |                         |                         |                             |            |
| Pregnancy                                                 | 0                       | 0                       | 1 (0.6)                     | 1 (0.2)    |
| Lack of efficacy                                          | 6 (3.6)                 | 5 (3.0)                 | 14 (8.3)                    | 25 (4.9)   |
| Adverse Event                                             | 5 (3.0)                 | 5 (3.0)                 | 4 (2.4)                     | 14 (2.8)   |
| Subject's request                                         | 8 (4.7)                 | 7 (4.1)                 | 6 (3.6)                     | 21(4.1)    |
| COVID-19                                                  | 1 (0.6)                 | 0                       | 0                           | 1 (0.2)    |
| Lost to follow-up                                         | 2 (1.2)                 | 1 (0.6)                 | 6 (3.6)                     | 9 (1.8)    |
| Protocol Deviation                                        | 1 (0.6)                 | 0                       | 1 (0.6)                     | 2 (0.4)    |
| Other                                                     | 5 (3.0)                 | 4 (2.4)                 | 4 (2.4)                     | 13 (2.6)   |
| COVID-19                                                  | 0                       | 0                       | 0                           | 0          |
| Rolled over to long-term extension                        | 145 (85.8)              | 152 (89.9)              | 136 (80.5)                  | 433 (85.4) |
| Completed follow-up                                       | 9 (5.3)                 | 9 (5.3)                 | 14 (8.3)                    | 32 (6.3)   |

ITT=intent-to-treat; N=number of subjects in the treatment group; n=number of subjects with available data; Nemo=nemolizumab; Q4W=every 4 weeks; Q8W=every 8 weeks

Note: Percentages were based on the number of subjects in each treatment group.

Total was for all subjects who were re-randomized to the Maintenance Period from nemolizumab 30 mg group in the Initial Treatment Period.

One subject (re-randomized to Q4W) was erroneously enrolled in the long-term extension study instead of being treated in the Maintenance Period. One subject (re-randomized to placebo) was not dosed with study drug because the subject had an abnormal electrocardiogram at the time per the Principal Investigator and discussions with medical monitor; therefore, no dosing was to occur at this visit.

The applicant was asked to submit the table Error! Reference source not found. below. Although the summary figures are not completely clarified and exactly consistent with previously submitted numbers, the total exposure is considered adequate for the evaluation of short-term safety profile.

<div style=\"page-break-after: always\"></div>

Table 52: Patient exposure in the Nemolizumab AD Population (10 March 2023) (modified)

|                                      | Patients enrolled   | Patients exposed*   | Patients exposed to the proposed dose   | Patients with long term** safety data   | Patients with long term** safety data   |
|--------------------------------------|---------------------|---------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                      |                     |                     | range                                   | ≥ 6 months                              | ≥ 12 months                             |
| Applicant sponsored                  |                     |                     |                                         |                                         |                                         |
| Blinded studies (placebo-controlled) | 1954                | 1304                | 1300                                    | 2                                       | 0                                       |
| Blinded studies (active-controlled)  | NA                  | NA                  | NA                                      | NA                                      | NA                                      |
| Open studies                         | 1775 #              | 1759                | 1758                                    | 1349                                    | 840                                     |
| Post marketing                       | 0                   | 0                   | 0                                       | 0                                       | 0                                       |
| Compassionate use                    | NA                  | NA                  | NA                                      | NA                                      | NA                                      |

AD = atopic dermatitis; NA = not applicable.

* Received at least 1 dose of active treatment.

** In general, this refers to 6 months and 12 months continuous exposure data, or intermittent exposure.

#  Subjects enrolled in open studies were already enrolled in blinded studies. Exposure duration (years) = ((date of last treatment + 30) - (date of first treatment) + 1))/ 365.2. Blinded studies are SPR.118161, SPR.118169, and SPR.114322. Open label studies are SPR.116912, SPR.201593,

## 2.6.11.1.2.  Adverse events

In the Initial Period, the frequency of TEAEs in nemolizumab 30 mg Q4W subjects was 47.5%. This is similar to what was observed in placebo subjects (47.8%). In the all nemolizumab group the frequency of TEAEs was slightly higher (50.6%). This is assessed to be acceptable. Most commonly reported AEs were in the Infections and infestations and Skin and subcutaneous tissue disorders SOC. The most common AEs regarding infections were nasopharyngitis, upper respiratory tract infection and COVID-19 and in skin-related AE's, the most common PT was atopic dermatitis.

During the Maintenance Period, TEAEs were most frequent in the group nemolizumab 30 mg Q4W to placebo (58,3%).

The overall higher frequency of TEAEs during the Maintenance Period compared to the Initial Period likely reflects the longer treatment duration.

<div style=\"page-break-after: always\"></div>

Table 53: TEAEs experienced by ≥ 1.0% of subjects in any treatment group by SOC and PT during the treatment period (primary safety population)

| SOC PT                                               | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|------------------------------------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| SOC PT                                               | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Subjects with at least 1 TEAE                        | 566 (47.5)                  | 660 (50.6)            | 306 (47.8)          | 91 (53.5)                         | 90 (53.9)                         | 98 (58.3)                             | 92 (50.0)                              |
| Blood and lymphatic system disorders                 | 19 (1.6)                    | 26 (2.0)              | 9 (1.4)             | 1 (0.6)                           | 2 (1.2)                           | 2 (1.2)                               | 2 (1.1)                                |
| Neutropenia                                          | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 2 (1.2)                           | 0                                     | 0                                      |
| Eye disorders                                        | 29 (2.4)                    | 34 (2.6)              | 15 (2.3)            | 3 (1.8)                           | 2 (1.2)                           | 7 (4.2)                               | 2 (1.1)                                |
| Conjunctivitis allergic                              | 7 (0.6)                     | 8 (0.6)               | 6 (0.9)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 0                                      |
| Dry eye                                              | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 3 (1.8)                               | 0                                      |
| Gastrointestinal disorders                           | 62 (5.2)                    | 72 (5.5)              | 40 (6.3)            | 18 (10.6)                         | 9 (5.4)                           | 12 (7.1)                              | 7 (3.8)                                |
| Diarrhoea                                            | 19 (1.6)                    | 22 (1.7)              | 12 (1.9)            | 4 (2.4)                           | 3 (1.8)                           | 6 (3.6)                               | 2 (1.1)                                |
| Nausea                                               | 14 (1.2)                    | 19 (1.5)              | 6 (0.9)             | 3 (1.8)                           | 0                                 | 1 (0.6)                               | 2 (1.1)                                |
| Abdominal pain upper                                 | 5 (0.4)                     | 7 (0.5)               | 2 (0.3)             | 4 (2.4)                           | 1 (0.6)                           | 0                                     | 2 (1.1)                                |
| Vomiting                                             | 5 (0.4)                     | 7 (0.5)               | 1 (0.2)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 1 (0.5)                                |
| Gastrooesophageal reflux disease                     | 3 (0.3)                     | 4 (0.3)               | 2 (0.3)             | 2 (1.2)                           | 0                                 | 0                                     | 0                                      |
| Duodenal ulcer                                       | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 2 (1.2)                           | 0                                 | 0                                     | 0                                      |
| Dyspepsia                                            | 1 (<0.1)                    | 1 (<0.1)              | 2 (0.3)             | 1 (0.6)                           | 1 (0.6)                           | 2 (1.2)                               | 0                                      |
| Angular cheilitis                                    | 0                           | 0                     | 0                   | 2 (1.2)                           | 0                                 | 0                                     | 0                                      |
| General disorders and administration site conditions | 78 (6.5)                    | 90 (6.9)              | 28 (4.4)            | 5 (2.9)                           | 8 (4.8)                           | 7 (4.2)                               | 7 (3.8)                                |
| Pyrexia                                              | 10 (0.8)                    | 13 (1.0)              | 5 (0.8)             | 3 (1.8)                           | 3 (1.8)                           | 0                                     | 3 (1.6)                                |
| Fatigue                                              | 12 (1.0)                    | 12 (0.9)              | 3 (0.5)             | 0                                 | 1 (0.6)                           | 1 (0.6)                               | 1 (0.5)                                |
| Vaccination site pain                                | 6 (0.5)                     | 6 (0.5)               | 3 (0.5)             | 1 (0.6)                           | 1 (0.6)                           | 3 (1.8)                               | 0                                      |
| Infections and infestations                          | 232 (19.5)                  | 293 (22.5)            | 144 (22.5)          | 53 (31.2)                         | 48 (28.7)                         | 55 (32.7)                             | 58 (31.5)                              |
| Nasopharyngitis                                      | 42 (3.5)                    | 68 (5.2)              | 31 (4.8)            | 14 (8.2)                          | 8 (4.8)                           | 12 (7.1)                              | 12 (6.5)                               |
| Upper respiratory tract infection                    | 20 (1.7)                    | 27 (2.1)              | 20 (3.1)            | 4 (2.4)                           | 5 (3.0)                           | 10 (6.0)                              | 11 (6.0)                               |
| COVID-19                                             | 24 (2.0)                    | 24 (1.8)              | 14 (2.2)            | 13 (7.6)                          | 13 (7.8)                          | 19 (11.3)                             | 16 (8.7)                               |
| Urinary tract infection                              | 14 (1.2)                    | 17 (1.3)              | 7 (1.1)             | 3 (1.8)                           | 3 (1.8)                           | 1 (0.6)                               | 2 (1.1)                                |
| Sinusitis                                            | 12 (1.0)                    | 16 (1.2)              | 5 (0.8)             | 0                                 | 3 (1.8)                           | 4 (2.4)                               | 1 (0.5)                                |
| Rhinitis                                             | 9 (0.8)                     | 11 (0.8)              | 8 (1.3)             | 0                                 | 2 (1.2)                           | 1 (0.6)                               | 1 (0.5)                                |
| Gastroenteritis                                      | 6 (0.5)                     | 10 (0.8)              | 5 (0.8)             | 3 (1.8)                           | 2 (1.2)                           | 1 (0.6)                               | 0                                      |
| Oral herpes                                          | 9 (0.8)                     | 13 (1.0)              | 5 (0.8)             | 3 (1.8)                           | 3 (1.8)                           | 1 (0.6)                               | 0                                      |
| Folliculitis                                         | 9 (0.8)                     | 9 (0.7)               | 6 (0.9)             | 1 (0.6)                           | 3 (1.8)                           | 2 (1.2)                               | 2 (1.1)                                |
| Pharyngitis                                          | 5 (0.4)                     | 9 (0.7)               | 1 (0.2)             | 3 (1.8)                           | 2 (1.2)                           | 1 (0.6)                               | 2 (1.1)                                |
| Conjunctivitis                                       | 6 (0.5)                     | 8 (0.6)               | 3 (0.5)             | 0                                 | 1 (0.6)                           | 0                                     | 2 (1.1)                                |
| Herpes dermatitis                                    | 5 (0.4)                     | 5 (0.4)               | 1 (0.2)             | 3 (1.8)                           | 2 (1.2)                           | 1 (0.6)                               | 0                                      |
| Herpes simplex                                       | 4 (0.3)                     | 5 (0.4)               | 7 (1.1)             | 1 (0.6)                           | 0                                 | 1 (0.6)                               | 2 (1.1)                                |
| Viral upper respiratory tract infection              | 3 (0.3)                     | 5 (0.4)               | 6 (0.9)             | 1 (0.6)                           | 1 (0.6)                           | 2 (1.2)                               | 4 (2.2)                                |
| Cellulitis                                           | 4 (0.3)                     | 4 (0.3)               | 2 (0.3)             | 0                                 | 3 (1.8)                           | 1 (0.6)                               | 0                                      |

<div style=\"page-break-after: always\"></div>

| SOC PT                                          | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|-------------------------------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| SOC PT                                          | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Influenza                                       | 3 (0.3)                     | 3 (0.2)               | 2 (0.3)             | 2 (1.2)                           | 0                                 | 0                                     | 0                                      |
| Tonsillitis                                     | 2 (0.2)                     | 3 (0.2)               | 1 (0.2)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 0                                      |
| Asymptomatic COVID-19                           | 2 (0.2)                     | 2 (0.2)               | 3 (0.5)             | 2 (1.2)                           | 3 (1.8)                           | 4 (2.4)                               | 2 (1.1)                                |
| Tooth abscess                                   | 1 (<0.1)                    | 1 (<0.1)              | 2 (0.3)             | 2 (1.2)                           | 0                                 | 0                                     | 0                                      |
| Gastrointestinal infection                      | 0                           | 0                     | 0                   | 1 (0.6)                           | 2 (1.2)                           | 0                                     | 1 (0.5)                                |
| Sinusitis bacterial                             | 0                           | 0                     | 0                   | 0                                 | 2 (1.2)                           | 1 (0.6)                               | 0                                      |
| Investigations                                  | 40 (3.4)                    | 51 (3.9)              | 27 (4.2)            | 6 (3.5)                           | 8 (4.8)                           | 5 (3.0)                               | 6 (3.3)                                |
| Blood creatine phosphokinase increased          | 8 (0.7)                     | 11 (0.8)              | 10 (1.6)            | 2 (1.2)                           | 3 (1.8)                           | 3 (1.8)                               | 2 (1.1)                                |
| Peak expiratory flow rate decreased             | 9 (0.8)                     | 9 (0.7)               | 4 (0.6)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 1 (0.5)                                |
| Blood pressure increased                        | 1 (<0.1)                    | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 2 (1.1)                                |
| Musculoskeletal and connective tissue disorders | 69 (5.8)                    | 81 (6.2)              | 27 (4.2)            | 11 (6.5)                          | 9 (5.4)                           | 11 (6.5)                              | 6 (3.3)                                |
| Back pain                                       | 18 (1.5)                    | 21 (1.6)              | 9 (1.4)             | 1 (0.6)                           | 1 (0.6)                           | 1 (0.6)                               | 2 (1.1)                                |
| Arthralgia                                      | 15 (1.3)                    | 17 (1.3)              | 3 (0.5)             | 0                                 | 2 (1.2)                           | 1 (0.6)                               | 1 (0.5)                                |
| Arthritis                                       | 3 (0.3)                     | 3 (0.2)               | 1 (0.2)             | 0                                 | 0                                 | 2 (1.2)                               | 0                                      |
| Neck pain                                       | 2 (0.2)                     | 3 (0.2)               | 0                   | 2 (1.2)                           | 1 (0.6)                           | 0                                     | 0                                      |
| Nervous system disorders                        | 70 (5.9)                    | 82 (6.3)              | 37 (5.8)            | 9 (5.3)                           | 11 (6.6)                          | 6 (3.6)                               | 7 (3.8)                                |
| Headache                                        | 50 (4.2)                    | 61 (4.7)              | 28 (4.4)            | 6 (3.5)                           | 7 (4.2)                           | 3 (1.8)                               | 4 (2.2)                                |
| Dizziness                                       | 6 (0.5)                     | 6 (0.5)               | 1 (0.2)             | 0                                 | 1 (0.6)                           | 0                                     | 2 (1.1)                                |
| Psychiatric disorders                           | 23 (1.9)                    | 30 (2.3)              | 11 (1.7)            | 3 (1.8)                           | 2 (1.2)                           | 1 (0.6)                               | 3 (1.6)                                |
| Depression                                      | 6 (0.5)                     | 8 (0.6)               | 2 (0.3)             | 2 (1.2)                           | 0                                 | 0                                     | 2 (1.1)                                |
| Reproductive system and breast disorders        | 13 (1.1)                    | 15 (1.2)              | 7 (1.1)             | 1 (0.6)                           | 2 (1.2)                           | 5 (3.0)                               | 3 (1.6)                                |
| Pelvic pain                                     | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 2 (1.2)                           | 0                                     | 0                                      |
| Respiratory, thoracic and mediastinal disorders | 97 (8.1)                    | 113 (8.7)             | 47 (7.3)            | 19 (11.2)                         | 15 (9.0)                          | 21 (12.5)                             | 9 (4.9)                                |
| Asthma                                          | 48 (4.0)                    | 59 (4.5)              | 21 (3.3)            | 6 (3.5)                           | 6 (3.6)                           | 6 (3.6)                               | 5 (2.7)                                |
| Cough                                           | 15 (1.3)                    | 18 (1.4)              | 8 (1.3)             | 2 (1.2)                           | 1 (0.6)                           | 4 (2.4)                               | 1 (0.5)                                |
| Dyspnoea                                        | 13 (1.1)                    | 14 (1.1)              | 5 (0.8)             | 4 (2.4)                           | 1 (0.6)                           | 3 (1.8)                               | 0                                      |
| Rhinitis allergic                               | 5 (0.4)                     | 5 (0.4)               | 5 (0.8)             | 1 (0.6)                           | 0                                 | 2 (1.2)                               | 2 (1.1)                                |
| Rhinorrhoea                                     | 4 (0.3)                     | 5 (0.4)               | 3 (0.5)             | 0                                 | 2 (1.2)                           | 1 (0.6)                               | 1 (0.5)                                |
| Wheezing                                        | 5 (0.4)                     | 5 (0.4)               | 1 (0.2)             | 2 (1.2)                           | 0                                 | 1 (0.6)                               | 1 (0.5)                                |
| Oropharyngeal pain                              | 2 (0.2)                     | 2 (0.2)               | 3 (0.5)             | 2 (1.2)                           | 3 (1.8)                           | 0                                     | 0                                      |
| Skin and subcutaneous tissue disorders          | 195 (16.4)                  | 232 (17.8)            | 90 (14.1)           | 22 (12.9)                         | 18 (10.8)                         | 23 (13.7)                             | 22 (12.0)                              |
| Atopic dermatitis                               | 124 (10.4)                  | 147 (11.3)            | 66 (10.3)           | 13 (7.6)                          | 11 (6.6)                          | 18 (10.7)                             | 15 (8.2)                               |
| Urticaria                                       | 13 (1.1)                    | 16 (1.2)              | 3 (0.5)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 1 (0.5)                                |
| Acne                                            | 6 (0.5)                     | 7 (0.5)               | 2 (0.3)             | 1 (0.6)                           | 6 (3.6)                           | 1 (0.6)                               | 1 (0.5)                                |
| Pruritus                                        | 4 (0.3)                     | 5 (0.4)               | 4 (0.6)             | 1 (0.6)                           | 0                                 | 2 (1.2)                               | 1 (0.5)                                |
| Vascular disorders                              | 16 (1.3)                    | 20 (1.5)              | 7 (1.1)             | 3 (1.8)                           | 2 (1.2)                           | 2 (1.2)                               | 0                                      |
| Hypertension                                    | 9 (0.8)                     | 12 (0.9)              | 4 (0.6)             | 2 (1.2)                           | 0                                 | 2 (1.2)                               | 0                                      |

ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects who

<div style=\"page-break-after: always\"></div>

experienced the events; Nemo=nemolizumab; PT=preferred term; Q4W=every 4 weeks; Q8W=every 8 weeks; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. Percentages were based on the number of subjects in each treatment group. All TEAEs that started on or after the first dosing date were summarized by period based on the onset date. For Studies SPR.118161 and SPR.118169, the Initial Period was defined as the period from start of treatment up to and including Week 16. For Study SPR.114322, the whole Treatment Period from the start of treatment up to and including Week 24 was included in the Initial Period. The Maintenance Period was defined as the period up to and including Week 48 after the Initial Period (not applicable to subjects from Study SPR.114322). In case of early discontinuation, the Treatment Period extended from the start of treatment until 4 weeks after the last dosing (inclusive) date or early termination date, whichever was earlier.

a) Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.

The most common TEAEs (reported by ≥ 2.0% of subjects in either the nemolizumab 30 mg Q4W or placebo groups) were atopic dermatitis, headache, nasopharyngitis, asthma, COVID-19, and upper respiratory tract infection.

The majority of subjects with TEAEs experienced events that were considered mild or moderate in severity in both the Initial Period and Maintenance Period.

A TEAE preferred term (PT) only qualified for consideration as an ADR after the sequential application of quantitative and qualitative criteria, as defined below:

-  Quantitative criteria: a list of TEAEs that occurred in ≥1.0% of subjects in the nemolizumab group and at a greater frequency than in the placebo group was derived.
-  Qualitative criteria: medical judgment was then applied to the above list of TEAEs meeting the quantitative criteria to decide which TEAEs should be retained/considered as ADRs. The medical evaluation of a potential causal relationship comprised several factors, including:
- f) The extent to which the TEAE was consistent with the pharmacology/mechanism of action of nemolizumab
- g) The timing of the TEAE relative to the time of first/initial drug exposure (event latency)
- h) Possible confounders/alternative explanations for the occurrence of the TEAE
- i) Causality per Investigator and Sponsor at the individual TEAE level

Ten TEAE PTs met the quantitative criteria (nemolizumab vs. placebo): atopic dermatitis (10.4% vs. 10.3%), asthma (4.0% vs. 3.3%), back pain (1.5% vs. 1.4%), arthralgia (1.3% vs. 0.5%) nausea (1.2% vs. 0.9%), urinary tract infection (1.2% vs. 1.1%), dyspnoea (1.1% vs. 0.8%), urticaria (1.1% vs. 0.5%), fatigue (1.0% vs. 0.5%), and sinusitis (1.0% vs. 0.8%).

These 10 TEAEs were then further evaluated medically using the qualitative criteria defined above to determine the final proposed list of ADRs for the AD indication. As such, urticaria was the only ADR identified. Non-serious and mild urticaria was reported with a close temporal link after initial nemolizumab 30 mg Q4W injections in some cases (2 events) and others after repeated injections (2 events). The applicant states that it is deemed that the data suggest a reasonable possibility of a causal relationship with nemolizumab.

## TEAEs considered to be related to study drug by investigator

Regarding study drug-related TEAEs experienced by ≥ 1.0% of subjects in any treatment group by SOC and PT during the Initial Period, it is noted that eye disorders are more frequent in nemolizumab 30 mg Q4W subjects (1%) and all nemolizumab subjects (1,1%) compared to placebo subjects (0,3%).

<div style=\"page-break-after: always\"></div>

## 2.6.11.1.3.  Serious adverse events, AEs of special interest, deaths, and other significant events

During the Initial Period, the frequency of treatment-emergent SAEs was slightly lower in placebo subjects (1.3%) than in nemolizumab 30 mg Q4W subjects (1.8%).

During the Maintenance Period, treatment emergent SAEs were experienced by 10 (5.9%), 3 (1.8%), 4 (2.4%), and 2 (1.1%) subjects in the nemolizumab 30 mg Q4W to Q4W, nemolizumab 30 mg Q4W to Q8W, nemolizumab 30 mg Q4W to placebo, and re-assigned to placebo groups, respectively.

Table 54: Study drug-related SAEs by SOC and PT during the treatment period (primary safety population)

| SOC PT                                               | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|------------------------------------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| SOC PT                                               | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Subjects with at least 1 study drug related SAE      | 6 (0.5)                     | 8 (0.6)               | 0                   | 1 (0.6)                           | 0                                 | 1 (0.6)                               | 0                                      |
| Blood and lymphatic system disorders                 | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Lymphadenopathy                                      | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Gastrointestinal disorders                           | 2 (0.2)                     | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Abdominal adhesions                                  | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Eosinophilic colitis                                 | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Small intestinal obstruction                         | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| General disorders and administration site conditions | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Oedema peripheral                                    | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Infections and infestations                          | 3 (0.3)                     | 4 (0.3)               | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Cellulitis                                           | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Herpes simplex                                       | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Herpes zoster                                        | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Ophthalmic herpes zoster                             | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Superinfection bacterial                             | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Gastroenteritis                                      | 0                           | 0                     | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Respiratory, thoracic and mediastinal disorder       | 0                           | 0                     | 0                   | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Pulmonary embolism                                   | 0                           | 0                     | 0                   | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Skin and subcutaneous tissue disorders               | 1 (<0.1)                    | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Atopic dermatitis                                    | 1 (<0.1)                    | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |

ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects who SAE=serious adverse event; SOC=system organ class; TEAE=treatment-emergent adverse event experienced the events; Nemo=nemolizumab; PT=preferred term; Q4W=every 4 weeks; Q8W=every 8 weeks; Note: Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. Percentages were based on the number of subjects in each treatment group. All TEAEs that started on or after the first dosing date were summarized by period based on the onset date. For Studies SPR.118161 and SPR.118169, the Initial Period was defined as the period from start of treatment up to and including Week 16. For Study SPR.114322, the whole Treatment Period from the start of treatment up to and including Week 24

Assessment report

<div style=\"page-break-after: always\"></div>

was included in the Initial Period. The Maintenance Period was defined as the period up to and including Week 48 after the Initial Period (not applicable to subjects from Study SPR.114322). In case of early discontinuation, the Treatment Period extended from the start of treatment until 4 weeks after the last dosing (inclusive) date or early termination date, whichever was earlier.

a) Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.

All nemolizumab-treated subjects who experienced treatment-emergent SAEs are presented in Table 55 . The majority of subjects with treatment-emergent SAEs had events considered mild or moderate in severity and that resolved.

Table 55: Nemolizumab-treated subjects with treatment-emergent SAEs by nemolizumab dose group (primary safety population) (modified )

| Preferred term                         | Start day/ end day    | Severity              | Related to study drug/ injection procedure   | Outcome                     |
|----------------------------------------|-----------------------|-----------------------|----------------------------------------------|-----------------------------|
| Nemolizumab 10 mg Q4W                  | Nemolizumab 10 mg Q4W | Nemolizumab 10 mg Q4W | Nemolizumab 10 mg Q4W                        | Nemolizumab 10 mg Q4W       |
| Atopic dermatitis                      | 29/ongoing            | Severe                | Yes/No                                       | Not recovered/ not resolved |
| Asthenia                               | 66/                   | Severe                | No/No                                        | Not recovered/ not resolved |
| Staphylococcal sepsis                  | 66/                   | Severe                | No/No                                        | Not recovered/ not resolved |
| Pneumonia aspiration                   | 70/                   | Severe                | No/No                                        | Fatal                       |
| Cardio-respiratory arrest              | 83/                   | Severe                | No/No                                        | Fatal                       |
| Post concussion syndrome               | 83/174                | Moderate              | No/No                                        | Recovered/resolved          |
| Post-traumatic amnestic disorders      | 83/174                | Moderate              | No/No                                        | Recovered/resolved          |
| Nemolizumab 30 mg Q4W                  | Nemolizumab 30 mg Q4W | Nemolizumab 30 mg Q4W | Nemolizumab 30 mg Q4W                        | Nemolizumab 30 mg Q4W       |
| Eosinophilic colitis                   | 106/194               | Moderate              | Yes/No                                       | Recovered/resolved          |
| Cellulitis                             | 39/49                 | Moderate              | Yes/No                                       | Recovered/resolved          |
| Congenital cyst                        | 71/ongoing            | Mild                  | No/No                                        | Not recovered/ not resolved |
| Infected cyst                          | 73/91                 | Moderate              | No/No                                        | Recovered/resolved          |
| Infected cyst                          | 112/ongoing           | Mild                  | No/No                                        | Not recovered/ Not resolved |
| Intervertebral disc protrusion         | 20/133                | Severe                | No/No                                        | Recovered/resolved          |
| Intervertebral disc protrusion         | 168/174               | Severe                | No/No                                        | Recovered/resolved          |
| Abdominal adhesions                    | 86/99                 | Severe                | Yes/No                                       | Recovered/resolved          |
| Small intestinal obstruction           | 86/99                 | Severe                | Yes/No                                       | Recovered/resolved          |
| Dermatitis exfoliative generalised a,b | 86/93                 | Severe                | Yes/No                                       | Recovered/resolved          |
| Atopic dermatitis                      | 14/21                 | Mild                  | No/No                                        | Recovered/resolved          |
| Atopic dermatitis                      | 84/95                 | Moderate              | No/No                                        | Recovered/resolved          |
| Psychogenic tremor                     | 100/101               | Moderate              | No/No                                        | Recovered/resolved          |
| Atopic dermatitis                      | 32/65                 | Severe                | No/No                                        | Recovered/resolved          |
| Renal colic                            | 61/65                 | Mild                  | No/No                                        | Recovered/resolved          |
| Salivary gland cancer                  | 21/ongoing            | Severe                | No/No                                        | Not recovered/ not resolved |

<div style=\"page-break-after: always\"></div>

| Preferred term                   | Start day/ end day               | Severity                         | Related to study drug/ injection procedure   | Outcome                          |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------------------|----------------------------------|
| Dermatomyositis                  | 172/ongoing                      | Moderate                         | Yes/No                                       | Not recovered/ not resolved      |
| Lymphadenopathy a                | 21/37                            | Moderate                         | Yes/No                                       | Recovered/resolved               |
| Oedema peripheral a,c            | 21/37                            | Moderate                         | Yes/No                                       | Recovered/resolved               |
| Atopic dermatitis a              | 21/37                            | Moderate                         | Yes/No                                       | Recovered/resolved               |
| Herpes simplex c                 | 25/30                            | Moderate                         | Yes/No                                       | Recovered/resolved               |
| Superinfection bacterial c       | 25/30                            | Moderate                         | Yes/No                                       | Recovered/resolved               |
| Atopic dermatitis                | 51/ongoing                       | Severe                           | No/No                                        | Not recovered/ not resolved      |
| Cholelithiasis                   | 50/51                            | Severe                           | No/No                                        | Recovered/resolved               |
| Intervertebral disc protrusion   | 32/216                           | Severe                           | No/No                                        | Recovered/resolved               |
| Atopic dermatitis                | 40/55                            | Moderate                         | No/No                                        | Recovered/resolved               |
| Herpes zoster                    | 96/112                           | Moderate                         | Yes/No                                       | Recovered/resolved               |
| Ophthalmic herpes zoster c       | 96/112                           | Moderate                         | Yes/No                                       | Recovered/resolved               |
| Groin pain                       | 101/116                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Lumbar radiculopathy             | 104/109                          | Moderate                         | No/No                                        | Recovered/resolved with sequelae |
| Uterine leiomyoma                | 73/190                           | Moderate                         | No/No                                        | Recovered/resolved               |
| Nemolizumab 90 mg Q4W            | Nemolizumab 90 mg Q4W            | Nemolizumab 90 mg Q4W            | Nemolizumab 90 mg Q4W                        | Nemolizumab 90 mg Q4W            |
| Septic shock a,b                 | 71/104                           | Severe                           | Yes/No                                       | Recovered/resolved               |
| Urinary tract infection          | 166/170                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Nemolizumab 30 mg Q4W to Q4W     | Nemolizumab 30 mg Q4W to Q4W     | Nemolizumab 30 mg Q4W to Q4W     | Nemolizumab 30 mg Q4W to Q4W                 | Nemolizumab 30 mg Q4W to Q4W     |
| Asthma                           | 226/228                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Duodenal ulcer haemorrhage       | 300/306                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Comminuted fracture              | 239/240                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Gastroenteritis a,b              | 292/ongoing                      | Moderate                         | Yes/No                                       | Not recovered/ not resolved      |
| Adenomyosis                      | 185/189                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Periarthritis                    | 267/269                          | Moderate                         | Yes/No                                       | Recovered/resolved               |
| COVID-19                         | 201/212                          | Severe                           | No/No                                        | Recovered/resolved               |
| Appendicitis                     | 289/306                          | Severe                           | No/No                                        | Recovered/resolved               |
| Dupuytren's contracture          | 207/209                          | Severe                           | No/No                                        | Recovered/resolved               |
| Nemolizumab 30 mg Q4W to Q8W     | Nemolizumab 30 mg Q4W to Q8W     | Nemolizumab 30 mg Q4W to Q8W     | Nemolizumab 30 mg Q4W to Q8W                 | Nemolizumab 30 mg Q4W to Q8W     |
| Anxiety                          | 319/320                          | Mild                             | No/No                                        | Recovered/resolved               |
| Splenic injury                   | 274/290                          | Severe                           | No/No                                        | Recovered/resolved               |
| Cellulitis                       | 133/141                          | Severe                           | No/No                                        | Recovered/resolved               |
| Nemolizumab 30 mg Q4W to placebo | Nemolizumab 30 mg Q4W to placebo | Nemolizumab 30 mg Q4W to placebo | Nemolizumab 30 mg Q4W to placebo             | Nemolizumab 30 mg Q4W to placebo |
| Pulmonary embolism               | 236/244                          | Severe                           | Yes/No                                       | Recovered/resolved with sequelae |
| Pulmonary embolism a,b           | 274/283                          | Severe                           | Yes/No                                       | Recovered/resolved with sequelae |
| Endometriosis                    | 254/256                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Erysipelas                       | 196/224                          | Moderate                         | No/No                                        | Recovered/resolved               |
| Struma multinodosa               | 207/218                          | Severe                           | No/No                                        | Recovered/resolved               |

<div style=\"page-break-after: always\"></div>

| Preferred term         | Start day/ end day   | Severity   | Related to study drug/ injection procedure   | Outcome                     |
|------------------------|----------------------|------------|----------------------------------------------|-----------------------------|
| Plasmablastic lymphoma | 286/ ongoing         | Severe     | No/No                                        | Not recovered/ not resolved |
| COVID-19               | 354/363              | Severe     | No/No                                        | Recovered/resolved          |

ISS=Integrated Summary of Safety; Q4W=every 4 weeks; Q8W=every 8 weeks; SAE=serious adverse event a) Event also led to study drug withdrawal.

b) Event also led to study discontinuation.

c) Event was also considered an adverse event of special interest (by Investigator).

An adverse event of special interest (AESI) was defined by the applicant as a noteworthy TEAE for the study drug that was to be monitored closely and reported promptly. The applicant was asked to further explain how and why the AEs of special interest were chosen as such. The applicant has clarified that most of the AESIs have been defined by the originator Company (Chugai Pharmaceutical Co., Ltd) based on Phase 1 and Phase 2 study data.

The following TEAEs were considered AESIs:

- -Injection-related reactions (IRRs), which included anaphylactic reactions, acute allergic reactions requiring treatment, and severe injection site reactions with a duration &gt;24 hours
- -Newly diagnosed asthma or worsening of asthma
- -Infections, which included any severe infection, any infection requiring treatment with parenteral antibiotics or with oral antibiotics/antivirals/antifungals for &gt;2 weeks, and any confirmed or suspected COVID-19 infection
- -Peripheral oedema: limbs, bilateral
- -Facial oedema
- -Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (&gt;3 × the upper limit of normal [ULN]) in combination with elevated bilirubin (&gt;2 × ULN).

An overall summary of AESIs (by Investigator) during the Treatment Period is presented in Table 56 .

<div style=\"page-break-after: always\"></div>

## Table 56: AESIs (by investigator) during the treatment period (primary safety population)

| Category                                                                     | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|------------------------------------------------------------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| Category                                                                     | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Any AESI                                                                     | 107 (9.0)                   | 118 (9.0)             | 42 (6.6)            | 24 (14.1)                         | 25 (15.0)                         | 31 (18.5)                             | 24 (13.0)                              |
| Injection-related reactions                                                  | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Newly diagnosed asthma or worsening of asthma                                | 51 (4.3)                    | 62 (4.8)              | 20 (3.1)            | 7 (4.1)                           | 6 (3.6)                           | 4 (2.4)                               | 5 (2.7)                                |
| TEAE related to study drug                                                   | 19 (1.6)                    | 20 (1.5)              | 12 (1.9)            | 4 (2.4)                           | 2 (1.2)                           | 1 (0.6)                               | 2 (1.1)                                |
| Serious TEAE                                                                 | 0                           | 0                     | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| TEAE leading to permanent discontinuation of study drug                      | 1 (<0.1)                    | 2 (0.2)               | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Infections                                                                   | 40 (3.4)                    | 40 (3.1)              | 22 (3.4)            | 16 (9.4)                          | 17 (10.2)                         | 25 (14.9)                             | 21 (11.4)                              |
| TEAE related to study drug                                                   | 9 (0.8)                     | 9 (0.7)               | 3 (0.5)             | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Serious TEAE                                                                 | 3 (0.3)                     | 3 (0.2)               | 1 (0.2)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 0                                      |
| TEAE leading to permanent discontinuation of study drug                      | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 1 (0.6)                           | 0                                     | 0                                      |
| Peripheral oedema: limbs, bilateral; facial oedema                           | 19 (1.6)                    | 19 (1.5)              | 2 (0.3)             | 1 (0.6)                           | 2 (1.2)                           | 3 (1.8)                               | 0                                      |
| TEAE related to study drug                                                   | 10 (0.8)                    | 10 (0.8)              | 2 (0.3)             | 0                                 | 1 (0.6)                           | 0                                     | 0                                      |
| Serious TEAE                                                                 | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| TEAE leading to permanent discontinuation of study drug                      | 3 (0.3)                     | 3 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Elevated ALT or AST (>3×ULN) in combination with elevated bilirubin (>2×ULN) | 0                           | 0                     | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |

AESI=adverse event of special interest; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects who experienced the events; Nemo=nemolizumab; Q4W=every 4 weeks; Q8W=every 8 weeks;

TEAE=treatment-emergent adverse event; ULN=upper limit of normal

Note: Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. Percentages were based on the number of subjects in each treatment group. All TEAEs that started on or after the first dosing date were summarized by period based on the onset date. For Studies SPR.118161 and SPR.118169, the Initial Period was defined as the period from start of treatment up to and including Week 16. For Study SPR.114322, the whole Treatment Period from the start of treatment up to and including Week 24 was included in the Initial Period. The Maintenance Period was defined as the period up to and including Week 48 after the Initial Period (not applicable to subjects from Study SPR.114322). In case of early discontinuation, the Treatment Period extended from the start of treatment until 4 weeks after the last dosing (inclusive) date or early termination date, whichever was earlier.

Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.

<div style=\"page-break-after: always\"></div>

## Malignancies

A total of 12 malignancies in 11 subjects exposed to nemolizumab have been reported across the entire nemolizumab clinical program conducted by Galderma and its partner Maruho up to 10 Mar 2023. Relevant risk factors have been properly described by the applicant. The applicant was asked to provide a summary table of neoplasms including assessment of causality between the neoplasm and study drug. In the AD primary safety population, the incidence of malignancies observed in the nemolizumab group was 2 (0.2%) subjects compared to 0 subjects in the placebo groups and the applicant was requested to discuss whether malignancies should be included as an important potential risk in the RMP for nemolizumab.

## Autoimmune diseases

In the Initial Period autoimmune disease as a TEAE was more common in placebo subjects than in nemolizumab 30 mg Q4W subjects.

During the Maintenance Period two (1.2%) nemolizumab 30 mg Q4W to Q8W subjects experienced an autoimmune disease. One (0.6%) nemolizumab 30 mg Q4W to Q4W subject experienced a TEAE of alopecia areata.

The applicant concludes that based on the review of reports of autoimmune diseases in the primary safety population considering also that AD has been associated with an increased risk for several autoimmune diseases, there is no evidence of an association between autoimmune diseases and nemolizumab.

## Injection site reactions

Reported injection site reactions were considered as a specific adverse reaction due to the subcutaneous route of administration of nemolizumab and a temporal link with the injection. However, no imbalance of injection site reactions was observed between nemolizumab 30 mg Q4W (1.3%) and placebo (1.1%). Injection site reactions include injection site erythema, injection site pain, injection site irritation, injection site oedema, injection site haematoma, and injection site pruritus reported in 15 nemolizumab subjects and injection site erythema, injection site pain, injection site reaction, injection site pruritus, and injection site inflammation reported in 7 placebo subjects.

Injection site reactions are included as an ADR in the SmPC and included events of injection site bruising (only mentioned as 'occurred in prurigo nodularis studies'), erythema, pruritus, pain, irritation, and oedema.

## Injection-related reactions

One (&lt;0.1%) nemolizumab 30 mg Q4W subject experienced an injection-related reaction during the Initial Period. The subject experienced injection site pain on Day 61 that qualified as an IRR since it was severe and lasted ≥ 24 hours.

In the Follow-up period one (0.1%) nemolizumab 30 mg Q4W subject experienced an injectionrelated reaction. The subject experienced dermatitis contact on Day 287 that was considered moderate in severity, not related to study drug or protocol procedure, and resolved on Day 318.

## Asthma

<div style=\"page-break-after: always\"></div>

At baseline of the Initial Period, 390 (32.7%) nemolizumab 30 mg Q4W subjects and 204 (31.9%) placebo subjects had a medical history of asthma. There were no serious AESIs of newly diagnosed asthma or worsening of asthma in the nemolizumab 30 mg Q4W group during the Initial Period.

At baseline of the Maintenance Period, 43 (25.3%) nemolizumab 30 mg Q4W to Q4W subjects, 51 (30.5%) nemolizumab 30 mg Q4W to Q8W subjects, 52 (31.0%) nemolizumab 30 mg Q4W to placebo subjects, and 47 (25.5%) re-assigned to placebo subjects had a medical history of asthma. There was 1 (0.6%) nemolizumab 30 Q4W to Q4W subject who experienced a serious AESI of newly diagnosed asthma or worsening of asthma.

AESIs of newly diagnosed asthma or worsening of asthma by SOC and PT during the treatment period (primary safety population) are presented in Table 57 .

Table 57: AESIs of newly diagnosed asthma or worsening of asthma by SOC and PT during the treatment period (primary safety population)

| Category SOC PT                                             | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|-------------------------------------------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| Category SOC PT                                             | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Any TEAE with newly diagnosed asthma or worsening of asthma | 51 (4.3)                    | 62 (4.8)              | 20 (3.1)            | 7 (4.1)                           | 6 (3.6)                           | 4 (2.4)                               | 5 (2.7)                                |
| Investigations                                              | 9 (0.8)                     | 9 (0.7)               | 4 (0.6)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 0                                      |
| Peak expiratory flow rate Decreased                         | 9 (0.8)                     | 9 (0.7)               | 4 (0.6)             | 2 (1.2)                           | 1 (0.6)                           | 1 (0.6)                               | 0                                      |
| Respiratory, thoracic and mediastinal disorders             | 42 (3.5)                    | 53 (4.1)              | 16 (2.5)            | 5 (2.9)                           | 5 (3.0)                           | 3 (1.8)                               | 5 (2.7)                                |
| Asthma                                                      | 42 (3.5)                    | 53 (4.1)              | 16 (2.5)            | 5 (2.9)                           | 5 (3.0)                           | 3 (1.8)                               | 5 (2.7)                                |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects who experienced the events; Nemo=nemolizumab; PT=preferred term; Q4W=every 4 weeks; Q8W=every 8 weeks; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. Percentages were based on the number of subjects in each treatment group. All TEAEs that started on or after the first dosing date were summarized by period based on the onset date. For Studies SPR.118161 and SPR.118169, the Initial Period was defined as the period from start of treatment up to and including Week 16. For Study SPR.114322, the whole Treatment Period from the start of treatment up to and including Week 24 was included in the Initial Period. The Maintenance Period was defined as the period up to and including Week 48 after the Initial Period (not applicable to subjects from Study SPR.114322). In case of early discontinuation, the Treatment Period extended from the start of treatment until 4 weeks after the last dosing (inclusive) date or early termination date, whichever was earlier.

a) Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.

In the Initial Period a total of 51 (4.3%) nemolizumab 30 mg Q4W subjects compared to 20 (3.1%) placebo subjects experienced an AESI meeting the per protocol definition of newly diagnosed asthma or worsening of asthma. During the Maintenance Period, the frequency of these AESIs were also higher in nemolizumab treated subjects compared to placebo subjects (4.1% nemolizumab 30 mg Q4W to Q4W subjects, 3.6% nemolizumab 30 mg Q4W to Q8W subjects 2.4% nemolizumab 30 mg Q4W to placebo subjects, and 2.7% re-assigned to placebo subjects).

Newly diagnosed asthma or worsening of asthma as a TEAE assessed as related to study drug was more common in placebo subjects than nemolizumab treated subjects in the Initial Period. However, during the Maintenance Period, the frequency of these TEAEs assessed as related to

<div style=\"page-break-after: always\"></div>

study drug was more than doubled for nemolizumab 30 mg Q4W to Q4W subjects compared to reassigned to placebo subjects (2,4% vs 1.1%).

## Adjudicated asthma events by the independent adjudication committee

Potential asthma-related AEs were assessed by an independent adjudication committee throughout pivotal Studies SPR.118161 and SPR.118169. It is noted that asthma-related AEs in Study SPR.114322 (also part of the primary safety population) are not assessed by the committee. The CHMP concludes that the pattern in asthma-related TEAEs assessed by the independent adjudication committee, is that asthma-related TEAEs are more common in nemolizumab treated subjects than in placebo subjects.

Adjudicated asthma-related TEAEs by SOC and PT during the treatment period are presented in Table 58 .

<div style=\"page-break-after: always\"></div>

Table 58: Adjudicated asthma-related TEAEs by SOC and PT during the treatment period (primary safety population)

| Adjudication SOC PT                             | Initial Period              | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|-------------------------------------------------|-----------------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| Adjudication SOC PT                             | Nemo 30 mg Q4W N=1135 n (%) | Placebo N=584 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Subjects with at least 1 adjudicated TEAE       | 60 (5.3)                    | 25 (4.3)            | 12 (7.1)                          | 7 (4.2)                           | 8 (4.8)                               | 6 (3.3)                                |
| Any confirmed asthma events                     | 43 (3.8)                    | 19 (3.3)            | 9 (5.3)                           | 6 (3.6)                           | 6 (3.6)                               | 5 (2.7)                                |
| Investigations                                  | 0                           | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Peak expiratory flow rate Decreased             | 0                           | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Respiratory, thoracic and mediastinal disorders | 43 (3.8)                    | 19 (3.3)            | 8 (4.7)                           | 6 (3.6)                           | 6 (3.6)                               | 5 (2.7)                                |
| Asthma                                          | 42 (3.7)                    | 19 (3.3)            | 6 (3.5)                           | 6 (3.6)                           | 6 (3.6)                               | 5 (2.7)                                |
| Wheezing                                        | 1 (<0.1)                    | 0                   | 2 (1.2)                           | 0                                 | 0                                     | 0                                      |
| Any confirmed new onset asthma events           | 4 (0.4)                     | 0                   | 2 (1.2)                           | 0                                 | 0                                     | 1 (0.5)                                |
| Respiratory, thoracic and mediastinal disorders | 4 (0.4)                     | 0                   | 2 (1.2)                           | 0                                 | 0                                     | 1 (0.5)                                |
| Asthma                                          | 4 (0.4)                     | 0                   | 2 (1.2)                           | 0                                 | 0                                     | 1 (0.5)                                |
| Any confirmed worsening of asthma events        | 39 (3.4)                    | 19 (3.3)            | 7 (4.1)                           | 6 (3.6)                           | 6 (3.6)                               | 4 (2.2)                                |
| Investigations                                  | 0                           | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Peak expiratory flow rate Decreased             | 0                           | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Respiratory, thoracic and mediastinal disorders | 39 (3.4)                    | 19 (3.3)            | 6 (3.5)                           | 6 (3.6)                           | 6 (3.6)                               | 4 (2.2)                                |
| Asthma                                          | 38 (3.3)                    | 19 (3.3)            | 4 (2.4)                           | 6 (3.6)                           | 6 (3.6)                               | 4 (2.2)                                |
| Wheezing                                        | 1 (<0.1)                    | 0                   | 2 (1.2)                           | 0                                 | 0                                     | 0                                      |
| Any events not confirmed by IAC                 | 17 (1.5)                    | 6 (1.0)             | 3 (1.8)                           | 1 (0.6)                           | 2 (1.2)                               | 2 (1.1)                                |
| Infections and infestations                     | 1 (<0.1)                    | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Bronchitis                                      | 1 (<0.1)                    | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Investigations                                  | 9 (0.8)                     | 4 (0.7)             | 1 (0.6)                           | 1 (0.6)                           | 1 (0.6)                               | 1 (0.5)                                |
| Peak expiratory flow rate Decreased             | 9 (0.8)                     | 4 (0.7)             | 1 (0.6)                           | 1 (0.6)                           | 1 (0.6)                               | 1 (0.5)                                |
| Respiratory, thoracic and mediastinal disorders | 7 (0.6)                     | 2 (0.3)             | 2 (1.2)                           | 0                                 | 1 (0.6)                               | 1 (0.5)                                |
| Wheezing                                        | 4 (0.4)                     | 1 (0.2)             | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Asthma                                          | 2 (0.2)                     | 1 (0.2)             | 0                                 | 0                                 | 0                                     | 1 (0.5)                                |
| Bronchospasm                                    | 1 (<0.1)                    | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Bronchial hyperreactivity                       | 0                           | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |

IAC=Independent Adjudication Committee; ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects who experienced the events; Nemo=nemolizumab; PT=preferred term; Q4W=every 4 weeks; Q8W=every 8 weeks; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. Percentages were based on the number of subjects in each treatment group. Only the TEAEs adjudicated by the IAC are included. All TEAEs that started on or after the first dosing date were summarized by period based on the onset date. The Initial Period was defined as the period from start of treatment up to and including Week 16. The Maintenance Period was defined as the period up to and including Week 48 after the Initial Period. In case of early discontinuation, the Treatment Period extended from the start of treatment until 4

<div style=\"page-break-after: always\"></div>

weeks after the last dosing (inclusive) date or early termination date, whichever was earlier. a) Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.

## PEF and Asthma Control Test (ACT)

No notable trends in actual PEF of the predicted value across all subjects, subjects with asthma history, and subjects without asthma history were observed between the nemolizumab 30 mg Q4W and placebo groups in the Initial Period. No notable trends in PEF &lt;80% of predicted value across all subjects, subjects with asthma history, and subjects without asthma history were observed between the nemolizumab and placebo groups in the Initial Period.

Table 59: Proportion of subjects with an ACT score ≤ 19 at weeks 4, 8, 12, and 16 - initial period (primary safety population)

| Timepoint        | Nemolizumab 30 mg Q4W N=1135 n/N (%)   | Placebo N=584 n/N (%)   |
|------------------|----------------------------------------|-------------------------|
| Initial baseline | 3/352 (0.9)                            | 3/180 (1.7)             |
| Week 4           | 13/339 (3.8)                           | 10/174 (5.7)            |
| Week 8           | 18/336 (5.4)                           | 3/172 (1.7)             |
| Week 12          | 17/328 (5.2)                           | 7/162 (4.3)             |
| Week 16          | 19/332 (5.7)                           | 6/168 (3.6)             |

ACT=asthma control test; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects with available data; Q4W=every 4 weeks

Note: Initial baseline value was the last valid value prior to first injection of study drug during the Initial Period. Percentages were calculated using the number of subjects with available results at the visit as the denominator. The ACT was assessed if subjects had a medical history of asthma at screening or if subjects had newly diagnosed asthma from a study visit.

Table 60: Proportion of subjects with an ACT score ≤ 19 at weeks 20, 32, and 48 maintenance period (primary safety population)

| Timepoint        | Nemolizumab 30 mg Q4W to Q4W N=170 n/N (%)   | Nemolizumab 30 mg Q4W to Q8W N=167 n/N (%)   | Nemolizumab 30 mg Q4W to placebo N=168 n/N (%)   | Re-assigned to placebo a N1=184 n/N1 (%)   |
|------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------|--------------------------------------------|
| Initial baseline | 0                                            | 0                                            | 0                                                | 0                                          |
| Week 20          | 3/47 (6.4)                                   | 1/50 (2.0)                                   | 2/52 (3.8)                                       | 2/45 (4.4)                                 |
| Week 32          | 4/47 (8.5)                                   | 0                                            | 0                                                | 1/48 (2.1)                                 |
| Week 48          | 1/47 (2.1)                                   | 0                                            | 1/38 (2.6)                                       | 1/51 (2.0)                                 |

ACT=asthma control test; ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects with available data; Q4W=every 4 weeks; Q8W=every 8 weeks

Note: Initial baseline value was the last valid value prior to first injection of study drug during the Initial Period. Week 16 measurements served as baseline measurements for the Maintenance Period (maintenance baseline). If Week 16 measurements were missing, the last valid non-missing measurements were taken as the baseline measurement for the Maintenance Period. Percentages were calculated using the number of subjects with available results at the visit as the denominator. The ACT was assessed if subjects had a medical history of asthma at screening or if subjects had newly diagnosed asthma from a study visit.

Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.

There seems to be a trend of a slightly higher proportion of subjects with an ACT score ≤19 at Weeks 4, 8, 12, and 16 during the Initial Period in nemolizumab 30 mg Q4W subjects compared to placebo subjects. The same trend is noted during the Maintenance Period with a higher proportion of subjects with an ACT score ≤19 in the Nemolizumab 30 mg Q4W to Q4W group compared to the re-assigned to placebo group.

<div style=\"page-break-after: always\"></div>

## Infections

All AESIs of infections included any severe infection, any infection requiring treatment with parenteral antibiotics or with oral antibiotics/antivirals/antifungals for &gt;2 weeks, and any confirmed or suspected COVID-19 infection. The CHMP considers that, by drawing the limit at &gt;2 weeks, there is a risk of missing infections with clinical relevance (e.g 10 days of antibiotic treatment is common). It is also assessed and questioned whether to select only severe infections, since an infection can be considered for inclusion in the SmPC section 4.8. regardless of severity. Below, the infections assessed as AESIs by the applicant are discussed.

## Initial Period

Of the herpetic infections reported as non-serious TEAEs (of mild or moderate severity) in 24 (2.0%) nemolizumab 30 mg Q4W subjects (oral herpes: 9 [0.8%] subjects; herpes dermatitis: 5 [0.4%] subjects; herpes simplex: 4 [0.3%] subjects; herpes virus infection: 5 [0.4%] subjects; nasal herpes: 1 [&lt;0.1%] subject; ophthalmic herpes: 1 [0.1%] subject) and 17 (2.7%) placebo subjects (oral herpes: 5 [0.8%] subjects; herpes simplex: 7 [1.1%] subjects; nasal herpes: 1 [0.2%] subjects; ophthalmic herpes simplex: 4 [0.6%] subjects; genital herpes: 1 [0.2%] subject), herpes simplex (1 [&lt;0.1%] nemolizumab subject) and ophthalmic herpes simplex (1 [0.2%] placebo subject) were reported as AESIs of infection.

Of TEAEs of herpes zoster-related events of mild or moderate severity reported in 5 nemolizumab 30 mg Q4W subjects (herpes zoster: 5 [0.4%] subjects; ophthalmic herpes zoster: 1 [&lt;0.1%] subject), ophthalmic herpes zoster in 1 (&lt;0.1%) nemolizumab 30 mg Q4W subject was reported as a serious AESI of infection.

The majority of study drug related AESIs of infection were non-serious, considered mild or moderate in severity, and resolved.

## Maintenance Period

Two (1.2%) nemolizumab 30 mg Q4W to Q4W subjects, 1 (0.6%) nemolizumab 30 mg Q4W to Q8W subject, and 1 (0.6%) nemolizumab 30 mg Q4W to placebo subject experienced serious AESIs of infection.

Herpetic infection TEAEs were reported in 8 (4.7%) nemolizumab 30 mg Q4W to Q4W subjects (oral herpes: 3 [1.8%] subjects; herpes dermatitis: 3 [1.8%] subjects; herpes simplex: 1 [0.6%] subject; ophthalmic herpes simplex: 1 [0.6%] subject), 6 (3.6%) nemolizumab 30 mg Q4W to Q8W subjects (oral herpes: 3 [1.8%] subjects; herpes dermatitis: 2 [1.2%] subjects; herpes ophthalmic: 1 [0.6%] subject), 4 (2.4%) nemolizumab 30 mg Q4W to placebo subjects (oral herpes: 1 [0.6%] subject; herpes dermatitis: 1 [0.6%] subject; herpes simplex: 1 [0.6%] subject; ophthalmic herpes simplex: 1 [0.6%] subject), and 5 (2.7%) re-assigned to placebo subjects (herpes simplex: 2 [1.2%] subjects; herpes virus infection: 1 [0.8%] subject; herpes ophthalmic: 1 [0.5%] subject).

Except for 1 serious and severe TEAE of cellulitis, TEAEs of skin infections were non-serious and were reported as:

(1) cellulitis in 3 (1.8%) nemolizumab 30 mg Q4W to Q8W subjects and 1 (0.6%) nemolizumab 30 mg Q4W to placebo subject; (2) breast cellulitis in 1 (0.5%) re-assigned to placebo subject; and (3) skin infection in 1 (0.5%) re-assigned to placebo subject. Two events of cellulitis in 2 (1.2%) nemolizumab 30 mg Q4W to Q8W subjects were reported as AESIs of infection, including 1 serious and severe.

<div style=\"page-break-after: always\"></div>

1 (0.6%) nemolizumab 30 mg Q4W to Q4W subject during the Maintenance Period experienced AESIs of infection that were considered study drug-related ( Table 61 ).

Table 61: AESIs of infections by SOC and PT during the treatment period (primary safety population)

| Category SOC PT                       | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|---------------------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| Category SOC PT                       | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Any TEAE with infections              | 40 (3.4)                    | 40 (3.1)              | 22 (3.4)            | 16 (9.4)                          | 17 (10.2)                         | 25 (14.9)                             | 21 (11.4)                              |
| Infections and infestations           | 40 (3.4)                    | 40 (3.1)              | 22 (3.4)            | 16 (9.4)                          | 17 (10.2)                         | 25 (14.9)                             | 20 (10.9)                              |
| COVID-19                              | 24 (2.0)                    | 24 (1.8)              | 14 (2.2)            | 13 (7.6)                          | 12 (7.2)                          | 19 (11.3)                             | 16 (8.7)                               |
| Skin infection                        | 3 (0.3)                     | 3 (0.2)               | 1 (0.2)             | 0                                 | 0                                 | 0                                     | 0                                      |
| Suspected COVID-19                    | 3 (0.3)                     | 3 (0.2)               | 1 (0.2)             | 0                                 | 0                                 | 0                                     | 0                                      |
| Asymptomatic COVID- 19                | 2 (0.2)                     | 2 (0.2)               | 3 (0.5)             | 2 (1.2)                           | 3 (1.8)                           | 4 (2.4)                               | 2 (1.1)                                |
| Superinfection bacterial              | 2 (0.2)                     | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Herpes simplex                        | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Infected cyst                         | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Ophthalmic herpes zoster              | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Staphylococcal impetigo               | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Staphylococcal infection              | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Tooth abscess                         | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Urinary tract infection               | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Appendicitis                          | 0                           | 0                     | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| COVID-19 pneumonia                    | 0                           | 0                     | 1 (0.2)             | 0                                 | 0                                 | 0                                     | 0                                      |
| Cellulitis                            | 0                           | 0                     | 0                   | 0                                 | 2 (1.2)                           | 0                                     | 0                                      |
| Eczema herpeticum                     | 0                           | 0                     | 0                   | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Erysipelas                            | 0                           | 0                     | 0                   | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Lyme disease                          | 0                           | 0                     | 0                   | 0                                 | 0                                 | 0                                     | 1 (0.5)                                |
| Ophthalmic herpes simplex             | 0                           | 0                     | 1 (0.2)             | 0                                 | 0                                 | 0                                     | 0                                      |
| Tinea manuum                          | 0                           | 0                     | 0                   | 0                                 | 0                                 | 0                                     | 1 (0.5)                                |
| Upper respiratory tract infection     | 0                           | 0                     | 1 (0.2)             | 0                                 | 0                                 | 0                                     | 0                                      |
| Investigations                        | 0                           | 0                     | 0                   | 0                                 | 0                                 | 0                                     | 1 (0.5)                                |
| Peak expiratory flow rate decreased b | 0                           | 0                     | 0                   | 0                                 | 0                                 | 0                                     | 1 (0.5)                                |

AESI=adverse event of special interest; IAC=Independent Adjudication Committee; ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects who experienced the events; Nemo=nemolizumab; PT=preferred term; Q4W=every 4 weeks; Q8W=every 8 weeks; SOC=system organ class; TEAE=treatment-emergent adverse event Note: Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. Percentages were based on the number of subjects in each treatment group. All TEAEs that started on or after the first dosing date were summarized by period based on the onset date. For Studies SPR.118161 and SPR.118169, the Initial Period was defined as the period from start of treatment up to and including Week 16. For Study SPR.114322, the whole Treatment Period from the start of treatment up to and including Week 24 was included in the Initial Period. The Maintenance Period was defined as the period up to and including Week 48 after the Initial Period (not applicable to subjects from Study SPR.114322). In case of early discontinuation,

<div style=\"page-break-after: always\"></div>

the Treatment Period extended from the start of treatment until 4 weeks after the last dosing (inclusive) date or early termination date, whichever was earlier.

- a) Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.
- b) This event was inadvertently grouped as an AESI of infection by the Investigator.

## Table 62: Subjects with study drug-related AESIs of infection (primary safety population)

| Preferred term                    | Start day/ end day           | Severity                     | Related to study drug/ injection procedure   | Outcome                      |
|-----------------------------------|------------------------------|------------------------------|----------------------------------------------|------------------------------|
| Nemolizumab 30 mg Q4W             | Nemolizumab 30 mg Q4W        | Nemolizumab 30 mg Q4W        | Nemolizumab 30 mg Q4W                        | Nemolizumab 30 mg Q4W        |
| Superinfection bacterial          | 42/ongoing                   | Moderate                     | Yes/No                                       | Not recovered/ not resolved  |
| Skin infection                    | 5/53                         | Moderate                     | Yes/No                                       | Recovered/resolved           |
| COVID-19                          | 87/108                       | Moderate                     | Yes/No                                       | Recovered/resolved           |
| COVID-19                          | 83/94                        | Mild                         | Yes/No                                       | Recovered/resolved           |
| Tooth abscess                     | 71/ongoing                   | Mild                         | Yes/No                                       | Not recovered/ not resolved  |
| Staphylococcal infection          | 19/ongoing                   | Moderate                     | Yes/Yes                                      | Not recovered/ not resolved  |
| COVID-19 b                        | 348/353                      | Mild                         | Yes/No                                       | Recovered/resolved           |
| Staphylococcal impetigo           | 50/63                        | Severe                       | Yes/No                                       | Recovered/resolved           |
| Herpes simplex a                  | 25/30                        | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Superinfection bacterial a        | 25/30                        | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Ophthalmic herpes zoster a        | 96/112                       | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Nemolizumab 30 mg Q4W to Q4W      | Nemolizumab 30 mg Q4W to Q4W | Nemolizumab 30 mg Q4W to Q4W | Nemolizumab 30 mg Q4W to Q4W                 | Nemolizumab 30 mg Q4W to Q4W |
| COVID-19                          | 224/240                      | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Placebo                           | Placebo                      | Placebo                      | Placebo                                      | Placebo                      |
| Upper respiratory tract infection | 32/57                        | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Ophthalmic herpes simplex         | 51/ongoing                   | Moderate                     | Yes/No                                       | Not recovered/ not resolved  |
| Skin infection                    | 42/55                        | Severe                       | Yes/Yes                                      | Recovered/resolved           |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; Q4W=every 4 weeks b) Event was also considered serious.

c) Event occurred during follow-up period.

## Peripheral oedema: limbs, bilateral; facial oedema

Peripheral oedema (limbs, bilateral) and facial oedema were grouped as a single entity for the purpose of signal detection. However, when analyzing the data, one should distinguish peripheral oedema (limb, bilateral) from facial oedema given the different etiologies of both medical concepts.

19 (1.6%) nemolizumab subjects and 2 (0.3%) placebo subjects experienced AESIs of peripheral oedema: limbs, bilateral; facial oedema during the Initial Period. 1 (0.6%) nemolizumab 30 mg Q4W to Q4W subject, 2 (1.2%) nemolizumab 30 mg Q4W to Q8W subjects, 3 (1.8%) nemolizumab 30 mg Q4W to placebo subjects and 0 re-assigned to placebo subjects experienced AESIs of peripheral oedema: limbs, bilateral; facial oedema during the Maintenance Period.

Two subjects had a relevant medical history (e.g. medical history of 'intermittent face oedema'). There were also some confounding factors in other cases. However, when assessing subjects with study drug-related AESIs of peripheral oedema, the imbalance is still present.

<div style=\"page-break-after: always\"></div>

Subjects with study drug-related AESIs of peripheral oedema: limbs, bilateral; facial oedema are presented in Table 63 .

Table 63: Subjects with study drug-related AESIs of peripheral oedema: limbs, bilateral; facial oedema (primary safety population)

| Preferred term               | Start day/ end day           | Severity                     | Related to study drug/ injection procedure   | Outcome                      |
|------------------------------|------------------------------|------------------------------|----------------------------------------------|------------------------------|
| Nemolizumab 30 mg Q4W        | Nemolizumab 30 mg Q4W        | Nemolizumab 30 mg Q4W        | Nemolizumab 30 mg Q4W                        | Nemolizumab 30 mg Q4W        |
| Oedema peripheral            | 78/97                        | Mild                         | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral            | 100/113                      | Mild                         | Yes/No                                       | Recovered/resolved           |
| Periorbital oedema           | 15/17                        | Mild                         | Yes/Yes                                      | Recovered/resolved           |
| Face oedema                  | 18/41                        | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral            | 49/140                       | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral            | 65/77                        | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral            | 95/102                       | Mild                         | Yes/No                                       | Recovered/resolved           |
| Face oedema                  | 43/48                        | Mild                         | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral a,b        | 39/54                        | Severe                       | Yes/No                                       | Recovered/resolved           |
| Nasal oedema a               | 41/51                        | Mild                         | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral a,c        | 21/37                        | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Eyelid oedema a,b            | 88/92                        | Moderate                     | Yes/Yes                                      | Recovered/resolved           |
| Nemolizumab 30 mg Q4W to Q8W | Nemolizumab 30 mg Q4W to Q8W | Nemolizumab 30 mg Q4W to Q8W | Nemolizumab 30 mg Q4W to Q8W                 | Nemolizumab 30 mg Q4W to Q8W |
| Joint swelling               | 207/ongoing                  | Mild                         | Yes/No                                       | Not recovered/ not resolved  |
| Placebo                      | Placebo                      | Placebo                      | Placebo                                      | Placebo                      |
| Oedema peripheral            | 67/99                        | Mild                         | Yes/Yes                                      | Recovered/resolved           |
| Face oedema                  | 8/18                         | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral            | 8/18                         | Moderate                     | Yes/No                                       | Recovered/resolved           |
| Oedema peripheral            | 36/63                        | Moderate                     | Yes/No                                       | Recovered/resolved           |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; Q4W=every 4 weeks; Q8W=every 8 weeks

a) Event also led to study drug withdrawal.

b) Event also led to study discontinuation.

c) Event was also considered serious.

One subject experienced urticaria and peripheral oedema during the Initial Period. The urticaria was assessed as aquagenic.

## Drug-induced liver injury

No subject had elevated ALT or AST &gt;3×ULN in combination with elevated bilirubin &gt;2×ULN during the Treatment Period or Follow-up Period.

## 2.6.11.1.4.  Laboratory findings

## Hematology

The laboratory reference range for eosinophils is defined as follows: minimum 0 - maximum 0.7 × 109/L. Any increase in eosinophils &gt;0.7 × 109/L when the value was ≤ 0.7 × 109/L at baseline was considered a potentially clinically significant value, regardless of the severity. The severity of eosinophilia has been arbitrarily divided into mild (ULN -1.5), moderate (1.5-5) and severe (&gt;5)

<div style=\"page-break-after: always\"></div>

In the initial Period, the proportion of subjects who experienced potentially clinically significant elevated eosinophils (worst post-baseline) was 10.2% in the nemolizumab 30 mg Q4W group and 5.8% in the placebo group; 2 (0.2%) nemolizumab 30 mg Q4W subjects experienced a TEAE of eosinophilia.

During the Maintenance Period, the proportion of subjects who experienced potentially clinically significant elevated eosinophils (worst post-baseline) was 8.9% in the nemolizumab 30 mg Q4W to Q4W group, 5.1% in the nemolizumab 30 mg Q4W to Q8W group, 3.2% in the nemolizumab 30 mg Q4W to placebo group, and 5.3% in the re assigned to placebo group; no subject experienced a TEAE of eosinophilia.

The applicant concludes that whilst there is an imbalance in the proportion of subjects who experienced potentially clinically significant elevated eosinophils in both the Initial Period and the Maintenance Period, only 1 event of mild eosinophilia was associated with clinical manifestation (serious dermatitis exfoliative generalised) and 1 severe eosinophilia (&gt;5 g/L) showed to be transient, reversible under treatment with nemolizumab, and without apparent clinical manifestations. The increase in eosinophils observed in this development program was not associated with eosinophilic disorders of clinical concern. Furthermore, data from a nemolizumab Phase 2b dose-finding study (10 mg, 30 mg, and 90 mg groups) did not show a dose-dependent increase of eosinophil counts, including potentially clinically significant elevated eosinophils.

## Clinical chemistry

Among the subjects who experienced potentially clinically significant elevated creatine kinase (defined as a &gt; 2.5 x upper limit of normal increase), 4 subjects presented with a TEAE of myalgia in temporal relationship with the abnormal creatine kinase value in the Initial Period. In 3 subjects, the reported myalgia was non-serious, mild in severity, and did not require any therapy. Of these 3 subjects, 1 subject was diagnosed with autoimmune thyroiditis (Hashimoto's disease) during the Maintenance Period, which may explain the symptoms of muscular weakness and myalgia. The applicant concludes that the transient nature of myalgia and single episode of elevated creatine kinase in another subject may suggest that the laboratory abnormality and symptoms may be linked to strenuous physical activity.

During the Maintenance Period, the proportion of subjects who experienced potentially clinically significant elevated creatine kinase (worst post-baseline) was 3.8% in the nemolizumab 30 mg Q4W to Q4W group, 5.1% in the nemolizumab 30 mg Q4W to Q8W group, 2.6% in the nemolizumab 30 mg Q4W to placebo group, and 1.8% in the re assigned to placebo group.

Among the subjects who experienced potentially clinically significant elevated creatine kinase, 1 (0.6%) a subject in the nemolizumab 30 mg Q4W to Q8W group with elevated creatine kinase (1220 U/L at Day 113; change from baseline: 1164 U/L) experienced a non-serious TEAE of myalgia of mild severity on Day 129. No action with nemolizumab was taken and the subject recovered without therapy on Day 154.

The applicant was requested to compile all cases of elevated creatine kinase in nemolizumab treated subjects and to report any occurrence of suspect myalgia in subjects with elevated creatine kinase as well as the overall myalgia occurrence in active treatment versus placebo.

In the initial period, CPK increased was less frequent in nemolizumab subjects compared to placebo subjects. In the Maintenance Period CPK increased was reported in 2 (1.2%), 3 (1.8%), 3 (1.8%) and 2 (1.1%) subjects in the nemolizumab 30 mg Q4W to Q4W, nemolizumab 30 mg Q4W to Q8W, nemolizumab 30 mg Q4W to placebo, and re-assigned to placebo groups, respectively.

<div style=\"page-break-after: always\"></div>

In the initial period, myalgia was more frequently reported in nemolizumab subjects (11 [0.9%]) than in  placebo  subjects  (1[0.2%]).  However,  this  trend  was  not  noted  during  the  maintenance period.  3  nemolizumab subjects (0.3%) and none with placebo had simultaneous events of CPK increased and myalgia during the initial period. The applicant states that alternative explanations including physical activity were available for most of them. No subject reported both events at the same time in any group during maintenance period. The proportion of subjects with at least one potentially clinically significant elevated CPK was similar with nemolizumab and placebo during the initial  period  but  higher  in  the  maintenance  period.  However,  none  of  the  subjects  reporting  a potentially clinically significant elevation appeared to have myalgia at the same time.

## Urinalysis

No notable trends were observed over time in continuous or categorical urinalysis data during the Initial Period and the Maintenance Period.

## Integrated summary of immunogenicity

In the pivotal AD studies (SPR.118161, SPR.118169) and LTE AD study (SPR.118163), the incidence of treatment-emergent anti-drug antibodies (ADAs) was 123 (11.2%), of which were persistent in 73 (6.6%) subjects and transient in 47 (4.3%) subjects. Treatment-boosted ADAs were rare and were observed in 3 (0.3%) subjects and neutralizing ADAs were observed in 5 (0.5%) subjects. The median time to the development of first post-baseline anti-drug antibody (ADA) was 24 weeks (range: 2.14-108 weeks).

## 2.6.11.2.  In vitro biomarker test for patient selection for safety

Not applicable

## 2.6.11.3.  Safety in special populations

## Age

A summary of TEAEs by age group during the Treatment Period is presented in Table 64 and Table 65 .

No major differences in the safety profile of nemolizumab across age groups were identified in the Initial Period or in the Maintenance Period by the applicant.

<div style=\"page-break-after: always\"></div>

Table 64: Summary of TEAEs by age group during the treatment period - initial period (primary safety population)

|                                                                                                         | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       |
|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                                                                                                         | Nemolizumab 30 mg Q4W n (%)                                                                             | Nemolizumab 30 mg Q4W n (%)                                                                             | Nemolizumab 30 mg Q4W n (%)                                                                             | Placebo n (%)                                                                                           | Placebo n (%)                                                                                           | Placebo n (%)                                                                                           |
|                                                                                                         | 12 to 17 (N=176 )                                                                                       | 18 to 65 (N=944 )                                                                                       | >65 (N=72 )                                                                                             | 12 to 17 (N=89 )                                                                                        | 18 to 65 (N=524 )                                                                                       | >65 (N=27 )                                                                                             |
| Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               |
| TEAE                                                                                                    | 64 (36.4)                                                                                               | 475 (50.3)                                                                                              | 27 (37.5)                                                                                               | 35 (39.3)                                                                                               | 261 (49.8)                                                                                              | 10 (37.0)                                                                                               |
| Severe TEAE                                                                                             | 4 (2.3)                                                                                                 | 36 (3.8)                                                                                                | 3 (4.2)                                                                                                 | 1 (1.1)                                                                                                 | 18 (3.4)                                                                                                | 1 (3.7)                                                                                                 |
| Study drug- related TEAE                                                                                | 19 (10.8)                                                                                               | 180 (19.1)                                                                                              | 8 (11.1)                                                                                                | 4 (4.5)                                                                                                 | 83 (15.8)                                                                                               | 4 (14.8)                                                                                                |
| SAE                                                                                                     | 3 (1.7)                                                                                                 | 17 (1.8)                                                                                                | 1 (1.4)                                                                                                 | 1 (1.1)                                                                                                 | 6 (1.1)                                                                                                 | 1 (3.7)                                                                                                 |
| SAE related to study drug                                                                               | 1 (0.6)                                                                                                 | 5 (0.5)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       |
| TEAE leading to study drug withdrawal                                                                   | 2 (1.1)                                                                                                 | 28 (3.0)                                                                                                | 1 (1.4)                                                                                                 | 1 (1.1)                                                                                                 | 16 (3.1)                                                                                                | 3 (11.1)                                                                                                |
| TEAE leading to study discontinuation                                                                   | 1 (0.6)                                                                                                 | 23 (2.4)                                                                                                | 1 (1.4)                                                                                                 | 1 (1.1)                                                                                                 | 4 (0.8)                                                                                                 | 1 (3.7)                                                                                                 |
| AESI (Investigator)                                                                                     | 16 (9.1)                                                                                                | 89 (9.4)                                                                                                | 2 (2.8)                                                                                                 | 3 (3.4)                                                                                                 | 39 (7.4)                                                                                                | 0                                                                                                       |
| Adjudicated asthma event                                                                                | 7 (4.0)                                                                                                 | 36 (3.8)                                                                                                | 0                                                                                                       | 4 (4.5)                                                                                                 | 15 (2.9)                                                                                                | 0                                                                                                       |
| TEAE leading to death                                                                                   | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       |
| TEAEs observed in ≥2.0% of subjects in either group in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in either group in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in either group in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in either group in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in either group in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in either group in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in either group in the primary safety population                    |
| Atopic dermatitis                                                                                       | 10 (5.7)                                                                                                | 107 (11.3)                                                                                              | 7 (9.7)                                                                                                 | 8 (9.0)                                                                                                 | 54 (10.3)                                                                                               | 4 (14.8)                                                                                                |
| Headache                                                                                                | 4 (2.3)                                                                                                 | 45 (4.8)                                                                                                | 1 (1.4)                                                                                                 | 2 (2.2)                                                                                                 | 26 (5.0)                                                                                                | 0                                                                                                       |
| Nasopharyngiti s                                                                                        | 9 (5.1)                                                                                                 | 32 (3.4)                                                                                                | 1 (1.4)                                                                                                 | 2 (2.2)                                                                                                 | 28 (5.3)                                                                                                | 1 (3.7)                                                                                                 |
| Asthma                                                                                                  | 8 (4.5)                                                                                                 | 40 (4.2)                                                                                                | 0                                                                                                       | 4 (4.5)                                                                                                 | 17 (3.2)                                                                                                | 0                                                                                                       |
| COVID-19                                                                                                | 2 (1.1)                                                                                                 | 21 (2.2)                                                                                                | 1 (1.4)                                                                                                 | 2 (2.2)                                                                                                 | 12 (2.3)                                                                                                | 0                                                                                                       |
| Upper respiratory tract infection                                                                       | 5 (2.8)                                                                                                 | 14 (1.5)                                                                                                | 1 (1.4)                                                                                                 | 3 (3.4)                                                                                                 | 16 (3.1)                                                                                                | 1 (3.7)                                                                                                 |
| Study drug-related TEAEs observed in ≥1.0% of subjects in either group in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in either group in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in either group in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in either group in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in either group in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in either group in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in either group in the primary safety population |
| Atopic dermatitis                                                                                       | 1 (0.6)                                                                                                 | 41 (4.3)                                                                                                | 2 (2.8)                                                                                                 | 0                                                                                                       | 12 (2.3)                                                                                                | 3 (11.1)                                                                                                |
| Asthma                                                                                                  | 4 (2.3)                                                                                                 | 16 (1.7)                                                                                                | 0                                                                                                       | 1 (1.1)                                                                                                 | 10 (1.9)                                                                                                | 0                                                                                                       |
| Headache                                                                                                | 1 (0.6)                                                                                                 | 14 (1.5)                                                                                                | 0                                                                                                       | 0                                                                                                       | 7 (1.3)                                                                                                 | 0                                                                                                       |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; Q4W=every 4 weeks; SAE=serious adverse event; TEAE=treatment-emergent adverse event

<div style=\"page-break-after: always\"></div>

Table 65: Summary of TEAEs by age group during the treatment period - maintenance period (primary safety population)

|                                                                                                         | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       | Age Group (years)                                                                                       |
|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                                                                                                         | Nemolizumab 30 mg Q4W to Q4W n (%)                                                                      | Nemolizumab 30 mg Q4W to Q4W n (%)                                                                      | Nemolizumab 30 mg Q4W to Q8W n (%)                                                                      | Nemolizumab 30 mg Q4W to Q8W n (%)                                                                      | Re-assigned to Placebo n (%)                                                                            | Re-assigned to Placebo n (%)                                                                            |
|                                                                                                         | 12 to 17 (N=35 )                                                                                        | 18 to 65 (N=128 )                                                                                       | 12 to 17 (N=32 )                                                                                        | 18 to 65 (N=128 )                                                                                       | 12 to 17 (N=42 )                                                                                        | 18 to 65 (N=129 )                                                                                       |
| Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               | Subjects with at least 1:                                                                               |
| TEAE                                                                                                    | 15 (42.9)                                                                                               | 75 (58.6)                                                                                               | 20 (62.5)                                                                                               | 66 (51.6)                                                                                               | 27 (64.3)                                                                                               | 65 (50.4)                                                                                               |
| Severe TEAE                                                                                             | 0                                                                                                       | 5 (3.9)                                                                                                 | 1 (3.1)                                                                                                 | 4 (3.1)                                                                                                 | 1 (2.4)                                                                                                 | 1 (0.8)                                                                                                 |
| Study drug- related TEAE                                                                                | 0                                                                                                       | 18 (14.1)                                                                                               | 5 (15.6)                                                                                                | 13 (10.2)                                                                                               | 3 (7.1)                                                                                                 | 11 (8.5)                                                                                                |
| SAE                                                                                                     | 3 (8.6)                                                                                                 | 7 (5.5)                                                                                                 | 1 (3.1)                                                                                                 | 1 (0.8)                                                                                                 | 0                                                                                                       | 2 (1.6)                                                                                                 |
| SAE related to study drug                                                                               | 0                                                                                                       | 1 (0.8)                                                                                                 | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       |
| TEAE leading to study drug withdrawal                                                                   | 0                                                                                                       | 4 (3.1)                                                                                                 | 1 (3.1)                                                                                                 | 2 (1.6)                                                                                                 | 1 (2.4)                                                                                                 | 3 (2.3)                                                                                                 |
| TEAE leading to study discontinuation                                                                   | 0                                                                                                       | 3 (2.3)                                                                                                 | 1 (3.1)                                                                                                 | 2 (1.6)                                                                                                 | 0                                                                                                       | 2 (1.6)                                                                                                 |
| AESI (Investigator)                                                                                     | 4 (11.4)                                                                                                | 20 (15.6)                                                                                               | 8 (25.0)                                                                                                | 15 (11.7)                                                                                               | 6 (14.3)                                                                                                | 18 (14.0)                                                                                               |
| Adjudicated asthma event                                                                                | 2 (5.7)                                                                                                 | 7 (5.5)                                                                                                 | 0                                                                                                       | 6 (4.7)                                                                                                 | 1 (2.4)                                                                                                 | 4 (3.1)                                                                                                 |
| TEAE leading to death                                                                                   | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       | 0                                                                                                       |
| TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population                    | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population                    |
| Atopic dermatitis                                                                                       | 2 (5.7)                                                                                                 | 11 (8.6)                                                                                                | 1 (3.1)                                                                                                 | 9 (7.0)                                                                                                 | 4 (9.5)                                                                                                 | 11 (8.5)                                                                                                |
| Headache                                                                                                | 1 (2.9)                                                                                                 | 5 (3.9)                                                                                                 | 1 (3.1)                                                                                                 | 6 (4.7)                                                                                                 | 2 (4.8)                                                                                                 | 2 (1.6)                                                                                                 |
| Nasopharyngiti s                                                                                        | 2 (5.7)                                                                                                 | 12 (9.4)                                                                                                | 1 (3.1)                                                                                                 | 7 (5.5)                                                                                                 | 2 (4.8)                                                                                                 | 10 (7.8)                                                                                                |
| Asthma                                                                                                  | 1 (2.9)                                                                                                 | 5 (3.9)                                                                                                 | 0                                                                                                       | 6 (4.7)                                                                                                 | 1 (2.4)                                                                                                 | 4 (3.1)                                                                                                 |
| COVID-19                                                                                                | 2 (5.7)                                                                                                 | 11 (8.6)                                                                                                | 4 (12.5)                                                                                                | 9 (7.0)                                                                                                 | 4 (9.5)                                                                                                 | 12 (9.3)                                                                                                |
| Upper respiratory tract infection                                                                       | 2 (5.7)                                                                                                 | 2 (1.6)                                                                                                 | 2 (6.3)                                                                                                 | 3 (2.3)                                                                                                 | 6 (14.3)                                                                                                | 5 (3.9)                                                                                                 |
| Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population |
| Atopic dermatitis                                                                                       | 0                                                                                                       | 5 (3.9)                                                                                                 | 1 (3.1)                                                                                                 | 1 (0.8)                                                                                                 | 0                                                                                                       | 3 (2.3)                                                                                                 |
| Asthma                                                                                                  | 0                                                                                                       | 3 (2.3)                                                                                                 | 0                                                                                                       | 2 (1.6)                                                                                                 | 1 (2.4)                                                                                                 | 1 (0.8)                                                                                                 |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; Q4W=every 4 weeks; Q8W=every 8 weeks; SAE=serious adverse event; TEAE=treatment-emergent adverse event

The applicant was asked to submit tables presenting 'AEs by age range' from the Initial Period and the Maintenance Period ( Table 66 and Table 67 ). The applicant states that no clinically relevant trends were observed with increasing age compared to what has been reported with the overall population.

<div style=\"page-break-after: always\"></div>

Table 66: AEs by age range during the Initial treatment period (AD primary safety population)

| MedDRA Terms                                                                          | Nemolizumab 30mgQ4W   | Nemolizumab 30mgQ4W   | Nemolizumab 30mgQ4W   | Nemolizumab 30mgQ4W   | Placebo             | Placebo              | Placebo             | Placebo           |
|---------------------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|---------------------|----------------------|---------------------|-------------------|
| MedDRA Terms                                                                          | Age <65 n (%) N=1112  | Age 65-74 n (%) N=63  | Age 75-84 n (%) N=17  | Age 85+ n (%) N=0     | Age <65 n (%) N=606 | Age 65-74 n (%) N=28 | Age 75-84 n (%) N=5 | Age 85+ n (%) N=0 |
| Total TEAEs                                                                           | 537 (48.3)            | 21 (33.3)             | 8 (47.1)              | 0                     | 294 (48.5)          | 12 (42.9)            | 0                   | 0                 |
| Serious AEs - Total                                                                   | 19 (1.7)              | 2 (3.2)               | 0                     | 0                     | 7 (1.2)             | 1 (3.6)              | 0                   | 0                 |
| - Fatal                                                                               | 0                     | 0                     | 0                     | 0                     | 0                   | 0                    | 0                   | 0                 |
| - Hospitalisation/ prolong existing hospitalisation                                   | 17 (1.5)              | 2 (3.2)               | 0                     | 0                     | 7 (1.2)             | 1 (3.6)              | 0                   | 0                 |
| - Life-threatening                                                                    | 0                     | 0                     | 0                     | 0                     | 0                   | 0                    | 0                   | 0                 |
| - Disability/incapacity                                                               | 0                     | 0                     | 0                     | 0                     | 0                   | 0                    | 0                   | 0                 |
| - Other (medically significant)                                                       | 2                     | 0                     | 0                     | 0                     | 0                   | 0                    | 0                   | 0                 |
| TEAE leading to drop-out                                                              | 23 (2.1)              | 1 (1.6)               | 1 (5.9)               | 0                     | 5 (0.8)             | 1 (3.6)              | 0                   | 0                 |
| Psychiatric disorders                                                                 | 22 (2.0)              | 1 (1.6)               | 0                     | 0                     | 10 (1.7)            | 1 (3.6)              | 0                   | 0                 |
| Nervous system disorders                                                              | 68 (6.1)              | 2 (3.2)               | 0                     | 0                     | 37 (6.1)            | 0                    | 0                   | 0                 |
| Accidents and injuries                                                                | 24 (2.2)              | 3 (4.8)               | 0                     | 0                     | 15 (2.5)            | 0                    | 0                   | 0                 |
| Cardiac disorders                                                                     | 8 (0.7)               | 3 (4.8)               | 0                     | 0                     | 3 (0.5)             | 1 (3.6)              | 0                   | 0                 |
| Vascular disorders                                                                    | 14 (1.3)              | 2 (3.2)               | 0                     | 0                     | 6 (1.0)             | 1 (3.6)              | 0                   | 0                 |
| Cerebrovascular disorders                                                             | 0                     | 0                     | 0                     | 0                     | 0                   | 0                    | 0                   | 0                 |
| Infections and infestations                                                           | 221 (19.9)            | 9 (14.3)              | 2 (11.8)              | 0                     | 138 (22.8)          | 6 (21.4)             | 0                   | 0                 |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 12 (1.1)              | 2 (3.2)               | 0                     | 0                     | 6 (1.0)             | 0                    | 0                   | 0                 |
| Autoimmune diseases                                                                   | 2 (0.2)               | 0                     | 0                     | 0                     | 4 (0.7)             | 0                    | 0                   | 0                 |
| Asthma                                                                                | 48 (4.3)              | 0                     | 0                     | 0                     | 21 (3.5)            | 0                    | 0                   | 0                 |
| Peripheral oedema                                                                     | 9 (0.8)               | 1 (1.6)               | 0                     | 0                     | 3 (0.5)             | 0                    | 0                   | 0                 |
| Arthralgia                                                                            | 13 (1.2)              | 1 (1.6)               | 1 (5.9)               | 0                     | 3 (0.5)             | 0                    | 0                   | 0                 |
| Dyspnoea                                                                              | 0                     | 0                     | 0                     | 0                     | 0                   | 0                    | 0                   | 0                 |
| Fatigue                                                                               | 10 (0.9)              | 2 (3.2)               | 0                     | 0                     | 3 (0.5)             | 0                    | 0                   | 0                 |
| Eye disorders                                                                         | 26 (2.3)              | 3 (4.8)               | 0                     | 0                     | 15 (2.5)            | 0                    | 0                   | 0                 |

AE = adverse event; AD = atopic dermatitis; MedDRA = Medical Dictionary for Regulatory Activities; N = number of subjects in the population of each group; n =number of subjects who experienced the event Percentage (%) is based on the N; TEAE = treatment emergent adverse event.

<div style=\"page-break-after: always\"></div>

Notes: For studies RD.06.SPR.118161 and RD.06.SPR.118169, the initial treatment period is defined as the period from start of treatment up to and including Week 16.

For study RD.03.SPR.114322, the whole treatment period from start of treatment up to and including Week 24 is included in the initial treatment period.

In case of early discontinuation, the treatment period extends from start of treatment until 4 weeks after last dosing date or early termination date.

Table 67: AEs by age range during the Maintenance treatment period (AD primary safety population)

| MedD RA Terms                                         | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   |
|-------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| MedD RA Terms                                         | Age <65 n (%) N=1 63         | Ag e 65- 74 n (% ) N= 5      | Ag e 75- 84 n (% ) N= 2      | Ag e 85 + n (% ) N= 0        | Age <65 n (%) N=15 8         | Age 65-74 n (%) N=8          | Age 75-84 n (%) N=1          | Age 85+ n (%) N=0            | Age <65 n (%) N=14 9              | Age 65-74 n (%) N=15              | Age 75-84 n (%) N=4               | Age 85+ n (%) N=0                 | Age <65 n (%) N=17 0     | Age 65-74 n (%) N=10     | Age 75-84 n (%) N=3      | Age 85+ n (%) N=1        |
| Total TEAEs                                           | 90 (55. 2)                   | 1 (20 .0)                    | 0                            | 0                            | 85 (53.8 )                   | 4 (50.0 )                    | 1 (100)                      | 0                            | 90 (60.4 )                        | 6 (40.0 )                         | 2 (50.0 )                         | 0                                 | 92 (54.1 )               | 0                        | 0                        | 0                        |
| Serious AEs - Total                                   | 10 (6.1)                     | 0                            | 0                            | 0                            | 2 (1.3)                      | 0                            | 1 (100)                      | 0                            | 3 (2.0)                           | 1 (6.7)                           | 0                                 | 0                                 | 2 (1.2)                  | 0                        | 0                        | 0                        |
| - Fatal                                               | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                                 | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| - Hospita lisation/ prolong existing hospital isation | 10 (6.1)                     | 0                            | 0                            | 0                            | 2 (1.3)                      | 0                            | 1 (100)                      | 0                            | 3 (2.0)                           | 0                                 | 0                                 | 0                                 | 2 (1.2)                  | 0                        | 0                        | 0                        |
| - Life- threaten ing                                  | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                                 | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| - Disabili ty/ incapaci ty                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                                 | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| - Other (medica lly signific ant)                     | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                                 | 1                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| TEAE leading to drop- out                             | 3 (1.8)                      | 0                            | 0                            | 0                            | 3 (1.9)                      | 1 (12.5 )                    | 1 (100)                      | 0                            | 3 (2.0)                           | 1 (6.7)                           | 0                                 | 0                                 | 2 (1.2)                  | 0                        | 0                        | 0                        |
| Psychia tric disorder s                               | 3 (1.8)                      | 0                            | 0                            | 0                            | 2 (1.3)                      | 0                            | 0                            | 0                            | 1 (0.7)                           | 0                                 | 0                                 | 0                                 | 3 (1.8)                  | 0                        | 0                        | 0                        |

<div style=\"page-break-after: always\"></div>

| MedD RA Terms                                                                             | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   |
|-------------------------------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| MedD RA Terms                                                                             | Age <65 n (%) N=1 63         | Ag e 65- 74 n (% ) N= 5      | Ag e 75- 84 n (% ) N= 2      | Ag e 85 + n (% ) N= 0        | Age <65 n (%) N=15 8         | Age 65-74 n (%) N=8          | Age 75-84 n (%) N=1          | Age 85+ n (%) N=0            | Age <65 n (%) N=14 9              | Age 65-74 n (%) N=15              | Age 75-84 n (%) N=4               | Age 85+ n (%) N=0                 | Age <65 n (%) N=17 0     | Age 65-74 n (%) N=10     | Age 75-84 n (%) N=3      | Age 85+ n (%) N=1        |
| Nervou s system disorder s                                                                | 9 (5.5)                      | 0                            | 0                            | 0                            | 11 (7.0)                     | 0                            | 0                            | 0                            | 5 (3.4)                           | 1 (6.7)                           | 0                                 | 0                                 | 7 (4.1)                  | 0                        | 0                        | 0                        |
| Acciden ts and injuries                                                                   | 4 (2.5)                      | 0                            | 0                            | 0                            | 7 (4.4)                      | 1 (12.5 )                    | 0                            | 0                            | 2 (1.3)                           | 0                                 | 0                                 | 0                                 | 5 (2.9)                  | 0                        | 0                        | 0                        |
| Cardiac disorder s                                                                        | 1 (0.6)                      | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 1 (0.7)                           | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| Vascula r disorder s                                                                      | 3 (1.8)                      | 0                            | 0                            | 0                            | 2 (1.3)                      | 0                            | 0                            | 0                            | 2 (1.3)                           | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| Cerebro vascular disorder s                                                               | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                                 | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| Infectio ns and infestati ons                                                             | 53 (32. 5)                   | 0                            | 0                            | 0                            | 46 (29.1 )                   | 1 (12.5 )                    | 1 (100)                      | 0                            | 51 (34.2 )                        | 3 (20.0 )                         | 1 (25.0 )                         | 0                                 | 58 (34.1 )               | 0                        | 0                        | 0                        |
| Sum of postural hypoten sion, falls, black outs, syncope , dizzines s, ataxia, fracture s | 2 (1.2)                      | 0                            | 0                            | 0                            | 2 (1.3)                      | 0                            | 0                            | 0                            | 1 (0.7)                           | 0                                 | 0                                 | 0                                 | 2 (1.2)                  | 0                        | 0                        | 0                        |
| Autoim mune diseases                                                                      | 1 (0.6)                      | 0                            | 0                            | 0                            | 1 (0.6)                      | 0                            | 0                            | 0                            | 0                                 | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| Asthma                                                                                    | 6 (3.7)                      | 0                            | 0                            | 0                            | 6 (3.8)                      | 0                            | 0                            | 0                            | 5 (3.4)                           | 1 (6.7)                           | 0                                 | 0                                 | 5 (2.9)                  | 0                        | 0                        | 0                        |
| Periphe ral oedema                                                                        | 1 (0.6)                      | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                                 | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| Arthral gia                                                                               | 0                            | 0                            | 0                            | 0                            | 1 (0.6)                      | 1 (12.5 )                    | 0                            | 0                            | 1 (0.7)                           | 0                                 | 0                                 | 0                                 | 1 (0.6)                  | 0                        | 0                        | 0                        |

<div style=\"page-break-after: always\"></div>

| MedD RA Terms   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ4W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4WtoQ8W   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Nemolizumab 30 mg Q4Wto Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   | Re-assigned to Placebo   |
|-----------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| MedD RA Terms   | Age <65 n (%) N=1 63         | Ag e 65- 74 n (% ) N= 5      | Ag e 75- 84 n (% ) N= 2      | Ag e 85 + n (% ) N= 0        | Age <65 n (%) N=15 8         | Age 65-74 n (%) N=8          | Age 75-84 n (%) N=1          | Age 85+ n (%) N=0            | Age <65 n (%) N=14 9              | Age 65-74 n (%) N=15              | Age 75-84 n (%) N=4               | Age 85+ n (%) N=0                 | Age <65 n (%) N=17 0     | Age 65-74 n (%) N=10     | Age 75-84 n (%) N=3      | Age 85+ n (%) N=1        |
| Dyspno ea       | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                            | 0                                 | 0                                 | 0                                 | 0                                 | 0                        | 0                        | 0                        | 0                        |
| Fatigue         | 0                            | 0                            | 0                            | 0                            | 1 (0.6)                      | 0                            | 0                            | 0                            | 1 (0.7)                           | 0                                 | 0                                 | 0                                 | 1 (0.6)                  | 0                        | 0                        | 0                        |
| Eye disorder s  | 3 (1.8)                      | 0                            | 0                            | 0                            | 2 (1.3)                      | 0                            | 0                            | 0                            | 6 (4.0)                           | 1 (6.7)                           | 0                                 | 0                                 | 2 (1.2)                  | 0                        | 0                        | 0                        |

AE = adverse event; AD = atopic dermatitis; MedDRA = Medical Dictionary for Regulatory Activities; N = number of subjects in the population of each group; n = number of subjects who experienced the event Percentage (%) is based on the N; TEAE = treatment emergent adverse event.

Notes: Included studies are RD.06.SPR.118161 and RD.06.SPR.118169.

Maintenance Treatment Period is defined as the period up to and including Week 48 after initial period. In case of early discontinuation, the treatment period extends from start of treatment until 4 weeks after last dosing date or early termination date.

<div style=\"page-break-after: always\"></div>

AESI was reported at a higher frequency with Nemolizumab 30 mg Q4W subjects in the age group 12 to 17 years (9.1%) compared to placebo subjects in the age group 12 to 17 years (3.4%) during the Initial Period. It is noted that this difference in frequency is greater compared to the difference seen in the age group 18 to 65 years (Nemolizumab 30 mg Q4W subjects 9.4%, placebo subjects 7.4%).

Table 68: Summary of TEAEs by Age Group by SOC and PT reported in ≥ 2.0% of subjects in either age group (Long Term Extension Study SPR.118163 safety population)

|                                                 | 12-17 Years                | 18-65 years                  |
|-------------------------------------------------|----------------------------|------------------------------|
|                                                 | Nemo 30 mg Q4W N=254 n (%) | Nemol 30 mg Q4W N=1408 n (%) |
| Any TEAE                                        | 164 (64.6)                 | 894 (63.5)                   |
| Gastrointestinal disorders                      | 19 (7.5)                   | 108 (7.7)                    |
| Diarrhoea                                       | 7 (2.8)                    | 29 (2.1)                     |
| Infections and infestations                     | 103 (40.6)                 | 595 (42.3)                   |
| Nasopharyngitis                                 | 23 (9.1)                   | 137 (9.7)                    |
| Upper respiratory tract infections              | 24 (9.4)                   | 73 (5.2)                     |
| COVID-19                                        | 28 (11.0)                  | 248 (17.6)                   |
| Asymptomatic COVID-19                           | 5 (2.0)                    | 32 (2.3)                     |
| Impetigo                                        | 6 (2.4)                    | 17 (1.2)                     |
| Rhinitis                                        | 6 (2.4)                    | 17 (1.2)                     |
| Bronchitis                                      | 7 (2.8)                    | 15 (1.1)                     |
| Urinary tract infections                        | 4 (1.6)                    | 34 (2.4)                     |
| Investigations                                  | 18 (7.1)                   | 85 (6.0)                     |
| Blood creatine phosphokinase increased          | 7 (2.8)                    | 36 (2.6)                     |
| Musculoskeletal and connective tissue disorders | 18 (7.1)                   | 119 (8.5)                    |
| Back pain                                       | 4 (1.6)                    | 29 (2.1)                     |
| Nervous system disorders                        | 11 (4.3)                   | 108 (7.7)                    |
| Headache                                        | 4 (1.6)                    | 73 (5.2)                     |
| Respiratory, thoracic and mediastinal disorders | 22 (8.7)                   | 161 (11.4)                   |
| Asthma                                          | 3 (1.2)                    | 65 (4.6)                     |
| Cough                                           | 6 (2.4)                    | 30 (2.1)                     |
| Rhinorrhoea                                     | 5 (2.0)                    | 12 (0.9)                     |
| Skin and subcutaneous tissue disorders          | 50 (19.7)                  | 285 (20.2)                   |
| Atopic dermatitis                               | 33 (13.0)                  | 185 (13.1)                   |
| Acne                                            | 7 (2.8)                    | 12 (0.9)                     |

N1 = number of subjects who responded to placebo and continue to receive placebo in the maintenance period; PBO = placebo; PT = Preferred Term; SOC = System Organ Class; TEAE = treatment emergent adverse event; Nemo = nemolizumab.

* Subjects randomized to placebo in the initial phase and continuing on placebo in the maintenance phase.

Due to the low number of nemolizumab 30 mg Q4W and placebo subjects in the &gt;65 years of age group (N=72 and N=27, respectively) in the Initial Period, the applicant has not compared this age group to other age groups.

<div style=\"page-break-after: always\"></div>

## Sex

The percentages of subjects who experienced at least 1 AESI (by Investigator) was higher in female subjects (10.3%) than male subjects (7.7%) in the Initial Period.

In the Initial Period, among TEAEs observed in ≥ 2.0% of subjects in the nemolizumab 30 mg Q4W or placebo groups in the primary safety population, the incidence of headache in the nemolizumab 30 mg Q4W group was higher in female subjects (6.4%) than male subjects (2.0%). However, among study drug-related TEAEs observed in ≥ 1.0% of subjects in the nemolizumab 30 mg Q4W or placebo groups in the primary safety population, the incidences of headache (0.3% and 2.2%) in the nemolizumab 30 mg Q4W group were more similar between male and female subjects.

The percentage of female subjects in the nemolizumab 30 mg Q4W group that experienced an AESI (by Investigator) was higher (10.3%) than the percentage of male subjects (7.7%) that experienced an AESI (by Investigator). However, the applicant states that no notable differences in the incidence of any specific AESI (by Investigator) for the categories of IRRs, newly diagnosed asthma or worsening of asthma, infections, peripheral oedema: limbs, bilateral; facial oedema, or ALT or AST &gt;3×ULN in combination with elevated bilirubin &gt;2×ULN were observed between male and female subjects. Overall, no major differences in the safety profile of nemolizumab between male and female subjects were identified in the Initial Period.

Table 69: Summary of TEAEs by sex during the treatment period - maintenance period (primary safety population) (modified)

|                                                                                      | Nemolizumab 30 mg Q4W to Q4W n (%)                                                   | Nemolizumab 30 mg Q4W to Q4W n (%)                                                   | Nemolizumab 30 mg Q4W to Q8W n (%)                                                   | Nemolizumab 30 mg Q4W to Q8W n (%)                                                   | Re-assigned to Placebo n (%)                                                         | Re-assigned to Placebo n (%)                                                         |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|                                                                                      | Male (N=70)                                                                          | Female (N=100)                                                                       | Male (N=71)                                                                          | Female (N=96)                                                                        | Male (N=91)                                                                          | Female (N=93)                                                                        |
| Subjects with at least 1:                                                            | Subjects with at least 1:                                                            | Subjects with at least 1:                                                            | Subjects with at least 1:                                                            | Subjects with at least 1:                                                            | Subjects with at least 1:                                                            | Subjects with at least 1:                                                            |
| TEAE                                                                                 | 38 (54.3)                                                                            | 53 (53.0)                                                                            | 34 (47.9)                                                                            | 56 (58.3)                                                                            | 50 (54.9)                                                                            | 42 (45.2)                                                                            |
| Severe TEAE                                                                          | 2 (2.9)                                                                              | 3 (3.0)                                                                              | 5 (7.0)                                                                              | 1 (1.0)                                                                              | 1 (1.1)                                                                              | 1 (1.1)                                                                              |
| Study drug-related TEAE                                                              | 5 (7.1)                                                                              | 13 (13.0)                                                                            | 3 (4.2)                                                                              | 17 (17.7)                                                                            | 7 (7.7)                                                                              | 7 (7.5)                                                                              |
| SAE                                                                                  | 5 (7.1)                                                                              | 5 (5.0)                                                                              | 2 (2.8)                                                                              | 1 (1.0)                                                                              | 1 (1.1)                                                                              | 1 (1.1)                                                                              |
| SAE related to study drug                                                            | 1 (1.4)                                                                              | 0                                                                                    | 0                                                                                    | 0                                                                                    | 0                                                                                    | 0                                                                                    |
| TEAE leading to study drug withdrawal                                                | 2 (2.9)                                                                              | 2 (2.0)                                                                              | 2 (2.8)                                                                              | 3 (3.1)                                                                              | 4 (4.4)                                                                              | 0                                                                                    |
| TEAE leading to study discontinuation                                                | 2 (2.9)                                                                              | 1 (1.0)                                                                              | 2 (2.8)                                                                              | 3 (3.1)                                                                              | 2 (2.2)                                                                              | 0                                                                                    |
| AESI (Investigator)                                                                  | 10 (14.3)                                                                            | 14 (14.0)                                                                            | 10 (14.1)                                                                            | 15 (15.6)                                                                            | 10 (11.0)                                                                            | 14 (15.1)                                                                            |
| Adjudicated asthma event                                                             | 3 (4.3)                                                                              | 6 (6.0)                                                                              | 1 (1.4)                                                                              | 5 (5.2)                                                                              | 2 (2.2)                                                                              | 3 (3.2)                                                                              |
| TEAE leading to death                                                                | 0                                                                                    | 0                                                                                    | 0                                                                                    | 0                                                                                    | 0                                                                                    | 0                                                                                    |
| TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population | TEAEs observed in ≥2.0% of subjects in all 3 groups in the primary safety population |
| Atopic dermatitis                                                                    | 6 (8.6)                                                                              | 7 (7.0)                                                                              | 3 (4.2)                                                                              | 8 (8.3)                                                                              | 10 (11.0)                                                                            | 5 (5.4)                                                                              |
| Headache                                                                             | 3 (4.3)                                                                              | 3 (3.0)                                                                              | 2 (2.8)                                                                              | 5 (5.2)                                                                              | 2 (2.2)                                                                              | 2 (2.2)                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                                                                         | Nemolizumab 30 mg Q4W to Q4W n (%)                                                                      | Nemolizumab 30 mg Q4W to Q4W n (%)                                                                      | Nemolizumab 30 mg Q4W to Q8W n (%)                                                                      | Nemolizumab 30 mg Q4W to Q8W n (%)                                                                      | Re-assigned to Placebo n (%)                                                                            | Re-assigned to Placebo n (%)                                                                            |
|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                                                                                                         | Male (N=70)                                                                                             | Female (N=100)                                                                                          | Male (N=71)                                                                                             | Female (N=96)                                                                                           | Male (N=91)                                                                                             | Female (N=93)                                                                                           |
| Nasopharyngitis                                                                                         | 3 (4.3)                                                                                                 | 11 (11.0)                                                                                               | 1 (1.4)                                                                                                 | 7 (7.3)                                                                                                 | 5 (5.5)                                                                                                 | 7 (7.5)                                                                                                 |
| Asthma                                                                                                  | 1 (1.4)                                                                                                 | 5 (5.0)                                                                                                 | 1 (1.4)                                                                                                 | 5 (5.2)                                                                                                 | 2 (2.2)                                                                                                 | 3 (3.2)                                                                                                 |
| COVID-19                                                                                                | 6 (8.6)                                                                                                 | 7 (7.0)                                                                                                 | 5 (7.0)                                                                                                 | 8 (8.3)                                                                                                 | 5 (5.5)                                                                                                 | 11 (11.8)                                                                                               |
| Upper respiratory tract infection                                                                       | 3 (4.3)                                                                                                 | 1 (1.0)                                                                                                 | 1 (1.4)                                                                                                 | 4 (4.2)                                                                                                 | 7 (7.7)                                                                                                 | 4 (4.3)                                                                                                 |
| Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population | Study drug-related TEAEs observed in ≥1.0% of subjects in all 3 groups in the primary safety population |
| Atopic dermatitis                                                                                       | 2 (2.9)                                                                                                 | 3 (3.0)                                                                                                 | 0                                                                                                       | 3 (3.1)                                                                                                 | 2 (2.2)                                                                                                 | 1 (1.1)                                                                                                 |
| Asthma                                                                                                  | 0                                                                                                       | 3 (3.0)                                                                                                 | 0                                                                                                       | 2 (2.1)                                                                                                 | 0                                                                                                       | 2 (2.2)                                                                                                 |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; Q4W=every 4 weeks; Q8W=every 8 weeks; SAE=serious adverse event; TEAE=treatment-emergent adverse event

The applicant concludes that although there was variability in the TEAE incidence across the different categories (subjects with at least 1 TEAE, severe TEAE, study drug-related TEAE, SAE, TEAE leading to study drug withdrawal, TEAE leading to study discontinuation, AESI [by Investigator], and adjudicated asthma event) for male and female subjects in the nemolizumab 30 mg Q4W to Q4W and nemolizumab 30 mg Q4W to Q8W groups, the small sample size for male subjects (N=70 and N=71, respectively) and female subjects (N=100 and N=96, respectively) most likely explains the observed variabilities. These small sample sizes also most likely explain the variation between male and female subjects in TEAEs observed in ≥ 2.0% of subjects and study drug-related TEAEs observed in ≥ 1.0% of subjects in the nemolizumab 30 mg Q4W to Q4W and nemolizumab 30 mg Q4W to Q8W groups in the primary safety population.

## Race

It is noted that in the Maintenance Period, TEAEs occurred more frequently in nemolizumab treated subjects (nemolizumab 30 mg Q4W to Q4W [73.3%]; nemolizumab 30 mg Q4W to Q8W [52.6%]) in the Asian group compared to placebo subjects (placebo [36.4%]; re-assigned to placebo [20.0%]) in the Asian group. The frequency of TEAEs in nemolizumab 30 mg Q4W to Q4W subjects was also higher in the Asian group compared to the other racial subgroups (White, Black or African American and Other Race).

## 2.6.11.4.  Immunological events

Please refer to laboratory finding section.

## 2.6.11.5.  Safety related to drug-drug interactions and other interactions

Please refer to the pharmacokinetics section.

The applicant states that nemolizumab is expected to be metabolized into small peptides by catabolic pathways; therefore, the victim potential of nemolizumab has not been studied and not considered necessary.

The ability of nemolizumab to modulate interferon/cytokine levels, which can lead to an altered cytochrome P450 expression, is unknown. A clinical drug interaction study (SPR.201593) assessed

<div style=\"page-break-after: always\"></div>

such impact on the PK of selected cytochrome P450 substrates in adult patients with moderate-tosevere AD. Please refer to Pharmacokinetic section for further information on this study.

Taking into account the molecular weight of nemolizumab (around 147 kilodaltons), the impact of nemolizumab as a transporter inhibitor and inducer has not been studied and not considered necessary by the applicant.

## 2.6.11.5.1.  Discontinuation due to adverse events

In the Initial Period, TEAEs leading to study drug withdrawal were similar in nemolizumab 30 mg Q4W subjects (2.6%) and placebo subjects (3.1%) ( Table 70 ). The most common TEAE leading to withdrawal in nemolizumab 30 mg Q4W subjects was atopic dermatitis.

In the Initial Period, the frequency of TEAEs leading to study discontinuation was more than doubled for nemolizumab 30 mg Q4W subjects compared to placebo subjects (2,1% vs 0.9%).

During the Maintenance Period, treatment-emergent AEs leading to study drug withdrawal were experienced by 4 (2.4%), 5 (3.0%), 5 (3.0%), and 4 (2.2%) subjects in the nemolizumab 30 mg Q4W to Q4W, nemolizumab 30 mg Q4W to Q8W, nemolizumab 30 mg Q4W to placebo, and re assigned to placebo groups, respectively ( Table 70 ).

## Table 70: TEAEs leading to study drug withdrawal by SOC and PT during the treatment period (primary safety population)

<div style=\"page-break-after: always\"></div>

| SOC PT                                                              | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|---------------------------------------------------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| SOC PT                                                              | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Subjects with at least 1 TEAE leading to study drug withdrawal      | 31 (2.6)                    | 41 (3.1)              | 20 (3.1)            | 4 (2.4)                           | 5 (3.0)                           | 5 (3.0)                               | 4 (2.2)                                |
| Blood and lymphatic system disorders                                | 2 (0.2)                     | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Lymphadenopathy                                                     | 2 (0.2)                     | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Eye disorders                                                       | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Eyelid oedema                                                       | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| General disorders and administration site conditions                | 3 (0.3)                     | 3 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Oedema peripheral                                                   | 2 (0.2)                     | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Face oedema                                                         | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Infections and infestations                                         | 1 (<0.1)                    | 2 (0.2)               | 0                   | 1 (0.6)                           | 1 (0.6)                           | 0                                     | 0                                      |
| COVID-19                                                            | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Septic shock                                                        | 0                           | 1 (<0.1) b            | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Cellulitis                                                          | 0                           | 0                     | 0                   | 0                                 | 1 (0.6)                           | 0                                     | 0                                      |
| Gastroenteritis                                                     | 0                           | 0                     | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Investigations                                                      | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Blood creatine phosphokinase increased                              | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2 (0.2)                     | 3 (0.2)               | 0                   | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Prostate cancer                                                     | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Salivary gland cancer                                               | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Squamous cell carcinoma                                             | 0                           | 1 (<0.1) b            | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Plasmablastic lymphoma                                              | 0                           | 0                     | 0                   | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Nervous system disorders                                            | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Bell's palsy                                                        | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Psychiatric disorders                                               | 2 (0.2)                     | 3 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Depression                                                          | 1 (<0.1)                    | 2 (0.2)               | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Panic attack                                                        | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Restlessness                                                        | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Respiratory, thoracic and mediastinal disorders                     | 2 (0.2)                     | 3 (0.2)               | 0                   | 1 (0.6)                           | 0                                 | 1 (0.6)                               | 0                                      |
| Asthma                                                              | 1 (<0.1)                    | 2 (0.2)               | 0                   | 1 (0.6)                           | 0                                 | 0                                     | 0                                      |
| Nasal oedema                                                        | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Pulmonary embolism                                                  | 0                           | 0                     | 0                   | 0                                 | 0                                 | 1 (0.6)                               | 0                                      |
| Skin and subcutaneous tissue disorders                              | 21 (1.8)                    | 28 (2.1)              | 20 (3.1)            | 2 (1.2)                           | 4 (2.4)                           | 3 (1.8)                               | 4 (2.2)                                |
| Atopic dermatitis                                                   | 20 (1.7)                    | 26 (2.0)              | 19 (3.0)            | 2 (1.2)                           | 4 (2.4)                           | 3 (1.8)                               | 4 (2.2)                                |
| Dermatitis                                                          | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Diffuse alopecia                                                    | 1 (<0.1)                    | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |

<div style=\"page-break-after: always\"></div>

| SOC                    | Initial Period              | Initial Period        | Initial Period      | Maintenance Period                | Maintenance Period                | Maintenance Period                    | Maintenance Period                     |
|------------------------|-----------------------------|-----------------------|---------------------|-----------------------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| PT                     | Nemo 30 mg Q4W N=1192 n (%) | All Nemo N=1304 n (%) | Placebo N=640 n (%) | Nemo 30 mg Q4W to Q4W N=170 n (%) | Nemo 30 mg Q4W to Q8W N=167 n (%) | Nemo 30 mg Q4W to placebo N=168 n (%) | Re- assigned to placebo a N1=184 n (%) |
| Skin burning sensation | 0                           | 1 (<0.1)              | 0                   | 0                                 | 0                                 | 0                                     | 0                                      |
| Alopecia areata        | 0                           | 0                     | 1 (0.2)             | 0                                 | 0                                 | 0                                     | 0                                      |

ISS=Integrated Summary of Safety; N=number of subjects in the population; N1=number of subjects who responded to placebo and continued to receive placebo in the Maintenance Period; n=number of subjects who experienced the events; Nemo=nemolizumab; PT=preferred term; Q4W=every 4 weeks; Q8W=every 8 weeks; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. Percentages were based on the number of subjects in each treatment group. All TEAEs that started on or after the first dosing date were summarized by period based on the onset date. For Studies SPR.118161 and SPR.118169, the Initial Period was defined as the period from start of treatment up to and including Week 16. For Study SPR.114322, the whole Treatment Period from the start of treatment up to and including Week 24 was included in the Initial Period. The Maintenance Period was defined as the period up to and including Week 48 after the Initial Period (not applicable to subjects from Study SPR.114322). In case of early discontinuation, the Treatment Period extended from the start of treatment until 4 weeks after the last dosing (inclusive) date or early termination date, whichever was earlier.

a) Subjects randomized to placebo in the Initial Period and continuing on placebo in the Maintenance Period.

b) Subject received nemolizumab 90 mg Q4W.

The majority of subjects with study drug-related TEAEs leading to study drug withdrawal had events considered mild or moderate in severity and that were ongoing.

## 2.6.11.5.2.  Supportive and additional studies not included in the primary analysis pool

## Supportive Phase 3 Long-term extension (LTE) study SIR.118163.

## Data through 30 Sep 2022

A total of 1110 (63.8%) subjects experienced at least 1 TEAE during the Treatment Period. Of these subjects, the majority experienced a TEAE that was considered mild or moderate in severity. The most common ( ≥ 5.0%) TEAEs during the Treatment Period were COVID-19 (16.1%), atopic dermatitis(13.0%), nasopharyngitis (9.5%), and upper respiratory tract infection (5.6%).

Study drug-related TEAEs were experienced by 291 (16.7%) subjects during the Treatment Period; the most common ( ≥ 1.0%) study drug related TEAEs were atopic dermatitis (3.6%), asthma (1.9%), nasopharyngitis (1.3%), and upper respiratory tract infection (1.1%). Study drug related TEAEs were experienced by 8 (2.7%) subjects during the Follow-up Period; the only TEAEs experienced by &gt;1 subject were atopic dermatitis(3 [1.0%] subjects) and blood creatine phosphokinase increased (2 [0.7%] subjects).

No subject died during the study. Treatment-emergent SAEs were experienced by 72 (4.1%) subjects during the Treatment Period; SAEs experienced by &gt;1 subject were atopic dermatitis(8 [0.5%] subjects) and myocardial infarction, cholecystitis acute, COVID-19, COVID-19 pneumonia, cellulitis, syncope, and urinary retention (2 [0.1%] subjects each). Treatment emergent SAEs were experienced by 8 (2.7%) subjects during the Follow-up Period; the only SAE experienced by &gt;1 subject was atopic dermatitis (2 [0.7%] subjects). Eight (0.5%) subjects and 2 (0.7%) subjects experienced SAEs considered study drug related during the Treatment Period and Follow-up Period, respectively; the majority of study drug-related SAEs experienced during the study resolved by data cut-off.

<div style=\"page-break-after: always\"></div>

Treatment-emergent AEs leading to study drug withdrawal were experienced by 57 (3.3%) subjects during the Treatment Period. Of these subjects, the majority (31 [1.8%] subjects) experienced events that were considered study drug related; study drug related TEAEs leading to study drug withdrawal that were experienced by &gt;1 subject during the Treatment Period were atopic dermatitis (14 [0.8%] subjects) and asthma and toxic skin eruption (2 [0.1%] subjects each).

Adverse events of special interest (by Investigator) were experienced by 413 (23.7%) subjects and 14 (4.8%) subjects during the Treatment Period and Follow-up Period, respectively. One (0.1%) nemolizumab subject experienced an IRR (by Investigator) (as per-protocol definition) during the Treatment Period; the subject experienced 1 event each of injection site pruritus and injection site swelling. The events were considered study drug related, moderate in severity, and resulted in study drug withdrawal and study discontinuation.

A total of 353 (20.3%) subjects and 9 (3.1%) subjects experienced an AESI (by Investigator) of infection during the Treatment Period and Follow-up Period, respectively. A total of 20 (1.1%) subjects experienced AESIs (by Investigator) of infection that were considered study drug-related during the Treatment Period; study drug-related AESIs (by Investigator) of infection that were experienced by &gt;1 subject were COVID-19 (10 [0.6%] subjects) and asymptomatic COVID-19 (2 [0.1%] subjects). One (0.3%) subject experienced a study drug related AESI (by Investigator) of infection (asymptomatic COVID 19) during the Follow-up Period.

A total of 17 (1.0%) subjects experienced AESIs (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema during the Treatment Period; no subject experienced an AESI (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema during the Follow-up Period. Eight (0.5%) subjects experienced AESIs (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema that were considered study drug-related during the Treatment Period; 3 (0.2%) subjects experienced face oedema, 2 (0.1%) subjects experienced oedema peripheral, and 1 (0.1%) subject each experienced eyelid oedema, periorbital ooedema, lip oedema, and non-pitting oedema. All study drug related AESIs (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema were nonserious and considered mild or moderate in severity; one-half of the subjects who experienced study drug related AESIs (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema had events that led to study drug withdrawal and study discontinuation.

A total of 75 (4.3%) subjects experienced an AESI (by Investigator) meeting the definition of newly diagnosed asthma or worsening of asthma (which included peak expiratory flow rate decreased) during the Treatment Period; 33 (1.9%) subjects experienced AESIs (by Investigator) of newly diagnosed asthma or worsening of asthma (which included peak expiratory flow rate decreased) that were considered study drug related.

After IAC review of AEs that were retrieved using the SMQ 'asthma/bronchospasm' during the Treatment Period, 41 (2.4%) subjects had TEAEs adjudicated by the IAC that were considered study drug-related; 31 (1.8%) subjects experienced confirmed worsening of (pre-existing) asthma (with 29 [1.7%] subjects with a PT of asthma and 1 [0.1%] subject each with PTs of peak expiratory flow rate decreased, asthma exercise induced, and wheezing) and 3 (0.2%) subjects experienced confirmed new onset asthma (with a PT of asthma). Except for an event of asthma in 2 subjects, all other subjects experienced events that did not result in study drug withdrawal or study discontinuation. The majority of subjects with confirmed worsening of (pre-existing) asthma considered study drug related as adjudicated by the IAC had events that resolved; 2 of the 3 subjects that experienced new onset asthma considered study drug related as adjudicated by the IAC had events that were ongoing at data cut-off.

After the 30 Sep 2022 database cut-off, 1 subject experienced non-small cell lung cancer leading to study drug discontinuation on 18 Jul 2022. The subject died on 04 Feb 2023, i.e. 4 months after

<div style=\"page-break-after: always\"></div>

discontinuation from the study (04 Oct 2022) (based on the safety database). The event resulting in death was severe and considered not related to study drug.

## Data through 10 March 2023

Cumulatively, there were 99 (5.2%) subjects who experienced serious TEAEs as of the 10 Mar 2023 data cut-off. Nine (0.5%) subjects experienced events of atopic dermatitis and 3 (0.2%) experienced events of acute cholecystitis. Myocardial infarction, food allergy, appendicitis, COVID-19, COVID-19 pneumonia, cellulitis, pneumonia, syncope, urinary retention, and asthma were experienced by 2 (0.1%) subjects each.

Of the subjects who experienced SAEs, 14 (0.7%) subjects experienced SAEs considered study drugrelated during the Treatment Period. Study-drug related SAEs of asthma and atopic dermatitis were experienced by 2 (0.1%) subjects each and 1 (0.1%) subject each experienced dyspepsia, appendicitis, dermatitis infected, diverticulitis intestinal perforated, erysipelas, eye infection, wound abscess, rectal adenocarcinoma, 3rd nerve paralysis, syncope and pneumothorax spontaneous.

Sixty-eight (3.6%) subjects experienced study drug-related AESIs during the Treatment Period. Thirty-one (1.6%) subjects experienced events of asthma, 12 (0.1%) subjects experienced events of COVID-19, 7 (0.4%) subjects experienced events of peak expiratory flow rate decreased, 3 (0.2%) subjects experienced events of asymptomatic COVID-19, 3 (0.2%) subjects experienced events of face oedema, and 2 (0.1%) subjects experienced events of peripheral oedema; all other events were experienced by 1 subject each.

Table 71: AESI (by Investigator) experienced by &gt;2 subjects during Treatment Period by Category and PT - All Causalities (Safety Population) - 10 March 2023 data cut-off.

| Preferred Term                      | Category of AESI                                   | Nemolizumab 30mg (N=1893) n   |
|-------------------------------------|----------------------------------------------------|-------------------------------|
| (%)                                 |                                                    |                               |
| Any TEAE of special interest        |                                                    | 483 (25.5)                    |
| COVID-19                            | Infections                                         | 331 (17.5)                    |
| Asthma                              | Newly diagnosed asthma or worsening of asthma      | 73 (3.9)                      |
| Asymptomatic COVID-19               | Infections                                         | 41 (2.2)                      |
| Peak expiratory flow rate decreased | Newly diagnosed asthma or worsening of asthma      | 28 (1.5)                      |
| Suspected COVID-19                  | Infections                                         | 8 (0.4)                       |
| Acne                                | Infections                                         | 5 (0.3)                       |
| Face oedema                         | Peripheral oedema: limbs, bilateral; Facial oedema | 5 (0.3)                       |
| Oedema peripheral                   | Peripheral oedema: limbs, bilateral; Facial oedema | 4 (0.2)                       |
| Impetigo                            | Infections                                         | 3 (0.2)                       |
| Appendicitis                        | Infections                                         | 2 (0.1)                       |
| COVID-19 pneumonia                  | Infections                                         | 2 (0.1)                       |
| Cellulitis                          | Infections                                         | 2 (0.1)                       |
| Dermatitis infected                 | Infections                                         | 2 (0.1)                       |
| Erysipelas                          | Infections                                         | 2 (0.1)                       |
| Pneumonia                           | Infections                                         | 2 (0.1)                       |
| Skin infection                      | Infections                                         | 2 (0.1)                       |
| Superinfection bacterial            | Infections                                         | 2 (0.1)                       |
| Periorbital oedema                  | Peripheral oedema: limbs, bilateral; Facial oedema | 2 (0.1)                       |
| Non-pitting oedema                  | Peripheral oedema: limbs, bilateral; Facial oedema | 2 (0.1)                       |
| Peripheral swelling                 | Peripheral oedema: limbs, bilateral; Facial oedema | 2 (0.1)                       |
| Angioedema                          | Peripheral oedema: limbs, bilateral; Facial oedema | 2 (0.1)                       |

Sixty-nine (3.6%) subjects experienced a TEAE leading to study drug withdrawal during the Treatment Period. Thirty-five (1.8%) subjects experienced events of atopic dermatitis, 2 (0.1%) subjects experienced events of toxic skin eruption and 2 (0.1%) subjects experienced events of asthma.

After the 10 May 2023 database cut off, 1 subject received first dose of LTE study drug (16 Nov 2022), and no further doses of study drug were administered. The subject died approximately 2 months later

<div style=\"page-break-after: always\"></div>

(04 Jan 2023) due to suffocation (PT: asphyxia; Verbatim: death due to suffocation. Reported immediate cause of death: asphyxiation due to massive inhalation of chyme). The event resulting in death was considered not related to study drug.

## CIM003JG - phase 2 multiple-dose study of nemolizumab in subjects with AD

Subcutaneous injections of nemolizumab (0.1 mg/kg, 0.5 mg/kg and 2.0 mg/kg Q4W and 2.0 mg/kg Q8W) were well tolerated in subjects treated for up to 64 weeks. During the placebo-controlled period, atopic dermatitis, oedema peripheral, headache, skin infection, and IRRs were reported at a higher incidence with nemolizumab than with placebo. An apparent dose relationship was seen for oedema peripheral in the nemolizumab Q4W groups. The incidence was 0% with placebo and was 3.8%, 5.6%, and 9.6% in the 0.1 mg/kg, 0.5 mg/kg, and 2.0 mg/kg Q4W groups, respectively.

In all nemolizumab groups pooled, the most frequently reported TEAEs (5% or more of all nemolizumab groups pooled) were atopic dermatitis (19.4%), nasopharyngitis (12.8%), upper respiratory tract infection (6.6%), oedema peripheral (5.7%), and CPK increased (5.2%).

The most frequently reported treatment-related TEAEs during the total treatment period were atopic dermatitis, upper respiratory tract infection, nasopharyngitis, oedema peripheral, blood CPK increased, and injection site reaction.

The majority of TEAEs reported throughout the study were mild to moderate in intensity.

7 SAEs (reported in 6 subjects) were assessed as being related to study drug (diverticulitis, atopic dermatitis, skin infection, lymphadenopathy, pyelonephritis, cataract, and dermatitis exfoliative).

Analysis of selected AEs suggested a possible dose-dependent effect on CPK as the incidence of CPK increased was higher in the nemolizumab 2.0 mg/kg Q4W and Q8W groups than in the nemolizumab 0.1 mg/kg and 0.5 mg/kg Q4W groups. Almost all cases of CPK increased were transient and all cases were confirmed as originating from skeletal muscle.

Over the whole study period, 12 AEs in 11 subjects were classified as cases of asthma: 5 AEs in 4 subjects in the placebo-controlled period and 7 AEs in 7 subjects in Part B or safety follow-up. Among the 6 cases for which the coded term was 'asthma,' 3 were newly occurring cases of asthma, 1 was recurrence of asthma, and 2 were exacerbation of asthma.

Most cases of skin infection were reported during the placebo-controlled period, and the incidence of skin infection in Part B was decreased with no evidence of a dose relationship.

## SRE.116912 - phase 2, open-label, PK study in adolescents with AD

One-third of subjects experienced TEAEs. Two subjects experienced 3 SAEs. One subject experienced a SAE of infectious eczematoid dermatitis and 1 subject experienced SAEs of right leg oedema and right leg staphylococcal skin infection.

All reported SAEs were considered to be study drug-related. Two of these SAEs (infectious eczematoid dermatitis and right leg staphylococcal skin infection) were classified as AESIs. The same 2 subjects experienced 2 additional treatment-emergent AESIs that were non serious (bilateral leg oedema and bilateral lower extremity distal oedema). All reported AESIs were considered study drug-related.

These same 2 subjects also had 7 related TEAEs that led to permanent discontinuation of the study drug (atopic dermatitis, bilateral leg oedema, bilateral leg pain, and rash pustular in 1 subject and bilateral leg oedema, right leg oedema, and staphylococcal skin infection in 1 subject). No TEAEs led to discontinuation of subjects from the study.

No deaths occurred during the study.

<div style=\"page-break-after: always\"></div>

## SRE.201590 - phase 1 AI PK study

The most common study drug-related TEAEs (reported by ≥ 5.0% of subjects overall) were headache (14% [26/192]) and weight increased (6% [12/192]). The incidence of study drug-related headache was higher in the DCS group (21% [20/96]) compared with the AI group (6% [6/96]), with the same incidence (6% [2/32]) across the AI group injection sites and a higher incidence in the DCS group for the abdomen (25% [8/32]) and thigh (22% [7/32]) compared with the arm (16% [5/32]). The incidence of study drug-related weight increased was similar between the AI (7% [7/96]) and DCS (5% [5/96]) groups, with a higher incidence in the arm (13% [4/32]) compared with the abdomen (6% [2/32]) and thigh (3% [1/32]) for the AI group and a similar incidence across injection sites in the DCS group (3% [1/32] to 6% [2/32]).

## CIM001JP - phase 1 single-dose study of nemolizumab in healthy adults and subjects with AD

Among the healthy Caucasian adult males, the adverse event (AE) of increased blood creatine kinase occurred in 6 subjects; each of these events was deemed by the investigator to have been caused by a certain activity.

## SPR.118380 - vaccine study

A total of 78 (35.5%) subjects have experienced a TEAE during the study; the most common TEAEs experienced were atopic dermatitis (6.8%), headache (3.2%), asthma (2.7%), and COVID 19 (2.3%). One (0.5%) subject has experienced an SAE (asthma) that was considered study drug-related. Six (2.7%) subjects have experienced TEAEs leading to study drug withdrawal; 4 (1.8%) subjects experienced atopic dermatitis and 1 (0.5%) subject each experienced asthma, rash papular, and urticaria.

## M525101-02 - phase 3 long-term study in Japanese AD subjects

The common TEAEs related to study drug were atopic dermatitis, cellulitis, impetigo, headache, and toxic skin eruption, and Kaposi's varicelliform eruption and cough.

A total of 10 SAEs were reported. Of these, 5 SAEs related to study drug were optic neuritis (severe in severity, not recovered in outcome), impetigo (moderate, recovering), cellulitis (1 of 2 events [severe, recovered]), viral infection (severe, recovering), and extranodal marginal zone B-cell lymphoma (MALT type) (mild, not recovered).

## 2.6.11.6.  Post marketing experience

On 28 Mar 2022, nemolizumab (60-mg syringes for SC injection) was approved in Japan under the commercial name of MITCHGA for the treatment of 'pruritus associated with AD (only when existing treatments are inadequate)' in patients 13 years and older. No new risks have been identified from the post-marketing experience in Japan.

<div style=\"page-break-after: always\"></div>

Table 72: Unlisted serious adverse reactions from post-marketing experience in Japan (Mitchga 60 mg; cut-off date 21 Jul 2023)

| Sex/Age   | Start date   | End date   | Treatment duration   | Preferred Term [reported term]                                                                                                      | Delay to event onset   | Event duration   | Outcome                                                 | Causality as reported   |
|-----------|--------------|------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------|------------------|---------------------------------------------------------|-------------------------|
|           | Unknown      | Unknown    | Unknown              | Neoplasm malignant [Malignant tumour]                                                                                               | Unknown                | Unknown          | Unknown                                                 | Unrelated               |
|           | 2022         | 2023       | 6 months 23 days     | Rash [Exacerbation of skin eruption]                                                                                                | Unknown                | Unknown          | Recovered/ Resolved                                     | Not reported            |
|           | 2022         | 2022       | 1 day                | Malaise [Strong sense of general malaise]                                                                                           | 3 days                 | 8 days           | Recovered/ Resolved                                     | Possible                |
|           | 2022 2022    | 2022 12022 | 1 day 1 day          | Pyrexia [Low grade fever] Erythrodermic atopic dermatitis [Atopic dermatitis aggravated                                             | 3 days 7 days          | 8 days 18 days   | Recovered/ Resolved Recovering/ Resolving               | Possible Possible       |
|           | 2022         | 2022       | 1 month 14 days      | Atopic dermatitis [exacerbation of atopic dermatitis]                                                                               | 1 month 1 day          | 13 days          | Recovered/ resolved                                     | Possible                |
|           | Unknown      | Unknown    | Unknown              | Death [Unknown cause of death]                                                                                                      | 20 days                | 1 day            | Fatal                                                   | Unrelated               |
|           | 2022         | 2022       | 28 days              | Oedema peripheral [oedema lower limb]                                                                                               | 1 month 2 days         | 1 month 26 days  | Recovered/ resolved                                     | Possible                |
|           | Unknown      | Unknown    | Unknown              | Interstitial lung disease [Interstitial pneumonia]                                                                                  | Unknown                | Unknown          | Unknown                                                 | Unrelated               |
|           | 2022         | 2022       | 1 day                | Erythema [Erythema] Pemphigoid [nodule site became like erythema and formed subepidermal blister and an erosion/Bullous pemphigoid] | 4 days 4 days          | 4 days 4 days    | Recovering/ resolving Recovering/ resolving             | Possible Possible       |
|           | 2022         | 2022       | 2 months             | Myocardial infarction [Myocardial infarction]                                                                                       | 3 months 18 days       | 1 day            | Fatal                                                   | Unrelated               |
|           | Unknown      | Unknown    | Unknown              | Interstitial lung disease [interstitial pneumonia]                                                                                  | Unknown                |                  | Recovering/ Resolving                                   | Unrelated               |
|           | Unknown      | Unknown    | Unknown              | Erythema [Erythema oedematous] Oedema peripheral [oedema below both knee]                                                           | Unknown Unknown        | Unknown Unknown  | Not recovered/ Not resolved Not recovered/ Not resolved | Possible Possible       |
|           | 2022         | 2023       | 28 days              | Alopecia areata [Rapidly progressive alopecia areata/hair loss]                                                                     | 1 month 17 days        | Unknown          | Unknown                                                 | Possible                |
|           | 2022         | 2022       | 1 month 25 days      | Radiation pneumonitis [Aggravated pneumonia after radiation therapy]                                                                | 2 months 10 days       |                  | Recovering/ resolving                                   | Unrelated               |
|           | Unknown      | Unknown    | Unknown              | Bronchioloalveolar carcinoma                                                                                                        | Unknown                | Unknown          | Fatal                                                   | Unrelated               |

<div style=\"page-break-after: always\"></div>

| Sex/Age   | Start date   | End date   | Treatment duration   | Preferred Term [reported term]                                      | Delay to event onset   | Event duration   | Outcome                                                 | Causality as reported   |
|-----------|--------------|------------|----------------------|---------------------------------------------------------------------|------------------------|------------------|---------------------------------------------------------|-------------------------|
|           |              |            |                      | [Pulmonary adenoma progression]                                     |                        |                  |                                                         |                         |
|           | Unknown      | Unknown    | Unknown              | Death [Unknown cause of death]                                      | Unknown                | 1 day            | Fatal                                                   | Possible                |
|           | 2023         | 2023       | 1 month 12 days      | Lumbar vertebral fracture [Lumbar vertebral fracture]               | Unknown                | Unknown          | Recovered/ recovered                                    | Unrelated               |
|           | 2023         | 2023       | 28 days              | Death [Death]                                                       | Unknown                | Unknown          | Fatal                                                   | Unrelated               |
|           | 2022         | 2023       | 1 month 6 days       | Cerebral infarction [Developed cerebral infarction]                 | Unknown                | Unknown          | Recovered/ recovered                                    | Possible                |
|           | Unknown      | Unknown    | Unknown              | Hepatobiliary cancer [Hepatobiliary cancer]                         | Unknown                | Unknown          | Fatal                                                   | Unrelated               |
|           | Unknown      | Unknown    | Unknown              | Cardiovascular disorder [Cardiovascular event]                      | Unknown                | Unknown          | Unknown                                                 | Not reported            |
|           | Unknown      | Unknown    | Unknown              | Renal impairment [Renal impairment]                                 | Unknown                | Unknown          | Not recovered/ Not resolved                             | Unrelated               |
|           | 2023         | 2023       | 1 day                | Vasculitis [Vasculitis]                                             | 29 days                |                  | Recovering/ resolving                                   | Possible                |
|           | 2023         | 2023       | 28 days              | Oedema [Oedema (Onset date:11-May-2023), (Onset date:10-Jun- 2023)] | 4 days                 |                  | Recovering/ resolving                                   | Possible                |
|           | Unknown      | Unknown    | Unknown              | Blister [Tense blisters] Eosinophil count increased [Eosinophilia]  | Unknown Unknown        | Unknown Unknown  | Not recovered/ Not resolved Not recovered/ Not resolved | Possible Possible       |
|           | Unknown      | Unknown    | Unknown              | Cerebral Infarction [Cerebral infarction]                           | Unknown                | Unknown          | Not recovered/ Not resolved                             | Unrelated               |

F=female; M=male

| Sex/Age             | Start date     | End date       | Treatment duration   | Preferred Term [reported term]                                                                      | Delay to event onset   | Event duration   | Outcome                         | Causality as reported   |
|---------------------|----------------|----------------|----------------------|-----------------------------------------------------------------------------------------------------|------------------------|------------------|---------------------------------|-------------------------|
| REDACTED /70 th     | Unknown        | Unknown        | Unknown              | Neoplasm malignant [Malignant tumour]                                                               | Unknown                | Unknown          | Unknown                         | Unrelated               |
| REDACTED / REDACTED | REDACTED -2022 | REDACTED -2023 | 6 months 23 days     | Rash [Exacerbation of skin eruption]                                                                | Unknown                | Unknown          | Recovered/ Resolved             | Not reported            |
| REDACTED / REDACTED | REDACTED -2022 | REDACTED -2022 | 1 day 1 day 1 day    | Malaise [Strong sense of general malaise] Pyrexia [Low grade fever] Erythrodermic atopic dermatitis | 3 days                 | 8 days           | Recovered/ Resolved             | Possible                |
|                     | REDACTED -2022 | REDACTED -2022 |                      |                                                                                                     | 3 days 7 days          | 8 days 18        | Recovered/ Resolved Recovering/ | Possible Possible       |
|                     | REDACTED -2022 | REDACTED -2022 |                      |                                                                                                     |                        | days             | Resolving                       |                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Sex/Age             | Start date     | End date       | Treatment duration   | Preferred Term [reported term]                                                                                                      | Delay to event onset   | Event duration   | Outcome                                                 | Causality as reported   |
|---------------------|----------------|----------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------|------------------|---------------------------------------------------------|-------------------------|
|                     |                |                |                      | [Atopic dermatitis aggravated (erythroderma)                                                                                        |                        |                  |                                                         |                         |
| REDACTED / REDACTED | REDACTED -2022 | REDACTED -2022 | 1 month 14 days      | Atopic dermatitis [exacerbation of atopic dermatitis]                                                                               | 1 month 1 day          | 13 days          | Recovered/ resolved                                     | Possible                |
| M/89                | Unknown        | Unknown        | Unknown              | Death [Unknown cause of death]                                                                                                      | 20 days                | 1 day            | Fatal                                                   | Unrelated               |
| REDACTED / REDACTED | REDACTED -2022 | REDACTED -2022 | 28 days              | Oedema peripheral [oedema lower limb]                                                                                               | 1 month 2 days         | 1 month 26 days  | Recovered/ resolved                                     | Possible                |
| Unk/60 th           | Unknown        | Unknown        | Unknown              | Interstitial lung disease [Interstitial pneumonia]                                                                                  | Unknown                | Unknown          | Unknown                                                 | Unrelated               |
| REDACTED / REDACTED | REDACTED -2022 | REDACTED -2022 | 1 day                | Erythema [Erythema] Pemphigoid [nodule site became like erythema and formed subepidermal blister and an erosion/Bullous pemphigoid] | 4 days 4 days          | 4 days 4 days    | Recovering/ resolving Recovering/ resolving             | Possible Possible       |
| F/84                | 09-Sep- 2022   | 07-Dec- 2022   | 2 months             | Myocardial infarction [Myocardial infarction]                                                                                       | 3 months 18 days       | 1 day            | Fatal                                                   | Unrelated               |
| REDACTED /50th      | Unknown        | Unknown        | Unknown              | Interstitial lung disease [interstitial pneumonia]                                                                                  | Unknown                |                  | Recovering/ Resolving                                   | Unrelated               |
| REDACTED / REDACTED | Unknown        | Unknown        | Unknown              | Erythema [Erythema oedematous] Oedema peripheral [edema below both knee]                                                            | Unknown Unknown        | Unknown Unknown  | Not recovered/ Not resolved Not recovered/ Not resolved | Possible Possible       |
| REDACTED / REDACTED | REDACTED -2022 | REDACTED -2023 | 28 days              | Alopecia areata [Rapidly progressive alopecia areata/hair loss]                                                                     | 1 month 17 days        | Unknown          | Unknown                                                 | Possible                |
| REDACTED /60 th     | REDACTED -2022 | REDACTED -2022 | 1 month 25 days      | Radiation pneumonitis [Aggravated pneumonia after radiation therapy]                                                                | 2 months 10 days       |                  | Recovering/ resolving                                   | Unrelated               |
| M/60 th             | Unknown        | Unknown        | Unknown              | Bronchioloalveolar carcinoma [Pulmonary adenoma progression]                                                                        | Unknown                | Unknown          | Fatal                                                   | Unrelated               |
| F/52                | Unknown        | Unknown        | Unknown              | Death                                                                                                                               | Unknown                | 1 day            | Fatal                                                   | Possible                |

<div style=\"page-break-after: always\"></div>

| Sex/Age             | Start date     | End date       | Treatment duration   | Preferred Term [reported term]                                       | Delay to event onset   | Event duration   | Outcome                                                 | Causality as reported   |
|---------------------|----------------|----------------|----------------------|----------------------------------------------------------------------|------------------------|------------------|---------------------------------------------------------|-------------------------|
|                     |                |                |                      | [Unknown cause of death]                                             |                        |                  |                                                         |                         |
| REDACTED /80 th     | REDACTED -2023 | REDACTED -2023 | 1 month 12 days      | Lumbar vertebral fracture [Lumbar vertebral fracture]                | Unknown                | Unknown          | Recovered/ recovered                                    | Unrelated               |
| M/91                | 31-Jan- 2023   | 28-Feb- 2023   | 28 days              | Death [Death]                                                        | Unknown                | Unknown          | Fatal                                                   | Unrelated               |
| REDACTED /50 th     | REDACTED -2022 | REDACTED -2023 | 1 month 6 days       | Cerebral infarction [Developed cerebral infarction]                  | Unknown                | Unknown          | Recovered/ recovered                                    | Possible                |
| M/80th              | Unknown        | Unknown        | Unknown              | Hepatobiliary cancer [Hepatobiliary cancer]                          | Unknown                | Unknown          | Fatal                                                   | Unrelated               |
| REDACTED /Unk       | Unknown        | Unknown        | Unknown              | Cardiovascular disorder [Cardiovascular event]                       | Unknown                | Unknown          | Unknown                                                 | Not reported            |
| REDACTED / REDACTED | Unknown        | Unknown        | Unknown              | Renal impairment [Renal impairment]                                  | Unknown                | Unknown          | Not recovered/ Not resolved                             | Unrelated               |
| REDACTED /          | REDACTED -2023 | REDACTED -2023 | 1 day                | Vasculitis [Vasculitis]                                              | 29 days                |                  | Recovering/ resolving                                   | Possible                |
| REDACTED / REDACTED | REDACTED -2023 | REDACTED -2023 | 28 days              | Oedema [Oedema (Onset date:11-May- 2023), (Onset date:10- Jun-2023)] | 4 days                 |                  | Recovering/ resolving                                   | Possible                |
| REDACTED /80 th     | Unknown        | Unknown        | Unknown              | Blister [Tense blisters] Eosinophil count increased [Eosinophilia]   | Unknown Unknown        | Unknown Unknown  | Not recovered/ Not resolved Not recovered/ Not resolved | Possible Possible       |
| REDACTED /70 th     | Unknown        | Unknown        | Unknown              | Cerebral Infarction [Cerebral infarction]                            | Unknown                | Unknown          | Not recovered/ Not resolved                             | Unrelated               |

F=female; M=male

It is noted that there was one patient with 'Erythrodermic atopic dermatitis' where the causality was reported as possible. There were two other patients who experienced erythema (causality reported as possible).

Two patients experienced 'Oedema peripheral' (and one case with 'Oedema'), where the causality was reported as possible. 'Eosinophil count increased' was reported with possible causality in one patient.

There was one death where causality was assessed as possible. Reported term for this death was 'Unknown cause of death'.

<div style=\"page-break-after: always\"></div>

## 2.6.11.7.  Prurigo nodularis

The primary safety population was defined as all randomized or enrolled subjects who received at least 1 dose of study drug in the 2 pivotal Phase 3 studies (SPR.202685 and SPR.203065). These studies were pooled because they were similar in study design, dose, dose regimen and population. Assessment of safety is primarily focusing on the 30 mg Q4W and 60 mg Q4W dose of nemolizumab proposed for marketing.

Data for the primary safety population are presented by Treatment Period (16 weeks in Study SPR.203065 and 24 weeks in Study SPR.202685) and Overall Period (includes both the Treatment Period and Follow-up Period [8 weeks in both studies]). Each study consisted of 3 periods over approximately 28 (SPR.203065) or 36 (SPR.202685) weeks: screening (up to 4 weeks), a 16-week (SPR.203065) or 24-week (SPR.202685) treatment period, and an 8-week follow-up period (12 weeks after the last study drug injection).

Eligible subjects were randomized 2:1 to receive either 60 mg of nemolizumab or placebo via 2 subcutaneous (SC) injections at baseline. Subjects were stratified by study centre and baseline body weight (&lt;90 kg and ≥ 90 kg). Thereafter, study drug was to be administered every 4 weeks (Q4W) at Weeks 4, 8, and 12 (SPR.203065) or at Weeks 4, 8, 12, 16, and 20 (SPR.202685) by a single SC injection of either nemolizumab 30 mg or placebo for subjects weighing &lt;90 kg at baseline or by 2 SC injections of either nemolizumab 30 mg or placebo for subjects weighing ≥ 90 kg at baseline.

## Supportive and additional studies

Long-term data are retrieved from interim results of the ongoing Study SPR.202699 (ongoing, Phase 3, open-label, multicentre study). The study population comprises subjects who had been enrolled in a prior nemolizumab Phase 2a study (SPR.115828) or prior Phase 3 pivotal study (SPR.202685 or SPR.203065).

There are 4 supportive studies (study CIM001JP appears twice: Parts A and B in healthy volunteers and Part C in subjects with AD): 2 Phase 1 healthy volunteer studies SPR.201590 and CIM001JP (Parts A and B), Phase 2a PN study SPR.115828, and ongoing, Phase 3 long-term extension (LTE) PN study SPR.202699 to support the approval of nemolizumab in its proposed indication.

There are also 14 additional studies (study CIM001JP appears twice: Parts A and B in healthy volunteers and Part C in subjects with AD) that provide a comprehensive assessment of the safety of nemolizumab:

-  Eight (8) Galderma-sponsored studies: 1 ongoing, blinded Phase 3b PN durability study (SPR.203890), 6 completed AD studies (1 Phase 1 study [CIM001JP Part C], 2 Phase 2 studies [CIM003JG and SPR.116912], 1 Phase 2b study [SPR.114322], and 2 Phase 3 studies [SPR.118161 and SPR.118169]), and 1 Phase 2 study in CKDaP (CIM106JP)
-  Six (6) studies in Japanese subjects conducted by Maruho: 3 completed AD studies (1 Phase 1 [M525101-05] and 2 Phase 3 [M525101-01 and M525101-02]), 2 Phase 1 studies in healthy volunteers (M525101-12 and M525101-13), and 1 ongoing Phase 2/3 PN study (M525101-11)

## 2.6.11.7.1.  Patient exposure

A total of 375 (64.9%) subjects in the All nemolizumab group had ≥ 1 year of exposure to nemolizumab.

## Table 73: Extent of exposure (PN exposure pool population)

<div style=\"page-break-after: always\"></div>

|                                                         | Nemolizumab 0.5 mg/kg N=34   | Nemolizumab FDWBWA a N=555   | All nemolizumab N=578   |
|---------------------------------------------------------|------------------------------|------------------------------|-------------------------|
| Treatment duration (days)                               |                              |                              |                         |
| Mean (SD)                                               | 84.9 (11.93)                 | 454.6 (208.93)               | 441.5 (219.02)          |
| Median                                                  | 87.0                         | 485.0                        | 479.0                   |
| Q1, Q3                                                  | 87.0, 88.0                   | 308.0, 619.0                 | 255.0, 619.0            |
| Minimum, maximum                                        | 31, 95                       | 31, 873                      | 31, 874                 |
| Treatment duration (years)                              |                              |                              |                         |
| Mean (SD)                                               | 0.23 (0.033)                 | 1.24 (0.572)                 | 1.21 (0.600)            |
| Median                                                  | 0.24                         | 1.33                         | 1.31                    |
| Q1, Q3                                                  | 0.24, 0.24                   | 0.84, 1.69                   | 0.70, 1.69              |
| Minimum, maximum                                        | 0.1, 0.3                     | 0.1, 2.4                     | 0.1, 2.4                |
| Number of treatments per subject                        |                              |                              |                         |
| Mean (SD)                                               | 2.9 (0.44)                   | 15.5 (7.18)                  | 15.1 (7.52)             |
| Median                                                  | 3.0                          | 17.0                         | 16.0                    |
| Q1, Q3                                                  | 3.0, 3.0                     | 10.0, 21.0                   | 9.0, 21.0               |
| Minimum, maximum                                        | 1, 3                         | 1, 31                        | 1, 31                   |
| Number of treatments per subject, n (%)                 |                              |                              |                         |
| 1-5                                                     | 34 (100)                     | 65 (11.7)                    | 87 (15.1)               |
| 6-10                                                    | 0                            | 74 (13.3)                    | 75 (13.0)               |
| 11-15                                                   | 0                            | 110 (19.8)                   | 110 (19.0)              |
| 16-20                                                   | 0                            | 155 (27.9)                   | 153 (26.5)              |
| 21-25                                                   | 0                            | 112 (20.2)                   | 110 (19.0)              |
| 26-30                                                   | 0                            | 38 (6.8)                     | 42 (7.3)                |
| 31-35                                                   | 0                            | 1 (0.2)                      | 1 (0.2)                 |
| Subjects with ≥6 months exposure to nemolizumab, n (%)  | 0                            | 471 (84.9)                   | 471 (81.5)              |
| Subjects with ≥1 year exposure to nemolizumab, n (%)    | 0                            | 375 (67.6)                   | 375 (64.9)              |
| Subjects with ≥1.5 years exposure to nemolizumab, n (%) | 0                            | 207 (37.3)                   | 207 (35.8)              |
| Subjects with ≥2 years exposure to nemolizumab, n (%)   | 0                            | 51 (9.2)                     | 54 (9.3)                |

FDWBWA=fixed dosing with body weight adjustment; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects with available data; PN=prurigo nodularis; Q1=first quartile; Q3=third quartile; Q4W=every 4 weeks

Note: Exposure data from the long-term extension study (SPR.202699) was pooled with the exposure data from the relevant feeder studies, to give a total overall exposure for each subject. Total exposure to a given dose of nemolizumab was presented under the corresponding column. Feeder studies were SPR.202685, SPR.203065, and SPR.115828. Treatment duration (days) = (date of last treatment + 30) - (date of first treatment) + 1. Treatment duration (years) = treatment duration (days) / 365.25. If the time between the last treatment in the feeder study and the first treatment in the long-term extension study was greater than 30 days, then the treatment duration was calculated separately for each study and summed to give an overall treatment duration.

d) Subject weight &lt;90 kg at baseline: nemolizumab 30 mg Q4W, with a 60-mg loading dose at baseline. Subject weight ≥ 90kg at baseline: nemolizumab 60 mg Q4W.

In the studies submitted as part of the marketing authorisation application a total of 578 patients with PN were exposed to between 1 and 30 treatments of nemolizumab. The mean duration of exposure to the fixed dosing with body weight adjustment is 454.6 days including 375 subjects exposed for at least 1 year.

The applicant was asked to complete the table below.

<div style=\"page-break-after: always\"></div>

Table 74: Patient exposure in the Nemolizumab PN Population (10 March 2023) (modified)

|                                      | Patients enrolled   | Patients exposed*   | Patients exposed to the dose range   | Patients with long term** safety data   | Patients with long term** safety data   |
|--------------------------------------|---------------------|---------------------|--------------------------------------|-----------------------------------------|-----------------------------------------|
|                                      |                     |                     | proposed                             | ≥ 6 months                              | ≥ 12 months                             |
| Applicant sponsored                  | Applicant sponsored | Applicant sponsored | Applicant sponsored                  | Applicant sponsored                     | Applicant sponsored                     |
| Blinded studies (placebo-controlled) | 630                 | 404                 | 403                                  | 2                                       | 0                                       |
| Blinded studies (active-controlled)  | NA                  | NA                  | NA                                   | NA                                      | NA                                      |
| Open studies                         | 508 #               | 508                 | 508                                  | 421                                     | 316                                     |
| Post marketing                       | 0                   | 0                   | 0                                    | 0                                       | 0                                       |
| Compassionate use                    | NA                  | NA                  | NA                                   | NA                                      | NA                                      |

NA = not applicable; PN = prurigo nodularis.

* Received at least 1 dose of active treatment.

** In general, this refers to 6 months and 12 months continuous exposure data, or intermittent exposure.

# Subjects enrolled in open studies were already treated in blinded studies.

Exposure duration (years) = ((date of last treatment + 30) - (date of first treatment) + 1))/ 365.2.

Blinded studies are SPR.202685, SPR.203065, and SPR.115828. Open label study: SPR.202699.

## Primary safety population

The primary safety population included 370 subjects in the nemolizumab group and 186 subjects in the placebo group. A total of 343 (92.7%) nemolizumab subjects completed treatment.

<div style=\"page-break-after: always\"></div>

Table 75: Extent of exposure (primary safety population)

|                                         | Nemolizumab N=370   | Placebo N=186   |
|-----------------------------------------|---------------------|-----------------|
| Treatment duration (days)               |                     |                 |
| Mean (SD)                               | 137.1 (35.43)       | 138.2 (34.81)   |
| Median                                  | 120.0               | 117.5           |
| Q1, Q3                                  | 115.0, 171.0        | 115.0, 171.0    |
| Minimum, maximum                        | 31, 191             | 31, 192         |
| Treatment duration (years)              |                     |                 |
| Mean (SD)                               | 0.375 (0.0970)      | 0.378 (0.0953)  |
| Median                                  | 0.329               | 0.322           |
| Q1, Q3                                  | 0.315, 0.468        | 0.315, 0.468    |
| Minimum, maximum                        | 0.08, 0.52          | 0.08, 0.53      |
| Number of treatments per subject        |                     |                 |
| Mean (SD)                               | 4.7 (1.23)          | 4.7 (1.21)      |
| Median                                  | 4.0                 | 4.0             |
| Q1, Q3                                  | 4.0, 6.0            | 4.0, 6.0        |
| Minimum, maximum                        | 1, 6                | 1, 6            |
| Number of treatments per subject, n (%) |                     |                 |
| 1                                       | 12 (3.2)            | 3 (1.6)         |
| 2                                       | 6 (1.6)             | 5 (2.7)         |
| 3                                       | 7 (1.9)             | 7 (3.8)         |
| 4                                       | 177 (47.8)          | 84 (45.2)       |
| 5                                       | 23 (6.2)            | 10 (5.4)        |
| 6                                       | 145 (39.2)          | 77 (41.4)       |

Table 76: Subject disposition in studies SPR.202685 and SPR.203065 (intent-to-treat population)

| Number of subjects                              | SPR.202685   | SPR.202685   | SPR.202685   | SPR.203065   | SPR.203065   | SPR.203065   | Overall Total   |
|-------------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|-----------------|
|                                                 | Nemo Q4W     | Placebo      | Total        | Nemo Q4W     | Placebo      | Total        |                 |
|                                                 | N=190        | N=96         | N=286        | N=183        | N=91         | N=274        | N=560           |
|                                                 | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)           |
| Randomized                                      | 190 (100)    | 96 (100)     | 286 (100)    | 183 (100)    | 91 (100)     | 274 (100)    | 560 (100)       |
| Randomized but not treated                      | 3 (1.6)      | 1 (1.0)      | 4 (1.4)      | 0            | 0            | 0            | 4 (0.7)         |
| Treated                                         | 187 (98.4)   | 95 (99.0)    | 282 (98.6)   | 183 (100)    | 91 (100)     | 274 (100)    | 556 (99.3)      |
| Completed treatment                             | 168 (88.4)   | 85 (88.5)    | 253 (88.5)   | 175 (95.6)   | 87 (95.6)    | 262 (95.6)   | 515 (92.0)      |
| Discontinued treatment                          | 19 (10.0)    | 10 (10.4)    | 29 (10.1)    | 8 (4.4)      | 4 (4.4)      | 12 (4.4)     | 41 (7.3)        |
| Primary reason for discontinuation of treatment |              |              |              |              |              |              |                 |
| Pregnancy                                       | 0            | 0            | 0            | 0            | 1 (1.1)      | 1 (0.4)      | 1 (0.2)         |
| Lack of efficacy                                | 0            | 0            | 0            | 1 (0.5)      | 1 (1.1)      | 2 (0.7)      | 2 (0.4)         |
| Adverse event                                   | 11 (5.8)     | 4 (4.2)      | 15 (5.2)     | 4 (2.2)      | 2 (2.2)      | 6 (2.2)      | 21 (3.8)        |
| Subject's request                               | 8 (4.2)      | 4 (4.2)      | 12 (4.2)     | 1 (0.5)      | 0            | 1 (0.4)      | 13 (2.3)        |
| Lost to follow-up                               | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Protocol deviation                              | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Physician/primary investigator decision         | 0            | 1 (1.0)      | 1 (0.3)      | 1 (0.5)      | 0            | 1 (0.4)      | 2 (0.4)         |
| Sponsor decision                                | 0            | 0            | 0            | 0            | 0            | 0            | 0               |
| Other: COVID-19                                 | 0            | 0            | 0            | 0            | 0            | 0            | 0               |

<div style=\"page-break-after: always\"></div>

| Number of subjects                                | SPR.202685   | SPR.202685   | SPR.202685   | SPR.203065   | SPR.203065   | SPR.203065   | Overall    |
|---------------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|------------|
|                                                   | Nemo Q4W     | Placebo      | Total        | Nemo Q4W     | Placebo      | Total        | Total      |
|                                                   | N=190        | N=96         | N=286        | N=183        | N=91         | N=274        | N=560      |
|                                                   | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)        | n (%)      |
| Other: inability to attend appointments           | 0            | 0            | 0            | 1 (0.5)      | 0            | 1 (0.4)      | 1 (0.2)    |
| Other: site permanently closed                    | 0            | 1 (1.0)      | 1 (0.3)      | 0            | 0            | 0            | 1 (0.2)    |
| Completed the study                               | 166 (87.4)   | 83 (86.5)    | 249 (87.1)   | 174 (95.1)   | 88 (96.7)    | 262 (95.6)   | 511 (91.3) |
| Discontinued from the study                       | 24 (12.6)    | 13 (13.5)    | 37 (12.9)    | 9 (4.9)      | 3 (3.3)      | 12 (4.4)     | 49 (8.8)   |
| Primary reason for discontinuation from the study |              |              |              |              |              |              |            |
| Pregnancy                                         | 0            | 0            | 0            | 0            | 1 (1.1)      | 1 (0.4)      | 1 (0.2)    |
| Lack of efficacy                                  | 0            | 0            | 0            | 0            | 0            | 0            | 0          |
| Adverse event                                     | 12 (6.3)     | 4 (4.2)      | 16 (5.6)     | 4 (2.2)      | 2 (2.2)      | 6 (2.2)      | 22 (3.9)   |
| Subject's request                                 | 10 (5.3)     | 6 (6.3)      | 16 (5.6)     | 2 (1.1)      | 0            | 2 (0.7)      | 18 (3.2)   |
| Lost to follow-up                                 | 0            | 0            | 0            | 2 (1.1)      | 0            | 2 (0.7)      | 2 (0.4)    |
| Protocol deviation                                | 2 (1.1)      | 1 (1.0)      | 3 (1.0)      | 0            | 0            | 0            | 3 (0.5)    |
| Physician decision                                | 0            | 1 (1.0)      | 1 (0.3)      | 1 (0.5)      | 0            | 1 (0.4)      | 2 (0.4)    |
| Sponsor decision                                  | 0            | 0            | 0            | 0            | 0            | 0            | 0          |
| Other: COVID-19                                   | 0            | 0            | 0            | 0            | 0            | 0            | 0          |
| Other: Permanent site closure                     | 0            | 1 (1.0)      | 1 (0.3)      | 0            | 0            | 0            | 1 (0.2)    |
| Rolled over to long-term extension                | 155 (81.6)   | 78 (81.3)    | 233 (81.5)   | 171 (93.4)   | 86 (94.5)    | 257 (93.8)   | 490 (87.5) |
| Completed follow-up                               | 19 (10.0)    | 10 (10.4)    | 29 (10.1)    | 6 (3.3)      | 3 (3.3)      | 9 (3.3)      | 38 (6.8)   |

## 2.6.11.7.2.  Adverse events

In this section, the Overall Period includes both the Treatment Period (the time from the start of treatment up to Week 16 in Study SPR.203065 and up to Week 24 in Study SPR.202685) and Followup Period (1 day after the end of the Treatment Period to the follow-up visit [8 weeks total in each study]).

## Primary safety population (Phase 3 studies (SPR.202685 and SPR.203065)

More subjects treated with nemolizumab compared to placebo treated, experienced at least 1 TEAE during the Overall Period (246 (66.5%) and 111 (59.7%) respectively).

Study drug-related TEAEs were experienced by 92 (24.9%) nemolizumab subjects and 34 (18.3%) placebo subjects.

Most AEs were mild or moderate in severity. Treatment-emergent SAEs were seen in 25 subjects (6.8%) for nemolizumab and 16 (8.6) for placebo. SAE related to study drug were seen in 3 subjects (0.8%) treated with nemolizumab and 2 (1.1%) treated with placebo. One (0.5%) placebo subject died (cardiogenic shock)

<div style=\"page-break-after: always\"></div>

Table 77: Overall summary of TEAEs during the overall period (primary safety population)

| Subjects with at least 1:                                                                | Nemolizumab N=370 n (%)   | Placebo N=186 n (%)   |
|------------------------------------------------------------------------------------------|---------------------------|-----------------------|
| TEAE                                                                                     | 246 (66.5)                | 111 (59.7)            |
| TEAE by maximum severity a                                                               |                           |                       |
| Mild                                                                                     | 128 (34.6)                | 61 (32.8)             |
| Moderate                                                                                 | 105 (28.4)                | 38 (20.4)             |
| Severe                                                                                   | 13 (3.5)                  | 12 (6.5)              |
| Study drug-related TEAE b                                                                | 92 (24.9)                 | 34 (18.3)             |
| TEAE related to protocol procedure (including topical background therapy) b              | 12 (3.2)                  | 6 (3.2)               |
| SAE                                                                                      | 25 (6.8)                  | 16 (8.6)              |
| SAE related to study drug b                                                              | 3 (0.8)                   | 2 (1.1)               |
| TEAE leading to study drug interruption                                                  | 14 (3.8)                  | 9 (4.8)               |
| TEAE leading to study drug withdrawal                                                    | 15 (4.1)                  | 5 (2.7)               |
| TEAE leading to study discontinuation                                                    | 15 (4.1)                  | 6 (3.2)               |
| AESIs (by Investigator)                                                                  | 53 (14.3)                 | 28 (15.1)             |
| AESIs (standardized and customized MedDRA queries)                                       | 116 (31.4)                | 46 (24.7)             |
| AESIs - adjudicated asthma events                                                        | 8 (2.2)                   | 5 (2.7)               |
| Serious AESIs (by Investigator)                                                          | 3 (0.8)                   | 4 (2.2)               |
| Serious AESIs (standardized and customized MedDRA queries)                               | 1 (0.3)                   | 3 (1.6)               |
| AESIs leading to study drug discontinuation (by Investigator)                            | 5 (1.4)                   | 0                     |
| AESIs leading to study drug discontinuation (standardized and customized MedDRA queries) | 6 (1.6)                   | 2 (1.1)               |
| TEAE leading to death                                                                    | 0                         | 1 (0.5)               |
| TEAE related to study drug leading to death                                              | 0                         | 0                     |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; MedDRA=Medical Dictionary for Regulatory Activities; N=number  of  subjects  in  the  population;  n=number  of  subjects  who  experienced  the  events;  SAE=serious  adverse  event; TEAE=treatment-emergent adverse event

Note: Subjects were summarized according to the treatment they actually received at the time of adverse event onset. Percentages were based on the number of subjects in each treatment group. Adverse events were coded using MedDRA Version 25.0. All TEAEs were defined as adverse events that occurred or worsened on or after the first study treatment date. All adverse events that were judged related to study treatment were classified as TEAEs, regardless of their occurrence date. The Overall Period included both the Treatment Period and Follow-up Period; TEAEs during the Overall Period were defined as TEAEs with an onset date on or after the first dose date until the follow-up visit date. If a subject had multiple occurrences of a TEAE within a treatment group, the subject was presented only once in the respective subject count for that treatment group.

e) If  subjects  experienced multiple events, the subjects were counted once at the event with maximum severity. If severity was missing then the greatest severity, i.e., 'severe' was imputed.

f) The relationship to study treatment or protocol procedure of 'reasonable possibility' was defined as 'related'. If relationship to study treatment or protocol procedure was missing then the closest relationship, i.e., 'related' was imputed.

<div style=\"page-break-after: always\"></div>

Table 78: TEAEs experienced by ≥1.0% of subjects in either treatment group by SOC and PT during the overall period (primary safety population)

| SOC PT                                               | Nemolizumab N=370 n (%)   | Placebo N=186 n (%)   |
|------------------------------------------------------|---------------------------|-----------------------|
| Subjects with at least 1 TEAE                        | 246 (66.5)                | 111 (59.7)            |
| Gastrointestinal disorders                           | 23 (6.2)                  | 16 (8.6)              |
| Diarrhoea                                            | 6 (1.6)                   | 3 (1.6)               |
| Gastritis                                            | 1 (0.3)                   | 3 (1.6)               |
| General disorders and administration site conditions | 33 (8.9)                  | 14 (7.5)              |
| Fatigue                                              | 14 (3.8)                  | 5 (2.7)               |
| Oedema peripheral                                    | 7 (1.9)                   | 2 (1.1)               |
| Pyrexia                                              | 5 (1.4)                   | 0                     |
| Injection site erythema                              | 1 (0.3)                   | 3 (1.6)               |
| Immune system disorders                              | 3 (0.8)                   | 3 (1.6)               |
| Seasonal allergy                                     | 3 (0.8)                   | 2 (1.1)               |
| Infections and infestations                          | 98 (26.5)                 | 47 (25.3)             |
| COVID-19                                             | 24 (6.5)                  | 17 (9.1)              |
| Nasopharyngitis                                      | 17 (4.6)                  | 12 (6.5)              |
| Upper respiratory tract infection                    | 7 (1.9)                   | 4 (2.2)               |
| Urinary tract infection                              | 7 (1.9)                   | 2 (1.1)               |
| Sinusitis                                            | 6 (1.6)                   | 1 (0.5)               |
| Oral herpes                                          | 3 (0.8)                   | 3 (1.6)               |
| Pharyngitis                                          | 4 (1.1)                   | 2 (1.1)               |
| Cystitis                                             | 4 (1.1)                   | 1 (0.5)               |
| Rhinitis                                             | 3 (0.8)                   | 2 (1.1)               |
| Folliculitis                                         | 4 (1.1)                   | 0                     |
| Pneumonia                                            | 4 (1.1)                   | 0                     |
| Cellulitis                                           | 1 (0.3)                   | 2 (1.1)               |
| Skin infection                                       | 0                         | 2 (1.1)               |
| Investigations                                       | 20 (5.4)                  | 9 (4.8)               |
| Peak expiratory flow rate decreased                  | 7 (1.9)                   | 0                     |
| Blood creatine phosphokinase increased               | 2 (0.5)                   | 4 (2.2)               |
| Aspartate aminotransferase increased                 | 2 (0.5)                   | 2 (1.1)               |
| Alanine aminotransferase increased                   | 1 (0.3)                   | 2 (1.1)               |
| Blood lactate dehydrogenase increased                | 1 (0.3)                   | 2 (1.1)               |
| Metabolism and nutrition disorders                   | 11 (3.0)                  | 5 (2.7)               |
| Gout                                                 | 2 (0.5)                   | 2 (1.1)               |
| Musculoskeletal and connective tissue disorders      | 43 (11.6)                 | 14 (7.5)              |
| Back pain                                            | 8 (2.2)                   | 2 (1.1)               |
| Myalgia                                              | 5 (1.4)                   | 4 (2.2)               |
| Arthralgia                                           | 6 (1.6)                   | 2 (1.1)               |
| Osteoarthritis                                       | 7 (1.9)                   | 1 (0.5)               |
| Pain in extremity                                    | 7 (1.9)                   | 1 (0.5)               |
| Nervous system disorders                             | 38 (10.3)                 | 18 (9.7)              |
| Headache                                             | 25 (6.8)                  | 6 (3.2)               |
| Dizziness                                            | 4 (1.1)                   | 3 (1.6)               |
| Polyneuropathy                                       | 0                         | 2 (1.1)               |
| Presyncope                                           | 0                         | 2 (1.1)               |
| Psychiatric disorders                                | 2 (0.5)                   | 4 (2.2)               |

<div style=\"page-break-after: always\"></div>

| Depression                                      | 1 (0.3)    | 2 (1.1)   |
|-------------------------------------------------|------------|-----------|
| Renal and urinary disorders                     | 4 (1.1)    | 3 (1.6)   |
| Proteinuria                                     | 1 (0.3)    | 2 (1.1)   |
| Respiratory, thoracic and mediastinal disorders | 34 (9.2)   | 17 (9.1)  |
| Cough                                           | 14 (3.8)   | 7 (3.8)   |
| Dyspnoea                                        | 9 (2.4)    | 6 (3.2)   |
| Asthma                                          | 6 (1.6)    | 5 (2.7)   |
| Skin and subcutaneous tissue disorders          | 103 (27.8) | 49 (26.3) |
| Neurodermatitis                                 | 25 (6.8)   | 29 (15.6) |
| Atopic dermatitis                               | 17 (4.6)   | 1 (0.5)   |
| Eczema                                          | 14 (3.8)   | 4 (2.2)   |
| Eczema nummular                                 | 13 (3.5)   | 0         |
| Dry skin                                        | 4 (1.1)    | 2 (1.1)   |
| Dermatitis contact                              | 5 (1.4)    | 0         |
| Pruritus                                        | 2 (0.5)    | 3 (1.6)   |
| Rash                                            | 4 (1.1)    | 1 (0.5)   |
| Dyshidrotic eczema                              | 2 (0.5)    | 2 (1.1)   |
| Stasis dermatitis                               | 4 (1.1)    | 0         |
| Vascular disorders                              | 13 (3.5)   | 5 (2.7)   |
| Hypertension                                    | 9 (2.4)    | 4 (2.2)   |

ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Subjects were summarized according to the treatment they actually received at the time of adverse event onset. Percentages were based on the number of subjects in each treatment group. Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. All TEAEs were defined as adverse events that occurred or worsened on or after the first study drug treatment date. The Overall Period included both the Treatment Period and Follow-up Period; TEAEs during the Overall Period were defined as TEAEs with an onset date on or after the first dose date until the follow-up visit date. If a subject had multiple occurrences of a TEAE within a treatment group, the subject was presented only once in the respective subject count for that treatment group.

Twenty-one TEAE PTs met the quantitative criteria (nemolizumab versus placebo): headache (6.8% versus 3.2%), atopic dermatitis (4.6% versus 0.5%), eczema (3.8% versus 2.2%), fatigue (3.8% versus 2.7%), eczema nummular (3.5% versus 0), hypertension (2.4% versus 2.2%), back pain (2.2% versus 1.1%), oedema peripheral (1.9% versus 1.1%), osteoarthritis (1.9% versus 0.5%), pain in extremity (1.9% versus 0.5%), peak expiratory flow rate decreased (1.9% versus 0), urinary tract infection (1.9% versus 1.1%), arthralgia (1.6% versus 1.1%), sinusitis (1.6% versus 0.5%), dermatitis contact (1.4% versus 0), pyrexia (1.4% versus 0), cystitis (1.1% versus 0.5%), folliculitis (1.1% versus 0), pneumonia (1.1% versus 0), rash (1.1% versus 0.5%), and stasis dermatitis (1.1% versus 0)-see previous table on TEAEs experienced by ≥ 1.0% of subjects in either treatment group by SOC and PT during the overall period (primary safety population).

These 21 TEAEs were then further evaluated medically using the qualitative criteria defined above to determine the final proposed list of ADRs for the PN indication. Overall, following medical evaluation, 4 ADRs were identified:

- Headache (including 1 PT of tension headache [hereafter referred to as headache]; nemolizumab 6.8% versus placebo 3.2%). In the nemolizumab group, the events of headache were non-serious, mostly mild or moderate in severity, and did not lead to nemolizumab withdrawal.
- ADRs grouped under the medical concept of eczematous reactions (atopic dermatitis, eczema, and eczema nummular).

Fatigue

<div style=\"page-break-after: always\"></div>

Fatigue was reported in 3.8% of nemolizumab treated patients compared to 2.7% of the placebo treated patients. Mean duration was: 22 days [1-56; N=7]. Although confounders were presented in 8 of 14 PN subjects, only 8/13 (61%) recovered.

## Hypertension

A medical history of hypertension was reported at baseline by 139 [37.6%] subjects in nemolizumab group and 58 [31.2%] subjects in placebo group reported. During the treatment period, hypertension was reported in 9 [2.4%] nemolizumab-treated subjects compared to 4 [2.2%] placebo subjects.

## Back Pain, Osteoarthritis, Pain in Extremity and Arthralgia

During treatment period, back-pain was reported in 2.2% of nemolizumab-treated subjects compared to 1.1% placebo subjects. Eight (8) nemolizumab-treated subjects experienced back pain of mild (7 subjects) to moderate (1 subject) in intensity. While on nemolizumab treatment, 6 of the 8 subjects recovered (1 subject without any treatment), 2 did not recover despite treatment with analgesics and antirheumatics, mainly ibuprofen. One of the events was reported as mechanical origin.

Concurrent or preexisting disease that may associated with symptom of back pain were present in 4 subjects.

Three subjects had ongoing medical history: one subject with osteoarthritis who was diagnosed with gonarthrosis and femoral nerve injury 8-9 days after back pain, one subject had ongoing medical history of cough, dyspnea, asthma, wheezing, one subject had ongoing sciatica.

During treatment period, osteoarthritis was reported in 1.9% of nemolizumab-treated subjects compared to 0.5% placebo subjects. A total of 6 nemolizumab subjects experienced osteoarthritis during the Treatment Period. Confounders were present in all subjects: ongoing medical history of left medial meniscus injury and arthritis left knee, arthrosis, and osteoarthritis. No action was taken to nemolizumab.

The applicant concludes that based on the above, it was assessed that besides a higher frequency of osteoarthritis in the nemolizumab group compared with the placebo group, there was no strong evidence of a reasonable possibility between nemolizumab and osteoarthritis.

During treatment period, pain in extremity was reported in 1.9% nemolizumab treated patients versus 0.5% in placebo treated patients. The events were confounded by the following factors: worsening of PN or an ongoing medical history of arthralgia, venous insufficiency and deep venous thrombosis of right lower limb, leg pain both sides and concomitant fatigue in a subject who had bruising on left leg 14 days prior and was diagnosed with facet joint syndrome. Other confounders were pain in arms with recovering without treatment while on nemolizumab and pain left arm and fatigue, history of hypertension and first degree AV block and Lyme disease 23 days after symptoms of pain left arm and fatigue.

The applicant concludes that based on the above, it was assessed that there was no reasonable possibility between nemolizumab and pain in extremity.

During treatment period, arthralgia was reported in 6 [1.6%] nemolizumab-treated subjects compared to 2 [1.1%] placebo subjects. One subject had a relevant medical history of coxalgia due to hip malformation for event of gonarthralgia left. Another subject with arthralgia right shoulder had a medical history of tendon rupture in left shoulder making possible an overuse of shoulders as a risk factor. A third subject had a relevant medical history of back pain for pain joints right leg. Other confounders included overweight.No action with nemolizumab was taken. One subject recovered without treatment. The event was reported as ongoing in the remaining subjects.

<div style=\"page-break-after: always\"></div>

The applicant concludes that based on the above, there is no evidence of a reasonable possibility of a relationship between nemolizumab and arthralgia.

## Urinary Tract Infection

During the treatment period, urinary tract infection was reported in 7 [1.9%] nemolizumab subjects compared to 2 [1.1%] placebo subjects.

Latency to the event was (median) 104 days [31-150]. Relevant confounders included incontinence, type 2 diabetes mellitus and postmenopause. All subjects continued on nemolizumab and recovered with treatment.

## Sinusitis

A medical history of sinusitis was reported at baseline, 4 [1.1%] subjects in the nemolizumab group only. In addition, 1 [0.3%] subjects in the nemolizumab group and 1 [0.5%] subject in the placebo group reported a medical history of chronic sinusitis.

During treatment period, sinusitis was reported in 6 [1.6%] nemolizumab-treated subjects compared 1 [0.5%] placebo subject.

## Dermatitis Contact

Dermatitis contact occurred in 1.4% nemolizumab treated subjects versus 0 in placebo treated subjects. Dermatitis contact was reported in 5 nemolizumab subjects. One event of dermatitis contact was caused by poison ivy. Another event of contact dermatitis reported as (verbatim) allergic contact eczema, eczema of the skin under left armpit, unknown etiology occurred on Day 66, with the most recent injection of nemolizumab on Day 57. Similarly, the (verbatim) irritant dermatitis - left leg, (verbatim) contact dermatitis eczematoid and contact dermatitis (both arms and legs) occurred in another subject 20, 10, and 26 days after the most recent injection, making a causal relationship with nemolizumab unlikely.

## Pyrexia

Pyrexia was reported in 5 (1.4%) nemolizumab subjects an in 0 subjects treated with placebo. Two events occurred after COVID-19 vaccination in two subjects. One event of non-serious, mild pyrexia occurred on Day 63 in another subject with a medical history of herpes simplex labialis and a TEAE of non-serious oral herpes of mild severity occurred from Day 29 to Day 74. An event of non-serious pyrexia of moderate severity occurred on Day 59 in one subject who was diagnosed with pneumonia on Day 69 (see below). Lastly, one subject presented with non-serious pyrexia and asthenia, both of moderate severity, on Day 43. Although no TEAE of allergy was reported, it is possible that the pyrexia was linked to seasonal allergy, part of the medical history of the subject.

## Cystitis

A medical history of cystitis interstitial was reported at baseline by 1 [0.3%] subjects in nemolizumab group and 0 subject in placebo group reported.

During treatment period cystitis was reported in 4 [1.1%] nemolizumab-treated subjects compared to 1 [0.5%] placebo subject.

## Folliculitis

Folliculitis was reported in 4 (1.1%) nemolizumab subjects compared to 0 placebo subjects. All subjects (2 males and 2 females), with a median age of 54 years had non-serious and mild events. Latency of onset varied from 1 day to 72 days. One subject with mild folliculitis from Day 72 had a relevant medical history of AD and a concurrent (verbatim) atopic dermatitis flare since Day 22. The

<div style=\"page-break-after: always\"></div>

latter may have increased their susceptibility to folliculitis. Possible infectious origin in these cases is not clear. It is noted that two subjects in the nemolizumab treated AD population had a staphylococcal infection that was considered related to study drug.

## Pneumonia

Pneumonia (including bacterial pneumonia and COVID-19 pneumonia) was reported in 5 (1.4%) nemolizumab subjects (pneumonia: 4 [1.1%]; pneumonia bacterial: 1 [0.3%]) compared to 1 (0.5%) placebo subject (COVID-19 pneumonia). Four out of the 5 nemolizumab subjects with pneumonia were non-serious and of moderate severity, and the subjects with a median age of 60 years recovered while continuing on nemolizumab after treatment with antibacterials.

Confounding risk factors were: history of asthma, treated with inhaled adrenergics in combination with corticosteroids, history of polymyalgia rheumatica, history of chronic left ventricular failure.

The remaining subject with pneumonia (verbatim double pneumonia) was serious, severe, and occurred concurrently to an SAE of severe pneumococcal sepsis from Day 51. Both events were also reported as AESIs of infection. The subject had no history of pneumonia or identifiable risk factors. Nemolizumab was interrupted during hospitalization and the subject recovered after 7 days of treatment with amoxicillin. On Day 80, the subject was diagnosed with non-serious symptomatic COVID-19 of mild severity and recovered without treatment on Day 87. Nemolizumab was reintroduced on Day 92. The subject completed the study on Day 118 without another episode of pneumonia. Causality was assessed as not related to nemolizumab. The placebo subject experienced serious and severe COVID 19 pneumonia from Day 51 to 60; study drug was interrupted.

## Rash

Rash was reported during the treatment period by 4 [1.1%] subjects in the nemolizumab group compared to 1 [0.5%] in the placebo group.

Nemolizumab-treated subjects included 2 females 2 males. All events were nonserious and mild (2 subjects) or moderate (2 subjects) in severity. One subject had a concurrent impetigo and an exanthema, unspecified, on arms, legs, and to a lesser extent on trunk (PT: rash) (both of moderate severity) from Day 15. Three subjects recovered without treatment while continuing on nemolizumab, suggesting another cause for the event of rash.

## Stasis Dermatitis

Stasis dermatitis was reported in 4 (1.1%) nemolizumab-treated subjects. At least 3 subjects had a relevant confounder: a medical history of varicose vein, Hashimoto's disease and peripheral oedema, and psoriasis and lichen planus. While there is no direct association between lichen planus and psoriasis and stasis dermatitis, subjects with these conditions may be more susceptible to developing stasis dermatitis due to the weakened skin barrier and increased risk of infections.

## 2.6.11.7.3.  Serious adverse events, deaths, AEs of special interest and other significant events

One (0.5%) placebo subject died during the Overall Period. This subject had a medical history of cardiac failure congestive since 2014 and hypertension since 2007 experienced fatal cardiogenic shock on Day 128 that was considered severe, serious and not related to study drug or protocol procedure.

The percentage experiencing a SAE was not higher in the nemolizumab exposed patient group compared to the placebo group.

<div style=\"page-break-after: always\"></div>

Table 79:SAEs by SOC and PT during the overall period (primary safety population)

| SOC PT                                                              | Nemolizumab N=370 n (%)   | Placebo N=186 n (%)   |
|---------------------------------------------------------------------|---------------------------|-----------------------|
| Subjects with at least 1 SAE                                        | 25 (6.8)                  | 16 (8.6)              |
| Cardiac disorders                                                   | 3 (0.8)                   | 4 (2.2)               |
| Acute myocardial infarction                                         | 1 (0.3)                   | 0                     |
| Atrial flutter                                                      | 0                         | 1 (0.5)               |
| Cardiac sarcoidosis                                                 | 0                         | 1 (0.5)               |
| Cardiogenic shock                                                   | 0                         | 1 (0.5)               |
| Coronary artery disease                                             | 1 (0.3)                   | 0                     |
| Coronary artery occlusion                                           | 0                         | 1 (0.5)               |
| Myocardial infarction                                               | 0                         | 1 (0.5)               |
| Supraventricular tachycardia                                        | 1 (0.3)                   | 0                     |
| Gastrointestinal disorders                                          | 1 (0.3)                   | 0                     |
| Gastritis                                                           | 1 (0.3)                   | 0                     |
| Pancreatitis                                                        | 1 (0.3)                   | 0                     |
| General disorders and administration site conditions                | 0                         | 1 (0.5)               |
| Oedema peripheral                                                   | 0                         | 1 (0.5)               |
| Hepatobiliary disorders                                             | 1 (0.3)                   | 0                     |
| Cholecystitis acute                                                 | 1 (0.3)                   | 0                     |
| Infections and infestations                                         | 6 (1.6)                   | 3 (1.6)               |
| Acarodermatitis                                                     | 2 (0.5)                   | 0                     |
| Cellulitis                                                          | 1 (0.3)                   | 1 (0.5)               |
| Appendicitis                                                        | 0                         | 1 (0.5)               |
| COVID-19 pneumonia                                                  | 0                         | 1 (0.5)               |
| Campylobacter colitis                                               | 1 (0.3)                   | 0                     |
| Pneumococcal sepsis                                                 | 1 (0.3)                   | 0                     |
| Pneumonia                                                           | 1 (0.3)                   | 0                     |
| Postoperative wound infection                                       | 0                         | 1 (0.5)               |
| Urinary tract infection                                             | 1 (0.3)                   | 0                     |
| Injury, poisoning and procedural complications                      | 1 (0.3)                   | 1 (0.5)               |
| Fall                                                                | 0                         | 1 (0.5)               |
| Subdural haemorrhage                                                | 1 (0.3)                   | 0                     |
| Metabolism and nutrition disorders                                  | 1 (0.3)                   | 0                     |
| Type 2 diabetes mellitus                                            | 1 (0.3)                   | 0                     |
| Musculoskeletal and connective tissue disorders                     | 3 (0.8)                   | 1 (0.5)               |
| Osteoarthritis                                                      | 2 (0.5)                   | 1 (0.5)               |
| Intervertebral disc protrusion                                      | 1 (0.3)                   | 0                     |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2 (0.5)                   | 0                     |
| Basal cell carcinoma                                                | 1 (0.3)                   | 0                     |
| Bladder neoplasm                                                    | 1 (0.3)                   | 0                     |
| Squamous cell carcinoma of skin                                     | 1 (0.3)                   | 0                     |

ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; PT=preferred term; SAE=serious adverse event; SOC=system organ class; TEAE=treatment-emergent adverse event Note: Subjects were summarized according to the treatment they actually received at the time of adverse event onset. Percentages were based on the number of subjects in each treatment group. Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. All TEAEs were defined as adverse events that occurred or worsened on or after the first study drug treatment date. The Overall Period included both the Treatment Period and Follow-up Period; TEAEs during the Overall Period were defined as TEAEs with an onset date on or after the first dose date until the follow-up visit date. If a subject had multiple occurrences of a TEAE within a treatment group, the subject was presented only once in the respective subject count for that treatment group.

<div style=\"page-break-after: always\"></div>

Table 80: Subjects with study drug-related treatment-emergent SAEs (primary safety population)

| Preferred term                         | Start day/ end day   | Severity   | Related to study drug/ injection procedure   | Outcome                          |
|----------------------------------------|----------------------|------------|----------------------------------------------|----------------------------------|
| Nemolizumab                            |                      |            |                                              |                                  |
| Campylobacter colitis a                | 64/70                | Severe     | Yes/No                                       | Recovered/resolved               |
| Pemphigoid b,c                         | 58/71                | Moderate   | Yes/No                                       | Recovered/resolved with sequelae |
| Pemphigoid b,c                         | 14/ongoing           | Severe     | Yes/No                                       | Not recovered/ not resolved      |
| Placebo                                |                      |            |                                              |                                  |
| Oedema peripheral a                    | 8/17                 | Severe     | Yes/No                                       | Recovered/resolved               |
| Dermatitis exfoliative generalised b,c | 19/62                | Severe     | Yes/No                                       | Recovered/resolved               |

ISS=Integrated Summary of Safety; SAE=serious adverse event

- a) Event was also considered an adverse event of special interest (by Investigator).

b) Event also led to study drug withdrawal.

c) Event also led to study discontinuation.

The following TEAEs were considered AESIs:

- Injection-related reactions (IRRs), which included anaphylactic reactions, acute allergic reactions requiring treatment, and severe injection site reactions with a duration &gt;24 hours
- Newly diagnosed asthma or worsening of asthma
- Infections, which included any severe infection, any infection requiring treatment with parenteral antibiotics or with oral antibiotics/antivirals/antifungals for &gt;2 weeks, and any confirmed or suspected COVID-19 infection
- Peripheral oedema: limbs, bilateral
- Facial oedema
- Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (&gt;3 × the upper limit of normal [ULN]) in combination with elevated bilirubin (&gt;2 × ULN).

<div style=\"page-break-after: always\"></div>

Table 81: AESIs (by investigator) during the overall period (primary safety population)

| Category                                                                     | Nemolizumab N=370 n (%)   | Placebo N=186 n (%)   |
|------------------------------------------------------------------------------|---------------------------|-----------------------|
| Any AESI                                                                     | 53 (14.3)                 | 28 (15.1)             |
| Injection-related reactions                                                  | 2 (0.5)                   | 0                     |
| TEAE related to study drug                                                   | 2 (0.5)                   | 0                     |
| Serious TEAE                                                                 | 0                         | 0                     |
| TEAE leading to permanent discontinuation of study drug                      | 2 (0.5)                   | 0                     |
| Newly diagnosed asthma or worsening of asthma                                | 12 (3.2)                  | 5 (2.7)               |
| TEAE related to study drug                                                   | 4 (1.1)                   | 4 (2.2)               |
| Serious TEAE                                                                 | 0                         | 0                     |
| TEAE leading to permanent discontinuation of study drug                      | 0                         | 0                     |
| Infections                                                                   | 31 (8.4)                  | 22 (11.8)             |
| TEAE related to study drug                                                   | 4 (1.1)                   | 0                     |
| Serious TEAE                                                                 | 3 (0.8)                   | 3 (1.6)               |
| TEAE leading to permanent discontinuation of study drug                      | 2 (0.5)                   | 0                     |
| Peripheral oedema: limbs, bilateral; facial oedema                           | 11 (3.0)                  | 3 (1.6)               |
| TEAE related to study drug                                                   | 7 (1.9)                   | 3 (1.6)               |
| Serious TEAE                                                                 | 0                         | 1 (0.5)               |
| TEAE leading to permanent discontinuation of study drug                      | 1 (0.3)                   | 0                     |
| Elevated ALT or AST (>3×ULN) in combination with elevated bilirubin (>2×ULN) | 0                         | 0                     |

AESI=adverse event of special interest; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; TEAE=treatment-emergent adverse event; ULN=upper limit of normal

Note: Note: Subjects were summarized according to the treatment they actually received at the time of adverse event onset. Percentages were based on the number of subjects in each treatment group. Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. All TEAEs were defined as adverse events that occurred or worsened on or after the first study drug treatment date. The Overall Period included both the Treatment Period and Follow-up Period; TEAEs during the Overall Period were defined as TEAEs with an onset date on or after the first dose date until the follow-up visit date. If a subject had multiple occurrences of a TEAE within a treatment group, the subject was presented only once in the respective subject count for that treatment group.

## Malignancies

A total of 11 malignancies in 10 subjects were reported in the PN indication (7 in Galderma sponsored studies with exposure to nemolizumab 30 mg Q4W and 4 in Maruho sponsored studies with exposure to nemolizumab 60 mg Q4W

Table 82 presents the malignancies reported after any exposure to nemolizumab in the clinical development program conducted by Galderma and its partner Maruho by indication and cancer type.

<div style=\"page-break-after: always\"></div>

Table 82: Malignancies reported after any exposure to nemolizumab in the clinical development program conducted by Galderma and its partner Maruho by indication and cancer type (cut-off date 10 Mar 2023) (modified)

| Indication        | Cancer type                         |   Number of events (frequency) | Reported events (number of events reported)                         |
|-------------------|-------------------------------------|--------------------------------|---------------------------------------------------------------------|
| Prurigo nodularis | Basal cell carcinoma                |                              2 | Basal cell carcinoma (2)                                            |
| Prurigo nodularis | Squamous cell carcinoma of the skin |                              3 | Squamous cell carcinoma of the skin (2) Squamous cell carcinoma (1) |
| Prurigo nodularis | Hodgkin's disease                   |                              2 | Hodgkin's disease stage IV (1) Hodgkin's disease stage III (1)      |
| Prurigo nodularis | Colorectal cancer                   |                              3 | Rectal adenocarcinoma (1) Rectal cancer (1) Rectosigmoid cancer (1) |
| Prurigo nodularis | Uterine cancer                      |                              1 | Uterine cancer (1)                                                  |

## Eczematous reactions

Eczematous reactions, reported as events of atopic dermatitis, eczema nummular, or eczema, were more frequently reported in subjects treated with nemolizumab as compared to subjects treated with placebo: atopic dermatitis (4.6% versus 0.5%), eczema (3.8% versus 2.2%) and eczema nummular (3.5% versus 0). All events were mild or moderate in severity. Most of the events resolved, with &gt;60.0% of the events being assessed as related to nemolizumab

## Autoimmune diseases

At baseline, autoimmune diseases were equally common in nemolizumab subjects and placebo subjects. During the Overall period, the following autoimmune diseases were reported: pemphigoid (3 [0.8%] nemolizumab subjects), psoriasis (2 [0.5%] nemolizumab subjects and 1 [0.5%] placebo subject), polymyalgia rheumatica and alopecia areata (1 [0.3%] nemolizumab subject each), and cardiac sarcoidosis (1 [0.5%] placebo subject).

One subject was diagnosed with alopecia areata - primary episode of mild severity on Day 89. Causality was assessed as not related to nemolizumab

## Headache

Headache (including tension headache) was reported at a higher frequency in the nemolizumab group (headache: 6.8%; tension headache: 0.3%) compared with the placebo group (headache: 3.2%; tension headache: 0%) during the Treatment Period.

All events in nemolizumab treated subjects were non-serious and mostly or moderate in severity. One event was severe, but the headache resolved the same day after treatment with ibuprofen. Five of 33 (15.2%) events for which no treatment had been administered did not resolve.

A total of 31 out of 33 (93.9%) events in nemolizumab treated subjects were considered study drugrelated compared to only 1 out of 6 (16.7%) events in placebo subjects.

The applicant concludes that considering the magnitude of the difference with placebo and the lack of confounders in most nemolizumab subjects, it was deemed that there is a reasonable possibility of a relationship between nemolizumab and headache.

## Injection site reactions

No imbalance of injection site reactions was observed between nemolizumab (1.1%) and placebo (1.6%). Injection site reactions included injection site erythema (1 event), injection site bruising (2 events), injection site pruritus (1 event) and injection site reaction (1 event) reported in 4

<div style=\"page-break-after: always\"></div>

nemolizumab subjects and injection site erythema (3 events), injection site pruritus (2 events) and injection site irritation (1 event) reported in 3 placebo subjects respectively.

## Injection-related reactions

All Injection-Related Reactions were considered AESIs, which included anaphylactic reactions, acute allergic reactions requiring treatment, and severe injection site reactions with a duration &gt;24 hours.

Two (0.5%) nemolizumab subjects experienced an IRR during the Overall period. The events (one dermatitis allergic and one drug eruption) were considered study drug-related. The applicant concludes that the evaluation of the data on IRRs suggests a low risk of serious hypersensitivity reactions and severe injection site reactions in association with the use of nemolizumab

## Asthma

At baseline, in the primary safety population, the frequency of subjects with medical history of asthma was 13.0% in the nemolizumab group and 14.0% in the placebo group.

## Newly diagnosed asthma or worsening of asthma AESIs as reported by the Investigator

Twelve (3.2%) nemolizumab subjects and 5 (2.7%) placebo subjects experienced an AESI meeting the per protocol definition of newly diagnosed asthma or worsening of asthma (which included peak expiratory flow rate decreased) during the Overall Period. Six (1.6%) nemolizumab subjects and 5 (2.7%) placebo subjects experienced asthma; 6 (1.6%) nemolizumab subjects experienced peak expiratory flow rate decreased.

Four (1.1%) nemolizumab subjects and 4 (2.2%) placebo subjects during the Overall Period experienced AESIs of newly diagnosed asthma or worsening of asthma that were considered study drug-related. All study drug-related AESIs of newly diagnosed asthma or worsening of asthma were non-serious, considered mild or moderate in severity, and did not result in study drug withdrawal or study discontinuation; half of the AESIs of newly diagnosed asthma or worsening of asthma were ongoing.

## Asthma events adjudicated by the IAC

Fifteen (4.1%) nemolizumab subjects and 5 (2.7%) placebo subjects had TEAEs adjudicated by the IAC during the Overall Period, with 8 (2.2%) nemolizumab subjects and 5 (2.7%) placebo subjects experiencing confirmed asthma events. Four (2.2%) placebo subjects and no nemolizumab subjects experienced TEAEs of asthma that were confirmed as new onset asthma. Eight (2.2%) nemolizumab subjects and 1 (0.5%) placebo subject experienced confirmed worsening of asthma events; 6 (1.6%) nemolizumab subjects and 1 (0.5%) placebo subject experienced TEAEs of asthma and 1 (0.3%) nemolizumab subject each experienced a TEAE of peak expiratory flow rate decreased and wheezing that were confirmed worsening of (pre existing) asthma.

## PEF and ACT

The applicant also presented data showing that actual PEF of the predicted value (%) decreased in asthmatic patients receiving nemolizumab compared to those receiving placebo for mean value of 2.85% vs -1% at week 4, -3.9% vs -2.6% at week 8, -2.9% vs -1.5% at week 12 and -2.7% vs 0.5% at week 16. Also, for subjects with asthma history, the proportion of subjects with at least one PEF &lt;80% of predicted value was 9/50 (18.0%) in nemolizumab group compared with 1/27 (3.7%) in placebo group. During 24 weeks of treatment, proportion of patients with PEF&lt;80% of predicted value was about 8-10% (2-5 patients) in nemolizumab group compared to 0 patients receiving placebo.

Contrary to asthmatic patients, no imbalance between nemolizumab and placebo was observed in patients without history of asthma regarding mean changes in actual PEF of the predicted value (%): -

<div style=\"page-break-after: always\"></div>

1% vs -1.6% at week 8 and -0.6% vs -1.1% at week 16, respectively. For subjects without asthma history, at least one PEF&lt;80% of predicted value was reported in 16/308 (5.2%) nemolizumab subjects and 6/155 (3.9%) placebo subjects. Proportion of patients with PEF&lt;80% was about 2-3% up to week 24 in both groups.

There was a higher percentage of nemolizumab subjects compared with placebo subjects with an ACT score ≤ 19 at Week 4 (11.8% vs. 4.0%) and Week 8 (6.4% vs. 0%). The proportions were more similar later, although consistenly higher in nemolizumab group, at Week 12 (10.0% and 8.0%) and Week 16 (7.4% and 6.9%).

## Infections

All AESIs of infections included any severe infection, any infection requiring treatment with parenteral antibiotics or with oral antibiotics/antivirals/antifungals for &gt;2 weeks, and any confirmed or suspected COVID-19 infection.

TEAEs in the SOC of Infections and Infestations (excluding COVID-19 infections) were more commonly reported in the nemolizumab group (74 [20.0%] subjects) than in the placebo group (30 [16.1%] subjects) in the Overall Period. However, AESIs of infection during the Overall Period, were more common in placebo subjects (11.8%) than in nemolizumab subjects (8.4%).

The percentage experiencing a SAE in the SOC Infections and infestations was not higher in the nemolizumab exposed patient group compared to the placebo group.

Treatment-emergent AEs of skin infections (including cellulitis) were reported in 3 (0.8%) nemolizumab subjects (cellulitis, fungal skin infection, and skin infection in 1 [0.3%] subject each) versus 4 (2.2%) placebo subjects (cellulitis and skin infection in 2 [1.1%] subjects each).

Fungal infections (reported as non-serious TEAEs and of mild or moderate severity) were reported exclusively in the nemolizumab group; body tinea (3 [0.8%] nemolizumab subjects versus 0 placebo subjects), tinea pedis (3 [0.8%] nemolizumab subjects versus 0 placebo subjects), fungal infection (2 [0.5%] nemolizumab subjects versus 0 placebo subjects), onychomycosis (2 [0.5%] nemolizumab subjects versus 0 placebo subjects), and fungal skin infection (1 [0.3%] nemolizumab subject versus 0 placebo subjects

## Peripheral oedema: limbs, bilateral; facial oedema

<div style=\"page-break-after: always\"></div>

Table 83: AESIs of peripheral oedema: limbs, bilateral; facial oedema by SOC and PT during the overall period (primary safety population)

| Category SOC PT                                                  | Nemolizumab N=370 n (%)   | Placebo N=186 n (%)   |
|------------------------------------------------------------------|---------------------------|-----------------------|
| Any TEAE with peripheral oedema: limbs, bilateral; facial oedema | 11 (3.0)                  | 3 (1.6)               |
| TEAEs of facial oedema                                           |                           |                       |
| General disorders and administration site conditions             | 10 (2.7)                  | 3 (1.6)               |
| Face oedema                                                      | 3 (0.8)                   | 0                     |
| Skin and subcutaneous tissue disorders                           | 1 (0.3)                   | 0                     |
| Angioedema                                                       | 1 (0.3)                   | 0                     |
| TEAEs of peripheral oedema                                       |                           |                       |
| General disorders and administration site conditions             | 10 (2.7)                  | 3 (1.6)               |
| Oedema peripheral                                                | 7 (1.9)                   | 2 (1.1)               |
| Non-pitting oedema                                               | 1 (0.3)                   | 1 (0.5)               |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Subjects were summarized according to the treatment they actually received at the time of adverse event onset. Percentages were based on the number of subjects in each treatment group. Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. All TEAEs were defined as adverse events that occurred or worsened on or after the first study drug treatment date. The Overall Period included both the Treatment Period and Follow-up Period; TEAEs during the Overall Period were defined as TEAEs with an onset date on or after the first dose date until the follow-up visit date. If a subject had multiple occurrences of a TEAE within a treatment group, the subject was presented only once in the respective subject count for that treatment group.

In the nemolizumab group, all events were non-serious and either mild (5 events) or moderate (3 events) in severity.

Of the subjects with AESIs of peripheral oedema: limbs, bilateral; facial oedema during the Overall Period, the majority had events that were considered study drug related.

<div style=\"page-break-after: always\"></div>

Table 84: Subjects with study drug-related AESIs of peripheral oedema: limbs, bilateral; facial oedema (primary safety population)

| Preferred term        | Start day/ end day   | Severity   | Related to study drug/ injection procedure   | Outcome                     |
|-----------------------|----------------------|------------|----------------------------------------------|-----------------------------|
| Nemolizumab           |                      |            |                                              |                             |
| Face oedema           | 11/18                | Moderate   | Yes/No                                       | Recovered/resolved          |
| Oedema peripheral     | 41/64                | Moderate   | Yes/No                                       | Recovered/resolved          |
| Oedema peripheral     | 64/ongoing           | Moderate   | Yes/No                                       | Not recovered/ not resolved |
| Oedema peripheral     | 21/61                | Moderate   | Yes/Yes                                      | Recovered/resolved          |
| Face oedema a,b       | 13/45                | Moderate   | Yes/No                                       | Recovered/resolved          |
| Oedema peripheral a,b | 13/45                | Moderate   | Yes/No                                       | Recovered/resolved          |
| Angioedema            | 48/48                | Mild       | Yes/No                                       | Recovered/resolved          |
| Oedema peripheral     | 20/ongoing           | Mild       | Yes/No                                       | Not recovered/ not resolved |
| Oedema peripheral     | 20/92                | Mild       | Yes/No                                       | Recovered/resolved          |
| Placebo               |                      |            |                                              |                             |
| Oedema peripheral c   | 8/17                 | Severe     | Yes/No                                       | Recovered/resolved          |
| Oedema peripheral     | 44/107               | Mild       | Yes/No                                       | Recovered/resolved          |
| Non-pitting oedema    | 11/104               | Mild       | Yes/No                                       | Recovered/resolved          |

AESI=adverse event of special interest; ISS=Integrated Summary of Safety

- a) Event also led to study drug withdrawal.
- b) Event also led to study discontinuation.
- c) Event was also considered serious.

Exposure-response analysis, did not identify a relationship between nemolizumab exposure at steady state and the incidence of facial and peripheral oedema.

## Elevated ALT or AST (&gt;3×ULN) in combination with elevated bilirubin (&gt;2×ULN)

No subject had elevated ALT or AST &gt;3×ULN in combination with elevated bilirubin &gt;2×ULN during the Overall Period (ISS Table 14.3.1.13.2).

The applicant concludes that evaluation of the data on elevated ALT or AST &gt;3×ULN in combination with elevated bilirubin &gt;2×ULN does not suggest any increased risk of drug-induced liver injury associated with the use of nemolizumab.

## 2.6.11.7.4.  Laboratory findings

## Hematology

In the primary safety population, the proportion of subjects who experienced potentially clinically significant elevated eosinophils (worst post-baseline) was 5.5% in the nemolizumab group and 2.7% in the placebo group.

The applicant concludes that while there was an imbalance in the proportion of subjects who experienced potentially clinically significant elevated eosinophils between nemolizumab and placebo, only 1 (0.3%) nemolizumab subject experienced a non-serious TEAE of eosinophilia of mild severity in the context of a TEAE of acarodermatitis (verbatim: scabies. The increase in eosinophils observed in this development program was not associated with eosinophilic disorders of clinical concern.

## Clinical chemistry

<div style=\"page-break-after: always\"></div>

In Phase 2 Study CIM003J, analysis of selected AEs suggested a possible dose-dependent effect on CPK as the incidence of CPK increase was higher in the nemolizumab 2.0 mg/kg Q4W and Q8W groups (15.4% and 11.5%, respectively) than in the nemolizumab 0.1 mg/kg and 0.5 mg/kg Q4W groups (7.5% and 5.6%, respectively)

In the PN primary safety population, potentially clinically significant elevated creatine kinase during treatment was more common in placebo subjects (4 [2.2%]) than in nemolizumab subjects (6 [1.6%]). 1 subject experienced a TEAE of blood creatine phosphokinase increased on Day 55. The event was considered mild in severity and resolved while on treatment with nemolizumab.

## Urinalysis

No notable trends were observed over time in continuous or categorical urinalysis data in the primary safety population.

## Integrated summary of immunogenicity

In the pivotal PN studies (SPR.202685 and SPR.203065) and LTE PN study (SPR.202699) with up to 116 weeks of treatment, the incidence of treatment-emergent anti-drug antibodies (ADAs) was 12.8% (46 out of 358 AD subjects), of which was persistent in 32 (8.9%) subjects and transient in 12 (3.4%) subjects. Treatment-boosted ADAs were observed in 2 (0.6%) subjects and neutralizing antibodies were observed in 12 (3.4%) subjects.

Drug hypersensitivity reactions and suspected immune-mediated AEs were rare and no discernible pattern was observed based on ADA category for subjects experiencing drug-related drug hypersensitivity reactions. The IRR rate was similar between subjects who were treatment -emergent ADA positive and subjects who were ADA negative.

Thorough analysis did not reveal any association between ADA positivity status and incidence or severity of acute or delayed hypersensitivity reactions to nemolizumab.

## Vital signs and ECGs

No notable trends were observed over time in vital signs.

Although there was a higher percentage of nemolizumab subjects compared with placebo subjects who experienced a ≥5% increase in weight from baseline at Week 12 (3.6% and 2.2%, respectively), Week 16 (5.1% and 1.1%, respectively), and Week 24 (8.9% and 5.9%, respectively), there were no associated study drug-related TEAEs of weight increased in any nemolizumab subject. In addition, based on last post-baseline values, subjects had generally normalized their baseline weight at study completion. No other notable trends in potentially clinically significant vital signs were observed over time.

<div style=\"page-break-after: always\"></div>

Table 85: Summary of ECG findings at baseline Week 16 and Week 24 (PN safety population)

| Parameter (criterion)                                                                    | Nemolizumab N=370 n/N (%)   | Placebo N=186 n/N (%)   |
|------------------------------------------------------------------------------------------|-----------------------------|-------------------------|
| Atrioventricular conduction (first degree atrioventricular block)                        |                             |                         |
| Baseline                                                                                 | 19/370 (5.1)                | 12/186 (6.5)            |
| Week 16                                                                                  | 13/172 (7.6)                | 3/87 (3.4)              |
| Week 24                                                                                  | 14/165 (8.5)                | 5/85 (5.9)              |
| Chamber hypertrophy or enlargement (left ventricular hypertrophy)                        |                             |                         |
| Baseline                                                                                 | 2/370 (0.5)                 | 1/186 (0.5)             |
| Week 16                                                                                  | 1/172 (0.6)                 | 0                       |
| Week 24                                                                                  | 1/165 (0.6)                 | 0                       |
| Intraventricular-intraatrial conduction (incomplete right bundle branch block)           |                             |                         |
| Baseline                                                                                 | 0                           | 0                       |
| Week 16                                                                                  | 2/172 (1.2)                 | 0                       |
| Week 24                                                                                  | 1/165 (0.6)                 | 0                       |
| Intraventricular-intraatrial conduction (intraventricular conduction delay, nonspecific) |                             |                         |
| Baseline                                                                                 | 4/370 (1.1)                 | 2/186 (1.1)             |
| Week 16                                                                                  | 0                           | 0                       |
| Week 24                                                                                  | 2/165 (1.2)                 | 0                       |
| Intraventricular-intraatrial conduction (right bundle branch block)                      |                             |                         |
| Baseline                                                                                 | 6/370 (1.6)                 | 2/186 (1.1)             |
| Week 16                                                                                  | 3/172 (1.7)                 | 1/87 (1.1)              |
| Week 24                                                                                  | 3/165 (1.8)                 | 0                       |
| Pacemaker (paced atrial rhythm)                                                          |                             |                         |
| Baseline                                                                                 | 1/370 (0.3)                 | 0                       |
| Week 16                                                                                  | 0                           | 0                       |
| Week 24                                                                                  | 1/165 (0.6)                 | 0                       |
| Pacemaker (paced rhythm)                                                                 |                             |                         |
| Baseline                                                                                 | 2/370 (0.5)                 | 0                       |
| Week 16                                                                                  | 0                           | 0                       |
| Week 24                                                                                  | 3/165 (1.8)                 | 0                       |
| ST segment, T wave, and U wave (QTc prolongation)                                        |                             |                         |
| Baseline                                                                                 | 5/370 (1.4)                 | 2/186 (1.1)             |
| Week 16                                                                                  | 0                           | 0                       |
| Week 24                                                                                  | 2/165 (1.2)                 | 0                       |
| ST segment, T wave, and U wave (ST depression)                                           |                             |                         |
| Baseline                                                                                 | 5/370 (1.4)                 | 3/186 (1.6)             |
| Week 16                                                                                  | 3/172 (1.7)                 | 0                       |
| Week 24                                                                                  | 4/165 (2.4)                 | 1/85 (1.2)              |

<div style=\"page-break-after: always\"></div>

| Parameter (criterion)                                   | Nemolizumab N=370 n/N (%)   | Placebo N=186 n/N (%)   |
|---------------------------------------------------------|-----------------------------|-------------------------|
| Baseline                                                | 13/370 (3.5)                | 4/186 (2.2)             |
| Week 16                                                 | 6/172 (3.5)                 | 0                       |
| Week 24                                                 | 7/165 (4.2)                 | 3/85 (3.5)              |
| ST segment, T wave, and U wave (T waves flat)           |                             |                         |
| Baseline                                                | 14/370 (3.8)                | 5/186 (2.7)             |
| Week 16                                                 | 4/172 (2.3)                 | 4/87 (4.6)              |
| Week 24                                                 | 11/165 (6.7)                | 2/85 (2.4)              |
| Ventricular arrhythmias (premature ventricular complex) |                             |                         |
| Baseline                                                | 7/370 (1.9)                 | 1/186 (0.5)             |
| Week 16                                                 | 3/172 (1.7)                 | 1/87 (1.1)              |
| Week 24                                                 | 3/165 (1.8)                 | 1/85 (1.2)              |
| Ventricular arrhythmias (ventricular bigeminy)          |                             |                         |
| Baseline                                                | 1/370 (0.3)                 | 0                       |
| Week 16                                                 | 0                           | 0                       |
| Week 24                                                 | 2/165 (1.2)                 | 1/85 (1.2)              |

ECG = electrocardiogram; QTc = heart rate-corrected QT.

## 2.6.11.7.5.  Safety in special populations

## Age

The applicant was requested to clarify the exact number of exposed subjects, duration of treatment including dosage and discontinuation rate of patients &gt; 65 in the PN population and submitted Table 86 . It is noted that 99 subjects were exposed to nemolizumab in this group. Mean treatment duration was 136.1 days. Most subjects received 4 or 6 number of treatments (n=44, n= 40 respectively).

Although the exposure data in the age group ≥ 65 years in the PN population is limited, it is considered sufficient to enable an initial assessment of this age group.

<div style=\"page-break-after: always\"></div>

Table 86: Summary of Exposure in Age Group ≥ 65 years (PN Primary Safety Population)

|                                                | Nemolizumab (N=99)   | Placebo (N=41)   |
|------------------------------------------------|----------------------|------------------|
| Dosage                                         |                      |                  |
| Nemolizumab 60-30 mg                           | 63                   | -                |
| Nemolizumab 60-60 mg Placebo                   | 36 -                 | - 41             |
| Treatment duration (days)                      |                      |                  |
| N                                              | 99                   | 41               |
| Mean (SD)                                      | 136.1 (38.50)        | 149.0 (35.10)    |
| Median                                         | 121.0                | 171.0            |
| Q1, Q3                                         | 115.0, 171.0         | 115.0, 173.0     |
| Min, Max                                       | 31, 191              | 31, 185          |
| Treatment duration (years)                     |                      |                  |
| N                                              | 99                   | 41               |
| Mean (SD)                                      | 0.373 (0.1054)       | 0.408 (0.0961)   |
| Median                                         | 0.331                | 0.468            |
| Q1. Q3                                         | 0.315, 0.468         | 0.315, 0.474     |
| Min, Max                                       | 0.08, 0.52           | 0.08, 0.51       |
| Number of treatments                           |                      |                  |
| N                                              | 99                   | 41               |
| Mean (SD)                                      | 4.7 (1.34)           | 5.1 (1.22)       |
| Median                                         | 4.0                  | 6.0              |
| Q1. Q3                                         | 4.0, 6.0             | 4.0, 6.0         |
| Min, Max                                       | 1, 6                 | 1, 6             |
| Number of treatments, n (%)                    |                      |                  |
| 1                                              | 4 (4.0)              | 1 (2.4)          |
| 2                                              | 4 (4.0)              | 0                |
| 3                                              | 1 (1.0)              | 2 (4.9)          |
| 4                                              | 44 (44.4)            | 12 (29.3)        |
| 5                                              | 6 (6.1)              | 2 (4.9)          |
| 6                                              | 40 (40.4)            | 24 (58.5)        |
| Any TEAE leading to study drug interruption    | 2 (2.0)              | 1 (2.4)          |
| Any TEAE leading to study drug discontinuation | 8 (8.1)              | 1 (2.4)          |
| Any TEAE leading to study discontinuation      | 9 (9.1)              | 1 (2.4)          |

PN = prurigo nodularis; SD = standard deviation; TEAE = treatment emergent adverse event.

In the PN population higher numbers of TEAES, study drug-related TEAEs, and TEAEs leading to study drug withdrawal or study discontinuation in patients &gt;65 years of age are noted.

<div style=\"page-break-after: always\"></div>

Table 87: Summary of TEAEs by Age Group in the overall treatment period (PN primary safety population)

|                                                                              | Overall treatment period   | Overall treatment period   | Overall treatment period   | Overall treatment period   |
|------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                              | > 65 Years                 | > 65 Years                 | 18-65 Years                | 18-65 Years                |
|                                                                              | Nemo 30 mg Q4W N=99 n (%)  | PBO N=41 n (%)             | Nemo 30 mg Q4W N=271 n (%) | PBO N=145 n (%)            |
| At least 1 TEAE                                                              | 74 (74.7)                  | 23 (56.1)                  | 172 (63.5)                 | 88 (60.7)                  |
| Any TEAE related to study drug                                               | 33 (33.3)                  | 3 (7.3)                    | 59 (21.8)                  | 31 (21.4)                  |
| Any severe                                                                   | 4 (4.0)                    | 2 (4.9)                    | 9 (3.3)                    | 10 (6.9)                   |
| Any TEAE leading to study drug discontinuation                               | 8 (8.1)                    | 1 (2.4)                    | 7 (2.6)                    | 4 (2.8)                    |
| Any serious TEAE                                                             | 9 (9.1)                    | 6 (14.6)                   | 16 (5.9)                   | 10 (6.9)                   |
| Any serious TEAE related to study drug                                       | 1 (1.0)                    | 1 (2.4)                    | 2 (0.7)                    | 1 (0.7)                    |
| Any TEAE of special interest                                                 | 14 (14.1)                  | 5 (12.2)                   | 39 (14.4)                  | 23 (15.9)                  |
| Injection-related reactions                                                  | 1 (1.0)                    | 0                          | 1 (0.4)                    | 0                          |
| Newly diagnosed asthma or worsening of asthma                                | 3 (3.0)                    | 0                          | 9 (3.3)                    | 5 (3.4)                    |
| Infections                                                                   | 6 (6.1)                    | 5 (12.2)                   | 25 (9.2)                   | 17 (11.7)                  |
| Peripheral oedema                                                            | 5 (5.1)                    | 0                          | 6 (2.2)                    | 3 (2.1)                    |
| Elevated ALT or AST (>3xULN) in combination with elevated Bilirubin (>2xULN) | 0                          | 0                          | 0                          | 0                          |

ALT = alanine transaminase; AST = aspartate aminotransferase; PBO = placebo; PN = prurigo nodularis;

TEAE = treatment emergent adverse event; ULN = upper limit of normal.

Dyspnoea was more frequent in nemolizumab subjects (5 [5.1%]) than placebo subjects (0%) in elderly. However, only 2 (2%) subjects in the age group &gt;65 reported this TEAE as related to study drug.

Among elderly, the most frequently reported SOC for TEAEs reported in ≥ 2% of subjects in the nemolizumab &gt;65 years group was `Skin and subcutaneous tissue disorders (Table 88). Eczematous reactions were more frequently reported in elderly nemolizumab subjects compared to younger adults: atopic dermatitis (5.1% subjects versus 4.4% subject respectively), eczema (7.1% subjects versus 2.6% subjects respectively) and eczema nummular (7.1% subjects versus 2.2% subjects respectively). The same trend is noted in these TEAEs when reported as related to study drug. The text `Patients &gt;65 years of age had a higher rate of eczematous reactions´ was therefore added to the description of selected adverse reactions in the SmPC, section 4.8. SmPC.

<div style=\"page-break-after: always\"></div>

Table 88: Summary of TEAEs (all causalities) by Age Group by SOC and PT reported in ≥ 2.0% of subjects in the nemolizumab &gt;65 years group in the overall treatment period (PN primary safety population)

|                                                      | Overall treatment period   | Overall treatment period   | Overall treatment period   | Overall treatment period   |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                      | > 65 Years                 | > 65 Years                 | 18-65 Years                | 18-65 Years                |
|                                                      | Nemo 30 mg Q4W N=99 n (%)  | PBO                        | Nemo 30 mg Q4W N=271 n (%) | PBO                        |
|                                                      |                            | N=41 n (%)                 |                            | N=145                      |
|                                                      |                            |                            |                            | n (%)                      |
| Any TEAE                                             | 74 (74.7)                  | 23 (56.1)                  | 172 (63.5)                 | 88 (60.7)                  |
| Cardiac disorders                                    | 4 (4.0)                    | 1 (2.4)                    | 3 (1.1)                    | 4 (2.8)                    |
| Gastrointestinal disorders                           | 7 (7.1)                    | 4 (9.8)                    | 16 (5.9)                   | 12 (8.3)                   |
| Diarrhoea                                            | 2 (2.0)                    | 0                          | 4 (1.5)                    | 3 (2.1)                    |
| Gastrooesophageal reflux disease                     | 2 (2.0)                    | 0                          | 0                          | 0                          |
| General disorders and administration site conditions | 8 (8.1)                    | 2 (4.9)                    | 25 (9.2)                   | 12 (8.3)                   |
| Oedema peripheral                                    | 5 (5.1)                    | 0                          | 2 (0.7)                    | 2 (1.4)                    |
| Fatigue                                              | 3 (3.0)                    | 0                          | 11 (4.1)                   | 5 (3.4)                    |
| Infections and infestations                          | 22 (22.2)                  | 9 (22.0)                   | 76 (28.0)                  | 38(26.2)                   |
| COVID-19                                             | 2 (2.0)                    | 5 (12.2)                   | 22 (8.1)                   | 12 (8.3)                   |
| Nasopharyngitis                                      | 5 (5.1)                    | 2 (4.9)                    | 12 (4.4)                   | 10 (6.9)                   |
| Upper respiratory tract infection                    | 2 (2.0)                    | 1 (2.4)                    | 5 (1.8)                    | 3 (2.1)                    |
| Cystitis                                             | 2 (2.0)                    | 0                          | 2 (0.7)                    | 1 (0.7)                    |
| Onychomycosis                                        | 2 (2.0)                    | 0                          | 0                          | 0                          |
| Urinary tract infection                              | 1 (1.0)                    | 1 (2.4)                    | 6 (2.2)                    | 1 (0.7)                    |
| Sinusitis                                            | 0                          | 1 (2.4)                    | 6 (2.2)                    | 0                          |
| Oral herpes                                          | 0                          | 0                          | 3 (1.1)                    | 3 (2.1)                    |
| Investigations                                       | 7 (7.1)                    | 1 (2.4)                    | 13 (4.8)                   | 8 (5.5)                    |
| Blood creatine phosphokinase increased               | 0                          | 0                          | 2 (0.7)                    | 4 (2.8)                    |
| Peak expiratory flow rate decreased                  | 3 (3.0)                    | 0                          | 4 (1.5)                    | 0                          |
| Musculoskeletal and connective tissue disorders      | 8 (8.1)                    | 2 (4.9)                    | 35 (12.9)                  | 12 (8.3)                   |
| Back pain                                            | 1 (1.0)                    | 0                          | 7 (2.6)                    | 2 (1.4)                    |
| Arthralgia                                           | 0                          | 0                          | 6 (2.2)                    | 2 (1.4)                    |
| Myalgia                                              | 1 (1.0)                    | 0                          | 4 (1.5)                    | 4 (2.8)                    |
| Pain in extremity                                    | 0                          | 0                          | 7 (2.6)                    | 1 (0.7)                    |
| Osteoarthritis                                       | 1 (1.0)                    | 1 (2.4)                    | 6 (2.2)                    | 0                          |
| Nervous system disorders                             | 5 (5.1)                    | 6 (14.6)                   | 33 (12.2)                  | 12 (8.3)                   |
| Headache                                             | 2 (2.0)                    | 0                          | 23 (8.5)                   | 6 (4.1)                    |
| Respiratory, thoracic and mediastinal Disorders      | 8 (8.1)                    | 1 (2.4)                    | 26 (9.6)                   | 16 (11.0)                  |
| Cough                                                | 3 (3.0)                    | 1 (2.4)                    | 11 (4.1)                   | 6 (4.1)                    |
| Dyspnoea                                             | 5 (5.1)                    | 0                          | 4 (1.5)                    | 6 (4.1)                    |
| Asthma                                               | 1 (1.0)                    | 0                          | 5 (1.8)                    | 5 (3.4)                    |
| Skin and subcutaneous tissue disorders               | 34 (34.3)                  | 12 (29.3)                  | 69 (25.5)                  | 37 (25.5)                  |
| Neurodermatitis                                      | 7 (7.1)                    | 6 (14.6)                   | 7 (2.6)                    |                            |
| Eczema                                               | 7 (7.1)                    | 1 (2.4)                    | 18 (6.6)                   | 23 (15.9) 3 (2.1)          |

<div style=\"page-break-after: always\"></div>

|                     | Overall treatment period   | Overall treatment period   | Overall treatment period   | Overall treatment period   |
|---------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                     | > 65 Years                 | > 65 Years                 | 18-65 Years                | 18-65 Years                |
|                     | Nemo 30 mg Q4W N=99 n (%)  | PBO N=41 n (%)             | Nemo 30 mg Q4W N=271 n (%) | PBO N=145 n (%)            |
| Eczema nummular     | 7 (7.1)                    | 0                          | 6 (2.2)                    | 0                          |
| Atopic dermatitis   | 5 (5.1)                    | 0                          | 12 (4.4)                   | 1 (0.7)                    |
| Rash                | 3 (3.0)                    | 1 (2.4)                    | 1 (0.4)                    | 0                          |
| Stasis dermatitis   | 3 (3.0)                    | 0                          | 1 (0.4)                    | 0                          |
| Dermatitis allergic | 2 (2.0)                    | 0                          | 0                          | 1 (0.7)                    |
| Pemphigoid          | 2 (2.0)                    | 0                          | 1 (0.4)                    | 0                          |
| Vascular disorders  | 4 (4.0)                    | 1 (2.4)                    | 9 (3.3)                    | 4 (2.8)                    |
| Hypertension        | 4 (4.0)                    | 1 (2.4)                    | 5 (1.8)                    | 3 (2.1)                    |

PBO = placebo; PN = prurigo nodularis; PT = Preferred Term; SOC = System Organ Class; TEAE = treatment emergent adverse event.

## Sex

During the Overall Period, a higher percentage of male subjects experienced atopic dermatitis in the nemolizumab group (8.1%) compared with female subjects (2.3%).

During the Overall Period, a higher percentage of male subjects in the nemolizumab group experienced eczema (6.8%) or eczema nummular (6.8 %) compared with the incidence of eczema and of eczema nummular in female subjects (1.8% and 1.4 %, respectively).

These ADRs are addressed in table 1 section 4.8 of the SmPC with frequency common

## Race, region and country

The sample sizes were quite variable in the different regions (N=391 [Europe], N=143 [North America], and N=22 [Asia Pacific]) and some ethnic groups and races were underrepresented.

## Weight at randomisation

The applicant states that no notable trends in TEAE incidence between weight at randomization subgroups (&lt;90 kg, ≥ 90 kg) were observed during the Treatment Period. The applicant was requested to provide a table presenting frequency of TEAEs in subjects treated with 60 mg Q4W and 30 mg Q4W respectively and submitted Table 89.

<div style=\"page-break-after: always\"></div>

Table 89: Overall Summary of Selected TEAEs by Dosage in the Treatment Period (PN primary safety population)

|                                                                              | Nemolizumab 60-30 mg (Body Weight <90 kg)   | Nemolizumab 60-30 mg (Body Weight <90 kg)   | Nemolizumab 60-60 mg (Body Weight ≥ 90 kg)   | Nemolizumab 60-60 mg (Body Weight ≥ 90 kg)   |
|------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                                                              | Nemolizumab                                 | Placebo                                     | Nemolizumab                                  | Placebo                                      |
|                                                                              | N = 246 n (%)                               | N = 133 n (%)                               | N = 124 n (%)                                | N = 53 n (%)                                 |
| Any TEAE                                                                     | 162 (65.9)                                  | 75 (56.4)                                   | 84 (67.7)                                    | 35 (66.0)                                    |
| Any TEAE related to study drug [1]                                           | 65 (26.4)                                   | 21 (15.8)                                   | 27 (21.8)                                    | 13 (24.5)                                    |
| TEAE by maximum severity [2]                                                 |                                             |                                             |                                              |                                              |
| Mild                                                                         | 90 (36.6)                                   | 45 (33.8)                                   | 40 (32.3)                                    | 17 (32.1)                                    |
| Moderate                                                                     | 64 (26.0)                                   | 24 (18.0)                                   | 40 (32.3)                                    | 13 (24.5)                                    |
| Severe                                                                       | 8 (3.3)                                     | 6 (4.5)                                     | 4 (3.2)                                      | 5 (9.4)                                      |
| Any TEAE leading to study drug discontinuation                               | 12 (4.9)                                    | 0                                           | 2 (1.6)                                      | 5 (9.4)                                      |
| Any serious TEAE                                                             | 10 (4.1)                                    | 9 (6.8)                                     | 10 (8.1)                                     | 6 (11.3)                                     |
| Any serious TEAE related to study drug [1]                                   | 1 (0.4)                                     | 1 (0.8)                                     | 1 (0.8)                                      | 1 (1.9)                                      |
| Any TEAE of special interest by categories                                   | 31 (12.6)                                   | 21 (15.8)                                   | 22 (17.7)                                    | 6 (11.3)                                     |
| Injection-related reactions                                                  | 2 (0.8)                                     | 0                                           | 0                                            | 0                                            |
| Newly diagnosed asthma or worsening of asthma                                | 4 (1.6)                                     | 3 (2.3)                                     | 8 (6.5)                                      | 0                                            |
| Infections                                                                   | 17 (6.9)                                    | 17 (12.8)                                   | 13 (10.5)                                    | 5 (9.4)                                      |
| Peripheral oedema: limbs, bilateral; Facial oedema                           | 9 (3.7)                                     | 2 (1.5)                                     | 2 (1.6)                                      | 1 (1.9)                                      |
| Elevated ALT or AST (>3xULN) in combination with elevated Bilirubin (>2xULN) | 0                                           | 0                                           | 0                                            | 0                                            |
| Any TEAE of special interest - adjudicated asthma events                     | 3 (1.2)                                     | 3 (2.3)                                     | 5 (4.0)                                      | 0                                            |
| Any serious TEAE of special interest                                         | 1 (0.4)                                     | 3 (2.3)                                     | 2 (1.6)                                      | 1 (1.9)                                      |
| Any TEAE of special interest leading to study drug discontinuation           | 4 (1.6)                                     | 0                                           | 1 (0.8)                                      | 0                                            |
| Any TEAE leading to death                                                    | 0                                           | 1 (0.8)                                     | 0                                            | 0                                            |
| Any TEAE related to study drug leading to death                              | 0                                           | 0                                           | 0                                            | 0                                            |

ALT = alanine transaminase; AST = aspartate aminotransferase; N = number of subjects in the Safety Analysis Set; n = number of subjects with any TEAE in each classification level; TEAE = treatment-emergent adverse event; % = percentage of subjects with any TEAE in each classification level; ULN = upper limit of normal.

TEAEs related to study drug was slightly more common in nemolizumab 60-30 mg subjects (26.4%) than in nemolizumab 60-60 mg subjects (21.8%). The same trend is noted in TEAEs leading to study drug discontinuation; Nemolizumab 60-30 mg subjects (4.9%), nemolizumab 60-60 mg subjects (1.6%). TEAEs of special interest, on the other hand, were more frequently reported in nemolizumab 60-60 mg subjects (17.7%) compared to (12.6%). The same applies to serious TEAEs.

## Other special populations

In the PN primary safety population, no nemolizumab subject and 1 placebo subject qualified for hepatic impairment. 4 nemolizumab (4/370, 1.1%) and 5 placebo subjects (5/186; 2.7%) qualified for renal impairment.

<div style=\"page-break-after: always\"></div>

Subjects who were pregnant or lactating were excluded from all clinical studies. However, 10 subjects with AD [9 nemolizumab, 1 placebo) and 1 subject with PN (placebo) became pregnant during participation in the studies. The spontaneous abortions were consistent with the range of expected spontaneous abortions in the general population.

The safety of nemolizumab has not been established in nursing mothers.

Data on the use of nemolizumab in pregnant patients is absent/limited and it is agreed that this topic should be included as Missing information in the RMP.

## 2.6.11.7.6.  Immunological events

Please refer to section 2.6.11.7.4. for further discussion on immunogenicity.

## 2.6.11.7.7.  Safety related to drug-drug interactions and other interactions

Please refer to the pharmacokinetics section and to safety related to drug-drug interactions and other interactions for information drug-drug interactions and other interactions

## 2.6.11.7.8.  Discontinuation due to adverse events

It appears that a higher proportion of nemolizumab subjects had a TEAE leading to study drug withdrawal or study discontinuation than placebo subjects (4.1% vs 2.7 % and 4.1% vs 3.2% respectively) ( Table 90 and Table 91 ). One of the treatment-emergent AEs leading to study drug withdrawal and study discontinuation that were experienced by &gt;1 subject for nemolizumab was pemphigoid (3 [0.8%] nemolizumab subjects, 0 placebo subjects. The other treatment-emergent AE leading to study drug withdrawal and study discontinuation that were experienced by &gt;1 subject in either group was atopic dermatitis (2 [0.5%] nemolizumab subjects, 1 [0.5%] placebo subject).

The most common PT's that led to drug/study discontinuations were from SOC Skin and subcutaneous tissue disorders

<div style=\"page-break-after: always\"></div>

Table 90: TEAEs leading to study drug withdrawal by SOC and PT during the overall period (primary safety population)

| SOC PT                                                              | Nemolizumab N=370 n (%)   | Placebo N=186 n (%)   |
|---------------------------------------------------------------------|---------------------------|-----------------------|
| Subjects with at least 1 TEAE leading to study drug withdrawal      | 15 (4.1)                  | 5 (2.7)               |
| Cardiac disorders                                                   | 0                         | 2 (1.1)               |
| Atrial flutter                                                      | 0                         | 1 (0.5)               |
| Cardiac sarcoidosis                                                 | 0                         | 1 (0.5)               |
| Myocardial infarction                                               | 0                         | 1 (0.5)               |
| Ear and labyrinth disorders                                         | 1 (0.3)                   | 0                     |
| Vertigo positional                                                  | 1 (0.3)                   | 0                     |
| General disorders and administration site conditions                | 1 (0.3)                   | 0                     |
| Face oedema                                                         | 1 (0.3)                   | 0                     |
| Oedema peripheral                                                   | 1 (0.3)                   | 0                     |
| Infections and infestations                                         | 3 (0.8)                   | 0                     |
| COVID-19                                                            | 1 (0.3)                   | 0                     |
| Nasopharyngitis                                                     | 1 (0.3)                   | 0                     |
| Staphylococcal skin infection                                       | 1 (0.3)                   | 0                     |
| Musculoskeletal and connective tissue disorders                     | 1 (0.3)                   | 0                     |
| Myalgia                                                             | 1 (0.3)                   | 0                     |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1 (0.3)                   | 0                     |
| Squamous cell carcinoma                                             | 1 (0.3)                   | 0                     |
| Skin and subcutaneous tissue disorders                              | 9 (2.4)                   | 3 (1.6)               |
| Atopic dermatitis                                                   | 2 (0.5)                   | 1 (0.5)               |
| Pemphigoid                                                          | 3 (0.8)                   | 0                     |
| Neurodermatitis                                                     | 1 (0.3)                   | 1 (0.5)               |
| Dermatitis allergic                                                 | 1 (0.3)                   | 0                     |
| Dermatitis contact                                                  | 1 (0.3)                   | 0                     |
| Dermatitis exfoliative generalised                                  | 0                         | 1 (0.5)               |
| Drug eruption                                                       | 1 (0.3)                   | 0                     |

ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Subjects were summarized according to the treatment they actually received at the time of adverse event onset. Percentages were based on the number of subjects in each treatment group. Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. All TEAEs were defined as adverse events that occurred or worsened on or after the first study drug treatment date. The Overall Period included both the Treatment Period and Follow-up Period; TEAEs during the Overall Period were defined as TEAEs with an onset date on or after the first dose date until the follow-up visit date. If a subject had multiple occurrences of a TEAE within a treatment group, the subject was presented only once in the respective subject count for that treatment group.

<div style=\"page-break-after: always\"></div>

Table 91:TEAEs leading to study discontinuation by SOC and PT during the overall period (primary safety population)

| SOC PT                                                              | Nemolizumab N=370 n (%)   | Placebo N=186 n (%)   |
|---------------------------------------------------------------------|---------------------------|-----------------------|
| Subjects with at least 1 TEAE leading to study discontinuation      | 15 (4.1)                  | 6 (3.2)               |
| Cardiac disorders                                                   | 0                         | 3(1.6)                |
| Cardiac sarcoidosis                                                 | 0                         | 1 (0.5)               |
| Cardiogenic shock                                                   | 0                         | 1 (0.5)               |
| Myocardial infarction                                               | 0                         | 1 (0.5)               |
| Ear and labyrinth disorders                                         | 1 (0.3)                   | 0                     |
| Vertigo positional                                                  | 1 (0.3)                   | 0                     |
| General disorders and administration site conditions                | 1 (0.3)                   | 0                     |
| Face oedema                                                         | 1 (0.3)                   | 0                     |
| Oedema peripheral                                                   | 1 (0.3)                   | 0                     |
| Infections and infestations                                         | 2 (0.5)                   | 0                     |
| Nasopharyngitis                                                     | 1 (0.3)                   | 0                     |
| Staphylococcal skin infection                                       | 1 (0.3)                   | 0                     |
| Musculoskeletal and connective tissue disorders                     | 1 (0.3)                   | 0                     |
| Myalgia                                                             | 1 (0.3)                   | 0                     |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2 (0.5)                   | 0                     |
| Bladder neoplasm                                                    | 1 (0.3)                   | 0                     |
| Squamous cell carcinoma                                             | 1 (0.3)                   | 0                     |
| Skin and subcutaneous tissue disorders                              | 9 (2.4)                   | 3 (1.6)               |
| Atopic dermatitis                                                   | 2 (0.5)                   | 1 (0.5)               |
| Pemphigoid                                                          | 3 (0.8)                   | 0                     |
| Neurodermatitis                                                     | 1 (0.3)                   | 1 (0.5)               |
| Dermatitis allergic                                                 | 1 (0.3)                   | 0                     |
| Dermatitis contact                                                  | 1 (0.3)                   | 0                     |
| Dermatitis exfoliative generalised                                  | 0                         | 1 (0.5)               |
| Drug eruption                                                       | 1 (0.3)                   | 0                     |

ISS=Integrated Summary of Safety; N=number of subjects in the population; n=number of subjects who experienced the events; PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event

Note: Subjects were summarized according to the treatment they actually received at the time of adverse event onset. Percentages were based on the number of subjects in each treatment group. Adverse events were coded using the Medical Dictionary for Regulatory Activities Version 25.0. All TEAEs were defined as adverse events that occurred or worsened on or after the first study drug treatment date. The Overall Period included both the Treatment Period and Follow-up Period; TEAEs during the Overall Period were defined as TEAEs with an onset date on or after the first dose date until the follow-up visit date. If a subject had multiple occurrences of a TEAE within a treatment group, the subject was presented only once in the respective subject count for that treatment group.

## 2.6.11.7.9.  Supportive and additional studies

## SPR.115828 - phase 2a study

The occurrence of TEAEs, treatment emergent SAEs, TEAEs leading to permanent discontinuation of study drug, and TEAEs leading to study withdrawal were similar in both treatment groups. The occurrence of study drug related TEAEs, TEAEs related to study procedure, and severe TEAEs were slightly higher in the nemolizumab group compared with the placebo group.

The most frequently reported treatment emergent AESI was systemic infection (defined as any infection that was not a skin infection).

<div style=\"page-break-after: always\"></div>

## SPR.202699 - phase 3 LTE study

Of the 508 treated subjects, lead-in enrolment studies included SPR.202685 (232 subjects), SPR.203065 (255 subjects), and SPR.115828 (21 subjects). A total of 92 (18.1%) subjects discontinued treatment. Primary reasons for discontinuation of treatment were similar among lead in studies. The most common reason overall for discontinuation of treatment was AE (35 [6.9%]).

A total of 407 (80.1%) subjects experienced at least 1 TEAE during the Overall Study Period. Of these subjects, the majority experienced a TEAE that was considered mild or moderate in severity. The most common ( ≥ 10.0%) TEAEs were COVID-19 (22.2%), nasopharyngitis (13.8%), and neurodermatitis; the coded term for worsening of PN (10.8%).

Two subjects experienced TEAEs leading to death. One subject experienced a fatal myocardial infarction and the other subject experienced fatal end stage renal disease; both events were considered severe, serious, and not related to study drug or protocol procedure.

Treatment-emergent SAEs were experienced by 54 (10.6%) subjects during the Treatment Period; SAEs experienced by &gt;1 subject were neurodermatitis (4 [0.8%] subjects), myocardial infarction (3 [0.6%] subjects), and angina pectoris, cardiac failure congestive, cholelithiasis, pneumonia, osteoarthritis, and carotid artery stenosis (2 [0.4%] subjects each). Treatment emergent SAEs were experienced by 7 (8.5%) subjects during the Follow-up Period; no SAE was experienced by &gt;1 subject. Four (0.8%) subjects experienced SAEs considered study drug-related during the Treatment Period; no subject experienced a study drug-related SAE during the Follow up Period. Two (0.1%) subjects experienced study drug related SAEs of cardiac failure congestive and 1 (0.2%) subject each experienced study drug related SAEs of pneumonia bacterial, Hodgkin's disease stage IV, Wernicke's encephalopathy, and respiratory failure; the majority of these events led to study drug withdrawal and study discontinuation.

Treatment-emergent AEs leading to study discontinuation were experienced by 31 (6.1%) subjects during the Treatment Period.

One (0.2%) subject experienced an IRR (by Investigator) (as per protocol definition) during the Treatment Period; the subject experienced an event of hypersensitivity that was considered moderate in severity, related to the protocol procedure (but not related to study drug), and resolved.

A total of 133 (26.2%) subjects experienced an AESI (by Investigator) of infection during the Treatment Period. Four (0.8%) subjects experienced AESIs (by Investigator) of infection that were considered study drug-related during the Treatment Period; 2 (0.4%) subjects experienced COVID-19 and 1 (0.2%) subject each experienced eczema herpeticum and pneumonia bacterial. One (1.2%) subject experienced an AESI (by Investigator) of infection (COVID-19) during the Follow-up Period that was not considered study drug related. The majority of study drug related AESIs (by Investigator) of infection were non serious, did not result in study drug withdrawal or study discontinuation, and were considered mild or moderate in severity.

A total of 15 (3.0%) subjects experienced AESIs (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema during the Treatment Period. Six (1.2%) subjects experienced AESIs (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema that were considered study drug related during the Treatment Period; 5 (1.0%) subjects experienced oedema peripheral and 1 (0.2%) subject each experienced face oedema and angioedema. No subject experienced an AESI (by Investigator) of peripheral oedema: limbs, bilateral; facial oedema during the Follow-up Period.

A total of 22 (4.3%) subjects experienced an AESI (by Investigator) meeting the definition of newly diagnosed asthma or worsening of asthma (which included peak expiratory flow rate decreased) during the Treatment Period.

<div style=\"page-break-after: always\"></div>

After IAC review of AEs that were retrieved using the SMQ 'asthma/bronchospasm' during the Treatment Period, 14 (2.8%) subjects experienced confirmed worsening of (pre-existing) asthma (with 12 [2.4%] subjects reporting an AESI with a PT of asthma, 4 [0.8%] subjects reporting an AESI with a PT of peak expiratory flow rate decreased, and 1 [0.2%] subject reporting an AESI with a PT of asthma exercise induced). Five (1.0%) subjects experienced confirmed new onset asthma with all subjects reporting an AESI with a PT of asthma. Of the adjudicated TEAEs, those considered study drug-related occurred in 5 (1.0%) subjects who experienced confirmed worsening of (pre-existing) asthma and in 3 (0.6%) subjects who experienced confirmed new onset asthma. One (1.2%) subject experienced confirmed worsening of (pre-existing) asthma (an AESI with a PT of asthma) during the Follow up Period that was considered study drug related. Except for 1 event of asthma that was serious and considered severe (as adjudicated by the IAC), all other subjects with adjudicated TEAEs had events that were non-serious and considered mild or moderate in severity (as adjudicated by the IAC). Except for 1 event of asthma that led to study drug withdrawal and study discontinuation, all other subjects experienced adjudicated TEAEs that did not result in study drug withdrawal or study discontinuation. The majority of events were considered not related to study drug and resolved; 3 of the 5 subjects with confirmed new onset asthma had events that were ongoing.

## Ongoing study SPR.203890 conducted by sponsor

A total of 33 subjects were treated. Nineteen out of 33 subjects (57.6%) have experienced a TEAE during the study; the most common TEAEs experienced were COVID-19 (4 [12.1%] subjects), headache (3 [9.1%] subjects), and uncoded events (3 [9.1%] subjects). Four (12.1%) subjects have experienced study drug related TEAEs; all study drug-related TEAEs were experienced by 1 (3.0%) subject each.

Six (18.2%) subjects have experienced AESIs; 4 (12.1%) subjects experienced COVID-19 and 1 (3.0%) subject each experienced peripheral swelling, peak expiratory flow rate decreased, and an uncoded event.

## Additional study in patients with PN conducted by another sponsor (Maruho)

## M525101-11 - phase 2/3 study in subjects with PN

M525101-11 is an ongoing, Phase 2/3, multicentre, 2-part study. Part A was the randomized, double blind, placebo controlled, parallel-group comparison part that evaluated the efficacy of nemolizumab 60 mg/body or 30 mg/body (60 mg/body for the initial dose only) administered Q4W in subjects ≥ 13 years with PN and at least moderate pruritus) despite existing treatment and investigated the optimal dose of nemolizumab. Part B was a double-blind, parallel-group part that evaluated long term treatment (52 weeks) with nemolizumab 60 mg/body or 30 mg/body Q4W in subjects who completed Part A.

The total study duration was up to 80 weeks, which included up a 4-week screening period, 16 week treatment period in Part A, 52-week treatment period in Part B, and an 8 week follow-up period.

Safety assessments included TEAEs, clinical laboratory tests, vital signs, and ECGs.

Interim results are presented as of the data cut-off date of 08 Sep 2022. In Part A, a total of 76 subjects received nemolizumab 60 mg Q4W, 77 subjects received nemolizumab 30 mg Q4W, and 76 subjects received placebo. Of these, 74 (97.4%) nemolizumab 60 mg Q4W subjects, 72 (93.5%) nemolizumab 30 mg Q4W subjects, and 74 (96.1%) placebo subjects completed Part A of the study and proceeded to Part B of the study (except for 1 nemolizumab 60 mg Q4W subject). A total of 41 (53.9%) nemolizumab 60 mg Q4W subjects, 40 (51.9%) nemolizumab 30 mg Q4W subjects, and 45 (58.4%) placebo subjects completed the entire study (Parts A and B).

<div style=\"page-break-after: always\"></div>

## 2.6.11.7.10.  Post marketing experience

Please refer to section 2.6.11.6 Error! Reference source not found. in the AD population for further information on Post marketing experience.

## 2.6.12.  Discussion on clinical safety

## 2.6.12.1.  Atopic dermatitis

Assessment of safety is primarily based on the two pivotal studies SPR.118161, SPR.118169 and the pooled data of the primary safety population- including also the Phase 2 Study SPR.114322- focusing on the 30 mg (Q4W) dose of nemolizumab proposed for marketing. Short-term safety data, up to 16 weeks, is derived from studies SPR.118161, SPR.118169, and up to 24 weeks in the phase 2 study SPR.114322. More long-term maintenance data up to week 48 is also derived from studies SPR.118161 and SPR.118169. Further supportive long-term data is derived from the ongoing Phase 3 Long-term extension (LTE) study SIR.118163. There are also additional studies with safety data presented separately.

In the studies submitted as part of the marketing authorisation application a total of 2111 patients/healthy volunteers were exposed to at least 1 dose of nemolizumab. In the primary safety population, a total of 1192 subjects were treated with nemolizumab 30 mg Q4W in the Initial period (up to week 16 or week 24). During the Maintenance period (week 16 to week 48) a total of 170 subjects, 167 subjects, 168 subjects, and 184 subjects were treated in the nemolizumab 30 mg Q4W to Q4W, nemolizumab 30 mg Q4W to Q8W, nemolizumab 30 mg Q4W to placebo, and re-assigned to placebo groups, respectively. The size of the safety database and the extent of exposure is considered adequate for assessment of safety.

In the Initial period, the frequency of TEAEs in nemolizumab 30 mg Q4W subjects was similar to what was observed in placebo subjects. In the all nemolizumab group the frequency of TEAEs was slightly higher, but still assessed as acceptable. The most common TEAEs were atopic dermatitis, headache, nasopharyngitis, asthma, COVID-19, and upper respiratory tract infection. The majority of subjects with TEAEs experienced events that were considered mild or moderate in severity in both the Initial period and the Maintenance period.

The frequency of treatment-emergent SAEs was generally low in the Initial period and slightly lower in placebo subjects compared to nemolizumab-treated subjects. During the Maintenance period, treatment-emergent SAEs were experienced by 10 (5.9%), 3 (1.8%), 4 (2.4%), and 2 (1.1%) subjects in the nemolizumab 30 mg Q4W to Q4W, nemolizumab 30 mg Q4W to Q8W, nemolizumab 30 mg Q4W to placebo, and re-assigned to placebo groups, respectively. The greatest difference in frequency of treatment-emergent SAEs was noted in the SOCs 'Infections and infestations' and 'Musculoskeletal and connective tissue disorders'. It is supported that the majority of the events in the SOC 'musculoskeletal and connective tissue disorder' were not related to study drug.

The criteria for identification of potential ADRs are generally acceptable. However, it should be emphasized that there may be exceptions to the proposed quantitative criteria (e.g. a SAE may occur at a frequency &lt;1%, but still meet other criteria for causality and thus be assessed as an ADR). Urticaria (type 1 hypersensitivity) was the only ADR identified by the criteria proposed by the applicant. One subject experienced urticaria and peripheral oedema during the Initial Period. The urticaria was assessed as aquagenic. The CHMP considers allergic reaction to be a differential diagnosis in this case considering concomitant urticaria and facial angioedema including nasal oedema. However, this is a single case. At present, further action is not required.

<div style=\"page-break-after: always\"></div>

The applicant concludes that the evaluation of the data on AESIs of peripheral oedema: limbs, bilateral; facial oedema, assessed as separate medical entities shows a slight imbalance between nemolizumab 30 mg Q4W and placebo subjects for peripheral oedema and facial oedema in the Initial Period as well as in the Maintenance Period. This is agreed. The applicant also states that, given the magnitude of the difference, the finding is deemed not clinically meaningful.

It is noted that in study CIM003JG an apparent dose relationship was seen for oedema peripheral in the nemolizumab Q4W groups. The incidence was 0% with placebo and was 3.8%, 5.6%, and 9.6% in the 0.1 mg/kg, 0.5 mg/kg, and 2.0 mg/kg Q4W groups, respectively. However, the CHMP considers the reported data and the imbalance noted not sufficient to require further action at present.

The applicant concludes that evaluation of the data on elevated ALT or AST &gt;3×ULN in combination with elevated bilirubin &gt;2×ULN does not suggest any increased risk of drug-induced liver injury associated with the use of nemolizumab. This is in principle agreed, but with the clarification that it is only serious liver damage that conclusions can be drawn about.

Injection site reactions are also listed as ADRs in SmPC section 4.8. Further, clear imbalance is noted in frequency of eosinophilia between nemolizumab treated subjects and placebo subjects. Following CHMP request, the applicant added eosinophilia as an ADR in SmPC section 4.8.

An evident dose-related increase in frequency of asthma AESI reports is seen in dose-finding study SPR.114322. Most of the reported events were confirmed worsening of pre-existing asthma. This trend was not seen during the pivotal phase 3 program. Overall, the evaluation of data presented does not suggest a clinically relevant increased risk of asthma associated with the use of nemolizumab for subjects with a medical history of asthma for the proposed dose. However, in accordance with the exclusion criteria, the SmPC section 4.4. includes that patients with poorly controlled asthma and COPD were excluded from the studies, as no safety data for these patients are provided. Please also see the discussion on asthma related events in PN.

No subject died during the treatment period, but one death was reported during the Follow-up period. The subject was 82 years old, diagnosed with staphylococcal sepsis, pneumonia aspiration and cardiorespiratory arrest. The event was considered as unrelated to study medication by the Investigator.

In the AD primary safety population, the incidence of malignancies observed in the nemolizumab group was slightly higher in nemolizumab treated subjects compared to placebo subjects. However, there is a diversity of different types of malignancies reported and the reported events are difficult to differ from what may be expected in the general population with a similar age distribution. The short latency period between the initiation of nemolizumab therapy and some of the reported malignancies is also acknowledged and may question a causal relationship. At present it is agreed there is no strong signal suggesting that malignancies should be an important safety concern. The applicant also submitted a product-specific Carcinogenicity Assessment Document (CAD) performed in accordance with the ICH S6 (R1) guideline, addressing the potential carcinogenic risk associated with nemolizumab treatment. There is limited support of a carcinogenic effect associated with blockade of IL-31R.

In the Initial period, TEAEs leading to study drug withdrawal were similar in nemolizumab treated subjects and placebo subjects. The most common TEAE leading to withdrawal in nemolizumab subjects was atopic dermatitis. A possible reason for this could be lack of effect rather than an adverse drug reaction. It is not completely clear if there were any serious TEAEs leading to study drug withdrawal or study discontinuation.

Although there is an imbalance noted between the groups, many cases are single cases from different SOCs. At present, these single cases are not considered to be sufficient to be considered as potential risks. It is noted that the greatest difference in frequency of treatment emergent SAEs was seen in the

<div style=\"page-break-after: always\"></div>

SOCs 'Infections and infestations' and 'Musculoskeletal and connective tissue disorders'; 1.8% in nemolizumab 30 mg Q4W to Q4W subjects compared to 0% in re-assigned to placebo subjects. In the SOC 'musculoskeletal and connective tissue disorder', one event each of intervertebral disc protrusion and Dupuytren's contracture is noted. The applicant concludes that these events are not related to study drug. Infections are reviewed more thoroughly below.

One event of anaphylactic reaction was reported during the initial period in nemolizumab 30 mg Q4W group. The applicant was requested to provide additional information on the event and discuss the inclusion as an ADR in the SmPC. The applicant clarified that the event of anaphylactic reaction was not considered related to study drug as it occurred 11 days after treatment and following ingestion of a cow´s milk product. Information was also provided on additional event of anaphylactic reaction in a subject (AD LTE study) related to cashew allergy. As both events were associated with food allergies, the issue is by the CHMP considered resolved.

There was one subject with dermatomyositis in the Follow-up Period. The Investigator and the Sponsor considered the SAE of dermatomyositis as having a reasonable possibility of a causal relationship to study drug. At present, this single case is not considered to be sufficient to consider dermatomyositis as a potential risk associated with exposure to nemolizumab. However, should additional future cases of dermatomyositis be reported, this may be reconsidered.

There was one subject with dermatitis exfoliative generalised in the Follow-up Period. The subject noted enlarged lymph nodes and was diagnosed with lymphadenomegaly in the axilla and inguina on both sides. Findings from a lymph node biopsy revealed a nonmalignant reactive lymph node. The subject was treated with amoxicillin trihydrate/clavulanate Potassium. The subject experienced erythroderma. The Investigator and the Sponsor considered the SAE of dermatitis exfoliative generalised as having a reasonable possibility of a causal relationship to study drug. The Investigator considered the AE of lymphadenopathy as having no reasonable possibility of a causal relationship to study drug or to study protocol procedure. It should be noted that, given the improvement with antibiotics, underlying infection could be considered a potential cause of the lymphadenomegaly. The genesis in this case may be of relevance if the infection would be considered as a serious infection.

No subject died during the Treatment Period. One death was reported during the Follow-up Period. The subject was 82 years old, male and diagnosed with staphylococcal sepsis. He experienced pneumonia aspiration on Day 70 and cardio-respiratory arrest on Day 83. The event was considered as unrelated to study medication by the Investigator. It is noted that two other subjects had a staphylococcal infection that was considered related to study drug.

The short latency period between the initiation of nemolizumab therapy and some of the reported malignancies was acknowledged and may question a causal relationship. Furthermore, according to the non-clinical overarching conclusion based on current knowledge and as presented in the productspecific Carcinogenicity Assessment Document (CAD) performed in accordance with the ICH S6 (R1) guideline, addressing the potential carcinogenic risk associated with nemolizumab treatment, there is limited support of a carcinogenic effect associated with blockade of IL-31R (please refer to the nonclinical assessment report).

In the Initial Period autoimmune disease as a TEAE was more common in placebo subjects than in nemolizumab 30 mg Q4W subjects, which is reassuring.

During the Maintenance Period two (1.2%) nemolizumab 30 mg Q4W to Q8W subjects experienced an autoimmune disease. One (0.6%) nemolizumab 30 mg Q4W to Q4W subject experienced a TEAE of alopecia areata. Since the latter subject had a medical history of 2 episodes of alopecia areata, it is agreed that there is no evidence of an association between autoimmune disease and nemolizumab in

<div style=\"page-break-after: always\"></div>

this particular case. There seem to be no reports of autoimmune diseases in the placebo groups during the Maintenance Period.

The applicant concludes that based on the review of reports of autoimmune diseases in the primary safety population considering also that AD has been associated with an increased risk for several autoimmune diseases, there is no evidence of an association between autoimmune diseases and nemolizumab. This is not fully endorsed, since there is a difference noted in frequency of autoimmune diseases between nemolizumab treated subjects and placebo subjects in the primary safety population (similar selected AD-population in both groups) during the Maintenance Period. However, at present data is assessed not to be sufficient to justify further action.

Injection site reactions are included as an ADR in the SmPC and included events of injection site bruising (only mentioned as 'occurred in prurigo nodularis studies'), erythema, pruritus, pain, irritation, and oedema. The applicant was asked to also include injection site haematoma for the AD population as it occurred in 2 patients (4 events) in nemolizumab 30 mg group during the Initial treatment period. The SmPC has been updated accordingly.

The applicant concludes that overall, data from the primary safety population suggest a low risk of serious and/or severe hypersensitivity reactions. This is endorsed.

At baseline of the Initial Period, 390 (32.7%) nemolizumab 30 mg Q4W subjects and 204 (31.9%) placebo subjects had a medical history of asthma. There were no serious AESIs of newly diagnosed asthma or worsening of asthma in the nemolizumab 30 mg Q4W group during the Initial Period.

At baseline of the Maintenance Period, 43 (25.3%) nemolizumab 30 mg Q4W to Q4W subjects, 51 (30.5%) nemolizumab 30 mg Q4W to Q8W subjects, 52 (31.0%) nemolizumab 30 mg Q4W to placebo subjects, and 47 (25.5%) re-assigned to placebo subjects had a medical history of asthma. There was 1 (0.6%) nemolizumab 30 Q4W to Q4W subject who experienced a serious AESI of newly diagnosed asthma or worsening of asthma.

The applicant concludes that overall evaluation of data on asthma and respiratory assessments, including adjudication results from the IAC, along with the understanding of the epidemiology of asthma in patients with AD, does not suggest any increased risk of asthma associated with the use of nemolizumab.

The CHMP considers the results of the assessment of asthma related events in the AD primary safety population during the Treatment period ambiguous. A dose-related increase in frequency of asthma AESI reports was seen in dose-finding study SPR.114322. Most of the reported events were confirmed worsening of pre-existing asthma. This trend was not seen during the pivotal phase 3 program. Following the discussion provided by the applicant, it can be agreed that the evaluation of all data presented does not suggest a clinically relevant increased risk of asthma associated with the use of nemolizumab for subjects with a medical history of asthma for the proposed dose. However, in accordance with the exclusion criteria, the product information should include that patients with poorly controlled asthma and COPD were excluded from the studies, as no safety data for these patients are provided. Please also see the discussion on asthma related events in PN.

The applicant concludes that there is no evidence of any increased risk of serious or severe infections or infections requiring prolonged treatment (with antibiotics, antifungals, or antivirals) in association with the use of nemolizumab. It is agreed that there is no evidence of any increased risk of infections requiring prolonged treatment (with antibiotics, antifungals, or antivirals) in association with the use of nemolizumab.

In the Primary safety population, Infections and infestations as study drug-related SAEs were more frequent during the Initial Period in nemolizumab 30 mg Q4W subjects (0,3%) compared to placebo

<div style=\"page-break-after: always\"></div>

subjects (0%). It is also noted that there are 3 nemolizumab 30 mg Q4W subjects with study drugrelated AESI of infection that was considered serious, compared to 0 placebo subjects. It is not clear whether the concerned events are the same events in different contexts. Regardless, the applicant was requested to discuss whether serious infections should be included in the RMP for nemolizumab as an 'Important potential risk'. Please see further discussion in the RMP section.

It is noted that frequency of treatment emergent SAEs in the SOC 'Infections and infestations' was 1.8% in nemolizumab 30 mg Q4W to Q4W subjects compared to 0% in re-assigned to placebo subjects. From the submitted response data the variety of different herpes infections PTs makes the understanding of the total picture of all herpes infections somewhat difficult. The applicant states that for the AD population during the initial treatment period the reported frequency of herpes infections was low not exceeding 0.5% for any term with nemolizumab and differences to placebo were small.

However, different PTs may cover more simple or more complex herpes conditions. Cases of herpes zoster in the AD population were only reported in the nemolizumab treated group during the initial treatment period compared to placebo treated, 5 (0.4%, EAIRS=1.4) and 0 respectively. Furthermore, serious herpetic infection TEAEs reported during the initial and maintenance treatment Periods (AD primary safety population) were only reported in the nemolizumab treated groups (3 events of Herpes simplex, Herpes zoster and Ophthalmic herpes zoster respectively.)

Data are still limited. The inclusion of skin infections in general in the SmPC may not be warranted.

Based on the imbalance in the proportion of subjects in nemolizumab-treated subjects compared to placebo subjects who experienced potentially clinically significant elevated eosinophils, it was proposed by the CHMP that the term `eosinophilia´ was added to section 4.8 of the SmPC. The applicant argued that although in both AD and PN, there were imbalances in potentially clinically significant eosinophilia in the recommended regimen nemolizumab 30mg Q4W group compared to placebo, the majority of the potentially clinically significant eosinophilia were mild ( ≤ 1.5× 109/L), few were moderate, and no severe eosinophilia was reported in the recommended treatment regimen of nemolizumab 30mg Q4W.It is agreed that the majority of the potentially clinically significant eosinophilia were mild, which is reassuring. It is also reassuring that TEAEs related to eosinophilia were rarely reported. Further, the applicant stated that the number of subjects reporting counts consistent with the broadly accepted definition of clinically significant eosinophilia (&gt;1500/mm 3 ) was low. Although it is agreed that the number of subjects reporting an eosinophil count &gt;1500/mm 3  (also known as hypereosinophilia) was low, it should be noted that in peripheral blood, an absolute eosinophil count of &lt;500/mm 3  is considered normal (lower reference varies in the literature between 0 and 350 mm 3 ). The term relevant for inclusion in section 4.8 is 'eosinophilia', not 'clinically significant eosinophilia/hypereosinophilia'.

Following CHMP request, the applicant added Eosinophilia as an ADR in SmPC section 4.8. The applicant argued that the frequency categorisation of eosinophilia in the ADR table should be determined using the percentage of adverse drug reactions of the active substance, rather than the percentage of patients with abnormal lab values. The Rapporteur considers that there is a risk of inconsistent reporting in this ADR, which may lead to underestimation of frequency. However, the proposed frequency `uncommon´ for eosinophilia was accepted. Information about eosinophilia under the section `Description of selected adverse reactions´ in the SmPC, section 4.8 was added.

The applicant considers that there is a lack of evidence for clinically relevant differences between the active treatment and placebo in respect to elevations in creatine kinase in nemolizumab treated subjects with or without simultaneous reporting of suspected myalgia. Overall, the CHMP considers the slight imbalance noted in the AD population insufficient to warrant any amendments of the SmPC at present.

<div style=\"page-break-after: always\"></div>

The overall safety profile was generally consistent between ADA-positive and ADA-negative subjects. There was no evidence for a clinical impact of ADA status on the safety profile of nemolizumab. Immunogenicity will continue to be assessed in the ongoing LTE study (SPR.118163) as well as in clinical trials in other indications.

Safety data in patients &gt;65 years of age is limited in the AD population. It is noted that in the Initial Period, Cardiac disorders in the age group 65-74 years were reported in 3 (4.8%) and 1 (3.6%) subjects in the nemolizumab and the placebo groups, respectively. This was slightly more than in the age group &lt;65 years, which is considered expected. Eye disorders in the age group 65-74 years were reported in 3 (4.8%) and 0 (0%) subjects in the nemolizumab and the placebo groups, respectively. Eye disorders in the age group &lt;65 years were reported in 26 (2.3%) in nemolizumab subjects. The imbalance noted in these AEs is considered by the CHMP insufficient to require further action at present.

The applicant states that, considering the limitations imposed by low subject numbers enrolled above the age of 75 years in the initial treatment period, and in the maintenance period for subjects 65 years of age or above, any differences need to be assessed with caution. This is agreed, as there are less than 20 subjects in each group mentioned above.

During the Maintenance Period it is noted that SAEs were more frequent in the age group 12-17 years in Nemolizumab 30 mg Q4W to Q4W subjects (8.6%) compared to Nemolizumab 30 mg Q4W to Q8W subjects (3.1%) and Re-assigned to Placebo subjects (0%) in the same age group. However, the SAEs are considered by the CHMP to be single cases (duodenal ulcer haemorrhage, comminuted fracture and asthma). In the age group 18 to 65 years SAEs were reported in 5.5% in Nemolizumab 30 mg Q4W to Q4W subjects. This trend is not noted in SAE related to study drug, which is reassuring. There was also a low number of subjects in the age group 12-17 years.

The applicant was requested to discuss whether there is reason to believe that the safety profile will differ between the age group 12-17 years of age and adults or whether safety data from adults can be extrapolated to patients 12-17 years of age. The applicant submitted a summary of TEAEs in the age group 12-17 years by SOC and PT reported in ≥ 2.0% of subjects in either group in the treatment period in the AD population. It is noted that in the initial period, nasopharyngitis was reported in 9 (5.1%) nemolizumab subjects compared to 2 (2.2%) placebo subjects. Nasopharyngitis was slightly less frequently reported in nemolizumab treated subjects in the age group 18-65 years (32 [3.4%]) in the initial period. The imbalance noted is by the CHMP assessed as insufficient to consider there to be a reasonable possibility of causal relationship between nemolizumab and nasopharyngitis in adolescents.

In the initial period, infections and infestations was reported in 31 (17.6%) nemolizumab subjects compared to 3 (14.6%) placebo subjects in the age group 12-17 years. Among events reported in more than 2 subjects in the initial treatment period, infections and infestations were reported as related to study-drug in 6 (3.4%) nemolizumab subjects versus 2 (2.2%) placebo subjects in the age group 12-17 years. Infections and infestations were slightly less frequently reported in nemolizumab treated subjects in the age group 12-17 years (31 [17.6%]) than in the age group 18-65 years (190 [20.1%]), which is reassuring.

The applicant states that due to the low number of subjects 12-17 years of age in the nemolizumab 30 mg Q4W to Q4W (N=35) and nemolizumab 30 mg Q4W to Q8W (N=32) groups, no meaningful conclusions between subjects 12-17 years of age and subjects 18-65 years of age could be made for either group during the Maintenance Period.

The applicant has provided a summary table of TEAEs by age group by SOC and PT reported in ≥ 2.0% of subjects in either age group from the LTE study SPR.118163 ( Table 68 ). The ongoing LTE study includes 257 patients 12-17 years of age exposed to nemolizumab. As of the 30 Sep 2022 cut off, 135

<div style=\"page-break-after: always\"></div>

adolescent subjects had treatment exposure ≥ 365 days based on the first nemolizumab injection date of the lead-in study. It is noted that some TEAEs, e.g. upper respiratory tract infections, impetigo, rhinitis and bronchitis, were reported with higher frequencies than in adults in the LTE study. However, the imbalance noted is by the CHMP considered insufficient to require further action.

There is more data on this age group in the PN population. Following the further discussion in the PN population, the CHMP considers that the data for the age group &gt;65 years in the PN population can be extrapolated to the age group &gt;65 years in the AD population.

In the initial period some TEAEs (e.g. nasopharyngitis) were slightly more frequently reported in nemolizumab treated subjects in the age group 12-17 years compared to 18-65 years. The imbalances noted may be due to the limited data and are by the CHMP assessed as insufficient to require further action. During the Maintenance Period SAEs were more frequent in the age group 12-17 years in nemolizumab 30 mg Q4W to Q4W subjects compared to nemolizumab 30 mg Q4W to Q8W subjects and Re-assigned to Placebo subjects in the same age group. The applicant states that due to the low number of subjects 12-17 years of age in the nemolizumab 30 mg Q4W to Q4W (n=35) and nemolizumab 30 mg Q4W to Q8W (n=32) groups, no meaningful conclusions between subjects 12-17 years of age and subjects 18-65 years of age could be made for either group during the Maintenance period. However, the reported SAEs are regardless considered by the CHMP to be single cases (duodenal ulcer haemorrhage, comminuted fracture and asthma). The ongoing LTE study includes 257 patients 12-17 years of age exposed to nemolizumab. As of the 30 Sep 2022 cut off, 135 adolescent subjects had treatment exposure ≥ 365 days based on the first nemolizumab injection date of the leadin study. It is noted that some TEAEs, e.g. upper respiratory tract infections, impetigo, rhinitis and bronchitis, were reported with higher frequencies than in adults in the LTE study. However, the imbalance noted is by the CHMP considered insufficient to require further action. Overall, it is agreed that safety data from adults can be extrapolated to patients 12-17 years of age. Further, it is supported that 'safety in patients 12-17 years of age' does not necessitate to be added as a safety concern of the RMP. However, the applicant is requested to monitor and address safety in adolescents in forthcoming PSURs.

The applicant concludes that after excluding the category 'Other Race' due to the very small number of subjects that does not allow any meaningful conclusions, no effects of race on the safety profile of nemolizumab was observed. The applicant also concludes that due to the variable sample sizes across racial subgroups (White, Black or African American, Asian, and Other Race), no meaningful conclusions of TEAE incidence by race could be made during the Treatment Period. Although data is currently limited for some races, at present no further action is required

The applicant was asked to submit tables presenting data for 'AE by special population' (hepatically impaired, renally impaired and pregnant subjects). The applicant submitted the requested tables although hepatic impairment could not be classified according to requested Child-Pugh classification.

During the Initial treatment period the proportion of subjects reporting hepatic and/or renal impairment was similar between nemolizumab and placebo groups in the AD primary safety population (hepatic impairment: 10/1192; 0.8% nemolizumab 30 mg Q4W subjects versus 4/640; 0.6% placebo subjects; renal impairment: 9/1192; 0.8% nemolizumab 30 mg Q4W versus 2/640; 0.3% placebo subjects). In the AD population, during the initial period, 4 (40%) nemolizumab subjects compared to 1 (25%) placebo subject with hepatic impairment reported 'Infections and infestations'. However, considering the limitations imposed by low subject numbers with hepatic impairment (10 nemolizumab subjects and 4 placebo subjects), the CHMP considers that the difference noted needs to be assessed with caution. Further, only 2 of the 4 cases with 'Infections and infestations' in the nemolizumab group were assessed as related to study drug. These 2 cases were mild to moderate in severity and reported as Recovered/Resolved. A similar slight imbalance in infections and infestations in subjects

<div style=\"page-break-after: always\"></div>

with renal impairment is noted in nemolizumab subjects compared to placebo subjects in the initial period in the AD population. However, these data are also limited (9 nemolizumab subjects and 2 placebo subjects qualified for renal impairment). 1 of the 2 cases with 'Infections and infestations' in the nemolizumab group were assessed as related to study drug. Overall, the issue is considered resolved by the CHMP and will not be pursued further.

Subjects who were pregnant or lactating were excluded from all clinical studies. However, 10 subjects with AD [9 nemolizumab, 1 placebo) became pregnant during participation in the studies. The spontaneous abortions were consistent with the range of expected spontaneous abortions in the general population.

The safety of nemolizumab has not been established in nursing mothers.

Data on the use of nemolizumab in pregnant and patients is absent/limited and it is agreed that this topic should be included as Missing information in the RMP.

Since subjects with hepatitis B and C were excluded from the studies, the applicant was requested to discuss whether a warning in section 4.4 in the SmPC regarding this population is warranted. The applicant was also asked to discuss if patients should be tested for HBV and/or HBC infection before initiating treatment with nemolizumab. The applicant states that the exclusion of subjects with active or history of hepatitis B and C infections is a common measure of caution in clinical trials. This is agreed. Further the applicant argues that clinically, there is no evidence that short- or long-term exposure to nemolizumab led to depression of the immune system that could favor the development of new infections or reactivation of latent ones, as evidenced by absence of any clinically relevant change in lymphocyte or neutrophil counts over time. It should be noted, that in the AD population potentially clinically significant decreased neutrophiles (worst post-baseline) was 14 (1.2%) in nemolizumab 30 mg Q4W compared to 3 (0.5%) in placebo in the Initial Period. Potentially clinically significant decreased leukocytes (worst post-baseline) was also slightly more common in the nemolizumab group compared to placebo in the Initial Period. During the AD LTE study and the PN LTE study, shift from high/normal lymphocythes at baseline to low seems more common than shift from low/normal at baseline to high. On the other hand, during the AD LTE study, shift from low/normal neutrophils at baseline to high seems more common than shift from high/normal at baseline to low. Even though these data are not completely in line with the applicant's discussion regarding the immunosuppressive potential of nemolizumab, the imbalance noted is by the CHMP considered insufficient to require any update of section 4.8 in the SmPC at present.

The applicant has submitted a summary of subjects with lymphocyte, neutrophil or liver-related TEAEs during the Treatment Period (selected PTs) for the AD and PN population. Most events were reported in low proportions.

No reports of hepatitis B or C or reactivation of these have been reported in pivotal studies in the AD or PN clinical programs. This is reassuring, although it should be noted that subjects with positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb] or hepatitis C antibody were excluded from the studies. One subject experienced hepatitis A on Day 509 in the LTE study, which was considered moderate in severity and not related to study drug. For this subject a home contact with hepatitis A had been and had not been vaccinated against hepatitis A. This single case is considered by the CHMP not to warrant any further action.

No data are available in patients with severe hepatic impairment. This is adequately reflected in section 5.2 in the SmPC.

Based on the submitted clinical data and the lack of evidence from the early studies in monkeys that nemolizumab would increase the risk of infections, the CHMP considers data insufficient to warrant amendments of section 4.4 in the SmPC.

<div style=\"page-break-after: always\"></div>

The applicant was asked to discuss if recommendations for patients to be tested for active or latent tuberculosis before starting nemolizumab should be included in Section 4.4. Overall, the role of IL-31 and possible effects of nemolizumab in patients with latent TB are currently unknown, but available data do not indicate significantly increased risk. It is agreed with the applicant that no update of SmPC is required at this point.

The most common TEAE leading to withdrawal in nemolizumab 30 mg Q4W subjects was atopic dermatitis.

It is noted that lymphadenopathy and oedema peripheral led to study drug withdrawal in two subjects each in the nemolizumab 30 mg Q4W group in the Initial Period. Infections and infestations were also more common in nemolizumab 30 mg Q4W subjects compared to placebo subjects.

Subjects who were pregnant or lactating were excluded from all clinical studies. However, 10 subjects with AD [9 nemolizumab, 1 placebo) became pregnant during participation in the studies. The spontaneous abortions were consistent with the range of expected spontaneous abortions in the general population. The SmPC wording reflects the fact that the data on the use of nemolizumab in pregnant and breastfeeding patients is absent/limited.

No notable trends were observed in the primary safety population over time in vital signs or in urinalysis

Supportive and additional studies not included in the primary analysis pool

The CHMP considers that the overall profile of TEAEs of treatment with nemolizumab during the (LTE) study SIR.118163. seems comparable with the outcome of the primary safety pool. Discontinuation due to TEAEs showed a similar level compared with the pivotal phase 3 studies and did not seem to increase. AESIs specifically analysed were malignancies, autoimmune diseases, asthma, infections, IRRs, peripheral oedema, facial oedema, and drug induced liver injury. Injection site reactions (e.g., erythema, pain, irritation, oedema, bruising, and pruritus) are considered an ADR and is addressed in section 4.8 of the SmPC. Asthma and infections are the major AESIs and addressed in relation to the primary safety pool. Please refer to the previous discussion on peripheral oedema in the primary safety population.

The cases of toxic skin eruption are further discussed below in relation to study CIM003JG.

Long term extension study LTE study SPR.118163 (up to 200 weeks of treatment) is currently ongoing. The safety profile observed in the LTE study through week 52 (interim analysis) was generally consistent with the safety profile of nemolizumab observed in the controlled studies in AD. Data on long-term safety (beyond 1 year) of nemolizumab treatment are limited. Updated safety data from LTE study SPR.118163 for long-term safety analyses will be provided after the study has been finalized.

Updated safety data from LTE study SPR.118163 for long-term safety analyses will be provided after the study has been finalized in Q1 2027.

The overall profile of TEAEs of treatment with nemolizumab during the CIM003JG study seems comparable with the outcome of the primary safety pool. It is noted that there was an indication of a dose relationship for oedema peripheral in the nemolizumab Q4W groups. The incidence was 0% with placebo and was 3.8%, 5.6%, and 9.6% in the 0.1 mg/kg, 0.5 mg/kg, and 2.0 mg/kg Q4W groups, respectively. Please refer to previous comments relating to study (LTE) study SIR.118163. A possible dose-dependent effect on CPK was also seen as the incidence of CPK increased was higher in the

<div style=\"page-break-after: always\"></div>

nemolizumab 2.0 mg/kg Q4W and Q8W groups than in the nemolizumab 0.1 mg/kg and 0.5 mg/kg Q4W groups.

Cases of toxic skin eruption were reported both from the CIM003JG study and the (LTE) study SIR.118163. The CHMP considers the term `toxic skin eruption´ a broad term. However, these were single cases. At present, further action is not required.

From SRE.116912 study it is noted that apart from the infected dermatitis and staphylococcal skin infection evaluated as drug-related AESIs, there are two cases of peripheral oedema reported in this group of AD adolescents. These two cases of bilateral leg oedema were considered drug-related. Please refer to previous comments relating to studies (LTE) SIR.118163.and CIM003JG on this topic.

The study drug-related weight increases reported in SRE.201590 - phase 1 AI PK study is assessed to not require any further action at present.

The CHMP considers that the overall profile of TEAEs reported from this study seems comparable with the outcome of the primary safety pool.

The CHMP considers that the overall profile of TEAEs reported from M525101-02 study seems comparable with the outcome of the primary safety pool. Kaposi's varicelliform eruption (eczema herpeticum) and optic neuritis were reported but these were single cases.

Based on the hitherto presented and available data, nemolizumab treatment seems to have an acceptable safety profile.

## 2.6.12.2.  Prurigo nodularis

Assessment of safety is primarily based on the pivotal studies SPR.202685 and SPR.203065 and their pooled data focusing on both the 30 mg Q4W and 60 mg Q4W dose of nemolizumab proposed for marketing. Treatment Period (of 16 weeks and 24 weeks respectively) includes short-term safety data derived from studies SPR.202685 and SPR.203065. Overall Period includes both the Treatment Period and Follow-up Period (8 weeks in both studies). Long-term data are retrieved from interim results of the ongoing Study SPR.202699. The study population comprises subjects who had been enrolled in a prior nemolizumab Phase 2a study (SPR.115828) or prior Phase 3 pivotal study (SPR.202685 or SPR.203065). There are also additional studies with safety data presented separately.

In the studies submitted as part of the marketing authorisation application a total of 578 patients with PN were exposed to between 1 and 30 treatments of nemolizumab. The mean duration of exposure to the fixed dosing with body weight adjustment is 454.6 days including 375 subjects exposed for at least 1 year. The size of the safety database and the extent of exposure is generally considered adequate for assessment of safety.

From the summary of subject dispositions of the pivotal studies included in the primary safety analyses, discontinuation rates in the nemolizumab treatment arm showed a slight difference between studies with 10 % in study SPR.202685a and 4.4 % in study SPR.203065 respectively. On the other hand, in each respective study the discontinuation rate was similar between the active treatment arm and placebo arm.

Although the exposure data in the age group ≥ 65 years in the PN population is limited, it is considered sufficient to enable an initial assessment of this age group. It is noted that the number of TEAEs, study drug-related TEAEs, TEAEs leading to study drug withdrawal or study discontinuation, were all higher among subjects exposed to nemolizumab &gt;65 years of age compared to subjects 1865 years of age in the PN population. Given a new mechanism of action in humans and remaining uncertainties of the safety profile relating to e.g. infections and malignancies, an elderly patient group

<div style=\"page-break-after: always\"></div>

may be more vulnerable for ADRs. However, SAEs and drug-related SAEs were less frequent in nemolizumab subjects than in placebo subjects in elderly, which is reassuring. Eczematous reactions were more frequently reported in elderly nemolizumab subjects compared to younger adults: atopic dermatitis (5.1% subjects versus 4.4% subject respectively), eczema (7.1% subjects versus 2.6% subjects respectively) and eczema nummular (7.1% subjects versus 2.2% subjects respectively). The percentage of subjects with TEAEs leading to study drug withdrawal or study discontinuation in the nemolizumab group was higher among subjects ≥ 65 years of age (8.1% and 9.1%, respectively) than subjects 18-65 years of age (2.6% and 2.2%, respectively). TEAEs leading to study drug discontinuation or study discontinuation in the age group ≥ 65 years were also more common in the nemolizumab group than in placebo, which argues against these TEAs being caused only by old age. The applicant has submitted a summary of TEAEs leading to study drug withdrawal by age in the nemolizumab group in the overall treatment period.

Following the above discussion, the CHMP considers that the data for the age group &gt;65 years in the PN population can be extrapolated to the age group &gt;65 years in the AD population. The applicant concludes that 'safety in patients &gt;65 years of age' does not necessitate to be added as a safety concern of the RMP at this point. This is agreed.

The applicant states that the ongoing LTE study in the PN indication will provide additional information on extended exposure in the elderly and updates to that study will be provided when completed. This is acknowledged.

The same trend is noted in these TEAEs when reported as related to study drug. It is proposed to add `Patients &gt;65 years of age had a higher rate of eczematous reactions´ under the section `Description of selected adverse reactions´ in the SmPC, section 4.8. However, it is agreed that 'safety in patients &gt;65 years of age' does not necessitate to be added as a safety concern of the RMP at this point. Concerning malignancies please refer to the discussion under the AD section, equally conclusions are made for the PN population.  As long-term safety beyond 1 year of treatment with nemolizumab is now included in the safety specification as missing information, and both LTE studies in AD and PN respectively included in the Pv Plan, further follow-up of the long-term safety of all the exposed populations will be performed.

The frequency of subjects experiencing at least 1 TEAE during the Overall Period was slightly higher in nemolizumab subjects compared to placebo subjects (66.5% and 59.7% respectively). The most common TEAEs were neurodermatitis (coded term for worsening of PN), COVID-19, nasopharyngitis, and headache. Of these, only headache occurred with a higher frequency for nemolizumab compared to placebo (6.8% nemolizumab, 3.2% placebo). Most AEs were mild or moderate in severity.

Of the most commonly reported AEs with nemolizumab (reported by ≥ 5.0% of subjects in either the nemolizumab or placebo group) i.e. neurodermatitis (coded term for worsening of PN), COVID-19, nasopharyngitis and headache, only headache occurred with a higher frequency for nemolizumab compared to placebo (6.8% nemolizumab, 3.2% placebo).

PTs from SOCs Infections and infestations and Skin and subcutaneous tissue disorders made up about 25% of all TEAEs each in both treatment groups.

A TEAE preferred term (PT) only qualified for consideration as an ADR after the sequential application of quantitative and qualitative criteria. As discussed in relation to the AD population, the criteria for identification of potential ADRs are generally acceptable though some clarification has been requestedplease refer to comments in section 2.6.11.1.2.relating to the AD population.

Twenty-one TEAE PTs met the quantitative criteria (nemolizumab versus placebo) These 21 TEAEs were then further evaluated medically using the qualitative criteria defined above to determine the

<div style=\"page-break-after: always\"></div>

final proposed list of ADRs for the PN indication. Overall, following medical evaluation, 4 ADRs were identified:

- Headache (including 1 PT of tension headache [hereafter referred to as headache]; nemolizumab 6.8% versus placebo 3.2%). In the nemolizumab group, the events of headache were non-serious, mostly mild or moderate in severity, and did not lead to nemolizumab withdrawal.
- ADRs grouped under the medical concept of eczematous reactions (atopic dermatitis, eczema, and eczema nummular).

It is agreed that headache and eczematous reactions should be listed as ADRs in section 4.8 of the SmPC.

Peripheral oedema and peak exploratory flow rate decreased are discussed in section 2.6.11.7.3. The 15 remaining TEAEs that met the quantitative criteria but did not qualify as ADRs are discussed below.

## Fatigue

The CHMP considers the imbalance noted not sufficient to require further action at present. Please also refer to section concerning fatigue in relation to the AD population.

## Hypertension

The applicant concludes that there is no evidence of a reasonable possibility of a relationship between nemolizumab and hypertension. This is agreed.

## Back Pain, Osteoarthritis, Pain in Extremity and Arthralgia

It is noted that in a number of different pain conditions relating to musculoskeletal tissue such as back pain, pain in extremity and arthralgia, the frequency was higher in the PN nemolizumab group compared to the placebo group. This was also the case for osteoarthritis. The applicant refers to possible confounders. At present, further action is not required.

## Urinary Tract Infection

The conclusion by the applicant is that none of the events were considered as having a reasonable possibility of a causal relationship with nemolizumab. This is agreed.

## Sinusitis

Sinusitis was considered as having no relationship with nemolizumab in most (5/6) of the subjects. The applicant concludes that based on the above, there is no evidence of a reasonable causal relationship between nemolizumab and sinusitis. This is agreed.

## Dermatitis Contact

Causal relationship with nemolizumab unlikely. This is agreed.

## Pyrexia

None of the TEAEs of pyrexia were assessed as related to nemolizumab.

## Cystitis

The applicants conclusion is that based on the above, there is no evidence of a reasonable possibility of a relationship between nemolizumab and cystitis. This is agreed.

## Pneumonia

<div style=\"page-break-after: always\"></div>

The case of serious pneumonia and severe pneumococcal sepsis in a young apparently previous healthy patient treated with nemolizumab is of concern. However, this affects a single case, and further data/events will be needed in order considering this a potential risk associated with exposure to nemolizumab. At present no further action is required.

## Rash

The conclusion by the applicant is that based on the reported rashes, there is no reasonable relationship between nemolizumab and rash. This is supported

## Stasis Dermatitis

While there is no direct association between lichen planus and psoriasis and stasis dermatitis, subjects with these conditions may be more susceptible to developing stasis dermatitis due to the weakened skin barrier and increased risk of infections. It is agreed that stasis dermatitis should not be listed as an ADR in the SmPC.

A higher frequency of malignancies in the PN population (compared to the AD population) is expected, since this age group is older. Relevant risk factors are properly described by the applicant.

Please refer to the previous discussion on malignancies in the section on AD population. The applicant was requested to discuss whether malignancies should be included as an important potential risk in the RMP for nemolizumab.

There is a diversity of different types of malignancies reported and these reported events are difficult to differ from what may be expected in the general population with a similar age distribution. The short latency period between the initiation of nemolizumab therapy and some of the reported malignancies may also question a causal relationship. The applicant was requested to discuss if malignancies should be included in the RMP as an important potential risk. At present it is agreed there is no strong signal suggesting that malignancies should be an important safety concern. Furthermore, the non-clinical overarching conclusion is that based on current knowledge and as presented in the CAD document-please refer to the non-clinical assessment-, there is limited support of a carcinogenic effect associated with blockade of IL-31R.

The applicant concludes that considering the magnitude of the difference with placebo, it is deemed that there is a reasonable possibility of a relationship between nemolizumab and eczematous reactions. This is agreed. Atopic dermatitis, eczema, and eczema nummular are listed as ADRs in section 4.8 of the SmPC. This is endorsed.

One subject was diagnosed with alopecia areata - primary episode of mild severity on Day 89. Causality was assessed as not related to nemolizumab. The CHMP considers that it is not completely clear why causality was assessed as not related to nemolizumab. Regardless, autoimmune disease assessed as related to study drug was more common in nemolizumab treated subjects than in placebo subjects during the treatment period in the primary safety population.

Three cases of bullous pemphigoid, whereof one severe, were reported from the PN population of 370 patients exposed to nemolizumab. The CHMP considers this to be a higher-than-expected number of subjects if considering a standard population, even if elderly. Two cases were considered related to the study drug/injection procedure by the investigator However, the clarification by the applicant seems reasonable. In fact, a nodular form of pemphigoid can appear similar to prurigo nodularis and these cases may by mistake have been included in the study. There were also one case of pemphigoid reported in the nemolizumab treated primary safety pool of AD patients. Study drug was interrupted, the patient recovered following treatment with systemic corticosteroids, nemolizumab was reintroduced and the patient completed the study. In conclusion, the assessment by the applicant not to introduce this event as an ADR is presently accepted.

<div style=\"page-break-after: always\"></div>

At present, data is assessed not to be sufficient to justify further action.

The applicant concludes that considering the magnitude of the difference with placebo and the lack of confounders in most nemolizumab subjects, it was deemed that there is a reasonable possibility of a relationship between nemolizumab and headache. Although the pharmacological rationale is unclear and confounders were identified for some subjects, the assessment of causality is agreed. Headache (including tension headache) is listed as an ADR in section 4.8 of the SmPC. This is also agreed.

No imbalance of injection site reactions was observed between nemolizumab (1.1%) and placebo (1.6%). Injection site reactions included injection site erythema (1 event), injection site bruising (2 events), injection site pruritus (1 event) and injection site reaction (1 event) reported in 4 nemolizumab subjects and injection site erythema (3 events), injection site pruritus (2 events) and injection site irritation (1 event) reported in 3 placebo subjects respectively.

Injection site reactions are listed as ADRs in SmPC section 4.8. This is endorsed. In the proposed SmPC, 'pain', 'irritation' and 'injection site oedema' are only mentioned as 'occurred in atopic dermatitis studies'.

All Injection-Related Reactions were considered AESIs, which included anaphylactic reactions, acute The applicant concludes that the evaluation of the data on IRRs suggests a low risk of serious hypersensitivity reactions and severe injection site reactions in association with the use of nemolizumab. At present, these single cases are not considered by the CHMP to be sufficient to consider inclusion of injection-related reactions in the list of ADRs in section 4.8 in the SmPC. However, should additional future cases of injection-related reactions be reported, this may be reconsidered.

The CHMP does not consider nemolizumab to be associated with events of new onset asthma. However, worsening of asthma and decrease in PEF rates during nemolizumab treatment cannot be excluded. Overall small number of asthmatic patients and even smaller number of those with PEF decreased/ACT worsened is acknowledged, however clear imbalance between groups cannot be dismissed.

At baseline, similar proportions of patients had a medical history of asthma in both groups (n=51 nemolizumab, n=28 placebo, i.e. about 13-14%). Among these subjects, 8/51 (15.7%) nemolizumab asthmatic subjects and 1/28 (3.6%) placebo asthmatic subject experienced IAC confirmed worsening of asthma during the Overall Period. The applicant's conclusion that those events are expected is not supported as an obvious imbalance in worsening of asthma exists between groups despite similar proportion of asthmatic patients in both treatment groups. Of note, the applicant's presentation of data on worsening of asthma is not supported as the denominator should be only asthmatic patients, and not the whole population (as presented in the dossier) as later significantly diminishes the magnitude of the effect in asthmatic patients and also true difference between treatment groups.

At the request of CHMP, the applicant further discussed worsening of asthma during nemolizumab treatment in the PN population.

To overcome the limitation of low number of asthmatic PN patients, the applicant presented an analysis of a larger pooled population of subjects with a medical history of asthma across both indications. Although this approach could seem reasonable, considering that no AD patient received more than 30 mg Q4W, pooling of data for AD and PN population in this case is misleading and cannot adequately address the concerns regarding possible causal relationship between higher nemolizumab dose and worsening of asthma. The applicant did not present data on body weight and nemolizumab dose administered to asthmatic PN patients therefore the Assessor reviewed patient listings by hand. Acknowledging possible mistakes due to manual counting, following is observed:

<div style=\"page-break-after: always\"></div>

- overall 51 asthmatic PN patients were identified. Due to weight ≥90 kg, 18 of those patients received nemolizumab 60 mg Q4W (versus 8 asthmatic patients with body weight ≥90 kg who received placebo), while remaining 33 patients with body weight &lt; 90 kg received nemolizumab 30 mg Q4W (versus 20 asthmatic patients with body weight &lt; 90 kg who received placebo). The incidence of worsening of asthma was 5/18 (27.8%) in nemolizumab 60 mg Q4W group, and 3/33 (9.1%) in nemolizumab 30 mg Q4W group. In other words, the incidence of worsening of asthma in PN patients receiving nemolizumab 30 mg Q4W was the same as incidence observed in asthmatic AD patients, and also similar as in placebo (about 10%). However, the incidence was about 3 times higher in patients receiving 60 mg Q4W (dose that was investigated only in PN studies).

When assessing this potential risk, it is also important to consider that worsening of asthma is clinically relevant issue with important implications for clinical use of nemolizumab and monitoring of patients, especially considering high prevalence of asthmatic patients in both pursued indications. Despite small number of asthmatic PN patients receiving 60 mg dose, it is considered important not to dismiss observed signal and to inform HCPs and patients on potential risk.

Finally, it is agreed with the applicant that at this point, nemolizumab at 30 mg Q4W seems not to be associated with worsening of asthma. However, it is considered that there is a reasonable possibility of causal relationship between higher nemolizumab dose (60 mg Q4W) and worsening of asthma.

Following CHMP request, worsening of asthma is included as ADR in SmPC section 4.8.

Also following CHMP request, information regarding worsening of asthma during nemolizumab treatment is provided in SmPC Section 4.4. Information that patients with an exacerbation of asthma requiring hospitalization in the preceding 12 months, those with uncontrolled asthma during the preceding 3 months, and patients with a current medical history of COPD and/or chronic bronchitis were excluded from the studies is also included in SmPC section 4.4.

All AESIs of infections included any severe infection, any infection requiring treatment with parenteral antibiotics or with oral antibiotics/antivirals/antifungals for &gt;2 weeks, and any confirmed or suspected COVID-19 infection. By drawing the limit at &gt;2 weeks, the CHMP considers that there is a risk of missing infections with clinical relevance (e.g. 10 days of antibiotic treatment is common). It is also assessed questionable to select only severe infections, since an infection can be considered for inclusion in the SmPC regardless of severity.

Treatment-emergent AEs of skin infections (including cellulitis) were reported in 3 (0.8%) nemolizumab subjects (cellulitis, fungal skin infection, and skin infection in 1 [0.3%] subject each) versus 4 (2.2%) placebo subjects (cellulitis and skin infection in 2 [1.1%] subjects each).

It is noted that during the overall period, there were some events reported in the eczematous reactions, where the subjects were treated antibacterials (3 subjects with topical antibacterial, 4 subjects with TCS combinations with antibiotic and 1 subject with antibacterial [clindamycin] tablet+ TCS combination with antiseptic). It may be assumed that these cases involved events of skin infections.

Overall, the fungal infections reported in the nemolizumab program in the PN indication were superficial and primarily of dermatophyte origin, with the exception of one case of bronchopulmonary aspergillosis allergic. The applicant has presented this case (a hypersensitivity reaction of the lung to Aspergillus inhalation) in more detail. The case was considered non-serious and not related to nemolizumab. Rapp considers the aspergillosis case to be a single case requiring no further action at present.

The applicant argues that the overall event frequency of the most frequent superficial dermatophyte infections is low compared to what is reported for the general population. However, if reported events

<div style=\"page-break-after: always\"></div>

would represent background risk in all PN patients, as argued by the applicant, similar rates of fungal infections would be expected in the placebo group.

Overall, based on available data, it is considered that there is a reasonable possibility of a causal relationship between nemolizumab and superficial fungal infections in the PN population. Following a CHMP request, the applicant added superficial fungal infections as an ADR in the SmPC section 4.8.

In the nemolizumab group, all events were non-serious and either mild (5 events) or moderate (3 events) in severity.

Of the subjects with AESIs of peripheral oedema: limbs, bilateral; facial oedema during the Overall Period, the majority had events that were considered study drug related.

Please refer to the previous discussion on peripheral oedema in the AD population. It is understood that peripheral oedema (limbs, bilateral) and facial oedema were grouped as a single entity for the purpose of signal detection. However, that when analysing the data, one should distinguish peripheral oedema (limb, bilateral) from facial oedema given the different etiologies of both medical concepts. Four (1.1%) nemolizumab subjects experienced face oedema (face oedema: 3 subjects; angioedema: 1 subject) compared to 0 placebo subjects. Angioedema is addressed as an ADR in the submitted SmPC.

The CHMP considers the imbalance in peripheral oedema noted between nemolizumab treated subjects and placebo subjects not sufficient to require further action at present. Confounding factors were also present in majority of cases.

Available data do not suggest increased risk of drug-induced liver injury associated with the use of nemolizumab. By reviewing reported PTs indicating increased liver enzymes, no significant finding could be observed either - AST increased, ALT increased were reported more often in placebo, and GGT increased and liver function test increased were reported in 2 and 1 nemolizumab patients, respectively.

Treatment-emergent SAEs were more common in placebo subjects compared to nemolizumab subjects. One placebo subject died (cardiogenic shock). There were also two subjects with TEAEs leading to death in the LTE study SPR.202699 (supportive study). However, of these two fatal cases, one subject died following a myocardial infarction and the other subject experienced fatal end stage renal disease; both events were considered not related to study drug or protocol procedure.

The criteria for identification of potential ADRs are acceptable. Headache and ADRs grouped under the medical concept of eczematous reactions (atopic dermatitis, eczema, and eczema nummular) were the only ADRs identified by the criteria proposed by the applicant. It is agreed that these should be listed as ADRs in section 4.8 of the SmPC. Type 1 hypersensitivity and injection site reactions are also listed as ADRs in SmPC section 4.8.

Adding eosinophilia as an ADR in the PN population has been discussed. However, the imbalance noted between nemolizumab subjects and placebo subjects in the PN population is not considered to be sufficient to warrant inclusion of eosinophilia in the list of adverse reactions in the SmPC, section 4.8.

CPK increase is not listed in the SmPC. Based on the above data, this is agreed.1 (0.6%) nemolizumab subject at Week 16 and no subjects at Week 24 had an abnormal clinically significant ECG finding. At present, this single case is not considered to be sufficient to consider an abnormal clinically significant ECG finding as a potential risk associated with exposure to nemolizumab.

Some ECG findings (e.g. atrioventricular conduction) were more common in nemolizumab subjects compared to placebo subjects at week 16 and week 24 in the safety population. The applicant was

<div style=\"page-break-after: always\"></div>

requested to discuss the ECG findings, the potential risk for cardiac adverse events and the potential role of IL-31 in the pathogenesis of fibrosis.

The applicant submitted a summary table of ECG findings at baseline Week 16 and Week 24 (Table 90e). At week 16 atrioventricular conduction was reported in 7.6% of nemolizumab subjects compared to 3.4% of placebo subjects. At week 24, atrioventricular conduction was still more common in nemolizumab subjects compared to placebo subjects. At baseline, 19/370 (5.1%) of nemolizumab subjects reported atrioventricular conduction. This is reassuring, as the actual number of subjects presenting with this ECG finding is somewhat stable over time (although it should be noted that data on whether any subjects with atrioventricular conduction discontinued the study during this time are missing).

It is noted that `ST segment, T wave, and U wave (T waves flat)' were reported more frequently in nemolizumab subjects compared to placebo subjects. In nemolizumab subjects this ECG finding was reported in 14/370 (3.8%) at baseline, 4/172 (2.3%) at week 16 and 11/165 (6.7%) at week 24. This trend is somewhat concerning. However, the same trend is noted in placebo subjects for `ST segment, T wave, and U wave (T wave inversion).

The applicant has provided some research findings supporting IL-31's role in cardiac fibrosis (e.g. Tatu et al, Interrelationship and Sequencing of Interleukins4, 13, 31, and 33 - An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives. J Inflamm Res. 2022 Sep 8;15:5163-5184). The applicant concludes that the role of IL-31 in fibrosis has been well described in the context of systemic sclerosis and idiopathic pulmonary fibrosis and that taken together, the data point to a deleterious role for IL-31 in fibrosis. This is acknowledged. However, since direct studies on IL-31's role in cardiac fibrosis are limited, the CHMP still considers the research findings to be insufficient to enable establishment of the actual impact of IL-31 on cardiac fibrosis.

Occurrence of pacemaker (paced rhythm) was reported in 3/165 patients (1.8%) in the nemolizumab arm vs 0 in the placebo arm. The applicant has clarified that the 3 subjects who exhibited paced rhythm in the nemolizumab cohort had a pacemaker noted as a medical condition at baseline, versus none in the placebo cohort. This is acknowledged.

Regarding a dedicated QT study, the applicant does not consider this to be warranted given that the size of nemolizumab precludes molecular entry into the human ether-a-go-go related gene (hERG) pore and exertion of acute electrophysiological effects.

Overall, the CHMP considers data to be insufficient to consider a causal relationship between nemolizumab and cardiac adverse events. Therefore, amendments of the SmPC regarding this issue or a dedicated QT study will not be required at present.

Fungal infections (reported as non-serious TEAEs and of mild or moderate severity) were reported exclusively in the nemolizumab group (nemolizumab 3-3.8% vs placebo group 0%). Overall, the fungal infections reported in the nemolizumab program in the PN indication were mostly superficial and primarily of dermatophyte origin. Based on available data, it is considered that there is a reasonable possibility of a causal relationship between nemolizumab and superficial fungal infections in the PN population. Following CHMP request, the applicant added superficial fungal infections as an ADR in the SmPC, section 4.8.

At baseline, similar proportions of patients had a medical history of asthma in both groups (n=51 nemolizumab, n=28 placebo, i.e. about 13-14%). Among these subjects, 8/51 (15.7%) nemolizumab asthmatic subjects and 1/28 (3.6%) placebo asthmatic subject experienced IAC confirmed worsening of asthma during the Overall Period. Considering that no increase in worsening of asthma was observed in AD studies, further assessment of the 8 patients experiencing worsening of asthma in PN studies was done. Reviewing available data, it was observed that 5 out of those 8 patients received

<div style=\"page-break-after: always\"></div>

higher nemolizumab dose, i.e. 60 mg Q4W. This dose was not investigated in AD program. Considering that overall there were 17 asthmatic PN patients who received 60 mg dose due to having weight ≥90 kg, this indicates that almost every third patient (5/17, 30%) who received higher nemolizumab dose, reported worsening of asthma. Additionally, proportions of patients with worsening of asthma among PN patients who received lower, 30 mg Q4W dose, was the same as reported in AD program with the same dose, and also in placebo (around 10%). Overall, despite limited number of patients experiencing the event, it is considered that there is a reasonable possibility of causal relationship between higher nemolizumab dose (60 mg Q4W) and worsening of asthma. The Section 4.8 of SmPC has been updated and include ADR of worsening of asthma in PN patients. Description of worsening of asthma is also added in Description of selected adverse reactions under the table. Section 4.4 of the SmPC is amended accordingly.

During the Overall Period, a higher percentage of male subjects experienced atopic dermatitis in the nemolizumab group (8.1%) compared with female subjects (2.3%).

During the Overall Period, a higher percentage of male subjects in the nemolizumab group experienced eczema (6.8%) or eczema nummular (6.8 %) compared with the incidence of eczema and of eczema nummular in female subjects (1.8% and 1.4 %, respectively).

These ADRs are addressed in table 1 section 4.8 of the SmPC with frequency common

The sample sizes were quite variable in the different regions (N=391 [Europe], N=143 [North America], and N=22 [Asia Pacific]) and some ethnic groups and races were underrepresented. At present, no further action is required.

TEAEs related to study drug was slightly more common in nemolizumab 60-30 mg subjects (26.4%) than in nemolizumab 60-60 mg subjects (21.8%). The same trend is noted in TEAEs leading to study drug discontinuation; nemolizumab 60-30 mg subjects (4.9%), nemolizumab 60-60 mg subjects (1.6%). TEAEs of special interest, on the other hand, were more frequently reported in nemolizumab 60-60 mg subjects (17.7%) compared to (12.6%). The same applies to serious TEAEs.

Overall, there does not seem to be a clear trend of higher frequency of different TEAEs in either group (nemolizumab 60-30 mg subjects compared to nemolizumab 60-60 mg subjects).

No nemolizumab subjects with renal impairment experienced a TEAE during the treatment period. Overall, no significant difference between nemolizumab and placebo was identified in PN population.

A higher proportion of nemolizumab subjects had a TEAE leading to study drug withdrawal or study discontinuation than placebo subjects (4.1% vs 2.7 % and 4.1% vs 3.2% respectively). The most common PT's that led to drug/study discontinuations were from SOC Skin and subcutaneous tissue disorders.

In the pivotal PN studies (SPR.202685 and SPR.203065) and LTE PN study (SPR.202699) with up to 116 weeks of treatment, the incidence of treatment-emergent anti-drug antibodies (ADAs) was 12.8% (46 out of 358 AD subjects). The majority had persistent ADAs.

The CHMP considers the overall profile of TEAEs reported from studies SPR.115828 - phase 2a study, SPR.202699 - phase 3 LTE study, ongoing study SPR.203890 conducted by Applicant to be comparable with the outcome of the primary safety pool.

## M525101-11 - phase 2/3 study in subjects with PN

The CHMP considers the overall profile of TEAEs reported from this study to be comparable with the outcome of the primary safety pool. The incidence of AEs judged to be related to the study drug in both Part A and part B was not higher in nemolizumab 60 mg groups compared to the nemolizumab 30 mg and (21.1% and 29.9% respectively and 38.1% and 38.4 % respectively. However, the two

<div style=\"page-break-after: always\"></div>

observed SAEs were in subjects of the nemolizumab 60 mg group. There were no fatal cases. Apparently the AEs that were observed comparatively frequently up to 16 weeks after the start of the treatment in the nemolizumab 30 mg and 60 mg groups were vaccination complications, neurodermatitis, eczema, erythema, dermatitis, and folliculitis. It is not fully clear what kind of vaccination complications that occurred. In section 4.4 of the SmPC under the heading 'Vaccinations' it is stated: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with Nemluvio. Avoid use of live vaccines in patients treated with Nemluvio. It is unknown if administration of live vaccines during Nemluvio treatment will impact the safety or efficacy of these vaccines. No data are available on the response to non-live vaccines.

At present, no further action is required.

Due to limited data, the applicant in their response concluded that `Long-term safety beyond 1 year of nemolizumab 30 mg Q4W and 60 mg Q4W dose´ is relevant for the RMP as Missing information. This is endorsed. Subjects who were pregnant or lactating were excluded from all clinical studies. However, 10 subjects with AD (9 nemolizumab, 1 placebo) and 1 subject with PN (placebo) became pregnant during participation in the studies. The spontaneous abortions were consistent with the range of expected spontaneous abortions in the general population. The SmPC wording reflects the fact that the data on the use of nemolizumab in pregnant and breastfeeding patients is absent/limited. In addition, use in pregnancy is listed as a missing information in the list of safety concerns in the RMP.

No notable trends were observed in the primary safety population over time in vital signs or in urinanalysis.

Based on the hitherto presented and available data, nemolizumab treatment seems to have an acceptable safety profile.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics

## 2.6.13.  Conclusions on the clinical safety

## 2.6.13.1.  Atopic dermatitis

The size of the safety database and the extent of exposure is considered adequate to allow for safety assessment. Additional data are awaited for long-term exposure (beyond 52 weeks) from LTE Study SPR.118163. Overall, nemolizumab treatment appears to be well tolerated, including the dose and method of administration proposed for licensing.

From a safety perspective the application for marketing authorisation for nemolizumab in the proposed indication is approvable.

## 2.6.13.2.  Prurigo nodularis

The size of the safety database and the extent of exposure is considered adequate to allow for safety assessment. Overall, nemolizumab treatment appears to be well tolerated, including the dose and method of administration proposed for licensing. Common ADRs were headache and eczematous skin reactions (atopic dermatitis, eczema and eczema nummular).

From a safety perspective the application for marketing authorisation for nemolizumab in the proposed indication is approvable.

<div style=\"page-break-after: always\"></div>

The CHMP considers the following measures necessary to address issues related to safety:

Category 3 PASS: Retrospective Cohort Study of Pregnancy and Infant Outcomes in Individuals With Moderate to Severe Atopic Dermatitis Exposed to Nemolizumab During Pregnancy: A Multidatabase Study

Category 3 PASS AD: Long term extension study RD.06.SPR.118163, ongoing, to evaluate the longterm safety and efficacy of nemolizumab in subjects with moderate-to-severe AD

Category 3 PASS PN: Long term extension study RD.06.SPR.202699, ongoing, to evaluate the longterm safety and efficacy of nemolizumab in subjects with moderate-to-severe PN

## 2.7.  Risk Management Plan

## 2.7.1.  Safety concerns

## Table 92: Summary of Safety Concerns

| Summary of Safety Concerns   |                                                                                   |
|------------------------------|-----------------------------------------------------------------------------------|
| Important identified risks   | None                                                                              |
| Important potential risks    | None                                                                              |
| Missing information          |  Use in pregnancy  Long-term safety beyond 1 year of treatment with nemolizumab |

## 2.7.2.  Pharmacovigilance plan

## Table 93: Ongoing and planned additional Pharmacovigilance Activities

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                             | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Safety Concerns addressed                                     | Milestones                                                    | Due dates                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                            | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| PASS A Study of Pregnancy and Infant Outcomes in Patients Exposed to Nemolizumab During Pregnancy: A Retrospective Observational Study Based on Healthcare Database(s) Planned                           | To estimate the frequency of select adverse pregnancy and birth outcomes (i.e., ectopic pregnancy, spontaneous abortion, foetal death/stillbirth, elective termination, and preterm birth) in pregnant patients exposed to nemolizumab and in disease- matched pregnant patients unexposed to nemolizumab To estimate the frequency of select adverse foetal, neonatal, and infant outcomes (i.e., major congenital malformations [MCMs] and small for gestational age [SGA]) among infants from pregnancies in patients exposed to nemolizumab during the defined exposure window and from pregnancies in disease-matched patients unexposed to nemolizumab To estimate the adjusted relative risks (RRs) for the study outcomes in pregnant patients exposed to nemolizumab compared with disease-matched pregnant patients unexposed to nemolizumab, if study size permits. | Missing information: Use in pregnant women                    | Protocol                                                      | Within 3 months of EC decision                                |
| A Phase 3, Prospective, Multicentre, Long- Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis - ARCADIA LTE (RD.06.SPR.11816 3) | To evaluate the long-term safety and efficacy of nemolizumab in subjects with moderate-to-severe AD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Missing information: Long term safety beyond 1 year           | Final Study Report                                            | Q1 2027                                                       |
| Ongoing A Phase 3, Prospective, Multicentre, Long- Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis - OLYMPIA LTE (RD.06.SPR.20269 9) Ongoing    | To evaluate the long-term safety and efficacy of nemolizumab in subjects with moderate-to-severe PN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Missing information: Long term safety beyond 1 year           | Final Study Report                                            | Q3 2027                                                       |

<div style=\"page-break-after: always\"></div>

## 2.7.3.  Risk minimisation measures

## Table 94: Table of Pharmacovigilance Activities and Risk Minimisation Measures by Safety Concern

| Safety concern                                               | Risk minimisation measures                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks                                    | Important potential risks                                                                                                                                                                                                                                                                                                                    | Important potential risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Not Applicable                                               | Not Applicable                                                                                                                                                                                                                                                                                                                               | Not Applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Missing information                                          | Missing information                                                                                                                                                                                                                                                                                                                          | Missing information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Use in pregnancy                                             | Routine risk minimisation measures: Information regarding the use of nemolizumab during pregnancy is presented in section 4.6 of the SmPC and in section 2 of the PIL. Preclinical data are presented in section 5.3 of the SmPC. Prescription only medicine. Additional risk minimisation measures: There are no risk minimisation measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: continuous benefit-risk assessment, production of periodic reports responses to questions from competent authorities and label maintenance Additional pharmacovigilance activities : Pregnancy non-interventional (observational) retrospective cohort study                                                                                                                                                                                                                                                                                                                         |
| Long-term safety beyond 1 year of treatment with nemolizumab | Routine risk minimisation measures: None Additional risk minimisation measures: There are no risk minimisation measures                                                                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: continuous benefit-risk assessment, production of periodic reports responses to questions from competent authorities and label maintenance Additional pharmacovigilance activities : A Phase 3, Prospective, Multicentre, Long- Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis -ARCADIA LTE (RD.06.SPR.118163) and A Phase 3, Prospective, Multicentre, Long- Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis - OLYMPIA LTE (RD.06.SPR.202699) |

## 2.7.4.  Conclusion

The CHMP considers that the risk management plan version 1.3 is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8.  Pharmacovigilance

## 2.8.1.  Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2.  Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 28 Mar 2022. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## 2.9.  Product information

## 2.9.1.  User consultation

The results of the user consultation with target patient groups on the package leaflet for the pre-filled pen submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

No full user consultation with target patient groups on the package leaflet for the pre-filled syringe has been performed on the basis of a bridging report to the pre-filled pen. The bridging report submitted by the applicant has been found acceptable.

The content of the instruction for use (IFU) for the pen and the syringe is identical in some parts but differs in other parts where the handling is different. However, as the two IFUs are designed the same way and uses the same kind of language the absence of a user test for the IFU of the pre-filled syringe is considered acceptable.

## 2.9.2.  Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Nemluvio (nemolizumab) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU. Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 3.  Benefit-risk balance

## 3.1.  Therapeutic context

## 3.1.1.  Disease or condition

Atopic dermatitis and prurigo nodularis are clinical syndromes characterized by itching and skin lesions of different kind. AD is a more common disease affecting a younger population while PN generally affects a middle-age and older populations. The aim of therapy is to improve skin symptoms and decrease itching.

The active compound nemolizumab is an IL-31RA blocking agent proposed to have beneficial efficacy in ameliorating pruritus and inhibiting inflammatory responses in both AD and PN. There is no other IL-31 blocking agent yet approved for human use.

The approved indications for Nemluvio are:

## Atopic dermatitis (AD)

Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

## Prurigo nodularis (PN)

Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

## 3.1.2.  Available therapies and unmet medical need

The most prescribed medications in both AD and PN are topical treatments with moisturizers, topical corticosteroids, and topical calcineurin inhibitors as first steps.

In PN, widespread skin-directed therapies like ultraviolet phototherapy, or systemic therapies targeting the immunologic (methotrexate or cyclosporine) and/or the neural (gabapentin, antidepressants) systems can be used but have limited evidence to support their efficacy and safety.

There are several biologic treatments (lebrikizumab, tralokinumab and dupilumab) approved for the more severe forms of AD. For adults with PN, dupilumab received market authorization in 2022.

There is an unmet clinical need for other treatment options, especially in PN, and for efficacious antipruritic therapy in both indications.

## 3.1.3.  Main clinical studies

## Atopic dermatitis

The main evidence of efficacy and safety submitted comes from two identical pivotal phase 3 studies, SRE.118161 (ARCADIA 1) and SRE.118169 (ARCADIA 2) that are randomised, double-blind, placebocontrolled, multicentre studies comparing nemolizumab 30 mg sc injection following a loading dose of 60 mg Q4W (n=1142) versus vehicle injection (n=586) in subjects above 12 years of age. At the end of the studies, subjects were invited to enter the extension study SIR.118163 with nemolizumab 30 mg sc injection Q4W. Safety was the primary endpoint in study SIR.118163, while efficacy and

<div style=\"page-break-after: always\"></div>

subject's perspective were secondary efficacy endpoints. A long-term study over 200 weeks in AD subjects is ongoing.

To be eligible for the study, subjects should have chronic AD for ≥2 years, EASI score ≥16, IGA score ≥3, AD involvement ≥10% of body surface area BSA, PP NRS score ≥4.0 at both screening and baseline visits. The subjects should also have a documented history of inadequate response to topical medications. Eligibility criteria were adequately reflecting the target patient group.

The subjects were randomised in a 2:1 ratio to receive either nemolizumab 30 mg or vehicle injection. Randomisation was stratified by baseline disease severity: PP NRS &lt; 7 and PP NRS &gt;= 7 as well as IGA = 3 and IGA = 4.

The co-primary efficacy endpoints were 1) the proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear]) and a ≥2-point reduction from baseline and 2) the proportion of subjects with EASI-75 (≥75% improvement in EASI from baseline) at Week 16.

## Prurigo nodularis

The main evidence of efficacy and safety submitted comes from two phase 3 randomised, doubleblind, placebo-controlled multi-centre studies, SPR.202685 (Olympia 1) and SPR.203065 (Olympia 2) comparing nemolizumab (n=373) vs. placebo (n=187) in adult patients with prurigo nodularis. Study duration was 24 and 16 weeks, respectively, with primary endpoints measured at week 16 in both studies. The subjects were randomised in a 2:1 ratio to receive either nemolizumab or placebo, stratified by study centre and baseline body weight (&lt; 90 kg vs. ≥ 90 kg). The dose of nemolizumab 30 mg (body weight &lt;90 kg) or nemolizumab 60 mg (body weight ≥ 90 kg) SC was administered every 4 weeks (Q4W) after the starting with a loading dose of 60 mg in subjects with a body weight &lt;90 kg.

Key eligibility criteria for the pivotal studies were age ≥18 years, clinical diagnosis of PN since at least 6 months and moderate or severe PN based on PP NRS score of ≥ 7 and a minimum of 20 PN lesions and IGA score ≥ 3. Key exclusion criteria were secondary PN due to other reasons and subjects with active AD the last 3 months. Eligibility criteria were adequately reflecting the target patient population.

The primary analysis of the pivotal studies consisted of meeting the primary endpoints proportion of subjects with an improvement of ≥ 4 from baseline in PP NRS at Week 16 and proportion of subjects with an IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥ 2-grade improvement from baseline) at Week 16.

## 3.2.  Favourable effects

## Atopic dermatitis

## Initial treatment period (week 0 - 16)

Both co-primary efficacy endpoints were met at week 16 in both pivotal trials. In study ARCADIA 1, nemolizumab was superior to placebo with respect to IGA success (35.6% vs 24.6%, the unadjusted proportion of difference for active - placebo was 11.0 (95% CI 5.0 to 17.1) in the full population, and 14.0 (95% CI 6.8 to 21.3) in the severe pruritus population. The corresponding results obtained in study ARCADIA 2 were 37.7% vs 26.0%, the difference for active - placebo was 11.7 (95% CI 5.0 to 18.4) in the full population, and 14.8 (95% CI 6.5 to 23.0) in the severe pruritus population.

In ARCADIA 1, results obtained with EASI-75 score were 43.5% for nemolizumab vs 29.0% for vehicle injection which resulted in a difference for active - placebo of 14.6 (95% CI 8.3 to 20.9) in the full population, and 17.8 (95% CI 10.3 to 25.3) in the severe pruritus population. The corresponding results obtained in ARCADIA 2 were 42.1% vs 30.2%, the difference for active - placebo was 12.0

<div style=\"page-break-after: always\"></div>

(95% CI 5.0 to 18.9) in the full population, and 16.1 (95% CI 7.6 to 24.7) in the severe pruritus population.

Onset of clinical efficacy (IGA and EASI) was observed after 4 weeks and was maintained over the duration of the 16-week study.

With respect to secondary endpoints, in study ARCADIA 1, the proportion of subjects with an improvement of PP NRS ≥ 4 at week 16, were 42.7% in the nemolizumab group and 17.8% in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 25.0 (95% CI 19.3 to 30.7) in the full population. The corresponding results obtained in ARCADIA 2 were 41.0% in the nemolizumab group and 18.1% in the vehicle group (p&lt;0.0001). The unadjusted proportion of difference for active - placebo was 22.9 (95% CI 16.6 to 29.2) in the full population.

## Efficacy in adolescents

The treatment effect of nemolizumab in the adolescent population, measured with the endpoints percent of subjects with IGA 0 or 1, percent of subjects with EASI-75, percent of subjects with PP NRS improvement ≥4, PP NRS &lt;2 and SD NRS improvement ≥4 at week 16, were generally consistent with the results in the overall population.

## Results in subgroups

Consistency of the effect as measured by the two co-primary efficacy endpoints was documented in subgroups based on age, sex, race, ethnicity, region, baseline IGA, baseline PP NRS, and previous use of systemic therapy for AD.

## Maintenance treatment period (week 16 - 48)

Among subjects with IGA 0/1 and EASI-75 response at Week 16, subjects re-randomised to nemolizumab Q4W and nemolizumab Q8W, had similar proportions of patients with IGA success at week 48 (approx. 60%) compared to approx. 50% success in the placebo group.

Concerning efficacy on itch, the proportion who maintained an improvement of ≥4 from initial baseline in weekly average PP NRS was higher in the nemolizumab Q4W and nemolizumab Q8W groups compared to placebo at Week 48.

## Prurigo nodularis

Both primary endpoints were met at week 16 in both main studies. Nemolizumab was superior to placebo with greater proportions of subjects with an improvement of ≥ 4 from baseline in weekly average PP NRS (nemolizumab 58.4% and 56.3%, placebo 16.7% and 20.9%, respectively) and with IGA success (defined as an IGA of 0 [clear] or 1 [almost clear] and a ≥ 2-grade improvement from baseline) (nemolizumab 26.3% and 37.7%, placebo 7.3% and 11.0%, respectively).

The superiority was shown for all key secondary endpoints (nemolizumab vs placebo):

-  Proportion of subjects with improvement of ≥ 4 from baseline in weekly average PP NRS at Week 4; (41.1% vs. 6.3% [SPR.202685] and 41.0% vs. 7.7% [SPR.203065]; p&lt;0.0001).
-  Proportion of subjects with PP NRS &lt;2 at Week 4; (21.6% vs. 1.0% [SPR.202685] and 19.7% vs. 2.2% [SPR.203065]; p&lt;0.0001).
-  Proportion of subjects with PP NRS &lt;2 at Week 16; (34.2% vs. 4.2% [SPR.202685] and 35.0% vs. 7.7% [SPR.203065]; p&lt;0.0001).
-  Proportion of subjects with improvement of ≥ 4 from baseline in weekly average SD NRS at Week 4; (31.1% vs. 5.2% [SPR.202685] and 37.2% vs. 9.9% [SPR.203065]; p&lt;0.0001).

<div style=\"page-break-after: always\"></div>

-  Proportion of subjects with improvement of ≥ 4 from baseline in weekly average SD NRS at Week 16; (50.0% vs. 11.5% [SPR.202685] and 51.9% vs. 20.9% [SPR.203065]; p&lt;0.0001).

The superiority of nemolizumab over placebo was supported by the other secondary endpoints.

Onset of clinical efficacy was observed from week 1 with greater proportion of subjects with an improvement of ≥ 4 from baseline in weekly average PP NRS in the nemolizumab group compared with the placebo group.

## Results in subgroups

The subgroup analyses for each primary and key secondary endpoint confirmed the consistency of the treatment effect for the subgroups defined by region, age group, sex, race, body weight at randomization and baseline IGA score.

## Maintenance of effect

The effect of nemolizumab was maintained at Week 24 in Olympia 1.

## 3.3.  Uncertainties and limitations about favourable effects

## Atopic dermatitis

There is a long-term safety and efficacy study (SPR.118163) beyond 1 year with nemolizumab ongoing in AD subjects (up to 200 weeks treatment) designed to evaluate the long-term safety, and efficacy as secondary objective. The study which does not contain any more adolescent subjects will be submitted in early 2027.

## Prurigo nodularis

Maintenance of efficacy beyond 24 weeks of treatment duration has not yet been evaluated. Efficacy of nemolizumab persisted until week 24 in study SPR.202685 for the primary endpoint, key secondary endpoints and other secondary endpoints. A long-term study (SPR. 202699, with the aim to evaluate long-term efficacy and safety of nemolizumab is ongoing. The final long-term study report is expected in 2027.

In the proposed SmPC, there was initially no information on at which timepoint efficacy of treatment should be clinically evaluated and discontinued in subject with lack of efficacy. The applicant suggested, based on post-hoc interim analysis from the long-term study SPR.202699 and the durability study SPR.203890, to consider discontinuation of treatment in non-responders after 24 weeks of treatment based on improvement in IGA success between week 16 and 24. Since the effect of nemolizumab on pruritus (PP NRS) was not superior over placebo beyond week 16 in Olympia 1, the CHMP suggested to consider discontinuation of treatment after 16 weeks in subjects with no response on pruritus, which has been agreed. However, effect on lesions may be seen after 24 weeks of treatment.

The magnitude of treatment response was consistent between pivotal studies for PP NRS endpoint, with almost complete overlap in CIs, but much less consistent for IGA endpoint and with only marginal overlap in CIs for treatment difference.

<div style=\"page-break-after: always\"></div>

## 3.4.  Unfavourable effects

Assessment of safety in the AD population is primarily based on the two pivotal studies SPR.118161, SPR.118169 and the pooled data of the primary safety population- including also the Phase 2 Study SPR.114322- focusing on the 30 mg (Q4W) dose of nemolizumab proposed for marketing.

Assessment of safety in the PN population is primarily based on the pivotal studies SPR.202685 and SPR.203065 and their pooled data focusing on both the 30 mg Q4W and 60 mg Q4W dose of nemolizumab proposed for marketing. The mean duration of exposure to the fixed dosing with body weight adjustment is 454.6 days including 375 subjects exposed for at least 1 year.

The incidence of urticaria in the AD population was 1.1 in the nemolizumab group and 0.5% in the placebo group.

The incidence of injection site reactions in the AD population during the initial period was 1.3% in nemolizumab subjects and 1.1% in placebo subjects.

The incidence of injection site reactions in the PN population was 1.1% in nemolizumab subjects and 1.6% in placebo subjects.

The frequency of headache in the PN population was 7% (tension headache 0.3%) in the nemolizumab group and 3.2% (tension headache 0%) in the placebo group during the Treatment Period.

Eczematous reactions in the PN population, reported as events of atopic dermatitis, eczema nummular, or eczema, were reported as follows in subjects treated with nemolizumab versus placebo: atopic dermatitis (4.6% versus 0.5%), eczema (3.8% versus 2.2%) and eczema nummular (3.5% versus 0). The incidence of angioedema in the PN population was 1.35% in the nemolizumab group and 0% in placebo subjects. The angioedema was assessed to be related to study drug, non-serious, mild facial (peri-ocular) and did not lead to discontinuation of treatment.

The proportion of subjects with fungal infection of skin or mucosa in the PN population was 3.8% in the nemolizumab group and 0% in placebo subjects.

In the initial Period, the proportion of subjects who experienced potentially clinically significant elevated eosinophils (worst post-baseline) was 10.2% in the nemolizumab 30 mg Q4W group and 5.8% in the placebo group in the AD population.

Among PN patients with history of asthma, 15.7% and 18% of nemolizumab subjects and 3.6% and 3.7% of placebo subject experienced IAC-confirmed worsening of asthma and had at least one PEF &lt;80% of predicted value, respectively. During 24 weeks of treatment, proportion of asthmatic patients with PEF&lt;80% of predicted value was about 8-10% in nemolizumab group compared to 0 patients receiving placebo.

## 3.5.  Uncertainties and limitations about unfavourable effects

Due to limited data, `Long-term safety beyond 1 year of nemolizumab 30 mg Q4W and 60 mg Q4W dose´ studies SPR.202699 (PN) and SPR.118163 (AD) have been included in the RMP.

Data on the use of nemolizumab in pregnant patients is absent/limited and it is agreed that this topic should be included as Missing information in the RMP.

<div style=\"page-break-after: always\"></div>

## 3.6.  Effects Table

Table 95: Effects Table for nemoluzimab for treatment for atopic dermatitis and prurigo nodularis (data cut-off: 10 March 2023)

| Effect                  | Short Description                                                                                | Unit                  | Nemoliz umab          | Placeb o              | Uncertainties/ Strength of evidence                                   | References            |
|-------------------------|--------------------------------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------------------------------------------------------|-----------------------|
| Favourable Effects AD   | Favourable Effects AD                                                                            | Favourable Effects AD | Favourable Effects AD | Favourable Effects AD | Favourable Effects AD                                                 | Favourable Effects AD |
| Co-primary endpoints    | Proportion of subjects with IGA success (IGA of 0 or 1 and ≥2 reduction from baseline at week 16 | %                     | 35.6                  | 24.6                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia1 Arcadia2     |
| Co-primary endpoints    | Proportion of subjects with IGA success (IGA of 0 or 1 and ≥2 reduction from baseline at week 16 | %                     | 37.7                  | 26.0                  | The effect of nemolizumab was consistent across sensitivity analyses. |                       |
| Co-primary endpoints    | Proportion of subjects with EASI-75 (≥ 75% improvement in EASI from baseline at week 16)         | %                     | 43.5                  | 29.0                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia1 Arcadia2     |
| Co-primary endpoints    | Proportion of subjects with EASI-75 (≥ 75% improvement in EASI from baseline at week 16)         | %                     | 42.1                  | 30.2                  | The effect of nemolizumab was consistent across sensitivity analyses. |                       |
| Key secondary endpoints | Proportion of subjects with PP NRS improvement ≥4 at week 16                                     | %                     | 42.7                  | 17.8                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia1              |
| Key secondary endpoints | Proportion of subjects with PP NRS improvement ≥4 at week 16                                     | %                     | 41.0                  | 18.1                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia2              |
| Key secondary endpoints | Proportion of subjects with PP NRS<2 at week 16                                                  | %                     | 30.6                  | 11.2                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia1              |
| Key secondary endpoints | Proportion of subjects with PP NRS<2 at week 16                                                  | %                     | 28.4                  | 11.3                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia2              |
| Key secondary endpoints | Proportion of subjects with PP NRS <2 at week 4                                                  | %                     | 16.0                  | 3.7                   | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia1              |
| Key secondary endpoints | Proportion of subjects with PP NRS <2 at week 4                                                  | %                     | 15.9                  | 2.6                   | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia2              |
| Key secondary endpoints | Proportion of subjects with SD NRS improvement                                                   | %                     | 37.9                  | 19.9                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia1              |
| Key secondary endpoints | Proportion of subjects with SD NRS improvement                                                   | %                     | 33.5                  | 16.2                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia2              |
| Key secondary endpoints | Proportion of subjects with EASI-75 and PP NRS improvement ≥4 at week 16                         | %                     | 23.7                  | 11.2                  | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia1              |
| Key secondary endpoints |                                                                                                  |                       | 23.0                  | 9.8                   | The effect of nemolizumab was consistent across sensitivity analyses. | Arcadia2              |

<div style=\"page-break-after: always\"></div>

| Effect                  | Short Description                                                            | Unit                  | Nemoliz umab          | Placeb o              | Uncertainties/ Strength of evidence                                                                                                                                                            | References            |
|-------------------------|------------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
|                         | Proportion of subjects with IGA success and PP NRS improvement ≥4 at week 16 |                       | 19.7                  | 9.3                   |                                                                                                                                                                                                | Arcadia1              |
| Favourable Effects PN   | Favourable Effects PN                                                        | Favourable Effects PN | Favourable Effects PN | Favourable Effects PN | Favourable Effects PN                                                                                                                                                                          | Favourable Effects PN |
| Co-primary endpoints    | Proportion of subjects with PP NRS improvement ≥4 at week 16                 | %                     | 58.4                  | 16.7                  | The effect of nemolizumab was consistent across sensitivity analyses. Tipping point and MI analyses indicated that the results were robust to missing data.                                    | Olympia 1             |
| Co-primary endpoints    | Proportion of subjects with PP NRS improvement ≥4 at week 16                 | %                     | 56.3                  | 20.9                  | The effect of nemolizumab was consistent across sensitivity analyses. Tipping point and MI analyses indicated that the results were robust to missing data.                                    | Olympia 2             |
|                         | Proportion of subjects with IGA success at week 16                           | %                     | 26.3                  | 7.3                   | The effect of nemolizumab was consistent across sensitivity analyses. Tipping point and MI analyses indicated that the results were robust to missing data.                                    | Olympia 1             |
|                         | Proportion of subjects with IGA success at week 16                           | %                     | 37.7                  | 11.0                  | The effect of nemolizumab was consistent across sensitivity analyses. Tipping point and MI analyses indicated that the results were robust to missing data.                                    | Olympia 2             |
| Key secondary endpoints | Proportion of subjects with PP NRS improvement                               | %                     | 41.1                  | 6.3                   |                                                                                                                                                                                                | Olympia 1             |
| Key secondary endpoints | Proportion of subjects with PP NRS improvement                               | %                     | 41.0                  | 7.7                   |                                                                                                                                                                                                | Olympia 2             |
|                         | Proportion of subjects with PP NRS <2 at week 4                              | %                     | 21.6                  | 1.0                   |                                                                                                                                                                                                | Olympia 1             |
|                         | Proportion of subjects with PP NRS <2 at week 4                              | %                     | 19.7                  | 2.2                   |                                                                                                                                                                                                | Olympia 2             |
|                         | Proportion of subjects with PP NRS <2 at week 16                             | %                     | 34.2                  | 4.2                   |                                                                                                                                                                                                | Olympia 1             |
|                         | Proportion of subjects with PP NRS <2 at week 16                             | %                     | 35.0                  | 7.7                   |                                                                                                                                                                                                | Olympia 2             |
|                         | Proportion of subjects with SD NRS improvement ≥4 at week 4                  | %                     | 31.1                  | 5.2                   |                                                                                                                                                                                                | Olympia 1             |
|                         | Proportion of subjects with SD NRS improvement ≥4 at week 4                  | %                     | 37.2                  | 9.9                   |                                                                                                                                                                                                | Olympia 2             |
|                         | Proportion of subjects with SD NRS improvement                               | %                     | 50.0                  | 11.5                  |                                                                                                                                                                                                | Olympia 1             |
|                         | Proportion of subjects with SD NRS improvement                               | %                     | 51.9                  | 20.9                  |                                                                                                                                                                                                | Olympia 2             |
| Unfavourable Effects    | Unfavourable Effects                                                         | Unfavourable Effects  | Unfavourable Effects  | Unfavourable Effects  | Unfavourable Effects                                                                                                                                                                           | Unfavourable Effects  |
| Urticaria               | Incidence of urticaria in AD population                                      | %                     | 1.0                   | 0.5                   | Non-serious and mild urticaria was reported with a close temporal link after initial nemolizumab 30 mg Q4W injections in some cases (2 events) and others after repeated injections (2 events) |                       |

<div style=\"page-break-after: always\"></div>

| Effect                   | Short Description                                                                 | Unit   | Nemoliz umab                                                | Placeb o                                                  | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                               | References   |
|--------------------------|-----------------------------------------------------------------------------------|--------|-------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Headache                 | Incidence of headache in the PN population during the Treatment Period.           | %      | headache : 7; tension headache : 0.3                        | headac he: 3.2; tension headac he: 0%                     | Lack of confounders in most nemolizumab subjects                                                                                                                                                                                                                                  |              |
| Eczematous reactions     | Incidence of eczematous reactions in the PN population                            | %      | atopic dermatitis 4.6, eczema 3.8 and eczema nummula r 3.5% | atopic dermati tis 0.5, eczema 2.2 and eczema nummul ar 0 |                                                                                                                                                                                                                                                                                   |              |
| Angiooedema              | Incidence of angiooedema in the PN population                                     | %      | 0.3                                                         | 0                                                         | The angiooedema was assessed to be related to study drug, non- serious, mild facial (peri-ocular) and did not lead to discontinuation of treatment.                                                                                                                               |              |
| Injection site reactions | Incidence injection site reactions during the initial period in the AD population | %      | 1.3                                                         | 1.1                                                       | No imbalance of injection site reactions was observed between nemolizumab 30 mg Q4W and placebo. However, reported injection site reactions were considered as a specific adverse reaction due to the subcutaneous route of                                                       |              |
| Injection site reactions | Incidence of injection site reactions in the PN population                        | %      | 1.1                                                         | 1.6                                                       | No imbalance of injection site reactions was observed between nemolizumab 30 mg Q4W and placebo. However, reported injection site reactions were considered as a specific adverse reaction due to the subcutaneous route of administration and a temporal link with the injection |              |

<div style=\"page-break-after: always\"></div>

| Effect                                               | Short Description                                                                                                       | Unit   | Nemoliz umab   |   Placeb o | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                | References   |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|--------|----------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Elevated eosinophils                                 | Proportion of subjects with clinically significant elevated eosinophils in the AD population in the Initial Period      | %      | 10.2           |        5.8 |                                                                                                                                                                                                                                                                    |              |
| Fungal infection of skin or mucosa                   | Proportion of subjects with fungal infection of skin or mucosa in the PN population                                     | %      | 3,8            |        0   |                                                                                                                                                                                                                                                                    |              |
| Worsening of asthma (asthmatic PN patients)          | Proportion of subjects with confirmed worsening of asthma in PN population (n=51 nemolizumab, n=28 placebo)             | %      | 15.7           |        3.6 | Despite similar proportion of asthmatic patients in both groups at baseline (about 13- 14%), all 8 adjudicated asthma related events in nemolizumab group were events of worsening of asthma. In placebo group 1/5 events were adjudicated as worsening of asthma. |              |
| PEF < 80% of predicted value (asthmatic PN patients) | Proportion of subjects with at least one PEF < 80% of predicted value in PN population (n=50 nemolizumab, n=27 placebo) | %      | 18             |        3.7 | For subjects without asthma history, this finding occurred in 5.2% nemolizumab subjects and 3.9% placebo subjects                                                                                                                                                  |              |

Abbreviations: Adverse event (AE), Confidence interval (CI), Least-square (LS), Serious adverse event (SAE), Standard error (SE), Urgency urinary incontinence (UUI)

## 3.7.  Benefit-risk assessment and discussion

## 3.7.1.  Importance of favourable and unfavourable effects

## Favourable effects

Indication moderate to severe atopic dermatitis

The main evidence of efficacy comes from two identical phase 3 studies with 16 weeks initial treatment periods followed by an additional 32-week maintenance period providing data for 48 weeks

<div style=\"page-break-after: always\"></div>

of treatment. The overall study program with two placebo-controlled trials is considered adequate and it is a strength that results are replicated in both studies. The studied population is representing the target population in the proposed indication.

The efficacy endpoints chosen for the application are considered clinically relevant and have previously been accepted for other biologic medicinal products indicated in moderate to severe atopic dermatitis. and are considered appropriate considering the aim of the studies.

Both pivotal trials (ARCADIA 1 and ARCADIA 2) showed clinically and statistically significant improvements in co-primary endpoints compared to placebo after 16 weeks of treatment. Considering the magnitude of improvement in IGA success, and the proportions of subjects with more than 75% improvement in EASI from baseline, the effect of nemolizumab could be considered as modest, but it is consistent in both trials and is considered as robustly documented. The effect on itch was more pronounced and had also a rapid onset and is of high importance for patients. A positive effect on sleep disturbance was also shown.

In the maintenance phase of the study, approximately 60 and 75 % of patients, respectively reached the co-primary endpoints at week 48. Thus, the effects seemed to be maintained in a relevant proportion of patients. Results were similar in the QW4 and QW8 groups, supporting the proposed posology.

Effects in adolescents at week 16 was similar compared to adults, but maintenance data is limited.

## Indication prurigo nodularis

The main evidence of efficacy comes from two pivotal phase 3 studies which showed statistically significant favourable effects of nemolizumab over placebo. The proposed posology is based on body weight, as studied in the phase III trials based on PK/PD models and assessed as well justified. The overall design with a placebo-controlled trial is considered adequate and the studies were, in general, well-conducted. The studied population is representative for the proposed target population as defined by the indication ( 'adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy ').

The efficacy endpoints chosen for this application are considered clinically relevant and are accepted.

Both co-primary efficacy endpoints were met as well as all key secondary endpoints in both pivotal studies. The results are of clinical relevance and are robustly documented, in particular the effect on itch is of high clinical relevance for patients. Final data is only available for 24 weeks treatment which is a limitation considering the chronicity of the condition.

## Unfavourable effects

The size of the safety database and the extent of exposure is considered adequate to allow for safety assessment for both indications. Overall, nemolizumab treatment appears to be well tolerated, including the dose and method of administration proposed for licensing. Common ADRs in the PN population were headache and eczematous skin reactions (atopic dermatitis, eczema and eczema nummular).

## 3.7.2.  Balance of benefits and risks

In terms of benefit, nemolizumab provides a significant and clinically meaningful beneficial treatment effect on moderate to severe AD in adolescent and adult patients at week 16, as compared to placebo.

<div style=\"page-break-after: always\"></div>

Similarly, nemolizumab provides a significant and clinically meaningful beneficial treatment effect on moderate to severe PN in adult patients, as measured by reductions in the PP NRS and IGA success from baseline to week 16, as compared to placebo.

From a safety perspective, nemolizumab was generally well tolerated and the safety profile was largely comparable to placebo. Most of the ADRs identified for nemolizumab occurred with relatively low frequency with nemolizumab treatment, and were generally mild and moderate, transient, and manageable.

The balance of benefits and risks can from a clinical perspective be considered positive for the AD and PN indication.

## 3.7.3.  Additional considerations on the benefit-risk balance

Not applicable.

## 3.8.  Conclusions

The overall benefit/risk balance of Nemluvio is positive, subject to the conditions stated in section 'Recommendations'.

## 4.  Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Nemluvio is favourable in the following indications:

## Atopic dermatitis (AD)

Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

## Prurigo nodularis (PN)

Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

##  Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

##  Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

-  At the request of the European Medicines Agency;
-  Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New active substance status

Based on the CHMP review of the available data, the CHMP considers that nemolizumab is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## LIST OF REFERENCES

1. Linnet 1999. Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol. 1999;140(2):268-72.
2. Ständer 2019. Ständer HF, Elmariah S, Zeidler C, Spellman M, Ständer S. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2019;82(2):460-8.
3. Whang 2021. Whang KA, Khanna R, Williams KA, Mahadevan V, Semenov Y, Kwatra SG. Health-Related QOL and Economic Burden of Chronic Pruritus. J Invest Dermatol. 2021;141(4):754-60.e1.
4. Whang 2022. Whang KA, Le TK, Khanna R, Williams KA, Roh YS, Sutaria, N et al. Healthrelated quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol 2022;86:573-80.
5. Kowalski 2019. Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163-72.
6. Huang 2020c. Huang AH, Canner JK, Williams KA, Grossberg AL, Kwatra MM , Kwatra SG. Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. Br J Dermatol. 2020;183:182-4.
7. Kwatra 2020. Kwatra SG. Breaking the itch-scratch cycle in prurigo nodularis. N Engl J Med. 2020;382(8):757-8.
8. Pereira 2020. Pereira MP, Hoffmann V, Weisshaar E, Wallengren J, Halvorsen JA, Garcovich S, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol. 2020;34(10):2373-83.
9. Ständer 2020a. Ständer S, Pereira MP, Berger T, Zeidler C, Augustin M, Bobko S, et al. IFSIguideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42.
10. Aggarwal 2021 Aggarwal P, Choi J, Sutaria N, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277-1284. doi:10.1111/ced.14722.
11. Elmariah 2021. Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol 2021;84:747-60.
12. Dhawan 2018 Dhawan L, Singh SM, Avasthi A, Kumaran MS, Narang T. The Prevalence of Psychiatric Comorbidity in Patients with Prurigo Nodularis. Indian Dermatol Online J. 2018;9(5):318-21.
13. Brenaut 2019 Brenaut E, Halvorsen JA, Dalgard FJ, Lien L, Balieva F, Sampogna F, et al. The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries. J Eur Acad Dermatol Venereol. 2019;33(1):157-62.
14. Weidinger 2016. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22.
15. Eichenfield 2014. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et

<div style=\"page-break-after: always\"></div>

al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32.

16. Langan 2020. Langan SM, Irvine AD, Weidinger S. [published correction appears in Lancet. 2020;396(10253):758]. Lancet. 2020;396(10247):345-60.
17. Ständer 2020b. Ständer S, Augustin M, Berger T, Elmariah S, Korman NJ, Weisshaar E, et al. Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. JAAD Int. 2020;2:28-30.
18. Huang 2020a. Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. J Invest Dermatol. 2020;140(2):4803.e4.
19. Ryczek 2020. Ryczek A, Reich A. Prevalence of Prurigo Nodularis in Poland. Acta Derm Venereol. 2020;100(10):adv00155.
20. Misery 2021. Misery L, Brenaut E, Torreton E, Bonte J, Bouée S. Prevalence and management of chronic nodular prurigo (CNPG) in Brittany (France): estimation by matching two databases. J Eur Acad Dermatol Venereol. 2021;35(9):e602-4.
21. Morgan 2022. Morgan CL, Thomas M, Ständer S, Jabbar-Lopez ZK, Piketty C, Gabriel S, et al. Epidemiology of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol. 2022;187(2):188-95.
22. Iking 2013. Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27(5):550-7.
23. Boozalis 2018 Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018;79(4):714-9.
24. Ständer 2020c. Ständer S, Ketz M, Kossack N, Akumo D, Pignot M, Gabriel S, et al. Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis. Acta Derm Venereol. 2020;100(18):adv00309.
25. Huang 2020b. Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-65.
26. Rutkowski 2014. Rutkowski K, Sowa P, Rutkowska-Talipska J, Sulkowski S, Rutkowski R. Allergic diseases: the price of civilisational progress. Postepy Dermatol Alergol. 2014;31(2):7783.
27. Dillon 2004. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752-60.
28. Gibbs 2019. Gibbs BF, Patsinakidis N, Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front Immunol. 2019;10:1383.

<div style=\"page-break-after: always\"></div>

29. Takamori 2018. Takamori A, Nambu A, Sato K, Yamaguchi S, Matsuda K, Numata T, et al. IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity. Sci Rep. 2018;8(1):6639.
30. Alkon 2021 Alkon N, Bauer WM, Krausgruber T, Goh I, Griss J, Nguyen V, et al. Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J Allergy Clin Immunol. 2022;149(2):624-39.
31. Garbers 2012. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012;23(3):85-97.
32. Bağci 2018 Bağci IS, Ruzicka T. IL-31: a new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3):858-66.
33. Zhang 2008. Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19(5-6):347-56.
34. Wang 2020. Wang F, Kim BS. Itch: a paradigm of neuroimmune crosstalk. Immunity. 2020;52(5):753-66.
35. Hashimoto 2021. Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021;30(6):804-10.
36. Kabashima 2021. Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021;8:69.
37. Tsoi 2022. Tsoi LC, Hacini-Rachinel F, Fogel P, Rousseau F, Xing X, Patrick MT, et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol. 2022;149(4):1329-39.
38. Sidbury 2023. Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20.
39. Wollenberg 2022. Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-31.
40. Saeki 2021. Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, et al; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, The Japanese Society of Allergology, The Japanese Dermatology Association. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448-58.
41. Davis 2023 Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2023:S0190-9622(23)02878-5.
42. European Dermatology Forum 2022. European Dermatology Forum. Living EuroGuiDerm Guideline for the systemic treatment of Atopic Eczema 2022. Available at:

<div style=\"page-break-after: always\"></div>

https://www.guidelines.edf.one/guidelines/atopic-ezcema Accessed 02 November 2023.

43. Boguniewicz 2017 Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519-31.
44. Ghazal 2022. Ghazal S, Ridha Z, D'Aguanno K, Nassim D, Quaiattini A, Netchiporouk E, et al. Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II. Front Med (Lausanne). 2022;9:821871.
45. Pereira 2021. Pereira MP, Zeidler C, Wallengren J, Halversen J, Weisshaar E, Garcovich S, et al. Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. Acta Derm Venereol. 2021;101(2):adv00403
46. Weisshaar 2012. Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92(5):563-81.
47. DUPIXENT USPI. Dupixent® United States Package Insert October 2022, Manufactured by Regeneron, Tarrytown, NY and Marketed by Sanofi-Aventis Bridgewater, NJ; Revised October 2023.
48. DUPIXENT SmPC. Dupixent® (dupilumab) [Product Information] September 2017, Manufactured by Regeneron, Rensselaer, NY and Marketed by Sanofi Winthrop Industrie Gentilly France; Revised October 2023.